Name of the drug,Amphetamine,Methamphetamine,Methylphenidate,Dexedrine,Modafinil,Armodafinil,Ephedrine,Cocaine,Caffeine,Nicotine,Atomoxetine,Phentermine,Diethylpropion,Benzphetamine,Levodopa,Amantadine,Rasagiline,Selegiline,Entacapone,Rivastigmine,Benztropine,Pramipexole,Ropinirole,Safinamide,Apomorphine,bromocriptine,Istradefylline,Trihexyphenidyl,Tolcapone,TRIAZOLAM,TEMAZEPAM,NITRAZEPAM,DIAZEPAM,LORAZEPAM,SECOBARBITAL,ZALEPLON,DOXEPIN,CLONAZEPAM,BUTABARBITAL,FLURAZEPAM,TRAZODONE,OXAZEPAM,RAMELTEON,SUVOREXANT,NA,Methotrexate,Temozolomide,Citalopram,Procarbazine,Vinblastine,Topotecan,Irinotecan,Etoposide,Paclitaxel,Dexamethasone,NA,Clotrimazole,Miconazole,Ketoconazole,Voriconazole,Posaconazole,Flucanazole,Itraconazole,Terbinafine,Butenafine,Naftifine,Nystatin,Micafungin,Caspofungin,Griseofulvin,Tolnaftate,INSULIN ASPART,GLIPIZIDE,TOLBUTAMIDE,ACARBOSE,MIGLITOL,GLIMEPIRIDE,VOGLIBOSE,PIOGLITAZONE,METFORMIN,INSULIN,HUMALOG,NOVOLOG R,REPAGLINIDE,LINAGLIPTIN,Fluoxetine,Sertraline,Venlafaxine,Duloxetine,Bupropion,Paroxetine,Amitriptyline,Trazodone,Mirtazapine,Nortriptyline,Fluvoxamine,Phenelzine,NA,Adagrasib,Alectinib,Binimetinib,Brigatinib,Ceritinib,Cisplatin,Etoposide,Docetaxel,Paclitaxel,Gemcitabine,Pemetrexed,Vinorelbine,Nivolumab,Lorlatinib,Entecavir,Tenofovir,Vemlidy,lamivudine,Hepsera,Epivir-HBV,Adefovir,tenofovir alafenamide,Telbivudine,Ezetimibe,Lonafarnib,Clevudine,Emtricitabine,Indinavir,Adefovir dipivoxil,Azathioprine,Acitretin,Fluphenazine,Methotrexate,Hydroxyurea,cyclosporine,Colbetasol,Betamethasone,Calcipotriene,Tazarotene,Pimecrolimus,Adalimumab,Apremilast,Etretinate,dimenhydrinate,Hyoscine,Dicyclomine,promethazine,Itopride,Ondansetron,ramosetron,apreitant,Meclizine,chlorpromazine,haloperidol,Palosetron,granisetron,maropitant,NA,Insulin Aspart,Insulin,Insulin determir,Humulin N,Tresiba,Humalog,Apidra,Symlin,Fiasp,Glimipiride,Octreotide,Tzield,Rezvoglar,Novolog R,Novolin R,Chloroquine,Amodiaquine,Piperaquine,Mefloquine,Quinine,Quinidine,Proguanil,Pyrimethamine,Primaquine,Sulfadoxine,sulfamethopyrazinee,Doxycycline,Clindamycin,Artesunate,Artemether,Arteether,Lumefantrine,Atovaquone,Ranitidine,Cimetidine,Famotidine,Tagamet,Bepridil,Cisapride,Dofetilide,Levoketoconazole,Pimozide,Piperaquine,Sparfloxacin,Terfenadine,Ziprasidone,Mesoridazine,Nizatidine,Amikacin,Plazomicin,Azithromycin,Amoxicillin,Cephalosporin,Temocillin,Ampicillin,Sulfadiazine,Eravacycline,Penicillin,Meropenem,Cefalexine,Ciprofloxacin,ceftolozane,Clarithromycin,Salbutamol,Theophylline,Terbutaline,Aminophylline,Ipratropium,Tiotropium Bromide,Montelukast,Zafirlukast,cromoglycate,Ketotifen,Hydrocortisone,Prednisolone,Beclomethasone,Budesonide,Flunisolide,Phenytoin,Carbamazepine,Valproic Acid,Lamotrigine,Levetiracetam,Topiramate,Oxcarbazepine,Clobazam,Felbamate,Vigabatrin,Tiagabine,Rufinamide,Gabapentin,Zonisamide,Pregabalin,Phenobarbital,Phenytoin sodium,Paragabilin,Zonismide,Gabapentin,Rufinamide,Tiagabin,Viga batrin,methsuximide,Volproic acid,Lomotrigine,Carbamazepine,Levetiracetam,Diazepam,Felbamate,Chlorpromazine,Thioridazine,Trifluoperazine,Thiothixene,Haloperidol,Loxapine,Clozapine,Risperidone,Aripiprazole,Brexpiprazole,Asenapine,Sertindole,Zotepine,Cariprazine,Lumateperone,Quidinine,Procainamide,Disopyramide,Lidocaine,Mexiletine,Flecainide,Adenosine,Digoxin,Verapmil,Diltiazem,Propranolol,Esmolol,Amiodorone,Sotalol,Acebutolol,Atezolizumab,Avastin,Gemcitabine,Cabometyx,Durvalumab,Cabozantinib-S-Malate,Cyramza,lenvima,Nexavar,Rozlytrek,Vitrakvi,Imfinzi,stivarga,Regorafenib,Pemazyre,methothrexate,mechlorethamine,thiotepa,Altretamine,busalfan,Melphalan,Bendamustine,Lomustine,Cyclophosphamide,Streptozocin,Etoposide,Chlorambucil,Procarbazine,Fludarbine,dacarbazine,Omeprazole,Lansoprazole,Cimetidine,Ranitidine,Pirenzepine,Propanthaline,Misoprostol,Tinidazole,Sodium citrate,Sodium bicarbonate,Sucralfate,Magaldrate,Amoxicillin,Clarithromycin,Metronidazole,Taxus brevifolia.,Cisplatin,Alectinib hydrochloride,Docitaxel,Braftovi,Methotrexate sodium,Crizotinib,Vinorelbine,Brigatinib,Erlotinib,Gemzar,Afatinib,DIAZEPAM,OXAZEPAM,HYDROXYZINE,PROPRANOLOL,BUSPIRONE,GEPIRONE,LORAZEPAM,CLONIDINE,ALPRAZOLAM,AMOBARBITAL,PHENOBARBITAL,CHLORDIAZEPOXIDE,PENTOBARBITAL,THIOPENTAL,PAROXETINE,Almotriptan,Eletriptan,Naratriptan,Zolmitriptan,Sumatriptan,Rizatriptan,Frovatriptan,Ergotamine,Artesunate,Propranolol,Cyproheptadine,Iasmiditan,Naproxen,Dihydroergotamine,Caffeine,promethazine,citirizine,Loratadine,fexofenadine,Diphenhydramine,Desloratadine,levocitirizine,Azelastine,Brompheniramine,clemastine,Hydroxyzine,Meclizine,Cyproheptadine,Ebastine,Doxylamine,Glasdegib,Venetoclax,Midostaurin,Nilotinib,Imatinib,Prednisone,Busulfan,Dasatinib,Dexamethasone,Azacitidine,Cytarabine,Nelarabine,Rituximab,Daunorubicin Hydrochloride,Chlorambucil,Ascorbic acid (Vitamin c) Folate ( Vitamin B9),Folate,Cobalamine ( vitamin B12),Niacin (Vitamin b3),Riboflavin (vitamin B2),Thiamine (vitamin B1),Choline,cholecalciferol,Biotin,Pantothenic Acid,Lutein,Astaxanthin,Resveratrol,phylloquinone,alpha-tocopherol,NA,Clotrimazole,Miconazole,Fluconazole,Itraconazole,Voriconazole,Posaconazole,Griseofulvin,Butenafine,Rezafungin,Caspofungin,Terbinafine,Butenafine,Naftifine,Flucytosin,Griseofulvin,Fluconazole,Itraconazole,Caspofungin,Clotrimazole,Econazole,Miconazole,Oxiconazole,Ketoconazole,Voriconazole,Terbinafine,Tolnaftate,Butenafine,Benzoic acid,Nystatin,Posaconazole,Glimepiride,Glipizide,Gliclazide,Tolbutamide,Chlorpropamide,Tolazamide,Acetohexamide,Glymidine,Glibornuride,Glisoxepide,Gliquidone,Glyclopyramide,Glyhexamide,Glibuzole,Glibenclamide,Omeprazole,Rebamipide,Esomeprazole,Pantoprazole,Amoxicillin,Rabeprazole,Tinidazole,Lansoprazole,Tetracycline,Rabeprazole,Sodium Bicarbonate,Misoprostol,cimetidine,Sodium Citrate,Ranitidine,Calcium Carbonate,Cimetidine,sodium Bicarbonate,Aluminium Hydroxide,Magnesium Hydroxide,Bismuth Subsalicylate,Omeprazole,Pantoprazole,Ranitidine,Rabeprazole,Citric Acid,esomeprazole,Sodium Citrate,Magnesium Carbonate,Magnesium Trisilicate,Evista (raloxifine hydrochloride),Saltomax(tamoxifen cirtate),Aredia,femara(letrozole),herceptin hylecta,kisqali(ribociclib),lynparza(olaparib),fareston,cyclophosphamide,capivasertib,faslodex,olaparib,lxabepilone,margenza,Neratinib maleate,Ribavirin,Sofosbuvir,Lamivudine,Lopinavir,Darunavir,Remdesivir,Favipiravir,Famciclovir,NA,carmustine,lomustine,Everolimus,bevacizumab,Afinitor Everolimus,Afinitor Disperz (Everolimus),Procarbazine,Avastin,Belzutifan,BiCNU (Carmustine),Cyclophosphamide,Cisplastin,Gliadel,CeeNU,Methotrexate,NA,voriconazole,POSACONAZOLE,MICAFUNGIN,Ketoconazole,Itraconazole,TERCONAZOLE,TERBINAFINE,NYSTATIN,MICONAZOLE,ECOAZOLE,CLOTRIMAZOLE,BUTACONAZOLE,ANIDULAFUNGIN,AMPHOTERICIN B,Almotriptan,Eletriptan,Naratriptan,Zolmitriptan,Sumatriptan,Rizatriptan,Frovatriptan,Ergotamine,Artesunate,Propranolol,Cyproheptadine,Iasmiditan,Naproxen,Dihydroergotamine,Caffeine,promethazine,citirizine,Loratadine,fexofenadine,Diphenhydramine,Desloratadine,levocitirizine,Azelastine,Brompheniramine,clemastine,Hydroxyzine,Meclizine,Cyproheptadine,Ebastine,Doxylamine,Glasdegib,Venetoclax,Midostaurin,Nilotinib,Imatinib,Prednisone,Busulfan,Dasatinib,Dexamethasone,Azacitidine,Cytarabine,Nelarabine,Rituximab,Daunorubicin Hydrochloride,Chlorambucil,NA,NA,Ascorbic acid (Vitamin c) Folate ( Vitamin B9),Folate,Cobalamine ( vitamin B12),Niacin (Vitamin b3),Riboflavin (vitamin B2),Thiamine (vitamin B1),Choline,cholecalciferol,Biotin,Pantothenic Acid,Lutein,Astaxanthin,Resveratrol,phylloquinone,alpha-tocopherol,NA,NA,NA,NA,NA,Clotrimazole,Miconazole,Fluconazole,Itraconazole,Voriconazole,Posaconazole,Griseofulvin,Butenafine,Rezafungin,Caspofungin,Terbinafine,Butenafine,Naftifine,Flucytosin,Griseofulvin,NA,NA,Fluconazole,Itraconazole,Caspofungin,Clotrimazole,Econazole,Miconazole,Oxiconazole,Ketoconazole,Voriconazole,Terbinafine,Tolnaftate,Butenafine,Benzoic acid,Nystatin,Posaconazole,NA,Glimepiride,Glipizide,Gliclazide,Tolbutamide,Chlorpropamide,Tolazamide,Acetohexamide,Glymidine,Glibornuride,Glisoxepide,Gliquidone,Glyclopyramide,Glyhexamide,Glibuzole,Glibenclamide,NA,Omeprazole,Rebamipide,Esomeprazole,Pantoprazole,Amoxicillin,Rabeprazole,Tinidazole,Lansoprazole,Tetracycline,Rabeprazole,Sodium Bicarbonate,Misoprostol,cimetidine,Sodium Citrate,Ranitidine,NA,Calcium Carbonate,Cimetidine,sodium Bicarbonate,Aluminium Hydroxide,Magnesium Hydroxide,Bismuth Subsalicylate,Omeprazole,Pantoprazole,Ranitidine,Rabeprazole,Citric Acid,esomeprazole,Sodium Citrate,Magnesium Carbonate,Magnesium Trisilicate,NA,Evista (raloxifine hydrochloride),Saltomax(tamoxifen cirtate),Aredia,femara(letrozole),herceptin hylecta,kisqali(ribociclib),lynparza(olaparib),fareston,cyclophosphamide,capivasertib,faslodex,olaparib,lxabepilone,margenza,Neratinib maleate,Ribavirin,Sofosbuvir,Lamivudine,Lopinavir,Darunavir,Remdesivir,Favipiravir,Famciclovir,NA,carmustine,lomustine,Everolimus,bevacizumab,Afinitor Everolimus,Afinitor Disperz (Everolimus),Procarbazine,Avastin,Belzutifan,BiCNU (Carmustine),Cyclophosphamide,Cisplastin,Gliadel,CeeNU,Methotrexate,voriconazole,POSACONAZOLE,MICAFUNGIN,Ketoconazole,Itraconazole,TERCONAZOLE,TERBINAFINE,NYSTATIN,MICONAZOLE,ECOAZOLE,CLOTRIMAZOLE,BUTACONAZOLE,ANIDULAFUNGIN,AMPHOTERICIN B,diazapam,Brivaracetam,Clonazepam,Phenobarbital,Ethosuximide,Lacosamide,phenytoin,Lorazepam,primidone,Topiramate,Rufinamide,Acetazolamide,tiagaine,Carbamazepine,Valproic acid,NA,Carbamazepine,Valproic acid,Olanzapine,Lamotrigine,Aripiprazole,Asenapine,Cariprazine,Ziprasidone,Quetiapine fumarate,Laurasidone,Risperidone,Dabigatran,Edoxaban,Fluphenazine,Haloperidol,Alendronic Acid,Raloxifene,Risedronic Acid,Ibandronic acid,Zolendronic acid,Bazedoxifene,Clodronic Acid,Etidronic Acid,Pamidronic Acid,Strontium ranelate,Teriparatide acetate hydrate,Abaloparatide,Calcitonin Salmon,Denosumab,Romosozumab,Baricitinib,Tofacitinib,Upadacitinib,Methotrexate,Leflunomide,Sulfasalazine,Azathioprine,Cyclosporine,Chloroquine,Hydroxychloroquine,Etanercept,Prednisolone,Anakinra,Adalimumab,Tocilizumab,NA,Imiquimod,Fluorouracil-Topical,Vismodegib,Sonidegib,Pembrolizumab,Aldesleukin,Binimetinib,Encorafenib,Cobimetinib,Debrafenib,Dacarbazine,Alitretinoin,Vemurafenib,Ipilimumab,Tebentafusp,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Rotatable bonds,Glyceryl trinitrate,Isosorbide dinitrate,Isosorbide mononitrate,Erythrityl tetranitrate,Pentaerythritol tetranitrate,Propanolol,Metoprolol,Atenolol,Verapamil,Diltiazem,Amlodipine,Nicorandil,Nifedipine,Felodipine,Dipyridamole,Amoxicilin,Cephalexin,Cefditoren,Azitromycin,Tetracyclines,Dalbavancin,Levofloxacin,Tobramycin,Ertapenem,Doxycycline,Cefepime,Lincomycin,Meropenem,Gemifloxacin,Amikacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Zanamivir,Peramivir,Oseltamivir,Abacavir,Acyclovir,Valacyclovir,Baloxavir,Cidofovir,Adefovir,Fostemsavir,Tenofovir,Amprenavir,Atazanavir,Boceprevir,Combivir,Phenytoin,Carbamazepine,Valproic Acid,Lamotrigine,Levetiracetam,Topiramate,Oxcarbazepine,Clobazam,Felbamate,Vigabatrin,Tiagabine,Rufinamide,Gabapentin,Zonisamide,Pregabalin,Phenytoin,Carbamazepine,Valproic Acid,Lamotrigine,Levetiracetam,Topiramate,Oxcarbazepine,Clobazam,Felbamate,Vigabatrin,Tiagabine,Rufinamide,Gabapentin,Zonisamide,Pregabalin
IUPAC name,?-methylphenethylamine,N-methyl-1-phenylpropan-2-amine,Methyl (2RS)-2-phenyl-2-[(2RS)-piperidin-2-yl]acetate,(RS)-1-phenylpropan-2-amine,2-[(diphenylmethyl)sulfinyl]acetamide,(–)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide,"(1R,2S)-2-methylamino-1-phenylpropan-1-ol","Methyl (1R,2R,3S,5S)-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate","1,3,7-trimethylxanthine",3-[(2S)-1-methylpyrrolidin-2-yl]pyridine,(R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine,"1,1-Dimethyl-2-phenylethylamine",2-(Diethylamino)-1-phenylpropan-1-one,"N-benzyl-N,N-dimethyl-2-phenylpropan-1-amine","(S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid",1-adamantanamine,"(1R)-2,3-dihydro-1H-inden-1-amine",(R)-N-methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine,"(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide",(S)-3-[1-(Dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate,3-(Diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane,"(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole","4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one",(S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide,"(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol","2-bromo-12'-hydroxy-2'-(1-methylpropyl)-5'-ethenylspiro[chroman-4,4'-imidazolidine]-2,6,10-trione","8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methyl-xanthine",benzhexol,"(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone","8-chloro-6-(o-chlorophenyl)-1-methyl-4H-triazolo-[4,3-a]-[1,4]-benzodiazepine","7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one"," 1,4-benzodiazepinone","7-Chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one","(RS)-9-chloro-6-(2-fluorophenyl)-4-hydroxy-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one","5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione","N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide",(3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N-methyl-N-(trideuteriomethyl)propan-1-amine;hydrochloride,"1,3-Dihydro-2H-1,4-benzodiazepin-2-one","5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione","7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one","2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one","7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one","N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide","(7R)-4-(5-chloro-2-benzoxazolyl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone",NA,"(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methylmethylamino]benzoyl]amino]pentanedioic acid","3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide","(RS)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile",N-isopropyl-4-[(2-methylhydrazino)methyl]benzamide,"(3?,5?,16?,20S)-20-(Acetyloxy)-1,2-dihydroxy-16-methyl-3-[(1-oxoethyl)amino]-7,11-dioxo-8,9,10,11,12,13,14,15-octahydro-6H-oxacyclotetradecino[4,3,2-gh:3',4',5'-ij]oxecin-6-yl 3,4,5-trihydroxybenzoate","(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione","(4S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'bipiperidine]-1'carboxylate","4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside","2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(Acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,9,11,12,12b-hexamethyl-4a,8,13,13a-hexahydro-3H-9,13-methanopyrano[3,4-b]oxepin-11-ol","(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one",NA,1-[(2-Chlorophenyl)(diphenyl)methyl]-1H-imidazole,"(RS)-1-(2-(2,4-Dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole","1-[4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone","(2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol","4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-[(1S,2S)-1-ethyl-2- hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one","2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol","1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one","[(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)(naphthalen-1-ylmethyl)amine",[(4-tert-butylphenyl)methyl](methyl)(naphthalen-1-ylmethyl)amine,(2E)-N-methyl-N-(1-naphthylmethyl)-3-phenylprop-2-en-1-amine,"6-dideoxy-?-L-mannopyranosyl)oxy]-1, 3,4,7,9,11,17,37-octahydroxy-15, 16,18-trimethyl-13-oxo-14, 39-dioxabicyclo[33.3.1]nonatriaconta-19,","{5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-2-carbamoyl-1-hydroxyethyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[(4-{5-[4-(pentyloxy)phenyl]-1,2-oxazol-3-yl}benzene)amido]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl}oxidanesulfonic acid","(10R,12S)-N-{(2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-12-[(2-Aminoethyl)amino]-20-[(1R)-3-amino-1-hydroxypropyl]-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l] [1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide","(2S,6'R)- 7-chloro- 2',4,6-trimethoxy- 6'-methyl- 3H,4'H-spiro [1-benzofuran- 2,1'-cyclohex[2]ene]- 3,4'-dione",O-2-Naphthyl methyl(3-methylphenyl)thiocarbamate,insulin aspart is 28B-L-aspartic acid-insulin,1-cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl]sulfonyl]urea,N-[(Butylamino)carbonyl]-4-methylbenzenesulfonamide," O-4,6-Dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-?-D-glucopyranosyl-(1?4)-O-?-D-glucopyranosyl-(1?4)-D-glucopyranose","(2R,3R,4R,5S)-1-(2-Hydroxyethyl)-2-(hydroxymethyl) piperidine-3,4,5-triol","3-Ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide","(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol","(RS)-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione","N,N-Dimethylimidodicarbonimidic diamide",NA,Insulin lispro,"alpha-Aspartyl-L-phenylalanine,28B-L-threonine)-human insulin.",(S)-2-ethoxy-4-(2-{[3-methyl-1-(2-{1-[2-(piperidin-1-yl)ethoxy]-3-methylbutyl}benzoyl)thiazolidin-4-yl]methyl}phenoxy)butanoic acid,"(R)-2-((4-(2,4,5-trifluorophenyl)thiazol-4-yl)methyl)-4-(2,4,6-trimethylphenyl)-1,3-thiazolidine-3,5-dione",(RS)-N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine,"(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine",1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol,(+)-(S)-N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propan-1-amine,(±)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one,"(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine","3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine","2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-1,2,4-triazol-3-one","1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine","(3S)-10,11-dihydro-N-methyl-5H-dibenzo[a,d][7]annulen-5-amine",5-methoxy-3-(trifluoromethyl)phenylmorpholin-2-one,"N’-2-phenylethane-1,2-diamine
• BCS classification: Class 3",(±)-trans-2-phenylcyclopropylamine,"2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-5H,6H,7H,8H-PYRIDO[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile","9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride","5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide","5-Chloro-2-N-(4-[4-(dimethylamino)piperidin-1-yl]-2-methoxtphenyl)-4-N-[2-(dimethylphosphoryl)phenylpyrimidine-2,4-diamine","5-Chloro-N^2-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N^4-[2[(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine",(SP-4-2)-diamminedichloridoplatinum(II),"4?-Dimethyl-epipodophyllotoxin-9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside], 4?-(dihydrogen phosphate)","1,7?,10?-trihydroxy-9-oxo-5?,20-epoxytax-11-ene-2?,4,13?-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}","(2?,4?,5?,7?,10?,13?)-4,10-Bis(acetylloxy)-13-{[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate","4-Amino-1-(2-deoxy-2,2-difluoro-?-D-erythro-pentofuranosyl)pyrimidin-2(1H)-on","(2S)-2-{[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino}pentanedioic acid","Methyl(2?,3?,4?,5?,12?,19?)-4-acetoxy-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0^3,11.0^4,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate",­,"(10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile","2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one",9-[(R)-2-(phosphonomethoxy)propyl]adenine,(2S)-2-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methylphosphoryl]propanoic acid hemifumarate,"(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one",(2S)-2-[[2-(6-amino-9H-purin-9-yl)ethoxy]methylphosphoryl]acetic acid,"(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one",9-[2-(phosphonomethoxy)ethyl]adenine,(R)-9-(2-phosphonylmethoxypropyl)adenine fumarate,"1-[(2S,4R)-4-hydroxy-5-methyl-2-(methylthiomethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione","(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one","4-(2-{4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperidin-1-yl}-2-oxoethyl)piperidine-1-carboxamide","1-(2-deoxy-?-D-ribofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione","4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one","N-[(2S,3R)-4-[(2,3-dihydro-1H-inden-2-yl)amino]-3-hydroxy-5-phenylpentanoyl]-L-valyl-N1-(3-methylbutyl)-L-alaninamide","(2S)-2-(6-amino-9H-purin-9-yl)-1-[(1S,2R)-1-hydroxy-3-{[(propan-2-yloxy)carbonyl]oxy}propoxy]propan-2-yl hydrogen",6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine,"(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid",4-[3-[2-(Trifloromethyl)phenothiazin-10-yl]piperazin-1-carboxylic acid,"4-[(2,4-diamino-6-pteridinyl)methylmethylamino]-2-[[(1,3-dioxo-1,3-dihydro-2H-isoquinolin-2-yl)carbonyl]amino]benzoic acid",hydroxyurea,"(2S,4R,6E)-N-methyl-4-propyl-2-[(E, R)-hex-2-en-1-yl]-1,4-dihydro-2H-pyrrolo[3,4-b]-1,3-benzodiazepin-6-one",": (6?,11?,16?)-21-chloro-9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione","9-Fluoro-11?,17,21-trihydroxy-16?-methylpregna-1,4-diene-3,20-dione","(5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1?,3?,24-triol","Ethyl 6-[2-(4,4-dimethylthiocarbamoyl)ethenyl]-1-naphthalenecarboxylate","(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)- 2-{(1R,3R,4S)-4-chloro-3-methoxycyclohexyl}-1-methylvinyl]-17-ethyl-1,14-dihydroxy-23,25- dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo",NA,"-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide","ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate","8-chlorotheophylline 1,2-dimethylhydrazinecarboxylate",Scopolamine,1-cyclohexyl-1-(2-piperidin-1-yl-ethyl)piperidine,NA,"4-amino-N-[2-diethylamino]-5-hydroxy-2,3-dimethylbenzamide","1,2,3,9-tetrahydro-9-methyl-3-[92-methyl-1h-imidazol-1-yl)methyl]-4-carbazol-4-one","(2R)-2-[(1S)-1,2,3,4-tetrahydroisoquinolin-2-yl]-N-[(1S)-1-(2,3-dihydro-1H-inden-2-yl)ethyl] acetamide","5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one",1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine,2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine,2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine,"(3aS)-2-[(S)-1-Azabutan-3-yl]-1,2,3,3a-tetrahydro-3-methyl-1H-benz[de]isoquinolin-1-one","(endo)-9-methyl-3-[(methylimino)methyl]-10-azatricyclo[7.3.1.02,7]trideca-1(9),11-dien-8-one
","(5S,8S)-8-butyl-6,11-dioxo-5,8,12,12a-tetrahydro-1H-imidazo[1,2a]pyrazino[1',2':1,6]pyrido[3,4-b]indole-8-carboxylic acid",NA,NA,Recombinant Human Insulin,Insulin determir,Insulin isophane,Insulin degludec,Insulin Lispro,Insulin glulisine,Pramlintide,Humulin R U 100,"1({p-[2-(3-ethyl-4-methyl-2-oxo-3-
pyrroline-1-carboxamido)ethyl]
phenyl}sulfonyl)-3-(trans-4-methy
lcyclohexyl)urea",Sandostatin,Teplizumab,Insulin glargine,"alpha-Aspartyl-L-phenylalanine, 
28B-L-threonine)-human insulin.",Human Insulin,"(R)-N^4-(7-chloroquinolin-4-yl)-N^1,N^1-diethylpentane-1,4-diamine",: 4-[(7-chloroquinolin-4-yl)amino]-2-[(diethylamino)methyl]phenol,"N,N-bis(7-chloroquinolin-4-yl)pentane-1,4-diamine","(RS)-2,8-Bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol","(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol","(S)-(6-Methoxyquinolin-4-yl)[(1S,2R,4S,5R)-5-vinylquinuclidin-2-yl]methanol",N-(diaminomethylidene)-N'-formimidoyl-N-methylguanidine,"5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine","(RS)-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine","N^1-(4,6-dimethylpyrimidin-2-yl)sulfanilamide",N^1-(6-methyl-2-pyrazinyl)sulfanilamide,"(4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide","Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-?-D-galacto-octopyranoside","(3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-ol","(3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-8(1H)-one","(3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin","9-[(Z)-2-chloro-1,2-dihydro-1-(dihydroxyethyl)-4-methoxy-6-methyl-5-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyrimidin-7-ylidene]-N-ethyl-1,4,8,12-tetraazacyclotetradecane-5,11-dione","2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione","N-(2-[(5-[(Dimethylamino)methyl]furan-2-yl)methylthio]ethyl)-N'-methyl-2-nitroethene-1,1-diamine.", 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine," 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide",1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine, N-benzyl-N-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)aniline,4-amino-5-chloro-N-(1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl)-2-methoxybenzamide,N-[4-(2-{[2-(4-methane sulfonamidophenoxy)ethyl] (methyl)amino}ethyl)phenyl]methanesulfonamide," 1-[4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone","1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazole-2-one"," 1,3-bis[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propane","5-Amino-1-cyclopropyl-7-[(3R,5S)3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-quinoline-3-carboxylic acid",1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-o,"5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one",10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine,"-1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine","(2S)-4-Amino-N-[(2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5R,6R)-6-(aminomethyl)-3,4,5-trihydroxy-oxan-2-yl]oxy-3-hydroxy-cyclohexyl]-2-hydroxybutanamide","(2S)-4-Amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[[(2S,3R)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2H-pyran-2-yl]oxy]-2-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide","(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo- 11-{[3,4,6-trideoxy-3-(dimethylamino)-?-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadec-13-yl 2,6-dideoxy-3C-methyl-3-O-methyl-?-L-ribo-hexopyranoside","(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid","(6R,7R)-3-(acetyloxymethyl)-7-[[(5R)-5-amino-5-carboxypentanoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid","(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid","(2S,5R,6R)-6-([(2R)-2-amino-2-phenylacetyl]amino) -3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2- carboxylic acid",4-amino-N-pyrimidin- 2-yl-benzenesulfonamide,"(4S,4aS,5aR,12aS)-4-(Dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[2-(pyrrolidin-1-yl)acetamido]-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide",(4-thia-1-azabicyclo[3.2. 0]heptan-7-one,"(4R,5S,6S)-3-(((3S,5S)-5-(Dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid",(7R)-3-methyl-7-(?-D-phenylglycylamino)-3-cephem-4-carboxylic acid monohydrate,1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid,"(5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side","6-(4-dimethylamino-3-hydroxy- 6-methyl-tetrahydropyran-2-yl) oxy-14-ethyl-12,13-dihydroxy- 4-(5-hydroxy-4-methoxy-4,6- dimethyl-tetrahydropyran-2-yl) oxy-7-methoxy-3,5,7,9,11, 13-hexamethyl-1- oxacyclotetradecane-2,10-dione",(RS)-4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol,"1,3-dimethylxanthine","(RS)-5-[2-(tert-Butylamino)-1-hydroxyethyl]benzene-1,3-diol","1,3-Dimethyl-7H-purine-2,6-dione; ethane-1,2-diamine","(1R,3r,5S,8r)-3-{(2R)-2-hydroxy-2,2-dithiophen-2-ylacetyl}oxy-8-methyl-8-azabicyclo[3.2.1]octane","(1R,2R,4S,5S)-7-[(2-hydroxy-2,2-dithiophen-2-ylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0^2,4]nonane bromide","(R,E)-1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid.",N-[3-[2-methoxy-4-[(1-methyl-1H-indol-3-yl)carbonyl]-1H-benzoimidazol-1-yl]propyl]methylbenzene-1-sulfonamide.,"disodium 5-[2-[(2R,3S)-2-[(2R,3S)-2-(2,4-dihydroxy-3-methoxyphenyl)-5-oxo-2,3-dihydro-1H-pyrrol-3-yl]butyl]-4,5-dihydro-1H-imidazol-1-yl]benzene-1,3-dicarboxylate.""","4-(1-Methyl-4-piperidylidene)-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-10(9H)-one","(11?)-11,17,21-trihydroxypregn-4-ene-3,20-dione","(11?)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione","9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-7-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl acetate","(RS)-11?,16?,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde","(6?,11?,16?)-6,9-difluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione","5,5-diphenyl-2,4-imidazolidinedione","5H-dibenz[b,f]azepine-5-carboxamide",2-propylpentanoic acid,"3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine",(S)-alpha-ethyl-2-oxo-pyrrolidine acetamide,"2,3:4,5-bis-O-(1-methylethylidene)-?-D-fructopyranose sulfamate","10,11-dihydro-10-oxo-5H-diben,azepine-5-carboxamide","7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine","2-phenyl-1,3-propanediol dicarbamate",(RS)-1-[2-(diaminomethyleneamino)ethyl]-1H-pyrazole-4-carboxamide,"(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid","N-{1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazol-4-yl}methanesulfonamide",2-[1-(aminomethyl)cyclohexyl]acetic acid,"1,2-Benzisoxazole-3-methanesulfonamide",(S)-3-(aminomethyl)-5-methylhexanoic acid,"5-ethyl-5-phenyl-2,4,6(1H,3H,5H)- pyrimidinetrione 5","5,5-diphenyl-2,4-imidazolidinedione",(S)-3-(aminomethyl)-5-methylhexanoic acid,"1,2-Benzisoxazole-3-methanesulfonamide",2-[1-(aminomethyl)cyclohexyl]acetic acid,"N-{1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazol-4-yl}methanesulfonamide","(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid",(RS)-1-[2-(diaminomethyleneamino)ethyl]-1H-pyrazole-4-carboxamide,"(RS)-3-Ethyl-3-methyl-pyrrolidine-2,5-dione",2-propylpentanoic acid,"3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine","5H-dibenz[b,f]azepine-5-carboxamide",(S)-alpha-ethyl-2-oxo-pyrrolidine acetamide,"9-chloro-2-methyl-6-phenyl-2,5-diazabicylo(5.4.0)undeca-5,8,10,12-tetraen-3one","2-phenyl-1,3-propanediol dicarbamate",2-chloro-10-[3-(dimethylamino)propyl]phenothiazine,2-methyl-1-phenothiazin-10-ylpropan-2-amine,2-[4-[3-(2-trifluoromethylphenothiazin-10-yl)propyl]piperazin-1-yl]ethanol,"9,10-dihydro-4-[3-(2-methoxyethyl)-2-thioxo-5H-1,4-benzothiazin-5-ylidene]-1-methyl-",4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,"2-Chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine","8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine","3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one","7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one",7-{4-[4-(1-Benzothiophen-4-yl)piperazin-1-yl]butoxy}-1H-quinolin-2-one,"(3aRS,12bRS)-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole","1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]-1,3-dihydro-2H-benzimidazol-2-one","2-chloro-11-(2-dimethylaminoethyl)-10H-dibenzo[b,f]azepine","(R)-3-(2-(4-carbamoyl-2,6-dimethylphenyl)ethyl)-4-(2-ethyl-2H-1,2,4-triazol-3-yl)piperazine-1-carboxamide","2-chloro-N,N,3-trimethylbenzo[b]thiophene-5-methanesulfonamide","(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol","4-[(2-methyl-5-phenyl-1H-imidazol-4-yl)methyl]benzene-1,3-diol.",N-(2-diisopropylaminoethyl)-3-phenylpropanamide,"2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide","N-(2,6-dimethylphenyl)-2-methylpropan-2-amine","N-(2-piperidin-2-yl-ethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide",9-?-D-Ribofuranosyladenine,"(3beta,5beta,12beta)-3-[(O-2,6-Dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-5-beta-card-20(22)-enolide","(RS)-2-(3,4-dimethoxyphenyl)-5-{2-(3,4-dimethoxyphenyl)ethylamino}-2-prop-2-ylpentanenitrile","(2S,3S)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one",(RS)-1-isopropylamino-3-(1-naphthyloxy)propan-2-ol.,(RS)-1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]propan-2-ol.,"(2-butyl-1-benzofuran-3-yl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone.",(±)-N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide.,(RS)-1-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]butan-1-ol.,n/a,Bevacizumab,"2'-deoxy-2',2'-difluorocytidine",cabozantinib,NA,Cabozantinib,Ramucirumab,(E)-4-(3-Chloro-4-(N'-((5-(4-methylpiperazin-1-yl)-2-oxido-4-(trifluoromethyl)phenyl)amino)quinazolin-6-yl)oxy-2-fluorobenzonitrile,Sorafenib tosylate,Entrectinib,Larotrectinib,Durvalumab,Regorafenib,4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide,Pemigatinib,"(2S)-2-[(4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)amino]pentanedioic acid",2-Chloro-N-(2-chloroethyl)-N-methylethanamine,"1,1?,1??-Phosphoro thioyltriaziridine","N2,N2,N4,N4,N6,N6-Hexamethyl-1,3,5-triazine-2,4,6-triamine","Butane-1,4-diyl dimethanesulfonate",4-[bis(2-Chloroethyl)amino]-L-phenylalanine, 4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea," (RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide","IUPAC name 5-(2,4-diguanidino- 3,5,6-trihydroxy-cyclohexoxy)- 4-[4,5-dihydroxy-6-(hydroxymethyl) -3-methylamino-tetrahydropyran-2-yl] oxy-3-hydroxy-2-methyl -tetrahydrofuran-3-carbaldehyde","4'-Demethyl-4-deoxy-4-(methylamino)epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside]",4-[bis(2-chlorethyl)amino]benzenebutanoic acid, N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide,"9-(2-deoxy-?-D- erythro- pentofuranosyl)-6-
fluoro-9H-purin-2- amine","5-(3,3- dimethyl-1- triazeno) imidazole-4- carboxamide","6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole","2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole",(Z)-N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine,"N-(2-[(5-[(Dimethylamino)methyl]furan-2-yl)methylthio]ethyl)-N'-methyl-2-nitroethene-1,1-diamine","2-[2-(4-methylpiperazin-1-yl)acetyl]-2,4,9-triazatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one",N-isopropyl-N-methyl-N-{2-[(9H-xanthen-9-ylcarbonyl)oxy]ethyl}propan-2-aminium bromide,"7-[(1R,2R,3R)-3-hydroxy-2-(4-hydroxy-4-methyloct-1-enyl)-5-",1-[2-(ethanesulfonyl)ethyl]-2-methyl-5-nitro-1H-imidazole,"trisodium 2-hydroxypropane-1,2,3-tricarboxylate",sodium hydrogen carbonate,"Hexadeca-?-hydroxytetracosahydroxy[?8-[1,3,4,6-tetra-O-sulfo-?-Dfructofuranosyl-?-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum",pentaaluminium(3+) decamagnesium(2+) hydrate hentriacontahydroxide disulfate,"2S,5R,6R)-6-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid","3R,4S,5S,6R,7R,9R,11S,12R,13S,14R)-6-{[(2S,3R,4S,6R) -4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy} -14-ethyl-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy -4-methoxy-4,6-dimethyloxan-2-yl]oxy}-7 -methoxy-3,5,7,9,11,13-hexamethyl -1-oxacyclotetradecane-2,10-dione",2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethan-1-ol," (2?,4?,5?,7?,10?,13?)-4,10-Bis(acetyloxy)-13-{[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate",(SP-4-2)-diamminedichloridoplatinum(II)," 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile","1,7?,10?-trihydroxy-9-oxo-5?,20-epoxytax-11-ene-2?,4,13?-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}",methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,"(2S)-2-[(4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)amino]pentanedioic acid","3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine","Methyl (2?,3?,4?,5?,12?,19?)-4-acetoxy-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate","(5Z)-7-fluoro-3-[(2,2-difluorophenyl)methoxy]-4-[(6-methoxy-2-methylpyrimidin-4-yl)amino]-1H-quinolin-2-one.","N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)
quinazolin-4-amine","4-Amino-1-(2-deoxy-2,2-difluoro-?-D-erythro-pentofuranosyl)pyrimidin-2(1H)-on",N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide,"7-Chloro-1,3-dihydro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one","7-Chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one",(±)-2-(2-{4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl}ethoxy)ethanol,(RS)-1-(1-methylethylamino)-3-(1-naphthyloxy)propan-2-ol,"8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione","4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione"," 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one"," N-(2,6-Dichlorophenyl)-4,5--1H-imidazol-2-amine"," 8-chloro-1-methyl-6-phenyl-4H-triazolo[4,3-a][1,4]benzodiazepine ","5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione","5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione.","7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxide"," 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione"," sodium 5-ethyl-5-pentan-2-yl-2-sulfanylidene-1,3-diazinane-4,6-dione"," (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine",NN-dimethyl-2-[5-(pyrolidin-1-ylsulfonylmethyl)-1H-indole-3-yl]-ethanamine,3{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(benzenrsulfonyl)ethyl]1H-indole,N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide,"4-({3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one",1-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide,"N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine","3-Methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole","5-Benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,7,8,9-hexahydroindoloquinoline-9-carboxamide","4- oxo- 4- { [ (3 R,5a S,6 R,8a S,9 R,10 S,12 R,12a R)- 3,6,9- trimethyldecahydro- 3,12- epoxypyrano [4,3- j ] [1,2]benzodioxepin- 10- yl]oxy}butanoic acid",1-(1-methylethylamino)-3-(1-naphthyloxy)propan-2-ol,"4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine","2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamide",2-(6-Methoxynaphthalen-2-yl)propanoic acid,"N-[(1,2,4,7)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclododecan-4-yl]-6-methyl-6,11-diazatetracyclohexadeca-1(16),9,12,14-tetraene-4-carboxamide","1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione","RS)-N,N-Dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine",[2-[4-[(4-chlorophenyl)phenylmethyl)]1-piperazinyl]ethoxy]acetic acid,"ethyl 4-{13-chloro-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene}piperidine-1-carboxylate",methyl 2-(4-{1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoate,2-(Diphenylmethoxy)-N-methylethylamine,"8-chloro-6,11-dihydro-11-(4-piperdinylidene)- 5H-benzo[5,6]cyclohepta[1,2-b]pyridine",2-(2-{4-[R)-(4-chlorophenyl)(phenyl) methyl]piperazin -1-yl}ethoxy)acetic acid,4-[(4-(chlorophenyl)methyl]-2-(1-methylazepan-4yl-)-phthalazin-1-one,"3-(4-bromphenyl)-N,N-dimethyl -1-3-pyridin-2-ylpropan-1-amine",(2R)-2-{2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine,2-2(2-{4-[(4-chlorophenyl)(phenyl methyl]piperazin-1-yl}ethoxy)ethanol,1-[(4-chlorophenyl)(phenyl)methyl]-4-(3-methylbenzyl)piperizine,"4-(5H-dibeno[a,b]cycloheptaen-5-ylidene)-1-methylpiperidine",4-(4-benzhydryloxy-1-piperidyl)-1-(4-tert-butylphenyl)butan-1-one,"RS)-N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethan-1-amine","1-((2R,4R)- 2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4yl)-3-(4-cyanophenyl)urea maleate","4-(4-{[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl}-1-piperazinyl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide","(9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j]benzodiamzonine-1-one",4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide,4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide,"(8S,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione","1,4-butanediol dimethanesulfonate","N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide","(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one","4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one","4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2(1H)-one","2-Amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6H-purin-6-one",Immunoglobulin G1 (human-mouse monoclonal IDEC-C2B8 gamma 1-chain anti-human antigen DC 20),"(8S,10S)-8-acetyl-10-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride",4-[Bis(2-chloroethyl)amino]benzenebutanoic acid,"(2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one ","(2S)-2-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid.","(5aR)-5-[(2R)-2-[(2R)-1,3-dihydroxy-2-(3,4,5-trimethylbenzyl)propyl]-2-hydroxyethyl]-4-methyl-2,5-dihydrofuran-3-one.",pyridine-3-carboxylic acid,"7,8-dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)benzo[g]pteridine-2,4(3H,10H)-dione",3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride,"IUPAC name - 2-hydroxy-N,N,N-trimethylethanaminium","(3?,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol","5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoic acid","3-[(2,4-dihydroxy-3,3-dimethylbutanoyl)amino]propanoic acid","(3R,3'R,6'R)-beta,epsilon-Carotene-3,3'-diol","(3S,3'S)-astaxanthin","5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol","2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecen-1-yl]naphthalene-1,4-dione","(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-ol",IUPAC name,1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole,"1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole","2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol","1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-[(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one","(3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol","4-{4-[4-(4-{[(3R,5R)-5-(2,4-difluorophenyl)-5-[(1H-1,2,4-triazol-1-yl)methyl]oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one","(2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H,4'H-spiro[1-benzofuran-2,1'-cyclohex[2]ene]-3,4'-dione",[(4-tert-butylphenyl)methyl](methyl)[(naphthalen-1-yl)methyl]amine,"(2-{[(3S,4E,6S,7E,9S,11R,15S,16E,18S,20R,21R,22E,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-5,8,11,17,20,23,25-heptahydroxy-18-[(Z)-[hydroxy({4-[4'-(pentyloxy)-[1,1'-biphenyl]-4-yl]phenyl})methylidene]amino]-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,14-dioxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosa-4,7,16,22-tetraen-21-yl]oxy}ethyl)trimethylazanium","(10R,12S)-N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-3-[(1R)-3-amino-1-hydroxypropyl]-21-[(2-aminoethyl)amino]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-18-yl]-10,12-dimethyltetradecanamide","[(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)[(naphthalen-1-yl)methyl]amine",[(4-tert-butylphenyl)methyl](methyl)[(naphthalen-1-yl)methyl]amine,methyl[(naphthalen-1-yl)methyl](3-phenylprop-2-en-1-yl)amine,"4-amino-5-fluoro-1,2-dihydropyrimidin-2-one","(2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H-spiro[1-benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione","2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol","1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-[(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one","3-[(1R)-3-amino-1-hydroxypropyl]-21-[(2-aminoethyl)amino]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-18-yl]-10,12-dimethyltetradecanamide",1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole,"1-{2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole","1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole","(Z)-[1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethylidene][(2,4-dichlorophenyl)methoxy]amine","1-[4-(4-{[2-(2,4-dichlorophenyl)-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one","(3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol","[(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)[(naphthalen-1-yl)methyl]amine",N-methyl-N-(3-methylphenyl)-1-(naphthalen-2-yloxy)methanethioamide,[(4-tert-butylphenyl)methyl](methyl)[(naphthalen-1-yl)methyl]amine,Benzenecarboxylic acid,"4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid","4-{4-[4-(4-{[(3R,5R)-5-(2,4-difluorophenyl)-5-[(1H-1,2,4-triazol-1-yl)methyl]oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one","3-Ethyl-4-methyl-N-[2-(4-{[(trans-4 methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide",1-cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl]sulfonyl]urea,1-(3-azabicyclo[3.3.0]oct-3-yl)-3-(p-tolylsulfonyl)urea,N-[(butylamino)carbonyl]-4-methylbenzenesulfonamide,1-(p-chlorophenylsulfonyl)-3-propylurea,N-(hexahydro-1H-azepin-1-ylcarbonyl)-4-methylbenzenesulfonamide,N-[cyclohexylcarbamoyl)-4-methylphenyl]acetamide,N-[5-(2-Methoxyethoxy)-2-pyrimidinyl]benzenesulfonamide ,N-[(4-chlorophenyl)sulfonyl]glycine,"6-[[4-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]phenyl]sulfonyl]-2,3-dihydro-1,4-thiazine",N-{4-[(6-methoxy-3-pyridinyl)carbonyl]phenyl}sulfonyl-N'-butylurea,1-phenyl-3-{3-(trifluoromethyl)phenyl}urea,N-[cyclohexylcarbamoyl)-4-methylphenyl]acetamide,1-(4-methoxyphenylsulfonyl)-3-(2-methyl-2-propenyl)urea,N-(2-{[4-(cyclohexylcarbamoylsulfamoyl)phenyl]methyl}ethyl)-5-methylpyrazine-2-carboxamide,"5-methoxy-2-[(4-methoxy-3,
5-dimethylpyridin-2-yl)
methylsulfinyl]-1H
-benzimidazole",(2E)-2- [(4-chlorophenyl)amino]-3-(2-morpholin-4-ylethyl)prop-2-enoic acid,"S)-5-methoxy-2-
[(4-methoxy-3,5-dimethylpyridin-
2-yl)methylsulfinyl]-1H-benzimidazole","(RS)-6-(Difluoromethoxy)-2
-[(3,4-dimethoxypyridin-2
-yl)methylsulfinyl]-1H-
benzo[d]imidazole","(2S,5R,6R)-6-[(2R)-2-Amino-2-
(4-hydroxyphenyl)acetamido]
-3,3-dimethyl-7-oxo-4-thia-1
-azabicyclo[3.2.0]heptane-2-
carboxylic acid",2-[[[4-(3-methoxypropoxy) -3-methyl -2-pyridinyl]methyl]sulfinyl] -1H-benzimidazole,1-(2-Ethylsulfonylethyl) -2-methyl-5-nitro- 1H-imidazole,"2-[[[3-methyl -4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulfinyl]- 1H-benzimidazole","(4S,4aS,5aR,12aS)-4- (dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1, 11-dioxo-2-naphthacenecarboxamide",2-({[4- (3-methoxypropoxy)-3-methylpyridin -2-yl]methyl}sulfinyl)- 1H-benzimidazole,Sodium hydrogen carbonate,"Methyl (1R,2R,3R)-3-hydroxy-2-[(E)-(4RS)-4-hydroxy -4-methyloct-1-enyl]-5-oxocyclopentaneacetate",N-cyano-N’-methyl-N” -[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine,"2-hydroxypropane-1,2,3-tricarboxylate","N-(2-((5-((dimethylamino)methyl)-2-furanyl)methylthio)ethyl)-N'-methyl-2-nitroethene-1,1-diamine.","""Calcium Carbonate""","1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)
methylsulfanyl]ethyl]guanidine",sodium hydrogencarbonate,Aluminium hydroxide,Milk of magnesia ,"2-Hydroxy-2H, 4H-benzo[d]1,3-dioxa-
2-bismacyclohexan-4-one","5-Methoxy-2-[(4-methoxy-3,5-dimethyl
pyridin-2-yl)methanesulfinyl]-1H-
benzimidazol","(RS)-6-(Difluoromethoxy)-2-[(3,4-dimethoxy
pyridin-2-yl)methylsulfinyl]-1H-benzo[d]imidazole","N-(2-[(5-[(Dimethylamino)methyl]furan-2-yl)
methylthio]ethyl)-N'-methyl-2-nitroethene-1,1-diamine","(RS)-2-([4-(3-Methoxypropoxy)-3-methylpyridin
-2-yl]methylsulfinyl)-1H-benzo[d]imidazole","2-hydroxypropane-1,2,3-tricarboxylic acid","(S)-(?)-5-Methoxy-2-[(4-methoxy-3,5-dimethylpyridin
-2-yl)methylsulfinyl]-3H-benzoimidazole","Trisodium citrate or Trisodium 2-hydroxypropane-1,2,3
-tricarboxylate",magnesium; carbonate,Dimagnesium dioxido-bis[(oxido-oxosilyl)oxy]silane,6-hydroxy-2-(4-hydroxyphenyl)-benzothiophen-3-yl]-[4-[2-(1-piperidyl)ethoxy]phenyl]-methanone,"Z)-2-[4-(1,2-Diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate",disodium;[3-amino-1-hydroxy-1-[hydroxy(oxido)phosphoryl]propyl]-hydroxyphosphinate,"4,4'-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile",Trastuzumab Hyaluronidase-oysk,"7-Cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide",4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one,"2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine","N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine","4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide","7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol",NA,"6,10-dihydroxy-1,5,7, 9,9-pentamethyl-14-[(E)-1-(2-methyl-1,3-thiazol- 4-yl)prop-1-en-2-yl]-17-oxa-13-azabicyclo[14.1.0] heptadecane-8,12-dione",NA,(2E)-N-[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide,"1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide","Isopropyl (2S)-2-[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl]methoxyphosphoryl]amino]propanoate","(2R,4S)-1-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-amine","(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide","(1S,2R)-1-[[(2S,3S)-3-hydroxy-2-[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethylbutanoyl]amino]-4-(1H-indol-3-yl)butanoyl]amino]-2-ethylpentyl carbamate","(2S)-2-[[[(1R,3R,8S)-3,8-Dihydroxy-2-6-dioxo-3,6-dihydropyrimidin-1-yl]methyl]phenoxy-phosphoryl]amino]propanoic acid",6-fluoro-3-hydroxy-2-pyrazinecarboxamide,2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate,IUPAC name,"1,3- bis(2-chloroethyl)-1-nitrosourea",NA,1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.,NA,"Dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0 hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone",NA,"(2R,3S)-N-methyl-3-(1-methylethyl)-4-[(2-methylhydrazino)methyl]-2-pyridinecarboxamide.","""bevacizumab.""","(2R,3S)-3-[(1H-pyrrolo[2,3-b]pyridin-3-yl)amino]-2-hydroxy-3-(4-methoxyphenyl)propanoic acid.","1,3-bis(2-chloroethyl)-1-nitrosourea.","""2-[bis(2-chloroethyl)amino]ethyl 3-(2-chloroethyl)-2-oxo-1-oxa-3-azaphosphoridine-3-oxide.""",cis-diamminedichloroplatinum(II).,"""1,3-bis(2-chloroethyl)-1-nitrosourea.""","1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.""","N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid.",IUPAC name,"(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol","(2R,3S)-3-[(2S,3S)-2-{2-[(1S,2S)-1-(2,4-Difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-2-hydroxyethyl]-1,3-thiazol-4-ylmethyl}-3-hydroxybutan-2-yl]-2,5-dihydrofuran.","dioxahexacyclo[22.9.2.13,6.15,8.110,14.019,23.025,28]nonacosa-3,5,7,9,15,19,25,27-octaen-24-yl]butane-1,2-diol.","(±)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine","(2R,4S)-rel-1-[rel-?-(2,4-Dichlorophenyl)ethyl]-?-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-4-ethanol","(2R,4S)-1-{(4R,6S)-6-[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}-1,4-dimethyl-4-propylpiperazine.","(E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine","(4R,5S,6S,7R,8S,9R,11E,16R,18E,20R,21S,23S,25S,26R,27S,28E)-22-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0^{4,9}]octacos-18-ene-24-carboxylic acid.","1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole","1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole",1-[(2-chlorophenyl)(diphenyl)methyl]-1H-imidazole,"1-[4-(4-Chlorophenyl)-2-(2,6-dichlorophenyl)tetrahydro-2H-pyran-4-yl]-1H-imidazole","(1R,2S)-1-[(4R,5S)-5-[(2-aminoethyl)amino]-4-hydroxy-N^2^-(10H-phenothiazin-10-yl)-8-methyl-6-oxo-7,9-diazaspiro[4.5]dec-7-yl]-3-[2-(3,5-dimethyl-1H-pyrrol-2-yl)ethyl]-2-methyl-4,6-dioxo-1,4-diazacyclohexane-2-carboxamide.","(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-?-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid",NN-dimethyl-2-[5-(pyrolidin-1-ylsulfonylmethyl)-1H-indole-3-yl]-ethanamine,3{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(benzenrsulfonyl)ethyl]1H-indole,N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide,"4-({3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one",1-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide,"N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine","3-Methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole","5-Benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,7,8,9-hexahydroindoloquinoline-9-carboxamide","4- oxo- 4- { [ (3 R,5a S,6 R,8a S,9 R,10 S,12 R,12a R)- 3,6,9- trimethyldecahydro- 3,12- epoxypyrano [4,3- j ] [1,2]benzodioxepin- 10- yl]oxy}butanoic acid",1-(1-methylethylamino)-3-(1-naphthyloxy)propan-2-ol,"4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine","2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamide",2-(6-Methoxynaphthalen-2-yl)propanoic acid,"N-[(1,2,4,7)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclododecan-4-yl]-6-methyl-6,11-diazatetracyclohexadeca-1(16),9,12,14-tetraene-4-carboxamide","1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione","RS)-N,N-Dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine",[2-[4-[(4-chlorophenyl)phenylmethyl)]1-piperazinyl]ethoxy]acetic acid,"ethyl 4-{13-chloro-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene}piperidine-1-carboxylate",methyl 2-(4-{1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoate,2-(Diphenylmethoxy)-N-methylethylamine,"8-chloro-6,11-dihydro-11-(4-piperdinylidene)- 5H-benzo[5,6]cyclohepta[1,2-b]pyridine",2-(2-{4-[R)-(4-chlorophenyl)(phenyl) methyl]piperazin -1-yl}ethoxy)acetic acid,4-[(4-(chlorophenyl)methyl]-2-(1-methylazepan-4yl-)-phthalazin-1-one,"3-(4-bromphenyl)-N,N-dimethyl -1-3-pyridin-2-ylpropan-1-amine",(2R)-2-{2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine,2-2(2-{4-[(4-chlorophenyl)(phenyl methyl]piperazin-1-yl}ethoxy)ethanol,1-[(4-chlorophenyl)(phenyl)methyl]-4-(3-methylbenzyl)piperizine,"4-(5H-dibeno[a,b]cycloheptaen-5-ylidene)-1-methylpiperidine",4-(4-benzhydryloxy-1-piperidyl)-1-(4-tert-butylphenyl)butan-1-one,"RS)-N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethan-1-amine","1-((2R,4R)- 2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4yl)-3-(4-cyanophenyl)urea maleate","4-(4-{[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl}-1-piperazinyl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide","(9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j]benzodiamzonine-1-one",4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide,4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide,"(8S,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione","1,4-butanediol dimethanesulfonate","N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide","(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one","4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one","4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2(1H)-one","2-Amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6H-purin-6-one",Immunoglobulin G1 (human-mouse monoclonal IDEC-C2B8 gamma 1-chain anti-human antigen DC 20),"(8S,10S)-8-acetyl-10-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride",4-[Bis(2-chloroethyl)amino]benzenebutanoic acid,NA,IUPAC name,"(2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one ","(2S)-2-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid.","(5aR)-5-[(2R)-2-[(2R)-1,3-dihydroxy-2-(3,4,5-trimethylbenzyl)propyl]-2-hydroxyethyl]-4-methyl-2,5-dihydrofuran-3-one.",pyridine-3-carboxylic acid,"7,8-dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)benzo[g]pteridine-2,4(3H,10H)-dione",3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride,"IUPAC name - 2-hydroxy-N,N,N-trimethylethanaminium","(3?,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol","5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoic acid","3-[(2,4-dihydroxy-3,3-dimethylbutanoyl)amino]propanoic acid","(3R,3'R,6'R)-beta,epsilon-Carotene-3,3'-diol","(3S,3'S)-astaxanthin","5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol","2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecen-1-yl]naphthalene-1,4-dione","(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-ol",NA,NA,NA,NA,NA,1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole,"1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole","2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol","1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-[(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one","(3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol","4-{4-[4-(4-{[(3R,5R)-5-(2,4-difluorophenyl)-5-[(1H-1,2,4-triazol-1-yl)methyl]oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one","(2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H,4'H-spiro[1-benzofuran-2,1'-cyclohex[2]ene]-3,4'-dione",[(4-tert-butylphenyl)methyl](methyl)[(naphthalen-1-yl)methyl]amine,"(2-{[(3S,4E,6S,7E,9S,11R,15S,16E,18S,20R,21R,22E,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-5,8,11,17,20,23,25-heptahydroxy-18-[(Z)-[hydroxy({4-[4'-(pentyloxy)-[1,1'-biphenyl]-4-yl]phenyl})methylidene]amino]-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,14-dioxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosa-4,7,16,22-tetraen-21-yl]oxy}ethyl)trimethylazanium","(10R,12S)-N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-3-[(1R)-3-amino-1-hydroxypropyl]-21-[(2-aminoethyl)amino]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-18-yl]-10,12-dimethyltetradecanamide","[(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)[(naphthalen-1-yl)methyl]amine",[(4-tert-butylphenyl)methyl](methyl)[(naphthalen-1-yl)methyl]amine,methyl[(naphthalen-1-yl)methyl](3-phenylprop-2-en-1-yl)amine,"4-amino-5-fluoro-1,2-dihydropyrimidin-2-one","(2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H-spiro[1-benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione",NA,IUPAC name,"2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol","1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-[(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one","3-[(1R)-3-amino-1-hydroxypropyl]-21-[(2-aminoethyl)amino]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-18-yl]-10,12-dimethyltetradecanamide",1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole,"1-{2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole","1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole","(Z)-[1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethylidene][(2,4-dichlorophenyl)methoxy]amine","1-[4-(4-{[2-(2,4-dichlorophenyl)-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one","(3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol","[(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)[(naphthalen-1-yl)methyl]amine",N-methyl-N-(3-methylphenyl)-1-(naphthalen-2-yloxy)methanethioamide,[(4-tert-butylphenyl)methyl](methyl)[(naphthalen-1-yl)methyl]amine,Benzenecarboxylic acid,"4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid","4-{4-[4-(4-{[(3R,5R)-5-(2,4-difluorophenyl)-5-[(1H-1,2,4-triazol-1-yl)methyl]oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one",IUPAC name,"3-Ethyl-4-methyl-N-[2-(4-{[(trans-4 methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide",1-cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl]sulfonyl]urea,1-(3-azabicyclo[3.3.0]oct-3-yl)-3-(p-tolylsulfonyl)urea,N-[(butylamino)carbonyl]-4-methylbenzenesulfonamide,1-(p-chlorophenylsulfonyl)-3-propylurea,N-(hexahydro-1H-azepin-1-ylcarbonyl)-4-methylbenzenesulfonamide,N-[cyclohexylcarbamoyl)-4-methylphenyl]acetamide,N-[5-(2-Methoxyethoxy)-2-pyrimidinyl]benzenesulfonamide ,N-[(4-chlorophenyl)sulfonyl]glycine,"6-[[4-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]phenyl]sulfonyl]-2,3-dihydro-1,4-thiazine",N-{4-[(6-methoxy-3-pyridinyl)carbonyl]phenyl}sulfonyl-N'-butylurea,1-phenyl-3-{3-(trifluoromethyl)phenyl}urea,N-[cyclohexylcarbamoyl)-4-methylphenyl]acetamide,1-(4-methoxyphenylsulfonyl)-3-(2-methyl-2-propenyl)urea,N-(2-{[4-(cyclohexylcarbamoylsulfamoyl)phenyl]methyl}ethyl)-5-methylpyrazine-2-carboxamide,IUPAC name,"5-methoxy-2-[(4-methoxy-3,
5-dimethylpyridin-2-yl)
methylsulfinyl]-1H
-benzimidazole",(2E)-2- [(4-chlorophenyl)amino]-3-(2-morpholin-4-ylethyl)prop-2-enoic acid,"S)-5-methoxy-2-
[(4-methoxy-3,5-dimethylpyridin-
2-yl)methylsulfinyl]-1H-benzimidazole","(RS)-6-(Difluoromethoxy)-2
-[(3,4-dimethoxypyridin-2
-yl)methylsulfinyl]-1H-
benzo[d]imidazole","(2S,5R,6R)-6-[(2R)-2-Amino-2-
(4-hydroxyphenyl)acetamido]
-3,3-dimethyl-7-oxo-4-thia-1
-azabicyclo[3.2.0]heptane-2-
carboxylic acid",2-[[[4-(3-methoxypropoxy) -3-methyl -2-pyridinyl]methyl]sulfinyl] -1H-benzimidazole,1-(2-Ethylsulfonylethyl) -2-methyl-5-nitro- 1H-imidazole,"2-[[[3-methyl -4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulfinyl]- 1H-benzimidazole","(4S,4aS,5aR,12aS)-4- (dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1, 11-dioxo-2-naphthacenecarboxamide",2-({[4- (3-methoxypropoxy)-3-methylpyridin -2-yl]methyl}sulfinyl)- 1H-benzimidazole,Sodium hydrogen carbonate,"Methyl (1R,2R,3R)-3-hydroxy-2-[(E)-(4RS)-4-hydroxy -4-methyloct-1-enyl]-5-oxocyclopentaneacetate",N-cyano-N’-methyl-N” -[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine,"2-hydroxypropane-1,2,3-tricarboxylate","N-(2-((5-((dimethylamino)methyl)-2-furanyl)methylthio)ethyl)-N'-methyl-2-nitroethene-1,1-diamine.",IUPAC name,"""Calcium Carbonate""","1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)
methylsulfanyl]ethyl]guanidine",sodium hydrogencarbonate,Aluminium hydroxide,Milk of magnesia ,"2-Hydroxy-2H, 4H-benzo[d]1,3-dioxa-
2-bismacyclohexan-4-one","5-Methoxy-2-[(4-methoxy-3,5-dimethyl
pyridin-2-yl)methanesulfinyl]-1H-
benzimidazol","(RS)-6-(Difluoromethoxy)-2-[(3,4-dimethoxy
pyridin-2-yl)methylsulfinyl]-1H-benzo[d]imidazole","N-(2-[(5-[(Dimethylamino)methyl]furan-2-yl)
methylthio]ethyl)-N'-methyl-2-nitroethene-1,1-diamine","(RS)-2-([4-(3-Methoxypropoxy)-3-methylpyridin
-2-yl]methylsulfinyl)-1H-benzo[d]imidazole","2-hydroxypropane-1,2,3-tricarboxylic acid","(S)-(?)-5-Methoxy-2-[(4-methoxy-3,5-dimethylpyridin
-2-yl)methylsulfinyl]-3H-benzoimidazole","Trisodium citrate or Trisodium 2-hydroxypropane-1,2,3
-tricarboxylate",magnesium; carbonate,Dimagnesium dioxido-bis[(oxido-oxosilyl)oxy]silane,IUPAC name,6-hydroxy-2-(4-hydroxyphenyl)-benzothiophen-3-yl]-[4-[2-(1-piperidyl)ethoxy]phenyl]-methanone,"Z)-2-[4-(1,2-Diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate",disodium;[3-amino-1-hydroxy-1-[hydroxy(oxido)phosphoryl]propyl]-hydroxyphosphinate,"4,4'-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile",Trastuzumab Hyaluronidase-oysk,"7-Cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide",4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one,"2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine","N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine","4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide","7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol",NA,"6,10-dihydroxy-1,5,7, 9,9-pentamethyl-14-[(E)-1-(2-methyl-1,3-thiazol- 4-yl)prop-1-en-2-yl]-17-oxa-13-azabicyclo[14.1.0] heptadecane-8,12-dione",NA,(2E)-N-[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide,"1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide","Isopropyl (2S)-2-[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl]methoxyphosphoryl]amino]propanoate","(2R,4S)-1-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-amine","(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide","(1S,2R)-1-[[(2S,3S)-3-hydroxy-2-[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethylbutanoyl]amino]-4-(1H-indol-3-yl)butanoyl]amino]-2-ethylpentyl carbamate","(2S)-2-[[[(1R,3R,8S)-3,8-Dihydroxy-2-6-dioxo-3,6-dihydropyrimidin-1-yl]methyl]phenoxy-phosphoryl]amino]propanoic acid",6-fluoro-3-hydroxy-2-pyrazinecarboxamide,2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate,IUPAC name,"1,3- bis(2-chloroethyl)-1-nitrosourea",NA,1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.,NA,"Dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0 hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone",NA,"(2R,3S)-N-methyl-3-(1-methylethyl)-4-[(2-methylhydrazino)methyl]-2-pyridinecarboxamide.","""bevacizumab.""","(2R,3S)-3-[(1H-pyrrolo[2,3-b]pyridin-3-yl)amino]-2-hydroxy-3-(4-methoxyphenyl)propanoic acid.","1,3-bis(2-chloroethyl)-1-nitrosourea.","""2-[bis(2-chloroethyl)amino]ethyl 3-(2-chloroethyl)-2-oxo-1-oxa-3-azaphosphoridine-3-oxide.""",cis-diamminedichloroplatinum(II).,"""1,3-bis(2-chloroethyl)-1-nitrosourea.""","1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.""","N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid.","(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol","(2R,3S)-3-[(2S,3S)-2-{2-[(1S,2S)-1-(2,4-Difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-2-hydroxyethyl]-1,3-thiazol-4-ylmethyl}-3-hydroxybutan-2-yl]-2,5-dihydrofuran.","dioxahexacyclo[22.9.2.13,6.15,8.110,14.019,23.025,28]nonacosa-3,5,7,9,15,19,25,27-octaen-24-yl]butane-1,2-diol.","(±)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine","(2R,4S)-rel-1-[rel-?-(2,4-Dichlorophenyl)ethyl]-?-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-4-ethanol","(2R,4S)-1-{(4R,6S)-6-[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}-1,4-dimethyl-4-propylpiperazine.","(E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine","(4R,5S,6S,7R,8S,9R,11E,16R,18E,20R,21S,23S,25S,26R,27S,28E)-22-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0^{4,9}]octacos-18-ene-24-carboxylic acid.","1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole","1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole",1-[(2-chlorophenyl)(diphenyl)methyl]-1H-imidazole,"1-[4-(4-Chlorophenyl)-2-(2,6-dichlorophenyl)tetrahydro-2H-pyran-4-yl]-1H-imidazole","(1R,2S)-1-[(4R,5S)-5-[(2-aminoethyl)amino]-4-hydroxy-N^2^-(10H-phenothiazin-10-yl)-8-methyl-6-oxo-7,9-diazaspiro[4.5]dec-7-yl]-3-[2-(3,5-dimethyl-1H-pyrrol-2-yl)ethyl]-2-methyl-4,6-dioxo-1,4-diazacyclohexane-2-carboxamide.","(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-?-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid","7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin 2-one",(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide," 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepine-2-one","5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione","(RS)-3-Ethyl-3-methyl-pyrrolidine-2,5-dione",N2-acetyl-N-benzyl-D-homoserinamide,"5,5-diphenylimidazolidine-2,4-dione","7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one","5-Ethyl-5-phenyl-1,3-diazinane-4,6-dione"," 2,3:4,5-Bis-O-(1-methylethylidene)-?-D-fructopyranose sulfamate","1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide"," N-(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide","(R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl] nipecotic acid hydrochloride","5H-dibenzo[b,f]azepine-5-carboxamide", 2-propylpentanoic acid,NA,"5H-dibenzo[b,f]azepine-5-caroxamide",2-propylpentanoic acid,"2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine","6-(2,3dichlorophenyl)-1,2,4-triazine-3,5-diamine","7-{4-[4-92,3-dichloophenyl)piperazin-1-yl]utoxy}-3,4-dihydroquinolin-2(1H)-one","(3aRS,12bRS)-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dienz[2,3:6,7]oxepino[4,5-c]pyrrole","3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea","5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one","2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol;(E)-but-2-enedioic acid","(3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione","3-[2-[4-(6-fluoro-1,2- benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2- a]pyrimidin-4-one.",Ethyl N-[2-[[(hexahydro-2-oxo-1H-azepin-1-yl)amino]carbonyl]phenyl]carbamate,"(1S,2R,4S)-5-chloro-N-((2S)-1-((2-oxo-1,4-dihydropyridin-3-yl)amino)-1-oxo-2-propanyl)-2-((5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino) cyclohexane-1-carboxamide",2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol,"4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
",(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid,[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone,(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid,[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid,(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid,1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol,[dichloro(phosphono)methyl]phosphonic acid,(1-hydroxy-1-phosphonoethyl)phosphonic acid,(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid,distrontium;5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyanothiophene-2-carboxylate,DL-seryl-DL-valyl-DL-seryl-DL-alpha-glutamyl-DL-isoleucyl-DL-glutaminyl-DL-leucyl-DL-methionyl-DL-histidyl-DL-asparagyl-DL-leucyl-glycyl-DL-lysyl-DL-histidyl-DL-leucyl-DL-asparagyl-DL-seryl-DL-methionyl-DL-alpha-glutamyl-DL-arginyl-DL-valyl-DL-alpha-glutamyl-DL-tryptophyl-DL-leucyl-DL-arginyl-DL-lysyl-DL-lysyl-DL-leucyl-DL-glutaminyl-DL-alpha-aspartyl-DL-valyl-DL-histidyl-DL-asparagyl-DL-phenylalanine,L-alanyl-L-valyl-L-seryl-L-alpha-glutamyl-L-histidyl-L-glutaminyl-L-leucyl-L-leucyl-L-histidyl-L-alpha-aspartyl-L-lysyl-glycyl-L-lysyl-L-seryl-L-isoleucyl-L-glutaminyl-L-alpha-aspartyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-lysyl-L-leucyl-L-leucyl-alpha-methyl-alanyl-L-lysyl-L-leucyl-L-histidyl-L-threonyl-L-alaninamide,L-cysteinyl-L-seryl-L-asparagyl-L-leucyl-L-seryl-L-threonyl-L-cysteinyl-L-valyl-L-leucyl-glycyl-L-lysyl-L-leucyl-L-seryl-L-glutaminyl-L-alpha-glutamyl-L-leucyl-L-histidyl-L-lysyl-L-leucyl-L-glutaminyl-L-threonyl-L-tyrosyl-L-prolyl-L-arginyl-L-threonyl-L-asparagyl-L-threonyl-glycyl-L-seryl-glycyl-L-threonyl-L-prolinamide (1->7)-disulfide,NA,NA,"2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile","3-[(3R,4R)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile","(3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide","(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid   / 4-Amino-10-methyl folic acid","5-methyl-N-[4-(trifluoromethyl) phenyl]-1,2-oxazole-4-carboxamide",2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid,6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine,"(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-{[E,4R]-4-methylhex-2-en-1-yl}-2-cyclohexene-1-one",4-[(7-chloroquinolin-4-yl)amino]-2-(diethylamino)pentan-2-ol,2-[(4-[(7-Chloroquinolin-4-yl)amino]pentyl)ethylamino]ethanol,N/A (Not applicable as it's a biologic),"(11?)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione",See below in last,See below in last,"4,7-bis(3-hydroxypropyl)-8-(2-methyl-4-(4-methylbenzoyl)benzoyl)-1,2,3,4,5,6,7,8-octahydroquinazoline-3-carboxylic acid",NA,"1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine","5-Fluoro-1H,3H-pyrimidine-2,4-dione", 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide. ,"N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide",NA,"des alanyl-1, serine-125 human interleukin-2.",5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide, Methyl [(2S)-1-{[4-(3-{5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate.,"S)-[3,4-Difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl] methanone","N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide"," 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide","(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl- 1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid","N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b] ...",NA,NA,"(2S,5R,6R)-6-([(2R)-2-amino-2-phenylacetyl]amino) -3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2- carboxylic acid","(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",(7R)-3-methyl-7-(?-D-phenylglycylamino)-3-cephem-4-carboxylic acid monohydrate,"(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)->2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)thio]methyl}"," (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid"," (4R,5S,6S)-3-(((3S,5S)-5-(Dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid","(3S,6R,7R,22R,23S,26S,36R,38aR)-44-[[2-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-?-L-lyxo-hexopyranosyl)-ß ","(4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-9 ... omadacycline."," (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1 ","(1S,2R,3S,4S,6R,7R,8R,14R)-3-Hydroxy-2,4,7,14-tetramethyl-9-oxo-4-vinyltricyclo[5.4.3.0~1,8~]tetradec-6-yl {[2-(diethylamino)ethyl]sulfanyl} …"," 1-Cyclopropyl-7-[(1S,6S)-2,8-diazabicyclo[4.3.0]nonan-8-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid","(2S,5R,6R)-6-{[(2R)-2-[(4-ethyl-2,3-dioxo-piperazine-1-carbonyl)amino]-2-phenyl-acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid","(2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl- 1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1- azabicyclo[3.2.0]heptane-2-carboxylic acid.","(6R,7R)-7-[[(2E)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[[4-(1-methylpyridin-1-ium-4-yl)","1,2,3-trinitroxypropane","1,4:3,6-dianhydro-2,5-di-O-nitro-D-glucitol","8-nitrooxy-2,6-dioxabicyclo[3.3.0]octan-4-ol","1,3,4-Trinitrooxybutan-2-yl] nitrate","2,2-Bis[(nitrooxy)methyl]propane-1,3-diyl dinitrate",1-(1-methylethylamino)-3-(1-naphthyloxy)propan-2-ol,1-[4-(2-Methoxyethyl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol,2-{4-[2-Hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide,"2-(3,4-Dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile","[2-(2-Dimethylaminoethyl)-5-(4-methoxyphenyl)-3-oxo-6-thia-2-azabicyclo[5.4.0]undeca-7,9,11-trien-4-yl]ethanoate","3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate",2-[(pyridin-3-ylcarbonyl)amino]ethyl nitrate,"3,5-dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate","3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate","2,2',2'',2'''-(4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl)tetraethanol","(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid","(6R,7R)-7-[(2R)-2-amino-2-phenylacetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid","(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid","(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo- 11-{[3,4,6-trideoxy-3-(dimethylamino)-?-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadec-13-yl 2,6-dideoxy-3C-methyl-3-O-methyl-?-L-ribo-hexopyranoside","(4S,6S,12aS)-4(dimethylamino)-1,4,4a,5,5a,6,11,12a octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide","(2S,3S,4R,5R,6S)-6-[[(1S,2R,19R,22R,34S,37R,40R,52S)-5,32-dichloro-52-[3-(dimethylamino)propylcarbamoyl]-2,26,31,44,49-pentahydroxy-22-(methylamino)-21,35,38,54,56,59-hexaoxo-47-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14(63),15,17(62),23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,65-henicosaen-64-yl]oxy]-3,4-dihydroxy-5-(10-methylundecanoylamino)oxane-2-carboxylic acid","(2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1 azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid","(2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol","(4R,5S,6S)-3-{[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid","(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide","1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-1-methylpyrrolidin-1-ium","(2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide","(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid","7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid","(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-{[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-{[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide","5-Methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-benzimidazole","5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole","2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole",2-[[[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methyl]sulfinyl]-1H-benzimidazole,"(S)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole","(R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole",N-cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine,3-[[[2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl]thio]-N-(aminosulfonyl)propanimidamide,"N-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine","N-(2-[(5-[(dimethylamino)methyl]furan-2-yl)methylthio]ethyl)-N'-methyl-2-nitroethene-1,1-diamine",4-Diphenylmethoxy-1-methylpiperidine,N-methyl-N-(1-methylethyl)-2-[(9H-xanthen-9-ylcarbonyl)oxy]ethanaminium bromide,(RS)-2-cyclohexyl-2-hydroxy-2-phenylacetate,"Methyl (1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyl-1-octen-6-ynyl]-5-oxocyclopentaneacetate","Methyl (1R,2S,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyl-1-octen-6-yn-1-yl]cyclopentane-1-carboxylate","(2R,3R,4S)-4-guanidino-3-(prop-1-en-2-
ylamino)-2-((1R,2R)-1,2,3-trihydroxypropyl)-
3,4-dihydro-2H-pyran-6-carboxylic acid","(1S,2S,31-(Acetylamino)-2-
et3-[(1S)-1-(Acetylamino)-2-
ethylbutyl]-4-(carbamimidoylamino)-
2-hydroxycyclopentanecarboxylic acid","ethyl (3R,4R,5S)-5-amino-4-acetamido-3
-(pentan-3-yloxy)-cyclohex-1-ene-1-
carboxylate"," {(1S,4R)-4-[2-amino-6-
(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol"," 2-Amino-1,9-dihydro-9-
((2-hydroxyethoxy)methyl)-3H-purin-6-one","2-[(2-Amino-6-oxo-1H-purin-9-yl)
methoxy]ethyl (2S)-2-amino-3-methylbutanoate","({(12aR)-12-[(11S)-7,8-Difluoro-6,11
-dihydrodibenzo[b,e]thiepin-11-yl]
-6,8-dioxo-3,4,6,8,12,12a-hexahydro
-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f]
[1,2,4]triazin-7-yl}oxy)methyl methyl carbonate","({[(S)-1-(4-amino-2-oxo-1,2
-dihydropyrimidin-1-yl)-3-
hydroxypropan-2-yl]oxy}methyl)phosphonic acid","{[2-(6-amino-9H-purin-9-yl)ethoxy]
methyl}phosphonic acid"," {3-[(4-Benzoyl-1-piperazinyl)(oxo)acetyl]
-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)
-1H-pyrrolo[2,3-c]pyridin-1-yl}methyl dihydrogen phosphate"," Bis{[(isopropoxycarbonyl)oxy]methyl}
({[(2R)-1-(6-amino-9H-purin-9-yl)-2-propanyl]oxy}methyl)phosphonate"," (3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy
-4-[N-(2-methylpropyl)(4-aminobenzene)
sulfonamido]-1-phenylbutan-2-yl]carbamate","methyl N-[(1S)-1-{[(2S,3S)-3-hydroxy
-4-[(2S)-2-[(methoxycarbonyl)amino]
-3,3-dimethyl-N'-{[4-(pyridin-2-yl)
phenyl]methyl}butanehydrazido]
-1-phenylbutan-2-yl]carbamoyl}-
2,2-dimethylpropyl]carbamate","(1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)
-2,3-dioxopropyl]-3-[2(S)-[[[(1,
1-dimethylethyl)amino]carbonyl]
amino]-3,3-dimethyl-1-oxobutyl]
-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide","3'-deoxy-3'-azido-thymidine 1-
[(2R,4S,5S)-4-Azido-5-
(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione","5,5-diphenyl-2,4-imidazolidinedione","5H-dibenz[b,f]azepine-5-carboxamide",2-propylpentanoic acid,"3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine",(S)-alpha-ethyl-2-oxo-pyrrolidine acetamide,"2,3:4,5-bis-O-(1-methylethylidene)-?-D-fructopyranose sulfamate","10,11-dihydro-10-oxo-5H-diben,azepine-5-carboxamide","7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine","2-phenyl-1,3-propanediol dicarbamate",(RS)-1-[2-(diaminomethyleneamino)ethyl]-1H-pyrazole-4-carboxamide,"(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid","N-{1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazol-4-yl}methanesulfonamide",2-[1-(aminomethyl)cyclohexyl]acetic acid,"1,2-Benzisoxazole-3-methanesulfonamide",(S)-3-(aminomethyl)-5-methylhexanoic acid,"5,5-diphenyl-2,4-imidazolidinedione","5H-dibenz[b,f]azepine-5-carboxamide",2-propylpentanoic acid,"3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine",(S)-alpha-ethyl-2-oxo-pyrrolidine acetamide,"2,3:4,5-bis-O-(1-methylethylidene)-?-D-fructopyranose sulfamate","10,11-dihydro-10-oxo-5H-diben,azepine-5-carboxamide","7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine","2-phenyl-1,3-propanediol dicarbamate",(RS)-1-[2-(diaminomethyleneamino)ethyl]-1H-pyrazole-4-carboxamide,"(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid","N-{1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazol-4-yl}methanesulfonamide",2-[1-(aminomethyl)cyclohexyl]acetic acid,"1,2-Benzisoxazole-3-methanesulfonamide",(S)-3-(aminomethyl)-5-methylhexanoic acid
BCS classification (I/II/III/IV),Class I,Class I,Class II,Class II,Class IV,Class IV,not conclusive,Not classified,Class I,Class I,Class I,Class III,Class III,Class III,III,III,BCS Class II,III,Class III,III,III,II (Pramipexole dihydrochloride),III,BCS Class II,III,III,III (Biopharmaceutics Classification System),Class I,"Class II (Low solubility, High permeability)",Class I,Class II,Class II,Class I,Class I,Class II,Class I,Class I,Class I,Class IV,Class I,Class III,Class I,Class IV,NA,NA,Class-III,Class-III,Class-III,Class-III,Class-III,Class-II,Class-IV,Class-II,Class-IV,Class-IV,NA,class I,class I,Class II,class II,class II,class-I,class II,Class IV,Class II,Class II,IV class,Class IIl,Class IIl,class II,class II,Class I,class II,Class II,class III,class III,class II,class III,class II,class III,class III,class III,class II,class II,class II,1,1,2,2,1,1,1,3,1,1,2,3,3,­,IV,IV,II,IV,III,IV,IV,IV,III,III,III,­,IV,Class III,Class III,Class IV,Class III,Class III,Class I,Class III,Class III,Class I,Class II,Class II,Class III,Class III,Class II,Class III,III,acitretin (ACT) are widely used antipsoriatic drugs that belong to BCS classes  IV,III,"1] Class I - High Solubility, High Permeability 2] Class II - Low Solubility, High Permeability 3] Class III - High Solubility, Low Permeability 4] Class IV - Low Solubility, Low Permeability",BCS Class I),classII,": BCS Class I (high solubility, high permeability)",class I,"BCS Class III (low solubility, high permeability",class III,NA,not applicable,class II,no class,class I,class III,class III,classII,class III,class IV,class III,class IV,class II,clas III,class II,class IV,class II,class III,NA,Class I,Class III,Class III,Class III,Class III,Class III,"BCS classifcation is not allpicable 
to insuline glulisine as it is a large molecule",Class II,class I,Class II,NA,NA,Class II,Class II,NA,Class III,Class 2,Class 2,Class II,Class 1,Class 1,Class III,Class II,Class 3,Class 4,Class IV,Class I,Class 1,Class 3,Class 2,Class II,Class II,Class II,class-3,class-3,class-2,class-3,class-4,NA,class-3,class-4,class2,class-2,class 4,class 2,class -2,class 2,class -3,Class lll,Class lV,Class lV,Class l,Class lV,Class l,Class l,Class lV,Class lV,Class l,Class lV,Class l,Class IV,NA,Class ll,CLASS III,Class I,Class II,Class I,Class III,Class I,Class II,Class II,Class III,Class I,Class I,Class I,Class III,Class I,Class III,"Class II (Low solubility, high permeability)",Class II,"Class II (Low solubility, high permeability)",BCS class II,II,III,Class II,II,"IV (Low solubility, Low permeability)",III,"III (High solubility, low permeability)",No,BCS Class I,III,BCS Class I,class 1,class 2,class 1,class 3,Class I,class 2,"III (High solubility, low permeability)",III,class 1,"Class II (Low solubility, high permeability)",class II,Class II,class ll,class 1,"IV (Low solubility, Low permeability)",IV,IV,III,III,III,II,II,II,III,II,II,"IV (Low solubility, low permeability)",III,II,II,"Class I or II, depending on the specific formulation and context.",Class I,Class II,Class I,Class I,class I,class IV,Class I,Class I,Class II,Class I,class II drug,Class II drug,Class III,class I,class 1,Class 3,class-III,class 2,NA,class 2,class 2,class 2,class 2,class 2,class 2,class 2,class 2,class 2,class 2,class IV,Class III or possibly Class IV,class 2 low solubility high permeability,class II due to high permeability low solubility, Class 3 drug.,class 2, Class III,Class II,Class III,class 1 and 3,Class IV,Class III,class IV,Class III,Class IV,Class II,Class II,Class III,Class III,Class III,Class III,Class II,Class II,No,No,Class III,Class IV,Class I,Class I,Class I, BCS IV ,BCS Classes III and IV,BCS class IV ,BCS class IV drug,BCS Class II,Class IV,Class I,BCS class IV,Class I, class II, class III,class I,class 1,schedule 4,class 1,class 1,BCS Class I,BCS class 3,class II ,class I or III,class II drug,class I AND III,class I,class II drug,barbiturate class,schedule III,Class I ,class 3,class 1,NA,class 3,class 3,class 3,class 2,class 1,class 2,class 1,class II,class I,class 2,class 1,class 1,class II,class II,class I,class III,class I,class I,class I,class IV,class III,class I,class I,class I,class II,class II,class I,Class IV,Class IV,BCS Class II,BCS Class II,BCS Class II,BCS Class 1,BCS Class 3,BCS Class 2,BCS Class 1,BCS Class 4,BCS Class 3,BCS Class 3,BCS class II,BCS Class 3,BCS Class 3,class I,Class I,Class III,Class I,Class I,Class I,Class I,Class II,Class !,Class I,Class I,Class I,Class I,Class III,Class II,BCS classification(I/II/III/IV),II,II,I,I,II,II,II,II,I,II,II,II,III,NA,II,Class-I,Class- II,Class-IV,Class-IV,Class-IV,Class-II,Class-II,Class-II,Class-II,Class-II,Class -II,Class-IV,Class-IV,Class-IV,Class-II, class II ,Class II,Class I or II,Class II,Class II,Class II,Class II,Class II,Class II or III,Class II,Class II or III,Class II,Class II or III,Class II or III,Class II,Class II,BCS Class III,BCS Class II,BCS Class II,BCS CLASS III,Class II,Class II,Class II,Class III,Class III,Class I,Class I,Class III,Class I,Class II,Class II,Class III,Class II,Class IV,Class I,Class I,Class II,class II,class III,Class II,class III,Class II,Class IV,Class I,Class IV,Class-II,class-ll,class-lll,class-1,class-ll,class-II,class-II,class-I,class-III,class-II,class-III,class-II,class-IV,CLASS-II,class-II,III,III,III,III,IV,III,III,III,BCS classification(I/II/III/IV),ll,ll,ll,l,IV,ll,l,ll,lV,lll,II,IV,ll,II,III,BCS classification(I/II/III/IV),class 2,class 4,CLASS 4,class 2,class 2,NA,NOT CLASSIFIED,NA,CLASS 1,CLASS 1,class 1,class 1,NA,NA,class 3,class 1,NA,class 3,class 3,class 3,class 2,class 1,class 2,class 1,class II,class I,class 2,class 1,class 1,class II,class II,class I,class III,class I,class I,class I,class IV,class III,class I,class I,class I,class II,class II,class I,Class IV,Class IV,BCS Class II,BCS Class II,BCS Class II,BCS Class 1,BCS Class 3,BCS Class 2,BCS Class 1,BCS Class 4,BCS Class 3,BCS Class 3,BCS class II,BCS Class 3,BCS Class 3,NA,BCS classification(I/II/III/IV),class I,Class I,Class III,Class I,Class I,Class I,Class I,Class II,Class !,Class I,Class I,Class I,Class I,Class III,Class II,NA,NA,NA,NA,NA,II,II,I,I,II,II,II,II,I,II,II,II,III,NA,II,NA,BCS classification( I/II/III/IV),Class-I,Class- II,Class-IV,Class-IV,Class-IV,Class-II,Class-II,Class-II,Class-II,Class-II,Class -II,Class-IV,Class-IV,Class-IV,Class-II,BCS classification(I/II/III/IV), class II ,Class II,Class I or II,Class II,Class II,Class II,Class II,Class II,Class II or III,Class II,Class II or III,Class II,Class II or III,Class II or III,Class II,BCS classification(I/II/III/IV),Class II,BCS Class III,BCS Class II,BCS Class II,BCS CLASS III,Class II,Class II,Class II,Class III,Class III,Class I,Class I,Class III,Class I,Class II,BCS classification(I/II/III/IV),Class II,Class III,Class II,Class IV,Class I,Class I,Class II,class II,class III,Class II,class III,Class II,Class IV,Class I,Class IV,BCS classification(I/II/III/IV),Class-II,class-ll,class-lll,class-1,class-ll,class-II,class-II,class-I,class-III,class-II,class-III,class-II,class-IV,CLASS-II,class-II,III,III,III,III,IV,III,III,III,BCS classification(I/II/III/IV),ll,ll,ll,l,IV,ll,l,ll,lV,lll,II,IV,ll,II,III,class 2,class 4,CLASS 4,class 2,class 2,NA,NOT CLASSIFIED,NA,CLASS 1,CLASS 1,class 1,class 1,NA,NA,CLASS 1,CLASS 1,CLASS 1,CLASS 2,CLASS 1,CLASS 2,CLASS 2,CLASS 2,CLASS 2,CLASS 2,CLASS 2,CLASS 4,CLASS 3,CLASS 2,CLASS 2,NA,CLASS 2,CLASS 2,CLASS 1,CLASS 2,CLASS 1,CLASS 1,CLASS 2,CLASS 1,CLASS 1,CLASS 2,CLASS 1,class II,Class II,CLASS II,CLASS III,Class III,Class II,Class III,Class III,Class III,Class III,Class III,Class III,Class III,NA,NA,NA,NA,NA,NA,Baricitinib belongs to class III,Tofacitinib citrate is characterized as BCS class III compound,Upadacitinib is a BCS class-I medication,Methotrexate is a BCS class IV medication.,Leflunomide belongs to class II,Sulfasalazine is a BCS class 4 compound.,Azathioprine is classified as a Biopharmaceutics Classification System (BCS) Class III drug.,Cyclosporine A (CsA) is classified as a biopharmaceutics classification system (BCS) class II drug,Class I,"Class I (High solubility, high permeability)",BCS classification: III,Class II,Class III,Class III,Class III,NA,Class 4,Class 3,Class 2,class2,NA,class 3,class 4,class 2,Class 1,class 2,class 4,class 4,class 4,NA,NA,BCS class I," BCS class I,",BCS class I ,(BCS) class 3,BCS class I, BCS class IV, BCS class III,Class III , class III, BCS class II , BCS class I , (BCS) class III ,CLASS I, class IV,Class -I,Class -I,Class-I,Class-I,Class -IV,Class-II,Class-I,Class-I,Class-II,Class - II,Class-II,Class-III,Class-I,Class-II,Class-III,Class-1,Class-1,Class-1,Class-2,Class-3,Class-4,Class-1,Class- 3,Class- 3,Class- 3,Class- 3,Class- 1,Class- 1,Class- 4,Class- 3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,III,III,III,III,III,III,II,IV,III,II,III,II,II,IV,I,"Class II (Low solubility, high permeability)",Class II,"Class II (Low solubility, high permeability)",BCS class II,II,III,Class II,II,"IV (Low solubility, Low permeability)",III,"III (High solubility, low permeability)",No,BCS Class I,III,BCS Class I,"Class II (Low solubility, high permeability)",Class II,"Class II (Low solubility, high permeability)",BCS class II,II,III,Class II,II,"IV (Low solubility, Low permeability)",III,"III (High solubility, low permeability)",No,BCS Class I,III,BCS Class I
Nature of the drug(Crystalline/Amorphous),Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Pc properties,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystaline,Crystalline,Crystalline,Crystalline,Crystalline,Crystaline,Crystaline,Crystalline,Crystalline,crystalline and amorphous complexes,Crystalline,Crystalline,Crystalline,Crystaline,Crystalline,Amorphous,crystalline,crystalline,Hygroscopic,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,amorphous,amorphous,crystalline,crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,­,crystalline,crystalline,­,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline powder,crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Cryatalline,crystalline,crystallin,crystalline, crystalline solid.,crystalline,Typically crystalline,crystalline,crystalline,Typically formulated as a topical cream or gel,Pimecrolimus is typically formulated as a topical cream,crystalline,crystalline,crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Cystalline,Crystalline,Crystalline,Crystalline,Amorphous,Crystalline,Crystalline,Amorphous,Crystalline,Amorphous,Amorphous,Amorphous,Amorphous,Crystalline,Amorphous,Crystaline,Amorphous/Crystalline,Amorphous,Crystalline,amorphous,crystalline,both forms,crystalline,Crystalline,Crystalline,Crystalline,Crystalline,crystalline,crystalline,Crystalline,Crystalline,Crystalline,Amorphous,Crystalline,Crystalline,both,crystalline/both,NA,crystalline powder,crystalline,Crystalline,crystalline,Crystalline,Amorphous,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Amorphous,Amorphous,Crystalline,Crystalline,Crystalline,Amorphous,Active again gram positive and gram negative bacteria,Crystalline,Crystalline,Crystalline,Crystalline,Amorphous,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,CRYSTALLINE,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Amorphous,crystalline,crytsalline,Crystalline,Crystalline,crystalline,Crystalline,Crystalline,crystalline,Crystalline,Crystalline,Crystalline,Crystalline,crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,crystalline,Crystalline,NA,Crystalline,Crystalline,crystalline,Crystalline,Crystalline,Crystalline,Crystalline,crystalline,crystalline form.,crystalline form.,crystalline form.,Crystalline,78°C,Crystalline,Crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,Crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,not specified,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline forms,crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Amorphus,Crystalline,Crystalline,Crystalline,Amorphus,Crystalline,Crystalline,Crystalline,Amorphus,Amorphous,NA,Amorphous,Amorphous anhydrous crystalline,Amorphous,Crystalline,amorphous / crystalline,Amorphous,Amorphous,"crystalline form B [29,30].",Crystalline,Crystallin," It has a role as a xenobiotic, an environmental contaminant, an anxiolytic drug, an anticonvulsant and a sedative."," a xenobiotic, an environmental contaminant and an anxiolytic drug.",an antihistamine,beta-adrenergic receptor antagonist,a class of medications called anxiolytics.,azapirone group ,It is a Depressants substance,an antihypertensive drug ," anxiolytic, anticonvulsant, muscle relaxant, hypnotic and amnesic",barbiturate derivative., long-lasting barbiturate and anticonvulsant,long-acting benzodiazepine ,barbiturate class,a barbiturate,antidepressant ,Amorphous,amorphus or crystaline,NA,crystalline,crystalline,Amorphous,amorphous or crystalline,amorphous,crystalline powder,crystalline,crystalline,crystalline,co-amorphous,crystalline or amorphous,amorphous,Amourphus,crystalline,crystalline,crystalline,co-amourphous,Amorphous,Crystalline,amourphous,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,Amorphous,Amorphous,Amorphous,Amorphous,Amorphous,crystalline powder,crystalline powder,Amorphous,"amorphous, crystalline",crystalline,colorless crystals,Amorphous,NA,crystalline powder,crystalline,Crystalline,Crystalline,Crystalline,Crystallinr,Crystalline,Crystallinr,Typically amorphous,Crystalline,Crystalline,Crystalline,Both,Both,Both,Crystalline,Crystalline,Nature of the drug(Crystalline/Amorphous),Amorphus,crystalline,Crystalline,Crystalline,crystalline Form A,Amorphus,Crystalline,Amorphus,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,crystalline,Crystalline,sparingly soluble in organic solvents,solubility in organic solvents,Insoluble in organic solvents,soluble in organic solvents,more soluble in organic solvents than in water,soluble in organic solvents,sparingly soluble in organic solvents.,sparingly soluble in organic solvents,Soluble in organic solvent,Sparingly soluble in organic solvent,Sparingly soluble in organic solvent,Sparingly soluble in organic solvents,Soluble in organic solvent,Insoluble in organic solvents,Sparingly soluble in organic solvents,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,crystalline,Crystalline,crystalline,Crystaline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Both,Both,Both,Both,Both,Both,Both,Both,Both,Both,Both,Both,Botj,Both,Both,Amorphous,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,amorphous,NA,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Nature of the drug(Crystalline/Amorphous),crystalline,crystalline,crystalline,crystalline,amorphous,amorphous,crystalline,crystalline,amorphous,amorphous,crystalline,crystalline,crystalline,crystalline,crystalline,Nature of the drug(Crystalline/Amorphous),crystalline,amorphous,amorphous,cryastalline,crystalline,crystalline,CRYSTALLINE,oral,crystalline,crstalline,crstalline,crstalline,amorphous,crystalline,Amorphous,amorphus or crystaline,NA,crystalline,crystalline,Amorphous,amorphous or crystalline,amorphous,crystalline powder,crystalline,crystalline,crystalline,co-amorphous,crystalline or amorphous,amorphous,Amourphus,crystalline,crystalline,crystalline,co-amourphous,Amorphous,Crystalline,amourphous,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,Amorphous,Amorphous,Amorphous,Amorphous,Amorphous,crystalline powder,crystalline powder,Amorphous,"amorphous, crystalline",crystalline,colorless crystals,Amorphous,NA,crystalline powder,crystalline,NA,Nature of the drug(Crystalline/Amorphous),Crystalline,Crystalline,Crystalline,Crystallinr,Crystalline,Crystallinr,Typically amorphous,Crystalline,Crystalline,Crystalline,Both,Both,Both,Crystalline,Crystalline,NA,NA,NA,NA,NA,Amorphus,crystalline,Crystalline,Crystalline,crystalline Form A,Amorphus,Crystalline,Amorphus,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,crystalline,Crystalline,NA,Solubility in other organic solvents,sparingly soluble in organic solvents,solubility in organic solvents,Insoluble in organic solvents,soluble in organic solvents,more soluble in organic solvents than in water,soluble in organic solvents,sparingly soluble in organic solvents.,sparingly soluble in organic solvents,Soluble in organic solvent,Sparingly soluble in organic solvent,Sparingly soluble in organic solvent,Sparingly soluble in organic solvents,Soluble in organic solvent,Insoluble in organic solvents,Sparingly soluble in organic solvents,Nature of the drug(Crystalline/Amorphous),Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Nature of the drug(Crystalline/Amorphous),Crystalline,crystalline,Crystalline,crystalline,Crystaline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Nature of the drug(Crystalline/Amorphous),Both,Both,Both,Both,Both,Both,Both,Both,Both,Both,Both,Both,Botj,Both,Both,Nature of the drug(Crystalline/Amorphous),Amorphous,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,amorphous,NA,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Nature of the drug(Crystalline/Amorphous),crystalline,crystalline,crystalline,crystalline,amorphous,amorphous,crystalline,crystalline,amorphous,amorphous,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,amorphous,amorphous,cryastalline,crystalline,crystalline,CRYSTALLINE,oral,crystalline,crstalline,crstalline,crstalline,amorphous,crystalline,exist in both form,amorphous,both form,crystalline,amorphous,amorphous,crystalline,amorphous,crystalline,crystalline,crystalline,crystalline,crystalline,crystalline,amrophous,NA,crystaline,amrophus,crystalline,crystaline,crystalline,crystalline,crystaline,crystalline,crystalline,crystalline,crystalline,Crystalline,crystalline,crystalline,crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,NA,NA,NA,NA,NA,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,NA,Crystalline,Crystalline,Crystalline,Amorphous,crystaliine,crystalline,crystalline,Amorphous,Amorphous,Amorphous,crystalline,amorphous,amorphous,NA,NA,semisynthetic penicillin derivative, semisynthetic derivative. , alternating layers of hydrogen bonds and van der Waals contacts parallel to the bc-plane., broad-spectrum cephalosporin antibiotic,Imipenem is a carbapenem antibiotic normally administered ,Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria,a branched tricyclic glycosylated peptide antibiotic,Omadacycline retains antibacterial activity against strains expressing the two most common tetracycline resistance,Ceftriaxone is a broad-spectrum cephalosporin antibiotic used for the treatment of bacterial infections ,"Tiamulin is an antibiotic approved exclusively in veterinary medicine, active against G-positive bacteria ","Moxifloxacin is an antibiotic, used to treat bacterial infections, including pneumonia","Piperacillin is used almost exclusively in combination with the beta lactamase inhibitor tazobactam for the treatment of serious, hospital-acquired infections.","Cefepime has a broad spectrum of activity against both gram-positive and gram-negative bacteria. It is effective against many common pathogens, including Enterobacteriaceae",Ceftaroline has a broad spectrum of activity against both gram-positive and gram-negative bacteria,Amorphous,Crystalline,Crystalline,Crystalline,Crystalline,Both,Crystalline,Crystalline,Crystalline,Both,Crystalline,Crystalline,Both,Crystalline,Crystalline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Class II,Class II,Class II,Class II,Class II,Class II,Class III,Class III,Class III,Class III,NA,NA,NA,Class III,NA,Crystalline,amorphous,amorphous,amorphous,Crystalline,Crystalline,amorphous,amorphous,amorphous,Crystalline,amorphous,amorphous,amorphous,amorphous,amorphous,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline
Melting Point,173-175°C,170-175°C,191-192°C,115-120°C,~164-166°C,~150-160°C,~187-188°C,~98°C,~235°C,~60°C,~131-135°C,~216-218°C,~147-148°C,~157-158°C,276-278°C,~137°C,Approximately 230°C,173-175°C,Approximately 130°C,200-201 °C,208-210°C,296-297°C,~243°C,Not available,Approximately 234°C,213-215°C,Not readily available,Approximately 135-137°C,~ 144-146 °C,Melting Point,239 – 243?.,159-160?.,225?.,131-134?.,226-230?,121-124?,157-158?,35-37,236-238,165-168,190-220,204-208,183-185,Not specified,Not specified,270°C,195-200°C,Not specified,not specified,166-170°C,280-282°C,213-216°C,249-251°C,288-290°C,213-216°C,262-264°C,147 to 149 °C,171-172,146-150°C,127-130,132-134°C,130-140°C,166-167 °C,204-208°C,109°C,129-132°C,44 - 46 °C.,211° C (dec.),204-206°C,217-220°C,110 to 111.5 °C,233° C,208 to 209 °C,128.5 to 129.5 °C,185 °C,197 to 200 °C,207 to 208°C,154 to 158°C,192 to 196°C,223 to 226°C,30°C,30°C,155 to 157°C,129 to 130 °C,190 to 192 °C,"173-178°C

",248-251°C,215-220°C,145-147°C,234-238°C,120-124°C,199-200°C,166-169°C,114-116°C,204-209°C,278-283°C,255-260°C,Room temperature,>262 mg/ml to <0.010mg/ml,274-276°C,190-195°C,>203°C,165-170°C,270°C,243.5°C,232°C,216-217°C,209-210°C,220-221°C,181-183°C,80-90°C,184-185°C,249-253°C,130-135°C,125-129°C,175-177°C,140-142°C,175-177°C,263-265°C,119-121°C,188-194°C,163-164°C,141-144°C,168-170°C,136-140°C,149-152°C,189-191°C,238-240 °C,229-230 °C,27-219,95-204 °C,133 to 136 °C (271 to 277 °F),148-151,Approximately 195-196°C,Approximately 235-238 °C,Approximately 120-122°C,Not applicable as it is usually formulated in a topical form,NA,not applicable,156-156,240-242,102-107,58-61,195-198,146-147,NA,185-200,NA,NA,168,70,146-147,NA,260,185,233° C,86°F(30°C),65° C,65° C,30°C or below,86°F(30°C),NA,25°C,86°F,207°c,153-156%,NA,253-255°C,155-157°c,149-151°c,Aminoquinoline,Quinoline derivative,Quinoline derivative,Quinoline,Quinoline alkaloid,Quinoline derivative,Guanidine derivative,Pyrimidine derivative,Pyrimidine derivative,Sulfonamide,Sulfonamide,Tetracycline antibiotic,Lincosamide antibiotic,Artemisinin derivative,Sesquiterpene lactone,Sesquiterpene lactone,Pyrazolopyrimidine,Naphthoquinone,NA,142-144°C.,approximately 139-144°C.,approximately 162-166°C.,approximately 139-144°C.,approximately 154-155°C.,approximately 192-196°C.,approximately 180-182°C.,approximately 240-242°C.,approximately 215-217°C.,approximately 175-180°C.,approximately 257-259°C.,approximately 119-121°C.,approximately 321-322,approximately 180-182°C.,approximately 140-142°C,203-204°c,185°c,126°c,194°c,147°c,NA,205°C,252 to 256 °C,128°c,214-217 °C.,150-153°c,326.8 °C,313°C to 322°C,NA,217-220°C,155°C,270-274°C,230°C,235°C,> 200°C,200°C,190-192°C,240-242°C,253°C,215-216°C,215°C,235-237°C,220°C,221°C,252-253°C,295-298°C,189-193°C,122-123 °C,228-229°C,94-95°C,125-126°C,215-219 °C,182-184°C,108-110°C,159-163 °C,186-189°C,Not specified,162-166°C,162-168°C,194-197°C,174-175°C,295-298°C,194-197°C,162-168°C,162-166°C,260-264 %,186-189°C,159-163 °C,100-105 °C,122-123 °C,228-229°C,189-193°C,94-95°C,131-134°C,108-110°C,69-72°C,135-140 °C,~217-220°C,~151 °C,146-147°C,134-136°C,183-184 °C,169-172°C,140-144°C,183°C,141-143°C,154-155°.,90ºC,"198.2 ± 2 ° C,",NA,167-172 °C,190-194°C,130-132°C,68-69 °C,75-78°C,269-271°C,234-237°C,249-251°C,147-150°C,213-214°C,163-165°C,225-229°C,156-158°C,200-205°C,116-118°C,88-90 °C,210°C,79-80°C,N/A,166-170°C,280-282°C,213-216°C,249-251°C,235-240°C,N/A,N/A,N/A,N/A,187-191°C,not specified,156.05g/mol,108 - 110°C,51.5°,172-174°, 114–118°C (237.2–244.4°F),180-181°C,149–151° C,90 °C,41-45 °C.,12 °C (54 °F),243.5 °C (470.3 °F), 65-69 °C, 223°C,187-189°C (368- 372°F),208-210 °C (406- 410 °F),155?,178-182?,142?,134?,140?,140-142?,261-263?,186?,300?,50?,220?,150?,194?,220?,160?,231-216°C,270° C,274-276°C,232°C,184-185°C,212-216°C,192 °C,25 °C,487.2 K,228-235°C,287-292°C,194.0 to 198.0 °C,257-259 c,205 c,193°.,96 °C,105-107 °C, 212°C,166-168°,305°.,228–229.5 °C,156-158 C, 174-178OC.,236-236.5°,130 °C,158-160 OC, 120° to 138°C ,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Chemical Structure,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"H H
\/
H --C -- N
| || \
H || C -- O -- CH3
| || /
H --C -- N
/\
H H","H H H
| | |
H --C--C--N--C--N--C--C--C--O--H
| | | | | | | |
H H H H H H H H","H
|
H--N--C--C--N--C--C--S--O--N
| | | | | | | | ||
H H H H H H H H O","H
|
H--N--C--C--N--C--C--S--O--N
| | | | | | | | ||
H H H H H H H H O","H H
| |
H-C--N--C--C--OH
| | |
H O H
|
S
/ \
/ \
/ \
/ \
H-C N--CH3
| |
H H","H
|
H--C--C--C--S--N
| | | | ||
H H H O H
|
CH3","H
|
H--C--N--N--C--H
| | ||
H H H","H
|
H--C--N--N--C--H
| | | ||
H H H H","H
|
H--C--C--C--C--C--C--O--CH3
| | | |
H--N H H H
|
H","O
||
H--C--N--S--C--H
| | | ||
H H O H","O
||
H--C--O--Na
|
H","CH3
|
H--C--C--C--C--O--CH2--CH2--OH
| | | |
H--N H H H
|
H","H
|
H--N--C--N--C--N
| | |
H H H","O O O O O O O O \ / \ / \ / \ /
H - O - C - C - O - C - C - C - C - C - O - C - H
| | | | | O O O O O
| | | | |
H - O - C - C - O - C - C - C - C - C - O - C - H
/ \ / \ / \ / \
O O O O O O O O","H
|
H-C-N-N-C-C-C-C-N
| | | |
H H H H",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Chemical Structure,"Cl Cl
\ /
C=N-N=C
/ \
Cl Cl","Cl Cl
\\ //
C==C
// \\
CH2 CH2
\\ //
N-CH3
|
CH3",NA,O | HO--C--C(CH3)2--O--CH2--O--C(CH3)3 | NH--C--CH3,C53H83NO14,C53H83NO14,"H H H
| | |
H--C===N---N--C---CH3
| | |
H H H","__ ___
| | | |
|Antigen| |Constant|
|Binding| | Region|
| | |__|
|___|",NA,H,Cl,Cl Pt Cl,H,H,HOOC,Chemical Structure,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,NA,Chemical Structure,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Chemical Structure,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Chemical Structure,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Chemical Structure,"H H
\/
H --C -- N
| || \
H || C -- O -- CH3
| || /
H --C -- N
/\
H H","H H H
| | |
H --C--C--N--C--N--C--C--C--O--H
| | | | | | | |
H H H H H H H H","H
|
H--N--C--C--N--C--C--S--O--N
| | | | | | | | ||
H H H H H H H H O","H
|
H--N--C--C--N--C--C--S--O--N
| | | | | | | | ||
H H H H H H H H O","H H
| |
H-C--N--C--C--OH
| | |
H O H
|
S
/ \
/ \
/ \
/ \
H-C N--CH3
| |
H H","H
|
H--C--C--C--S--N
| | | | ||
H H H O H
|
CH3","H
|
H--C--N--N--C--H
| | ||
H H H","H
|
H--C--N--N--C--H
| | | ||
H H H H","H
|
H--C--C--C--C--C--C--O--CH3
| | | |
H--N H H H
|
H","O
||
H--C--N--S--C--H
| | | ||
H H O H","O
||
H--C--O--Na
|
H","CH3
|
H--C--C--C--C--O--CH2--CH2--OH
| | | |
H--N H H H
|
H","H
|
H--N--C--N--C--N
| | |
H H H","O O O O O O O O \ / \ / \ / \ /
H - O - C - C - O - C - C - C - C - C - O - C - H
| | | | | O O O O O
| | | | |
H - O - C - C - O - C - C - C - C - C - O - C - H
/ \ / \ / \ / \
O O O O O O O O","H
|
H-C-N-N-C-C-C-C-N
| | | |
H H H H",Chemical Structure,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Chemical Structure,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Chemical Structure,"Cl Cl
\ /
C=N-N=C
/ \
Cl Cl","Cl Cl
\\ //
C==C
// \\
CH2 CH2
\\ //
N-CH3
|
CH3",NA,O | HO--C--C(CH3)2--O--CH2--O--C(CH3)3 | NH--C--CH3,C53H83NO14,C53H83NO14,"H H H
| | |
H--C===N---N--C---CH3
| | |
H H H","__ ___
| | | |
|Antigen| |Constant|
|Binding| | Region|
| | |__|
|___|",NA,H,Cl,Cl Pt Cl,H,H,HOOC,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,crystalline,crystalline,Usually amorphous,Typically amorphous,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Particle size (microns),Upto 10 microns,<1.0 µm to >2.5 µm,1000 nm,Micron-sized,Micron-sized,Micron-sized,Micron-sized,Microcrystalline,Microcrystalline,Microcrystalline,Microcrystalline,Micron-sized,Microcrystalline,Microcrystalline,10-45microns,NA,255-590microns,73.8microns,65.23micrometer,95.6nm,NA,550nm,lower than 250nm,NA,Not specified,Not available,Not readily available,Not specified,Not specified,Particle size,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not specified,Not specified,Not specified,195°C,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2-10 microns,209.6 micron,90,NA,670,3 microns,NA,8-16 micron,400-600 microns,1-3 micron,2 -5 micron,2-10 micron,71.3 ± 1.3 nm,< 50 micrun,4.1,3.3,3.1,3.2,2.3,4.1,5.1,4.5,4.1,3.3,3.1,2.3,2.1,5.16,5.59,3,5.17,0.02,-2.19,0.6,2.4,3,-1.4,0.001,4,0.0052,2.01,micron range,formulation and manufacturing process,0.5 to 5 microns,1 to 10 microns,25 microns,10 to 30 microns,1 to 10 microns,1 to 10 microns,30-Oct,1 to 100,5-Oct,20-May,NA,NA,NA,125 micron,Around 10 micron,NA,The specific particle size is not readily available.,The specific particle size is not readily available.,varies,This information may vary depending on the formulation,Not typically specified in general information,may vary depending on the formulation,NA,not be commonly available,NA,not,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2 to 10 microns,1 to 3 microns,NA,2 to 10 Microns,NA,2 to 5 microns,NA,NA,NA,NA,NA,NA,NA,2-10 microns,2-10 microns,87-92 °C,208 °C,199-204 °C,174-176°C,177-178 °C,172-176°C,129°C,231-233°C,197-198°C,190-194°C,176°C,212-219°C,143°C,140-142°C,86-90°C,82-84°C,128-131°C,216-219°C,NA,1-300 microns,2-10 microns,100-1000 microns,2-10 microns,5-6 microns,100-200nm,2.7-3 microns,16-65 microns,vary depending on its formulation and manufacturing process.,10-100 microns,5-10 microns,2-10 microns,50-100 microns,100-150 microns,50-100 microns,1-10 micron,1-3 micron,2-4 micron,10-30 micron,20 microns,0.5 - 15 micro meter,100 micron,5 micron,Less than 10 micron,Less than 6 microns,2.0 to 1652.4 nm.,10-100 micro meter,10 ?m to about 35 ?m.,NA,NA,1-5 ?m,0.2-0.3 ?m,<0.5 ?m,1-100 ?m,1-5 ?m,1-5 ?m,NA,1-5 ?m,1-5 ?m,1-5 ?m,1-10 ?m,1-100 ?m,1-5 ?m,1-5 ?m,1-5 ?m,190 microns,between 15 and 336 microm,NA,120 - 200 microns,Not available,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,5-50 micron,not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,10-50 micron,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,NA,NA,Not specified,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,it is typically in the micron range depending on the formulation.,NA,NA,typically in the micron range.,NA,NA,typically in the micron range.,typically in the micron range,"Not readily available, typically micronized for pharmaceutical use",typically in the micrometer range,Typically in the micron range,NA,specific size may vary depending on formulation.,NA,NA,10-20 nanometers,N/A,Not specified,n/a,n/a,NA,NA,NA,NA,NA,NA,NA,187-191°C,Not Specified,not specified,"less than about 10 ?m, preferably less than about 7.5 ?m, and most preferably less than 5 ?m"," 0.093, 0.107, 0.255, and 0.340. ",50m,depending on its form,40 micron,"One micron is 1/1000 mm (1/25,000 of an inch).",less than 50 microns.,50 micron,D90 particle size less than 100 microns., 10 to 30 microns,114.4 nm to 136.7 nm.,40 micron,60 micron,depending on the specific formulation,depending on the specific formulation,1 - 5µ,1 - 4µ,1 - 5µ,1 - 6µ,1 - 4µ,1 - 3µ,1 - 8µ,1 - 6µ,1 - 3µ,1 - 5µ,1 - 8µ,1 - 4µ,1 - 7µ,1 - 6µ,1 - 3µ,130 nm,285±0.052 nm ,NA,1.115 × 105,5 ?M, 10 ?m,120 an,150 to 350 nm,"(176?787 nm),", 2 µm to 3.5 µm,264 to 334 nm.,189 nm,0.2 to 3 microns,10 to 40 microns," 10 milligrams (mg), 25 mg, and 50 mg.",10 to 50 microns, 226.7±2.52nm ,NA,6.7 ± 0.1 ?m,40 microns to about 410 microns ,"0.25,0.5", 20 ?L,178 nm, <250 ?m, less than 44 mum,68.07,184.20 ± 1.1 nm,169-71?c,168-173?c,246?c,139-141°c,165-166°c,178-180?c,NA,213?c,140-142c,96c,214-216,255c,152-155c,239c,236c,60°C,220-230,134-136,196-198,116,150-159,214,225-229,130-135,171.0 to 175.0,143-144,168-172,214-216,120-124,103-105,235.2 °C (onset) and 237.2 °C (peak), 138.6 ± 0.1 • C,235-247°C,230-242°C,214-216°C,231-234°C,114–118 °C,280°–286° C,262-264°C, 235–237°C ,212-213°C,209° and 217° C.,61°C,167°C,65-69 °C,191 dec °C,482 °F (decomposes),NA,234°C,277-282°C,NA,NA,83-86°C,NA,NA,NA,NA,253-255°C,32-33°C,2-3°C,Melting Point,147-149°C,178-179°C,223-224°C,166.2°,129-134°C,170-172°,217-220°C,210-214°C,40 °C,204-206°C,195-198°,210-214°C,177°,295-297°,220°,138-140?,166.2?,166.2?,147-149?,162?,159 -163?,137–138?,148-152?,129-134?,42-44?,110-115?,208-210?,122.3?,44-46?,170- 172?, 207 °C,208-209°C,170-173°C,158-162°C,160-162°C,188-190°C,177-179°C,221-226,195-198°,189°C,180-182°.,200°C,205-210 °C.,98-99°C,162-164°C,156-158°C,196-198°C,176-180°C,140°C to 150°C.,196-198°C,138-139°C,125-128°C,177-178°C,220°C,183-186°C,50°C (122°F),135-136°C,139-144°C,300°C,140-150°C,825 °C,142°C,270.0°C,300°C,350 °C,255°C,156 °C,159-162°C,133-134°C,140-141° C,153 °C,155°C,300 °C,990 °C,1910?,143-147°c,140-142°C,not specified,181°c,NA,NA,NA,108°C,41-45°C,NA,NA,NA,NA,NA,NA,174-176°C,218-222°C,170-175°C,Not specified,Not specified,Not specified,140-141°C,102-104°C,Melting Point,30-34°C,90-93°C,216-221°C,60°C,107-113 °C,NA,173-175 C,dose not have a melting point,NA,86-91 C,NA,NA,NA,NA,NA,Melting Point,127-130°C,NA,NA,146-153 C,166-170 C,180-184 C,208-209 C,decomposes,170 c,108-110 c,147 c,102 to 104 c,NA,160 c,169-71?c,168-173?c,246?c,139-141°c,165-166°c,178-180?c,NA,213?c,140-142c,96c,214-216,255c,152-155c,239c,236c,60°C,220-230,134-136,196-198,116,150-159,214,225-229,130-135,171.0 to 175.0,143-144,168-172,214-216,120-124,103-105,235.2 °C (onset) and 237.2 °C (peak), 138.6 ± 0.1 • C,235-247°C,230-242°C,214-216°C,231-234°C,114–118 °C,280°–286° C,262-264°C, 235–237°C ,212-213°C,209° and 217° C.,61°C,167°C,65-69 °C,NA,Melting Point,191 dec °C,482 °F (decomposes),NA,234°C,277-282°C,NA,NA,83-86°C,NA,NA,NA,NA,253-255°C,32-33°C,2-3°C,NA,NA,NA,NA,NA,147-149°C,178-179°C,223-224°C,166.2°,129-134°C,170-172°,217-220°C,210-214°C,40 °C,204-206°C,195-198°,210-214°C,177°,295-297°,220°,NA,Melting Point,138-140?,166.2?,166.2?,147-149?,162?,159 -163?,137–138?,148-152?,129-134?,42-44?,110-115?,208-210?,122.3?,44-46?,170- 172?,Melting Point, 207 °C,208-209°C,170-173°C,158-162°C,160-162°C,188-190°C,177-179°C,221-226,195-198°,189°C,180-182°.,200°C,205-210 °C.,98-99°C,162-164°C,Melting Point,156-158°C,196-198°C,176-180°C,140°C to 150°C.,196-198°C,138-139°C,125-128°C,177-178°C,220°C,183-186°C,50°C (122°F),135-136°C,139-144°C,300°C,140-150°C,Melting Point,825 °C,142°C,270.0°C,300°C,350 °C,255°C,156 °C,159-162°C,133-134°C,140-141° C,153 °C,155°C,300 °C,990 °C,1910?,Melting Point,143-147°c,140-142°C,not specified,181°c,NA,NA,NA,108°C,41-45°C,NA,NA,NA,NA,NA,NA,174-176°C,218-222°C,170-175°C,Not specified,Not specified,Not specified,140-141°C,102-104°C,Melting Point,30-34°C,90-93°C,216-221°C,60°C,107-113 °C,NA,173-175 C,dose not have a melting point,NA,86-91 C,NA,NA,NA,NA,NA,127-130°C,NA,NA,146-153 C,166-170 C,180-184 C,208-209 C,decomposes,170 c,108-110 c,147 c,102 to 104 c,NA,160 c,131-134,74-76,236-238,174-175,42-43,171- 174,295.5,162-164,273-276,125-126,220-222,260-262,198-200,189-190,108-110,NA,189-190°C,108-110° C,195-200° C,177-178° C,139-140° C,86-91° C,175-177° C,314-316° C,171-178° C,176-178° C,169-170° C,160°C,107-109°C,114-116°C,144-146°C,235 °C,268-272°C,252-262°C,113-115°C,245 °C,174-178°C,250°C,198-199°C,254-262°C,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,292-294 C,282-283 C,186–188 ºC*,180-185 C,NA,61-63 C,175-177 C,182-185 C,240 C,214-216 C,205C,190-191 C,266.5-270 C,80-90 C,NA, 202°C,194 °C,326.8 °C, 155 °C,193.0°C to 198.0°C,150-153 ?C,>175° C,150 c,201-210°C,143 - 149 °C,324-325°C, 183-185°,191-193°C,204-208°C,14 degree C,73 degree C,90-100 degree C,146-148 degree C,141.3 degree C,163-166 degree C,120-125 degree C,155-157 degree C,143-144 degree C,214-216 degree C,178-179 degree C,131-133 degree C,171-174 degree C,140-142 degree C,166-174 degree C,194 °C,326.8°C,127-129°C,126°C,172.5°C,NA,225- 227°C,215°C,230-234°C,201°C,150°C,187-190°C,141-143°C,204-206°C,214°C,Approximately 156-158°C,~ 138-140°C,~177-178°C,~138-140°C,~140-141°C,~180-184°C,Approximately 140-147°C,Approximately 163-167°C,Approximately 140-142°C,Approximately 139-142°C,Approximately 208-210°C,Approximately 215-219°C,~189 - 194,Approximately 195-196°C,NA,256°,257-262°C,190–206 ºC,165 °C,255°C,159-162°C,190–206 ºC,260 °C,98-102ºC,163-165 °C,117-120°C, 72-74°C,195-209°C,>107°C,160-162 °C,295-298°C,189-193°C,122-123 °C,228-229°C,94-95°C,125-126°C,215-219 °C,182-184°C,108-110°C,159-163 °C,186-189°C,Not specified,162-166°C,162-168°C,194-197°C,295-298°C,189-193°C,122-123 °C,228-229°C,94-95°C,125-126°C,215-219 °C,182-184°C,108-110°C,159-163 °C,186-189°C,Not specified,162-166°C,162-168°C,194-197°C
Log P (Lipophilicity value),1.96,2.21,1.78,1.2,~0.98,~0.75,~1.91,~1.35,~0.07,~1.03,~3.72,~2.81,~3.22,~4.16,-1.48,~2.3,1.7,2.36,1.77,2.92,2.91,1.1,2.66,3.5,1.73 (estimated),3.37,3.51 (estimated),2.6,2.57,Log p,2.4,2.2,2.2,3.37,2.8,2.6,0.9,5.02,2.41,1.65,3.8,3.01,1.63,2.83,4,2.1 (estimated),0.86 (estimated),0.63 (estimated),N/A,1.94,0.4,1.23 (estimated),1.49 (estimated),1.83 (estimated),3.96 (estimated),1.23, 3.98,4.41,3.9,1.6,4.1,0.74,6.1,4.52,5.5,5.4,0.5, -0.39,0.0016,3.8,6.08,NA,approx 3.9,2.34,NA,-2.29,3.1,0.52,approx 3.35,-1.43,approx -0.3 to -0.5,NA,NA,3.6,2.8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8.46,7.05,5.3,8.14±0.42,9.7 and 4.1,6.41,-3.7,-3,-1.2,3.6,0.81,8.66,­,5.71,1.06,1.4 to -1.8,2.82,-0.77 at a pH of 7.4,0.29 at pH 7.4,0.51,1.86,1.3,0.1,3.14,5.76,0.85,0.8 to -1.2,4.26,-0.2 to -0.3,0.9,Approxmitiy 6.2,4.8,2.5,approx 1.12,around 2.9,3.2,1.64,6.5,6.23,2.7,NA,2.46,7.56,1.4,2.3,3.37,5.1,2.56,1.77,3.91,5.1,5.28,4.6,3.83,2.37,4.1,4.43,NA,appx.-0.3 to -0.5,0 or even negative,NA,very low,NA,NA,NA,0.09,3.1,NA,NA,3.21,NA,NA,66.50 ± 1.21 nm,2.01-15.9µm, 339 ± 9 mg ,0.22–0.39 ?m,176 ± 8 nm,10nm,100?, 5?m,929.47 ± 37.72 nm, 5?m,1000nm,1.16-5.2 µm,"203.35 ± 12.04, 323.5 ± 16.39, 827.4 ± 10.20 nm",1.6-60 ?m,692.6 (d. nm),692.6 (d. nm),95.34 nm,340 ± 20 nm,NA,approximately 0.79.,approximately 0.79,approximately 0.74,approximately 0.79,approximately 3.3.,approximately 2.36.,approximately 2.28,approximately 2.3,approximately 4.7,approximately 8.2,approximately 3.8,approximately 5.3,approximately 4.8,approximately 4.07,approximately 1.65,8.58,6.1,2.44,0.75,0.7,Less than 0.05,1.77,NA,0.24,0.75,0.6,0.6,-0.86,NA,3.18,0.34,0.07,1.43,-0.16,2.29,3.36,7.07,4.3,0.58,3.4,1.27,1.6,2.26,1.6,2.96,2.24,2.48,2.88,2.27 (estimated),0.48,1.47,2.58,3.51,1.51,0.72,3.74,Not specified,-1.1,2.49,1.5,1.47,2.24,1.5,2.49,-1.1,Not specified,3.74,0.72,1.01,2.88,2.27 (estimated),2.48,0.48,3.37,1.51,3.7,4.35,5.31,4.44,3.02,5.5,4.12,3.92,3.41,3.78,4.22,5.2,5.24,3.69,5.3,2.47,0.02,2.5,2.02,2.83,2.05,1.45,1.35,3.9,3.74,3.16,0.23,5.4,1.7,1.83,N/A,N/A,1.64,3.2,1.63,2.6,1.8,4.4,3.8,4.4,4.04,n/a,5.7,5.7,not specified,"-0.24,-2.29 & 0.89",0.91,0.53,2.42,-0.76,?0.5,4.2,4.5,0.097,?7.6,1.2 to 1.7,4.05 to >8.0,1.3,approx 0.5,0.3,2.23,2.84,-0.11,0.2,1.26,2.66,3.88,-0.41,-0.55,0.25,0.74,-0.84,0.87,3.16,-0.02,3.96,2.19,5.4,4.1,4.4,0.91,4.28,7.2,NA,NA,1.4,NA,2.82,2.25,2.36. ,3.12 ± 0.14),2.36. ,1.35, 2.98,1.6,2.12.,7.88,7.88 ,2.4, 7.88 ,3.52, 3.95,5 micrometer,0.215+-0.0031 micrometer,5 micrometer,0.1499 micrometer,0.192-0.301 micrometer,3.17-9.74 micrometer,0.264+-0.0004 micrometer,50 micrometer,1.6-60 micrometer,10-50 microns,75-355 micrometer,0.020-0.20 micrometer,30.5-74.31 micrometer,0.39-0.68 micrometer,0.0096 micrometer,45-63 to 500-700 microns,10 to 100 microns,5 to 30 microns,10 and 280 microns,182.5 mocrons,less than 250 microns,5 to 200 microns,92-129 microns,100 microns,less than 250 microns,depend on formulation,5-20 microns,75 to 355 microns,available fine powder,250mm approx,>100 microns,NA,NA,>10 microns,140.53 ± 0.87 nm,0.5 and 100 ?m in size,NA,0.5-1.5µm,0.5 µm, 1.1 ?m, 136.80 +/- 3.24 nm,NA,10.5–11.1 nm,45 nm.,30–34 nm ,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Particle size(microns),1 to 10 micrometers.,1 to 10 micrometers.,150-300 ?m,0.78 micrometers,81.2±1nm,Below 1 ?m,4 ?m,13.12 ± 0.24 nm,0.78 micrometers,NA,69.6 ± 1.23 nm,13.12 ± 0.24 nm,In micrometer,122.9±5.5,4 ?m,150-300µm,0.5 to 10µm,10µm,18.15µm,455.6±11µm,102.36µm,480.60 to 753.46µm,178µm,81.2±1µm,69.6± 1.23µm,179.8µm,119.29µm,69- 218µm,10-15µm,2.3- 2.7µm,"3.00 ?m, more preferably equal to or less than", less than about 2 microns,mean particle size of 131±7.7 nm ,90 micron,7 ?m,90 micron,30 microns , 2.5 microns,less than 10 µm,40 micron ,100 ?M. ,"200 microns ,",3.75 microns,220 nm,mean particle size of 772 nm,NA,NA,NA,micron range.,NA,NA,NA,NA,NA,NA,Varies,NA,NA,NA,NA,0.1 to 100 microns,1 to 100 microns,1 to 100 microns,1 to 100 microns,1 to 10 microns,1 to 10 microns,1 to 30 microns,2 to 50 microns.,1 to 10 microns.,1 to 10 microns.,10 to 200 microns.,1 to 10 microns,1 to 10 microns,1-10 microns,1-10 microns,114.8 nm,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Particle size(microns),1 to 10 microns,less than 100 nm,1 to 10 microns.,0.15-0.2 microns.,submicron or microparticulate,NA,chemotherapy drug,NA,NA,NA,chemotherapy drug,NA,NA,NA,NA,Particle size(microns),NA,NA,NA,micronized,micronized,NA,NA,NA,not specified,micronized,micronized,micronized,not well documented,7.88,5 micrometer,0.215+-0.0031 micrometer,5 micrometer,0.1499 micrometer,0.192-0.301 micrometer,3.17-9.74 micrometer,0.264+-0.0004 micrometer,50 micrometer,1.6-60 micrometer,10-50 microns,75-355 micrometer,0.020-0.20 micrometer,30.5-74.31 micrometer,0.39-0.68 micrometer,0.0096 micrometer,45-63 to 500-700 microns,10 to 100 microns,5 to 30 microns,10 and 280 microns,182.5 mocrons,less than 250 microns,5 to 200 microns,92-129 microns,100 microns,less than 250 microns,depend on formulation,5-20 microns,75 to 355 microns,available fine powder,250mm approx,>100 microns,NA,NA,>10 microns,140.53 ± 0.87 nm,0.5 and 100 ?m in size,NA,0.5-1.5µm,0.5 µm, 1.1 ?m, 136.80 +/- 3.24 nm,NA,10.5–11.1 nm,45 nm.,30–34 nm ,NA,Particle size(microns),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1 to 10 micrometers.,1 to 10 micrometers.,150-300 ?m,0.78 micrometers,81.2±1nm,Below 1 ?m,4 ?m,13.12 ± 0.24 nm,0.78 micrometers,NA,69.6 ± 1.23 nm,13.12 ± 0.24 nm,In micrometer,122.9±5.5,4 ?m,NA,Particle size(microns),150-300µm,0.5 to 10µm,10µm,18.15µm,455.6±11µm,102.36µm,480.60 to 753.46µm,178µm,81.2±1µm,69.6± 1.23µm,179.8µm,119.29µm,69- 218µm,10-15µm,2.3- 2.7µm,Particle size(microns),"3.00 ?m, more preferably equal to or less than", less than about 2 microns,mean particle size of 131±7.7 nm ,90 micron,7 ?m,90 micron,30 microns , 2.5 microns,less than 10 µm,40 micron ,100 ?M. ,"200 microns ,",3.75 microns,220 nm,mean particle size of 772 nm,Particle size(microns),NA,NA,NA,micron range.,NA,NA,NA,NA,NA,NA,Varies,NA,NA,NA,NA,Particle size(microns),0.1 to 100 microns,1 to 100 microns,1 to 100 microns,1 to 100 microns,1 to 10 microns,1 to 10 microns,1 to 30 microns,2 to 50 microns.,1 to 10 microns.,1 to 10 microns.,10 to 200 microns.,1 to 10 microns,1 to 10 microns,1-10 microns,1-10 microns,Particle size(microns),114.8 nm,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Particle size(microns),1 to 10 microns,less than 100 nm,1 to 10 microns.,0.15-0.2 microns.,submicron or microparticulate,NA,chemotherapy drug,NA,NA,NA,chemotherapy drug,NA,NA,NA,NA,NA,NA,NA,micronized,micronized,NA,NA,NA,not specified,micronized,micronized,micronized,not well documented,7.88,below 500 nm,below 200 micrometer,12 micrometer,16.2 mg,175.5-1.5 micron,1-5 microns,20 microns,145-180 microns,4-14 microns,120-300 microns,1.2-39 microns,12-69 microns,below 200 microns,10-100 microns,below 5.8 microns,NA,10-100 microns,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5-10 micron,1-2 micron,2-3 micron,<45,45.28,0.0108,200,0.0148,<260,0.8,63,NA,0.16,NA,<3.0,0.22,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10 microns,50.6 Microns,0.1-100 microns,184.82 nm to 252.62 nm,39 microns,20 microns,3.0 microns,5 microns,1.6 microns,91 microns,16.3 ± 8.1 nm,5 microns,3.5 microns,NA,NA, 220–430 nm ,10 ?m to 30 ?m, less than 250 ?m. ,  249 nm,<40 ?m ,2.0 to 1652.4 nm.,"minimum 123.3 nm to maximum 236.2 nm, ",Omadacycline exhibited an MIC90 of 0.5 µg/mL,cefotaxime loaded NPs were in the size range of less than 100 nm.,Particle size distribution of 45% granulate,"particle size, ranging between 164–490 nm ", 5 µm particle size; 125 × 4 mm, 550?750 ? m, 3.5-?m particle size,1-10 microns,10-50 microns,10-15 microns,5-10 microns,1-10 microns,20-60 microns,20-50 Microns,10-50 microns,1-10 microns,5-20 microns,2-10 Microns,10-50 microns,5-30 microns,5-10 microns,2-5 microns,10 ?m to 30 ?m,10–100 ?m,5?m,200-450?m,NA,NA,3.18 ?m,2.8 ?m,1 to 1000nm,80 and 110 µm,400-750µm,1-5µm,1.9 ± 0.3µm,22.23 ± 2 nm.,190nm,~35.516,~60 to 250,~0.0834 to 0.0190,~10 to 55,~10,~5 to 17,less than 200 micron,350 to 800 micron,2 to 10 micron,~180 to 600 micron,~1 to 1000 micron,NA,NA,200 mcg,NA,1.5 ?m,2.8-3.5 ?m,10 µm to about 200 µm,2-10µm, 0.8 ?m,100 ?600µm,10µm to about 200µm,0.1 to 10µm,0.2 to 2.5 ?M ,10µm,434.82 µm and 456.18 µm,120-270µm,2-10µm,3 to10µm,0.05µm,190 microns,between 15 and 336 microm,NA,120 - 200 microns,Not available,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,190 microns,between 15 and 336 microm,NA,120 - 200 microns,Not available,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified
Pka,9.96,9.87,8.2,~9.9,7.5 (for the acid form),~7.5 (for the acid form),9.3,~8.6,~14,~8.0,~9.8,~10.6,~9.45,~9.9,9.31 (amino group),~10.0,8.5,8.91,7.1,8.17,9.1,8.1,7.9,8.5,8.6,2.8 and 4.5,Not readily available,8.4,6.87,PkA,1.52 & 6.5,1.6 (Uncertain),2.25-2.90,3.32,1.3,7.5,1.88,9.36,NA,7.48,8.71,4.67,5.24,4.03,Not specified,NA,3.8,3.5-4.0,3.1,8.5,9.6,Not specified,Not specified,9.1,8.2,Not specified,6.07,6.37,6.5,"3.3 ,8.6","3.6,9.3","2.2,3.2,6.4","3.7,7.6",7.9,9.06,8.7,3.61, -2.2,0 to 14,6.3,6.9,0.80-1.25,5.9,4.33,5.1,5.9,5.9,8.7,6.8,12.4,approx 7.4,2 to 12,8.2,4.3,5.9,8.6,5.4,10.2,9.4,9.4,4,9.4,8.6,7.8,8.7,8.5,NA,NA,0.0115 mg/ml,0.0105 mg/ml,0.0499 mg/ml,Insoluble,0.00222 mg/ml,69.6 mg/ml,0.978 mg/ml,0.0127 mg/ml,0.00556 mg/ml,22.3 mg/ml,Sparingly soluble,0.0122 mg/ml,50 mg/ml,0.108 mg/ml,4.7,1.8 and 9.7,7.2,2.7,2.86,2.7 and 9.3,2.67,2.53 and 7.14,2.7,2.2 and 4.4,8.57,1.77,2.65,9.7,2.8,its pKa values are specific to its ionizable functional groups.,Pka value of aciterine is 4.6,NA,"2.0, 9.5",approx 8.28,4.7,4.2,12,3.7,NA,8.7,anot applicable as it is a protine,not applicable,NA,7.6,7.55,7.9,9.1,7.64,7.4,7.84,5.9,9.79,9.3,8.18,7.5,8.5,8.6,0.80-1.25,appx. 7.4,7.4,7.4,5 to 7,2 to 12,NA,2.25,7,5.9,NA,NA,8.82,8.2,5.4,4.67,3.8,6.16,4.3,2.6,2.25,2.53,3.17,2.1-3.2,0.71,0.7,1.3,1.29,3.1,~3.7,3.53,4.37,3.44,NA,approximately 7.7,approximately 7.7.,approximately 7.6.,approximately 7.7.,approximately 8.5.,approximately 9.0.,approximately 8.5.,approximately 7.2,approximately 8.8,approximately 10.5,approximately 6.7,approximately 5.7,approximately 7.4.,approximately 9.8,approximately 7.6,7.5 for amino group and 9.3 for carboxylic group,Acid-12.48 and base-9.89,8.5,"Amoxicillin was reported with pKa values of 2.67, 7.11 and 9.55",pKa values 2.74 ± 0.01,3.1,8.42,2.01,Acid - 2.96 and base - 9,Acid 3.22 and base-7. 22,2.9,7.23,Acid - 5.56 and basic - 8.77,"pKa is 9.3, 3.2, and 1.9.",12.46,10.12,8.8,9.65,9-Aug,9.65,9.13,4.5,9.4,2.5,10.4,12,12.5,11.3,5.6,9.03,8.3,10.1,4.76,5.68 (basic pKa),12.45,9.6,10.1,3.6,"pKa1 = 9.4, pKa2 = 11.1",10.01,3.9,Not specified,4.5,10.2,4.2,7.3,8.3,4.2,10.2,4.5,Not specified,3.9,10.01,8.5,4.76,5.68 (basic pKa),10.1,12.45,3.3,"pKa1 = 9.4, pKa2 = 11.1",9.07,8.86,8.75,~6,8.73,7.46,5.08,7.75,8.69,8.9 (basic),7.1,8.1,8.93,"7.6 (pKa1), 10.0 (pKa2)",8.84,8.5,9.28,8.7,7.86,9.4,9.3,3.5 and 12.5.,8.1,8.9,7.89,9.5,9.3.,7.8,9.29,9.1,N/A,N/A,Not specified,n/a,n/a,n/a,n/a,5.5,10.1,6.6,NA,NA,4.2,n/a,not specified,4.8 and 5.5.,6.08,7.6,8.75(strongest base),2.45, ~ 2.5.,6.65,1.8.,0.2 to 12.1,11.09 for the strongest acidic and 11.6 for the strongest base,pKa 9.8,5.8,5.56,approx 7.5,01:01.5,9.29,9.35,6.8,8.2,14.78,17.63,14.69,3.28,3.05,6.3,13.53,-3,3.23,8.99,2.57,10.9,5.06,7.05,10.97,14,3.26,9.4,8.66,6,5.42,3.6,"5.28, 7.17","pKa 3.4. Sol in chloroform, DMF, benzene, acetone, alc.","pKa 1.6/11.6(5% MeOH in H2O,t =20,I=0.15) (Uncertain)",1.96± 0.05,9.67,1.96± 0.05,7.62, 4.62,8.16,5.08,7.48, 7.3,-2.7, 8.1,2.08, 9.9 ,NA,3.77,1.44,2.25,1.07 at a pH of 10.7,1.4,0.9,2,2.6,3.03,4.38,2.75-3.3,3.3,2.71,-0.07,4.1,5.4,3.32,3,3.65,NA,low lipophilic,NA,NA,low lipophilic,3.8,4.05,4.5,5.8,highly lipophilic,NA,99,4.46,4.51,2.86,1.45,0.72 ± 0.07,3.5,1.61,-1.22,-2.8,-1.6,NA,1.68,1.74,-1.6,-2.5,-2.7,0.147,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Log P(Lipophilicity value),5.84,5.86,0.58,5.66,1.65,5.41,3.3,6.6,-1,-4.8,5.53,5.85,5.24,NA,2.71,0.5,5.66,0.17,5.48,4.67,5.86,5.28,4.3,1.65,5.51,4.87,5.85,1.72,3.1,5.41, 6.2 ± 0.1 at 37 °C,1.91,1.73,2.34,2.27,2.69,2.44,1.27,2.48,1.57,4.5,3.9,3.6,2.5,3.754,2.23,3.14,4.1,2.5,NA,3.92,0.66,3.36,-0.54,1.77,-0.82 (at 25°C),NA,0.78,-2.38,0.8,NA,NA,NA,NA,-0.57,0.84,2.8,-1.34,0.67,1.91,-1.62,4.1 to 4.5.,-2.3,NA,0.85.,5.46,5.93,NA,4.5,NA,NA,1.2,4.3,1.2,NA,lipophilic,NA,4.3,NA,NA,-2.13,2.1,-1.33,4.8,4.8,1.61,-0.22,1.8,Log P(Lipophilicity value),1.83,2.31,3.32,no,4.9,4.5,1.8,0.001,1.35,1.53,0.097,-2.19,39.9,2.83,-1.85,Log P(Lipophilicity value),2.6,4.56,0.69,3.4,6.1,4.7,4.9,NA,6,4.72,5.66,5.29,NA,1.84,NA,3.77,1.44,2.25,1.07 at a pH of 10.7,1.4,0.9,2,2.6,3.03,4.38,2.75-3.3,3.3,2.71,-0.07,4.1,5.4,3.32,3,3.65,NA,low lipophilic,NA,NA,low lipophilic,3.8,4.05,4.5,5.8,highly lipophilic,NA,99,4.46,4.51,2.86,1.45,0.72 ± 0.07,3.5,1.61,-1.22,-2.8,-1.6,NA,1.68,1.74,NA,Log P(Lipophilicity value),-1.6,-2.5,-2.7,0.147,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5.84,5.86,0.58,5.66,1.65,5.41,3.3,6.6,-1,-4.8,5.53,5.85,5.24,NA,2.71,NA,Log p (Lipophilicity value),0.5,5.66,0.17,5.48,4.67,5.86,5.28,4.3,1.65,5.51,4.87,5.85,1.72,3.1,5.41,Log P(Lipophilicity value), 6.2 ± 0.1 at 37 °C,1.91,1.73,2.34,2.27,2.69,2.44,1.27,2.48,1.57,4.5,3.9,3.6,2.5,3.754,Log P(Lipophilicity value),2.23,3.14,4.1,2.5,NA,3.92,0.66,3.36,-0.54,1.77,-0.82 (at 25°C),NA,0.78,-2.38,0.8,Log P(Lipophilicity value),NA,NA,NA,NA,-0.57,0.84,2.8,-1.34,0.67,1.91,-1.62,4.1 to 4.5.,-2.3,NA,0.85.,Log P(Lipophilicity value),5.46,5.93,NA,4.5,NA,NA,1.2,4.3,1.2,NA,lipophilic,NA,4.3,NA,NA,-2.13,2.1,-1.33,4.8,4.8,1.61,-0.22,1.8,Log P(Lipophilicity value),1.83,2.31,3.32,no,4.9,4.5,1.8,0.001,1.35,1.53,0.097,-2.19,39.9,2.83,-1.85,2.6,4.56,0.69,3.4,6.1,4.7,4.9,NA,6,4.72,5.66,5.29,NA,1.84,3.37,0.98,3.43,2.42,0.43,0.19,1.5,2.2,1.59,1.3,1.98,-0.64,3.2,2.06,2.67,NA,2.06,2.67,5.1,1.65,4.15,2.5-3.5,5.3,4.8,6.07,5.6,3.76,1.2,2.6.,4.1,3.59,-4.2,5.2,-3.6,-2.1,-4.2,6.01,-2.4,-3.8,-4.7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2.7,-0.89,2.7,6.67,NA,NA,3.81,4.16,5.04,2.9,-0.32,4.2,5.1,NA,NA,0.05,0.01 and 0.02 ?g/g, 0.65 and 3.2,0.01 and 0.02 ?g/g,0.3,(log P ?0.6),(log P ?3.1).,P value <0.001,. Log P. 0.64. , log Kd values of 1.54-1.58,0.95 ,0.68,log P value is 0.69 log ,log P value is 0.69 log ,0.43,0.58,Low lipid solubility,Low lipid solubility,Low,Low,Low,Low,Low,3.4,3.6,0.35,3.8,3.5,1.42,0.87,0.65,1.7,3.03,-0.56,NA,-0.02,6.5,3.2,0.6,0.37,0.56,0.69,0.92,3.2,~2.64,~3.7,~3.6,~3.5,~4.1,~3.7,~0.6,~0.3,~2.1,~0.6,~3.5,NA,NA,~3.6,NA,-4.1,-0.27,1.3,1.42,-0.95,-1.5,2.12,-3.1 to -2.3,1.49,0.64,2.65,1.85,4.36,1.93,-1.3,2.24,2.48,2.88,2.27 (estimated),0.48,1.47,2.58,3.51,1.51,0.72,3.74,Not specified,-1.1,2.49,1.5,2.24,2.48,2.88,2.27 (estimated),0.48,1.47,2.58,3.51,1.51,0.72,3.74,Not specified,-1.1,2.49,1.5
Solubility in water ( g/mL),7.6 g/ml,166 mg/mL,1.5 mg/mL,Moderate,Slightly soluble,Slightly soluble,Soluble,Soluble,Highly soluble,Highly soluble,Slightly soluble,Slightly soluble,Slightly soluble,Slightly soluble,Soluble,2.5 g/mL,Insoluble,Insoluble,0.61 (at 25°C),2.04 mg/mL,0.18 at 25°C,11.5 mg/mL (at 25°C),200 mg/mL,0.0006 (at 25°C),3.52 mg/mL,Insoluble,> 10 (estimated),Insoluble,~ 0.01 g/mL,Solubility,"sparingly soluble in formamide, slightly soluble in ethanol, insoluble in water.",very slightly soluble in water and sparingly soluble in alcohol USP,sparingly soluble in water,slightly soluble in water,slightly soluble in water,"slightly soluble in water,soluble in organic solvents","slightly soluble in water,soluble in organic solvents","slightly soluble in water,soluble in organic solvents","soluble in water,insoluble in benzene,slightly soluble in acetone,methanol,chloroform","Insoluble in benzene,sodium salt",Soluble in organic solvents,"Soluble in alcohol,chloroform,slightly soluble in ether","Soluble in alcohol,chloroform,slightly soluble in ether",slightly soluble in water,Not specified,Highly soluble,Slightly soluble,Moderate to low,9.5,Moderate,Slightly soluble,Moderate to low,Low,Low,Low,Low,Poor,Low,Poor,Moderate,Poor,Good,Poor,Poor,Poor,Poor,Soluble,Soluble,Sparingly soluble,Insoluble,practically insoluble,0.02g/ml,NA,0.30 mg/ml,NA,5 mg/ml,1-2 mg/ml,1.4 mg/ml,sparingly soluble,50mg/ml,5.6 mg/ml,3.5 mg/ml,100 mg/ml,0.4 mg/ml,NA,9.6,9.5,10.1,9.4,9.4,9.3,9.4,9,10.1,9.4,9.7,8.6,9.6,­,low to high,"ethanol, DMSO, and dimethylformide(DMF)",Soluble,"Ethanol, DMSO, and dimethylformide(DMF)",DMF and DMSO,Soluble,ethanol and tetrahydrofuran,"ethanol, DMSO, and dimethylformide(DMF)",insoluble - Ethanol and polar organic solvents,DMSO and dimethylformamide (DMF),Soluble DMSO at 46mg/ml,­,"methanol, ethanol, and DMSO",0.8 g/mL,13.5 mg/mL,11.3 mg/mL at 25°C,70 mg/mL,9.1 mg/mL at 25°C,70 mg/mL,9.9 mg/mL,10 mg/mL at 25°C,10 mg/mL,10-12 mg/mL,0.02 g/mL,13.9 mg/mL,112 mg/mL,0.02 to 0.04 g/mL,0.002 g/mL,in soluble in water,limited solubility in water,limited soluble,in soluble in water,"Hydroxyurea is freely soluble in water, to at least 50 mg/ml (5%).",limited soluble,Low solubility,limited water soluble,low water solublity,: Low water solubility,Limited water solubility,NA,soluble,insolube,50,0.9,NA,<0.1,5.45,NA,NA,<0.5%,5.3,10,0.00026,no,no,no,0.02g/ml,5.6g/ml,0.03g/ml,0.6mg/ml,NA,3.5mg/ml,100to 300mg/ml,0.02mg/ml,1 to 2g/ml,0.5mg/ml,NA,Highly Soluble,0.003-0.005mg/ml,100mg/ml,100U/ml,10.1,9,8.47,7.2,8.5,8.6,11.17,8.8,3.2-10.4,7.3,5.91,"pKa1 = 2.4, pKa2 = 7.6, pKa3 = 9.6",7.5,-4.2,~14,3.48,8.73,7.26,NA,"Ranitidine is sparingly soluble in water, with a solubility of about 0.5 mg/mL",approximately 200 mg/mL,Famotidine is sparingly soluble in water.,approximately 200 mg/mL,sparingly soluble in water.,Cisapride is soluble in water.,sparingly soluble in water.,: Levoketoconazole has low solubility in water.,Pimozide has low solubility in water.,low solubility in water.,sparfloxin has limited solubility in water.,Terfenadine has low solubility in water.,Ziprasidone has low solubility in water.,Mesoridazine has low solubility in water.,Nizatidine has moderate solubility in water,It's soluble in water (50mg/ml),Slightly soluble in water,Insoluble in water,Soluble in water,Soluble in water,Soluble in water,Slightly soluble in water,Insoluble in water,Water solubility 0.838,Solubility in water,Sparingly soluble in water,Solubility in water is low at room temperature,Insoluble in water,Poorly soluble in water,Insoluble in water,2.15mg/ml,Slightly soluble (8.3mg/ml),10Mg/ml,20 mg/ml,1 mg/ml,1 mg/ml,Partially insoluble in water,sparingly soluble,5 mg/mL.,160 mg/L,0.2 to 0.5 mg/ml,10 mg/ml,insoluble in water,Sparingly insoluble in water,partially insoluble,Practically insoluble,0.17,6.7 mg/mL at 25 °C,0.017 (at 25°C),250 mg/mL at 25°C,0.02,0.0024,Practically insoluble,0.056 (at 25°C),Soluble,~0.5,Not specified,40 mg/mL (at 25°C),0.09 (at 25°C),0.04,poorlly soluble in water,Practically insoluble,0.04,0.09 (at 25°C),40 mg/mL (at 25°C),Not specified,~0.5,Soluble,spraingly soluble,6.7 mg/mL at 25 °C,0.017 (at 25°C),0.17,250 mg/mL at 25°C,spraingly soluble in water,0.056 (at 25°C),0.0002,0.01,~0.005,<0.1,0.0093,Insoluble,0.89 (at 25 °C),0.009,0.0005 at 25°C,Insoluble,0.62,0.02,0.002 (at 25°C),0.007 (pH 7.4),0.011,"It has limited water solubility, approximately 0.12 g/mL at room temperature.",Freely soluble,less than 1 g/mL.,66 g/L,15 mg/mL.,10 mg/mL,1.5 g/mL,1 g/mL,freely soluble in water.,2.5 mg/mL.,1.8 mg/mL at 25°C,freely soluble in water,0.001 g/mL,70 mg/mL at 25°C,30 mg/mL,100 mg/ml,Insoluble,>1 g/mL,moderate,limited,moderate,limited,limited,moderate,insoluble,insoluble,insoluble,slightly soluble,Slightly soluble,not specified,insoluble,33.4 mg/mL.,"dimethyl sulfoxide (DMSO), ethanol, and methano",Practically insoluble in water,9 mg/L (dec.),practically insoluble ,15 milligrams per milliliter at 25° C,approximately 25 mM,(40 mg/ml),(50mg/ml), ~20-50 µM,less than 0.1 mg/mL at 72°F,0.228 mg/mL,sparingly soluble in water,sparingly soluble in water,0.359 mg/ml,0.97mg/ml,9.38mg/ml,0.0795 mg/ml,0.682mg/ml,7.22mg/ml,1.6mg/ml,3.03mg/ml,29.4mg/ml,28.2mg/ml,0.774mg/ml,0.583mg/ml,0.958mg/ml,0.33mg/ml,5.92mg/ml,Poorly soluble in water, soluble in water at 25 °C (0.253 g/100 g).,Water Solubility : 0.0105 mg/Ml,exhibits poor aqueous solubility (6–7 µg/mL in water) and permeability,sparingly soluble,0.345 mg/mL, very poorly soluble in water with maximum solubility ~10-20 µM,10 mg/ml.,poor solubility, dependent on pH with increased solubility at a pH of less than 5,2 mg/ml,Insoluble in water,not water soluble,Practically insoluble in water,Very soluble in water,soluble in water,Very soluble in water,NA,aqueous solubility 0.08 mg/ml,Soluble in water (50 mg/ml),not very soluble in water,soluble in water,poor water solubility (1 mg/ml),it is soluble in water., very soluble, 1.5 parts of water.,a solubility of 5.4 mg/mL in water.,955%,8.4,9.7,9.6,9.63,9.56,10.42,6.3,-4.2,9.67,8.05,7.99,4.19,8.39,10.4,8.2,9.4,5.7,4.25 and 9.53,8.98,more inorganic solvent,3.59,8.88,NA,9.4,9.7 and 12.0,9.5,9.7 and8.7,6.1,5.8 and 9.3,NA,3.4,13.45,12.38,12.69,12.58,32,"6.8, 3.1, and 10.8",1.89 and 6.18,13.46±0.70., 4.22,12.45, 9.4.,8.01,5.75,4.7,2.8.,1.82,4.76.,2.7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Pka,6.26,6.74,2.5,3.7,4.36,3.6 - 4.6,6.8, 9.06,2.86,9.76,8.86,9.06,8.99,1.36,1.45,1.76,3.7,8.75,6.26,6.48,6.48,6.74,6.42,12.7,8.86,0.075,9.06,4.08,3.61,14.83,8.07 ( 0.02),5.9,4.07,5.16,5.13,4.07,4.31,6.92,4.32,4.07,4.32,NA,NA,NA,NA,7,4.49,4,4.0.,"2.5 (carboxyl group)
and 7.5 (amino group)",4.7,2.7,8.65,3.3 (basic),4.29,10.32 (at 25°C),6.6,6.8 (basic),3.13,7.7,9,6.808 and 6.93.,6.4,5,"strong acidic 15.7,Basic -1.8",NA,4.0.,7.5,7.7,4.7,"3.13, 4.76, and 6.40.",4,6.40.,NA,10.4,NA,8.76,0.69,1.8,NA,NA,5.2,8.7,7.51,NA,basic,acidic,not specified,NA,NA,"1.96 (Triazole nitrogen), 9.73 (Ribose hydroxyl)",3.3,"2.95, 7.25, 9.7 (three dissociation constants)",Not specified,Not specified,Not specified,5.4,"2.66, 7.24",Pka,1.8,3.1,14.1,No,14.1,8.85,6.6,NA,NA,1.5,7.5,NA,1.5,NA,4.75,Pka,3.3,3.7,4.6,5.6,3.7,5.5,7.6,7.3,6.4,6.03,6.02,7.1,NA,2.4,955%,8.4,9.7,9.6,9.63,9.56,10.42,6.3,-4.2,9.67,8.05,7.99,4.19,8.39,10.4,8.2,9.4,5.7,4.25 and 9.53,8.98,more inorganic solvent,3.59,8.88,NA,9.4,9.7 and 12.0,9.5,9.7 and8.7,6.1,5.8 and 9.3,NA,3.4,13.45,12.38,12.69,12.58,32,"6.8, 3.1, and 10.8",1.89 and 6.18,13.46±0.70., 4.22,12.45, 9.4.,8.01,5.75,NA,Pka,4.7,2.8.,1.82,4.76.,2.7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6.26,6.74,2.5,3.7,4.36,3.6 - 4.6,6.8, 9.06,2.86,9.76,8.86,9.06,8.99,1.36,1.45,NA,PkA,1.76,3.7,8.75,6.26,6.48,6.48,6.74,6.42,12.7,8.86,0.075,9.06,4.08,3.61,14.83,Pka,8.07 ( 0.02),5.9,4.07,5.16,5.13,4.07,4.31,6.92,4.32,4.07,4.32,NA,NA,NA,NA,Pka,7,4.49,4,4.0.,"2.5 (carboxyl group)
and 7.5 (amino group)",4.7,2.7,8.65,3.3 (basic),4.29,10.32 (at 25°C),6.6,6.8 (basic),3.13,7.7,Pka,9,6.808 and 6.93.,6.4,5,"strong acidic 15.7,Basic -1.8",NA,4.0.,7.5,7.7,4.7,"3.13, 4.76, and 6.40.",4,6.40.,NA,10.4,Pka,NA,8.76,0.69,1.8,NA,NA,5.2,8.7,7.51,NA,basic,acidic,not specified,NA,NA,"1.96 (Triazole nitrogen), 9.73 (Ribose hydroxyl)",3.3,"2.95, 7.25, 9.7 (three dissociation constants)",Not specified,Not specified,Not specified,5.4,"2.66, 7.24",Pka,1.8,3.1,14.1,No,14.1,8.85,6.6,NA,NA,1.5,7.5,NA,1.5,NA,4.75,3.3,3.7,4.6,5.6,3.7,5.5,7.6,7.3,6.4,6.03,6.02,7.1,NA,2.4,3.32,0.43,3.4,7.2,8.17,7.2,8.5,1.3,8.2,9.7,4.9,7.2,4.1,12.1,4.9,NA,12.1,4.9,7.4,5.7,8.3,8.4,9.3,7.4,8.73,7.6,8.1,4,5.7.,7.4,8.48,"pKa (Strongest Acidic) - 0.69
pKa (Strongest Basic) - 9.91","pKa (Strongest Acidic) - 9
pKa (Strongest Basic) - 8.42","pKa (Strongest Acidic) - 0.68
pKa (Strongest Basic) - 4.91","pKa (Strongest Acidic) - 0.66
pKa (Strongest Basic) - 9.93","pKa (Strongest Acidic) - 0.66
pKa (Strongest Basic) - 6.67","pKa (Strongest Acidic) -9.63
pKa (Strongest Basic) - 9.09",pKa (Strongest Acidic) - 0.62,pKa (Strongest Acidic) - 0.7 pKa (Strongest Basic) - (-5.1),"pKa (Strongest Acidic) -0.68
pKa (Strongest Basic) - 9.86",pKa (Strongest Acidic) - 1.63,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7.3,8.02,3.8,14.21,NA,NA,10.26,8.45,13.37,-1.5,1.72,4.76,7.1,NA,NA,8.42,"f 2.67, 7.11 and 9.55",0.65 and 3.2, pKa1 = 3.0,"pKa1 ~3.2, pKa2 ~9.9.",2.9 and 7.4.,(pKa = 7.75 at 298 K), pKa is 12.4," pKa (Strongest Acidic), 2.74, ",The pKa of tiamulin is estimated as 9.51,"pKa (Strongest Acidic), 5.49", pKa value of piperacillin was 3.19 ± 0.02 at 25°C ,pKa1 values of 1.12 and 1.62 ,(pKa 1.22 and 5.10),7.6,7.7,7.7,1.5,8.5,9.5,9.7,9.7,8.9,8.8,8.6,13.7,8.6,6.4,2.8 and 9.3,2.6,3.26,2.27,8.5,9.25,NA,5.35,9.66,3.22,8.3,2.82,7.9,9.39,5.35,8.1,~4.0,~8.4,~8.7,~4.0,~4.0,~4.0,~6.8,~7.6,~6.8,~7.7,~9.5,NA,NA,~0.95,NA,"One basic pka value is approximately
11.3 and acidic pka value is approximately 3.8","One basic pka value is approximately
12.46 and acidic pka value is approximately 4.09","One basic pka value is approximately
9.31 and acidic pka value is approximately 14.03","One basic pka value is approximately
5.8 and acidic pka value is approximately 15.41","One basic pka value is approximately
3.02 and acidic pka value is approximately 11.98","One basic pka value is approximately
20.4 and acidic pka value is approximately -6.3","One basic pka value is approximately -0.6 and acidic pka value is
approximately 6.4","One basic pka value is approximately 1.76 and acidic pka value is
approximately 1.05","One basic pka value is approximately 3.75 and acidic pka value is
approximately 1.35","One basic pka value is approximately 0.97 and acidic pka value is
approximately 1.75","One basic pka value is approximately 3.74 and acidic pka value is
approximately 18.55","One basic pka value is approximately 2.39 and acidic pka value is
approximately 13.61","One basic pka value is approximately 4.88 and acidic pka value is
approximately 3.36","One basic pka value is approximately 
-0.91 and acidic pka value is
approximately 12.44","One basic pka value is approximately 4.3 and acidic pka value is
approximately 14.29",8.3,10.1,4.76,5.68 (basic pKa),12.45,9.6,10.1,3.6,"pKa1 = 9.4, pKa2 = 11.1",10.01,3.9,Not specified,4.5,10.2,4.2,8.3,10.1,4.76,5.68 (basic pKa),12.45,9.6,10.1,3.6,"pKa1 = 9.4, pKa2 = 11.1",10.01,3.9,Not specified,4.5,10.2,4.2
Solubility in other organic solvents,"soluble in organic solvents like ethanol, methanol, chloroform, acetone","Soluble in organic solvents like ethanol, methanol, etc",Soluble in organic solvents,Moderate,"Soluble in organic solvents like methanol, ethanol, chloroform","Soluble in organic solvents like methanol, ethanol, chloroform","Soluble in organic solvents like ethanol, chloroform","Soluble in organic solvents like ethanol, chloroform","Soluble in organic solvents like ethanol, chloroform","Soluble in organic solvents like ethanol, chloroform","Soluble in organic solvents like methanol, ethanol","Soluble in organic solvents like methanol, ethanol","Soluble in organic solvents like ethanol, chloroform","Soluble in organic solvents like ethanol, chloroform",Slightly soluble,NA,Soluble in organic solvents,"Soluble in organic solvents like chloroform, ethanol",Insoluble in organic solvents,Soluble in organic solvents,"Soluble in organic solvents like chloroform, ethanol","Soluble in ethanol, slightly soluble in methanol",Soluble in chloroform and methanol,Slightly soluble in organic solvents,"Soluble in ethanol, slightly soluble in chloroform",Soluble in organic solvents,Not readily available,Soluble in organic solvents like chloroform,Soluble in organic solvents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Insoluble,Insoluble,"DMSO, ethanol, and acetone",18.5 mg/mL,"ethanol, methanol, and acetone","ethanol, methanol, and acetone","DMSO, ethanol, and acetone","DMSO, ethanol, and acetone","DMSO, ethanol, and acetone","ethanol, methanol, and DMSO",ethanol and methanol,Moderate,Moderate,Moderate,Moderate,Moderate,Moderate,Moderate,Moderate,Moderate,Moderate,Insoluble,Insoluble,Insoluble,Moderate,Soluble,NA,NA,30mg/ml,NA,NA,NA,NA,NA,NA,NA,insoluble,NA,NA,NA,"Soluble in chloroform, methanol, and ethanol.","Soluble in chloroform, methanol, and ethanol.","Soluble in chloroform, methanol, and ethanol.","Soluble in chloroform, methanol, and ethanol.","Soluble in chloroform, methanol, and ethanol.","Soluble in chloroform, methanol, and ethanol.","Soluble in chloroform, methanol, and ethanol.","Soluble in chloroform, methanol, and ethanol.","Soluble in chloroform, methanol, and ethanol.","Soluble in chloroform, methanol, and ethanol.","Soluble in chloroform, methanol, and ethanol.","Soluble in chloroform, methanol, and ethanol.","Soluble in chloroform, methanol, and ethanol.",604.13g/mol,482.62g/mol,441.233g/mol,584.1g/mol,558.14g/mol,300.05g/mol,588.562g/mol,807.890 g/mol,853.918g/mol,263.201 g/mol,427.417 g/mol,778.947 g/mol,143599.39 g/mol,406.4 g/mol,ethanol and methanol,methanol and dimethyl sulfoxide,NA,"ethanol, methanol, acetone, and chloroform",ethanol and methanol,"ethanol, methanol, and acetone",ethanol and methanol,soluble in most organic solvents,"methanol, ethanol, and dimethyl sulfoxide (DMSO)",sparingly soluble in organic solvents,"methanol, ethanol, acetone, and dimethyl sulfoxide","methanol, ethanol, acetone, and dimethyl sulfoxide",sparingly soluble,"ethanol, methanol, and acetone",practically insoluble,It is more soluble in organic solvents than in water.,"readiysoluble in solvent like ethnol, methanol and acetone",moderately soluble,dimethyl sulfoxide (DMSO),soluble in organic solvet such as dmethyl sulfoxide diethylformamide,soluble in organic solvent,Soluble in organic solvents,Soluble in organic solvents like acetone and chloroform,: Insoluble in most organic solvents,NA,Pimecrolimus is soluble in organic solvents such as ethanol.,NA,soluble,soluble,sparingly soluble,soluble,soluble,sparingly soluble,sparingly soluble,soluble,sparingly soluble,sparingly soluble,soluble,moderatey,soluble,soluble,soluble,soluble,NA,NA,NA,NA,NA,insoluble,NA,NA,NA,NA,NA,NA,NA,NA,NA,Soluble in water (0.5 mg/mL at 25 °C),4.41x10^6,soluble in water(0.0167 mg/ml),3.26x10^5,insoluble in water,sparingly soluble,0.03 g/mL at room temperature,0.016 g/mL,0.5 to 1.5 mg/mL,100 mg/mL,0.4 g/mL,150 mg/mL at 25°C.,50 mg/mL,70 mg/mL at 25°C,0.015 to 0.020 g/mL at room temperature,0.005 g/mL,low solubility,low solubility,NA,"Ranitidine is more soluble in organic solvents such as methanol, ethanol, and dimethyl sulfoxide (DMSO)","methanol, ethanol, and dimethyl sulfoxide (DMSO)",methanol and ethanol compared to water.,"methanol, ethanol, and dimethyl sulfoxide (DMSO)",Ethanol,"Methanol,propanol","DMSO,methanol","ethanol, methanol, acetone, and chloroform.","Chloroform, Acetone","ethanol, methanol, acetone, and chloroform.","ethanol, methanol, acetone, and chloroform","ethanol, methanol, acetone, and chloroform.","ethanol, methanol, acetone, and chloroform.","ethanol, methanol, acetone, and chloroform.","ethanol, methanol, acetone, and chloroform",No,It's soluble in dimethyl sulfoxide,"ethanol, DMSO, and dimethyl formamide (DMF).","soluble in methanol (7.5 mg/mL) and absolute ethanol (3.4 mg/mL); and insoluble in hexane, benzene, ethyl acetate and acetonitrile.",DMSO and dimethyl formamide,DMSO and methyl alcohol,"ethanol, DMSO, and dimethyl formamide","ethanol, DMSO, and dimethyl formamide (DMF)","Ethanol, DMSO, dimethyl formamide","butanol, hexanol, heptanol, octanol, ethyl hexanol, decanol, butyl acetate,","% monobasic potassium phosphate solution, very slightly soluble in hydrated ethanol, and practically insoluble in acetone or ether.",DMS6,"very slightly soluble in dehydrated alcohol and in dichloromethane, and soluble in dilute acetic acid.",Ethanol and acetone,"soluble in acetone, slightly soluble in methanol, ethanol, and acetonitrile,","Ethanol, Diethyl foramide, DMSO",Methanol and Ethanol,"Ethanol, Diethyl foramide","methanol, ethanol","ethanol, methanol, chloroform","ethanol, methanol","ethanol, methanol, chloroform","ethanol, methanol",sparingly soluble,sparingly soluble in ethanol and acetone,ethanol and acetone,ethanol and acetone,"Ethanol, methanol, acetone","Chloroform, ethanol","methanol, acetone",Soluble in organic solvents,Soluble in organic solvents,Soluble in organic solvents,Soluble in organic solvents,Practically insoluble in common organic solvents,"Freely soluble in acetone, methanol, and ethanol",Insoluble in most organic solvents,Soluble in organic solvents like ethanol,"Freely soluble in acetone, chloroform; sparingly soluble in methanol","Soluble in acetone, slightly soluble in ethanol",Soluble in organic solvents,Not specified,Insoluble in common organic solvents,Soluble in organic solvents,Insoluble in most organic solvents,freely soluble in ethanol,Soluble in organic solvents,Insoluble in most organic solvents,Soluble in organic solvents,Insoluble in common organic solvents,Not specified,Soluble in organic solvents,"Soluble in acetone, slightly soluble in ethanol",soluble,Soluble in organic solvents,Soluble in organic solvents,Soluble in organic solvents,Practically insoluble in common organic solvents,soluble in ethanol,"Freely soluble in acetone, chloroform; sparingly soluble in methanol",Soluble in organic solvents,"Soluble in chloroform, slightly soluble in ether",Insoluble in most organic solvents,Soluble in organic solvents,"Soluble in chloroform, acetone",Soluble in organic solvents,Soluble in organic solvents,Soluble in organic solvents,"Soluble in methanol, ethanol",Soluble in organic solvents,Soluble in organic solvents,Moderate,Soluble in organic solvents,Not Available,Soluble in organic solvents,Quinidine is more soluble in organic solvents than in water.,NA,NA,Highly soluble in ethanol and chloroform,"Soluble in ethanol, methanol, and dimethyl sulfoxide (DMSO).",ethanol and methanol.,ethanol and chloroform,"alcohol, chloroform, and ether",sparingly soluble in ethanol and methanol.,"sparingly soluble in ethanol, methanol, and chloroform.","ethanol, methanol, and chloroform",ethanol and methanol.,"chloroform, methanol, and ethanol.","ethanol, methanol, and DMSO.","chloroform, sparingly soluble in ethanol and methanol","dimethylformamide,dimethyl sulfoxide",N/A,n/a,n/a,"Soluble in DMSO, slightly soluble in methanol","Soluble in DMSO, slightly soluble in methanol","Soluble in DMSO, slightly soluble in methanol",Soluble in organic solvents,Soluble in organic solvents,Soluble in organic solvents,Soluble in organic solvents,Soluble in organic solvents,Freely soluble in organic solvents,Freely soluble in organic solvents,not specified,dimethyl formamide,not soluble,"dimethyl sulfoxide (DMSO), ethanol, and methanol.","dimethyl sulfoxide (DMSO), ethanol, and methanol.","DMSO and dimethyl formamide, with a solubility of about 16.7 mg/ml",methanol and DMSO approx 2&5mg/ml,"ethanol, DMSO, and dimethyl formamide",ethanol and DMSO," 1, 5, and 1.4 mg/ml ethanol DMSO dimethyl formamide","2 and 13 mg/ml, DMSO dimethyl formamide"," 10 and 0.5 mg/ml,","ethanol, chloroform, ethyl acetate, benzene, and ether,","ethanol, DMSO, and dimethyl formamide",limited,no,Sparingly Soluble,Sparingly Soluble,Soluble,Soluble,Sparingly Soluble,Soluble,Soluble,Soluble,Soluble,Insoluble,Insoluble,Insoluble,Soluble,Soluble,Soluble,NA,NA,NA,NA,"Ethanol-15 mg/ml,DMSO-20 mg/ml, DMFO-25 mg/ml",NA,"Soluble in ethanol, DMSO, and dimethyl formamide (DMF).",Soluble in DMSO,"Soluble in ethanol, DMSO, and dimethyl formamide (DMF).","Solubility in ethanol, DMSO, and dimethyl formamide (DMF) is Soluble in ethanol, DMSO, and dimethyl formamide (DMF).","slightly soluble in methanol, and practically insoluble in ethanol",The solubility of gefitinib in ethanol is approximately 0.3 mg/ml and approximately 20 mg/ml in DMSO and DMF.,The solubility of diazepam in WFI was 0.041 mg/ml after equilibration for 24 hours at 25 degrees C. The solubility of diazepam in the LVPs ranged from 0.04 to 0.05 mg/ml at 25 degrees C.,slightly soluble in ethanol (96 per cent).,"soluble in chloroform, slightly soluble in acetone,practically insoluble in ether","Very little soluble in D, sparingly soluble in PEG, easily soluble in MeOH.","soluble in chloroform, slightly soluble in acetone,practically insoluble in ether",NA,"The solubility of lorazepam in deionized water, 5% dextrose, lactated Ringer's, and 0.9% sodium chloride injections ","methanol, chloroform (slightly), and dehydrated alcohol.","soluble in chloroform,ethanol,methanol","Soluble in alcohol,insoluble in ether and chloroform",freely soluble in ethanol (100 mg/ml),soluble in ethanol,"freely soluble in alcohol, and practically insoluble in ether.","partially soluble in alcohol and is practically insoluble in ether, benzene, and petroleum ether."," ethanol, DMSO, and dimethyl formamide (DMF).",0.121 mg/ml,12.6 and 14.7 mg/mL,0114 mg/ml,1.3 mg/mL,101 mg/mL,42 mg /mL,0.123 mg/mL,Insoluble,0.26 mg/ml,slightly soluble,0.05 mg/ml,0.0175 mg/ml,0.00030 mg/ml,0.05mg/ml,20 g/ml at room temperature,25 mg/Lat RT,10 mg/ml at RT,0.9mg/ml,1.45mg/ml,3060mg -1,3.82*10 (-4)g/ml,94.6g/100ml,25mg/ml,5mg/ml,moderatly soluble,sparingly soluble in water,sparingly oluble,limited soluble,soluble in water,(1:1),Slightly,Not soluble,Sparingly soluble in water,sparingly,Soluble,Freely soluble,Sparingly soluble,: Sparingly,Sparingly soluble,Sparingly soluble,soluble,soluble,completely miscible,Soluble in water,sparingly soluble,245.0 mg/mL,NA,0.0127 mg/mL,83.1 mg/mL,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Solubility in water( g/mL),0.49 mg/l,0.000763 mg/mL,1mg/mL,1 mg/mL,2.7 mg/ml,<1 ?g/m,0.1 to 0.5 mg/mL,7.56-05 mg/mL,Freely soluble,3 mg/ml,4mg/ml,7.56e-05 mg/mL,0.000229 mg/mL,1.5 g/100 ml,8.64 mg/L,1.39 mg/ml,0.00964 mg/ml,0.367 mg/ml,0.00147 mg/ml,0.00148 mg/mL,0.000763 mg/ml,0.00191 mg/ml,0.00931 mg/ml,0.0978 g/mol,0.000738 mg/ml,0.000546 mg/ml,7.56-05 mg/ml,7.08 mg/ml,0.086 mg/ml,Insoluble, less than 4 ?g/mL,20 mg L in water at room temperature,34–37 µg/mL,30 mg/ml., 0.157 mg/mL,27.8 mg per 100 mL., 0.0483 mg/mL,0.124 mg/mL,0.20 mg/mL,0.103 mg/mL,less than 22.4 mg/mL,303.77 g/mo,NA,5.5 µg/ml, 0.04 mg/mL ,82.3 mg/L at 25 °C,0.2 mg/mL,NA,NA,NA,0.04 mg/mL,0.06 mg/mL,0.0049 mg/mL at 25°C,0.5 mg/mL at 25°C,0.01 mg/mL at 25°C,9 g/100 mL at 20°C,0.5 mg/mL,800 mg/mL at 25°C,1 g/mL),0.16 g/mL,0.0013 g/ml,14.5 g/ml,6.9 g/100 ml,0.0001 g/ml,0.00122 g/100 ml,0.005 g/ml,0.25 g/mL,0.04 g/mL,0.2 g/ml,0.04 g/mL,NA,0.25 g/mL,109 g/ml,0.02 g/mL,0.1 g/mL,1.05 × 10-5.g/ml,0.00102,41.9mg/ml,poorly soluble,soluble in water,NA,limited,moderated,soluble in water,NA,limited,moderated,POORLY SOLUBLE,NA,NA,Soluble,Poorly soluble,Soluble,Insoluble,Poorly soluble,Soluble,Slightly soluble,0.024 at 25°C,Solubility in water( g/mL),0.02 mg/mL,1.1 mg/mL,less than 0.1 g/mL.,0.03,0.1mg/mL,NA,NA,NA,NA,NA,NA,less than 1mg/mL,NA,NA,NA,Solubility in water( g/mL),6.4mg/ml,limited solubilty,freely soluble,0.01g/ml,poorly soluble,slightly soluble,SLIGHTLY SOLUBLE,practically soluble,poorly soluble,0.01g/mol,slightly soluble,slghtly soluble,soluble,insoluble,0.121 mg/ml,12.6 and 14.7 mg/mL,0114 mg/ml,1.3 mg/mL,101 mg/mL,42 mg /mL,0.123 mg/mL,Insoluble,0.26 mg/ml,slightly soluble,0.05 mg/ml,0.0175 mg/ml,0.00030 mg/ml,0.05mg/ml,20 g/ml at room temperature,25 mg/Lat RT,10 mg/ml at RT,0.9mg/ml,1.45mg/ml,3060mg -1,3.82*10 (-4)g/ml,94.6g/100ml,25mg/ml,5mg/ml,moderatly soluble,sparingly soluble in water,sparingly oluble,limited soluble,soluble in water,(1:1),Slightly,Not soluble,Sparingly soluble in water,sparingly,Soluble,Freely soluble,Sparingly soluble,: Sparingly,Sparingly soluble,Sparingly soluble,soluble,soluble,completely miscible,Soluble in water,sparingly soluble,NA,Solubility in water( g/mL),245.0 mg/mL,NA,0.0127 mg/mL,83.1 mg/mL,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.49 mg/l,0.000763 mg/mL,1mg/mL,1 mg/mL,2.7 mg/ml,<1 ?g/m,0.1 to 0.5 mg/mL,7.56-05 mg/mL,Freely soluble,3 mg/ml,4mg/ml,7.56e-05 mg/mL,0.000229 mg/mL,1.5 g/100 ml,8.64 mg/L,NA,Solubility in water (g/ml),1.39 mg/ml,0.00964 mg/ml,0.367 mg/ml,0.00147 mg/ml,0.00148 mg/mL,0.000763 mg/ml,0.00191 mg/ml,0.00931 mg/ml,0.0978 g/mol,0.000738 mg/ml,0.000546 mg/ml,7.56-05 mg/ml,7.08 mg/ml,0.086 mg/ml,Insoluble,Solubility in water( g/mL), less than 4 ?g/mL,20 mg L in water at room temperature,34–37 µg/mL,30 mg/ml., 0.157 mg/mL,27.8 mg per 100 mL., 0.0483 mg/mL,0.124 mg/mL,0.20 mg/mL,0.103 mg/mL,less than 22.4 mg/mL,303.77 g/mo,NA,5.5 µg/ml, 0.04 mg/mL ,Solubility in water( g/mL),82.3 mg/L at 25 °C,0.2 mg/mL,NA,NA,NA,0.04 mg/mL,0.06 mg/mL,0.0049 mg/mL at 25°C,0.5 mg/mL at 25°C,0.01 mg/mL at 25°C,9 g/100 mL at 20°C,0.5 mg/mL,800 mg/mL at 25°C,1 g/mL),0.16 g/mL,Solubility in water( g/mL),0.0013 g/ml,14.5 g/ml,6.9 g/100 ml,0.0001 g/ml,0.00122 g/100 ml,0.005 g/ml,0.25 g/mL,0.04 g/mL,0.2 g/ml,0.04 g/mL,NA,0.25 g/mL,109 g/ml,0.02 g/mL,0.1 g/mL,Solubility in water( g/mL),1.05 × 10-5.g/ml,0.00102,41.9mg/ml,poorly soluble,soluble in water,NA,limited,moderated,soluble in water,NA,limited,moderated,POORLY SOLUBLE,NA,NA,Soluble,Poorly soluble,Soluble,Insoluble,Poorly soluble,Soluble,Slightly soluble,0.024 at 25°C,Solubility in water( g/mL),0.02 mg/mL,1.1 mg/mL,less than 0.1 g/mL.,0.03,0.1mg/mL,NA,NA,NA,NA,NA,NA,less than 1mg/mL,NA,NA,NA,6.4mg/ml,limited solubilty,freely soluble,0.01g/ml,poorly soluble,slightly soluble,SLIGHTLY SOLUBLE,practically soluble,poorly soluble,0.01g/mol,slightly soluble,slghtly soluble,soluble,insoluble,YES,YES,YES,SLIGHTLY,YES,YES,SLIGHTLY,YES,YES,FREELY,NO,YES,FREELY,POORLY SOLUBLE,SLIGHTLY,NA,POORLY SOLUBLE,SLIGHTLY,YES,SLIGHTLY,YES,YES,SLIGHTLY,YES,SLIGHTLY,SLIGHTLY,YES,14 mg/mL,3.5 mg/mL.,4.5 g/ml,0.03 mg/ml,16.9 mg/mL,0.000512 mg/mL,10.4 mg/mL,13.4 mg/mL,3.27 mg/mL,0.000564 mg/mL,7.47 mg/mL,11.5 mg/mL,15.8 mg/mL,2.17 mg/mL,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.247 mg/ml poorly soluble,low soluble in water 5.09 mg/ml,partially in soluble in water,0.00155 mg/ml poor water soluble,poorly soluble in water,Highly soluble,0.0499 mg/ml,0.0112 mg/ml,0.0422 mg/ml,very slightly soluble at pH 1,1.36 mg/ml,0.6 mg/l,<1mg/ml,50 mg/ml,NA, soluble in water (50 mg/ml)., 1 mg/ml. , 1 or 2 mg/mL, approximately 6.7.,readily soluble in water, approximately 5 mg/ml.," readily soluble in water, ",0.213 mg/mL, (>50mg/ml).,water at pH <5., soluble in water (24 mg/ml),0.34 mg/mL,0.0173 mg/mL, 8.6 mg/mL.,0.22g/L,1 g/ml,Moderately soluble,Highly soluble,0.4g/100ml,Moderately soluble,Highly soluble,Highly soluble,Limited solubilty,200 mg /ml,0.0095mg/ml,1.4 mg /ml,20 mg/ml,Limited solubility,Limited Solubility,0.958 mg/mL,10mg/mL,0.0441mg/ml,0.514mg/ml,1.33mg/ml,NA,1.44mg/ml,53.7 mg/mL,0.286 mg/mL,50mg/ml,0.017g/ml,29.3 mg/mL,5.63mg/ml,0.21mg/ml,50mg/ml,"Slightly soluble, around 0.5 mg/mL at 25°C","Slightly soluble, about 0.09 mg/mL at 25°C.","Slightly soluble, about 0.004 mg/mL at 25°C.","Slightly soluble, about 0.3 mg/mL at 25°C.","Slightly soluble, about 0.25 mg/mL at 25°C","Slightly soluble, about 0.11 mg/mL at 25°C","Freely soluble, about 1.5 mg/mL at 25°C","Freely soluble, about 2.5 mg/mL at 25°C.","Moderately soluble, about 100 mg/mL at 25°C","Moderately soluble, about 14 mg/mL at 25°C.","Limited solubility, approximately 0.01 g/mL at 25°C",NA,NA,Poorly soluble in water,Limited solubility in water,It is soluble in water is 36mg/ML,It is soluble in water is 0.38mg/mL,It is soluble in water is 0.686mg/ML,It is soluble in water is 1.21mg/ML,It is soluble in water is 1.2 to 1.6mg/ML,It is soluble in water is 170mg/ML,It is soluble in water is 1mg/ML,It is soluble in water is 22mg/ML,It is soluble in water is 19 mg/mL,It is soluble in water is 0.431 mg/mL,It is soluble in water is 1.87 mg/mL,It is soluble in water is 0.0491 mg/mL,It is soluble in water is 4-5 mg/mL,It is soluble in water is 0.0234 mg/mL,It is soluble in water is 20.1 mg/mL,Practically insoluble,0.17,6.7 mg/mL at 25 °C,0.017 (at 25°C),250 mg/mL at 25°C,0.02,0.0024,Practically insoluble,0.056 (at 25°C),Soluble,~0.5,Not specified,40 mg/mL (at 25°C),0.09 (at 25°C),0.04,Practically insoluble,0.17,6.7 mg/mL at 25 °C,0.017 (at 25°C),250 mg/mL at 25°C,0.02,0.0024,Practically insoluble,0.056 (at 25°C),Soluble,~0.5,Not specified,40 mg/mL (at 25°C),0.09 (at 25°C),0.04
Molecular Weight (Daltons),135.21 g/mol,149.24 g/mol,233.31 Da,135.2062 g/mol,~273.35 g/mol,~273.35 g/mol,~165.23 g/mol,~303.35 g/mol,~194.19 g/mol,~162.23 g/mol,~291.41 g/mol,~149.23 g/mol,~177.26 g/mol,~240.35 g/mol,197.19,151.27 Da,215.28,187.27,305.27,219.32 Da,303.4,211.32,260.37 g/mol,302.36,267.34 g/mol,750.62,406.5,337.48,273.24 Da,Molocular Weight, 343.21,300.7,281.266,284.74,321.2,226.4,305.54,318.9,315.71,212.25,387.9,371.87,286.7,259.35,450.91,300.05 Da,454.44 Da,194.15 Da,"Slightly soluble in ethanol, acetone",169.21 Da,811.04 Da,421.46 Da,586.68 Da,588.59 Da,853.91 Da,392.47 Da,344.837 g/mol,416.127 g/mol,531.431 g/mol,349.3 g/mol,700.8 g/mol,306.271 g/mol,705.64 g/mol,291.43 g/mol,317.47 g/mol,287.398 g/mol,926.1 g/mol,"1,270.28 g/mol","1,291.4 g/mol",352.76 g/mol,307.411 g/mol,5826 Dalton,approx 445.5 Dalton,270 Dalton,645 Dalton,207 Dalton,490.6 Dalton,268.25 Dalton,356.44 Dalton,165.63 Dalton,6063.0 Dalton,5807.7 Dalton,5825.8 Dalton,452.6 Dalton,472.55 Dalton,309.33 g/mol,306.30g/mol,297.35 g/mol,239.31 g/mol,329.80 g/mol,NA,NA,NA,NA,NA,NA,NA,NA,­,Type II and Type III,crystal,­,crystal,crystal,crystal,crystal,crystal,crystal,crystal,crystal,crystal,crystal,277.25 grams,635.5 grams,476.52 g/mol,229.25 grams,501.44,229.3 (g/mol),273.21 grams,476.52 grams,229.2,409.4 g/mol,489.63 grams,229.21 gram,247.24 grams,613.76 grams,501.43 grams,277.2g/mol,326.44 dalton,437.7g/mol,454.444 g/mol,76.055 g/mol,1202.6 dalton,466.97 Da,Approximately 392.47 Daltons,412.65,351.1dalton,810.05 dalton,148 kda,4615g/mol,approx 326.42g/mol,352.27 dalton,303.4,345.49,320.88,312.4,365.88,348.45,534.6,343.88,318.86,375.27,348.44,312.4,332.47,"5,810dalton",6063.0Dalton,5916.9 Dalton,5808.0Dalton,6103.97Dalton,5807.7Dalton,5823.0Dalton,3949.44Dalton,5825.8Dalton,490.62Dalton,"1,007.2 daltons",150000.0 daltons,6063.0Dalton,5825.8Dalton,NA,"ethanol, methanol, acetone, chloroform.","ethanol, DMSO, dimethyl formamide","limited solubility in chloroform,ethanol","limited soludity in ethanol,methanol",NA,"ethanol,methanol,chloroform",sparingly soluble,limited soludity,"more soluble eg methano,chloroform,ethanol",NA,mostly soluble,limited solubility,sparingly soluble,sparingly soluble,most organic solvents.,mostly soluble in organic solvent,higher solubility,soluble,NA,314.4 Daltons.,252.34 g/mol.,approximately 337.43 g/mol.,252.34 g/mol.,approximately 368.51 g/mol.,approximately 427.58 g/mol.,approximately 441.59 g/mol.,approximately 375.62 g/mol.,approximately 461.1 g/mol,approximately 534.6 g/mol.,approximately 392.4 g/mol.,approximately 471.64 g/mol.,approximately 412.94 g/mol.,approximately 386.50 g/mol.,approximately 331.39 g/mol.,585.6 g /mol,592.69 g/mol,749.0 g/mol,365.4 g/mol.,415.42 g·mol?1,414.45 g·mol?1,349.406 g/mol,250.28 g·mol?1,631.5,334.39 g/mol,383.464 g/mol,347.39 g/mol,331.346 g/mol,666.18g/mol,747.953 g/mol,239.311 g\mol,180.16 g/mol,225.35 g/mol,410.4 g/mol,430.54 g/mol,392.5 g/mol,586.07 g/mol,575.73 g/mol,512.4 g/mol,310.42 g/mol,362.47 g/mol,360.44 g/mol,521.4 g/mol,430.5 g/mol,443.52 g/mol,252.3,236.27,144.21,256.09,170.21,339.36,252.27,300.7,238.21 g/mol,129.1,312.44,Not specified,171.24,212.22,159.23,232.26 dalton,252.3,159.23,212.22,171.24,Not specified,312.44,129.1,141.16,144.21,256.09,236.27,170.21,284.74,238.21 g/mol,318.86,371.96,480.9,395.54,375.3,327.82,326.87,410.48,448.38,433.57 g/mol,285.77,384.85,331.83,427.51,448.94,324.42 g/mol,221.67 Dalton,380.9 Daltons,234.34 Daltons,179.26 Daltons.,267.7 Daltons.,267.24 Daltons,780 Daltons,454.98 Daltons.,414.5 Daltons.,259.34 Daltons,331.82 g/mol.,645.3 Daltons,272.35 g/mol,336.4 Daltons,145000,149000,263.21,501.5,146000,NA,147000,426.85,637.02,560.61,428.37,147000,482.95,482.95,465.53,454.44g/mol,156.05 g/mol,189.22g/mol,210.28g/mol,264.30 g/mol,305.20 g·mol?1,358.262 g/mol,233.69 g/mol, 261.086 g/mol, 1457.4 g/mol,588.56.,304.71g/mol,221.30 g/mo,285.2 g,182.17 g,345.42 dalton,369.36 dalton,252.34 dalton,314.38 dalton,330.43 dalton,361.47 dalton,382.55 dalton,247.3 dalton,258.07 dalton,84.01 dalton,2100-4000 dalton,391.3 dalton,365.41 dalton,747.01 dalton,171.14 dalton, 853.906 g/mol,301.1 g/mol, 519.08 g/mol,807.879g/mol,540.0 g/mol,454.4 g/mol,450.337 g/mol,778.932 g/mol,584.1 g/mol.,429.9g/mol.,263.198 g/mol,446.90 g/mol,284.7 g/mol,286.71 g/mol,374.904 g\mol,259.34 g\mol, 422.0 g/mol. ,395.9 g\mol,321.2 g/mol,230.093 g/mol,308.765 g/mol,226.27 g/mol,232.235 g/mol,299.75 g/mol,226.276 g/mol,264.32 g/mol,374.8 g/mol ,0.1 and 0.2 mg/ml,0.1 mg/ml,8 mg/mL,10-30 mg/mL,30 mg/ml,15 mg/ml,72mg/ml,750 g/mL,11-20 mg/ml,11-14 mg/ml,30mg/ml,61.9 mg/ml,25-50 mg/ml,1-20mg/ml,0.2-10 mg/ml,50 Mg/ml,more soluble in ethanol,propylene glycol,"ethanol,DMSO","ethanol,DMSO",ethanol,methanol and hcl,Dimethyl formamide,ethanol,"ethanol ,methanol",ethanol and methanol,ethanol and methanol,ethanol and chloroform,ethanol and methanol,"alcohol ,ether",Saparingly soluble in methanol,Slightly soluble,soluble,soluble,Soluble,sparingly soluble,soluble,solube,soluble,soluble,soluble,soluble,NA,Soluble,freely soluble,slightly soluble in organic solvents like ethanol and ether.,limited solubility in organic solvents.,sparingly soluble in organic solvents.,soluble in alcohol and other organic solvents.,soluble in organic solvents like methanol and ethanol.,soluble in organic solvents such as chloroform.,less soluble in most organic solvents.,soluble in organic solvents like ethanol and acetone.,soluble in organic solvents like methanol,slightly soluble in organic solvents like ethanol.,soluble in some organic solvents like acetone.,soluble in organic solvents such as ethanol and acetone.,soluble in some organic solvents like ethanol.,soluble in organic solvents like ethanol.,soluble in organic solvents like ethanol.,Solubility in other organic solvents,20 mg/ml,0.1 mg/ml ,16 mg/ml,0.7 grams/ml,20 mg/m,less than 1 g/m,0.5 - 1.5 g/100 mL,?23.6 mg/mL,4.30%,NA,5.00%,2%,5 mg/ml,NA,2.95 mg/mL,306.271 g/mol,705.633 g/mol,1093.331 g/mol,344.837 g/mol,381.684 g/mol,416.129 g/mol,429.12 g/mol,531.431 g/mol,349.310 g/mol,291.429 g/mol,307.409 g/mol,317.467 g/mol,122.123 g/mol,926.107 g/mol,700.777 g/mol,Lightly soluble in methylene chloride (Dichloromethane) and very slightly soluble in methanol.,Glipizide is soluble in organic solvents such as DMSO and dimethyl formamide,"freely soluble in methylene chloride, sparingly soluble in acetone and slightly soluble in ethanol"," organic solvents such as ethanol, DMSO, and dimethyl formamide","in organic solvents such as ethanol, acetone, and chloroform.","in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF).","freely soluble in dimethylformamide, sparingly soluble in acetone, slightly soluble in methanol and in ethanol ",soluble in organic solvents such as DMSO and dimethyl formamide,"slightly soluble in alcohol,soluble in acetone",NA,NA,NA,NA,NA," in aqueous solutions of methanol, n-propanol, isopropanol,","Soluble in organic solvents
like methanol, ethanol","Soluble in methanol, ethanol, and dimethyl sulfoxide; slightly soluble in acetonitrile","Soluble in organic
solvents like
methanol, ethanol.",NA,NA,"Soluble in methanol, ethanol, and dimethyl sulfoxide; slightly soluble in acetonitrile","Soluble in methanol, ethanol, and dimethyl sulfoxide",Soluble in organic solvents such as methanol and dimethyl sulfoxide,"methanol, ethanol, and chloroform",Soluble in organic solvents such as methanol and ethanol,ether and chloroform.,"methanol, ethanol, and dimethyl sulfoxide",methanol and ethanol,ether and chloroform.,"ethanol, methanol, and dimethyl sulfoxide (DMSO)","It has high solubility in acids, like hydrochloric acid,
but limited solubility in nonpolar or organic solvents.","ethanol, methanol, and dimethyl sulfoxide","insoluble in ethanol and slightly soluble in
methanol and acetone.","Practically Insoluble in H2O &ethanol,soluble in hydrochloric acid and sodium hydroxide.","soluble in dilute acid and ammonium salt solution,but almost insoluble in H2O,alcohol.",Sparingly soluble in other organic solvents such as ethanol and acetone.,"ethanol, methanol,acetone, and dimethyl sulfoxide(DMSO)","sparingly soluble in most organic solvents such as ethanol, acetone,chloroform","Soluble in various organic solvents such as methanol, acetone, and dimethyl sulfoxide (DMSO),ethanol.","More soluble in organic solvents like methanol, ethanol, acetone, and dimethyl sulfoxide","more soluble in polar organic solvents such as ethanol &
acetone compared to nonpolar solvents like hexane or benzene","sparingly soluble in ethanol, methanol, and acetone, but it is freely soluble in dimethyl sulfoxide, & dimethyl
formamide.","soluble in organic solvents such as ethanol, methanol,
acetone, and ethyl acetate","sparingly soluble in most organic solvents,including ethanol,
acetone, and ether",sparingly soluble in organic solvents such as ethanol and acetone,soluble in organic solvent,Soluble in organic solvents,NA,soluble in organic solvrnts,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Insoluble in most organic solvents,Soluble in organic solvents,Insoluble in most organic solvents,Slightly soluble,Not specified,Not specified,Not specified,"Soluble in acetone, sparingly soluble in ethanol, practically insoluble in hexane",Solubility in other organic solvents,ethanol & methanol,"ethanol, methanol, chloroform",NA,"ethanol, methanol, acetone, and dimethyl sulfoxide (DMSO).",ethanol & methanol,"ethanol,acetonitrile",chloroform & ethanol,protein,ethanol,"carmustine , sparingly",NA,sparingly,NA,sparingly,sparingly,Solubility in other organic solvents,soluble in organic solvents like dmso,in organic solvents,practically insoluble in organic solvents,in organic solvents,in organic solvents,in organic solvents,SOLUBLE IN ORGANIC SOLVENTS,insoluble,soluble in organic solvents,organic solvents,soluble in organic solvents,soluble in organic solvents,not well documented,soluble in dmso,0.1 and 0.2 mg/ml,0.1 mg/ml,8 mg/mL,10-30 mg/mL,30 mg/ml,15 mg/ml,72mg/ml,750 g/mL,11-20 mg/ml,11-14 mg/ml,30mg/ml,61.9 mg/ml,25-50 mg/ml,1-20mg/ml,0.2-10 mg/ml,50 Mg/ml,more soluble in ethanol,propylene glycol,"ethanol,DMSO","ethanol,DMSO",ethanol,methanol and hcl,Dimethyl formamide,ethanol,"ethanol ,methanol",ethanol and methanol,ethanol and methanol,ethanol and chloroform,ethanol and methanol,"alcohol ,ether",Saparingly soluble in methanol,Slightly soluble,soluble,soluble,Soluble,sparingly soluble,soluble,solube,soluble,soluble,soluble,soluble,NA,Soluble,freely soluble,NA,Solubility in other organic solvents,slightly soluble in organic solvents like ethanol and ether.,limited solubility in organic solvents.,sparingly soluble in organic solvents.,soluble in alcohol and other organic solvents.,soluble in organic solvents like methanol and ethanol.,soluble in organic solvents such as chloroform.,less soluble in most organic solvents.,soluble in organic solvents like ethanol and acetone.,soluble in organic solvents like methanol,slightly soluble in organic solvents like ethanol.,soluble in some organic solvents like acetone.,soluble in organic solvents such as ethanol and acetone.,soluble in some organic solvents like ethanol.,soluble in organic solvents like ethanol.,soluble in organic solvents like ethanol.,NA,NA,NA,NA,NA,20 mg/ml,0.1 mg/ml ,16 mg/ml,0.7 grams/ml,20 mg/m,less than 1 g/m,0.5 - 1.5 g/100 mL,?23.6 mg/mL,4.30%,NA,5.00%,2%,5 mg/ml,NA,2.95 mg/mL,NA,Molocular Weight (Dalton),306.271 g/mol,705.633 g/mol,1093.331 g/mol,344.837 g/mol,381.684 g/mol,416.129 g/mol,429.12 g/mol,531.431 g/mol,349.310 g/mol,291.429 g/mol,307.409 g/mol,317.467 g/mol,122.123 g/mol,926.107 g/mol,700.777 g/mol,Solubility in other organic solvents,Lightly soluble in methylene chloride (Dichloromethane) and very slightly soluble in methanol.,Glipizide is soluble in organic solvents such as DMSO and dimethyl formamide,"freely soluble in methylene chloride, sparingly soluble in acetone and slightly soluble in ethanol"," organic solvents such as ethanol, DMSO, and dimethyl formamide","in organic solvents such as ethanol, acetone, and chloroform.","in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF).","freely soluble in dimethylformamide, sparingly soluble in acetone, slightly soluble in methanol and in ethanol ",soluble in organic solvents such as DMSO and dimethyl formamide,"slightly soluble in alcohol,soluble in acetone",NA,NA,NA,NA,NA," in aqueous solutions of methanol, n-propanol, isopropanol,",Solubility in other organic solvents,"Soluble in organic solvents
like methanol, ethanol","Soluble in methanol, ethanol, and dimethyl sulfoxide; slightly soluble in acetonitrile","Soluble in organic
solvents like
methanol, ethanol.",NA,NA,"Soluble in methanol, ethanol, and dimethyl sulfoxide; slightly soluble in acetonitrile","Soluble in methanol, ethanol, and dimethyl sulfoxide",Soluble in organic solvents such as methanol and dimethyl sulfoxide,"methanol, ethanol, and chloroform",Soluble in organic solvents such as methanol and ethanol,ether and chloroform.,"methanol, ethanol, and dimethyl sulfoxide",methanol and ethanol,ether and chloroform.,"ethanol, methanol, and dimethyl sulfoxide (DMSO)",Solubility in other organic solvents,"It has high solubility in acids, like hydrochloric acid,
but limited solubility in nonpolar or organic solvents.","ethanol, methanol, and dimethyl sulfoxide","insoluble in ethanol and slightly soluble in
methanol and acetone.","Practically Insoluble in H2O &ethanol,soluble in hydrochloric acid and sodium hydroxide.","soluble in dilute acid and ammonium salt solution,but almost insoluble in H2O,alcohol.",Sparingly soluble in other organic solvents such as ethanol and acetone.,"ethanol, methanol,acetone, and dimethyl sulfoxide(DMSO)","sparingly soluble in most organic solvents such as ethanol, acetone,chloroform","Soluble in various organic solvents such as methanol, acetone, and dimethyl sulfoxide (DMSO),ethanol.","More soluble in organic solvents like methanol, ethanol, acetone, and dimethyl sulfoxide","more soluble in polar organic solvents such as ethanol &
acetone compared to nonpolar solvents like hexane or benzene","sparingly soluble in ethanol, methanol, and acetone, but it is freely soluble in dimethyl sulfoxide, & dimethyl
formamide.","soluble in organic solvents such as ethanol, methanol,
acetone, and ethyl acetate","sparingly soluble in most organic solvents,including ethanol,
acetone, and ether",sparingly soluble in organic solvents such as ethanol and acetone,Solubility in other organic solvents,soluble in organic solvent,Soluble in organic solvents,NA,soluble in organic solvrnts,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Insoluble in most organic solvents,Soluble in organic solvents,Insoluble in most organic solvents,Slightly soluble,Not specified,Not specified,Not specified,"Soluble in acetone, sparingly soluble in ethanol, practically insoluble in hexane",Solubility in other organic solvents,ethanol & methanol,"ethanol, methanol, chloroform",NA,"ethanol, methanol, acetone, and dimethyl sulfoxide (DMSO).",ethanol & methanol,"ethanol,acetonitrile",chloroform & ethanol,protein,ethanol,"carmustine , sparingly",NA,sparingly,NA,sparingly,sparingly,soluble in organic solvents like dmso,in organic solvents,practically insoluble in organic solvents,in organic solvents,in organic solvents,in organic solvents,SOLUBLE IN ORGANIC SOLVENTS,insoluble,soluble in organic solvents,organic solvents,soluble in organic solvents,soluble in organic solvents,not well documented,soluble in dmso,YES,SPARINGLY,YES,"YES, IN ACETONE & ETHANOL",INSOLULE,LOW,NA,YES,YES,"YES, ETHANOL",YES,SPARINGLY SOLULE IN ETHANOL & METHANOL,"YES, IN ETHANOL","YES , EDTA","YES, ETHANOL, ACETONE",NA,"YES , EDTA","YES, ETHANOL, ACETONE",NA,NA,NA,NA,NA,NA,NA,"YES, ETHANOL",NA,"acetonitrile, slightly soluble in methanol, practically insoluble in ethanol",practically insoluble in most organic solvents.,NA,"YES, ETHANOL",Very slightly soluble in Alcohol,"Freely soluble in dimethylsulfoxide; sparingly soluble in methanol; slightly soluble in alcohol; very slightly soluble in water, isopropyl alcohol, octanol.",Insoluble,NA,insoluble,"ethanol, dimethyl formamide",NA,NA,soluble in dimethylsulfoxide,insoluble in methanol,NA,NA,NA,NA,NA,213–215 ºC,198-202° C,16-19 ° C,195 ° C,"165-166 °C
",464 to 473 °F,243.5°C,148-151 °C,~ 87-92°C,Approximately 155-160°C,71 °C,240-243°C,Not applicable (peptide),Not applicable (biological macromolecule),do not have a specific melting point,NA,poorly soluble,slightly soluble in organic solvent,sparingling soluble in organic solvent,"higher solubility in organic solvents like methanol, etanol, and DMSO",slightly soluble,poorly soluble,"it is soluble in organic solvents like ethanol,DMSO, and dimethyl formamide","Encorfenib is soluble in organic solvents like ethanol, DMOS,and dimethyl formamide (DMF).The solubility is approximately 15,20,and 25 mg/ml, respectively",it is soluble in organic solvent such as dimethyl sulfoxide (DMSO) and acetonitrile,The solubility of dabrafenib in ethanol is approximately 1 mg/ml and approximately 30 mg/ml in DMSO and DMF,"Dacarbazine is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide,approximately 0.2, 0.5, and 0.3 mg/ml, respectively.
",NA,Vemurafenib is soluble in organic solvents at 25 °C ,NA,NA,Ampicillin is reported as slightly soluble in water,"soluble in methanol (7.5 mg/mL) and absolute ethanol (3.4 mg/mL); and insoluble in hexane, benzene, ethyl acetate and acetonitrile.",". DMSO, 5 mg/mL (14.39 mM).","sparingly soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide.","more soluble in water than in ethanol,",soluble in organic solvents such as DMSO and dimethyl formamide. ,moderately soluble in aqueous methanol,The solubility of omadacycline in these solvents is approximately 1 mg/ml. Omadacycline is slightly soluble in ethanol,soluble in organic solvents such as DMSO and dimethyl formamide.,"Tiamulin (fumarate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide.",Moxifloxacin (hydrochloride) is soluble in organic solvents such as DMSO and dimethyl formamide.,"Piperacillin (sodium salt) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide",is soluble in organic solvents such as DMSO and dimethyl formamide. ,"Organic solvent, first dissolves crude product with water","Ethanol,acetone , chloroform",Acetone and ethanol,Sparingly soluble,Limited,"Better solubility in acetone,ethyl acetate nitromethane",Sparingly soluble,Limited solubilty,Low solubility,Higher solubilty,Sparingly soluble,Better solubility in methanol and ethanol,Soluble in methanol and ethanol,Soluble in ethanol and menthol,Soluble in ethanol and methanol,Soluble in ethanol and methanol,"Antiboitic, bacterial infection","Antiboitic, bacterial infection","Antiboitic, bacterial infection","Antiboitic, respiratory and skin infection","Antiboitic, bacterial infection","Antiboitic, skin and soft tissue infection",Antiboitic,Antibiotic,Antibotics,Antibiotic,Antibiotic,Antibiotic,Antibiotic,Antibiotic,Antibiotic,"methanol, ethanol, and dimethyl sulfoxide (DMSO).","methanol, ethanol, and DMSO","methanol, ethanol, and DMSO.","methanol, ethanol, and DMSO.","methanol, ethanol, and DMSO.","methanol, ethanol, and DMSO.","methanol, ethanol, and DMSO.","methanol, ethanol, and DMSO.","methanol, ethanol, and DMSO.","methanol, ethanol, and DMSO.","methanol, ethanol, and DMSO.","methanol, ethanol, and DMSO","methanol, ethanol, and DMSO","methanol, ethanol, and DMSO","ethanol, methanol, and DMSO",It is insoluble in ethanol,"Zanamivir is soluble in the organic 
solvent DMSO at a concentration of approximately 0.13 mg/ml.",Oseltamivir (phosphate) is soluble in organic solvents such as DMSO and dimethyl formamide(10 & 0.5mg/mL),"Abacavir (sulfate) is soluble in
the organic solvent DMSO at a 
concentration of approximately 0.15 mg/ml",Acyclovir is soluble in organic solvents such as DMSO and dimethyl formamide(16 & 1mg/mL),"It is slightly soluble in ethanol (<1 mg/mL), methanol",Valacyclovir is soluble in organic solvents such as DMSO and dimethyl formamide(1mg/mL),Cidofovir is soluble in organic solvents such as DMSO (2mg/mL),"Adefovir dipivoxil is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide(30mg/mL)",Fostemsavir is soluble in organic solvents such as DMSO (100mg/mL),"Tenofovir is soluble in organic 
solvents such as ethanol, DMSO, and dimethyl formamide(15,14 & 16mg/mL)","Amprenavir is soluble in organic 
solvents such as ethanol, DMSO, and dimethyl formamide(30mg/Ml)","Atazanavir is soluble in organic
solvents such as ethanol, DMSO, and dimethyl formamide(2,16,25mg/Ml)","Freely soluble in methanol, ethanol, and
isopropanol","Combivir is soluble in organic 
solvents such as ethanol, DMSO, and dimethyl formamide",Soluble in organic solvents,Soluble in organic solvents,Soluble in organic solvents,Soluble in organic solvents,Practically insoluble in common organic solvents,"Freely soluble in acetone, methanol, and ethanol",Insoluble in most organic solvents,Soluble in organic solvents like ethanol,"Freely soluble in acetone, chloroform; sparingly soluble in methanol","Soluble in acetone, slightly soluble in ethanol",Soluble in organic solvents,Not specified,Insoluble in common organic solvents,Soluble in organic solvents,Insoluble in most organic solvents,Soluble in organic solvents,Soluble in organic solvents,Soluble in organic solvents,Soluble in organic solvents,Practically insoluble in common organic solvents,"Freely soluble in acetone, methanol, and ethanol",Insoluble in most organic solvents,Soluble in organic solvents like ethanol,"Freely soluble in acetone, chloroform; sparingly soluble in methanol","Soluble in acetone, slightly soluble in ethanol",Soluble in organic solvents,Not specified,Insoluble in common organic solvents,Soluble in organic solvents,Insoluble in most organic solvents
Polymorphism (if Exist name the form),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not specified,Multiple forms,No polymorphs reported,Not specified,Not specified,Exist (Specify form if known),Not reported,Existence not specified,Not specified,Not available,Not specified,Polymorphic forms exist,Not readily available,No specific polymorphs mentioned,Not specified,Polymorphism,crystal polymorphism,crystalline,polymorphism(21 forms),Crystalline,Not specified,Not specified,Crystalline,NA,crystalline,micro-crystalline,NA,crystalline,crystalline,crystalline,crystalline,Not specified,Not specified,Not specified,311.34 Da,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,CMZ polymorph, ?-cyclodextrin,—,Voriconazole (1R)-(-)- 10-camphorsulfonate.,—,"FLU I, II, III, or IV,","Forms I, II, and III",—,Butenafine Hydrochloride - API,"I types, II types, type III and IV types","polyene antibiotics mepartricin and nystatin ... Antibiotics, polyene—mepartricin and nystatin",Mycamine,—,form II and form III,thiocarbamate fungicidal,Amorphous form,crystalline form,crystalline form,no polymorphim,crystal form,crystal form,crystal form,crystal form,crystal form,crystal form,Amophous,Amorphous form,crystal form,crystal form,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Oral,Oral,Oral,Oral,Oral,intravenous,Intravenous,Intravenous,Intravenous,Intravenous,Intravenous,Intravenous,Intravenous,Oral,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,not readily available,NA,NA,it is not readily awalable,NA,multial polymorphic form,Specific details may vary based on the formulation,Specific polymorphic forms not commonly discussed,NA,NA,NA,NA,NA,NA,NA,hyoscine hydrobromide,NA,NA,NA,NA,NA,NA,NA,multipe form,monomorphic,NA,NA,NA,Amorphous form,Crystal form,crystal form,Amorphous form,Crystal form,Amorphous,Amorphous,Amorphous,Amorphous,Amorphous,Amorphous,Crystal,Amorphous/Crystal,Amorphous form,Crystal form,319.872 g/mol,355.86 g/mol,640.99 g/mol,414.42g/mol,324.41 g/mol,324.43 g/mol,253.73 g/mol,248.71 g/mol,259.29 g/mol,310.36 g/mol,267.3 g/mol,444.44 g/mol,424.98 g/mol,384.4 g/mol,298.4 g/mol,~384.55 g/mol,528.97 g/mol,366.84 g/mol,NA,"Forms I, II, and III.",Not exist.,may vary,Not exist.,May vary,"may exhibit polymorphism, meaning it can exist in different crystalline forms or polymorphs",it can exist in different crystalline forms or polymorphs,may vary.,polymorphism of Pimozide may vary.,polymorphism of Piperaquine may vary.,May vary,it can exist in different crystalline forms or polymorphs. Specific information about the polymorphism of Terfenadine may vary.,"Ziprasidone may exhibit polymorphism, meaning it can exist in different crystalline forms or polymorphs","Mesoridazine may exhibit polymorphism, meaning it can exist in different crystalline forms or polymorphs. Specific information about the polymorphism of Mesoridazine may vary.",": Nizatidine may exhibit polymorphism, meaning it can exist in different crystalline forms or polymorphs",Amorphous form,Amorphous form,Amorphous form,"There are generally three different hydrate forms of amoxicillin: monohydrate, dihydrate, and trihydrate.",NA,Crystalline,"monohydrate, trihydrate, forms I and II.","polymorphs (SDZ-PIP ? and SDZ-PIP II), SDZ-PIP ? is the more stable form at low temperature, room temperature and high temperature.",Crystalline from,Crystalline form,Crystalline form,NA,Crystalline form,Crystalline,Crystalline,Single Polymorph,Polymorphic form IV,Terbutaline sulphate form II,single polymorph,Crystal form,crystal form,crystal form,NA,Crystral form,NA,crystal form,crystal form,crystal form,crystal form,crystal form,"Exist, different crystalline forms","Polymorphic, various forms",Exists (different crystal forms),"Polymorphs exist, including Form I and Form II",Exists in an amorphous form,Multiple polymorphic forms,Monomorphic,Not specified,"Polymorphic forms exist, with Form I being the most stable",Not specified,Not specified,Not specified,Polymorphic (Various forms),Not specified,"Exists, various forms",polymorphism in drug metabolllize enzyme,"Exist, different crystalline forms","Exists, various forms",Not specified,Polymorphic (Various forms),Not specified,Not specified,Not specified,yes Form I and Form ll,Exists (different crystal forms),"Polymorphs exist, including Form I and Form II","Polymorphic, various forms",Exists in an amorphous form,"yes, Form I","Polymorphic forms exist, with Form I being the most stable",NA,Polymorphic forms: I and II,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Yes, multiple forms",NA,NA,NA,specific forms would need to be determined based on the manufacturing process.,NA,disopyramide hydrochloride Form I and Form II.,exists in an amorphous form,NA,"does not exhibit polymorphism,",can exist in multiple polymorphic forms,No polymorphic forms reported for digoxin,does not present the phenomenon of polymorphism ,"exhibits polymorphism, with multiple crystalline forms known.",different crystal structures,"available in its hydrochloride salt form,",NA,NA,NA,not available,N/A,Not specified,Not specified,not specified,not specified,not specified,not specified,not specified,not specified,not specified,not specified,not applicable,not applicable,not specified,RFC and C677T polymorphisms are associated with better efficacy of MTX.,crystalline forms,crystalline forms,crystalline forms,crystalline forms,crystalline forms,crystalline forms,crystalline forms,crystalline forms,crystalline forms,crystalline forms,crystalline forms,crystalline forms,crystalline forms,crystalline,No,Yes,Yes,Yes,Yes,No,Yes,No,No,Yes,Yes,No,No,Yes,No,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"the metabolism of diazepam involves the CYP2C19 isoenzyme, whose activity is highly dependent on polymorphism of the encoding gene.","UGT2B15 D85Y polymorphism is identified as a major determinant of oxazepam disposition,",NA,CYP2D6 genetic variant could affect the pharmacokinetics of propranolol., buspirone hydrochloride can exist in two distinct polymorphic forms ,"at least three polymorphic forms which melted at 180 degrees C (I), 212 degrees C (II), and 200 degrees C (III). ","Lorazepam exhibits polymorphism,",no polymorphic forms,", has been investigated by means of X-ray powder diffraction (XRPD), single crystal X-ray diffraction, and differential scanning calorimetry (DSC).", by measurement of the dissolution rate and in vivo absorption of two forms (Form I and Form II)," eleven polymorphs (I–XI), a hydrate (form XII), a hemihydrate (form XIII) and an amorphous phase (form XIV) ",", including X-ray diffractometry, differential scanning calorimetry, infrared spectroscopy, microscopy, solution calorimetry, and solid-state nuclear magnetic resonance.",There are four authentic nonsolvated polymorphic forms and four fully characterized solvatomorphic forms in which the substance has solidified.,NA, crystallized in four genuine nonsolvated polymorphic forms and in four fully characterized solvatomorphic forms.,33546%,382.52 g/mol,335.465 g/mol,287.356 g/mol,295.40 g/mol,269.345 g/mol,269.34 g/mol,581.66 g/mol,384.42 g/mol,259.34 g/mol,287.39 g/mol,377.4 g/mol,230.26 g/mol,583.67 g/mol,194.19 g/mol,284.4dalton,461.82 dalton,382.9 dalton,501.68 dalton,241.32816 g/mol,310.82 dalton,388.888 dalton,381.898 dalton,319.246 dalton,343.9 dalton,374.9 dalton,343.9 dalton,350.89 daltons,469.65 dalton,270.369 dalton,490.51/mol,868.4 g/mol,570.64,529.5158,493.6027,358.42 g/mol,264.30 g/mol,488.01 g/mol,392.47 g/mol,244.21 g/mol,243.22 g/mol,252.24 g/mol,145 kDa,563.98 g/mol,304.71 g/mol,176.12 ,441.4,1329.37,123.1,376.36,337.27,139.62,384.64,244.31,219.24,568.87,596.84,228.25,450.7,430.71,Molecular Weight(Daltons),344.89 daltons.,416.85 g/mol.,306.271 g/mol,705.6 g/mol,306.271 g/mol,700.8 g/mol,352.76 g/mol,352.3 (g/mol),1226.412 g·mol?1,1093.331 g·mol,327.89 g.mol,317.5 g/mol,287.4 g/mol,129.094 g·mol?1,352.766 g·mol?1,Amorphous and crystalline form,Crystalline and amorphous,Crystalline Form,Crystalline or amorphous,Crystalline,Crystalline form,Crystalline form,Crystalline form,Crystalline form,Crystalline form,Crystalline form,Crystalline form,Crystalline form,Crystalline form,Crystalline form,490.62 ,445.535,323.41, 270.348,276.74,311.4,324.395,309.341,366.48,449.524,527.632,303.77,322.4,297.4,494,345.42 g/mol,359.82 g/mol,345.42 g/mol,383.37 g/mol.,352.81 g/mol,359.4 g/mol,247.27 g/mol,369.33 g/mol,444.44 g/mol,359.36 g/mol,84.007 g/mol,382.54 g/mol,252.34 g/mol,258.07 g/mol,314.35 Daltons,100.09 daltons.,252.34 daltons.,84.01 daltons,78.0 daltons,58.319(Daltons).,362.2 Daltons.,345.42 Daltons,383.88 Daltons,314.37 Daltons,359.35 Daltons,192.12 Daltons,345.42 Daltons,258.07 Daltons,NA,NA,510.05 g/mol,371.524 g mol,NA,NA,148k da,434.548,434.4 g/mol,405.91g/mol,261.1g/mol,NA,NA,434.45g/mol,609.8g/mol,148kda,NA,244.21,529.46,229.25,628.81,579.69,602.61,157.1,321.29,Molecular Weight(Daltons),214.05 g/mol,214.1 g/mol,958.22,149 kDa,958.22 daltons,958.22 dalton,257.28 dalton,"149,000 dalton",NA,214.05,261.08 daltons,300.05 daltons,214.05 daltons,233.21 daltons,454.44 daltons,Molecular Weight(Daltons),349.2da,700.77 da,1291.42da,531.44,705.64da,532.68 da,291.44 DA,926g/ml,416.3g/mol,381.35 da,344.84 da,474.74 da,1140.73da,924.09 da,33546%,382.52 g/mol,335.465 g/mol,287.356 g/mol,295.40 g/mol,269.345 g/mol,269.34 g/mol,581.66 g/mol,384.42 g/mol,259.34 g/mol,287.39 g/mol,377.4 g/mol,230.26 g/mol,583.67 g/mol,194.19 g/mol,284.4dalton,461.82 dalton,382.9 dalton,501.68 dalton,241.32816 g/mol,310.82 dalton,388.888 dalton,381.898 dalton,319.246 dalton,343.9 dalton,374.9 dalton,343.9 dalton,350.89 daltons,469.65 dalton,270.369 dalton,490.51/mol,868.4 g/mol,570.64,529.5158,493.6027,358.42 g/mol,264.30 g/mol,488.01 g/mol,392.47 g/mol,244.21 g/mol,243.22 g/mol,252.24 g/mol,145 kDa,563.98 g/mol,304.71 g/mol,NA,Molecular Weight(Daltons),176.12 ,441.4,1329.37,123.1,376.36,337.27,139.62,384.64,244.31,219.24,568.87,596.84,228.25,450.7,430.71,NA,NA,NA,NA,NA,344.89 daltons.,416.85 g/mol.,306.271 g/mol,705.6 g/mol,306.271 g/mol,700.8 g/mol,352.76 g/mol,352.3 (g/mol),1226.412 g·mol?1,1093.331 g·mol,327.89 g.mol,317.5 g/mol,287.4 g/mol,129.094 g·mol?1,352.766 g·mol?1,NA,Nature of the drug (Crystalline/Amorphous),Amorphous and crystalline form,Crystalline and amorphous,Crystalline Form,Crystalline or amorphous,Crystalline,Crystalline form,Crystalline form,Crystalline form,Crystalline form,Crystalline form,Crystalline form,Crystalline form,Crystalline form,Crystalline form,Crystalline form,Molecular Weight(Daltons),490.62 ,445.535,323.41, 270.348,276.74,311.4,324.395,309.341,366.48,449.524,527.632,303.77,322.4,297.4,494,Molecular Weight(Daltons),345.42 g/mol,359.82 g/mol,345.42 g/mol,383.37 g/mol.,352.81 g/mol,359.4 g/mol,247.27 g/mol,369.33 g/mol,444.44 g/mol,359.36 g/mol,84.007 g/mol,382.54 g/mol,252.34 g/mol,258.07 g/mol,314.35 Daltons,Molecular Weight(Daltons),100.09 daltons.,252.34 daltons.,84.01 daltons,78.0 daltons,58.319(Daltons).,362.2 Daltons.,345.42 Daltons,383.88 Daltons,314.37 Daltons,359.35 Daltons,192.12 Daltons,345.42 Daltons,258.07 Daltons,NA,NA,Molecular Weight(Daltons),510.05 g/mol,371.524 g mol,NA,NA,148k da,434.548,434.4 g/mol,405.91g/mol,261.1g/mol,NA,NA,434.45g/mol,609.8g/mol,148kda,NA,244.21,529.46,229.25,628.81,579.69,602.61,157.1,321.29,Molecular Weight(Daltons),214.05 g/mol,214.1 g/mol,958.22,149 kDa,958.22 daltons,958.22 dalton,257.28 dalton,"149,000 dalton",NA,214.05,261.08 daltons,300.05 daltons,214.05 daltons,233.21 daltons,454.44 daltons,349.2da,700.77 da,1291.42da,531.44,705.64da,532.68 da,291.44 DA,926g/ml,416.3g/mol,381.35 da,344.84 da,474.74 da,1140.73da,924.09 da,284.74 gm/mol,212.27 gm/mol,315.71 gm/mol,232.26 gm/mol,141.16 gm/mol,250.29 g/mol,252.24 gm/mol,321.2 g/mol,218.25 g/mol,339.36 g/mol,238.23 g/mol,222.25 g/mol,312.43 g/mol,236.27 g/mol,144.21 g/mol,NA,236.27 g/mol,144.21 g/mol,312.44 g/mol,256.09 g/mol,448.39 g/mol,285.75 g/mol,427.55 g/mol,412.94 g/mol,883.11 g/mol,492.68 g/mol,410-49 g/mol,471.5 g/mol,548.6g/mol,439.49 g/mol,375.3 g/mol,249.1,473.5,305.1,341.1,272.1,442.6,288.93,206.03,235.09,513.5,NA,NA,NA,NA,NA,90 % of particles or more is smaller than 10 µm (d(0.9) < 10 µm.,A crystalline particle of tofacitinib citrate having a median particle size of less than about 40 ?m.,micronized,0.1882?m,Leflunomide and formulations containing leflunomide having a mean particle diameter of less than 200 micrometers,0.91 ?m,0.18-0.22 microns,0.213 microns,1 to 10 microns,1 to 100 micrometers (?m).,N/A (Biologic), 0.45 ?m,Not available,Not applicable (biological macromolecule),not typically specified in terms of traditional particle size measurements like microns.,NA,240.3 g/mol,130.077 Da,421 Da,485.5 g/mol,149000.0 Da,15314.8 Da,441.233 Da,540.0 g/mol,531.67 g/mol,519.56 ng/mol,182.8 g/mol,300.44 g/mol,489.92 g/mol,148000.0 Da,NA,349.406 g/mol,365.4 g/mol,347.39 g/mol,554.g/mol,299.347 g/mol,383.464 g/mol,"1,449.3 g/mol", 556.6 g/mol, 455.46 g·mol,493.74,401.4 g/mol., 517.6 g/mol., 480.6 g/mol,604.7 g/mol,227.09,236.136,191.138,302.108,316.137,259.68,684.81,266.34,454.59,450.98,567.1,211.22,346.3,384.51,504.57,365.4 g/mol,347.389g/mol,506.578g/mol,748.50g/mol,444.43g/mol,1816.7g/mol,361.367g/mol,467.51g/mol,475.5g/mol,444.4g/mol,480.5g/mol,406.54g/mol,383.4g/mol,389.3g/mol,585.6g/mol,~ 345.42 g/mol,~383.8 g/mol,~369.38 g/mol,~359.37 g/mol,~345.42 g/mol,~369.37 g/mol,~252.34 g/mol,Approximately 337.43 g/mol,Approximately 331.42 g/mol,Approximately 314.41 g/mol,Approximately 303.42 g/mol,Approximately 392.45 g/mol (bromide salt),Approximately 337.44 g/mol,Approximately 382.53 g/mol,Approximately 386.54 g/mol,332.31g/mol,328.41g/mol,312.4 g/mol,286.332g/mol,225.21 g/mol,324.336 g/mol,571.6 g/mol,279.187 g/mol,273.186 g/mol, 704.6 g/mol,287.216 g·mol?1,505.628 g/mol,704.856 g/mol, 519.7 g/mol, 507.18 g/mol,252.3,236.27,144.21,256.09,170.21,339.36,252.27,300.7,238.21 g/mol,129.1,312.44,Not specified,171.24,212.22,159.23,252.3,236.27,144.21,256.09,170.21,339.36,252.27,300.7,238.21 g/mol,129.1,312.44,Not specified,171.24,212.22,159.23
Route of adminstration,"Oral, Intranasal","Oral, Intranasal",Oral,Oral,Oral,Oral,"Oral, intravenous, intramuscular","Nasal, oral, intravenous",Oral,"Oral, transdermal, inhalation",Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,"Subcutaneous, Intestinal (tablet)",Oral,Oral,Oral,Oral,Dose Rout,Oral/sublingual,oral,oral,"oral,i.v,i.m","oral,i.v,i.m,rectal",oral,oral,oral,"oral,i.v",oral,oral,oral,oral,oral,oral,Intravenous,"Oral, Intravenous, Intramuscular, Subcutaneous, Intrathecal","Oral, Intravenous",Yes,Oral,Intravenous,Intravenous,Intravenous,"Intravenous, oral",Intravenous,"Oral, intravenous, intramuscular, topical, intra-articular, intralesional",Oral and topical,Topical oral and vaginal,Oral topical,Oral intravenous,Oral intravenous,Oral intravenous,Oral intravenous,"Topical route , oral route",Topical route,Topical route,Oral topical,Intravenous,Intravenous,Oral route,Topical route,"Subcutaneous,Intravenous",oral,Oral,Oral,oral,oral,oral,oral,oral,Subcutaneous,Subcutaneous,Subcutaneous,oral,oral,oral,oral,oral,oral,oral,oral,oral,oral,oral,oral,oral,oral,oral,600mg,600 mg,45 mg,90 mg,450 mg,75 mg/m2,50 mg/m2,75mg/m2,200 mg/m2,1000 mg/m2,500 mg/m2,30 mg/m2,240 mg/m2,100 mg,Oral,tablets or oral solutions,tablets taken by mouth once daily,Oral tablet,orally with or without food,Oral solution,Oral,Oral route,Oral,Orally,Oral,Oral,Oral,Oral,Orally,commonly administered orally.,typically administratered orally. It is commonly prescribed in form of capsule,"typically oral, but formulation for intramuscular injection","It can be administered orally, intravenously, intramuscularly, or subcutaneously.",orally in form of tblrt and capsue,"topically oral, but also use topically and intravenously","Typically topical (cream, ointment, or solution)","Topical, oral, or injectable, depending on the formulation",Typically topical (ointment or cream),Topical (for dermatological use,Pimecrolimus is administered topically for dermatological conditions.,subcuteneous injection,30 mg orally twice dailt,oral,oral,"oral ,transdermal",oral,"oral ,intramuscular Iv",oral,"oral ,IV",oral,oral,oral,"oral ,IV,IM","oral,im",IV,oral IM,oral,"Subcutaneous, intravenous",Subcutaneous,Subcutaneous,Subcutaneous,Subcutaneous,Subcutaneous,Subcutaneous,Subcutaneous,Subcutaneous,Subcutaneous,Subcutaneous,Intravenous,Subcutaneous,Subcutaneous,Subcutaneous,yes,yes,yes/Piperaquine Tetraphosphate Tetrahydrate,NA,NA,"alpha, beta, gamma","alpha, beta, gamma","alpha,beta,gama",NA,NA,Form I (alpha form),"doxycycline hyclate,",no,NA,NA,NA,NA,NA,NA,oral,"orally, although it can also be administered intravenously in certain clinical settings.","orally, although it can also be administered intravenously in certain clinical settings.","orally, although it can also be administered intravenously in certain clinical settings.",Bepridil is typically administered orally.,Cisapride is typically administered orally.,administered orally.,administered orally.,orally,orally.,orally.,orally.,orally.,orally,orally,Intravenous or intramuscular,Intravenous,Azithromycin is available for both oral and parenteral (intravenous) administration.,Amoxicillin is administered orally,"oral, intramuscular, or intravenous.",Temocillin (6 g daily) given by continuous infusion,"Ampicillin administration can be oral, intramuscular, or intravenous. Parenteral administration is preferable for severe or moderately severe infections.","orally, intramuscularly, intravenously, intraperitoneally, intrauterally and topically",The mean exposure of eravacycline after single and multiple intravenous infusions (approximately 60 minutes) of 1 mg/kg administered to healthy adults every 12 hours is presented,intravenous or intramuscular route.,Intravenous,Oral,Orally,intravenous infusion,Oral,"intraveneous, inhalation, oral",Oral,"Oral, Subcutaneous","Oral, Intravenous",Inhalation,Inhalation,oral,20 mg,"Inhalation, ophthalmic, oral","Oral, ophthalmic","Topical, oral, intravenous","Oral, intravenous, topical, etc.","Inhalation, nasal spray, topical, etc.","Inhalation, oral (for inflammatory bowel diseases), nasal spray, etc.","Inhalation (aerosol or powder), nasal spray",Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,"oral , Intravenus , intra muscular",oral,Oral,Oral,Oral,Oral,Oral,Oral,oral,Oral,Oral,Oral,Oral,"oral , IV , IMM , rectal",Oral,"Oral, Intramuscular, Intravenous",Oral,Oral,"Oral, IM","Oral, IM, IV",Oral,Oral,Oral,Oral,Oral,Sublingual,Oral,Oral,Oral,Oral,orally,Usually oral or intravenous.,orally,"intravenously, topically, or via injection for local anesthesia",administered orally.,orally in the form of tablets or capsules.,intravenously (IV),orally and intravenously,"administered orally, intravenously, or intramuscularly","orally or intravenously,",Oral and intravenously,intravenously,"orally, but can also be given intravenously.",orally,oral,intravenously,Intravenous,Intravenous infusion,oral,intravenous,oral,intravenous,oral,oral,oral,oral,Intravenous,Oral,Oral,oral,"oral,subcutaneous,im",vein (IV).,"Intravenous ,intramuscular,intrapleural,intrapericardial",oral route, intravenously via a central venous catheter,"injecting slowly into a fast-running IV infusion via an injection port,",injected intravenously,by mouth,"By mouth, by injection into a vein",Intramuscular, slow intravenous infusion ,oral, by mouth,Intravenously,Intravenously,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,"Topical, Oral",Oral,Oral,Oral,Oral,Oral,Intravenous,Intravenous,Oral,Intravenous,Oral,"Intramuscular, intravenous, subcutaneous, or intrathecal",Oral,Intravenous,Oral,Oral,Intravenous,Oral,intravenously or intramuscularly ,orally,orally in the form of tablets.,oral or intravenous. ,orally,Oral Route,"orally, intravenously, or sublingually",Subcutaneous or intramuscular injection , orally disintegrating tablet,parenteral administration.,Oral Elixir,by mouth.,Intramuscular Administration, intravenous route., orally. ,NA,alfa form and beta form,N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide,NA,form I and form II,rizatriptan benzoate,phenotypic,CYP2D6,NA,form II,T102C,5-HTT,cocrystal hydrate cocrystal solvate,ergotamine,CYP1A2,CYP2D6 and CYP2B6,exhibits,exist,exist,not exist,Form I and II,exist,exist,phenotypic,topical,topical,stability and dissolition,stability and solubility,self exist in crystallin form,Doxylamine succinate & crystals,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Polymorphism(if Exist name the form),Form 2,Form 1/2,Form 1,"Form 1,2,3","Form 1,2,3,4",Form 4,Form 6,Form 2,Form 1,NA,Form 1,Form1,NA,NA,Form 6,Oral and Intravenous route,Oral route,Intravenous route,Mainly hepatic,Not available,Topical and oral route,Topical route,Oral route,Oral route,Oral route,Topical route,Topical route,NA,Oral route,Intravenous route,GLIM form I and GLIM form II,"Glipizide Form I
Glipizide Form II
Glipizide Form III",NA,NA,Chlorpropamide Form I & ChlorpropamideForm II,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"no known
polymorphism.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"exhibit polymorphism, with different crystalline forms.",Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,yyes,not specified,NA,not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Polymorphism(if Exist name the form),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Polymorphism(if Exist name the form),form 1 and 2,specific form,not commonly reported,different form,exists in different form,NA,NA,NA,not specified,form 1 and form 2,exicts in various form,not well documented,not well documented,NA,NA,alfa form and beta form,N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide,NA,form I and form II,rizatriptan benzoate,phenotypic,CYP2D6,NA,form II,T102C,5-HTT,cocrystal hydrate cocrystal solvate,ergotamine,CYP1A2,CYP2D6 and CYP2B6,exhibits,exist,exist,not exist,Form I and II,exist,exist,phenotypic,topical,topical,stability and dissolition,stability and solubility,self exist in crystallin form,Doxylamine succinate & crystals,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Polymorphism(if Exist name the form),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Form 2,Form 1/2,Form 1,"Form 1,2,3","Form 1,2,3,4",Form 4,Form 6,Form 2,Form 1,NA,Form 1,Form1,NA,NA,Form 6,NA,Route of administration,Oral and Intravenous route,Oral route,Intravenous route,Mainly hepatic,Not available,Topical and oral route,Topical route,Oral route,Oral route,Oral route,Topical route,Topical route,NA,Oral route,Intravenous route,Polymorphism(if Exist name the form),GLIM form I and GLIM form II,"Glipizide Form I
Glipizide Form II
Glipizide Form III",NA,NA,Chlorpropamide Form I & ChlorpropamideForm II,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Polymorphism(if Exist name the form),NA,NA,NA,"no known
polymorphism.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"exhibit polymorphism, with different crystalline forms.",Polymorphism(if Exist name the form),Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Crystal and Amorphous,Polymorphism(if Exist name the form),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,yyes,not specified,NA,not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Polymorphism(if Exist name the form),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,form 1 and 2,specific form,not commonly reported,different form,exists in different form,NA,NA,NA,not specified,form 1 and form 2,exicts in various form,not well documented,not well documented,NA,yes ( form 2),NA,NA,YES,YES,NA,NA,NA,YES,NA,NA,YES,YES,FORM 1 & FORM 3,NA,NA,FORM 1 & FORM 3,polymorphic,polymorphic,polymorphic,polymorphic,NA,polymorphic,polymorphic,polomorphic,polymorphic,polymorphic,polymorphic,NA,polymorphic,NA,NA,Yes ( two forms such as Form 1 and Form 2),NA,NA,NA,"Bazedoxifene (acetate) type 1,2,3 & 4",NA,NA,NA,NA,NA,NA,NA,NA,NA,3.7,1.808,2.57,0.86.,3.59,1.6,0.56,2.7,~ 4.67,~4.67,N/A (Biologic),1.6 (approx.),N/A,Not applicable (biological macromolecule),Not available,NA,NO,"Yes DPYD,MTHFR",YES polymorph B,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"We prepared 4 polymorphs of : monohydrate, trihydrate, forms I and II.",The polymorphic transformation of amoxicillin under high pressure.,cephalexin polymorphs in four commercial medicines was evaluated., polymorphisms (SNPs) known to be associated with ceftriaxone resistance.,"amorphous and crystalline form of imipramine pamoate, and a crystalline form of imipramine hydrochloride.", non-synonymous single-nucleotide polymorphisms (nsSNPs) that alter the penicillin-binding proteins, non-synonymous single-nucleotide polymorphisms (nsSNPs) that alter the penicillin-binding proteins,"Crystalline forms of omadacycline, ", Investigation of polymorphism has become a requirement in the pharmaceutical industry because the physical properties and bioavailabilities of crystalline ," The polymorphisms at C2055 and C2499 are new mutations associated with tiamulin resistance,",Moxifloxacin may also be used to complete a course of therapy in ... The drug substance exhibits polymorphism and the crystalline,Pharmaceutical development Piperacillin and tazobactam do not present polymorphism. Tazobactam has two chiral carbons,The polymorphic transformation of amoxicillin under high pressure.," Ceftaroline resistance in MRSA might be the result of clone-specific PBP2a polymorphism, ","Alpha,Beta and gama form of nitroglycerin",Form -1 and 2,Form -1 and 2,"Forms alpha, beta and gama","Alpha , beta and gama phase",Propanolol HCL form-1,Metoprolol tartrate,Form -1 and 2,Verapamil hcl form-1and 2,Diltiazem hcl form -1,None,Form -1 and 2,Form 1-2,Form -1,None,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,typically administered orally,typically administered orally or intravenously.,typically administered orally.,typically administered orally.,typically administered orally.,Dexlansoprazole is typically administered orally,Cimetidine is typically administered orally or intravenously.,Famotidine is typically administered orally or intravenously.,Nizatidine is typically administered orally.,Ranitidine is typically administered orally or intravenously.,Pirenzepine is typically administered orally.,Propantheline is typically administered orally.,Oxyphenonium is typically administered orally.,Misoprostol is typically administered orally or vaginally.,Rioprostil is usually administered orally., crystal form, crystal form,monoclinic crystal form,monoclinic crystal form,monoclinic crystal form,Crystal form,Bolaxavir marboxil,amorphous form,Crystal form,amorphous form,Crystal form,Crystal form,Crystal form,Crystal form,Crystal form,"Exist, different crystalline forms","Polymorphic, various forms",Exists (different crystal forms),"Polymorphs exist, including Form I and Form II",Exists in an amorphous form,Multiple polymorphic forms,Monomorphic,Not specified,"Polymorphic forms exist, with Form I being the most stable",Not specified,Not specified,Not specified,Polymorphic (Various forms),Not specified,"Exists, various forms","Exist, different crystalline forms","Polymorphic, various forms",Exists (different crystal forms),"Polymorphs exist, including Form I and Form II",Exists in an amorphous form,Multiple polymorphic forms,Monomorphic,Not specified,"Polymorphic forms exist, with Form I being the most stable",Not specified,Not specified,Not specified,Polymorphic (Various forms),Not specified,"Exists, various forms"
Dose of the drug,5-10 mg,5 mg,20-30 mg,5 mg,100-200 mg/day,150-250 mg/day,"Variable depending on indication (e.g., 25-50 mg orally for asthma)",20-100mg (snorted),Variable depending on indication (typically 100-200 mg),Variable depending on formulation and use (typically 1-4 mg for smoking cessation),Variable depending on indication (typically 40-100 mg/day for ADHD),"15-37.5 mg once daily, typically before breakfast or 1-2 hours after breakfast",25-75 mg once daily,25-50 mg once daily,Varies,"Variable, depending on condition",0.5 mg once daily,"Dosage varies, typically 5-10 mg per day",Typically 200 mg,Varies based on indication,Typically 1 to 4 mg daily,Varies based on medical condition,Varies depending on condition,Variable (Depends on the condition being treated),Varies depending on condition,"Varies based on condition, e.g., for hyperprolactinemia: 2.5 to 15 mg daily",Typically 20 mg/day,Typically 1-4 mg per day,Typically 100 mg to 200 mg,Moa,"GABA receptor binding GABA receptor binding
Enhanced GABA effects
Chloride ion influx
Neuronal inhibition","Binding to GABAA receptors Binding to GABAA receptors
Enhancement of GABA binding
Increased chloride ion influx
Hyperpolarization and neuronal inhibition","Binding to GABAA Receptors
Enhancement of GABA Binding
Increased Chloride Ion Influx
Hyperpolarization and Neuronal Inhibition","Binding to GABAA Receptors
Enhancement of GABA Binding
Increased Chloride Ion Influx
Hyperpolarization and Neuronal Inhibition","Binding to GABAA Receptors
Enhancement of GABA Binding
Increased Chloride Ion Influx
Hyperpolarization and Neuronal Inhibition","Binding to GABAA Receptors
Enhancement of GABA Binding
Increased Chloride Ion Influx
Hyperpolarization and Neuronal Inhibition","GABA receptor binding GABA receptor binding
Enhanced GABA effects
Chloride ion influx
Neuronal inhibition",Blocks reuptake of serotonin and norepinephrine,Enhances activity of GammaAminoButyricAcid(GABA),"Acts on GABA receptors,enhancing inhibitory neurotransmission","Enhances GABA at GABAa receptors,resulting in sedative and anxiolytic effect","serotonin antagonist and reuptake inhibitor (SARI), also antagonizes alpha-adrenergic receptors, leading to sedative effects","Enhances GABA at GABAa receptors,resulting in sedative and anxiolytic effect","Agonist at melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus, regulating the sleep-wake cycle",Blocks orexin receptors which are involved in wakefulness and sleep regulation,Variable,Variable,Variable,Oral,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,100 units/Ml,5 mg,500 mg,100mg,100mg,1-2 mg,0.2 mg,15-30 mg,500/850 mg,10 to 100 unit/day,0.5 to 1 unit/day,NA,16 mg/ml,NA,20mg/day,50mg/day,37.5mg/day,20mg/day,150mg/day,20mg/day,25-50mg/day,150mg/day,15mg/day,25mg/day,50mg/day,15mg/day,10mg/day,Twice,Twice,Twice,Once,Once,3 weeks,4 days ( 2 times 35 mg/m2,Once,Every 3 weeks,once in week,Every 3 weeks,Once a week,Every 2 weeks,Once,0.5 mg,300 mg,25 mg,300mg,10mg,100mg,10 mg,25 mg,600mg,10 mg,115 to 150 mg/m^2/day,30mg,200mg,800mg,10mg,The dose of Azathioprine can vary depending on the medical condition being treated. It is often used in the treatment of autoimmune disorders and as an immunosuppressant. Dosing is typically individualized based on patient response,commonly initiated dose range from 25to 50mg/day,2.-10 mg IM,"It can be administered orally, intravenously, intramuscularly, or subcutaneously.",15mg/kg of body weight per day,varies depending on the indication,The dosage and frequency depend on the specific formulation and the condition being treated.,Varied depending on the condition and formulation,The dosage and frequency depend on the specific formulation and the condition being treated.,The dosage can vary based on the specific condition being treated and the formulation. It is usually applied once daily in the evening,The dosage can vary based on the specific skin condition being treated,typically administered 40 mg every other week,twice daily,25-50 mg,50mg,10mg,based on condition,12mg,50mg,4mg,100mcg,12mg,25mg,varies,100mg/ml,5ML,varies,varies,100unit/ml,10 to 100units/day,0.2to 0.4 units/kg,0.4 to 1.0units/day,10 to 40units/day,0.5 to1unit/day,0.15 to 0.3units/meal,NA,NA,NA,NA,NA,0.4-0.9U/Kg,NA,0.1unit/kg,Oral,Oral,Oral,Oral,Oral/IV,Oral,Oral,Oral,Oral,Oral,Oral,Oral/IV,"Oral, Topical, Parenteral",Oral/IV/IM,Oral,Oral/IV/IM,Oral,Oral,NA,150 mg,"200 mg to 800 mg,",20 mg to 40 mg,"200 mg to 800 mg,",200-300 mg,10 mg to 20 mg,125 ?g orally,20-40 mg,2-4 mg,320 mg to 640 mg,200-400 mg,60-120 mg,80 mg,50 mg,150 mg,"15 mg/kg/day divided IV/IMq8-12hr  
Urinary Tract Infection250 mg IV/IM q12hr","Plazomicin is dosed on a milligram -per-kilogram-of body -weight basis and administered by a 30 min intravenous infusion every 24hours,with dose adjustment being made for renal impairment and abody weight.",The amount of medicine that you take depends on the strength of the medicine. Azithromycin tablets come as either 250mg or 500mg strengths. The capsules are 250mg. The liquid comes as 200mg in 5ml.,"The usual dose of amoxicillin capsules is 250mg to 500mg, taken 3 times a day. The dose may be lower for children.","1–4 grams per day taken in divided doses. The usual dose is 250 mg taken every 6 hours, or a dose of 500 mg every 12 hours may be given","The common dose is 2 g intravenously every 12 hours and the high dose, notably in critically ill patients, is 2g every 8 hours.",250mg; 500 mg; 125 mg/5 mL; 250 mg/5 mL; 125 mg; 1 g; 2 g; 10 g,"Adults and teenagers—2 to 4 grams for the first dose, then 1 gram every four to six hours.Children 2 months of age and older—Dose is based on body weight. The usual dose is 75 milligrams (mg) per kilogram (kg) (34 mg per pound) of body weight for the first dose, then 37.5 mg per kg (17 mg per pound) of body weight every six hours, or 25 mg per kg (11.4 mg per pound) of body weight every four hours.",1 mg/kg IV q12hr x 4-14 days; infuse IV over ~60 minutes. 50mg/single-dose vial,The normal dose ranges from 125 mg to 500 mg every 6 to 8 hours based on the clinical indication and patient weight.,The specific dosage and administration guidelines for meropenem should be determined by a healthcare professional based on the individual patient's condition. It's crucial to follow the prescribed dosage,"1–4 grams per day taken in divided doses. The usual dose is 250 mg taken every 6 hours, or a dose of 500 mg every 12 hours may be given","Adults—500 milligrams (mg) 2 times a day, taken every 12 hours for 60 days. · Children—Dose is based on body weight",3 grams (two 1.5 g vials) over 1-hour period every 8 hours for 8 to 14 days.,Dosing · Adults—250 milligrams (mg) every 12 hours for 7 to 14 days. · Children 6 months of age and older—Dose is based on body weight,0.3-0.4 mg,12-14mg,2.5-5 mg,200-600mg,20 mcg,18 mcg,10 mg,oral,1 to 20 mg,1 to 2 mg,15-25 mg,5-60 mg,100-200 mcg,0.2 mg to 2 mg,250-500 mcg,"Varies, depending on the condition",Varies based on condition,Variable depending on condition,"Varies based on condition, typically starting at 25 mg daily",Varies based on condition; typically 1000-3000 mg/day,Varies depending on the condition; typical starting dose for epilepsy: 25-50 mg/day,Varies depending on the condition; consult a healthcare professional,Varies depending on the condition being treated,"Varies depending on the condition, typically starting at 1200 mg/day","Varies, depending on condition",Depends on the condition; typically 4-56 mg/day,"Varies depending on the condition, consult healthcare provider",Varies depending on condition,Varies based on indication,"Variable, depending on the condition",adult - 60 to 180 milligram per day children - 2 to 6 milligram,"Varies, depending on the condition","Variable, depending on the condition",Varies based on indication,Varies depending on condition,"Varies depending on the condition, consult healthcare provider",Depends on the condition; typically 4-56 mg/day,"Varies, depending on condition",250 mg per day,Variable depending on condition,"Varies based on condition, typically starting at 25 mg daily",Varies based on condition,Varies based on condition; typically 1000-3000 mg/day,2-10 mg,"Varies depending on the condition, typically starting at 1200 mg/day",Varies,Varies,Varies,Varies,Varies based on condition,Varies based on condition,"Variable, individualized",Varies based on condition,Variable,Varies depending on condition,5 mg or 10 mg,Varies depending on condition,Varies depending on condition,Varies depending on condition,Varies,depending on the medical condition being treated,NA,NA,NA,200 mg every 8 hours.,100-150 mg every 12 hours,140 mcg/kg/minute for up to 6 minutes.,0.125 to 0.25 mg once daily,80 mg to 480 mg per day for oral administration.,120 mg to 360 mg per day,40 mg twice daily,500 mcg/kg over 1 minute,100 to 400 mg/day,80 mg twice daily.,200 mg once daily,1200 mg to 1680,V/A,"Variable, depending on indication and patient condition",varies,varies,varies,varies,varies,varies,varies,varies,varies,varies,varies,varies,for adult  25 to 75 milligrams (mg) once a week, 0.4 mg/kg of body weight,0.3 to 0.4 mg/kg intravenously,260 mg/m²/day PO divided q6hr for 14-21 days,0.8 mg/kg of ideal body weight or actual body,between 1 and 3 mg/day , 100mg/4mL (25mg/mL) ,130 mg/m^2, 1 to 5 mg per kg of body weight per day,120 grams ,of 3 to 5 doses,0.1 to 0.2 mg/kg body weight daily for 3 to 6 weeks, Single or divided doses of 2 to 4 mg/kg/day orally for one week,25 mg/m^2/day,25 mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,135 to 250mg/m²,20 to 120 mg/m²,300-600mg,60 to 100 mg/m²,50 mg to 700 mg,25 to 75 milligrams,250mg,25mg,90mg,150mg,1000 mg/m2,250mg,"Children 6 months of age and older—At first, 1 to 2.5 mg 3 or 4 times per day.Adults—2 to 10 milligrams (mg) 2 to 4 times a day.","In adults with mild to moderate anxiety: administer 10 to 15 mg orally every 6 to 8 hours, do not exceed 120 mg daily. In adults with severe anxiety or agitation: administer 15 to 30 mg orally every 6 to 8 hours",Adults—50 to 100 milligrams (mg) 4 times a day.,"Adults—At first, 40 milligrams (mg) three times a day. Your doctor may increase your dose as needed.", 7.5 mg ,40 mg,0.5 to 2 mg ,4.2 Dose ,NA,500 mg (2 mmol), 20 mg/5 mL,100 mg/5 ml. , 150 to 200 mg , no fixed dosage. ,20 mg ,oral,oral,oral,Nasal spray,"oral, subcutaneous nasal spray, rectal",oral,oral,oral,intravenous or intamuscular,oral or intravenous,oral,oral,oral,intramuscular or intravenous,oral,orally,orally,orally,orally,"IM,IV,orally",Orally,orally,topical,orally,orally,orally,orally,orally,orally,orally,"Oral,IV",Oral,Oral,Oral,Oral,"Oral administration, intravenous, intramuscular, topical,","intravenous,oral",Oral administration,"Oral, intravenous, intramuscular, or topical administration",Subcutaneous or intravenous administration,"Intravenous, intrathecal, or subcutaneous administration",Intravenous administration,Intravenous administration,Intravenous administration,Oral administration,"oral, iv,","Oral, IM","Oral,IV,IM",oral,Oral,"Oral,IM",Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Route of adminstration,Topically,Topical,"Oral , intravenous",Oral,Oral,Intravenous,Oral,Topical,Iv,Iv,Oral,Topical,Topical,"Oral, IV",Mouth,Fluconazole is a very selective inhibitor of fungal cytochrome P450 dependent enzyme lanosterol 14-?-demethylase.,"Traconazole interacts with the cytochrome P-450 enzyme 14-? demethylase, which is required to change lanosterol into ergosterol.","Beta-(1,3)-D-glucan is a crucial part of the cell walls of Aspergillus and Candida species, and aspergin inhibits its synthesis. There is no beta-(1,3)-D-glucan in mammalian cells.","Clotrimazole inhibits the ergosterol synthesis in fungal cells by targeting 14?-demethylase. The cell membrane is compromised by this disturbance, which increases permeability and causes fungal cell death.","The mechanism by which econazole inhibits fungal growth and replication is by interfering with the manufacture of ergosterol, an essential component of fungal cell membranes.","By preventing the synthesis of ergosterol, miconazole disrupts the integrity of fungal cell membranes, causing damage to the cells and ultimately stopping fungal development.","When used to treat skin infections, oxiconazole prevents the creation of fungal cell membranes by interfering with 14?-demethylase, which blocks the synthesis of ergosterol and causes compromised membrane integrity and fungal cell death.","ergosterol is an essential part of fungal cell membranes, ketoconazole prevents its synthesis, which damages the integrity of the membrane and stops fungal development.","Voriconazole inhibits fungal growth by blocking ergosterol synthesis through interference with lanosterol 14?-demethylase, disrupting cell membrane integrity and causing fungal cell death","Terbinafine acts by blocking the squalene epoxidase enzyme, which prevents fungal cells from synthesizing ergosterol and ultimately causes them to die. This method effectively combats a variety of skin and nail illnesses by targeting dermatophytes.","Tolnaftate prevents the synthesis of ergosterol, which hinders the creation of fungal cell membranes and impeding fungal growth.","Butenafine causes cell death by inhibiting squalene epoxidase, which damages the integrity of fungal cell membranes.","By producing an acidic environment, interfering with the operation of microbial cells, and inhibiting the growth of bacteria, molds, and yeasts in a variety of items, benzoic acid serves as a preservative","Nystatin works by binding to ergosterol in fungal cell, membrane distributing their integrity and causing cell death. This selective action makes it effective against fungal infections minimal impact on human cell.","posaconazole works by inhibiting the synthesis of ergosterol, a vital component of fungal cell membrane disrupting their structure and leading to fungal cell death.",Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral,Oral,Oral,orally,Oral,Oral,Oral,Oral,"Oral, intravenous, and topical",Oral,"orally
intravenously, or topically.","Oral, sublingual, vaginal, or bucally","Oral, intravenous",orally or intravenously.,"Oral, intravenous","oral,intravenous",oral,Oral,orally or liquid suspensions,orally,Orally,oral or parenteral route.,orally or Intravenously,orally or Intravenously,Orally,"Orally,intravenous",orally,orally or Intravenously,orally,orally,oral,oral,intravenous,oral,intravenous,oral,oral,oral,oral/iv,NA,ORAL,oral,intravenous,NA,oral,"Oral, Inhalation, Intravenous",Oral,"Oral, Intravenous",Oral,Oral,Intravenous,Oral,Oral,Route of adminstration,Intravenous,orally,Intravenous,"Intravenous, intravitreal",orally,oral,orally,intravenous,orally,intravenous,oral,intravenously,NA,orally,oral,Route of adminstration,oral,oral suspension,intravenous,oral,oral,vaginal,ORAL,oral,topical,topical,topical,topical,intravenous infusion,intravenous,oral,oral,oral,Nasal spray,"oral, subcutaneous nasal spray, rectal",oral,oral,oral,intravenous or intamuscular,oral or intravenous,oral,oral,oral,intramuscular or intravenous,oral,orally,orally,orally,orally,"IM,IV,orally",Orally,orally,topical,orally,orally,orally,orally,orally,orally,orally,"Oral,IV",Oral,Oral,Oral,Oral,"Oral administration, intravenous, intramuscular, topical,","intravenous,oral",Oral administration,"Oral, intravenous, intramuscular, or topical administration",Subcutaneous or intravenous administration,"Intravenous, intrathecal, or subcutaneous administration",Intravenous administration,Intravenous administration,Intravenous administration,Oral administration,NA,Route of adminstration,"oral, iv,","Oral, IM","Oral,IV,IM",oral,Oral,"Oral,IM",Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,NA,NA,NA,NA,NA,Topically,Topical,"Oral , intravenous",Oral,Oral,Intravenous,Oral,Topical,Iv,Iv,Oral,Topical,Topical,"Oral, IV",Mouth,NA,Mode of action,Fluconazole is a very selective inhibitor of fungal cytochrome P450 dependent enzyme lanosterol 14-?-demethylase.,"Traconazole interacts with the cytochrome P-450 enzyme 14-? demethylase, which is required to change lanosterol into ergosterol.","Beta-(1,3)-D-glucan is a crucial part of the cell walls of Aspergillus and Candida species, and aspergin inhibits its synthesis. There is no beta-(1,3)-D-glucan in mammalian cells.","Clotrimazole inhibits the ergosterol synthesis in fungal cells by targeting 14?-demethylase. The cell membrane is compromised by this disturbance, which increases permeability and causes fungal cell death.","The mechanism by which econazole inhibits fungal growth and replication is by interfering with the manufacture of ergosterol, an essential component of fungal cell membranes.","By preventing the synthesis of ergosterol, miconazole disrupts the integrity of fungal cell membranes, causing damage to the cells and ultimately stopping fungal development.","When used to treat skin infections, oxiconazole prevents the creation of fungal cell membranes by interfering with 14?-demethylase, which blocks the synthesis of ergosterol and causes compromised membrane integrity and fungal cell death.","ergosterol is an essential part of fungal cell membranes, ketoconazole prevents its synthesis, which damages the integrity of the membrane and stops fungal development.","Voriconazole inhibits fungal growth by blocking ergosterol synthesis through interference with lanosterol 14?-demethylase, disrupting cell membrane integrity and causing fungal cell death","Terbinafine acts by blocking the squalene epoxidase enzyme, which prevents fungal cells from synthesizing ergosterol and ultimately causes them to die. This method effectively combats a variety of skin and nail illnesses by targeting dermatophytes.","Tolnaftate prevents the synthesis of ergosterol, which hinders the creation of fungal cell membranes and impeding fungal growth.","Butenafine causes cell death by inhibiting squalene epoxidase, which damages the integrity of fungal cell membranes.","By producing an acidic environment, interfering with the operation of microbial cells, and inhibiting the growth of bacteria, molds, and yeasts in a variety of items, benzoic acid serves as a preservative","Nystatin works by binding to ergosterol in fungal cell, membrane distributing their integrity and causing cell death. This selective action makes it effective against fungal infections minimal impact on human cell.","posaconazole works by inhibiting the synthesis of ergosterol, a vital component of fungal cell membrane disrupting their structure and leading to fungal cell death.",Route of adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Oral Adminstration,Route of adminstration,Oral,Oral,Oral,orally,Oral,Oral,Oral,Oral,"Oral, intravenous, and topical",Oral,"orally
intravenously, or topically.","Oral, sublingual, vaginal, or bucally","Oral, intravenous",orally or intravenously.,"Oral, intravenous",Route of adminstration,"oral,intravenous",oral,Oral,orally or liquid suspensions,orally,Orally,oral or parenteral route.,orally or Intravenously,orally or Intravenously,Orally,"Orally,intravenous",orally,orally or Intravenously,orally,orally,Route of adminstration,oral,oral,intravenous,oral,intravenous,oral,oral,oral,oral/iv,NA,ORAL,oral,intravenous,NA,oral,"Oral, Inhalation, Intravenous",Oral,"Oral, Intravenous",Oral,Oral,Intravenous,Oral,Oral,Route of adminstration,Intravenous,orally,Intravenous,"Intravenous, intravitreal",orally,oral,orally,intravenous,orally,intravenous,oral,intravenously,NA,orally,oral,oral,oral suspension,intravenous,oral,oral,vaginal,ORAL,oral,topical,topical,topical,topical,intravenous infusion,intravenous,"oral, intravenous, intramuscular, rectal","oral, intravenous",oral,"oral, intravenous",oral,"oral, intravenous","oral, intravenous","oral, intravenous, intramuscular, sulingual",Oral,"oral, intravenous",Oral,"oral, intravenous",oral,"oral, intravenous",oral,NA,"oral, intravenous",oral,"oral, intramuscular",oral,"oral, intramuscular","Sulingual, oral",oral,"oral, intramuscular",oral,oral,oral,oral,oral,"oral, intramuscular, intravenous","oral, intramuscular, intravenous",Oral,Oral,Oral,"IV, Oral",IV,Oral,Oral,Oral,IV,oral,IV/subcutaneous injection,"Subcutaneous Injection, solution",Intramuscular; Subcutaneous,Subcutaneous,Subcutaneous,pKa (strongest acidic) 13.89 and pKa (strongest basic) 3.91,pKa (Strongest Acidic)= 9.15 pKa (Strongest Basic)= 6.44,pKa (Strongest Acidic)= 13.99 pKa (Strongest Basic)= 4.11,pKa (Strongest Acidic)=2.95 pKa (Strongest Basic) 14.55,pKa (Strongest Acidic) 13.72 pKa (Strongest Basic) -0.45,pKa (Strongest Acidic)=3.23 pKa (Strongest Basic) 0.55,pKa (Strongest Acidic)=8.62 pKa (Strongest Basic) 2.16,pKa (Strongest Acidic)=11.83 pKa (Strongest Basic) -2.4,10.3,pKa1: 8.3 pKa2: 10.2,N/A (Biologic),11.6,~6.5,Not applicable (biological macromolecule),Not available,NA,Topical,topical,Oral,Oral,intravenous infusion,intravenous infusion,oral,oral,oral,oral,intravenous,topical,oral,intravenous,NA," oral, intramuscular, or intravenous.",Amoxicillin is administered orally,"Cephalexin comes as a capsule, tablet, and suspension (liquid) to take by mouth", intravenously (into a vein) , injected into a vein, intravenous infusion,it must be administered intravenously.,IV infusion over 60 minutes or 100 mg by IV infusion over 30 minutes twice on day 1, intramuscular or intravenous routes.,oral medicated feed or water,Administer via IV infusion only, intravenous infusion (over 30 minutes). ,intravenously (IV) or intramuscularly (IM),intravenously (into a vein),Sublingual,Sublingual,Oral,Oral,Oral,"Oral, rectal and IV",Oral and I.V,Orally,Orally and I.V,Orally and I.V,Orally,Orally,Orally and topically,Orally,Orally and I.V,Crystalline and Amorphous,Crystalline and Amorphous,Crystalline,Crystalline and amorphous,Crystalline and amorphous,NA,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,Crystalline,around 20-40 mg daily for adults.,around 20-40 mg daily for adults.,around 15-30 mg daily for adults.,around 20-40 mg daily for adults,around 20-40 mg daily for adults.,around 30-60 mg daily for adults.,around 200-800 mg daily for adults.,around 20-40 mg daily for adults.,around 150 mg twice daily or 300 mg at bedtime for adults.,around 150 mg twice daily or 300 mg at bedtime for adults.,around 25-50 mg twice daily for adults.,around 15-30 mg three to four times daily for adults.,around 5-10 mg three to four times daily for adults.,"for the prevention of gastric ulcers induced by NSAIDs, a typical dose is 200 mcg four times a day with food","for the prevention of NSAID-induced gastric ulcers, a common dose is 100 to 200 micrograms four times a day.",Inhale(breathe in) by mouth,IV,oral,oral,oral or IV,oral or IV,oral,intravenous infusion,oral,oral,oral powder to taken by mouth,oral,oral,oral,oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral
how many times ( once/twice/thrice),once or twice daily,Once or twice daily,1-3 times daily,Once to twice daily,Once daily,Once daily,every 4-6 hours,binge use for addicts,Multiple times daily,Multiple times daily,Once or twice daily,Once daily,Once daily,Once daily,Multiple doses,Usually once or twice daily,Once daily,Usually once or twice daily,Usually three times a day,Typically twice daily,Usually taken once or twice daily,Typically once or twice daily,Usually taken once or twice daily,Typically taken once or twice daily,As prescribed by healthcare provider,Usually once or twice daily,Once daily,Usually taken two to three times daily,Usually three times a day,Pgp substrate/inhibitor,pgp substrate as well as inhibitor,pgp substrate,pgp substrate,pgp substrarate,pgp substrarate,Not specified,NA,Not a pgp substrate,pgp substrate as well as inhibitor,Not specified,pgp inhibitor,pgp substrate,pgp inhibitor,Not specified,Not specified,Depends on treatment protocol,Depends on treatment protocol,Usually once daily,Variable,Usually once or twice daily,Usually once weekly,Depends on treatment protocol,Depends on treatment protocol,Depends on treatment protocol,Depends on treatment protocol,Depends on indication and severity of condition,Varies from person to person,Varies,Varies,Varies,Varies,Varies,Varies,Varies,Varies,Varies,Varies,Varies,Varies,Varies,Varies,once/twice,once,once,thrice,thrice,once,thrice,once,once/twice,unce,thrive,NA,twice,twice,once,once,once,once,once,once,once,once,once,once,once,thrice,two to thrice,"Targets the mutated KRAS protein, inhibiting its ability to promote abnormal cancer cell growth.",Inhibits ALK and RET proteins by preventing their phosphorylation.,"It is an inhibitor of mitogen-activated protein kinase(MEK), or a MAP2K inhibitor. MEK is part of the RAS pathway, which is involved in cell proliferation and survival.",Blocking the action of an abnormal protein that signals cancer cells to multiply,"Inhibit auto phosphorlyation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells.","It induces its cytotoxic properties through binding to nuclear DNA and subsequent interference with normal transcription, and/or DNA replication mechanisms.",Etoposide poisons the Topoll cleavage complexes and inhibits the second step of the reaction,1) Inhibition of microtubular depolymerization. 2)Attenuation of the effects of bcl-2 and bcl-xl gene expression,The promotion of microtubule assembly and inhibition of microtubule disassembly.,Inhibit processes required for DNA synthesis and incorporation of dFdCTP into DNA which causes cell death.,Inhibits > or = 3 enzymes involved in folate metabolism and purine and pyrimidine synthesis.,Inhibition of microtubule dynamics to a mitotic arrest and cell death.,It binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2.,It is a small molecule kinase inhibitor of ALK and ROS1 as well as a number of other kinases.,Once,Once,Once,Once,Once,Once,Once,Once,Once,Once,Twice,Once,Once,Thrice,Once,The frequency of administration depends on the specific treatment regimen prescribed by the healthcare provider.,once,every 6 to 8 houes,Depend on the specific medical condition,many cases once a day.and cay very based on the healthcare,topically twice dailyfor some condition,NA,"Typically once or twice daily, as prescribed",NA,NA,"Typically applied twice daily, but the frequency can vary.",once every other week,"he inhibition of PDE4 by apremilast leads to increased intracellular cAMP levels. An increase in cAMP results in the suppression of inflammation by decreasing the expression of TNF-?, IL-17, IL-23, and other inflammatory mediators",once daily,thrice,varies,multiple times,once,thrice,thrice,once,daily,twice,thrice,once,NA,twice,twice,once/Twice,Once,once/twice,NA,Once,Thrice,depend upon no. of meals,Thrice,Twice/thrice,Once,Twice/Thrice,Once/Twice,Once,NA,Thrice,Dose of the drug, 1000mg,200-600mg,320-960mg,750mg,600mg,200-400mg,200mg,25-75mg,15-30mg,1500mg,50-100mg,100mg,150-450mg,2.4 mg/kg body weight in IV,80mg twice daily,150mg once daily,150mg,1000mg,once,Multiple times,Twice,Multiple times,twice-thrice,thrice,Twice,Twice,once- twice,Once,once,Twice,Twice,Thrice,once-twice,Twice a day(equally divided doses at equally interval),Once a day,Twice a day,Twice a day,Twice a day,Three times a day,Three to four times a day,"Adults—2000 to 4000 milligrams (mg) per day, divided and given in 3 to 6 doses per day.",Once a day,Twice a day,Twice a day - pneumonia,Twice a day,Twice a day,"medication is given by injection into a vein as directed by your doctor, usually every 8 hours. It should be injected slowly over 1 hour.",Twice a day,Thrice,Every 6-8 hrs,4-6 hrs,6-8hrs,4 times a day,once,once,twice,four times a day,Twice,trice,Varies based on condition,twice,twice,twice a day,Typically 1-3 times daily,Typically divided into two doses,Typically divided into 2 or 3 doses per day,Typically once or twice daily,Usually twice a day,Usually twice daily,Typically administered twice daily,Usually once or twice daily,Divided into two or three doses per day,Usually taken twice daily,Usually twice daily,Usually twice daily,Typically 3 times a day,Usually once or twice daily,Usually administered twice or thrice daily,twice or thrice,Typically 1-3 times daily,Usually administered twice or thrice daily,Usually once or twice daily,Typically 3 times a day,Usually twice daily,Usually twice daily,Usually taken twice daily,usually taken twice daily,Typically divided into 2 or 3 doses per day,Typically once or twice daily,Typically divided into two doses,Usually twice a day,twice or thrice daily,Divided into two or three doses per day,Multiple times,Multiple times,Multiple times daily,Usually once or twice a day,Usually once or twice daily,Usually 2-4 times a day,Typically divided into two or more doses,Once or twice daily,Once daily,Once daily,Twice daily,Typically once or twice daily,Usually once or twice daily,Once or twice daily,Once or twice,Two or three times per day,multiple times a day.,multiple times a day,NA,three times daily,twice daily,once during a cardiac stress test.,"once daily, but in some cases, it may be given twice daily.",1 to 3 times per day,two to four times per day,once to four times daily,administered continuously via intravenous infusion.,"twice daily,","twice daily,",Once daily,every 3 week,O/A,Depends on treatment protocol,Depends on treatment protocol,Depends on treatment protocol,Depends on treatment protocol,Depends on treatment protocol,varies,once or twice,once daily,Once or twice daily,Variable based on indication,Once daily,Once daily,once daily,once a week or in three divided doses over 36 hours once a week,once a day,once a week for 4 weeks,four times a day, every 6 hours,35 days 4 week,once, once every 6 weeks on an empty stomach. , 10 to 15 mg/kg given every 7 to 10 days or 3 to 5 mg/kg twice weekly.,once,two times the IV dose rounded to the nearest 50 milligrams,"0.1 milligram (mg) per kilogram (kg) of body weight per day, taken as a single dose, for 3 to 6 weeks",depend upon treatment,depend on treatment,depend on treatment,Once,Once,Multiple times,Twice,Multiple times,Multiple times,Multiple times,Once-Twice,Once,Once,Multiple times,Multiple times,Two- Three times,Twice,Two- Three times,once every 2 weeks,3 weeks,2 times a day,once in 3 weeks,once daily,Once a week,Twice daily,Once a week,Once daily,Once daily,21 days cycle,Once daily,"2mg, taken 3 times a day",every 6 to 8 hours,4 times a day.,taken twice a day., two times a day or 5 mg 3 times a day.,once,every 6 hours as needed., two times a day at evenly spaced intervals.,two to four times a day.,as directed,1\3 times a day, one to four times a day with or without food.,once,2\4 fractional doses," once a day, in the morning.",6.25 mg to 12.5 mg,20-40 mg,1-2.5 mg,1.25-2.5 mg,25-100 mg,10mg,2.5-7.5 mg,2mg,2.4 mg/kg for IV,8-320 mg,4-32 mg/day,50-200 mg,750-825 mg,2mg/24 hrs IV route,400 mg,12.5 to 25 mg every 4 to6 hr,5 to 10mg,10 mg,60 ml,50mg,5 mg,5 mg,1 or 2sprays in nostrils,0.125 mg/kg,1.34mg,25 to 100 mg/day,25 to 50 mg,4 mg,10 mg,25 to 50 mg,"25mg,100mg","10mg,50mg,100mg",50 mg,300 mg,400mg,5 to 60 mg,60mg,"20mg,50mg,80mg,100mg,140mg","4 mg, 6mg",75 mg/m2 IV,"20mg\ml,100mg\ml",5mg/mL,"10mg/mL (10mL, 50mL vials)",5mg/mL,2mg,"90mg for mens,75mg for women",400 micrograms (mcg),2.4 micrograms,16mg,1.3mg,1.2mg,550mg,600 IU,30–35 micrograms,5mg,6 to 20mg.,NA,NA,120 micrograms,15mg (22.4 IU),Dose of the drug,1-2%,2-4%,400mg,200 mg,?400 mg/day,300 milligrams,250 milligrams,1 week/ once a day for 4 weeks,400 mg,200 mg,250 mg,1%,2 times,25 mg/kg ,375mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Adults—, 1 to 2 milligrams (mg) once a day","5 mg once daily,not exceeding 40 mg per day.",for adults is 40 to 80 mg once daily,"500 mg to 1 gram once or twice daily, taken with meals.",adults is 100 to 250 mg once daily,adults is 100 to 250 mg once daily,"250 mg to 500 mg once or twice daily, taken with meals.","0.5g given twice daily,","adults is 0.1 to 0.2 grams once daily, taken with breakfast or the first meal of the day.","adults is 10 to 80 mg once daily, taken with breakfast","adults is 30 to 60 mg once daily, taken with breakfast or the first meal of the day.","125 to 250 mg daily,",the daily dose is 30 mg to 120 m,1.5 mg to 3 mg orally once a day,5 mg 2 times daily,20 mg orally once a day,100 mg three times daily,once daily,NA,NA,20 mg once daily,2 grams as a single dose for most infections,15-30 mg once daily,250-500 mg every 6 hours for oral administration,20 mg once daily for gastroesophageal reflux disease,"325 to 2,000 milligrams taken
by mouth one to
four times per day.",200 mcg to 800 mcg for the prevention and treatment of gastric ulcers,200-800 mg every 6-8 hours for oral administration,2 grams of sodium citrate mixed with water three times a day,oral dose for adults is 150 mg twice daily or 300 mg once daily,500mg,200mg,650mg,500mg,400mg,262mg,20mg,40mg,150mg,40mg,35mg,20mg,70mg,500mg,500mg,30 to 150 mg,20-40mg,30mg or 90 mg,2.5mg,4mg/kg,200mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,Varies based on indication,Varies based on indication and combination with other drugs,Varies based on indication and combination with other drugs,Varies based on indication,Varies based on indication,Varies based on indication and severity,Varies based on indication,Varies depending on the condition,Dose of the drug,150-200 mg/m^2 every 6 weeks.,NA,130 to 200 mg/m^2 every 6 to 8 weeks.,NA,10mg,5mg,NA,NA,NA,NA,NA,NA,8 to 16 wafers,orally onces ever 6 weeks,NA,Dose of the drug,200mg every 12hr,300mg twice daily,50-150mg,varies depending on cindition being treated,varies depending on cindition being treated,varies depending on cindition being treated,varies depending on condition being treated,oral suspension,varies depending on formulation and indication,varies depending on formulation and indication,varies depending on formulation and indication,typically single application,varies depending on patients,varies depending on patients,6.25 mg to 12.5 mg,20-40 mg,1-2.5 mg,1.25-2.5 mg,25-100 mg,10mg,2.5-7.5 mg,2mg,2.4 mg/kg for IV,8-320 mg,4-32 mg/day,50-200 mg,750-825 mg,2mg/24 hrs IV route,400 mg,12.5 to 25 mg every 4 to6 hr,5 to 10mg,10 mg,60 ml,50mg,5 mg,5 mg,1 or 2sprays in nostrils,0.125 mg/kg,1.34mg,25 to 100 mg/day,25 to 50 mg,4 mg,10 mg,25 to 50 mg,"25mg,100mg","10mg,50mg,100mg",50 mg,300 mg,400mg,5 to 60 mg,60mg,"20mg,50mg,80mg,100mg,140mg","4 mg, 6mg",75 mg/m2 IV,"20mg\ml,100mg\ml",5mg/mL,"10mg/mL (10mL, 50mL vials)",5mg/mL,2mg,NA,Dose of the drug,"90mg for mens,75mg for women",400 micrograms (mcg),2.4 micrograms,16mg,1.3mg,1.2mg,550mg,600 IU,30–35 micrograms,5mg,6 to 20mg.,NA,NA,120 micrograms,15mg (22.4 IU),NA,NA,NA,NA,NA,1-2%,2-4%,400mg,200 mg,?400 mg/day,300 milligrams,250 milligrams,1 week/ once a day for 4 weeks,400 mg,200 mg,250 mg,1%,2 times,25 mg/kg ,375mg,NA,Polymorphism (if exist name the form),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Dose of the drug,"Adults—, 1 to 2 milligrams (mg) once a day","5 mg once daily,not exceeding 40 mg per day.",for adults is 40 to 80 mg once daily,"500 mg to 1 gram once or twice daily, taken with meals.",adults is 100 to 250 mg once daily,adults is 100 to 250 mg once daily,"250 mg to 500 mg once or twice daily, taken with meals.","0.5g given twice daily,","adults is 0.1 to 0.2 grams once daily, taken with breakfast or the first meal of the day.","adults is 10 to 80 mg once daily, taken with breakfast","adults is 30 to 60 mg once daily, taken with breakfast or the first meal of the day.","125 to 250 mg daily,",the daily dose is 30 mg to 120 m,1.5 mg to 3 mg orally once a day,5 mg 2 times daily,Dose of the drug,20 mg orally once a day,100 mg three times daily,once daily,NA,NA,20 mg once daily,2 grams as a single dose for most infections,15-30 mg once daily,250-500 mg every 6 hours for oral administration,20 mg once daily for gastroesophageal reflux disease,"325 to 2,000 milligrams taken
by mouth one to
four times per day.",200 mcg to 800 mcg for the prevention and treatment of gastric ulcers,200-800 mg every 6-8 hours for oral administration,2 grams of sodium citrate mixed with water three times a day,oral dose for adults is 150 mg twice daily or 300 mg once daily,Dose of the drug,500mg,200mg,650mg,500mg,400mg,262mg,20mg,40mg,150mg,40mg,35mg,20mg,70mg,500mg,500mg,Dose of the drug,30 to 150 mg,20-40mg,30mg or 90 mg,2.5mg,4mg/kg,200mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,Varies based on indication,Varies based on indication and combination with other drugs,Varies based on indication and combination with other drugs,Varies based on indication,Varies based on indication,Varies based on indication and severity,Varies based on indication,Varies depending on the condition,Dose of the drug,150-200 mg/m^2 every 6 weeks.,NA,130 to 200 mg/m^2 every 6 to 8 weeks.,NA,10mg,5mg,NA,NA,NA,NA,NA,NA,8 to 16 wafers,orally onces ever 6 weeks,NA,200mg every 12hr,300mg twice daily,50-150mg,varies depending on cindition being treated,varies depending on cindition being treated,varies depending on cindition being treated,varies depending on condition being treated,oral suspension,varies depending on formulation and indication,varies depending on formulation and indication,varies depending on formulation and indication,typically single application,varies depending on patients,varies depending on patients,variable,changes,varies,varies,varies,varies,varies,varies,varies,varies,varies,varies,varies,varies,varier,NA,varies,varier,varier,varies,varier,varier,varier,varier,varier,varier,varier,varier,varier,2.5-20 mg,0.5-5 mg,70mg,60mg,35mg,"6mg, 50mg",5mg/100ml,20mg,400mg,200mg,9mg/1ml,2mg,20mcg,80mcg/40mcl,200 [USP'U]/1mL,60 mg/ml,105 mg,very poorly soluble in water 0.357 mg/mL,slightly soluble in water (0.299 mg/mL),Upadacitinib is sparingly soluble in aqueous buffers (0.0707 mg/mL),Insoluble in water,Leflunomide is poorly soluble in water,Slightly soluble (0.1 g/mL),Slightly soluble,Slightly soluble in water ~0.001-0.004 g/mL,"0.5 g/mL, very slightly soluble",0.12 g/Ml,Highly soluble,Slightly soluble,Soluble,Limited solubility,Not available,NA,"On face (12.5-mg doses), Scalp (25-mg doses), hand/arms (75-mg doses)","Fluorouracil cream USP, 5%(Doses of 125 to 250 mg/kg)",Recommeded dose is 150 mg/day orally,Recommended dose is once daily on an empty stomach,recommended dose 2mg/kg administered as an intravenous infusion,maximum of 14 doses,45 mg,450 mg(six 75 mgcapsules),60 mg,150 mg,"Dacarbazine 100 mg and 200 mg vials should be reconstituted with 9.9 ml and 19.7 ml respectively, with Water for Injections BP.",30 mg,960 mg(4 tablets of 250 mg),10 mg/kg IV,NA,250 mg/kg/day ,"Adults, teenagers, and children weighing 40 kilograms (kg) or more—250 to 500 milligrams (mg) every 8 hours"," Adults and children 15 years of age and older—1000 to 4000 milligrams (mg) per day, ", 1-2 g/day IV in single daily dose or divided q12hr for 4-7 days,"<1 week, >1.5 kg: 25 mg/kg IV q12hr for non-CNS infections.", 1 g IV every 8 hours,Dosage Forms & Strengths ; capsule (Vancocin). 125mg; 250mg ,Oral: 300 mg orally once a day.,1 to 2 g IM or IV every 8 hours,3.5 mg tiamulin hydrogen fumarate per pound for,dults—400 milligrams (mg) once every 24 hours,134 mcg/mL (2.25-g dose);,1 g q12hr ·,usually every 8 or 12 hours,0.6 mg,5-20 mg,20 mg,10-20 mg,100mg,40-320 mg,25-200 mg,25-100 mg,80-480 mg,120-420 mg,2.5-10 mg,5-20mg,30-90 mg,2.5-10 mg,25-75 mg,Oral,Oral,Oral,Oral and opthalmic,"Oral, topical and opthalmic",intravenous,"Oral, intravenous, opthalmic","Opthalmic, intravenous","Intravenous, intramuscular",Oral,Intravenous,"Intravenous ,intramuscular",Intravenous,Oral,"Intramuscular , intravenous",once daily.,once daily.,once daily.,once daily.,once daily.,once daily.,2-4 times daily.,1-2 times daily.,1-2 times daily.,1-2 times daily.,1-2 times daily,three to four times daily for adults.,3-4 times daily,four times a day,3-4 times daily.,Inhaled twice daily for 5 days,"600 mg once a day, administered
intravenously for 5 to 10 days."," 75 mg twice daily or 12.5 ML of oral
suspension twice daily","300mg twice per day or 600mg once per
day",for oral adults & children 12 yrs age & older 200mg five times a day for 10 days,"20mg per kg taken three times a day 
for 5 days",80mg taken as a single dose per day,"5mg per kg is injected slowly into a 
vein once a week for two weeks in a row","500 mg daily for 2 weeks and 250 mg
daily for 12 weeks","600mg tablet taken orally twice daily 
with or without food",300 mg orally once a day, 1200 mg orally twice a day,300mg with 100mg ritonavir once a day,"800 mg orally three times daily
(every 7 to 9 hours) with food in combination with peginterferon and ribavirin", 150mg/300mg twice daily,"Varies, depending on the condition",Varies based on condition,Variable depending on condition,"Varies based on condition, typically starting at 25 mg daily",Varies based on condition; typically 1000-3000 mg/day,Varies depending on the condition; typical starting dose for epilepsy: 25-50 mg/day,Varies depending on the condition; consult a healthcare professional,Varies depending on the condition being treated,"Varies depending on the condition, typically starting at 1200 mg/day","Varies, depending on condition",Depends on the condition; typically 4-56 mg/day,"Varies depending on the condition, consult healthcare provider",Varies depending on condition,Varies based on indication,"Variable, depending on the condition","Varies, depending on the condition",Varies based on condition,Variable depending on condition,"Varies based on condition, typically starting at 25 mg daily",Varies based on condition; typically 1000-3000 mg/day,Varies depending on the condition; typical starting dose for epilepsy: 25-50 mg/day,Varies depending on the condition; consult a healthcare professional,Varies depending on the condition being treated,"Varies depending on the condition, typically starting at 1200 mg/day","Varies, depending on condition",Depends on the condition; typically 4-56 mg/day,"Varies depending on the condition, consult healthcare provider",Varies depending on condition,Varies based on indication,"Variable, depending on the condition"
Mode of action,"CNS stimulation, releasing agent","CNS stimulant, releases dopamine","CNS stimulant, dopamine reuptake inhibitor",CNS stimulant,Promotes wakefulness,Promotes wakefulness,Alpha and beta adrenergic agonist,"Blocks reuptake of neurotransmitters like dopamine, serotonin, and norepinephrine","Adenosine receptor antagonist, phosphodiesterase inhibitor",Agonist at nicotinic acetylcholine receptors,Selective norepinephrine reuptake inhibitor,"Sympathomimetic amine, appetite suppressant","Sympathomimetic amine, appetite suppressant","Sympathomimetic amine, appetite suppressant",Precursor to dopamine,NMDA receptor antagonist,Monoamine oxidase-B (MAO-B) inhibitor,"Selective MAO-B inhibitor, increases dopamine levels",Inhibitor of COMT (Catechol-O-methyltransferase),Acetylcholinesterase inhibitor,Antimuscarinic/anticholinergic,Dopamine agonist,"Agonist at dopamine receptors, primarily D2 and D3 receptors",Monoamine oxidase-B (MAO-B) inhibitor and sodium channel modulator,"Dopamine receptor agonist, primarily D2 and D3 receptors","Dopamine receptor agonist, mainly D2 receptors",Adenosine A2A receptor antagonist,"Antimuscarinic, blocks acetylcholine receptors",COMT (Catechol-O-methyltransferase) inhibitor,A,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"DNA crosslinking, cell cycle nonspecific","Inhibition of dihydrofolate reductase, leading to inhibition of DNA synthesis and cell proliferation","Alkylating agent, forms methyl adducts on DNA leading to cell death",Once daily,"Alkylating agent, interferes with DNA and RNA synthesis","Inhibits microtubule formation, disrupting mitosis","Inhibits topoisomerase I, leading to DNA damage and cell death","Inhibition of topoisomerase I, leading to DNA damage and cell death","Inhibition of topoisomerase II, leading to DNA strand breaks and cell death","Stabilizes microtubules, inhibiting their disassembly, leading to cell cycle arrest and apoptosis","Glucocorticoid receptor agonist, anti-inflammatory and immunosuppressive effects",Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,ANTIFUNGAL,Antifungal,Antifungal,It regulates the metabolism of glucose,involves stimulating insulin release from the beta cells of the pancreas,"stimulating insulin release from pancreatic beta cells, promoting glucose uptake by tissues, and reducing hepatic glucose production","by inhibiting alpha-glucosidase enzymes in the intestine, slowing down the breakdown of complex carbohydrates into glucose. This delays glucose absorption",is an alpha-glucosidase inhibitor inhibiting enzymes in the small intestine that break down complex carbohydrates into glucose. This slows down the absorption of glucose,"ATP-sensitive potassium channels on the beta cell membrane, leading to depolarization, calcium influx, and subsequent insulin secretio","by inhibiting enzymes in the intestine, particularly alpha-glucosidase, which are responsible for breaking down complex carbohydrates into glucose. By slowing down this process","involves activating peroxisome proliferator-activated receptor gamma (PPAR?) in target tissues, such as adipose tissue, skeletal muscle, and liver. This activation enhances insulin sensitivity, leading to improved glucose utilization and decreased hepatic glucose production",by decreasing glucose production in the liver and improving insulin sensitivity in peripheral tissues. It also reduces the absorption of,Insulin regulates blood sugar by facilitating glucose uptake into cells.,"facilitating glucose uptake by cells, inhibiting the liver's glucose production, and suppressing the release of glucagon","promoting glucose uptake by cells and inhibiting the liver's glucose production, helping to regulate blood sugar levels",stimulating insulin release from the beta cells of the pancreas by binding to the ATP-sensitive potassium channels on these cells. This leads to an increase in insulin secretion,"inhibiting the enzymatic activity of DPP-4, which in turn increases the concentration of incretin hormones",selective serotonin reuptake inhibitor,selective serotonin reuptake inhibitor,serotonin norepinephrine reuptake inhibitor,serotonin norepinephrine reuptake inhibitor,dopamine and norephinephrine reuptake inhibitor,selective serotonin reuptake inhibitor,NA,serotonin antagonist and reuptake inhibitor,alpha 2 adrenergic antagonist and serotonin antagonist,tricyclic antidepressant,selective serotonin reuptake inhibitor,monoamine oxidase inhibitor,monoamine oxidase inhibitor,Antineoplastic agent,Antineoplastic Tyrosine Kinase Inhbitor,Antineoplastic agent,Antineoplastic agent,Antineoplastic agent,Antineoplastic agent,Antineoplastic agent,Antineoplastic agent,"Antineoplastic agent, Antimicrotubule agent",Antineoplastic agent Antimetabolite,"Antineoplastic agent, antimetabolite","Antineoplastic agent, Antimitotic agent,","Antineoplastic agent, Antibodies",Antineoplastic agent,HBV infection,inhibit HIV replication,DNA by HBV reverse transcriptase and inhibits the growth of the virus by halting the HBV replication,DNA chain termination,"(HBV) polymerase enzyme, which is essential for the replication of the virus",DNA chain termination,DNA chain termination,DNA synthesis and viral replication,metabolized to 5-triphosphate derivative,absorption of cholesterol from the small intestine,farnesyltransferase inhibitor,nucleoside analog reverse transcriptase inhibitor,nucleoside analog reverse transcriptase inhibitor,protease inhibitor,nucleotide analog reverse transcriptase inhibitor,"Azathioprine is a prodrug that is converted to 6-mercaptopurine (6-MP) in the body. 6-MP interferes with DNA and RNA synthesis, exerting immunosuppressive effects.","The mechanism of action of acitretin is unknown, however it is believed to work by targeting specific receptors (retinoid receptors such as RXR and RAR) in the skin which help normalize the growth cycle of skin cells.",Fluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain,"Methotrexate is an antimetabolite that inhibits dihydrofolate reductase (DHFR), interfering with the synthesis of DNA, RNA, and proteins. It is used in cancer chemotherapy and autoimmune diseases."," Hydroxyurea is well absorbed after oral administration, converted to a free radical nitroxide in vivo, and transported by diffusion into cells where it quenches the tyrosyl free radical at the active site of the M2 protein subunit of ribonucleotide reductase, inactivating the enzyme.","immunosoppresant, nhbits Tcell activation",Clobetasol is a potent corticosteroid with anti-inflammatory and immunosuppressive properties.,": Betamethasone exerts anti-inflammatory and immunosuppressive effects by binding to glucocorticoid receptors, regulating gene expression and inhibiting the release of inflammatory mediators.",: Calcipotriene is a synthetic vitamin D analog that regulates skin cell production and differentiation.,"Tazarotene is a prodrug that is converted to its active form (tazarotenic acid), which binds to retinoic acid receptors, modulating cell differentiation and proliferation.","Pimecrolimus is an immunomodulator that inhibits the activation of T-lymphocytes and mast cells, helping to reduce inflammation associated with certain skin conditions.",it bind to TNF-alpha and block its interaction with p55 and p75 cell surface TMF receptor there by nutrilise thr TNF- alpha,phosphodiesterase inhibitors.,it is thought to interfere with the terminal differentiation of keratinocytes,NA,muscarinic Ach receptor antagonist,antimuscarinic,h1 receptor antagonist,d2 receptor antagonist,5-ht3 receptor antagonist,serotonin antagonist,n1 receptor antagonist,antihistamine,d2 receptor antagonist,d2 receptor antagonist,5-ht3 antagonist,5-ht3 receptorantagonist,nk1 receptor antagonist,"It regulates the metabolism
of glucose","It works by lowering blood
glucose levels","Binds to albumin via fatty 
acid chain","lowers blood glucose by stimulating 
peripheral glucose uptake by skeletal 
muscle and fats","protracted absorption involving the form
ation of a depot of soluble multihexamer 
chains after subcutaneous injection","It work by replacing the insulin that 
is normally produced by the body
and by helping move sugar from blo-
od into other body tissues.",NA,"Pramlintide is an amlyinomimetic, a functional analog of the naturally occurring pancreatic hormone amylin","Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two ex tracellular alpha units and two transmembrane
beta units",NA,Inhibition of hormones secretion,"eplizumab is a monoclonal antibody therapy designed to target and modulate the immune system, particularly in the context of type 1 diabetes mellitus","Insulin glargine lowers blood glucose by 
stimulating peripheral glucose uptake 
and inhibiting hepatic glucose produc
tion.",NA,"Novolin R works by replacing the insuli
n that is normally produced by the
pancreas",how many times( once/twice/thrice),once,once,once,thrice,thrice,thrice,once,once,once,once,once,once,thrice,once,once,once,once,once,"Ranitidine is a histamine H2-receptor antagonist. It works by blocking the action of histamine on the stomach's acid-producing cells, thereby reducing the amount of acid produced.",", cimetidine works by blocking the action of histamine on the histamine H2 receptors in the stomach. By doing so, it reduces the production of stomach acid.",": Famotidine works by competitively blocking the H2 receptors in the stomach, thereby reducing gastric acid secretion",", cimetidine works by blocking the action of histamine on the histamine H2 receptors in the stomach. By doing so, it reduces the production of stomach acid.",": Bepridil works by blocking calcium channels, thereby reducing calcium influx into cardiac and smooth muscle cells, leading to vasodilation and decreased myocardial contractility.","Cisapride acts as a selective agonist at serotonin 5-HT4 receptors, enhancing gastrointestinal motility and accelerating gastric emptying.",Dofetilide is a class III antiarrhythmic agent that prolongs the cardiac action potential duration by selectively inhibiting the rapid component of the delayed rectifier potassium current (IKr).,"Levoketoconazole is a potent inhibitor of steroidogenesis, specifically targeting the enzyme 11?-hydroxylase involved in cortisol synthesis.","Pimozide is a dopamine antagonist, specifically blocking dopamine D2 receptors, which contributes to its antipsychotic effects.","Piperaquine acts by interfering with the function of heme detoxification in the malaria parasite, leading to its death.","Sparfloxacin is a broad-spectrum fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV enzymes, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.",": Terfenadine is a selective antagonist of the histamine H1 receptor. It blocks the action of histamine, thereby alleviating allergic symptoms such as itching, sneezing, and runny nose.",Ziprasidone is an atypical antipsychotic medication that exerts its therapeutic effects through a combination of serotonin (5-HT2A) and dopamine (D2) receptor antagonism.,"Mesoridazine acts as a dopamine receptor antagonist, specifically blocking dopamine receptors in the brain. It also has anticholinergic, antiadrenergic, and weak antihistaminic properties.","Nizatidine is a histamine H2 receptor antagonist. It works by inhibiting the action of histamine on H2 receptors in the stomach, thereby reducing gastric acid secretion.","Amikacin binds to the 30 S bacterial ribosome subunit, resulting in interference with a reading of the genetic code and inhibition of protein synthesis, e.g., elicits premature protein termination and incorporation of incorrect amino acid.",Plazomicin exerts a bactericidal action against susceptible bacteria by binding to bacterial 30S ribosomal subunit 1. Aminoglycosides typically bind to the ribosomal aminoacyl-tRNA site (A-site) and induce a conformational change to further facilitate the binding between the rRNA and the antibiotic 5. This leads to codon misreading and mistranslation of mRNA during bacterial protein synthesis,"Azithromycin mechanism of action including the inhibition of bacterial protein synthesis, inhibition of proinflammatory cytokine production, inhibition of neutrophil infestation, and macrophage polarization alteration","Amoxicillin competitively inhibit penicillin binding proteins, leading to upregulation of autolytic enzymes and inhibition of cell wall synthesis. Amoxicillin has a long duration of action as it is usually given twice daily.","Cephalosporins are bactericidal and, like other ?-lactam antibiotics, disrupt the synthesis of the peptidoglycan layer forming the bacterial cell wall. The peptidoglycan layer is important for cell wall structural integrity. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by penicillin-binding proteins (PBPs). PBPs bind to the D-Ala-D-Ala at the end of muropeptides (peptidoglycan precursors) to crosslink the peptidoglycan.",Temocillin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity.,"The mechanisms of action of ampicillin are interference with cell wall synthesis by attachment to penicillin-binding proteins (PBPs), inhibition of cell wall peptidoglycan synthesis and inactivation of inhibitors to autolytic enzymes.",Sulfadiazine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.,"eravacycline exerts its antibacterial action by reversibly binding to the bacterial ribosomal 30S subunit, thereby preventing the incorporation of amino acid residues into elongating peptide chains and leading to disruption of bacterial protein synthesis","Penicillin kills bacteria through binding of the beta-lactam ring to DD-transpeptidase, inhibiting its cross-linking activity and preventing new cell wall formation.","Meropenem exerts its bactericidal action by binding to penicillin-binding proteins (PBPs) in the bacterial cell wall and inhibiting peptidoglycan cross-linking associated with cell wall synthesis, which ultimately leads to cell death","Within a bacterial cell, peptidoglycan provides mechanical stability to the cell wall. Cephalexin, along with other beta-lactam antibiotics, utilizes its beta-lactam ring to inhibit the synthesis of peptidoglycan, a crucial process in forming the bacterial cell wall.","Ciprofloxacin is a broad-spectrum antibiotic that affects its target by inhibiting the DNA gyrase, which is known as topoisomerase II and topoisomerase IV (10). DNA gyrase contains subunits A and B.","Ceftolozane/tazobactam is an intravenous cephalosporin combined with a ?-lactamase inhibitor in a fixed 2:1 ratio. Similar to other cephalosporins, ceftolozane inhibits cell-wall synthesis via binding of PBPs.",The antibacterial effect of CAM is related to its capacity to inhibit protein synthesis in bacteria by binding to subunit 50S of the bacterial ribosome,Beta 2- Adregenic Agonist,Phosphodiesterase inhibitor,Selective ?2-adrenergic receptor agonist,"Non-selective adenosine receptor antagonist, phosphodiesterase inhibitor",Antimuscarinic (blocks muscarinic receptors),Antimuscarinic (blocks muscarinic receptors),"Leukotriene receptor antagonist, specifically cysteinyl leukotriene receptor 1 (CysLT1)","Leukotriene receptor antagonist, specifically cysteinyl leukotriene receptor 1 (CysLT1)",Inhibits release of inflammatory mediators,"Histamine H1 receptor antagonist, mast cell stabilizer","Glucocorticoid, anti-inflammatory","Glucocorticoid, anti-inflammatory","Glucocorticoid, anti-inflammatory","Glucocorticoid, anti-inflammatory","Glucocorticoid, anti-inflammatory","Stabilizes neuronal membranes, inhibits sodium channels","Blocks sodium channels, stabilizing neuronal membranes","Multiple, including increased GABA levels, sodium channel inhibition","Anticonvulsant, voltage-gated sodium channel blocker",Exact mechanism not fully understood; believed to modulate synaptic neurotransmission,Antiepileptic; precise mechanism not fully understood,"Blocks voltage-sensitive sodium channels, stabilizing neuronal membranes","Binds to GABA-A receptors, enhances inhibitory neurotransmission",Exact mechanism is not fully understood; may involve modulation of NMDA receptors and inhibition of voltage-gated sodium channels,Irreversible GABA transaminase inhibitor,"Binds to GABA reuptake transporter, increasing GABA levels in the brain",Anticonvulsant,Anticonvulsant; exact mechanism unclear,Antiepileptic; Carbonic anhydrase inhibitor,Binds to voltage-gated calcium channels in CNS,this action occur by acting on GABA-A receptor subunit,"Stabilizes neuronal membranes, inhibits sodium channels",Binds to voltage-gated calcium channels in CNS,Antiepileptic; Carbonic anhydrase inhibitor,Anticonvulsant; exact mechanism unclear,Anticonvulsant,"Binds to GABA reuptake transporter, increasing GABA levels in the brain",Irreversible GABA transaminase inhibitor,block T type calcium channel,"Multiple, including increased GABA levels, sodium channel inhibition","Anticonvulsant, voltage-gated sodium channel blocker","Blocks sodium channels, stabilizing neuronal membranes",Exact mechanism not fully understood; believed to modulate synaptic neurotransmission,inhibit neurotransmitter in central nervous system,Exact mechanism is not fully understood; may involve modulation of NMDA receptors and inhibition of voltage-gated sodium channels,Dopamine receptor antagonist,Blocks dopamine receptors,Dopamine receptor antagonist,Dopamine receptor antagonist,Dopamine D2 receptor antagonist,Dopamine receptor antagonist,Atypical antipsychotic,Atypical antipsychotic,Atypical antipsychotic,Partial agonist at serotonin receptors; antagonist at dopamine receptors,Antipsychotic,"Atypical antipsychotic, 5-HT2 antagonist",Atypical antipsychotic,"Partial agonist of dopamine D2/D3 receptors, and serotonin 5-HT1A receptors",Atypical antipsychotic,"class I antiarrhythmic medication, working by blocking sodium channels in the heart.",stabilizing the cardiac cell membrane and delaying repolarization.,NA,"local anesthetic by inhibiting voltage-gated sodium channels, preventing nerve impulses",class IB antiarrhythmic medication that works by inhibiting sodium channels,"works by blocking sodium channels in cardiac tissue,","works by causing vasodilation in the coronary arteries, leading to increased blood flow to the heart. It also has antiarrhythmic effects.",works by inhibiting the sodium-potassium,calcium channel blocker.,calcium channel blocker,non-selective beta-blocker,cardioselective ?1-adrenergic receptor blocker.,class III antiarrhythmic agent that primarily works by prolonging the action potential duration,non-selective beta-adrenergic antagonist and a class III antiarrhythmic agent,"selective beta-1 adrenergic receptor antagonist, also known as a beta blocker.",atezolizumab helps to restore the ability of the immune system to recognize and attack cancer cells,Vegf inhibitors,Inhibits DNA synthesis and repair by acting as a nucleoside analog,tyrosine kinase inhibitor,PD-L1 inhibitor,multi-kinase inhibitor,NA,Multikinase inhibitor,Multikinase inhibitor,TRK and ROS1 inhibition,Tyrosine kinase inhibitor,Variable based on indication,Multikinase inhibitor,Multikinase inhibitor,FGFR kinase inhibitor,"inhibition of enzymes responsible for nucleotide synthesis including dihydrofolate reductase, thymidylate synthase, aminoimidazole caboxamide ribonucleotide transformylase (AICART), and amido phosphoribosyltransferase.1 Inhibtion of nucleotide synthesis prevents cell division.","attachment of alkyl groups to DNA bases, resulting in fragmentation and cell death, DNA damage via the formation of cross-links, and induction of mispairing of nucleotides leading to mutation.","The alkyl group is attached to the guanine base of DNA, at the number 7 nitrogen atom of the imidazole ring. They stop tumor growth by crosslinking guanine nucleobases in DNA double-helix strands, directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. These drugs act nonspecifically",", the drug is metabolized into alkylating agents by N-demethylation. These alkylating species consequently damage tumor cells.","a bifunctional alkylating agent, which has an immunosuppressive effect on bone marrow","Melphalan exerts its cytotoxicity by inducing inter-strand cross-links in DNA,16 and it may also induce lesions in RNA, proteins, and lipids. Melphalan has been used in the treatment of lymphoma and leukemia and several types of solid tumor, including neuroblastoma, melanoma, sarcoma, and ovarian cancer.to treat multiple myeloma"," p53-dependent activation of DNA-damage stress response and apoptosis, (2) inhibition of mitotic checkpoints, and (3) induction of mitotic catastrophe.",Lomustine acts by slowing this process down. It kills cancer cells by damaging the DNA (the genetic material inside the cells) and stops them from dividing. Lomustine is a highly lipophilic nitrosourea compound which undergoes hydrolysis in vivo to form reactive metabolites.,"An activated form of cyclophosphamide, phosphoramide mustard, alkylates, or binds, to DNA. Its cytotoxic effect is mainly due to cross-linking of strands of DNA and RNA, and to inhibition of protein synthesis.", inhibition of protein synthesis of mycobacteria in the ribosome,inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.,"attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.",activated in the liver to highly reactive alkylating intermediates. ,"The combined effects of inhibiting DNA synthesis, causing chain termination, and promoting apoptosis contribute to the cytotoxic effects of fludarabine on cancer cells","It is an alkylating agent and works by interfering with the DNA synthesis and replication process in rapidly dividing cells, including cancer",irreversibly blocking the proton pump in parietal cells.,irreversibly blocking the proton pump in parietal cells.,blocking H2 receptors on parietal cells.,inhibiting the action of histamine on H2 receptors,Muscarinic receptor antagonist that selectively inhibits gastric acid secretion,"muscarinic receptor antagonist, used to reduce excessive salivation and treat conditions",synthetic prostaglandin E1 analogue that is used to prevent and treat gastric ulcers,"interferes with the DNA structure of the microorganisms, leading to DNA damage and inhibition of DNA synthesis","acts as a buffer and stabilizer by chelating calcium ions, preventing clotting in blood","acts as an alkalizing agent by releasing carbon dioxide, which helps neutralize acidity","forms a protective barrier over ulcers and erosions in the gastrointestinal tract, promoting healing",aluminum-containing antacid that neutralizes stomach acid,"nhibits bacterial cell wall synthesis, effectively treating various bacterial infections","macrolide antibiotic that inhibits bacterial protein synthesis, preventing the growth and spread of bacteria",antibiotic and antiprotozoal medication that disrupts the DNA structure,"Paclitaxel targets microtubules. At high concentration, PTX causes mitotic arrest at G2/M phase whereas at low concentration, apoptosis is induced at G0 and G1/S phase either via Raf-1 kinase activation or p53/p21 depending on the dose concentration.","Cisplatin induces its cytotoxic properties through binding to nuclear DNA and subsequent interference with normal transcription, and/or DNA replication mechanisms.",Alectinib is an orally bioavailable tyrosine kinase inhibitor that inhibits ALK and RET proteins by preventing their phosphorylation. Inhibition of ALK activation prevents downstream signaling of cell proliferation and decreases tumor survivability.,"By inhibition of microtubular depolymerization, and attenuation of the effects of bcl-2 and bcl-xL gene expression."," Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. ","The mechanisms of action of methotrexate are complex. Developed as a folic acid analogue, methotrexate inhibits purine and pyrimidine synthesis, which accounts for its efficacy in the therapy of cancer as well as for some of its toxicities.","Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d'Origine Nantais (RON)",mechanism of action is related to the inhibition of microtubule dynamics leading to a mitotic arrest and cell death.,It acts by inhibiting ALK phosphorylation and the activation of downstream signaling proteins,Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).,Gemcitabine is a nucleoside analog that mediates its antitumour effects by promoting apoptosis of malignant cells undergoing DNA synthesis.,"Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK).","anxiolytic,sedative,muscl relaxant,anti convulsant,amnestic effects, facilitation of the action of gamma amimobutyric acid",central acting CNS depressant,by blocking the action of histamine a substance in the body that causes allergic symptoms.," blocking the action of the endogenous catecholamines, epinephrine and norepinephrine, at beta adrenoceptors.",suppressing serotonergic activity while enhancing dopaminergic and noradrenergic cell firing., has a differential action at presynaptic (agonist) and post-synaptic (partial agonist) 5-HT1A receptors.,binds to benzodiazepine receptors on the postsynaptic GABA-A ligand-gated chloride channel neuron at several sites within the central nervous system (CNS). ,"stimulating the pre-synaptic alpha 2 adrenoceptors, thereby decreasing noradrenaline release from both central and peripheral sympathetic nerve terminals", metabolized in the liver by cytochrome P450 3A4 (CYP3A4) to 4-hydroxyalprazolam and alpha-hydroxyalprazolam metabolites,decreased input resistance by activating GABAA receptors.," increases the amount of time chloride channels are open, consequently depressing the central nervous system.", The drug blocks EEG arousal from stimulation of the brain stem reticular formation., binding to gamma-aminobutyric acid (GABA) A subtype receptors,"induces hypnosis and anesthesia, but not analgesia. ",block the serotonin reuptake transporter (SERT) and thus increase the concentration of synaptic serotonin.,twice,thrice,once or twice,once,twice,twice,once or twice,twice,once,twice,once,once,twice,once,once,depends on helthcare,once in a day,once in a day,twice in a day,as per prescribed,once in a day,once in aday at evening,2 times,once in a day,every 12 hours/2 day,2 or 3,twice in a day,every 8 hours,once in a day,once in a day,1 dose in 24 hour,"Week 1: 20 mg PO qDay
Week 2: 50 mg PO qDay
Week 3: 100 mg PO qDay
Week 4: 200 mg PO qDay
Week 5 and beyond: 400 mg PO qDay",50 mg orally twice daily with food on days 8 to 21 of induction and consolidation chemotherapy cycles.,"chronic phase CML, the recommended dose is 300 mg orally twice daily.",400 mg once a day,once a day,once a day,100 mg PO qDay (morning or evening),"8-12 mg PO/IV alone or in combination with other antiemetics before chemotherapy, then 8 mg PO/IV q24hr for 1-3 days after chemotherapy (days 2-4)",75 mg/m2 IV or subcutaneously daily for 7 days in a 28-day cycle,100 mg/m2 IV continuous infusion for 7 days OR 100 mg/m2/dose IV continuous infusion q12hr for 7 days,"1500 mg/sq.meter IV over 2 hours on Days 1, 3, and 5; repeat q21Days","375 mg/m2 IV infusion on Day 1 of 1st cycle (for 1st cycle, administer 1 day before chemotherapy with FC), THEN 500 mg/m2 IV on Day 1 of cycles 2-6 (administer on same day as chemotherapy with FC)
500 mg/m2 IV on Day 1 of cycles 2-6 (administer on same day as chemotherapy with FC)","In combination with cytarabine 100 mg/m²/day IV for 7 days first course, for 5 days subsequent courses , <60 years old: 45 mg/m² IVP days 1, 2, 3 first course; days 1, 2 subsequent courses ,>60 years old: 30 mg/m² IVP days 1, 2, 3 first course; days 1, 2 subsequent courses",0.1 mg/kg/day for 3-6 weeks ,once-,once,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,how many times( once/twice/thrice),2 to 3 times a day,Twice,once every 72 hours ,once/Twice,Every 12 hrs,Twice,Every 12 hrs,once a day for 2 weeks,Once weekly,once per 1 hr,once in 12 weeks,once,twice,4 times,Single,once,Once or twice,Once,Once or twice,Once to thrice,Once or twice,Once or twice,Once,Twice,Once,Once or twice,Once or twice,Once or twice,Oral - Multiple times,Once or twice,twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),Typically once daily.,multiple times per day.,NA,NA,multiple times a day.,Once daily,once daily,once daily,Multiple times daily,Usually taken once daily,one to four times per day.,multiple times per day,multiple times daily,three times a day.,"twice daily,","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)",NA,once,twice in day,once in a day,once in a day,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Usually twice daily (depends on indication),Once daily (typically),Once or twice daily (depends on indication),Typically twice daily,Typically once or twice daily,Usually once daily,Typically twice daily,"Usually administered multiple times a day, depending on the condition",how many times( once/twice/thrice),once,once,once,twice,once,once,twice,once,once,twice,once,once,twice,twice,twice,how many times( once/twice/thrice),twice,twice,once,once or twice,once or twice,once,ORAL IN DAILY,several times in daily,varies depending on formulation and indication,once,once,once,once,once,twice,thrice,once or twice,once,twice,twice,once or twice,twice,once,twice,once,once,twice,once,once,depends on helthcare,once in a day,once in a day,twice in a day,as per prescribed,once in a day,once in aday at evening,2 times,once in a day,every 12 hours/2 day,2 or 3,twice in a day,every 8 hours,once in a day,once in a day,1 dose in 24 hour,"Week 1: 20 mg PO qDay
Week 2: 50 mg PO qDay
Week 3: 100 mg PO qDay
Week 4: 200 mg PO qDay
Week 5 and beyond: 400 mg PO qDay",50 mg orally twice daily with food on days 8 to 21 of induction and consolidation chemotherapy cycles.,"chronic phase CML, the recommended dose is 300 mg orally twice daily.",400 mg once a day,once a day,once a day,100 mg PO qDay (morning or evening),"8-12 mg PO/IV alone or in combination with other antiemetics before chemotherapy, then 8 mg PO/IV q24hr for 1-3 days after chemotherapy (days 2-4)",75 mg/m2 IV or subcutaneously daily for 7 days in a 28-day cycle,100 mg/m2 IV continuous infusion for 7 days OR 100 mg/m2/dose IV continuous infusion q12hr for 7 days,"1500 mg/sq.meter IV over 2 hours on Days 1, 3, and 5; repeat q21Days","375 mg/m2 IV infusion on Day 1 of 1st cycle (for 1st cycle, administer 1 day before chemotherapy with FC), THEN 500 mg/m2 IV on Day 1 of cycles 2-6 (administer on same day as chemotherapy with FC)
500 mg/m2 IV on Day 1 of cycles 2-6 (administer on same day as chemotherapy with FC)","In combination with cytarabine 100 mg/m²/day IV for 7 days first course, for 5 days subsequent courses , <60 years old: 45 mg/m² IVP days 1, 2, 3 first course; days 1, 2 subsequent courses ,>60 years old: 30 mg/m² IVP days 1, 2, 3 first course; days 1, 2 subsequent courses",0.1 mg/kg/day for 3-6 weeks ,NA,how many times( once/twice/thrice),once-,once,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2 to 3 times a day,Twice,once every 72 hours ,once/Twice,Every 12 hrs,Twice,Every 12 hrs,once a day for 2 weeks,Once weekly,once per 1 hr,once in 12 weeks,once,twice,4 times,Single,NA,How many times (once/twice/thrice),once,Once or twice,Once,Once or twice,Once to thrice,Once or twice,Once or twice,Once,Twice,Once,Once or twice,Once or twice,Once or twice,Oral - Multiple times,Once or twice,how many times( once/twice/thrice),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),twice (according to the sugar level of patient),how many times( once/twice/thrice),Typically once daily.,multiple times per day.,NA,NA,multiple times a day.,Once daily,once daily,once daily,Multiple times daily,Usually taken once daily,one to four times per day.,multiple times per day,multiple times daily,three times a day.,"twice daily,",how many times( once/twice/thrice),"Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)","Drug has given once a day, twice a day and thrice a day its
totally depend upon drug half life (Tmax half ,tmax, cmax)",how many times( once/twice/thrice),NA,once,twice in day,once in a day,once in a day,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Usually twice daily (depends on indication),Once daily (typically),Once or twice daily (depends on indication),Typically twice daily,Typically once or twice daily,Usually once daily,Typically twice daily,"Usually administered multiple times a day, depending on the condition",how many times( once/twice/thrice),once,once,once,twice,once,once,twice,once,once,twice,once,once,twice,twice,twice,twice,twice,once,once or twice,once or twice,once,ORAL IN DAILY,several times in daily,varies depending on formulation and indication,once,once,once,once,once,2 times,1 time,2 times,NA,3 times,2 times,1 time,depends,1 time,3 time,1 time,3 times,5 times,1 time,4 time,NA,Once,Thrice,Thrice,Once,Thrice,Twice,Thrice,Twice,Once,Thrice,Thrice,Twice,Thrice,Twice,Thirce,once,once,once,once,once,once,once,once,once,once,once,once,once,once,once,Baricitinib is soluble in organic solvents such as DMSO and dimethyl formamide (DMF).,Tofacitinib (citrate) is soluble in organic solvents such as DMSO and dimethyl formamide.,soluble in organic solvents such as DMSO and dimethyl formamide,"Insoluble in water , alcohol, chloroform, ether","Soluble in dimethyl sulfoxide (DMSO), slightly soluble in ethanol, and insoluble in chloroform.",Insoluble in most organic solvents,"Soluble in DMSO, DMF","Soluble in ethanol, methanol, chloroform, and acetone","Soluble in chloroform, slightly soluble in ethanol","Soluble in ethanol, chloroform, and methanol.",N/A (Biologic),Soluble in organic solvents,Insoluble,generally insoluble in organic solvents.,Not available,NA,3 times per week or once a day for 2 treatment cycles or 5 times perweek for six weeks,for adults apply 2 times a day for 3 to 6 weeks to affected area,Once a day,once daily on empty stomach one hour before or 2 hours after a meal,over 30 minutes every 3 weeks,every 8 hours for up to 5 days,twice daily approximately 12 hours apart,orally once daily,once daily,"Adults—150 milligrams (mg) 2 times a day, taken 12 hours apart.",once a day for 10 days,once daily,every 12 hours with or without meal,every 3 weeks for upto 4 doses,NA, Orally: every 6 hours. Intravenously/intramuscularly: 1-2 g every, 3 times a day. ," every 6 or 12 hours for 7 to 14 days, ","once or twice a day for 4-14 days,"," once or twice a day for 4-14 days,", 500 mg every 6 hours or 1 to 2 g every 8 hours,3 or 4 doses for 7 to 10 days.,once a day ,Adults and children over 12 years in general receive 1 g Cefotaxime every 12 hours.,r 5 days to 6 weeks and for treatment-related ,Adults—400 milligrams (mg) once every 24 hours.,"every 6 hours, but children 9 months of age and older may receive it every 8 hours.", 1-2 g IV q8-12hr for 7-10 days , every 8 or 12 hours.,Thrice,Thrice,Once,Thrice,Not daily,> thrice,Twice,Twice,More than thrice,More than thrice,Once,Twice,More than thrice,Once,Thrice,"Amoxicillin blocks key proteins needed for bacterial cell wall formation, causing the bacteria to lose the ability to build and repair their cell walls. This leads to bacterial death.","Cephalexin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis, causing breakdown and cell death, and is more resistant to beta-lactamase than penicillins.",The bactercidal activity of cefeditoren results from the inhibition of cell wall synthesis via affinity for penicillin binding proteins,"Azithromycin inhibits bacterial protein synthesis by binding to the 23S rRNA of the 50S ribosomal subunit, disrupting transpeptidation/translocation and subunit assembly, thereby controlling a range of bacterial infections.","Tetracycline enters bacteria through porin channels and binds to the 30S ribosomal subunit. This binding prevents tRNA from attaching to the mRNA-ribosome complex, disrupting protein synthesis in bacteria.","Dalbavancin disrupts bacterial cell-wall formation, weakening the structure by preventing key components from being incorporated. This interference inhibits bacterial growth and, along with alterations in membrane permeability and RNA synthesis, contributes to its antibacterial action.","Levofloxacin is a fluoroquinolone antibiotic that specifically targets type II topoisomerases, namely bacterial DNA gyrase and topoisomerase IV. During replication, DNA gyrase adds negative supercoils, which are essential for chromosome condensation and transcription start. It consists of four subunits, the antibiotic targeting the A subunits. In the last stages of DNA replication, topoisomerase IV is essential for relaxing positive supercoils and enabling the separation of freshly replicated chromosomes for cell division.","Tobramycin is an antibiotic effective against certain Gram-negative and some Gram-positive bacteria. It contains a DOS ring and works similarly to other aminoglycosides, although its exact mechanism of action isn't fully understood","Ertapenem operates in a bactericidal manner by binding to bacterial penicillin-binding proteins (PBPs), particularly PBPs 2 and 3 in Escherichia coli. This binding inhibits the lengthening and strengthening of the peptidoglycan component of the bacterial cell wall, ultimately preventing cell wall synthesis and exerting its antibacterial effect.","Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain, which ultimately halts bacterial growth.","Cefepime, a potent cephalosporin, acts like other beta-lactam antibiotics. It disrupts bacterial cell walls by inhibiting penicillin-binding proteins (PBPs), crucial for peptidoglycan synthesis. This disruption leads to the lysis and demise of susceptible bacteria. Cefepime's broad spectrum covers both Gram-positive and Gram-negative microbes, with specific affinity for various PBPs in bacteria like Escherichia coli and Pseudomonas aeruginosa.","Lincomycin contains propyl hygric acid linked to ?-MTL, mimicking L-Pro-Met-tRNA. It binds to bacterial ribosomal subunits, primarily at the A-site, then shifts to the P-site. Crystal structures reveal interactions with 23S rRNA. Resistance mechanisms, like methylation of key residues, can reduce efficacy, akin to other related antibiotics.","The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding- protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus.","The bactericidal action of gemifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.","Amikacin, like other aminoglycosides, primarily acts by binding to bacterial 30S ribosomal subunits. This interferes with mRNA binding and tRNA acceptor sites, disrupting normal protein synthesis. This leads to the production of non-functional or toxic peptides, ultimately inhibiting bacterial growth. Aminoglycosides, including amikacin, are generally bactericidal against both gram-positive and gram-negative bacteria.","inhibits gastric parietal cells, suppressing gastric acid secretion.","inhibits gastric parietal cells, suppressing gastric acid secretion","inhibits gastric parietal cells, suppressing gastric acid secretion.","inhibits gastric parietal cells, suppressing gastric acid secretion.","inhibits gastric parietal cells, suppressing gastric acid secretion.","inhibits gastric parietal cells, suppressing gastric acid secretion","It competitively inhibits histamine at the H2 receptors of the gastric parietal cells,","It competitively inhibits histamine at the H2 receptors of the gastric parietal cells,","It competitively inhibits histamine at the H2 receptors of the gastric parietal cells,",It competitively inhibits histamine at the H2 receptors of the gastric parietal cells,"It selectively blocks the action of acetylcholine at M1 receptors in the stomach, reducing gastric acid secretion.",Propantheline is a synthetic antimuscarinic agent that competitively inhibits the action of acetylcholine at muscarinic receptors in the gastrointestinal tract.,"It competitively inhibits the action of acetylcholine at muscarinic receptors in the gastrointestinal tract, leading to smooth muscle relaxation and a decrease in gastrointestinal motility.","It acts by binding to prostaglandin receptors on the gastric parietal cells, inhibiting gastric acid secretion.","It acts by binding to prostaglandin receptors on the gastric parietal cells, inhibiting gastric acid secretion, and promoting mucosal protection and healing.",Twice,once a day 15-20 min(IV),Twice,depends on dose(twice or once),five times,Thrice,once,once a week,once,Twice,once,Twice,once,Thrice,once or twice,Typically 1-3 times daily,Typically divided into two doses,Typically divided into 2 or 3 doses per day,Typically once or twice daily,Usually twice a day,Usually twice daily,Typically administered twice daily,Usually once or twice daily,Divided into two or three doses per day,Usually taken twice daily,Usually twice daily,Usually twice daily,Typically 3 times a day,Usually once or twice daily,Usually administered twice or thrice daily,Typically 1-3 times daily,Typically divided into two doses,Typically divided into 2 or 3 doses per day,Typically once or twice daily,Usually twice a day,Usually twice daily,Typically administered twice daily,Usually once or twice daily,Divided into two or three doses per day,Usually taken twice daily,Usually twice daily,Usually twice daily,Typically 3 times a day,Usually once or twice daily,Usually administered twice or thrice daily
Category/ Used for ( analgesic/anticancer etc),Psychostimulant,"Psychostimulant, used for ADHD, narcolepsy",ADHD treatment,"ADHD, Narcolepsy","Narcolepsy, sleep disorders","Narcolepsy, sleep disorders","Decongestant, bronchodilator, stimulant","Illicit drug, local anesthetic","Stimulant, cognitive enhancer","Smoking cessation aid, addictive substance",ADHD treatment,"Weight loss, obesity management","Weight loss, obesity management","Weight loss, obesity management",Antiparkinsonian,"Antiviral, Parkinson's disease",Antiparkinsonian agent,"Antidepressant, Parkinson's disease",Adjunctive therapy for Parkinson's disease,Treatment of Alzheimer's disease and Parkinson's disease dementia,Used for treating Parkinson's disease and extrapyramidal symptoms induced by antipsychotic medications,Antiparkinsonian agent,Antiparkinsonian agent,Adjunctive treatment for Parkinson's disease,"Antiparkinsonian, antiemetic","Used for hyperprolactinemia, acromegaly, Parkinson's disease, etc.",Adjunctive treatment for Parkinson's disease,"Antiparkinsonian, antimuscarinic",Adjunctive treatment in Parkinson's disease,Bioavailability:,44-50%,96-99%,53-94%,100%,90-100%,90-95%,30%,30%,90%,85-100 %,80-90%,65%,93%,1.80%,Not specified,Anticancer (alkylating agent),"Anticancer,",Anticancer,Serotonin reuptake inhibition,Anticancer (alkylating agent),Anticancer (antineoplastic agent),Anticancer,Anticancer,Anticancer,Anticancer,"Anti-inflammatory, immunosuppressive, and anti-allergic",Antifungal,Antifungal,"Amtifungal, antiadgrinogenic",Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,ANTIFUNGAL,Antifungal,Antifungal,Antidiabetic,Antidiabetic,Antidiabetic,Antidiabetic,Antidiabetic,Antidiabetic,Antidiabetic,Antidiabetic,Antidiabetic,Antidiabetic,Antidiabetic,Antidiabetic,Antidiabetic,Antidiabetic,antidepresant,antidepresant,antidepresant,antidepresant,antidepresant,antidepresant,antidepresant,antidepresant,antidepresant,antidepresant,antidepresant,antidepresant,antidepresant,Inhibitor,Alectinib: Kinase inhibitor M4: Pgp substrate,Pgp substrate,Pgp substrate,Pgp substrate (in vitro),Pgp inhibitor,Pgp substrate,Pgp substrate,Pgp substrate,Pgp inhibitor,Pgp inhibitor,Pgp inhibitor,Pgp inhibitor,Pgp substrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Anti cancer,NA,"Azathioprine is used as an immunosuppressive agent and is commonly prescribed to prevent organ rejection in transplant recipients. It is also used in the treatment of autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease","citretin is used to treat severe skin disorders, such as psoriasis",antipsychotic,antipsoriatic,antineoplastic agent,immunosuppressive agent used autoimmune disease and dermatology condition,NA,": Anti-inflammatory, used in various conditions such as dermatitis, psoriasis, and allergic reactions.",Used topically for the treatment of psoriasis,"Used for the treatment of acne vulgaris, psoriasis, and photoaging","Used for the treatment of inflammatory skin conditions, such as atopic dermatitis","autoimmune condition, psoriatic arthritis",NA,to treat several psoriasis and other dermatological condition,anti emetics,anti emetic,"anti emetic ,anti spasmodic",anti histamine and antiemetics,anti emetics,anti emetics,anti emetics,anti emetic,"antihistamine ,anti emetics",antiemetics,psycotic and antiemetic,antiemetics,anti emetics,anti emetics,Antidiabetic,Antidiabetic,"Binds to albumin via fatty 
acid chain",Antidiabetic,Antidiabetic,Antidiabetic,NA,NA,NA,NA,Antidiabetic,Antidiabetic,Antidiabetic,Antidiabetic,Antidiabetic,Mode of action,nhibits DNA and RNA biosynthesis and produces rapid degradation of ribosomes and dissimilation of ribosomal RNA,interferes with haemozoin formation through complexation with haem.,accumulating in the parasite digestive vacuole and interfering with the detoxification of heme into hemozoin,inhibiting protein synthesis and causing subsequent schizonticidal effects.,"nhibits nucleic acid synthesis, protein synthesis, and glycolysis in Plasmodium falciparum and can bind with hemazoin in parasitized erythrocytes.",targeting the erythrocytic stage of the Plasmodium species,nhibiting parasitic dihydrofolate reductase enzyme,inhibits the dihydrofolate reductase of plasmodia and thereby blocks the biosynthesis of purines and pyrimidines,generating reactive oxygen species or by interfering with the electron transport in the parasite,inhibits the activity of dihydropteroate synthase,a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase,inhibits bacterial protein synthesis by allosterically binding to the 30S prokaryotic ribosomal subunit.,inhibiting bacterial protein synthesis at the level of the 50S ribosome,"inhibiting heme polymerization, generating ROS, destabilizing parasite membrane, alkylating proteins and inhibiting PfATP",NA,NA,inhibits the formation of ?-hematin by forming a complex with hemin and inhibits nucleic acid and protein synthesis,inhibiting the mitochondrial electron transport chain at the bc1 complex.,histamine H2-receptor antagonists,histamine H2-receptor antagonists,histamine H2-receptor antagonists.,histamine H2-receptor antagonists,calcium channel blockers with antiarrhythmic properties.,Sympathomimetics,antiarrhythmic agents.,steroidogenesis inhibitors.,antipsychotic medications.,antimalarial medications.,fluoroquinolone antibiotics.,antihistamines.,antipsychotics.,antipsychotic,histamine H2 receptor antagonists.,Antibiotics,Antibiotics,Antibiotic,Antibiotic,Antibiotic,Antibiotic,Antibiotic,Antibiotic,Antibiotic,Antibiotics,Antibiotics,Antibiotics,Antibiotics,Antibiotics,Antibiotics,"Bronchodialators, Anti-asthmatic","Bronchodialators, Anti-asthmatic","Bronchodialators, Anti-asthmatic","Bronchodialators, Anti-asthmatic","Anticholinergic ,anti asthmatic","Anticholinergic ,anti asthmatic","Leukotriene receptor antagonist, Anti asthma","Leukotriene receptor antagonist, Anti asthma","Mast cell stabilizers,anti asthmatic","Mast cell stabilizers,anti asthmatic","Corticosteroids,antiasthmatic","Corticosteroids,antiasthmatic","Corticosteroids,antiasthmatic","Corticosteroids,antiasthmatic",Anti IgE Antibody,Anticonvulsant,"Anticonvulsant, mood stabilizer","Anticonvulsant, mood stabilizer, and for migraines",Antiepileptic,Antiepileptic,"Antiepileptic, migraine prophylaxis, weight loss in some cases",Antiepileptic,Antiepileptic,Antiepileptic,Antiepileptic,Anticonvulsant,Used for the treatment of seizures in epilepsy,Antiepileptic/Neuropathic pain,Antiepileptic,"Anticonvulsant, Analgesic",anti seizure management,Anticonvulsant,"Anticonvulsant, Analgesic",Antiepileptic,Antiepileptic/Neuropathic pain,Used for the treatment of seizures in epilepsy,Anticonvulsant,Antiepileptic,anti epileptic,"Anticonvulsant, mood stabilizer, and for migraines",Antiepileptic,"Anticonvulsant, mood stabilizer",Antiepileptic,anti convulsion,Antiepileptic,Antipsychotic,Antipsychotic,Antipsychotic,Antipsychotic,Antipsychotic,Antipsychotic,Antipsychotic,Antipsychotic,Antipsychotic,Antipsychotic,Antipsychotic,NA,Antipsychotic,Antipsychotic,Antipsychotic,"antiarrhythmic, treating irregular heartbeats.",Antiarrhythmic medication,Class I antiarrhythmics,"Analgesic (local anesthesia), antiarrhythmic",ventricular arrhythmias.,class of antiarrhythmic drugs.,anti-inflammatory agent.,used in the treatment of heart failure and atrial fibrillation.,antiarrhythmic agent,antiarrhythmic agent,"used to treat hypertension, angina, cardiac arrhythmias, migraines, and anxiety disorders.",supraventricular tachycardias and hypertension,antiarrhythmic,anti arrthymathic,"hypertension, angina pectoris, and cardiac arrhythmias.",anti-cancer,Anticancer,Anticancer (nucleoside analog chemotherapy),"anticancer,antiangiogenic","anti-cancer,immunotherapy","anti-cancer,antiangiogenic",anti-cancer,anti-cancer,anti-cancer,anti-cancer,anti-cancer,anti-cancer,anti-cancer,anti-cancer,anti-cancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,Anticancer,anticancer,Anti-ulcer,Anti-ulcer,Anti-ulcer,Anti-ulcer,Anti-ulcer,Anti-ulcer,Anti-ulcer,Anti-ulcer,Anti-ulcer,Anti-ulcer,Anti-ulcer,Anti-ulcer,Anti-ulcer,Anti-ulcer,Anti-ulcer,Anticancer,Anticancer,Anticancer,Anticancer,Anticancer,Anticancer,Anticancer,Anticancer,Anticancer,Anticancer,Anticancer,Anticancer,Benzodizepines,Benzodizepines,antihistamines.,beta blockers.,novel anxiolytic agent,serotonin modulators., benzodiazepines.,antihypertensives,benzodiazepines.,barbiturate derivative , barbiturates.,benzodiazepines.,barbiturate class, barbiturate , selective serotonin-reuptake inhibitors (SSRIs).,selective serotonin agonist on the 5-HT1B and 5-HT1D receptor,act at serotonin 5-HT1B receptors on intracranial blood vessel &5-HT1D receptors,selectively binding to the serotonin receptors 5-HT1B ana 5-HT1D,its agonist action upon theb5-HT1D receptor ends the aseptic inflammation,inducing vasoconstriction in the basilar artery and blood vessel,"works by narrowing blood vessels in brain, stopping pain signals from brain",action of fravotriptan is unknown,"directly stimulates vascular smooth muscle, result in vasoconstriction","inhibiting heme polymerization, generating ROS, alkylating proteins",blocks the action of epinephrine and noradrenaline at both receptors,competing with free histamine and serotonin for binding at receptor,inhibition of neuropeptide and neurotransmitter release and inhibition of PNS,blocks arachidonate binding to competitively inhibit both,involve constricting the pain -producing intracranial extracerebral blood vessel,inhibiting phosphodiesterase enzymes in skeletal muscle .,works by blocking histamine receptors in the body,Reduce symptoms of allergic reactions,alleviate allergy symptoms,atagonizes H1receptors on the surface cells in different organ systems,inverse agonist of H 1 receptor,H1 receptor antagonist,regulates the H 1receptor on the surface of mast cells,"Anti-inflammatory,anti-allergic",blocking the action of histamine,blocking the action of H 1,antagonizes h 1 receptors,antagonist antihistamine,blocking h 1 receptors,blocking H1 receptors,inhibiting histaminergic signaling to the vomating centrein the medulla,"inhibits the smoothen (SMO) receptor, a transmembrane protein involved in hedgehog (Hh) signal transduction, thereby disrupting the Hh pathway
SMO inhibition of Hh signaling impacts tumor biology by disrupting the regulation of cancer stem cell survival; this may inhibit development of drug resistance and prevent relapse","Venetoclax helps restore the process of apoptosis by binding directly to the Bcl-2 protein, displacing proapoptotic proteins like BIM (a novel member of the Bcl-2 family), triggering mitochondrial outer membrane permeabilization, and activating caspases","MoA (Mechanism of Action): Rydapt is a small molecule kinase inhibitor that targets multiple receptor tyrosine kinases including FLT3 (FMS-like tyrosine kinase 3), KIT (stem cell factor receptor), and PDGFR (platelet-derived growth factor receptor).","Nilotinib is a tyrosine kinase inhibitor that specifically targets the BCR-ABL protein, an abnormal tyrosine kinase associated with chronic myeloid leukemia (CML). By inhibiting BCR-ABL, nilotinib blocks the signaling pathways involved in cell proliferation and survival, leading to the induction of apoptosis in leukemic cells.","Imatinib is a tyrosine kinase inhibitor that selectively targets certain protein tyrosine kinases, including BCR-ABL, c-KIT, and PDGF-R. By inhibiting these kinases, imatinib interferes with the abnormal signaling pathways that contribute to the development and progression of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).","The mechanism of prednisone as an anticancer drug primarily involves its immunosuppressive and anti-inflammatory properties. By inhibiting the activity of immune cells and reducing inflammation, prednisone can help manage symptoms and improve treatment outcomes in certain types of cancer. Additionally, prednisone is often used in combination chemotherapy regimens to enhance the efficacy of other anticancer drugs and induce apoptosis (cell death) in cancerous cells, particularly in lymphoproliferative disorders like lymphoma.","Busulfan is an alkylating agent that interferes with DNA replication and transcription, ultimately leading to cell death.","Dasatinib is a multitargeted kinase inhibitor that acts by inhibiting the activity of several tyrosine kinases, including BCR-ABL, SRC family kinases, c-KIT, and others.","Dexamethasone is a synthetic corticosteroid that exerts anti-inflammatory, immunosuppressive, and anti-allergic effects by binding to intracellular glucocorticoid receptors and modulating gene expression.","Azacitidine is a nucleoside analog that works as a DNA methyltransferase inhibitor. It incorporates into DNA and RNA, leading to hypomethylation of DNA and inhibition of DNA methyltransferases, ultimately inducing apoptosis in rapidly dividing cells, including cancer cells.","Cytarabine is a pyrimidine analog that inhibits DNA synthesis by competing with deoxycytidine triphosphate (dCTP) for incorporation into DNA. It disrupts DNA replication and repair in rapidly dividing cells, leading to cell death.","Nelarabine is a prodrug of ara-G (adenosine analog), which gets phosphorylated intracellularly to its active triphosphate form. Ara-GTP disrupts DNA synthesis by inhibiting DNA polymerase and ribonucleotide reductase, leading to DNA damage and apoptosis in rapidly dividing cells, including cancer cells.","Rituximab targets the CD20 antigen present on the surface of B-lymphocytes. By binding to CD20, rituximab induces antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis, leading to the depletion of B-cells.","Daunorubicin inhibits DNA and RNA synthesis by intercalating into DNA strands and inhibiting topoisomerase II activity. It also generates free radicals that cause DNA damage and trigger apoptosis in rapidly dividing cells, including cancer cells.","Chlorambucil is an alkylating agent that forms covalent bonds with DNA, leading to cross-linking and DNA strand breakage. This interferes with DNA replication and transcription, ultimately inducing apoptosis in rapidly dividing cells, including cancer cel","Acts as an antioxidant, scavenging free radicals, and is essential for collagen synthesis, wound healing, and immune function","Critical for DNA synthesis and repair, supporting cell division and preventing neural tube defects during pregnancy","Essential for red blood cell formation, neurological function, and DNA synthesis.","Niacin acts to decrease levels of very low density lipoproteins and low density lipoproteins, while increasing levels of high density lipoprotein","Necessary for energy production, cellular growth, and maintaining healthy skin and eyes",Supports energy metabolism by aiding in the conversion of carbohydrates into energy.,"Important for neurotransmitter synthesis, cell membrane structure, and liver function","Promotes calcium and phosphorus absorption, crucial for bone health and immune system function.","Essential for metabolism, particularly in the breakdown of fatty acids and amino acids","A component of coenzyme A, involved in energy metabolism and the synthesis of fatty acids","Acts as an antioxidant, particularly beneficial for eye health and reducing the risk of age-related macular degeneration.","Potent antioxidant with anti-inflammatory properties, supporting skin health and cardiovascular function","Exhibits antioxidant and anti-inflammatory effects, potentially contributing to cardiovascular health and longevity.",Essential for blood clotting and bone metabolism.,"Functions as a potent antioxidant, protecting cells from oxidative damage.",Mode of action,"inhibits ergosterol biosynthesis, disrupting fungal cell membranes, and affects other cellular targets, broadening its pharmacological effects.","disrupts fungal cell membranes, leading to cell death by inhibiting ergosterol synthesis.","Fluconazole disrupts fungal cell membrane formation by inhibiting lanosterol 14-alpha-demethylase, leading to cell death.","Inhibits the synthesis of ergosterol in fungal cell membranes by interfering with the enzyme lanosterol 14-alpha-demethylase, resulting in fungal cell death.","Disrupts fungal cell membrane integrity by inhibiting lanosterol 14?-demethylase, leading to cell death.","Posaconazole disrupts fungal cell membrane formation by inhibiting ergosterol synthesis, ultimately leading to fungal growth inhibition and cell death.","Griseofulvin stops fungal cells from dividing by interfering with their microtubules, leading to their death.","Griseofulvin disrupts fungal cell division, causing the death of dermatophyte fungi responsible for superficial infections.","Rezafungin disrupts fungal cell wall synthesis, leading to fungal cell death.","Caspofungin disrupts fungal cell wall synthesis by inhibiting ?-(1,3)-D-glucan formation, resulting in fungal cell death.","Terbinafine disrupts fungal cell membrane synthesis by inhibiting squalene epoxidase, leading to fungal cell death.","Butenafine inhibits fungal growth by blocking ergosterol synthesis, disrupting cell membrane integrity.","Naftifine disrupts fungal cell membrane integrity by inhibiting squalene epoxidase, hindering ergosterol synthesis.",Flucytosine inhibits fungal DNA and RNA synthesis by conversion to 5-fluorouracil within fungal cells.,Griseofulvin disrupts fungal cell division by inhibiting microtubule formation.,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion ","Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage.","Gliclazide binds to the ? cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the ? cells. This opens voltage-dependent calcium channels in the ? cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating ? cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release.","Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating ? cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic ? cell receptor. ","Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glycodiazine likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin","sulfonylurea drugs used to treat type 2 diabetes, works primarily by stimulating insulin secretion from pancreatic beta cells. It binds to specific receptors on the beta cells known as sulfonylurea receptors, causing them to close ATP-sensitive potassium channels. This closure leads to depolarization of the cell membrane, which triggers calcium influx and subsequent release of insulin. Essentially, Glibornuride enhances insulin secretion, thereby lowering blood glucose levels in individuals with type 2 diabetes.","Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues. Glisoxepide functions as a non-selective K(ATP) channel blocker. It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin","The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin","Glyclopyramide is a sulfonylurea antidiabetic medication, and its mechanism of action involves stimulating insulin secretion from pancreatic beta cells. This occurs by binding to specific receptors on the pancreatic beta cells known as ATP-sensitive potassium channels. By blocking these channels, glyclopyramide leads to depolarization of the cell membrane, which triggers calcium influx and subsequently stimulates insulin release. Overall, glyclopyramide helps to lower blood sugar levels by promoting insulin secretion from the pancreas.","Glyhexamide, also known as glyhexide, is a sulfonylurea antidiabetic medication. Its mechanism of action involves stimulating insulin release from pancreatic beta cells by binding to ATP-sensitive potassium channels (KATP channels) on the cell membrane. This binding leads to depolarization of the cell membrane, opening of voltage-gated calcium channels, influx of calcium ions, and subsequent release of insulin. Ultimately, this process helps to lower blood sugar levels in individuals with type 2 diabetes.","Glibuzole, also known as gliquidone, is an antidiabetic medication belonging to the sulfonylurea class. Its mechanism of action involves stimulating insulin secretion from pancreatic beta cells. Specifically, Glibuzole binds to ATP-sensitive potassium channels on the beta cells, leading to their closure. This closure triggers depolarization of the cell membrane, which ultimately results in calcium influx and subsequent insulin release. In summary, Glibuzole works by promoting insulin secretion from the pancreas, thereby lowering blood sugar levels in individuals with type 2 diabetes.","Glibenclamide (also known as glyburide) involves its action as a sulfonylurea drug used to treat type 2 diabetes. In short, Glibenclamide works by stimulating insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the beta cell membrane. This binding leads to closure of ATP-sensitive potassium channels, depolarization of the cell membrane, opening of voltage-gated calcium channels, and subsequent influx of calcium ions. The increase in intracellular calcium triggers the release of insulin-containing vesicles from the beta cells, leading to increased insulin secretion and thereby helping to lower blood glucose levels.","Omeprazole is a proton pump
inhibitor that reduces stomach acid
production by inhibiting the proton pump in gastric parietal cells.","Rebamipide exerts its therapeutic effects by enhancing the secretion of mucin, prostaglandin E2, and epidermal growth factor (EGF), which promote mucosal protection and repair in the gastrointestinal tract.","proton pump inhibitors, esomeprazole inhibits the proton pump in
gastric parietal cells, reducing stomach
acid production.","inactivating the
(H+/K+)-ATPase
function in the stomach,
reducing gastric
acid secretion","Rebamipide is known for its mucoprotective and anti-inflammatory effects
contributing to the
protection
and repair of the
gastrointestinal mucosa.","Rabeprazole inhibits the enzyme H+/K+-ATPase in the gastric parietal cells, thereby reducing acid production in the stomach.",Inhibits DNA synthesis in susceptible microorganisms by interfering with their DNA,Proton pump inhibitor; suppresses gastric acid secretion by irreversibly blocking the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell,Bacteriostatic; inhibits protein synthesis in susceptible bacterial organisms by preventing the binding of aminoacyl-tRNA to the ribosome,Proton pump inhibitor; suppresses gastric acid secretion by irreversibly blocking the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell,"Sodium bicarbonate acts as a systemic alkalizer by buffering excess hydrogen ions in the body, leading to increased pH levels. It also serves as an antacid by neutralizing stomach acid when taken orally.","Misoprostol is a synthetic prostaglandin E1 analogue that exerts its therapeutic effects by promoting mucosal protection, decreasing gastric acid secretion, increasing bicarbonate and mucus secretion, and enhancing mucosal blood flow in the gastrointestinal tract.","H2 receptor antagonist; competitively inhibits histamine at the histamine H2 receptors of the stomach, resulting in reduced gastric acid secretion","Sodium citrate acts as an alkalinizing agent and urinary pH regulator. It is metabolized to bicarbonate in the body, which increases urinary pH and solubilizes uric acid and cystine, thus preventing the formation of kidney stones.",histamine H2-receptor antagonist,"It acts as an antacid by neutralizing excess stomach acid.
It raises the pH of the stomach contents, which helps alleviate symptoms of indigestion and heartburn.","It is a histamine H2 receptor antagonist. reducing
stomach acid production.","It acts as a buffer in the body, helping to
regulate pH levels.","It involves reacting with hydrochloric acid in the stomach to form aluminum chloride & H2O, thereby reducing acidity.","Neutralizes gastric acid by reacting with hydrochloric acid in
the stomach to form magnesium chloride and water. ","blocks the adhesion of H. pylori to the gastric epithelial cells and blocks the bacteria's enzyme activities, including phospholipase, protease, and urease.",blocks acid secretion in response to all stimuli.,"binds irreversibly and specifically to the proton pump, thereby reducing gastric acid secretion. ","reduces the secretion of gastric acid by reversible binding
to histamine (H2) receptors,",It is a PPI and as such covalently binds with and inactivates the gastric parietal cell proton pump (H+/K+-ATPase),"chelates calcium and is used by blood banks,",It is a PPI that suppresses gastric acid secretion by specific inhibition of H+/K+-ATPase in the gastric parietal cell.,Citrate is a weak base and so reacts with hydrochloric acid in the stomach to raise the pH,"Reduces gastric acid by binding with phosphate in the intestine,& then is excreted as aluminum carbonate in feces",Increasing the pH of gastric juice via a neutralisation reaction.,NA,Estrogen receptor modulators,osteoclast inhibitor,NA,HER2 RECEPTOR,cyclin-dependent kinase(CDK),PARP inhibitor,estrogen receptor antagonist,alkylates DNA,NA,NA,NA,microtubule inhibitor,NA,NA,Inhibition of RNA synthesis,Nucleotide analog NS5B polymerase inhibitor,Nucleoside reverse transcriptase inhibitor,Protease inhibitor,Protease inhibitor,Nucleotide analog RNA polymerase inhibitor,Inhibition of RNA-dependent RNA polymerase,Antiviral,Mode of action,alkyl group of DNA Standard,NA,covalent bonds with DNA,NA,inhibiting the mTOR,Afinitor Disperz (Everolimus) mTOR,alkylation,vascular endothelial growth factor,targeting & inhibiting HIF-2a,NA,"alkylating agent , DNA","chemotherapy drug, DNA",chemotherapy treatment,alkylating DNA,inhibiting dihydrofolate,Mode of action,inhibits fungal cytochrome p-450mediated 14 alpha-lanosterol demthylation,inhibits fungal cytochrome p-450mediated 14 alpha-lanosterol demthylation,"inhibits fungal 1,3 beta D - glucan synthesis",inhibits synthesis of ergosterol,inhibits synthesis of ergosterol,inhibits synthesis of ergosterol,inhibits in squalene epoxidase,binds to sterols in fungal cell membrane,inhibits fungal cytochrome p450 dependent 14a demethylase,antifungal activity by inhibiting synthesis of ergostreol,antifungal activity by inhibiting synthesis of ergostreol,antifungal,"antifungal activity by inhibiting synthesis of b-1,3 -glucan",binds to ergostreol,selective serotonin agonist on the 5-HT1B and 5-HT1D receptor,act at serotonin 5-HT1B receptors on intracranial blood vessel &5-HT1D receptors,selectively binding to the serotonin receptors 5-HT1B ana 5-HT1D,its agonist action upon theb5-HT1D receptor ends the aseptic inflammation,inducing vasoconstriction in the basilar artery and blood vessel,"works by narrowing blood vessels in brain, stopping pain signals from brain",action of fravotriptan is unknown,"directly stimulates vascular smooth muscle, result in vasoconstriction","inhibiting heme polymerization, generating ROS, alkylating proteins",blocks the action of epinephrine and noradrenaline at both receptors,competing with free histamine and serotonin for binding at receptor,inhibition of neuropeptide and neurotransmitter release and inhibition of PNS,blocks arachidonate binding to competitively inhibit both,involve constricting the pain -producing intracranial extracerebral blood vessel,inhibiting phosphodiesterase enzymes in skeletal muscle .,works by blocking histamine receptors in the body,Reduce symptoms of allergic reactions,alleviate allergy symptoms,atagonizes H1receptors on the surface cells in different organ systems,inverse agonist of H 1 receptor,H1 receptor antagonist,regulates the H 1receptor on the surface of mast cells,"Anti-inflammatory,anti-allergic",blocking the action of histamine,blocking the action of H 1,antagonizes h 1 receptors,antagonist antihistamine,blocking h 1 receptors,blocking H1 receptors,inhibiting histaminergic signaling to the vomating centrein the medulla,"inhibits the smoothen (SMO) receptor, a transmembrane protein involved in hedgehog (Hh) signal transduction, thereby disrupting the Hh pathway
SMO inhibition of Hh signaling impacts tumor biology by disrupting the regulation of cancer stem cell survival; this may inhibit development of drug resistance and prevent relapse","Venetoclax helps restore the process of apoptosis by binding directly to the Bcl-2 protein, displacing proapoptotic proteins like BIM (a novel member of the Bcl-2 family), triggering mitochondrial outer membrane permeabilization, and activating caspases","MoA (Mechanism of Action): Rydapt is a small molecule kinase inhibitor that targets multiple receptor tyrosine kinases including FLT3 (FMS-like tyrosine kinase 3), KIT (stem cell factor receptor), and PDGFR (platelet-derived growth factor receptor).","Nilotinib is a tyrosine kinase inhibitor that specifically targets the BCR-ABL protein, an abnormal tyrosine kinase associated with chronic myeloid leukemia (CML). By inhibiting BCR-ABL, nilotinib blocks the signaling pathways involved in cell proliferation and survival, leading to the induction of apoptosis in leukemic cells.","Imatinib is a tyrosine kinase inhibitor that selectively targets certain protein tyrosine kinases, including BCR-ABL, c-KIT, and PDGF-R. By inhibiting these kinases, imatinib interferes with the abnormal signaling pathways that contribute to the development and progression of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).","The mechanism of prednisone as an anticancer drug primarily involves its immunosuppressive and anti-inflammatory properties. By inhibiting the activity of immune cells and reducing inflammation, prednisone can help manage symptoms and improve treatment outcomes in certain types of cancer. Additionally, prednisone is often used in combination chemotherapy regimens to enhance the efficacy of other anticancer drugs and induce apoptosis (cell death) in cancerous cells, particularly in lymphoproliferative disorders like lymphoma.","Busulfan is an alkylating agent that interferes with DNA replication and transcription, ultimately leading to cell death.","Dasatinib is a multitargeted kinase inhibitor that acts by inhibiting the activity of several tyrosine kinases, including BCR-ABL, SRC family kinases, c-KIT, and others.","Dexamethasone is a synthetic corticosteroid that exerts anti-inflammatory, immunosuppressive, and anti-allergic effects by binding to intracellular glucocorticoid receptors and modulating gene expression.","Azacitidine is a nucleoside analog that works as a DNA methyltransferase inhibitor. It incorporates into DNA and RNA, leading to hypomethylation of DNA and inhibition of DNA methyltransferases, ultimately inducing apoptosis in rapidly dividing cells, including cancer cells.","Cytarabine is a pyrimidine analog that inhibits DNA synthesis by competing with deoxycytidine triphosphate (dCTP) for incorporation into DNA. It disrupts DNA replication and repair in rapidly dividing cells, leading to cell death.","Nelarabine is a prodrug of ara-G (adenosine analog), which gets phosphorylated intracellularly to its active triphosphate form. Ara-GTP disrupts DNA synthesis by inhibiting DNA polymerase and ribonucleotide reductase, leading to DNA damage and apoptosis in rapidly dividing cells, including cancer cells.","Rituximab targets the CD20 antigen present on the surface of B-lymphocytes. By binding to CD20, rituximab induces antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis, leading to the depletion of B-cells.","Daunorubicin inhibits DNA and RNA synthesis by intercalating into DNA strands and inhibiting topoisomerase II activity. It also generates free radicals that cause DNA damage and trigger apoptosis in rapidly dividing cells, including cancer cells.","Chlorambucil is an alkylating agent that forms covalent bonds with DNA, leading to cross-linking and DNA strand breakage. This interferes with DNA replication and transcription, ultimately inducing apoptosis in rapidly dividing cells, including cancer cel",NA,Mode of action,"Acts as an antioxidant, scavenging free radicals, and is essential for collagen synthesis, wound healing, and immune function","Critical for DNA synthesis and repair, supporting cell division and preventing neural tube defects during pregnancy","Essential for red blood cell formation, neurological function, and DNA synthesis.","Niacin acts to decrease levels of very low density lipoproteins and low density lipoproteins, while increasing levels of high density lipoprotein","Necessary for energy production, cellular growth, and maintaining healthy skin and eyes",Supports energy metabolism by aiding in the conversion of carbohydrates into energy.,"Important for neurotransmitter synthesis, cell membrane structure, and liver function","Promotes calcium and phosphorus absorption, crucial for bone health and immune system function.","Essential for metabolism, particularly in the breakdown of fatty acids and amino acids","A component of coenzyme A, involved in energy metabolism and the synthesis of fatty acids","Acts as an antioxidant, particularly beneficial for eye health and reducing the risk of age-related macular degeneration.","Potent antioxidant with anti-inflammatory properties, supporting skin health and cardiovascular function","Exhibits antioxidant and anti-inflammatory effects, potentially contributing to cardiovascular health and longevity.",Essential for blood clotting and bone metabolism.,"Functions as a potent antioxidant, protecting cells from oxidative damage.",NA,NA,NA,NA,NA,"inhibits ergosterol biosynthesis, disrupting fungal cell membranes, and affects other cellular targets, broadening its pharmacological effects.","disrupts fungal cell membranes, leading to cell death by inhibiting ergosterol synthesis.","Fluconazole disrupts fungal cell membrane formation by inhibiting lanosterol 14-alpha-demethylase, leading to cell death.","Inhibits the synthesis of ergosterol in fungal cell membranes by interfering with the enzyme lanosterol 14-alpha-demethylase, resulting in fungal cell death.","Disrupts fungal cell membrane integrity by inhibiting lanosterol 14?-demethylase, leading to cell death.","Posaconazole disrupts fungal cell membrane formation by inhibiting ergosterol synthesis, ultimately leading to fungal growth inhibition and cell death.","Griseofulvin stops fungal cells from dividing by interfering with their microtubules, leading to their death.","Griseofulvin disrupts fungal cell division, causing the death of dermatophyte fungi responsible for superficial infections.","Rezafungin disrupts fungal cell wall synthesis, leading to fungal cell death.","Caspofungin disrupts fungal cell wall synthesis by inhibiting ?-(1,3)-D-glucan formation, resulting in fungal cell death.","Terbinafine disrupts fungal cell membrane synthesis by inhibiting squalene epoxidase, leading to fungal cell death.","Butenafine inhibits fungal growth by blocking ergosterol synthesis, disrupting cell membrane integrity.","Naftifine disrupts fungal cell membrane integrity by inhibiting squalene epoxidase, hindering ergosterol synthesis.",Flucytosine inhibits fungal DNA and RNA synthesis by conversion to 5-fluorouracil within fungal cells.,Griseofulvin disrupts fungal cell division by inhibiting microtubule formation.,NA,Category/ Used for( analgesic/anticancer),Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Mode of action,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion ","Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage.","Gliclazide binds to the ? cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the ? cells. This opens voltage-dependent calcium channels in the ? cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating ? cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release.","Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating ? cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic ? cell receptor. ","Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glycodiazine likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin","sulfonylurea drugs used to treat type 2 diabetes, works primarily by stimulating insulin secretion from pancreatic beta cells. It binds to specific receptors on the beta cells known as sulfonylurea receptors, causing them to close ATP-sensitive potassium channels. This closure leads to depolarization of the cell membrane, which triggers calcium influx and subsequent release of insulin. Essentially, Glibornuride enhances insulin secretion, thereby lowering blood glucose levels in individuals with type 2 diabetes.","Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues. Glisoxepide functions as a non-selective K(ATP) channel blocker. It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin","The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin","Glyclopyramide is a sulfonylurea antidiabetic medication, and its mechanism of action involves stimulating insulin secretion from pancreatic beta cells. This occurs by binding to specific receptors on the pancreatic beta cells known as ATP-sensitive potassium channels. By blocking these channels, glyclopyramide leads to depolarization of the cell membrane, which triggers calcium influx and subsequently stimulates insulin release. Overall, glyclopyramide helps to lower blood sugar levels by promoting insulin secretion from the pancreas.","Glyhexamide, also known as glyhexide, is a sulfonylurea antidiabetic medication. Its mechanism of action involves stimulating insulin release from pancreatic beta cells by binding to ATP-sensitive potassium channels (KATP channels) on the cell membrane. This binding leads to depolarization of the cell membrane, opening of voltage-gated calcium channels, influx of calcium ions, and subsequent release of insulin. Ultimately, this process helps to lower blood sugar levels in individuals with type 2 diabetes.","Glibuzole, also known as gliquidone, is an antidiabetic medication belonging to the sulfonylurea class. Its mechanism of action involves stimulating insulin secretion from pancreatic beta cells. Specifically, Glibuzole binds to ATP-sensitive potassium channels on the beta cells, leading to their closure. This closure triggers depolarization of the cell membrane, which ultimately results in calcium influx and subsequent insulin release. In summary, Glibuzole works by promoting insulin secretion from the pancreas, thereby lowering blood sugar levels in individuals with type 2 diabetes.","Glibenclamide (also known as glyburide) involves its action as a sulfonylurea drug used to treat type 2 diabetes. In short, Glibenclamide works by stimulating insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the beta cell membrane. This binding leads to closure of ATP-sensitive potassium channels, depolarization of the cell membrane, opening of voltage-gated calcium channels, and subsequent influx of calcium ions. The increase in intracellular calcium triggers the release of insulin-containing vesicles from the beta cells, leading to increased insulin secretion and thereby helping to lower blood glucose levels.",Mode of action,"Omeprazole is a proton pump
inhibitor that reduces stomach acid
production by inhibiting the proton pump in gastric parietal cells.","Rebamipide exerts its therapeutic effects by enhancing the secretion of mucin, prostaglandin E2, and epidermal growth factor (EGF), which promote mucosal protection and repair in the gastrointestinal tract.","proton pump inhibitors, esomeprazole inhibits the proton pump in
gastric parietal cells, reducing stomach
acid production.","inactivating the
(H+/K+)-ATPase
function in the stomach,
reducing gastric
acid secretion","Rebamipide is known for its mucoprotective and anti-inflammatory effects
contributing to the
protection
and repair of the
gastrointestinal mucosa.","Rabeprazole inhibits the enzyme H+/K+-ATPase in the gastric parietal cells, thereby reducing acid production in the stomach.",Inhibits DNA synthesis in susceptible microorganisms by interfering with their DNA,Proton pump inhibitor; suppresses gastric acid secretion by irreversibly blocking the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell,Bacteriostatic; inhibits protein synthesis in susceptible bacterial organisms by preventing the binding of aminoacyl-tRNA to the ribosome,Proton pump inhibitor; suppresses gastric acid secretion by irreversibly blocking the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell,"Sodium bicarbonate acts as a systemic alkalizer by buffering excess hydrogen ions in the body, leading to increased pH levels. It also serves as an antacid by neutralizing stomach acid when taken orally.","Misoprostol is a synthetic prostaglandin E1 analogue that exerts its therapeutic effects by promoting mucosal protection, decreasing gastric acid secretion, increasing bicarbonate and mucus secretion, and enhancing mucosal blood flow in the gastrointestinal tract.","H2 receptor antagonist; competitively inhibits histamine at the histamine H2 receptors of the stomach, resulting in reduced gastric acid secretion","Sodium citrate acts as an alkalinizing agent and urinary pH regulator. It is metabolized to bicarbonate in the body, which increases urinary pH and solubilizes uric acid and cystine, thus preventing the formation of kidney stones.",histamine H2-receptor antagonist,Mode of action,"It acts as an antacid by neutralizing excess stomach acid.
It raises the pH of the stomach contents, which helps alleviate symptoms of indigestion and heartburn.","It is a histamine H2 receptor antagonist. reducing
stomach acid production.","It acts as a buffer in the body, helping to
regulate pH levels.","It involves reacting with hydrochloric acid in the stomach to form aluminum chloride & H2O, thereby reducing acidity.","Neutralizes gastric acid by reacting with hydrochloric acid in
the stomach to form magnesium chloride and water. ","blocks the adhesion of H. pylori to the gastric epithelial cells and blocks the bacteria's enzyme activities, including phospholipase, protease, and urease.",blocks acid secretion in response to all stimuli.,"binds irreversibly and specifically to the proton pump, thereby reducing gastric acid secretion. ","reduces the secretion of gastric acid by reversible binding
to histamine (H2) receptors,",It is a PPI and as such covalently binds with and inactivates the gastric parietal cell proton pump (H+/K+-ATPase),"chelates calcium and is used by blood banks,",It is a PPI that suppresses gastric acid secretion by specific inhibition of H+/K+-ATPase in the gastric parietal cell.,Citrate is a weak base and so reacts with hydrochloric acid in the stomach to raise the pH,"Reduces gastric acid by binding with phosphate in the intestine,& then is excreted as aluminum carbonate in feces",Increasing the pH of gastric juice via a neutralisation reaction.,Mode of action,NA,Estrogen receptor modulators,osteoclast inhibitor,NA,HER2 RECEPTOR,cyclin-dependent kinase(CDK),PARP inhibitor,estrogen receptor antagonist,alkylates DNA,NA,NA,NA,microtubule inhibitor,NA,NA,Inhibition of RNA synthesis,Nucleotide analog NS5B polymerase inhibitor,Nucleoside reverse transcriptase inhibitor,Protease inhibitor,Protease inhibitor,Nucleotide analog RNA polymerase inhibitor,Inhibition of RNA-dependent RNA polymerase,Antiviral,Mode of action,alkyl group of DNA Standard,NA,covalent bonds with DNA,NA,inhibiting the mTOR,Afinitor Disperz (Everolimus) mTOR,alkylation,vascular endothelial growth factor,targeting & inhibiting HIF-2a,NA,"alkylating agent , DNA","chemotherapy drug, DNA",chemotherapy treatment,alkylating DNA,inhibiting dihydrofolate,inhibits fungal cytochrome p-450mediated 14 alpha-lanosterol demthylation,inhibits fungal cytochrome p-450mediated 14 alpha-lanosterol demthylation,"inhibits fungal 1,3 beta D - glucan synthesis",inhibits synthesis of ergosterol,inhibits synthesis of ergosterol,inhibits synthesis of ergosterol,inhibits in squalene epoxidase,binds to sterols in fungal cell membrane,inhibits fungal cytochrome p450 dependent 14a demethylase,antifungal activity by inhibiting synthesis of ergostreol,antifungal activity by inhibiting synthesis of ergostreol,antifungal,"antifungal activity by inhibiting synthesis of b-1,3 -glucan",binds to ergostreol,enhance the effect of GABA in the CNS,SV2A ligand,enhance the effect of GABA in the CNS,enhance the effect of GABA in the CNS,Blocks T-type calcium channel,enchanches slow inactivation of volatage gated sodium channels,hinder voltage sensetive sodium channels,enhance the effect of GABA in the CNS,enhance the effect of GABA activity,enhance the effect of GABA in the CNS,sodium channel Blocker,inhibits carbonic anhydrase enzyme,selectivw GABA reuptake inhibitor,sodium channel blocker,enhances GABA levels,NA,sodium channel blocker,enhances GABA levels,Antagonist of dopamine and seotonin receptor,"Blocks voltage-gated sodium channels, inhiits glutamate release",Partial agonist of dopamine &seotonin receptors,Antagonist of serotonin & dopamine receptor,partial agonist at dopamine D2 and serotonin 5-HT1A receptor,Antagoinst of dopamine and serotonin receptor,Antagonist of dopamine and serotonin receptor,Antagomist of dopamine and serotonin receptor,Antagonist of dopamine and serontnin receptor,"Direct thrombin inhibitor; it inhibits free and clot-bound thrombin, as well as thrombin-induced platelet aggregation.",Anticoagulation,Dopamine antagonist,Dopamine D2 receptor antagonist,Inhibits bone resorption.,Estrogen agonist/antagonist.,Inhibits bone resorption.,Inhibits bone resorption,Inhibits bone resorption.,Selective estrogen receptor modulator (SERM),Inhibits bone resorption.,Inhibits bone resorption.,Inhibits bone resorption.,"Stimulate bone formation, inhibits bone resorption.",Stimulates bone formation,Stimulates bone formation,"inhibits bone resorption, promotes bone formation.",inhibits osteoclast activity,targets and inhibits the protein sclerostin,371.4 daltons,312.4 daltons,380.4 daltons,454.4 daltons,270.21 daltons,398.4 daltons,277.27 daltons,1202.6 daltons,319.9 Daltons,~335.87 Daltons,Approximately 150000 Daltons,360.44 Da,~17300 daltons,Approximately 148000 Daltons,Approximately 148000 daltons,NA,Involves stimulation of the immune system. It acts as immune response modifier by binding to toll like receptor,fluorouracil is thought to be the binding of deoxyribonucleotide of drug,Blocks Hh signaling by binding to smoothened homologue and inhibiting activation of downstream Hh target genes,"Sonidegib effectively inhibits the regulator called smoothened (Smo), preventing the hedgehog pathway from functioning.","the binding of PD-1 prevents this inhibitory pathway, causing a physiological shift towards immune reactivity and enhancing anti-tumor response",binds to the IL-2 receptor which leads to the heterodimerization of cytoplasmic domains of the IL-2R beta and gamma chains,"Binimetinib, noncompetitive with ATP,binds reversibly to and inhibits the activity of mitogen-activated extracellular signal-regulated kinase 1 and 2","Inhibit in vitro growth of tumor cell lines expressing BRAF V600 E,D, and K mutations.",Cobimetinib is a reversible inhibitor of mitogen-activated protein kinase,Dabrafenib is a potent inhibitor of the RAF proteins BRAF and CRAF through ATP competitive binding of the active conformation of BRAF kinase ,mode of action not known but appears to exert cytotoxic effects via action as an alkylatin agent,alitretinoin binds to and activates all known intracellular retinoid receptor subtypes,vemurafenib is an orally available inhibitor pf mutated BRAF-serine-threonine kinase,cytotoxic T-lymphocyte antigen-4 (CTLA4) is an inhibitory molecule thst competes with the stimulatory CD28 for binding to B7 on antigen presenting cells,NA,kills susceptible bacteria by specifically inhibiting the transpeptidase that catalyzes,"competitively inhibit penicillin binding proteins, leading to upregulation of autolytic enzymes and inhibition of cell wall synthesis.","utilizes its beta-lactam ring to inhibit the synthesis of peptidoglycan,", inhibition of bacterial cell wall synthesis.,inhibits cross-linking of peptidoglycan during cell wall synthesis by inactivating penicillin binding proteins, binding to penicillin-binding proteins (PBPs) in the bacterial cell wall and inhibiting peptidoglycan cross-linking associated with cell wall synthesis, inhibiting the second stage of cell wall synthesis of susceptible bacteria.,Omadacycline inhibits protein synthesis in the presence of Tet(O).,inhibition of bacterial cell wall synthesis., inhibiting the synthesis of microbial proteins, inhibiting the synthesis of microbial proteins,inhibition of cell wall synthesis , inhibits bacterial cell wall synthesis by covalently binding enzymes responsible for the final step in transpeptidation during peptidoglycan wall synthesis,"Like other ?-lactams, ceftaroline's mechanism of action is mediated by binding to the penicillin-binding protein (PBP)","Vasodilation due to release of nitric oxide, reducing cardiac workload.","Vasodilation due to release of nitric oxide, reducing cardiac workload.","Vasodilation due to release of nitric oxide, reducing cardiac workload.","Vasodilation due to release of nitric oxide, reducing cardiac workload.","Vasodilation due to release of nitric oxide, reducing cardiac workload.",Propranolol is a nonselective ?-adrenergic receptor antagonist,Metoprolol is a beta-1-adrenergic receptor inhibitor specific to cardiac cells with negligible effect on beta-2 receptors,"Blocks response to beta-adrenergic stimulation; cardioselective for beta1 receptors at low doses, with little or no effect on beta2 receptors",Verapamil inhibits L-type calcium channels by binding to a specific area of their alpha-1 subunit,Inhibits extracellular calcium ion influx across membranes of myocardial cells and vascular smooth muscle cells,Inhibits transmembrane influx of extracellular calcium ions across membranes of myocardial cells and vascular smooth muscle cells without changing serum calcium concentrations,"involves both vasodilation through nitric oxide release and opening of ATP-sensitive potassium channels, reducing cardiac workload and improving blood flow.",Calcium-channel blocker; inhibits transmembrane influx of extracellular calcium ions across myocardial and vascular smooth muscle cell membranes without changing serum calcium concentrations,Calcium-channel blocker; inhibits transmembrane influx of extracellular calcium ions across myocardial and vascular smooth muscle cell membranes without changing serum calcium concentrations,Phosphodiesterase inhibition increasing cAMP in platelet,Not Pgp substrate/inhibitor,Not Pgp substrate/inhibitor,Not Pgp substrate/inhibitor,Potential Pgp substrate,Not a Pgp substrate,Not a Pgp substrate,substrate,Substrate,Substrate,Substrate,Substrate,Substrate,Substrate,Substrate,Substrate,"gastroesophageal reflux disease (GERD), peptic ulcer disease.","gastroesophageal reflux disease (GERD), peptic ulcer disease.","gastroesophageal reflux disease (GERD), peptic ulcer disease.","gastroesophageal reflux disease (GERD), peptic ulcer disease.","gastroesophageal reflux disease (GERD), peptic ulcer disease.","gastroesophageal reflux disease (GERD), peptic ulcer disease","treatment of peptic ulcer disease, gastroesophageal reflux disease (GERD)","treatment of peptic ulcer disease, gastroesophageal reflux disease (GERD)","treatment of peptic ulcer disease, gastroesophageal reflux disease (GERD)","treatment of peptic ulcer disease, gastroesophageal reflux disease (GERD)","treatment of peptic ulcer disease, gastroesophageal reflux disease (GERD)","Propantheline is primarily used for the treatment of peptic ulcer disease, irritable bowel syndrome, and gastrointestinal motility disorders.","the treatment of gastrointestinal disorders such as irritable bowel syndrome, functional dyspepsia, and peptic ulcer disease.","Misoprostol is used for the prevention and treatment of NSAID-induced gastric ulcers, induction of labor, medical abortion, and postpartum hemorrhage.","Rioprostil is primarily used for the prevention and treatment of NSAID-induced gastric ulcers, as well as for the management of other gastrointestinal conditions.","MOA of Zanamivir is via inhibition of
influenza virus neuraminidase with the possibility of alteration of virus partcle
aggregation and release
","Peramivir is a cyclopentane analogue that
 competitively binds to the active site of the influenza virus neuraminidase.","Oseltamivir is an orally administered
antiviral medication that selectively 
inhibits the influenza neuraminidase 
enzymes that are essential for viral replication.","Abacavir is phosphorylated to active
metabolites that compete for 
incorporation into viral DNA.
They inhibit the HIV reverse
transcriptase enzyme 
competitively and act as a chain terminator of DNA synthesis","Acyclovir triphosphate competitively 
inhibits viral DNA polymerase by 
acting as an analog to deoxyguanosine
triphosphate (dGTP). Incorporation of 
acyclovir triphosphate into DNA results in chain termination since the absence of a 3' hydroxyl group prevents the attachment of additional nucleosides","Valacyclovir is converted to acyclovir,
which is converted to its triphosphate 
form, acyclovir triphosphate (ACV-TP). 
ACV-TP competitively inhibits viral
DNA polymerase, incorporates into
and terminates the growing viral
DNA chain, and inactivates of the viral DNA polymerase","Baloxavir inhibits the endonuclease 
activity of the polymerase acidic (PA)
protein found in influenza virus to 
ultimately inhibit virus replication"," It competitively inhibits the incorporation 
of deoxycytidine triphosphate (dCTP) 
into viral DNA by viral DNA polymerase","Adefovir is phosphorylated to its active 
metabolite, adefovir diphosphate
which inhibits HBV DNA polymerase
resulting in inhibition of viral replication.","It acts by preventing the viral connection
to CD4 by binding gp120.","Tenofovir–diphosphate works to inhibit
HIV replication by competing with the natural substrate deoxyadenosine 5?-triphosphate for incorporation into DNA during HIV transcription. Tenofovir–diphosphate inhibits replication of HBV by inhibiting HBV polymerase","Amprenavir is an inhibitor of HIV-1
protease. Amprenavir binds to the active site of HIV-1 protease and thereby prevents the processing of viral gag and gag-pol polyprotein precursors, resulting in the formation of immature non-infectious viral particles","Atazanavir is an azapeptide HIV-1 PI that 
prevents the formation of mature virions through the potent and selective inhibition of viral Gag and Gag–Pol polyprotein processing in HIV-1-infected cells ","boceprevir inhibits the proteolytic cleavage of the HCV encoded polyprotein, an essential step in the viral life cycle for the production of mature forms of the viral proteins NS4A, NS4B, NS5A, and NS5B","It has demonstrated a reduction in the
number and activation of inflammatory cells in the epithelium and sub-mucosa after regular Inhaled corticosteroids, together with healing of damaged epithelium. Inflammation is an important component in the pathogenesis of COPD and asthma","Stabilizes neuronal membranes, inhibits sodium channels","Blocks sodium channels, stabilizing neuronal membranes","Multiple, including increased GABA levels, sodium channel inhibition","Anticonvulsant, voltage-gated sodium channel blocker",Exact mechanism not fully understood; believed to modulate synaptic neurotransmission,Antiepileptic; precise mechanism not fully understood,"Blocks voltage-sensitive sodium channels, stabilizing neuronal membranes","Binds to GABA-A receptors, enhances inhibitory neurotransmission",Exact mechanism is not fully understood; may involve modulation of NMDA receptors and inhibition of voltage-gated sodium channels,Irreversible GABA transaminase inhibitor,"Binds to GABA reuptake transporter, increasing GABA levels in the brain",Anticonvulsant,Anticonvulsant; exact mechanism unclear,Antiepileptic; Carbonic anhydrase inhibitor,Binds to voltage-gated calcium channels in CNS,"Stabilizes neuronal membranes, inhibits sodium channels","Blocks sodium channels, stabilizing neuronal membranes","Multiple, including increased GABA levels, sodium channel inhibition","Anticonvulsant, voltage-gated sodium channel blocker",Exact mechanism not fully understood; believed to modulate synaptic neurotransmission,Antiepileptic; precise mechanism not fully understood,"Blocks voltage-sensitive sodium channels, stabilizing neuronal membranes","Binds to GABA-A receptors, enhances inhibitory neurotransmission",Exact mechanism is not fully understood; may involve modulation of NMDA receptors and inhibition of voltage-gated sodium channels,Irreversible GABA transaminase inhibitor,"Binds to GABA reuptake transporter, increasing GABA levels in the brain",Anticonvulsant,Anticonvulsant; exact mechanism unclear,Antiepileptic; Carbonic anhydrase inhibitor,Binds to voltage-gated calcium channels in CNS
Pgp substrate/inhibitor,Substrate,Pgp substrate,Pgp substrate,Substrate,Substrate,Substrate,Substrate,substrate,Both substrate and inhibitor,Substrate,None,Substrate,None,None,Substrate,Substrate,Not a P-glycoprotein substrate or inhibitor,Substrate,Not specified,Not a P-gp substrate or inhibitor,Not a P-glycoprotein substrate or inhibitor,Not specified,Substrate,Not a P-gp substrate or inhibitor,Not specified,Substrate,Not readily available,Not specified,Not specified,Absorption enhancers:,"pH level,food,transporter interactions,solubitlity,dosage formulation","increased gastric emptying rate,consistent time for administration",Empty stomach,none specified,"increased gastric emptying rate,consistent time for administration","pH level,food,transporter interactions,solubitlity,dosage formulation",NA,"pH level,food,transporter interactions,solubitlity,dosage formulation","increased gastric emptying rate,consistent time for administration","presence of fatty food,prodrugs,certain drugs with additives such as surfactants","presence of dietary fats food,certain drugs with additives such as surfactants","increased gastric emptying rate,consistent time for administration","pH level,food,transporter interactions,solubitlity,dosage formulation",NA,Not specified,Not specified,Not specified,Not specified,Antidepressant,Not specified,Substrate,Substrate,Substrate,Substrate,Substrate,Not applicable,NA,Inhibitors,Inhibitors,Inhibitors,Inhibitors,Substrate,Inhibitors,Substrate,NA,NA,NA,NA,NA,NA,NA,Pgp inhibitor,Pgp inhibitor,Pgp substrate,Pgp inhibitor,Pgp substrate,weak Pgp inhibitor,none,none,NA,none,none,NA,NA,Pgp substrate/inhibitor,substrate,substrate,substrate,substrate,substrate,substrate,substrate,inhibitor,inhibitor,inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Methotrexate is a substrate for P-glycoprotein (Pgp), which is a drug efflux pump that can affect drug distribution in the body.",NA,"The percentage bioavailability of Cyclosporine can vary depending on the formulation and route of administration. For the oral formulation, it is typically around 30-40%, due to extensive first-pass metabolism.",Not typically associated with P-glycoprotein interactions.,: It is a substrate for P-glycoprotein,", approximately 98%.",NA,NA,no applicable,app 73%,NA,NA,substrate,substrate,substrate,substrate,substrate,substate,substrate,substrate,inhibitor,substrate,substrate,substrate,NA,substrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Category/ Used for( analgesic/anticancer etc),"Antimalarial, anti-inflammatory",Antimalarial,Antimalarial,Antimalarial,Antimalarial,"Antimalarial, Antiarrhythmic","Antimalarial agent, biguanide class",Antimalarial; Antifolate,Antimalarial,anti-malarial,anti-malarial,anti-malarial,anti-malarial,Antimalarial - Artemisinin-based,Antimalarial,Antimalarial,Antimalarial,Antimalarial,NA,NA,NA,an inhibitor of gastric acid secretion rather than a P-glycoprotein (P-gp) inhibitor or enhancer.,", cimetidine is primarily known as a substrate of P-gp rather than an inhibitor.",P-glycoprotein (P-gp) substrate rather than an inhibitor.,", cimetidine is primarily known as a substrate of P-gp rather than an inhibitor.",Bepridil is primarily known as a substrate of P-glycoprotein (P-gp),Cisapride is primarily known as a substrate of P-glycoprotein (P-gp),Dofetilide is primarily known as a substrate of P-glycoprotein (P-gp),may vary.,Pimozide is primarily known as a substrate of P-glycoprotein (P-gp),: Specific information on whether Piperaquine acts as a substrate or inhibitor of P-glycoprotein (P-gp) is not readily available.,"Sparfloxacin may act as a substrate for P-glycoprotein (P-gp), an efflux transporter protein involved in drug elimination.","Terfenadine is a substrate of P-glycoprotein (P-gp), an efflux transporter protein involved in drug elimination.",": Ziprasidone is a substrate of P-glycoprotein (P-gp), an efflux transporter protein involved in drug elimination.","Mesoridazine may act as a substrate for P-glycoprotein (P-gp), an efflux transporter protein involved in drug elimination.",Nizatidine is not known to be a substrate or inhibitor of P-glycoprotein (P-gp).,"Amikacin, an antibiotic, is not a known substrate or inhibitor of P-glycoprotein.",Plazomicin is not a substrate or inhibitor of pgp,azithromycin increases the intracellular accumulation of the P-glycoprotein substrate doxorubicin in adriamycin-resistant human myelogenous leukemia cells (K562/ADR) overexpressing P glycoprotein,"Amoxicillin is a substrate of P-glycoprotein (P-gp), which means it can be actively transported by this protein.",Neither a inhibitor nor a substrate,"As for its substrate, temocillin is a substrate for beta-lactamases, enzymes that can hydrolyze beta-lactam antibiotics.In terms of inhibitors, beta-lactamase inhibitors like clavulanic acid, sulbactam, and tazobactam are commonly used to enhance the effectiveness of beta-lactam antibiotics,","Ampicillin is not a substrate for P-glycoprotein (P-gp), as it is primarily an antibiotic that inhibits bacterial cell wall synthesis. inhibitors or substrates of P-gp, you would typically consider drugs that are actively transported by this protein.","Sulfadiazine is known to be a substrate for P-glycoprotein (P-gp), which is an efflux transporter present in the intestinal epithelium. P-gp plays a role in actively pumping substances, including drugs, out of cells.not a P-gp inhibitor; instead, it is a substrate, meaning it is recognized and transported by P-gp.","eravacycline is a substrate for P-gp, it means that P-gp is involved in its transport across cell membranes, which can impact its bioavailability and distribution.","Penicillin antibiotics are not known to be significant substrates for P-glycoprotein (P-gp). P-gp is a transporter protein that plays a role in drug absorption, distribution, and excretion. It is primarily associated with pumping drugs out of cells, limiting their absorption and enhancing their eliminationg",whether meropenem is a substrate for P-glycoprotein (PGP). Meropenem is a broad-spectrum antibiotic used to treat various bacterial infections.To determine if a drug is a substrate for P-glycoprotein or other transporters,"Cephalexin is a substrate of P-glycoprotein (P-gp), meaning it is a compound that is recognized and transported by P-gp.","Ciprofloxacin is a substrate of P-glycoprotein (P-gp), which means it is recognized and transported by this efflux transporter. inhibitors include verapamil, quinidine, and certain antiretroviral drugs. When co-administered with these inhibitors, ciprofloxacin levels in the body may increase.","Ceftolozane is a cephalosporin antibiotic, and it is not a substrate or inhibitor of P-glycoprotein (Pgp). Pgp is a drug transporter protein involved in the absorption, distribution, and elimination of various drugs, but ceftolozane does not significantly interact with it.","Clarithromycin is both a substrate and an inhibitor of P-glycop.rotein (P-gp). As a substrate, it is actively transported by P-gp, and as an inhibitor, it can affect the function of P-gp in other drugs. This dual interaction with P-gp can contribute to potential drug interactions.When clarithromycin is administered concurrently with P-gp substrates, it may increase the concentrations of these drugs by inhibiting P-gp-mediated efflux, leading to a potential for increased side effects or toxicity",Substrate,Substrate,Substrate,substrate,substrate,substrate,substrate,Substrate,substrate,Substrate,substrate,substrate,substrate,substrate,substrate,Substrate,Substrate,Not a substrate or inhibitor of P-glycoprotein,Substrate,Substrate,Not a substrate or inhibitor of P-glycoprotein,Not a P-glycoprotein substrate,No,Not a substrate or inhibitor of P-glycoprotein,Not specified,Substrate,Not specified,Not a substrate or inhibitor,Substrate,Not a substrate or inhibitor of P-gp,pgp substrate,Substrate,not a substrate not inhibitor,Substrate,Not a substrate or inhibitor,Not specified,Substrate,Not specified,substrate,Not a substrate or inhibitor of P-glycoprotein,Substrate,Substrate,Substrate,substrate,Not a substrate or inhibitor of P-glycoprotein,NA,PGP Substrate,Not Available,Unknown,PGP Substrate,PGP substrate,PGP Substrate,PGP Substrate,PGP Substrate,PGP substrate,PGP Substrate,PGP Substrate,NA,PGP substrate,P-glycoprotein substrate,"Quinidine is both a substrate and an inhibitor of P-glycoprotein (P-gp), also known as multidrug resistance protein 1 (MDR1)",NA,NA,Lidocaine is a substrate,substrate,inhibit,substrate for Pgp,Both substrate and inhibitor,is both a substrate and inhibitor,substrate,substrate and inhibitor,Both substrate and inhibitor,"inhibitor, administered drugs that are substrates for P-gp, potentially leading to increased systemic exposure.",substrate,Acebutolol is not a substrate or inhibitor of P-glycoprotein.,inhibitor,Not applicable,Not specified,substrate,not applicable,substrate,NA,Pgp substrate,Pgp substrate,pgp substrate,pgs substrate,pgs substrate,NA,NA,not specified,cyclosporine and verapami,not typically inhibitor or substrate,not typically inhibitor or substrate,not typically inhibitor or substrate,not typically inhibitor or substrate,not typically inhibitor or substrate,not typically inhibitor or substrate,not typically inhibitor or substrate,not typically inhibitor or substrate,not typically inhibitor or substrate,not typically inhibitor or substrate,not typically inhibitor or substrate,not typically inhibitor or substrate,Fludarabine is not known to be a substrate or inhibitor of P- glycoprotein,dacarbazine is not known to be a substrate or inhibitor of P-glycoprotein.,Substrate,Substrate,Both,No,No,Both,No,Substrate,No,No,No,No,No,Both,Substrate,NA,NA,NA,NA,Pgp substrate,Pgp substrate,Pgp substrate,Pgp susbtrate,Inhibitor,Pgp substrate,Pgp substrate,pgp substrate,behaved as activators of the P-glycoprotein ATPase activity,NA,not P-gp substrates,"essentially ""transparent"" to PGP ", inhibited P-gp without affecting CYP3A. ,NA,NA,excitatory cardiovascular neurons,"Non-substrate, 0.5099",telithromycin is a substrate of both P glycoprotein and Mrp2,induce P-gp in hepatic and intestinal cells through the activation of the nuclear receptors PXR and CAR,NA,"P-glycoprotein substrate, Substrate, 0.5947. P-glycoprotein inhibitor",NA,"paroxetine is both a substrate and inhibitor of P-gp [50,69].",heavy migrain headache,used to treat acute miagrain headaches in adults,to treat acute migraine headache in adults,to treat the symptoms of miagrain headaches,to treat acute migrain headaches in adults,to treat acute migraine headache with or without aura,to treat acute migrain headaches in adults,migrain and cluster headaches,to treat severe malaria and migraine,treat high blood pressure and miagraine,relieve allergic symptoms and migrain,to treat the symptoms of migrain,used to treat migrain and headache,used to treat migraine,used to treat migraine,"sedative,antiemetic",Antihistamines,antiallergic,Antihistamines,Antihistamine,Antihistamines,Antihstamines,"Anti-inflammatory,anti-allergic",Antihistamines,Antihistaine,Antihistaminic,Antihistamines,Antihistamine,second generation antihistamines,Antihistamine,AML,AML,AML,CML,CML,"ALL,AML",CML,"CML,ALL",CML,CML,"ANL,ML,RL","ALL, CLL",CLL,"ANL,ALL",CLL,"Antioxidant, Boosting the immune system, collagen synthesis, antioxidant protection.","B Vitamin,DNA synthesis, cell division, prevention of neural tube defects during pregnancy.","B Vitamin , Red blood cell formation, neurological function, DNA synthesis.","B Vitamin, Cholesterol regulation, energy production, skin health","B Vitamin, Energy production, skin health, vision","B Vitamin, Energy metabolism, nerve function.","Essential Nutrient, Brain development, neurotransmitter synthesis, liver function.","Vitamin, Calcium absorption, bone health, immune function.","B Vitamin, Metabolism of fats, carbohydrates, and proteins.","B Vitamin, Energy production, synthesis of fatty acids","Carotenoid, Eye health, particularly in preventing age-related macular degeneration.","Carotenoid, Antioxidant, anti-inflammatory effects.","Polyphenol, Antioxidant, anti-inflammatory effects, potential cardiovascular benefits.","Vitamin, Blood clotting, bone metabolism.","Vitamin, Antioxidant, skin health.",Category/ Used for( analgesic/anticancer etc),Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Non-substrate,Substrate,Substrate/ Non inhibitor,Non substrate,Non substrate,Non substrate/inhibitor,Non substrate/inhibitor,Substrate,Substrate,Substrate,Non- Substrate,Substrate,Non substrate,Substrate,Substrate,anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),"Antiulcer agent, used for conditions
like GERD, peptic ulcers.","Gastrointestinal mucoprotective agent; used for the treatment of peptic ulcer disease, gastritis, and other gastrointestinal conditions.","Antiulcer agent, used for conditions
like GERD, peptic ulcers.","esophagitis, GERD, and Zollinger-Ellison
syndrome.","Used for the treatment of various gastrointestinal
conditions, including
gastritis and gastric ulcers.","Proton pump inhibitor; used for the treatment of GERD, peptic ulcers, and other acid-related conditions.",Antibacterial and antiprotozoal agent,"Treatment of GERD, gastric ulcers, duodenal ulcers, and other conditions associated with excessive gastric acid secretion","Antibiotic used to treat various bacterial infections, including respiratory tract infections, urinary tract infections, acne, and sexually transmitted infections","Treatment of GERD, gastric ulcers, duodenal ulcers, and other conditions associated with excessive gastric acid secretion","Sodium bicarbonate is used as an antacid to relieve heartburn,
indigestion, and acid reflux. It is also
used to treat certain medical conditions
such as metabolic acidosis and hyperkalemia.","Prostaglandin analogue; used for the prevention and treatment of gastric ulcers induced by NSAIDs, as well as for medical abortion and induction of labor.","Treatment of peptic ulcers, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and other conditions associated with excessive gastric acid secretion",Sodium citrate is used as a urinary alkalinizer to prevent the formation of kidney stones and to treat conditions such as metabolic acidosis.,prevent ulcers,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,anticancer,anticancer(Breast cancer),anticancer,anticncer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,Antiviral (primarily for hepatitis C and respiratory syncytial virus infections),Antiviral (Hepatitis C),"Antiretroviral (HIV treatment, hepatitis B)",Antiretroviral (HIV treatment),Antiretroviral (HIV treatment),Antiviral (primarily for COVID-19),Antiviral (primarily for influenza and COVID-19),Antiviral (for herpes infections),Category/ Used for( analgesic/anticancer etc),anti-cancer,Anti -cancer,anti -cancer,Anti- cancer,anti-cancer,anti-cancer,analgesic,analgesic,analgesic,anti-cancer,chemotherapy drug,NA,anti-cancer,anti-cancer,anti-cancer,Category/ Used for( analgesic/anticancer etc),antifungal,antifungal,antifungal,antifungal,antifungal,antifungal,antifungal,antifungal,antifungal,antifungal,vaginal yeast infections,vaginal yeast infections,antifugal,antifungal,heavy migrain headache,used to treat acute miagrain headaches in adults,to treat acute migraine headache in adults,to treat the symptoms of miagrain headaches,to treat acute migrain headaches in adults,to treat acute migraine headache with or without aura,to treat acute migrain headaches in adults,migrain and cluster headaches,to treat severe malaria and migraine,treat high blood pressure and miagraine,relieve allergic symptoms and migrain,to treat the symptoms of migrain,used to treat migrain and headache,used to treat migraine,used to treat migraine,"sedative,antiemetic",Antihistamines,antiallergic,Antihistamines,Antihistamine,Antihistamines,Antihstamines,"Anti-inflammatory,anti-allergic",Antihistamines,Antihistaine,Antihistaminic,Antihistamines,Antihistamine,second generation antihistamines,Antihistamine,AML,AML,AML,CML,CML,"ALL,AML",CML,"CML,ALL",CML,CML,"ANL,ML,RL","ALL, CLL",CLL,"ANL,ALL",CLL,NA,Category/ Used for( analgesic/anticancer etc),"Antioxidant, Boosting the immune system, collagen synthesis, antioxidant protection.","B Vitamin,DNA synthesis, cell division, prevention of neural tube defects during pregnancy.","B Vitamin , Red blood cell formation, neurological function, DNA synthesis.","B Vitamin, Cholesterol regulation, energy production, skin health","B Vitamin, Energy production, skin health, vision","B Vitamin, Energy metabolism, nerve function.","Essential Nutrient, Brain development, neurotransmitter synthesis, liver function.","Vitamin, Calcium absorption, bone health, immune function.","B Vitamin, Metabolism of fats, carbohydrates, and proteins.","B Vitamin, Energy production, synthesis of fatty acids","Carotenoid, Eye health, particularly in preventing age-related macular degeneration.","Carotenoid, Antioxidant, anti-inflammatory effects.","Polyphenol, Antioxidant, anti-inflammatory effects, potential cardiovascular benefits.","Vitamin, Blood clotting, bone metabolism.","Vitamin, Antioxidant, skin health.",NA,NA,NA,NA,NA,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,Antifungal,NA,Pgp substrate/inhibitor,Non-substrate,Substrate,Substrate/ Non inhibitor,Non substrate,Non substrate,Non substrate/inhibitor,Non substrate/inhibitor,Substrate,Substrate,Substrate,Non- Substrate,Substrate,Non substrate,Substrate,Substrate,Category/ Used for( analgesic/anticancer etc),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),anti- diabets/type 2 diabetes ( Sulonyl urea),Category/ Used for( analgesic/anticancer etc),"Antiulcer agent, used for conditions
like GERD, peptic ulcers.","Gastrointestinal mucoprotective agent; used for the treatment of peptic ulcer disease, gastritis, and other gastrointestinal conditions.","Antiulcer agent, used for conditions
like GERD, peptic ulcers.","esophagitis, GERD, and Zollinger-Ellison
syndrome.","Used for the treatment of various gastrointestinal
conditions, including
gastritis and gastric ulcers.","Proton pump inhibitor; used for the treatment of GERD, peptic ulcers, and other acid-related conditions.",Antibacterial and antiprotozoal agent,"Treatment of GERD, gastric ulcers, duodenal ulcers, and other conditions associated with excessive gastric acid secretion","Antibiotic used to treat various bacterial infections, including respiratory tract infections, urinary tract infections, acne, and sexually transmitted infections","Treatment of GERD, gastric ulcers, duodenal ulcers, and other conditions associated with excessive gastric acid secretion","Sodium bicarbonate is used as an antacid to relieve heartburn,
indigestion, and acid reflux. It is also
used to treat certain medical conditions
such as metabolic acidosis and hyperkalemia.","Prostaglandin analogue; used for the prevention and treatment of gastric ulcers induced by NSAIDs, as well as for medical abortion and induction of labor.","Treatment of peptic ulcers, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and other conditions associated with excessive gastric acid secretion",Sodium citrate is used as a urinary alkalinizer to prevent the formation of kidney stones and to treat conditions such as metabolic acidosis.,prevent ulcers,Category/ Used for( analgesic/anticancer etc),Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Antacid,Category/ Used for( analgesic/anticancer etc),anticancer,anticancer(Breast cancer),anticancer,anticncer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,anticancer,Antiviral (primarily for hepatitis C and respiratory syncytial virus infections),Antiviral (Hepatitis C),"Antiretroviral (HIV treatment, hepatitis B)",Antiretroviral (HIV treatment),Antiretroviral (HIV treatment),Antiviral (primarily for COVID-19),Antiviral (primarily for influenza and COVID-19),Antiviral (for herpes infections),Category/ Used for( analgesic/anticancer etc),anti-cancer,Anti -cancer,anti -cancer,Anti- cancer,anti-cancer,anti-cancer,analgesic,analgesic,analgesic,anti-cancer,chemotherapy drug,NA,anti-cancer,anti-cancer,anti-cancer,antifungal,antifungal,antifungal,antifungal,antifungal,antifungal,antifungal,antifungal,antifungal,antifungal,vaginal yeast infections,vaginal yeast infections,antifugal,antifungal,"anti-epileptic, anti-seizure",anti-epileptic,anti-epileptic,"Anti-convulsant, hypnotic",Treatment of seizures,"anti-epileptic, partial onset","Anti-epileptic, anti-seizures","anti-anxiety, anti-nsommia, anti-seizures","anti-convulsant, anti-epileptic","used for migrane, epilepsy, prophylaxis, weight loss","anti-seizure, treatment of lennox gastaut syndrome",treatment of glaucoma and seizures,"anti-epileptic, and to treat seizures","used for epilepsy, bipolar disorder,trigeminal neuraglia",anti- epileptic,NA,"used for epilepsy, bipolar disorder,trigeminal neuraglia",anti- epileptic,Antipstchotic,Anticonvulsant,Antipsychotic,Antipstchotic,"Antipsychotic, Antidepressant",Antipsychotic,Antipsychotic,Antipsychotic,polymorphic,Anticoagulant,Anticoagulant,Antipsychotic,Antipsychotic,anti osteoporosis,"Osteoporosis prevention/treatment, breast cancer prevention.",Osteoporosis treatment.,"Osteoporosis treatment, bone metastases.","Osteoporosis treatment, bone metatases.","Osteoporosis treatment, menopausal symptoms.","Osteoporosis treatment, hypercalcemia of malignancy","Osteoporosis treatment, hypercalcemia of malignancy","Osteoporosis treatment, bone metatases.",Osteoporosis treatment,Osteoporosis treatment,Osteoporosis treatment,"Osteoporosis treatment, hypercalcemia","Osteoporosis treatment, metastases",Osteoporosis treatment, Crystalline form I,Not reported,crystalline form A and crystalline form B,"May exist in multiple forms, but no specific polymorphisms are commonly mentioned.","?-Form, ?-Form, ?-Form, ?-Form, ?-Form",Form I and Form II.,Not specified,"Form I, Form II, Form III, amorphous",Single form,"Hydroxychloroquine Sulfate Form I, II, III, IV",N/A,Prednisolone forms I and II,No,None,None,NA,Anti-cancer (used to treat skin cancer),Anti-cancer (used in skin cancer),Anti-cancer (used tp treat skin cancer),Anti-cancer drug used in treatment of skin cancer,Anti-cancer drug used to treat skin cancer,Anti-cancer used in treatment of skin cancer,Anticancer drug used to treat skin cancer,Anti-cancer used in treatment of skin cancer,Anti-cancer drug used in treatment of skin cancer,Anti-cancer drug used in treatment of skin cancer,anti cancer drug used to treat skin cancer,anti-cancer drugs used to treat skin cancer,anti cancer drug used to treat skin cancer,"Anticancer drug,used in treatment of skin cancer",NA, manage and treat certain bacterial infections, penicillin antibiotics. ,cephalosporin antibiotics.,cephalosporin antibiotics.,carbapenem antibiotics,carbapenem antibiotic,category B drug for use in pregnancy., tetracycline antibiotics. ,third-generation cephalosporin,Tiamulin is a pleuromutilin antibiotic drug, quinolone antibiotics, penicillins and beta-lactamase inhibitors,Cefepime is a cephalosporin in the beta-lactam class of antibiotics ,Ceftaroline is in a class of medications called cephalosporin antibiotics.,Anti anginal,Anti anginal,Anti anginal,Anti anginal,Anti anginal,Anti anginal,Anti anginal,Anti anginal,Anti anginal,Anti anginal,Anti anginal,Anti anginal,Anti anginal,Anti anginal,Anti anginal,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not a substrate or inhibitor of Pgp.,Not a substrate or inhibitor of Pgp.,Not a substrate or inhibitor of Pgp.,Not a substrate or inhibitor of Pgp.,Not a substrate or inhibitor of Pgp.,Not a substrate or inhibitor of Pgp.,Cimetidine may inhibit Pgp.,Not a substrate or inhibitor of Pgp.,Not a substrate or inhibitor of Pgp.,Not a substrate or inhibitor of Pgp.,Not a substrate or inhibitor of Pgp.,Not a substrate or inhibitor of Pgp.,Not a substrate or inhibitor of Pgp.,NA,Not a substrate or inhibitor of Pgp.,"Zanamivir is used in the treatment 
of the infection caused by the flu
virus(influenza A & influenza B)","Peramivir injection is used to treat acute
uncomplicated influenza in patients who
have flu symptoms (eg, weakness, headache, fever, cough, runny or stuffy nose, sore throat) for no more than 2 days.","Oseltamivir is used in the treatment
of the infection caused by the flu
virus (influenza A and influenza B).
Oseltamivir may also be used to 
prevent and treat swine influenza A. Oseltamivir may reduce flu symptoms (weakness, headache, fever, cough, runny or stuffy nose, and sore throat) by 1 day","Abacavir is used along with other medications 
to treat human immunodeficiency virus (HIV) infection","Acyclovir is used to treat the symptoms 
of chickenpox, shingles, herpes virus
infections of the genitals (sex organs)
, the skin, the brain, and mucous membranes 
(lips and mouth), and widespread herpes 
virus infections in newborns. Acyclovir is also used to prevent recurrent genital herpes infections","Valacyclovir is used to treat herpes virus
infections, including herpes labialis
(also known as cold sores), herpes zoster 
(also known as shingles), and herpes simplex
(also known as genital herpes) in adults. 
It is also used to treat chickenpox and cold sores in children","Baloxavir marboxil is used to treat the flu
(influenza) in patients who have had flu
symptoms (eg, cough, fever, runny nose,
headache, joint or muscle pain) for not 
more than 48 hours","Cidofovir injection is used along with 
another medication (probenecid) to 
treat cytomegaloviral retinitis (CMV retinitis) in people with acquired immunodeficiency
syndrome (AIDS). Cidofovir is in a class of medications called antivirals. It works by slowing the growth of CMV","Adefovir is used to treat chronic (long-term) hepatitis B virus (HBV) infection in patients who are at least 12 years of age. Adefovir is not a cure for the hepatitis B virus, but it may lower the amount of virus in your body. It may also lower the ability of the virus to
multiply in your body","Fostemsavir is used along with other 
medications to treat human immunodeficiency
virus (HIV) infection in adults whose HIV
could not be successfully treated with
other medications, including their current therapy.
Fostemsavir is in a class of medications called HIV attachment inhibitors","Tenofovir alafenamide  is 
used to treat chronic (long term) HBV in adults and children 12 years of age and older who have stable liver disease","Amprenavir is a protease inhibitor
used to treat HIV infection","Atazanavir is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults and children who are at least 3 months of age and weigh at least 22 lb
(10 kg)","Boceprevir is approved for use in 
combination with peginterferon and ribavirin to treat adults with genotype 1 chronic hepatitis C infection and compensated liver disease","Combivir Rotacap is indicated in the regular treatment of asthma, where use of a combination (long acting beta -agonist and inhaled 2 corticosteroid) has been found to be appropriate",Anticonvulsant,"Anticonvulsant, mood stabilizer","Anticonvulsant, mood stabilizer, and for migraines",Antiepileptic,Antiepileptic,"Antiepileptic, migraine prophylaxis, weight loss in some cases",Antiepileptic,Antiepileptic,Antiepileptic,Antiepileptic,Anticonvulsant,Used for the treatment of seizures in epilepsy,Antiepileptic/Neuropathic pain,Antiepileptic,"Anticonvulsant, Analgesic",Anticonvulsant,"Anticonvulsant, mood stabilizer","Anticonvulsant, mood stabilizer, and for migraines",Antiepileptic,Antiepileptic,"Antiepileptic, migraine prophylaxis, weight loss in some cases",Antiepileptic,Antiepileptic,Antiepileptic,Antiepileptic,Anticonvulsant,Used for the treatment of seizures in epilepsy,Antiepileptic/Neuropathic pain,Antiepileptic,"Anticonvulsant, Analgesic"
Absorption,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Rapid,Rapid and complete,"Well-absorbed, bioavailability is approximately 36%",Well absorbed in the gastrointestinal tract,Rapid and extensive,Well absorbed in the GI tract,Well-absorbed after oral administration,Rapid and efficient,Rapid and extensive,Rapid and extensive,Rapid,"Well absorbed, extensive first-pass metabolism",Rapid and extensive absorption after oral administration,Well-absorbed in the gastrointestinal tract,Rapid and extensive,Absorption inhibitors:,"Macrolide Antibiotics,Cimetidine","antacids,fatty food",food,none specified,"antacids,fatty food",none specified,Avoid alcohol. Ingesting alcohol may increase the CNS depressant effects of zaleplon.,Avoid alcohol. Co-administration may enhance CNS adverse effects such as drowsiness and sedation.,"Macrolide Antibiotics,Cimetidine","Antacids,certain medications","Antacids,Grapefruit juice","Antacids,certain medications",Avoid alcohol. Co-administration may enhance CNS adverse effects such as drowsiness and sedation.,NA,Not specified,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,High & oral bioavailability was 50.72%,37%,50%,90%,? 25%,100%,"Highly variable, 25 to 75%",Oral: 8%,6.5%(by mouth),10%,NA,43±14%(oral),69.80%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Pgp substrate/inhibitor,Substrate,Substrate,substrate,Substrate,Substrate,Substrate,substrate,substrate,substrate,substrate,substrate,Substrate,Substrate,substrate,Substrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Rapid and complete absorption,Rapid and complete,Rapid and almost complete from the GI tract,Rapid and well-absorbed from the gastrointestinal tract,Rapid and almost complete,Rapid and nearly complete absorption,Rapid and complete absorption,Well-absorbed,"Well-absorbed, with peak plasma concentrations reached within 2-4 hours",Rapid and complete absorption,Well absorbed,Rapid and complete,Rapid and almost complete,Well-absorbed,Rapid and extensive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Well-absorbed,Well-absorbed,Well-absorbed,Well-absorbed in the gastrointestinal tract,Rapid,Well absorbed,Well-absorbed in the gastrointestinal tract,Well-absorbed,Well-absorbed,Well-absorbed,Rapid and well-absorbed,Rapid and extensive,Rapid and well-absorbed,Rapid and extensive,Well-absorbed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"administered intravenously, methotrexate bypasses the gastrointestinal tract, leading to complete and immediate absorption.","It is partially absorbed after intracavitary administration, likely due to rapid deactivation by body fluids",thiotepa is generally well-absorbed from the gastrointestinal tract.,is administered orally in the form of capsule absorption can be variable,Busulfan is usually administered orally. It is well-absorbed in the gastrointestinal tract.,"absorbed from the gastrointestinal tract with a wide range in bioavailability (range 25–89%, mean 56%) (Sweetman, 2008).",The absorption of the drug from the gastrointestinal tract is incomplete resulting in an absolute bioavailability of about 40%.,Oral absorption and high membrane penetration are attributed to high lipophilicity well-absorbed from the gastrointestinal tract, well absorbed after oral administration with a bioavailability greater than 75%.,"administered, streptozocin is rapidly absorbed into the bloodstream.",etoposide is absorbed from the gastrointestinal tract,absorbed from the gastrointestinal tract. The absorption process may vary among individuals and can be influenced by factors such as gastrointestinal motility and the presence of food in the stomach.,procarbazine is rapidly and well absorbed from the gastrointestinal tract,"It is available in oral and intravenous (IV) formulations, and the absorption of the drug depends on the route of administration","Dacarbazine is commonly administered intravenously. When given intravenously, the drug is directly introduced into the bloodstream, leading to rapid and complete absorptio",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,substrate,substrate,substrate,substrate,NA,NA,NA,NA,yes,predominantly eliminated through renal excretion,no,yes(verapamil),Amiodarone,no,levocitirizine,verapamil,no,no,no,yes,yes,yes,yes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,non substrate,substrate/Non inhibitor,NA,Non-substrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Pgp substrate/inhibitor,P-glycoprotein inhibitors,Apixaban,colchicine,Digoxin,Amiodarone,Rivaroxaban,6-desmethylgriseofulvin ,NA,?-glucan synthase,NA,NA,NA,0.525,NA,2.71,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Substrate,Substrate,Substrate,Substrate,Substrate,Substrate,inhibitor,inhibitor,Substrate,inhibitor,Substrate,inhibitor,Substrate,inhibitor,inhibitor,Substrate,NA,Substrate,"(P-gp)
substrate or inhibitor.",NA,Not a P-glycoprotein substrate or inhibitor,NA,NA,NA,NA,Not a substrate or inhibitor of P-gp.,NA,NA,Not a substrate,"not a substrate for P-glycoprotein (Pgp), but it may inhibit Pgp-mediated drug transport at higher concentrations.",Both,Both,NA,Both,Both,Both,Inhibitor,Both,Both,Inhibitor,Both,Both,Both,Both,Both,NA,NA,cholesterol,NA,NA,NA,NA,NA,substrate,NA,not specified,NA,NA,NA,NA,Not specified,Not specified,Not specified,Inhibitor,Not specified,Not specified,Not specified,Substrate,Pgp substrate/inhibitor,substrate,substrate,substrate,substrate,substrate,substrate,substrate,substrate,NA,substrate,not know to be substrate,not substrate for pgp,NA,substrate,substrate,Pgp substrate/inhibitor,inhibits p-glycoprotein,inhibits p-glycoprotein,mot specified,not a p-glycoprotein,p-glycoprotein substrate,NA,not a substrate,not a substrates,not specified,not a substrates,not a substrates,not a substrates,antifungal,not substrates,NA,NA,NA,NA,NA,NA,NA,substrate,substrate,substrate,substrate,NA,NA,NA,NA,yes,predominantly eliminated through renal excretion,no,yes(verapamil),Amiodarone,no,levocitirizine,verapamil,no,no,no,yes,yes,yes,yes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Pgp substrate/inhibitor,non substrate,substrate/Non inhibitor,NA,Non-substrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,P-glycoprotein inhibitors,Apixaban,colchicine,Digoxin,Amiodarone,Rivaroxaban,6-desmethylgriseofulvin ,NA,?-glucan synthase,NA,NA,NA,0.525,NA,2.71,NA,Absorption,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Pgp substrate/inhibitor,Substrate,Substrate,Substrate,Substrate,Substrate,Substrate,inhibitor,inhibitor,Substrate,inhibitor,Substrate,inhibitor,Substrate,inhibitor,inhibitor,Pgp substrate/inhibitor,Substrate,NA,Substrate,"(P-gp)
substrate or inhibitor.",NA,Not a P-glycoprotein substrate or inhibitor,NA,NA,NA,NA,Not a substrate or inhibitor of P-gp.,NA,NA,Not a substrate,"not a substrate for P-glycoprotein (Pgp), but it may inhibit Pgp-mediated drug transport at higher concentrations.",Pgp substrate/inhibitor,Both,Both,NA,Both,Both,Both,Inhibitor,Both,Both,Inhibitor,Both,Both,Both,Both,Both,Pgp substrate/inhibitor,NA,NA,cholesterol,NA,NA,NA,NA,NA,substrate,NA,not specified,NA,NA,NA,NA,Not specified,Not specified,Not specified,Inhibitor,Not specified,Not specified,Not specified,Substrate,Pgp substrate/inhibitor,substrate,substrate,substrate,substrate,substrate,substrate,substrate,substrate,NA,substrate,not know to be substrate,not substrate for pgp,NA,substrate,substrate,inhibits p-glycoprotein,inhibits p-glycoprotein,mot specified,not a p-glycoprotein,p-glycoprotein substrate,NA,not a substrate,not a substrates,not specified,not a substrates,not a substrates,not a substrates,antifungal,not substrates,p-gylcoprotien (pgp sustrate),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,P-glycoprotien,NA,NA,P-glycoprotien,NA,P-glycoprotein (p-gp) sustrate,NA,P-glycoprotein (P-gp) sustrate,NA,NA,P-glycoprotein,P-glycoprotein,NA,NA,P-glycoprotein,Sustrate,Substrate,Substrate,No,No,No,No,No,No,No,No,No,No,NA,NA,NA,NA,NA,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Oral,Subcutaneous injection,"Oral, topical, intravenous, intra-articular, intramuscular",Subcutaneous injection,Subcutaneous injection,Intravenous (IV),NA,Substrate,Substrate,sustrate,inhibitor,it do not act as pgp sustrate or inhibitor. It is monoclonal antibody that works as programmed call death protein 1 (PD-1) inhibitor,it is not pgp sustrate or inhibitor,not pgp sustrate or inhibitor,Substrate,substrate,substrate,substrate,inhibitor,substrate,substrate,NA, manage and treat certain bacterial infections, P-gp substrates with poor and inconsistent oral bioavailability due to poor permeability may have a marked benefit from combining," P-glycoprotein substrate, Substrate, 0.786. P-glycoprotein inhibitor I, Non-inhibitor, 0.9033. P-glycoprotein inhibitor II,",", are substrates of P-gp, which might account for low brain penetration[27–30].",mipenem is active against aerobic and anaerobic Gram positive as well as Gram negative bacteria including Pseudomonas aeruginosa and the Enterococcus.,Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria,"P-glycoprotein substrate, Substrate, 0.8562. P-glycoprotein inhibitor I, Non-inhibitor, 0.8781. P-glycoprotein inhibitor II",Omadacycline is a weak substrate for P-gp (but not MRP-2 or BCRP)," Drugs that are substrates of P-gp are subject to low intestinal absorption, low blood-brain barrier permeability",Tiamulin fumarate (TIF) is a pleuromutilin antibiotic and has high activity against animal bacterial pathogens, moxifloxacin is a substrate of MDR1 and MRP2 efflux transporters, piperacillin or ceftolozane to broaden the spectrum of piperacillin antibacterial action,nvestigated whether these drugs are substrates and/or inhibitors of efflux transporters especially of P-glycoprotein ,"Ceftaroline fosamil is an antibacterial drug. Absorption. Not ... P-glycoprotein substrate, Substrate, 0.7512. P-glycoprotein inhibito",Substrate,None,None,None,None,Substrate,Substrate,Inhibitors,Both,Both,None,None,Substrate,Substrate,Substrate,60% bioavailable for 250mg,100% bioavailability,14%, 37%,"Intrmucular- less than 40% intramuscular- 100% , orally- 60-80%",NA,99%,11.70%,90%,73-95%,100%,30%,30%,71%,95%,Rapidly absorbed in the small intestine.,Rapidly absorbed in the small intestine.,Rapidly absorbed in the small intestine.,Rapidly absorbed in the small intestine.,Rapidly absorbed in the small intestine.,Rapidly absorbed in the small intestine.,Rapidly absorbed from the gastrointestinal tract.,Rapidly absorbed from the gastrointestinal tract,Rapidly absorbed from the gastrointestinal tract.,Rapidly absorbed from the gastrointestinal tract,Rapidly absorbed from the gastrointestinal tract,Propantheline is well absorbed from the gastrointestinal tract after oral administration.,Oxyphenonium is well absorbed from the gastrointestinal tract after oral administration.,"Misoprostol is well absorbed from the gastrointestinal tract, and absorption is enhanced in the presence of food.",Rioprostil is well absorbed from the gastrointestinal tract after oral administration.,Inhibitor,Non-substrate or Non-inhibitor, influenza neuraminidase inhibitor,"nucleoside reverse transcriptase
inhibitors ",HSV-1 DNA polymerase,"nucleoside analog DNA polymerase
enzyme inhibitor",cap-dependent endonuclease,pgp substrate,pgp substrate,pgp substrate,pgp substrate,pgp substrate,inhibitor,pgp substrate,pgp substrate,Substrate,Substrate,Not a substrate or inhibitor of P-glycoprotein,Substrate,Substrate,Not a substrate or inhibitor of P-glycoprotein,Not a P-glycoprotein substrate,No,Not a substrate or inhibitor of P-glycoprotein,Not specified,Substrate,Not specified,Not a substrate or inhibitor,Substrate,Not a substrate or inhibitor of P-gp,Substrate,Substrate,Not a substrate or inhibitor of P-glycoprotein,Substrate,Substrate,Not a substrate or inhibitor of P-glycoprotein,Not a P-glycoprotein substrate,No,Not a substrate or inhibitor of P-glycoprotein,Not specified,Substrate,Not specified,Not a substrate or inhibitor,Substrate,Not a substrate or inhibitor of P-gp
Percentage Bioavailability,75-80%,70-80%,11-52%,75-100%,~80%,~75%,75%-90%,"100% (IV), 60%-80% (intranasally)",99% (orally),"30%-60% (from smoking tobacco), 25%-50% (smokeless tobacco)",~63-94%,70-80%,75%-85% (oral route),50%-70%,10-30%,~86%,36%,10%,Approximately 35%,40-55%,Approximately 50%,Approximately 90%,55%,Approximately 95%,"2% (oral), 100% (subcutaneous)",Low (about 28%),Approximately 95%,Not specified,~ 65-67%,D,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not applicable,60-90% (oral),Approximately 100% (oral),Not applicable,Approximately 60-80%,Not applicable,Not applicable,Not applicable,Approximately 50-75%,Not applicable (IV administration),Not applicable,Percentage Bioavailability,Low,Low,Low,96%,54%,90%,55%,70%,NA,NA,Very low,NA,NA,25%,NA,100%,90%,NA,2%,50-70%,approx 100%,90%,83-89%,50-60 %,100%,100%,70-80%,approx 63%,Percentage Bioavailability,72,80,45,50,5-20 %,50,30-60%,65-80%,50,30-50%,53,N/A,NA,­,­,­,­,­,­,­,­,­,­,­,­,­,NA,100%,25% to 40%,25%,80% to 85%,59%,80-85%,59%,25%,60-75%,35%,No,65%,93%,60-65%,NA,ranging from 37% to 46%,Acitretin is widely distributed in the body and systemic bioavailability is approximately 60%.,2.7% for the immediate release formulation and 3.4% for the slow release formulation,60-95 % absorption after oral administration,"After oral administration of 20 mg/kg of hydroxyurea, a rapid absorption is observed with peak plasma levels of about 30 mg/L ",can vary depending on formulation nd route of administration. For orl around 30-40% due to extensive first pss metabolism,NA,Betamethasone has low oral bioavailability due to extensive first-pass metabolism. The bioavailability can be affected by factors such as the formulation and presence of food.,NA,"Tazarotene is primarily used topically, and its bioavailability in the systemic circulation is generally low.","Low systemic absorption, resulting in low bioavailability","high bioavailability, typically around 64-74%",30-50%,NA,72%,13%,50-60%,80%,60%,60-70%,30%,65%,70%,25%,60-70%,20-30%,95%,NA,100%,100%,60%,80-85%,99%,100%,75-80%,30-40%,1%-2%,100%,60-90%,NA,1%-5%,70%-80%,80%-90%,NA,Absorption,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,approximately 50% to 60% when administered orally.,approximately 60% to 70%,approximately 40% to 45%,approximately 60% to 70%,approximately 50% to 70%,approximately 30% to 40%,approximately 90%,approximately 50 %,approximately 50-60%,approximately 50-70%,approximately 80-90%,approximately 40-60%,approximately 60%,approximately 60%,approximately 70-90%,"Amikacin is typically administered intravenously or intramuscularly, and its bioavailability is nearly 100% with these routes. However, when administered orally, amikacin has poor bioavailability","The bioavailability of plazomicin is approximately 99% when administered intravenously. However, its oral bioavailability is extremely low, around 1%.",The bioavailability of azithromycin is approximately 37%. Concomitant administration of oral azithromycin with food significantly decreases by 50% drug bioavailability.,"The AUC after oral administration was 77.4% of the intravenous AUC. On the other hand, recovery from the urine was 43.4% after the oral dose and 57.4% after the intravenous dose, indicating 76.5% bioavailability.","Generally, oral cephalosporins have variable bioavailability, ranging from approximately 30% to 50%.",NA,"ampicillin's bioavailability is approximately 40-50%, indicating that a significant portion undergoes first-pass metabolism. Administering it intravenously avoids the first-pass effect, resulting in higher bioavailability.",oral sulfadiazine has a bioavailability ranging from 70% to 80%.,NA,typically absorbed from the gastrointestinal tract at around 50-60% bioavailability.,"Bioavailability was 99.69% (IM) and 96.52 % (SC). Elimination half-lives for the IV, IM and SC administration were 1.35, 2.10 and 2.26 h, respectively.",The bioavailability of cephalexin is approximately 90% when taken orally.,"Ciprofloxacin has relatively high bioavailability, with oral formulations typically achieving around 70-80% absorption.",Bioavailability: 70–85% (it decreases with increasing doses),"Generally, the bioavailability of the immediate-release oral formulation is around 50%, while the extended-release formulation has a higher bioavailability, typically ranging from 65% to 75%.",50% (oral),60-90%,30%,100%,7%,19%,(64-82%),83%,3-7%,50-60%,70-90%.,70-90%,1-2 %,10-20 %,20%,Highly variable (40-90%),High (75-85%),High,Approximately 98%,Nearly 100%,Approximately 80%,95%,Approximately 90%,Approximately 90%,Approximately 60-70%,Not specified,Not specified,~60%,~100%,Approximately 90%,90%,Highly variable (40-90%),~100%,~100%,~60%,Not specified,Not specified,Approximately 60-70%,90%,High,Approximately 98%,High (75-85%),Nearly 100%,93-100 %,Approximately 90%,30-40%,30-40%,~40-60%,Approximately 40-65%,60-70%,60-70%,Approximately 50-60%,70-80%,Approximately 87%,Not available,~35%,~90%,High,Not Available,Not available,70-90%,NA,"30% to 60%,",3-5%,90%.,90%.,100%,60-80%,"depending on individual factors such as formulation, administration route, and interactions with other drugs or substances",40-45%,30-40%,100%,20% to 50%,90%,40-50%,100%,Not applicable,Not specified,60%,not specified,39%,not applicable,85%,Variable bioavailability,high bioavaiblity,not available,not applicable,69%,69%,not specified,36%(+/-10%),0.016% gel once daily,20%-78%,20% to 40%.,10% to 30%.,"(range 25–89%, mean 56%)",76% of the dose. ,approximately 100%,greater than 75%,10%, 50% (range of 25% - 75%),25% to 30%,75% to 80%,around 25-30%.,25%,30 – 40%,80-90%,60-70%,50-60%,20-30%,25-40%,less than 90%,80-90%,40%,50-6%,20-30%,30-40%,60%,40-50%,70%,10% ,31%,41%,5% to 25%,85%,36% (+/- 10%).,"43%, ranging from 32% to 66%.",40%,NA,59%,10%,92%,70% to 90% ,92.8%.,80%. ,26%,4%,14%., 90%.,70% to 80%.,80 to 100%.,NA, 94.9 per cent (range 81-111.9 per cent).,not less than 100%,70–90% (oral); 90% (rectal),0.30%, 30-60%.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption, 5 to 10%,less than 1% ,above 90%,55%, > 90% ,54%,20%-70%,25% to 70%,90%,92%,>70%,80%,6%,NA,70%,99%,55%,Less than 0.2%,0.5 to 10%,98%,25 to 30%,0.30%,76%,44.6–64.5%,45%,30%,1.5- 3%,95%,0%,8 to 47 %,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Rapid and extensive absorption after oral administration,Rapid and high bioavailability after oral administration,Rapid and extensive absorption after oral administration,Rapid and extensive absorption,Absorbed in the gastrointestinal tract,Intravenous administration,Rapid and high bioavailability,Rapid and extensive,Absorption,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption,well absorbed orally,well absorbed orally,iv administration,well absorbed orally,in variable,vaginal mucosa,well observed orally,poorly absorbed,not specified,poorly absorbed,poorly absorbed through skin,poorly absorbed through skin,poorly absorbed through skin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA, 5 to 10%,less than 1% ,above 90%,55%, > 90% ,54%,20%-70%,25% to 70%,90%,92%,>70%,80%,6%,NA,70%,NA,Percentage Bioavailability:,99%,55%,Less than 0.2%,0.5 to 10%,98%,25 to 30%,0.30%,76%,44.6–64.5%,45%,30%,1.5- 3%,95%,0%,8 to 47 %,Absorption,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Rapid and extensive absorption after oral administration,Rapid and high bioavailability after oral administration,Rapid and extensive absorption after oral administration,Rapid and extensive absorption,Absorbed in the gastrointestinal tract,Intravenous administration,Rapid and high bioavailability,Rapid and extensive,Absorption,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,well absorbed orally,well absorbed orally,iv administration,well absorbed orally,in variable,vaginal mucosa,well observed orally,poorly absorbed,not specified,poorly absorbed,poorly absorbed through skin,poorly absorbed through skin,poorly absorbed through skin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2 mg once daily orally,Immediate-release tablets: 5 mg orally twice a day Extended-release tablets: 11 mg orally once a day,The recommended dosage of RINVOQ (Upadacitinib) for maintenance treatment is 15 mg once daily,Oral low dose of 7.5- 15 mg weekly,100 mg daily for 3 days followed by 20 mg OD.,"Initial dose: Usually 500 mg to 1,000 mg per day in divided doses. Maintenance dose: 2,000 mg to 3,000 mg per day in divided doses.",the starting dose of azathioprine for RA is in the range of 1 to 2.5 mg per kilogram of body weight per day., 1.25 mg/kg orally 2 times a day, 250 mg daily,200 to 400 milligrams (mg) per day,50 mg subcutaneously once a week,around 5–10 milligrams (mg) per day,1 to 2 milligrams (mg) per kilogram (kg),Initial dose: 160 mg subcutaneously on Day 1 followed by 80 mg subcutaneously 2 weeks later,4 mg/kg IV every 4 weeks followed by an increase to 8 mg/kg IV every 4 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Clavulanic Acid, Probiotics","Empty stomach, consistent timing","Adequate hydration,High fat meal",Sodium lauryl sulphate,"Fatty acids, citric acid, chelating agent",NA,NA,Not specific,Not applicaple,Not require,"Surfactant, permeation enhancer, piperine","Bioavilabity enhancer, lipid based formulation",No need,"Medium chain fattya acid, phospolipids,surfactant,piperin",No,Approximately 30-40% due to significant first-pass metabolism.,Approximately 77% due to its resistance to degradation by gastric acid.,Approximarely 80-85% due to its resistance to degradation by gastric acid,Approximately 52% due to its susceptibility to degradation by gastric acid.,Approximately64% due to its resistance to degradation by gastric acid.,Approximately 64% due to its resistance to degradation by gastric acid.,Approximately 70-80%.,Approximately 40-45%,Approximately 70-80%.,Approximately 50%.,Approximately 30-40%.,NA,NA,Approximately 80-90%.,Approximately 90%.,"Between 4% and 17% of an inhaled 
dose of zanamivir is absorbed systemically","Only 5% to 15% of the total dose 
is absorbed and excreted in the urine","Absorption of oseltamivir is high
( >70%) in all species","Abacavir is rapidly absorbed after
oral administration; the oral bioavailability is 83%."," Acyclovir is slowly and poorly absorbed
from the gastrointestinal tract and bioavailability decreases with increasing dose.","Valacyclovir is a prodrug that is rapidly
converted to acyclovir after oral dosing.","baloxavir marboxil is rapidly metabolized, with baloxavir acid achieving peak plasma concentration 4 h after administration.","Cidofovir is metabolized intracellularly to mono- and diphosphate moieties, as well as to cidofovir monophosphate choline."," adefovir dipivoxil is rapidly converted 
to adefovir. 45% of the dose is recovered as adefovir in the urine.","The absorption of temsavir is significantly 
limited by suboptimal dissolution and solubility following oral administration.","tenofovir is rapidly converted to tenofovir, which is metabolised intracellularly to its 
active anabolite tenofovir diphosphate, which is a competitive inhibitor of HIV-1 reverse transcriptase and terminates the growing DNA chain","Amprenavir was rapidly absorbed after
oral administration in HIV-1-infected patients with a time to peak concentration (tmax) typically between 1 and 2 hours after a single oral dose"," oral administration with low-dose ritonavir,atazanavir is rapidly absorbed into the systemic circulation, reaching its peak concentration (Cmax) in approximately 3 h (Tmax) and steady-state concentration between days 4 and 8, with approximately 2.3-fold accumulation "," Boceprevir is metabolized by the
liver predominantly; approximately 79% is eliminated in stool and approximately 9% in urine.","The extent of lamivudine and zidovudine
absorption (AUC) following administration of COMBIVIR with food was similar when compared to fasting healthy subjects ",Rapid and complete absorption,Rapid and complete,Rapid and almost complete from the GI tract,Rapid and well-absorbed from the gastrointestinal tract,Rapid and almost complete,Rapid and nearly complete absorption,Rapid and complete absorption,Well-absorbed,"Well-absorbed, with peak plasma concentrations reached within 2-4 hours",Rapid and complete absorption,Well absorbed,Rapid and complete,Rapid and almost complete,Well-absorbed,Rapid and extensive,Rapid and complete absorption,Rapid and complete,Rapid and almost complete from the GI tract,Rapid and well-absorbed from the gastrointestinal tract,Rapid and almost complete,Rapid and nearly complete absorption,Rapid and complete absorption,Well-absorbed,"Well-absorbed, with peak plasma concentrations reached within 2-4 hours",Rapid and complete absorption,Well absorbed,Rapid and complete,Rapid and almost complete,Well-absorbed,Rapid and extensive
Absorption enhancers,Basic medium like gut,"Acids, antacids, high fat meals","CYP2D6 inhibitors, grapefruit juice,pH modifiers","Acidic substances, Carbonated beverages,Vitamin C",None,None,"Acidic Environment, Caffeine, Piperine, Quercetin",Not specific as cocaine is already highly bioavailable through mucous membranes,"Empty stomach, acidity","Acidic beverages, Quitting aids, mouth rinses","Food, pH, dosage form","Empty stomach, pH level, Gastrointestinal Motility, Drug Interactions","Surfactants, lipid-based formulations,pH modifiers, nanoparticles","Acidic environment, food interactions, lipid-based Formulations",Not specified,NA,Not specified,Not specified,Not specified,Not specified,Not applicable,Not specified,Not specified,Not specified,Not specified,Not applicable,Not applicable,Not specified,Not specified,Plasma protein binding:,80-90%,96%,80-90%,89%,85-90%,45-60%,60%,75-76%,82-86%,45-60%,83%,89-95%,85-95%,82%,Not specified,Not applicable,Not specified,Not specified,80%,Not specified,Not applicable,Not applicable,Not applicable,Not applicable,Not specified,Not applicable,Absorption enhancers:,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,not for insulin injections,"Consuming it alongside a meal, especially one that contains fats, may improve its absorption","piperine, which is found in black pepper. It may improve the bioavailability of certain drugs",NA,co-administration with certain foods or substances that enhance solubility or reduce metabolism,"can be enhanced by taking it with food. Consuming it alongside a meal, especially one that contains some fat",factors like food intake can affect its absorption,can be enhanced by taking it with a meal high in fat,"enhancers for metformin, such as dietary fiber, particularly soluble fibers like guar gum","substances, like bile salts or surfactants, can act as absorption enhancers for insulin. They help improve insulin absorption through the intestinal membrane",not for insulin injection,not for insulin injection,factors like taking it with meals or adjusting the timing may influence absorption.,Absorption enhancers:,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,KRAS G12C,Anaplastic lymphoma kinase inhibitor,MEK inhibitor,tyrosine kinase inhibitor,tyrosine kinase inhibitor,­,Topoisomerase II inhibitor,Mitotic inhibitor,­,­,Yes,Mitotic inhibitor,­,NA,oral administration,mucosal membrane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Information on specific absorption enhancers for Azathioprine is not commonly discussed in standard references. Absorption enhancers are substances that can improve the absorption of a drug across biological membranes.,"Absorption of Acitetin can be enhanced by taking it wth meal , presence of dietery fat can increase the absorption of Acitretin as it is lipophilic(fat soluble) medication",NA,1] Folate supplementation 2] Proton pump inhibitors (PPIs),administration of certain compound such as sodium butyrate or di methylsulfoxide may act as enhancer of hydroxyure,NA,NA,"These are substances that improve the absorption of a drug. For betamethasone, specific enhancers may be used in formulations to enhance skin penetration in topical applications.",NA,The topical formulation itself may contain ingredients that enhance skin absorption.,Not typically associated with specific absorption enhancers,not applicable,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Insulin aspart doesn't 
typically utilize absorption
enhancers","Penetration,physical, chem-
cal enhancer.","insulin detemir doesn't 
typically utilize absorption
enhancers",Warmth of the injection,NA,NA,NA,"Absorption enhancers are typically not used with Symlin (pramlintide), as it is administered via subcutaneous injection rather than oral administration.","Fiasp, typically does not require absorption
enhancers because it is formulated to have a 
rapid onset of action.",NA,NA,Absorption enhancers are typically used with oral medications to improve their absorption across the gastrointestinal tract,"Piperine, Quercetin",Not required,NA,NA,Percentage Bioavailability,78-89%,Moderate,High,~75%,~70%,70-90%,High,high,80-90%,high,high,95-100%,90%,~95%,95%,high,"Food, Histamine H2 receptors agonists",Cimetidine absorption can be enhanced by factors such as acidic environments in the stomach,acidic beverages like orange juice.,Cimetidine absorption can be enhanced by factors such as acidic environments in the stomach,acidic beverages like orange juice.,acidic beverages like orange juice,acidic beverages like orange juice.,acidic beverages like orange juice.,Acid beverages,Acid beverages,Acid beverages,Acid beverages,Acid beverages,Acid beverages,Acid beverages,"absorption enhancers for antibiotics is not a common practice, as their efficacy and safety may vary.","Plazomicin does not have a specific absorption enhancer associated with it. Its oral bioavailability is inherently low, and efforts to improve absorption may involve formulation strategies or co-administration with certain agents","Azithromycin is generally well-absorbed orally, and its absorption is not significantly enhanced by absorption enhancers.","Amoxicillin absorption can be enhanced by taking it with food. The presence of food in the stomach can increase the absorption of amoxicillin, leading to higher and more consistent blood levels.","Co-administration with food can enhance the absorption of some cephalosporins. It's important to note that the specific cephalosporin and its formulation can impact absorption, so the influence of absorption enhancers may vary among different drugs within the cephalosporin class.",NA,"Ampicillin is typically absorbed in the small intestine. Probenecid, an agent used to treat gout, has been shown to increase the blood levels of ampicillin by slowing its elimination and can act as an absorption enhancer when co-administered.","Sulfadiazine itself is generally well-absorbed from the gastrointestinal tract after oral administration. However, the addition of probenecid is sometimes used as an absorption enhancer for sulfadiazine.",NA,"The absorption of penicillin is generally effective without the need for specific absorption enhancers. However, certain factors can influenceEmpty Stomach: Some penicillins are recommended to be taken on an empty stomach for optimal absorption. However, others, like amoxicillin, can be taken with or without food.
Food Interactions: Certain foods or antacids containing divalent cations (e.g., calcium, magnesium) may interfere with the absorption of specific penicillins. It's advisable to follow healthcare provider instructions on timing and conditions for penicillin",The use of absorption enhancers for meropenem isn't common due to its intravenous administration.,Cephalexin is generally well-absorbed from the gastrointestinal tract without the need for absorption enhancers. The presence of food in the stomach may enhance the absorption of cephalexin.,"Ciprofloxacin is generally well-absorbed, and there isn't a specific absorption enhancer routinely used with it.",The area under the curve (AUC) of ceftolozane-tazobactam after an injected dose of 1 g/0.5 g every 8 hours for 1 day was 172 mcg•h/mL.,"Taking clarithromycin with food, especially a meal that includes fat, can enhance its absorption. The presence of food can increase the bioavailability of clarithromycin, meaning that more of the medication is absorbed into the bloodstream. This is particularly relevant for immediate-release formulations of clarithromycin.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,CYP3A4,NA,Not specified,P-Glycoprotein,NA,P-Glycoprotein,CYP3A4,CYP3A4,GABA.,CYP3A4,NA,NA,CYP3A4,NA,yes,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,not specified,Not specified,Not specified,Not specified,Not applicable,not specified,Not specified,Cytochrome P450 3A4,Not available,Not specified,Not available,Not available,CYP3A4,Not Available,Not Available,Not Available,Not Available,Cytochrome P450,Enterokinase,Not Available,Not Available,Not Available,absorbed in the gastrointestinal tract,NA,NA,"certain formulations or additives, can increase lidocaine absorption",absorbed in the small intestine.,no specific absorption enhancers,enhancers like cyclodextrins or lipid-based formulations,absorption enhancers such as food (especially high-fat meals),"absorption enhancers include certain foods, such as grapefruit juice,",Absorption enhancers like food can increase its bioavailability,Absorption enhancers like food or certain formulations can increase bioavailability,"Absorption enhancers, such as certain foods or drugs, can potentially increase its oral bioavailability",NA,NA,NA,not applicable,Not applicable,Not specified,not applicable,not specified,not applicable,not applicable,not applicable,n/a,not applicable,not available,not applicable,not applicable,not applicable,not specified,salicylic acid,may not be directly applicable,DMSO,antacids or proton pump inhibitors,these strategies are not typically employed.,depending on its formulation,no specific absorption enhancers known,no specific absorption enhancers known,no specific absorption enhancers known,no specific absorption enhancers known,no specific absorption enhancers known,no specific absorption enhancers known,no specific absorption enhancers known,There are no specific absorption enhancers associated with fludarabine because it is typically administered intravenously.,the focus in dacarbazine administration is on achieving appropriate distribution throughout the body and maximizing its therapeutic effects.,No,No,No,No,Yes,Yes,No,Yes,yes,Yes,No,No,Yes,No,No,NA,NA,NA,NA,NA,salicylic acid,NA,NA,NA,NA,NA,NA,"Benzalkonium chloride, known for its superior lipophilicity.","A benzodiazepine with a short duration of action is prescribed for the treatment of alcohol withdrawal, as well as for managing anxiety disorders and tension.",Hydroxyzine blocks the activity of histamine to relieve allergic symptoms such as pruritus., increased when it is combined with Aminophenazone.,enhanced iontropic delivery of it across human skin using cgemical enhancers,"A high-fat meal increases exposure to gepirone, with the effect increasing dependent on the amount of fat in the meal.",benzalkonium chloride,hydrocortisone and magnesium-aluminum hydroxide ,??pyridylamine/nanographene oxide regions., + 24°,NA,to relieve anxiety and to control agitation caused by alcohol withdrawal. ,Orlistat can cause a decrease in the absorption of Pentobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy.,the Treatment of Conditions of the Central Nervous System.,NA,70%,50%,63-74%,40%,14%,40-45%,22-30%,oral<1% rectal 1.3%,82%,90%,34%,40%,80%,38.40%,99.00%,approx 25%,70-85%,40%,33%,40% to 60%,50% to 90%,04.4+or - 18.5%,40%,36%,30-50%,40-50%,77%,approx 54%,40%,24.70%,55%. ,5.40%,28%.,30-45%,98%,80%,80% ± 20%.,30% to 40%,80-90%,80%,25%,40%,100%.,40 to 50% ,20-25%,70% to 90%,85-100%,50%,50-60%,90%,70-90%,90-100%.,50-90%,90-100%.,50-70%.,40-50%,75-95%.,1%.,80-90%,20-80%.,Percentage Bioavailability,0.5-1%,25-30%,over 90%,55%,82.60%,8% to 47%.,25–70%,NA,90%,less than 0.2%,45%,1.5-3%,1%,2%,methyl propionate,"food intake, PH Levels","Food, Gastric acidity, Gastrointestinal motility","gastrointestinal tract, factors such as food, gastric pH, or gastrointestinal motility","Lipophilic nature, Skin integrity, Topical formulations","Food, Cream solution, PH, Skin condition","Creams, Ointment, gels and suppositories","Cream, lotion, Optimized solubility","Fatty meals, acidic formulations,","Higher concentration, Hepatic metabolism, Acidic environment, Proper liver function","Fat, food, PH of the stomach","Skin cleanliness, Avoiding occlusive dressings",Clean and Dry skin,"Concentration, solubility, Skin integrity","Mucosal surface, Synergy with other ingredients","Food, Acidic environment, Liquid formulation",oral bioavailability is approximately 100%, a single oral dose bioavailabilty 100%,Approximately 60-70% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 30-40%,85%,64%,77%,"Moderate
bioavailability.",52%,80%,80%,75% under fasting conditions,52%,100% when taken orally.,NA,60-70%,100% when taken orally.,50%,20-30%,60-70%,100%,0.1 to 0.3%,4% to 5%.,10-20%,60-70%.,77%,50%.,52%.,95-100%.,64%,100%.,5-30%.,5-10%,NA,100%,1%,99%,NA,NA,High about 50%,100%,variable,NA,NA,high,NA,NA,NA,~45%,~92%,86%,~25%,~37%,Not applicable (administered intravenously),~54-73%,77% (approximate),Percentage Bioavailability,100%,100%,100%,100%,20-30%,70-80%,30-40%,100%,NA,40-60%,75-80%,100%,NA,20-305,60-80%,Percentage Bioavailability,96%,highly variable,100%,90%,55%,NA,90%,NA,not specified,NA,NA,NA,NA,NA,70%,50%,63-74%,40%,14%,40-45%,22-30%,oral<1% rectal 1.3%,82%,90%,34%,40%,80%,38.40%,99.00%,approx 25%,70-85%,40%,33%,40% to 60%,50% to 90%,04.4+or - 18.5%,40%,36%,30-50%,40-50%,77%,approx 54%,40%,24.70%,55%. ,5.40%,28%.,30-45%,98%,80%,80% ± 20%.,30% to 40%,80-90%,80%,25%,40%,100%.,40 to 50% ,20-25%,NA,Percentage Bioavailability,70% to 90%,85-100%,50%,50-60%,90%,70-90%,90-100%.,50-90%,90-100%.,50-70%.,40-50%,75-95%.,1%.,80-90%,20-80%.,NA,NA,NA,NA,NA,0.5-1%,25-30%,over 90%,55%,82.60%,8% to 47%.,25–70%,NA,90%,less than 0.2%,45%,1.5-3%,1%,2%,methyl propionate,NA,Absorption enhancers:,"food intake, PH Levels","Food, Gastric acidity, Gastrointestinal motility","gastrointestinal tract, factors such as food, gastric pH, or gastrointestinal motility","Lipophilic nature, Skin integrity, Topical formulations","Food, Cream solution, PH, Skin condition","Creams, Ointment, gels and suppositories","Cream, lotion, Optimized solubility","Fatty meals, acidic formulations,","Higher concentration, Hepatic metabolism, Acidic environment, Proper liver function","Fat, food, PH of the stomach","Skin cleanliness, Avoiding occlusive dressings",Clean and Dry skin,"Concentration, solubility, Skin integrity","Mucosal surface, Synergy with other ingredients","Food, Acidic environment, Liquid formulation",Percentage Bioavailability,oral bioavailability is approximately 100%, a single oral dose bioavailabilty 100%,Approximately 60-70% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Approximately 90-100% bioavailability,Percentage Bioavailability,Approximately 30-40%,85%,64%,77%,"Moderate
bioavailability.",52%,80%,80%,75% under fasting conditions,52%,100% when taken orally.,NA,60-70%,100% when taken orally.,50%,Percentage Bioavailability,20-30%,60-70%,100%,0.1 to 0.3%,4% to 5%.,10-20%,60-70%.,77%,50%.,52%.,95-100%.,64%,100%.,5-30%.,5-10%,Percentage Bioavailability,NA,100%,1%,99%,NA,NA,High about 50%,100%,variable,NA,NA,high,NA,NA,NA,~45%,~92%,86%,~25%,~37%,Not applicable (administered intravenously),~54-73%,77% (approximate),Percentage Bioavailability,100%,100%,100%,100%,20-30%,70-80%,30-40%,100%,NA,40-60%,75-80%,100%,NA,20-305,60-80%,96%,highly variable,100%,90%,55%,NA,90%,NA,not specified,NA,NA,NA,NA,NA,93%,NA,90-95%,90%,100%,100%,70-100%,90-100%,70-90%,80%,85%,100%,90%,85%,90%,NA,85%,90%,60-65%,98%,87%,35%,52%,60%,100%,9-19%,70-80%,6.5% to 7.2%,High,60%,60-70%,women is 0.64% and in men is 0.59%,2%,0.63%,0.63%,100%,6%,1-2%,1-10%,100%,20-25%,95%,36%,"71% (subcutaneous injection), 66% (I.M), 3 to 5%(nasal route)",NA,50 to 70%,Once,Once,Once,Weekly,Once,Twice,once or twice,Twice,Typically once daily,single daily dose or divided into two doses.,once a week,Once to several times daily,Once daily,two 80-mg injections in 1 day or as one 80-mg injection per day for 2 consecutive days.,Varies (typically once every 2-4 weeks),NA,"vary depending on formulation, bioavailability of imiquimod cream applied topically is low i.e 5%",28-100%,31.80%,31%,64%,80%,50%,85%,46%,95%,90%,20%,between 32 and 115% (mean 64%) ,NA,NA,62% ±17% (parenteral) < 30–55% (oral),bioavailability of 77–93%,nearly 100% oral bioavailability.,less than 1% bioavailable,95% for imipenem and 75%, poor bioavailability., bioavailability of less than 10%. ,34.50%," 52.3%, 47.9%, ",85%,91.80%," 85.47% and 67.89%,", 82.3 (±15)%,s was less than 1%.,40-50%,25%,>95%,10-20%,10-20%,30-40%,50%,46-60%,20-30%,40%,64-90%,75-80%,40-77%,20%,37-66%,"Gastric PH,Certain food and beverages","Antaacid, Food interaction, Calcium rich food","Iron supplement ,Antacid",Calciuum containing proucts such as dairy product and anatacid,"Empty stomach intake, divalent cations interaction, avoid calcium rich product",NA,"Antacids containing aluminum or magnesium, sucralfate, metal cations",Not specific,Not applicaple,"Antacid, calcium, magnesium, iron supplement",NA,"Medium chain fatty acid, phospolipid,",Noneed,"Calcium supplement, iron supplement, antacid,cholestyramine",No,No,No,No,No,No,No,NA,NA,NA,NA,NA,NA,NA,Food enhances the absorption of misoprostol.,NA,Oral inhalation 4% to 17%,<3%,80%,83%,10-20%,55%,80%,(<5%) oral bioavailability, 30% to 60%,80–122%, 39%,>70%,60% to 68%,26%, 60-74% ,Highly variable (40-90%),High (75-85%),High,Approximately 98%,Nearly 100%,Approximately 80%,95%,Approximately 90%,Approximately 90%,Approximately 60-70%,Not specified,Not specified,~60%,~100%,Approximately 90%,Highly variable (40-90%),High (75-85%),High,Approximately 98%,Nearly 100%,Approximately 80%,95%,Approximately 90%,Approximately 90%,Approximately 60-70%,Not specified,Not specified,~60%,~100%,Approximately 90%
Absorption inhibitors,"Antacids, PPIs and H2 blockers","Activated charcoal, AlOH3, MgOH3, PPIs, CaCO3","Antacids, PPIs,alcohol, H2 receptor antagonists",PPIs,"Ketoconazole, Clarithromycin, Ritonavir, Grapefruit juice","Grapefruit Juice, Acidic beverages, antacids","Antacids,PPIs,Calcium salts,Antidiabetic agents","Benzodiazepines, alcohol, Buprenorphine,Levamisole","Calcium, high-fiber foods, fats, medications","Acidity, CYP450 inhibitors, Stomach pH modifiers","Fluoxetine, Paroxetine, Duloxetine, Bupropion",high-fat meals may delay the absorption of phentermine,"Food, gastric pH modifiers, drug-drug interactions","PPIs, antacids (not specific)",Not specified,NA,Not specified,Not specified,Not specified,Not specified,Not applicable,Not specified,Not specified,Not specified,Not specified,Not applicable,Not applicable,Not specified,Not specified,Tissue distribution:,"Brain,liver,adipose","Brain,liver,adipose","Brain,liver,adipose","Brain,liver,adipose","Brain,liver,adipose","Brain,liver,adipose","Brain,liver,adipose","Brain,liver,adipose","Brain,liver,adipose","Brain,liver,adipose","Brain,liver,adipose","Brain,liver,adipose, Crosses placenta, enters breast milk","Brain,liver,adipose, Crosses placenta, enters breast milk","Brain,liver,adipose",Not specified,Not applicable,Not specified,Not specified,NONE,Not specified,Not applicable,Not specified,Not applicable,Not applicable,Not specified,Not applicable,Absorption inhibitors:,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption inhibitors:,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"aluminum, magnesium,calcium","Calcium , High-fat meals",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Specific absorption inhibitors for Azathioprine are not widely reported. Absorption inhibitors are substances that may decrease the absorption of a drug, potentially leading to reduced bioavailability.",certain substance such as Chiestyramine and Activated charcol can reduce the absorption of fat soluble drugs,NA,"1] Nonsteroidal anti-inflammatory drugs (NSAIDs) - aspirin, ibuprofen, diclofenac, naproxen, piroxicam and etoricoxib. 2] Probenecid: Probenecid, a uricosuric agent, may decrease the renal clearance of Methotrexate.","calcium containing product, such as ntacid, and food high in calcium can interfere with its absorption","commonly use with cyclosporine, its worth noting that certain subs or condition that effect the function of pgp or cyt p450 may influence cylosporin absorption",NA,"In the context of betamethasone, there might not be specific absorption inhibitors commonly used. However, factors such as certain foods or drugs may affect the absorption of betamethasone when taken orally",NA,Specific absorption inhibitors are not typically associated with Tazarotene,: Specific absorption inhibitors are not commonly described for Pimecrolimus.Distribution,not applicable,no applicable,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption inhibitors:,"Lipohypertrophy, Scar tiss-
ue, cold injection sites","Insulin degradation,Lipohyp
ertrophy, scar tissue","Lipohypertrophy, depth of 
injection,poor injection technique.","Lipohypertrophy, depth of 
injection,poor injection 
technique.","injection technique, site of injection, 
local blood flow","Lipohypertrophy, depth of 
injection,poor injection 
technique.","injection technique, site of injecti
on, local blood flow","Factors such as gastrointestinal motility, pH
levels, and food intake can influence how Sym-
lin is absorbed","Fiasp does not typically contain absorption 
inhibitors.",NA,NA,NA,NA,NA,NA,NA,Absorption enhancers:,Sodium salicylate 20% (W/W),with food,sodium laruryl sulfate,with food,NA,NA,NA,NA,NA,NA,bile salts,"bile salts,Organic acids,Cyclodextrins","bile salts,Organic acids,Cyclodextrins","bile salts,Organic acids,Cyclodextrins","bile salts,Organic acids,Cyclodextrins","Antacids,protein pump inhibitors(PPI)","administration of antacids, proton pump inhibitors (PPIs)","antacids or proton pump inhibitors, may decrease famotidine absorption.","administration of antacids, proton pump inhibitors (PPIs)",antacids or proton pump inhibitors,"antacids or proton pump inhibitors, may decrease cisapride absorption.","PPI, antacids",Antacids,proton pump I nhibitors,proton pump Inhibitors,Antacids,(PPI),proton pump Inhibitors,Antacids,proton Inhibitor pumps,"There aren't specific absorption inhibitors for amikacin, as it's primarily administered intravenously or intramuscularly.",absorption inhibitors is not commonly associated with this antibiotic.,"The absorption of azithromycin can be hindered by the concurrent administration of antacids containing aluminum or magnesium. To optimize absorption, it's advisable to separate the administration of azithromycin and antacids by at least 1-2 hours.","Calcium-containing products, such as antacids or supplements, can inhibit the absorption of amoxicillin.","Absorption inhibitors of cephalosporins are not commonly identified, as these antibiotics are generally well-absorbed after oral administration. However, certain factors or substances may interfere with their absorption. Calcium-containing products, such as antacids or dietary supplements, can form chelates with some cephalosporins, potentially reducing their absorption.",NA,"Calcium-containing products (e.g., antacids, dairy) and food can reduce the absorption of ampicillin. Therefore, it's generally recommended to take ampicillin on an empty stomach, preferably 1 hour before or 2 hours after a meal, to optimize absorption.","Sulfadiazine absorption can be affected by certain substances or conditions that act as absorption inhibitors. Calcium-containing products, such as antacids or dairy products, can interfere with the absorption of sulfadiazine. It's advisable to avoid taking sulfadiazine concurrently with these products",NA,The concept of absorption inhibitors for antidotes to penicillin isn't commonly applicable.,"Meropenem is typically administered intravenously, so absorption inhibitors are not relevant in this","Calcium-containing products, such as antacids, can potentially reduce the absorption of cephalexin. It's advisable to avoid taking cephalexin with calcium-rich supplements or antacids containing calcium.","The absorption of ciprofloxacin can be significantly reduced when taken concurrently with certain divalent cations, such as magnesium, calcium, or aluminum. These cations are found in various antacids, supplements, and certain multivitamins. It is advisable to avoid taking ciprofloxacin together with these products to prevent interference with its absorption.",NA,"Proton pump inhibitors (PPIs) and H2 blockers are known to reduce the absorption of clarithromycin when co-administered. These medications decrease gastric acidity, which can impact the absorption of clarithromycin. Therefore, it's generally recommended to avoid taking clarithromycin with these acid-reducing agents.",NASIDs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,P-Glycoprotein,Not specified,Not specified,CYP3A4,NA,CYP3A4,NA,NA,NA,NA,NA,NA,NA,NA,no,Not specified,Not applicable,Not specified,Not specified,Not specified,Not specified,Not specified,not specified,Not specified,Not specified,Not specified,Not applicable,Not specified,Not specified,Gastric Lipase,Not available,Not specified,Not available,Not available,Cytochrome P450 2D6,CYP3A4,Not Available,Not Available,Not Available,Cytochrome P450,Pepsin,Not Available,Not Available,Not Available,absorption inhibitor of quinidine is aluminum hydroxide,NA,NA,"Inhibitors, on the other hand, may reduce absorption, potentially altering the effectiveness of the drug",affecting gastrointestinal pH,no specific inhibitor enhancer,Adenosine's absorption inhibitors are not extensively studied,"absorption inhibitors such as antacids,kaolin-pectin, and certain drugs like cholestyramine and neomycin",absorption inhibitors can decrease the bioavailability of verapamil by inhibiting its absorption in the gastrointestinal tract,absorption inhibitors like grapefruit juice can decrease it.,absorption inhibitors like antacids can decrease it.,absorption inhibitors may decrease it.,no specific absorption inhibitors,absorption may be decreased by co-administration with antacids containing aluminum or magnesium hydroxide.,NA,not applicable,Not applicable,Not specified,not applicable,not specified,not applicable,not applicable,not applicable,n/a,not applicable,not available,not applicable,not applicable,not applicable,not specified,neomycin paromomoycin,"urea, and propylene glycol.",not relevant,antacids or proton pump inhibitors,hese strategies are not typically employed.,anticholinergic agents or opioid analgesics.,proton pump inhibitors or antacids.,proton pump inhibitors or antacids.,decreases levels of digoxin by inhibition of GI absorption. ,proton pump inhibitors or antacids.,proton pump inhibitors or antacids.,proton pump inhibitors or antacids.,proton pump inhibitors or antacids.,"Fludarabine absorption may be reduced by drugs that contain cations, such as oral calcium or magnesium supplements. These should be taken at least two hours before or after fludarabine.","There are no specific absorption inhibitors for dacarbazine, but certain factors can affect its absorption and bioavailabilit",No,No,No,No,No,No,No,No,No,No,No,Yes,No,No,No,No specific as administered intravenously.,No specific because it does not undergo oral absorption.,NA,NA,NA,neomycin and paromomycin ,NA,NA,NA,NA,NA,NA,small doses of theophylline may inhibit the action of diazepam,NA,"Hydroxyzine functions as an antihistamine by inhibiting the actions of histamine, a naturally occurring substance generated by the body.",propranolol-induced changes in the disposition of other drugs or in effects of the other drugs on the pharmacokinetics of propranolol. ,ketoconazole\rotonavir,NA,action in the amygdala is baneficial in anxiety disorders, clonidine inhibits Na:H exchange in crypt cells.,ketoconazole and itraconazole,NA,seizures, neurotransmitter GABA,"by inhibiting glutamate,which is respomsible for the nerve depolarisation",IV anesthetic induction agent, selective inhibition of the neuronal high affinity uptake of serotonin. ,NA,DMSO,TC,Azone,NA,rizatriptan benzoate,NA,Isosorbide dinitrate,NA,alkane or alkanol,antiserotonin,NA,NA,NA,DL-Caf,minimum metabolism by the gastrointestinal mucosa,from gastrointestinl,not significantly enhanced,erythromycin,not significantly enhaced,well absorbed from gut,urine and feces,NA,exipients effects,food effects,well absorbed by orally,no specific,surfactants,absorbed well,rapidly absorbed in nasal mucosa,NA,NA,NA,NA,NA, propyl and butyl compounds,NA,NA,NA,NA,NA,NA,NA, chitosan based polymeric nanoparticles,NA,",Iron,Sugar Transporters,Low pH Environment:","Foods rich in folate, such as leafy greens, legumes, and fortified grains. Absorption can also be enhanced by vitamin C.","Intrinsic factor, a glycoprotein produced in the stomach, is essential for B12 absorption. Animal products, such as meat, fish, and dairy, are natural sources of B12.","Tryptophan, an amino acid found in protein-rich foods, can be converted to niacin. Foods like poultry, fish, and nuts contribute to niacin intake.","Riboflavin absorption is facilitated by the presence of other B-vitamins. Dairy products, eggs, and lean meats are good sources of riboflavin.","Thiamine absorption is influenced by alkaline conditions in the small intestine. Whole grains, nuts, seeds, and pork are good sources of thiamine.","Choline absorption is generally efficient, but it can be found in foods like eggs, meat, and liver.","Vitamin D is fat-soluble, so its absorption is enhanced when consumed with dietary fats. Foods rich in vitamin D include fatty fish, fortified dairy products, and exposure to sunlight.","Biotin is found in a variety of foods, including eggs, nuts, seeds, and certain vegetables.","Pantothenic acid is widely distributed in foods, with good sources including meat, legumes, and whole grains.","Lutein is found in leafy green vegetables like kale, spinach, and broccoli. Consuming these foods with a small amount of fat may enhance absorption.","Astaxanthin is commonly found in seafood, especially in salmon and shrimp.","Resveratrol is present in grapes, berries, and red wine. Its absorption may be enhanced when consumed with a small amount of fat","Vitamin K1 is found in green leafy vegetables like kale, spinach, and broccoli. Consuming these foods with dietary fat can aid absorption.","Vitamin E is fat-soluble, so consuming it with dietary fats enhances absorption. Nuts, seeds, and vegetable oils are good sources.",Absorption enhancers:,combination of sodium lauryl sulphate ,"Nitrate cream,",Sodium deoxycholate,cyclodextrins,Lactose,cyclodextrins,ethyl acetoacetate,Cyclodextrins,Bile salts,NA,NA,NA,NA,NA,NA,"Antacids, food, beverages","Gastric acid reducing agent, Antacids","Liver dysfunction, Albumin level",NA,"Impaired skin integrity, barrier creams,medication interaction,","Optimal solubility, PH of the formulation","Impaired skin integrity, Certain skin condition","Alkaline environment, impaired liver function","Gastric acidity, impaired liver function","Antacid, Gastric PH","Excessive moisture, Thickened Skin or Nails",Blood circulation and Dry Skin,"Low skin permeability, High molecular weight, Low concentration","Low gastrointestinal absorption, Skin penetration","Low fat diet, Antacid",the secretion of insulin granules from pancreatic islet beta cells by blocking ATP-sensitive potassium channels ,sensitize pancreatic beta cells and stimulate insulin release,PEG 6000,olbutamide is detectable in plasma 30-60 minutes, enhance AVP stimulation of renal medullary cAMP by augmenting adenylate cyclase sensitivity to AVP,activity of hypersensitive site 2 of the beta-globin locus control region.,"ncrease absorption by enhancing membrane permeation,",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,not require,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Yes,NA,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,NA,NA,NA,NA,NA,NA,NA,NA,NA,none,NA,NA,not applicable,not specified,NA,NA,NA,Not specified,Not specified,Not specified,Not specified,Not specified,Not applicable,Not specified,Not specified,Absorption enhancers,"surfactants,bile salt",No,"Polysorbate 80, Hydroxypropyl cellulose,Propylene glycol",NA,"food interaction, drug interaction",administration with water,NA,NA,NA,intracranially,food intake,bloodstrem,enhancers,interactions with other medications,folate supplementation,Absorption enhancers:,NA,NA,NA,NA,food and acidic,NA,NA,NA,not specified,NA,NA,NA,NA,NA,NA,DMSO,TC,Azone,NA,rizatriptan benzoate,NA,Isosorbide dinitrate,NA,alkane or alkanol,antiserotonin,NA,NA,NA,DL-Caf,minimum metabolism by the gastrointestinal mucosa,from gastrointestinl,not significantly enhanced,erythromycin,not significantly enhaced,well absorbed from gut,urine and feces,NA,exipients effects,food effects,well absorbed by orally,no specific,surfactants,absorbed well,rapidly absorbed in nasal mucosa,NA,NA,NA,NA,NA, propyl and butyl compounds,NA,NA,NA,NA,NA,NA,NA, chitosan based polymeric nanoparticles,NA,NA,Absorption enhancers:,",Iron,Sugar Transporters,Low pH Environment:","Foods rich in folate, such as leafy greens, legumes, and fortified grains. Absorption can also be enhanced by vitamin C.","Intrinsic factor, a glycoprotein produced in the stomach, is essential for B12 absorption. Animal products, such as meat, fish, and dairy, are natural sources of B12.","Tryptophan, an amino acid found in protein-rich foods, can be converted to niacin. Foods like poultry, fish, and nuts contribute to niacin intake.","Riboflavin absorption is facilitated by the presence of other B-vitamins. Dairy products, eggs, and lean meats are good sources of riboflavin.","Thiamine absorption is influenced by alkaline conditions in the small intestine. Whole grains, nuts, seeds, and pork are good sources of thiamine.","Choline absorption is generally efficient, but it can be found in foods like eggs, meat, and liver.","Vitamin D is fat-soluble, so its absorption is enhanced when consumed with dietary fats. Foods rich in vitamin D include fatty fish, fortified dairy products, and exposure to sunlight.","Biotin is found in a variety of foods, including eggs, nuts, seeds, and certain vegetables.","Pantothenic acid is widely distributed in foods, with good sources including meat, legumes, and whole grains.","Lutein is found in leafy green vegetables like kale, spinach, and broccoli. Consuming these foods with a small amount of fat may enhance absorption.","Astaxanthin is commonly found in seafood, especially in salmon and shrimp.","Resveratrol is present in grapes, berries, and red wine. Its absorption may be enhanced when consumed with a small amount of fat","Vitamin K1 is found in green leafy vegetables like kale, spinach, and broccoli. Consuming these foods with dietary fat can aid absorption.","Vitamin E is fat-soluble, so consuming it with dietary fats enhances absorption. Nuts, seeds, and vegetable oils are good sources.",NA,NA,NA,NA,NA,combination of sodium lauryl sulphate ,"Nitrate cream,",Sodium deoxycholate,cyclodextrins,Lactose,cyclodextrins,ethyl acetoacetate,Cyclodextrins,Bile salts,NA,NA,NA,NA,NA,NA,NA,Absorption inhibitors:,"Antacids, food, beverages","Gastric acid reducing agent, Antacids","Liver dysfunction, Albumin level",NA,"Impaired skin integrity, barrier creams,medication interaction,","Optimal solubility, PH of the formulation","Impaired skin integrity, Certain skin condition","Alkaline environment, impaired liver function","Gastric acidity, impaired liver function","Antacid, Gastric PH","Excessive moisture, Thickened Skin or Nails",Blood circulation and Dry Skin,"Low skin permeability, High molecular weight, Low concentration","Low gastrointestinal absorption, Skin penetration","Low fat diet, Antacid",Absorption enhancers:,the secretion of insulin granules from pancreatic islet beta cells by blocking ATP-sensitive potassium channels ,sensitize pancreatic beta cells and stimulate insulin release,PEG 6000,olbutamide is detectable in plasma 30-60 minutes, enhance AVP stimulation of renal medullary cAMP by augmenting adenylate cyclase sensitivity to AVP,activity of hypersensitive site 2 of the beta-globin locus control region.,"ncrease absorption by enhancing membrane permeation,",NA,NA,NA,NA,NA,NA,NA,NA,Absorption enhancers:,NA,NA,NA,not require,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption enhancers:,Yes,Yes,NA,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,NA,NA,Absorption enhancers:,NA,NA,NA,NA,NA,NA,NA,none,NA,NA,not applicable,not specified,NA,NA,NA,Not specified,Not specified,Not specified,Not specified,Not specified,Not applicable,Not specified,Not specified,Absorption enhancers,"surfactants,bile salt",No,"Polysorbate 80, Hydroxypropyl cellulose,Propylene glycol",NA,"food interaction, drug interaction",administration with water,NA,NA,NA,intracranially,food intake,bloodstrem,enhancers,interactions with other medications,folate supplementation,NA,NA,NA,NA,food and acidic,NA,NA,NA,not specified,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Empty Stomach, Water& Upright Position",Food,"Empty Stomach, & Water","Empty Stomach, & Water",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Baricitinib is a selective and reversible inhibitor of JAK1 and JAK2 with less affinity for JAK3 and TYK2,Tofacitinib is a partial and reversible janus kinase (JAK) inihibitor that will prevent the body from responding to cytokine signals,"It works by inhibiting the Janus Kinases (JAKs), which are essential downstream cell signalling mediators of pro-inflammatory cytokines.","Inhibtion of cytokine production, chemotaxis and cell-mediated immune reaction. Proliferation of immune-inflammatory cells is inhibited.",This immunomodulator inhibits proliferation of stimulated lymphocytes in patients with active RA.,sulfasalazine inhibits leukotrienes and prostaglandins by blocking the cyclo-oxygenase and lipoxygenase pathway.,"Inhibition of purine synthesis, along with inhibition of B and T cells.",inhibition of antigen/mitogen-induced secretion of lymphokines at the transcriptional level from T cell., interference of lysosomal activity and autophagy.,the interference of lysosomal activity and autophagy.,It inhibits TNF-alpha,Prednisone decreases inflammation via suppression of the migration of polymorphonuclear leukocytes and reversing increased capillary permeability,Anakinra is an interleukin-1 receptor antagonist,Monoclonal antibody targeting tumor necrosis factor alpha (TNF-?),"Tocilizumab binds soluble and membrane bound IL-6 receptors, preventing IL-6 mediated inflammation.",NA,No (its primary function is an immune system modifier),It is not primarily known as absorbtion enhancer,it is not typically refferd as absorbtion enhancer,No,no,no,NO, no,no,no,no,no,no,no,NA, AM-C10-enhanced absorption of ampicillin, Nigella was found to be efficient absorption enhancer for amoxicillin, rapidly absorbed in the upper intestine.," Ceftriaxone, available only for injection, needs absorption enhancers to achieve adequate bioavailability via nonparenteral administration.",Absorption enhancers are functional excipients included in formulations to improve the absorption of a pharmacologically active drug.,Imipenem and meropenem are not absorbed orally,Orally-administered vancomycin is poorly absorbed,t absorption of omadacycline in the rat was rapid and bioavailability was low. The poor absorption,"— Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers"," Tiamulin administered at therapeutic levels is relatively quickly absorbed, metabolized in the liver, and eliminated",ustained-release nanoparticles may improve the residence time and hence increase absorption of the drug from the corneal surface,piperacillin and application to the development of charged liposaccharides as oral penetration enhancers,Compassionate use of a novel ?-lactam enhancer-based investigational antibiotic cefepime ,Ceftaroline (600 mg intravenously every 12 hours) has been shown effective in phase III studies in the treatment of complicated skin and soft tissue,Grapefruit juice,Empty stomach,Empty stomach,None,None,Lipid based formulation,None,None,Grapejuice,Food,With or without food,With food,Lipid based formulation,High fat meal,With foods,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,No,No,No,No,No,NA,NA,NA,NA,NA,NA,NA,NA,NA,Does not require,Does not require,Does not require,Does not require,Does not require,Does not require,Does not require,Does not require,Does not require,Does not require,Does not require,Does not require,Does not require,Does not require,Does not require,NA,CYP3A4,NA,Not specified,P-Glycoprotein,NA,P-Glycoprotein,CYP3A4,CYP3A4,GABA.,CYP3A4,NA,NA,CYP3A4,NA,NA,CYP3A4,NA,Not specified,P-Glycoprotein,NA,P-Glycoprotein,CYP3A4,CYP3A4,GABA.,CYP3A4,NA,NA,CYP3A4,NA
Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Widely distributed,Widely distributed,Extensively distributed,Widely distributed in the body,Widely distributed in tissues,Widely distributed in the body,Widely distributed in the body,Widely distributed in the body,Widely distributed in the body,Widely distributed,Extensive,Widely distributed in tissues,Widely distributed in the body,Widely distributed in the body,Widely distributed in tissues,Blood-brain barrier penetration:,crosses BBB,crosses BBB,crosses BBB,crosses BBB,crosses BBB,crosses BBB,crosses BBB,crosses BBB,crosses BBB,crosses BBB,crosses BBB,crosses BBB,crosses BBB,crosses BBB,crosses BBB,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,98%,>99%,97%,91%,97%,90.00%,95%,94.00%,89 to 98%,<10%,81%,66%,95%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,hi,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption inhibitors:,Aluminium in 1M HCL,antacids,"proton pump inhibitors, h2 receptor antagonists,antacids",high-fat meals,high-fat meals,antacids or proton pump inhibitors,antacids or proton pump inhibitors,gastrointestinal motility or gastric acidity,gastric acidity,high-fat meals,NA,"Calcium-containing products,Aluminum-containing antacids,Proton pump inhibitors",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Widely distributed in tissues,Widely distributed in tissues,Widely distributed in body tissues,Widely distributed in tissues,"Widely distributed in the body, including crossing the blood-brain barrier",Widely distributed in tissues,Widely distributed in the body,Widely distributed in the body,Widely distributed in tissues,Widely distributed in the body,Widely distributed in the body,Widely distributed,Widely distributed in the body,Widely distributed in tissues,Widely distributed in tissues,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Widely distributed,Widely distributed,Widely distributed in the body,Widely distributed,Widely distributed,Widely distributed,Widely distributed in the body,Widely distributed in tissues,Widely distributed in the body,Widely distributed,Widely distributed,Widely distributed in tissues,Widely distributed,Widely distributed,Extensively distributed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"distributed widely in the body.It enters cells through an active transport mechanism, particularly into rapidly dividing cells.","distribute widely throughout the body. It is found in various tissues, including the liver, kidneys, and bone marrow. It is important in the treatment of certain cancers as it can reach and affect rapidly dividing cells in different organs.","distribute widely throughout the body. It is found in tissues, including the liver, kidneys, and bone marrow. The drug can cross the blood-brain barrier, which is important in its efficacy against certain cancers, especially those involving the central nervous system.","widely distributed in body It is known to accumulate in tissues, with higher concentrations observed in the liver and kidney.","It is distributed throughout the body, with higher concentrations in tissues like the liver and spleen.","distributed widely in the body, with higher concentrations observed in tissues such as the liver, kidney, and spleen drug can cross bbb and enter the cerebrospinal fluid","various tissues, including the bone marrow, lymph nodes, and spleen tissues beyond the bloodstream.","distributed widely in the body.crosses the blood-brain barrier, making it effective in the treatment of brain tumors.","distributed widely throughout the bodydrug penetrates into tissues, including the liver, kidneys, and bladder..","The distribution of streptozocin within the body is influenced by factors such as blood flow, tissue perfusion, and the presence of binding proteins. Streptozocin may also undergo reversible binding to plasma proteins, although the extent of protein binding is relatively low.",Etoposide distributes widely throughout the body,"Chlorambucil distributes widely throughout the body following absorption. It crosses cell membranes and can reach various tissues, including tumor cells. The distribution of chlorambucil throughout the body is facilitated by its relatively small molecular size and lipophilic nature",distributes widely throughout the body,"It distributes widely into tissues, including the bone marrow, where it exerts its cytotoxic effects on lymphocytes.","Dacarbazine distributes widely throughout the body, entering various tissues and organs.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,hydrobromide,NA,cimentidin and aspirin.,NA,readily absorbed,NA,NA,NA,CYP2D6,NA,NA,NA,NA,polyphenol,aluminium hydroxide,not affected,affected by taking with grape juice,ketoconazole,chlorpheniramine,Antidr=epressants,citirizine hydrochloride,azelastine hydrochloride,levodopa,antacids,antacids,no widely recognized inhibitor,no widely recognized inhibitor,no widely recognized inhibitor,no widely recognized inhibitor,gastrointestinal pH,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,",Copper Supplements, High Doses of Zinc, Antacids (Aluminum and Magnesium), Cooking and Food Processing, Alcohol Consumption, Smoking","Alcohol, certain medications (e.g., methotrexate, sulfasalazine), and high doses of zinc and iron supplements","PPIs (proton pump inhibitors), H2 blockers (histamine H2-receptor antagonists), and certain medications for diabetes.","Alcohol, high doses of aspirin, and certain cholesterol-lowering medications.",NA,"High doses of caffeine, raw fish, and certain medications (e.g., diuretics).",NA,"Certain medications that interfere with fat absorption (e.g., orlistat), and mineral oil.",NA,NA,NA,NA,NA,"Certain medications that interfere with fat absorption (e.g., orlistat).",High doses of iron supplements.,Absorption inhibitors:,Formulation & physiological factors, liver enzymes,Antacids,Rifampicin,Small intestine,Skin,cancer cell division,Small intestine,GI Tract,Liver,Liver,skin,skin,liver,GI Tract,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"not
significantly affected",NA,NA,NA,NA,"Calcium, aluminum, magnesium, iron, and zinc- containing preparations, as well as antacids, can impair absorption",NA,NA,NA,NA,NA,NA,No,Yes,No,Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Yes,NA,NA,NA,NA,NA,NA,NA,none,NA,NA,not applicable,not specified,NA,NA,NA,Not specified,Not specified,Not specified,Not specified,Not specified,Not applicable,Not specified,Not specified,Absorption inhibitors:,No,No,oral formulations,No,No,No,"food intake,other medication",gastrointestinal tract,No,intravenous or intracranial,food intake,intravenous,carmustine,carmustine,"food , antacids",Absorption inhibitors:,NA,NA,NA,NA,antacids,NA,NA,NA,not specified,NA,NA,NA,NA,NA,NA,hydrobromide,NA,cimentidin and aspirin.,NA,readily absorbed,NA,NA,NA,CYP2D6,NA,NA,NA,NA,polyphenol,aluminium hydroxide,not affected,affected by taking with grape juice,ketoconazole,chlorpheniramine,Antidr=epressants,citirizine hydrochloride,azelastine hydrochloride,levodopa,antacids,antacids,no widely recognized inhibitor,no widely recognized inhibitor,no widely recognized inhibitor,no widely recognized inhibitor,gastrointestinal pH,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption inhibitors:,",Copper Supplements, High Doses of Zinc, Antacids (Aluminum and Magnesium), Cooking and Food Processing, Alcohol Consumption, Smoking","Alcohol, certain medications (e.g., methotrexate, sulfasalazine), and high doses of zinc and iron supplements","PPIs (proton pump inhibitors), H2 blockers (histamine H2-receptor antagonists), and certain medications for diabetes.","Alcohol, high doses of aspirin, and certain cholesterol-lowering medications.",NA,"High doses of caffeine, raw fish, and certain medications (e.g., diuretics).",NA,"Certain medications that interfere with fat absorption (e.g., orlistat), and mineral oil.",NA,NA,NA,NA,NA,"Certain medications that interfere with fat absorption (e.g., orlistat).",High doses of iron supplements.,NA,NA,NA,NA,NA,Formulation & physiological factors, liver enzymes,Antacids,Rifampicin,Small intestine,Skin,cancer cell division,Small intestine,GI Tract,Liver,Liver,skin,skin,liver,GI Tract,NA,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption inhibitors:,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absorption inhibitors:,NA,NA,NA,"not
significantly affected",NA,NA,NA,NA,"Calcium, aluminum, magnesium, iron, and zinc- containing preparations, as well as antacids, can impair absorption",NA,NA,NA,NA,NA,NA,Absorption inhibitors:,No,Yes,No,Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Yes,Absorption inhibitors:,NA,NA,NA,NA,NA,NA,NA,none,NA,NA,not applicable,not specified,NA,NA,NA,Not specified,Not specified,Not specified,Not specified,Not specified,Not applicable,Not specified,Not specified,Absorption inhibitors:,No,No,oral formulations,No,No,No,"food intake,other medication",gastrointestinal tract,No,intravenous or intracranial,food intake,intravenous,carmustine,carmustine,"food , antacids",NA,NA,NA,NA,antacids,NA,NA,NA,not specified,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Calcium and Minerals, antacids, proton pump inhibitors (PPIs), and H2 blockers.",Cholestyramine & Estrogen-containing products,"Calcium and Minerals, antacids, proton pump inhibitors (PPIs), and H2 blockers.","Calcium and Minerals, antacids, proton pump inhibitors (PPIs), and H2 blockers.",NA,NA,NA,Calcium and certain minerals,NA,"Food, milk and derivative products, and medicines containing calcium",NA,NA,NA,NA,NA,Anti Rheumatic Drug,Anti Rheumatic drugs,Anti Rheumatic Drug,Anti Rheumatic drug,Anti Rheumatic drugs,Anti Rheumatic drugs,Anti Rheumatic drug,Anti Rheumatic drug,Non biological DMARDs and anti malarial,Non biological DMARDs and anti malarial,"Anti-inflammatory, TNF-alpha inhibitor","anti rheumatic, Corticosteroid, anti-inflammatory",Anti Rheumatic IL 1 antagonist,TNF alpha inhibitors anti rheumatic,Anti Rheumatic drugs,NA,it is immune system modifier,No,NO,no,no,no,It is MEK inhibitor,no,no,no,no,no,no,no,NA, sulbactam is a ?-lactamase inhibitor.,amoxicillin was a mixed type inhibitor of the enzyme,Cephalexin is not absorbed in the stomach but is absorbed in the upper intestine.,inhibiting the mucopeptide synthesis in the bacterial cell wall,cell wall synthesis of various gram-positive and gram-negative bacteria. , cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative,inhibits cell wall biosynthesis by targeting the d-Ala-d-Ala terminus of peptidoglycan (PG).,"omadacycline is a protein synthesis inhibitor that ... Absorption may be impaired by antacids containing aluminum, calcium","omadacycline is a protein synthesis inhibitor that ... Absorption may be impaired by antacids containing aluminum, calcium",The antibiotic tiamulin is a potent inducer and inhibitor of cytochrome P4503A via the formation of a stable metabolic intermediate complex. ,moxifloxacin to be a potent inhibitor of MATE1- and MATE2K-mediated metformin transport and identified ethambutol,Absorption and distribution. The components are not absorb.,Cefepime is not well absorbed by the gastrointestinal tract and must be administered intravenously (IV) or intramuscularly (IM),The absorption of ceftaroline has been analyzed in healthy adults. The prodrug ceftaroline fosamil acetate (CFA) and inactivated ceftaroline ,Sildenfil,Antacids,High fat meals,None,Lipid rich food,Antacids,Gastric ph,Antacids,High fiber foods,Grapefruit juice,Grapefruit juice,Antacids,Grapefruit juice,Grapefruit juice,Antacids and dairy products,20%,10-15%,88%,37%,20-67%,93%,24-38%,Negligible,85%,80-90%,20%,28-86%,2%,60%,Less than 10%,Widely distributed throughout the body.,Widely distributed throughout the body,Widely distributed throughout the body,Widely distributed throughout the body,Widely distributed throughout the body,Widely distributed throughout the body,"Widely distributed throughout the body, including in the gastric mucosa.",Widely distributed throughout the body.,Widely distributed throughout the body.,Widely distributed throughout the body.,Widely distributed throughout the body.,"Widely distributed throughout the body, with some affinity for muscarinic receptors in the gastrointestinal tract.","Widely distributed throughout the body, with some affinity for muscarinic receptors in the gastrointestinal tract.","Widely distributed throughout the body, but its distribution into the central nervous system is limited.","Widely distributed throughout the body, with some affinity for gastric mucosa.",Does not require,Inhibitors are not applicable,Proton Pump Inhibitor,Proton Pump Inhibitor,Proton Pump Inhibitor,Does not require,Proton Pump Inhibitor,Does not require,Proton Pump Inhibitor,Proton Pump Inhibitor,Does not require,Does not require,Does not require,Proton Pump Inhibitor,Does not require,NA,P-Glycoprotein,Not specified,Not specified,CYP3A4,NA,CYP3A4,NA,NA,NA,NA,NA,NA,NA,NA,NA,P-Glycoprotein,Not specified,Not specified,CYP3A4,NA,CYP3A4,NA,NA,NA,NA,NA,NA,NA,NA
Plasma protein binding,Low,15-40%,10-33%,Moderate,~60%,~60%,30%-50%,70%-80%,35%,5%-10%,~98%,10%-30%,80% to 95% (not exact),NA,~10%,~67%,Approximately 88%,94-98%,Moderate (35%),Approximately 40% bound to plasma proteins,About 95% bound to plasma proteins,Approximately 15%,~40%,Approximately 90%,Approximately 30%,90%,Approximately 97%,Approximately 90% bound to plasma proteins,~ 98%,C-max,12–22 ng/L,362 ng/ml,23 to 66 ng/mL and 55 to 107 ng/mL,variable,33.4ng/mL,6.54 ± 1.70 ng/mL,26±4.4ng/mL,8.8-45.8 ng/m,20-70ng/mL,50ng/mL,100-200ng/mL,100-500ng/mL,100-500ng/mL,20-40ng/mL,crosses BBB,Minimal,50-60%,Approximately 5-10%,Minimal,Approximately 50-60%,Approximately 80-90%,30-35%,Approximately 65-70%,Approximately 97%,Approximately 85-90%,Approximately 80-90%,Plasma protein binding:,90%,90%,99%,58%,98%,11-12%,99.80%,99%,NA,NA,NA,99%,99%,84-88%,NA,98 - 99 %,95%,NA,<4%,99%,94-97%,99%,10-17%,30%,55%,30%,98%,NA,Plasma protein binding:,94.50%,80%,27%,95%,84%,93-95 %,96%,89-95 %,85%,93%,77-90 %,N/A,NA,"Wide distribution. The conc. in liver, spleen, kidney & lung increased rapidly after administration & they were higher tham the conc. of drug in plasma at same time","Red blood cell compartment in animal tissues, including the brain","Wide through the bloodstream, reaching various tissues.",Throughout the body and target tissue include the cancer cells.,To red blood cells relative to plasma,Rapidly distributed into pleural effusions and ascitic fluid,"Detected in saliva, liver, lungs, kidney, spleen, myometrium, healthy brain tissue, and brain tumour tissue, minimally in pleural fluid",Widely distributed,"Initial distribution to peripheral compartment, then slow efflux from the peripheral compartment; widely distributed into the body fluids and tissues",Widely distributed into tissues; also present in ascitic fluid,Plasma and interstitial compartments,"Widely distributed in the body, mostly in spleen, liver, kidneys, lungs, thymus",Distribution is not known,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Azathioprine exhibits moderate plasma protein binding, with approximately 30-35% bound to plasma proteins. This moderate binding allows for a portion of the drug to be in the free, active form in the bloodstream.","Acitretn is extensvely bound to plasma protie, primarily albumin. Approx 99%of Acitretin is bound to plasma protine",NA,"Methotrexate binds to plasma proteins, primarily albumin.","hydroxyurea has a moderate binding affiniy to plasma protine, primiraly binding to albumin.this protne binding can influence the distribution, metabolism, andelimination","high, aprox 90%, primarily bound to lipoprotine","High plasma protein binding, around 99%.",": Betamethasone is highly bound to plasma proteins, primarily to albumin",NA,Tazarotene and its metabolites are bound to plasma proteins to some extent.,Pimecrolimus binds extensively to plasma proteins,extensively bind to IgG molecule,approx 68%,NA,70-85%,91-95%,95-91%,93-96%,95-96%,67-80%,30%,95%,50%,90-95%,92%,95%,65-75%,NA,NA,NA,NA,NA,>99%,NA,38%-46%,40%,<10%,99.50%,65%,NA,NA,NA,<10%,NA,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,approximately 15% to 20% of the drug bound to plasma proteins,approximately 15-20% of the drug,approximately 20% to 25%,approximately 15-20% of the drug,approximately 90% bound to plasma proteins.,Cisapride exhibits moderate plasma protein binding,approximately 60% to 70%,High plasma protein binding,approximately 90% bound to plasma proteins.,approximately 99%,approximately 60-70%,approximately 97-99%,approximately 99%,approximately 90-95%,approximately 35-42%,"Amikacin has minimal plasma protein binding, with approximately 0-11% of the drug binding to proteins in the bloodstream.","The plasma protein binding of plazomicin is relatively low, about 16 ± 5%, with plasma AUC values high against most gram-negative bacteria studied.","The serum protein binding of azithromycin varies in humans, decreasing from 51% at 0.02 g/mL to 7% at 2 g/mL",Amoxicillin is 17% protein bound in serum.,"Cephalosporins generally exhibit low to moderate plasma protein binding. The extent of protein binding can vary among different cephalosporins. Typically, they bind to plasma proteins, such as albumin, to some degree, but they also often have a significant portion that remains unbound and available for therapeutic action.",NA,"Ampicillin exhibits low plasma protein binding, with approximately 20-30% of the drug binding to proteins in the bloodstream.","Sulfadiazine exhibits significant plasma protein binding, primarily binding to albumin. The extent of binding can influence the distribution and elimination of the drug in the body.","Eravacycline has a high plasma protein binding, approximately 97%.","Resistance to penicillin among bacteria is often associated with specific mechanisms, such as the production of enzymes (beta-lactamases) that inactivate the antibiotic, or changes in the bacterial cell wall that reduce the binding affinity of penicillin. This is distinct from how penicillin behaves in the human body regarding plasma protein binding.","The total concentration of meropenem ranged from 6.86 to 81.1 mg/L (median 18.3 mg/L), and the calculated fu was 98.4% ± 3.5%. The results from both centers demonstrated negligible protein binding (2%) of meropenem","Cephalexin exhibits low plasma protein binding, typically ranging from 10% to 15%. This means that a relatively small percentage of cephalexin in the bloodstream binds to plasma proteins. The majority of the drug remains in its free, unbound form, which contributes to its pharmacological activity.","Ciprofloxacin has a moderate degree of plasma protein binding, ranging from approximately 20% to 40%.",16% to 21% bound to plasma proteins.13,"Clarithromycin has a high binding affinity to plasma proteins, primarily to alpha-1 acid glycoprotein. Approximately 70-80% of clarithromycin is bound to plasma proteins.",50%,40%,25%,40%,0-9%,72%,99%,99%,65%,75-80%,90-95%,70-90 %,87%,85-90%,50%,90-95%,70-80%,~90-95%,Low (55%),Low (less than 10%),Approximately 15-41% bound to plasma proteins,40-50%,Approximately 80%,Approximately 22%,Low (20%),~96%,Approximately 70%,~20%,40-60%,About 90% bound to plasma proteins,50 % bound to serum proteins,Not specified,About 90% bound to plasma proteins,40-60%,~20%,Approximately 70%,~96%,Low (20%),10-30 %,~90-95%,Low (55%),70-80%,Low (less than 10%),98-99 %,Approximately 22%,High,High (96-98%),High (approximately 99%),High (97-99%),High (92-97%),90-95%,97%,High (90%),Approximately 99%,High (95%),95%,High (99%),High (97-99%),High (greater than 90%),High (96%),70-90%.,15-20%.,50-60%,60-80%,50%.,40-50%,4% to 33%.,25-30%,90-95%,70-80%,90%,55%,96% to 98%,10 to 30% bound.,88-93%,10%,90%,<10%,99.70%,80%,99.70%,60%,85%,99.50%,90%,74%,not applicable,99.50%,99.50%,95%,"MTX binds to two kinds of albumins binding sites, with different binding constants: K1 = 8.88 mM-1 and K2 = 1.76 mM-1",binds nuclear proteins to chromosomal DNA.,less than 15% of thioTEPA is bound to plasma proteins,6%,30% to 40%.,60% to 90%,94-96%,50% to 60%., extent greater than 60%,84% to 88% (est.),94%,99%,15% to 40%,20% to 40%.,30%,95%,97%,22.50%,15%,12%,12%,22%,55%,30%,38%,40%,55%,17%,70%,20%,89-98%,95%,99%,94%,86%,50.4 +/- 1.9,91%,90%,90%,95%,<10%,95%,"Diazepam binds almost exclusively to albumin, DLM binds hydrophobically to both albumin and lipoprotein. Albumin and lipoprotein binding account for 60 and 30% of the insecticide in adult human plasma (16).",The R(-) glucuronide was bound to the same extent (55%) in both protein solutions. The binding of the S(+) glucuronide was also examined in non-defatted HSA (3.0 g/dl).,"Hydroxyzine has been shown to bind to human albumin in vitro, but the extent of protein binding in plasma has not been evaluated.",Around 90% of propranolol in plasma is bound to proteins. Different investigations have indicated a range of 85-96%.,86%,72% and is not concentration-dependent. The in vitro plasma protein binding for metabolite 3'-OH gepirone is 59% and 42% for 1-PP.,capacity of 85–91%,"20-40% bound to plasma proteins, especially albumin."," 80% bound to serum protein, mainly albumin.", works by binding to the GABAA receptor at either the alpha or the beta sub unit. ,over 95% bound to proteins, plasma levels of the drug do not develop for up to 4 hours. , correlate significantly with the plasma albumin concentration," Percentage bound ranged from 96.7 (n equals 4, SD equals 0.8) at 150 micrograms/ml.",about 95%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11 to 12%,99.80%,97%,98%,Not available,88.20%,Not available,84%,58%,99%,99%,77-88%,95%,NA,98 to 99%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Widely distributed in body tissues,Widely distributed in body tissues,Widely distributed in body tissues,Widely distributed in body tissues,Widely distributed in body tissues,Widely distributed in body tissues,Widely distributed in body tissues,Widely distributed in tissues,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Plasma protein binding:,11 to 12%,99.80%,97%,98%,Not available,88.20%,Not available,84%,58%,99%,99%,77-88%,95%,NA,98 to 99%,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Widely distributed in body tissues,Widely distributed in body tissues,Widely distributed in body tissues,Widely distributed in body tissues,Widely distributed in body tissues,Widely distributed in body tissues,Widely distributed in body tissues,Widely distributed in tissues,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Pgp Substrate,Pgp substrate,Pgp Substrate,The results of the present study suggest that it is a P-gp substrate,Leflunomide is known to be a substrate of P-glycoprotein,Not considered a substrate or inhibitor of P-glycoprotein (P-gp).,Azathioprine is not considered a substrate or inhibitor of P-glycoprotein (P-gp).,Cyclosporine is a substrate of P-glycoprotein (P-gp),Inhibitor,NA,Etanercept is not known to be a substrate or inhibitor of P-glycoprotein (P-gp),substrate,not known to be a substrate or inhibitor of P-glycoprotein (P-gp),not a substrate or inhibitor of P-glycoprotein (P-gp).,not a substrate or inhibitor of P-glycoprotein (P-gp).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,lungs and skin,"Skin, soft tissues and respiratory tissues","Skin , respiratory tract, urinary tractand soft tissue","Respiratory tissue, skin and soft tissue","Liver, kidney, lungs, spleen and skin",Skin and soft tissue,"Kidney, prostate and skin tissue","Lungs , skin and kidney",Soft tissue and organs,"Skin, respiratory tract, genitourinary tract, bones and joints","Skin and soft tissue, lung, bloodstream, urinary tract","Soft tissue, respiratory tract, bone , bloodstream","Blood, respiratort tract, abdo,inal organ, urinary tract","Lung tissue, genitourinary tract, prostate tissue,inta-Abdominal oragan, bloodstraem","Kidney, lungs, heart and skeletal muscle","Omeprazole is highly bound to plasma proteins, primarily albumin.","highly bound to plasma proteins, primarily albumin.","highly bound to plasma proteins, primarily albumin.","highly bound to plasma proteins, primarily albumin.","highly bound to plasma proteins, primarily albumin.","highly bound to plasma proteins, primarily albumin.",Approximately 20-30%.,Approximately 15-20%,Approximately 35-40%.,Approximately 15-20%.,Approximately 20-30%,NA,~93 %,Approximately 85%,NA,16L of volume,23 to 37L volume,23 to 26L Volume,0.86±0.19L/kg,0.6 to 0.8L/kg,0.7 to 1.0L/Kg,6.9 to 8.2L/Kg,0.5 to 0.6L/kg,0.57 to 0.8L/kg,16.4 to 18.9L/kg,1.3±0.6L/kg,0.7 to 0.9L/kg,6.2 to 7.5L/kg,727L,depends on formulation,Widely distributed in tissues,Widely distributed in tissues,Widely distributed in body tissues,Widely distributed in tissues,"Widely distributed in the body, including crossing the blood-brain barrier",Widely distributed in tissues,Widely distributed in the body,Widely distributed in the body,Widely distributed in tissues,Widely distributed in the body,Widely distributed in the body,Widely distributed,Widely distributed in the body,Widely distributed in tissues,Widely distributed in tissues,Widely distributed in tissues,Widely distributed in tissues,Widely distributed in body tissues,Widely distributed in tissues,"Widely distributed in the body, including crossing the blood-brain barrier",Widely distributed in tissues,Widely distributed in the body,Widely distributed in the body,Widely distributed in tissues,Widely distributed in the body,Widely distributed in the body,Widely distributed,Widely distributed in the body,Widely distributed in tissues,Widely distributed in tissues
Tissue distribution,Wide,Widely distributed,Rapid and extensive,Wide spread,Distributed widely,Distributed widely,Distributed widely,"Rapidly distributed throughout the body, including the brain",Rapidly distributed throughout the body,"Rapidly distributed throughout the body, including the brain",Distributed widely,Distributed widely,Distributed widely,Distributed widely,Crosses blood-brain barrier,NA,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses blood-brain barrier,Crosses the blood-brain barrier,Penetrates various tissues,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Penetrates into the brain,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Penetrates various tissues,Crosses the blood-brain barrier,Crosses blood-brain barrier,Half life,1.5-5.5 hrs,8-22 hrs,16-48 hrs,20-30 hrs,10-20 hrs,15-40hrs,1 hr,15-40hrs,18-50 hrs,100 hrs,47-100 hrs,5-9 hrs,4-15 hrs,1-2.6 hrs,12 hrs,Penetrates well into tissues,"Penetrates well into tissues, including the CNS","Penetrates well into tissues, including the CNS",80%,Penetrates well into tissues,Distributed to various tissues including tumors,"Penetrates well into tissues, including tumors","Penetrates well into tissues, including tumors","Penetrates well into tissues, including tumors","Penetrates into tissues, including tumors","Penetrates into tissues, including the central nervous system",Tissue distribution:,Wide,Wide,Wide,Wide,Wide,Wide,Wide,Wide,NA,NA,LIMITED,Wide,Wide,Limited,LIMITED,high,NA,NA,very low,high,high,"adipose tissue,liver",low,"liver,brain","adipose tissue , brain",skeletal adipose tissue,liver,liver,Tissue distribution:,"Wide distribution , including the brain","Wide distribution , including the brain","Wide distribution , including the brain","Wide distribution , including the brain","Wide distribution , including the brain","Wide distribution , including the brain","Wide distribution , including the brain","Wide distribution , including the brain","Wide distribution , including the brain","Wide distribution , including the brain","Wide distribution , including the brain",N/A,NA,Access to CNS,Yes,No information found,No information found,Cross- (in vivo),Not readily,In low and variable concentrations,Yes very low levels,No,No information found,No information found,Brain and plasma levels comparable in animal studies,No information found,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Azathioprine is widely distributed throughout the body, with concentrations found in various tissues, including the liver, kidney, and gastrointestinal tract. The drug undergoes extensive metabolism, and its metabolites are distributed to tissues.","it can accumulate in the skin, liver, and other fatty tissue","All metabolites were detected in tissues at higher levels than in plasma, and the levels increased with dose. FLU was 10- to 27-fold higher in brain regions than in plasma.","It is distributed widely throughout the body, including various tissues and organs High concentrations may be found in the liver, kidneys, and bone marrow, reflecting its uptake by cells actively involved in folate metabolism.","Hydroxyurea distributes rapidly throughout the human body, enters the cerebrospinal fluid","hgh conc found in liver, kidney nand intestine","Primarily stays within the site of application, limited systemic absorption",": It has a wide distribution in the body, with significant accumulation in tissues",": Limited systemic absorption, primarily stays within the site of application","The drug has local effects on the skin, and systemic distribution is limited","It primarily acts locally on the skin, with limited systemic distribution","distribute throughout the body, with hgh conc found tssue affected by inflammation","apremilist is widely distributed, with extensive tissue distribution throughout the body",NA,widely distributed,wide,wide,wide,extensive,wide,extensive,wide,wide,wide,wide,extensive,wide,NA,NA,"Liver, Brain, Adipose tissue","Its tissue distribution is similar to
other insulin formulations, 
primarily affecting tissues invol-
ved in glucose metabolism","The tissue distribution primarily involv-es subcutaneous tissue, where it is 
absorbed into the bloodstream","primarily distributes to peripheral tissues 
such as muscle and adipose tissue after 
subcutaneous injection.","Liver, Brain, Adipose tissue","Its distribution pattern primarily
involves uptake by peripheral
tissues such as muscle and adip
ose tissue, where it acts to regul
ate glucose uptake and metabolism",NA,"After subcutaneous injection, Fiasp is distributed
throughout the body's tissues via the 
bloodstream","Glimepiride, being a small molecule oral anti
diabetic medication, is distributed widely t
hroughout the body's tissues after absorpti
on from the gastrointestinal tract",NA,Monoclonal antibodies like teplizumab are large protein molecules that distribute primarily in the extracellular fluid space rather than penetrating deeply into tissues.,"Resveratrol has been found to distribute
to various tissues throughout the body
after administration.","primarily targets tissues with insuli
n receptors, such as skeletal 
adipose tissue, and liver","It primarily targets insulin-responsive 
tissues such as skeletal muscle, liver,
and adipose tissue.",NA,Plasma protein binding:,~55%,94%,97-99%,98%,70-90%,70-90%,~50%,87-92%,92-95%,70-90%,high,80-95%,93-94%,~30%,35%,56%,"stomach, liver, kidneys, and possibly the central nervous system","Cimetidine distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.","Famotidine distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.","Cimetidine distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.","Bepridil distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.","Cisapride distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.","Dofetilide distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.",": Levoketoconazole distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.","Pimozide distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.","Piperaquine distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.","Sparfloxacin distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.","Terfenadine distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.","Ziprasidone distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.","Mesoridazine distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.","Nizatidine distributes widely throughout the body after systemic absorption, with concentrations found in various tissues and organs.","Amikacin has a wide distribution throughout various body tissues, including the lungs, kidneys, liver, heart, and skeletal muscle. The drug can penetrate well into tissues, allowing it to reach therapeutic concentrations at sites of infection.","Plazomicin exhibits good distribution in various tissues, with concentrations observed in the lungs, kidneys, liver, and other tissues.","Azithromycin is extensively distributed into tissues, as attested by a large volume of distribution of 23 liters/kg",The central volume of distribution of amoxicillin is 27.7L.,"They can penetrate various tissues and body fluids, allowing them to target and treat infections effectively.",NA,"It penetrates well into organs such as the lungs, liver, kidneys, and the female reproductive organs. Ampicillin can also cross the blood-brain barrier, although the concentrations in cerebrospinal fluid may be lower compared to plasma. The distribution of ampicillin into tissues contributes to its effectiveness against various bacterial infections.","Sulfadiazine exhibits widespread tissue distribution throughout the body. After absorption into the bloodstream, it can reach various tissues and organs. The distribution is influenced by factors such as blood flow, tissue permeability, and drug-binding proteins.","penetrates well into tissues such as lung, kidney, liver, and skin. The distribution profile is influenced by factors such as tissue blood flow, drug binding to proteins, and specific tissue characteristics.","The distribution of penicillin in the body occurs relatively quickly after administration. Penicillin antibiotics, once absorbed into the bloodstream, distribute to various tissues and body fluids.","Meropenem exhibits widespread distribution in various tissues, including but not limited to the lungs, kidneys, liver, and skin. Its ability to penetrate tissues contributes to its effectiveness in treating a broad spectrum of infections.","Cephalexin has good tissue penetration and is distributed widely in various tissues, including the skin, soft tissues, respiratory tract, and bones. However, its concentration in the central nervous system is generally lower, especially when the meninges are not inflamed. The distribution of cephalexin throughout the body allows it to effectively target and treat infections in different tissues.","Ciprofloxacin exhibits good tissue distribution, allowing it to penetrate various body tissues. It is found in high concentrations in tissues such as the lungs, kidneys, liver, skin, and prostate. This broad tissue distribution contributes to the effectiveness of ciprofloxacin in treating infections in different parts of the body.","Tissue distribution of ceftalozone-tazobactam is rapid and shows good penetration into the lung, rendering it an ideal treatment for bacterial pneumonia","Clarithromycin exhibits good tissue distribution, and it can penetrate various body tissues effectively. The drug is known to accumulate in tissues such as lung, tonsil, and prostate, making it effective in treating respiratory tract infections and other infections involving these tissues.",3 L/kg,0.5 L/Kg,1.6 L/kg,varies,varies,NA,NA,NA,Concentrated in lungs,"liver, lungs, kidney and heart","liver, kidneys, muscles, and adipose tissue.","Liver, kidney, lungs and skin",Lungs and nasal tissues,"GIT tract, Raspiratory tract","GIT tract, Raspiratory tract","Crosses placenta, enters breast milk",Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier and distributed in the brain,Distributed throughout various tissues,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Not specified,Penetrates well into tissues,Crosses the blood-brain barrier,Crosses the blood-brain barrier,equally distribute white and gray mattar,Not specified,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Penetrates well into tissues,Not specified,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier and distributed in the brain,Crosses the blood-brain barrier,Distributed throughout various tissues,crosses the placenta,Crosses the blood-brain barrier,Crosses BBB,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Penetrates into various tissues,Crosses BBB,Crosses into various tissues,Crosses the blood-brain barrier,Crosses blood-brain barrier,Crosses the blood-brain barrier,Crosses blood-brain barrier,NA,Crosses blood-brain barrier,Crosses blood-brain barrier,Crosses blood-brain barrier,Wide distribution in tissues,wide tissue distribution,Disturbrtated in various tissues,extensive tissue distribution,"accumulate in adipose tissue, leading to a longer duration of action.","distributes widely throughout the body tissues, with higher concentrations found in the heart, liver, and kidneys.","distributes extensively throughout the body,","highest concentrations found in tissues with high metabolic activity such as the heart, brain, and skeletal muscle.","found in tissues such as the heart, liver, kidneys, and skeletal muscles","found in various tissues including the heart, liver, and kidneys.","highest concentrations found in the liver, kidneys, and heart.","throughout the body, including into tissues such as the heart, liver, and kidneys.",distributes in blood plasma rather than extravascular tissues.,"adipose tissue, liver, lungs, and myocardium.","widely distributed throughout the body, with high concentrations found in the heart, liver, and kidneys.",Widely distributed throughout the body.,no,Limited,Not specified,wide,limited,wide,wide,extensive,Wide distribution,wide,Widely distributed,Systemic,Widely distributed,Widely distributed,limited,liver and kidneys CNS synovial fluid,Mechlorethamine is a vesicant that can cause severe tissue necrosis if not administered through a running intravenous infusion,"distribution into various tissues depends on factors such as blood flow, tissue permeability, and affinity for different tissues","tissue perfusion, and tissue characteristics.","liver, kidneys, lungs, and bone marrow",The volume of distribution of melphalan ranges from approximately 35.5 to 185.7 L/m2. Penetration into cerebrospinal fluid is low.,"tissues, including tumors, lymph nodes, and bone marrow.","tissues, including the liver, lungs, and bone marrow,"," distributed to all tissues, are assumed to cross the placenta and are known to be present in breast milk","Streptomycin diffuses fairly rapidly into most body tissues, but is distributed only in the extracellular fluid","including the lungs, liver, and bone marrow.","liver, spleen, and bone marrow","including the brain, liver, and spleen","After administration, fludarabine is rapidly taken up by cells and undergoes intracellular phosphorylation to its active form",tissue organ,Liver & GI,GI,GI,GI & Small intestine,Liver & GI,GI & Small intestine,GI,Liver & GI,GI & Small intestine,Small intestine,Liver & GI,Liver,GI,GI & Small intestine,GI & Small intestine,NA,Vdss = 0.43 mL/g,NA,NA,70%,NA,NA,"mainly distributed into the blood cells, especially platelets (78%) and lymphocytes (4.8%)",NA,NA,NA,NA,"The distribution of diazepam involves its penetration through the blood-brain and placental barriers, as well as its presence in breast milk. It is worth noting that the volume of distribution ranges from 0.8 to 1.0 L/kg.","Tissue-specific bioconcentration was determined by sampling muscle, liver, brain tissue, and blood plasma after administering oxazepam for a duration of 6 days.",The complete characterization of hydroxyzine distribution in human body tissues and fluids has not been achieved yet.,"extensively distributed throughout various body tissues, encompassing the lungs, liver, kidneys, and heart.",5.3L\Kg,NA,1.3 L/kg.,monoexponential curve with half-lives of 30 to 120 min.,The highest alprazolam tissue concentrations were found in fat and liver and the lowest levels were observed in lungs and brain.,"with high concentrations in the brain, liver, and kidneys.","very rapidly to the liver and kidneys, less rapidly to the muscle and gut, and much more slowly to the brain.",SIGNIFICANTLY LARGER IN FEMALE SUBJECTS THAN IN THE MALES,the drug dispersed into the recipients' corneas and other ocular tissues.,Redistribution occurs quickly (2-3 minutes) to the lean tissue and then more slowly to body fat.,"throughout the body, including the CNS, with only 1% remaining in the plasma. ",35%,80%,28-31%,25%,less than 20%,14%,15%,98%,93%,91-96%,96-99%,55-60%,99.91%,93%,37.80%,93%,93-96%,97-99%,60-7-%,80 to 85 %,83-87%,96.10%,88% and 97%,90%to 95%,95%,93-96%,50%,96-99%,95%,97%, 91%,(>99%),95%,98%,95%,70%,30% to 35%,96%,77%,15% to 35%,13% to 35%,19% to 23%, 49% ,60% to 70%,99%,25%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Plasma protein binding:,98%,88.20%,14%,99.80%,58%,>98%,NA,NA,>98.6% ,97%,>99%,90%,80%,85%,80%,"Liver, kidney, lung",Plasma,92% tissue distribution within 36-48 hours,Skin and mucus membrane,"plasma concentration, elimination and metabolism",Skin and mucous membrane,Skin or mucous membrane,"Skin, Liver and organ","Lung, liver, Skin and eyes","Skin, Nails and fatty tissues",Skin and Nails,Skin and it's layers,Skin,"Mucus membrane, Skin","Liver, spleen, adipose tissue",greater than 99.5%.,"Glipizide is about 98-99% bound to serum proteins, with albumin being the main plasma protein.","94%, highly bound to plasma proteins",Approximately 95% bound to plasma proteins.,Highly bound to plasma proteins,70%,90%,90% bound to plasma proteins.,NA,NA,NA,NA,NA,NA,NA,NA,70%,NA,high plasma protein binding (98%),NA,96.30%,12%,97%,60-80%,96%,NA,85%,15-20%,Minimal,15%,NA,15-20%,NA,10%,NA,95%,95%,98%,15-20%,96.30%,NA,97%,10%,NA,15-20%.,About 95%,98%,low (approximately 50%),60%,82%,NA,82%,NA,20-30%,high,high,NA,NA,NA,NA,~60%,Greater than 99%,Low (less than 36%),~98%,~95%,~88%,~54%,20%,Plasma protein binding:,50% to 60%.,50-60%,74-78%,less than 10%,74-78%,74-78%,67%,90 to 99 %,98%,30%,20% to 305,90 to 95%,30 to 50%,50% to 60%,50% to 60%,Plasma protein binding:,58%,98%,99%,99%,99.80%,NA,99%,negligible,not specified,90%,90%,90%,90%,90%,35%,80%,28-31%,25%,less than 20%,14%,15%,98%,93%,91-96%,96-99%,55-60%,99.91%,93%,37.80%,93%,93-96%,97-99%,60-7-%,80 to 85 %,83-87%,96.10%,88% and 97%,90%to 95%,95%,93-96%,50%,96-99%,95%,97%, 91%,(>99%),95%,98%,95%,70%,30% to 35%,96%,77%,15% to 35%,13% to 35%,19% to 23%, 49% ,60% to 70%,99%,NA,Plasma protein binding:,25%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,98%,88.20%,14%,99.80%,58%,>98%,NA,NA,>98.6% ,97%,>99%,90%,80%,85%,80%,NA,Tissue distribution:,"Liver, kidney, lung",Plasma,92% tissue distribution within 36-48 hours,Skin and mucus membrane,"plasma concentration, elimination and metabolism",Skin and mucous membrane,Skin or mucous membrane,"Skin, Liver and organ","Lung, liver, Skin and eyes","Skin, Nails and fatty tissues",Skin and Nails,Skin and it's layers,Skin,"Mucus membrane, Skin","Liver, spleen, adipose tissue",Plasma protein binding:,greater than 99.5%.,"Glipizide is about 98-99% bound to serum proteins, with albumin being the main plasma protein.","94%, highly bound to plasma proteins",Approximately 95% bound to plasma proteins.,Highly bound to plasma proteins,70%,90%,90% bound to plasma proteins.,NA,NA,NA,NA,NA,NA,NA,Plasma protein binding:,NA,70%,NA,high plasma protein binding (98%),NA,96.30%,12%,97%,60-80%,96%,NA,85%,15-20%,Minimal,15%,Plasma protein binding:,NA,15-20%,NA,10%,NA,95%,95%,98%,15-20%,96.30%,NA,97%,10%,NA,15-20%.,Plasma protein binding:,About 95%,98%,low (approximately 50%),60%,82%,NA,82%,NA,20-30%,high,high,NA,NA,NA,NA,~60%,Greater than 99%,Low (less than 36%),~98%,~95%,~88%,~54%,20%,Plasma protein binding:,50% to 60%.,50-60%,74-78%,less than 10%,74-78%,74-78%,67%,90 to 99 %,98%,30%,20% to 305,90 to 95%,30 to 50%,50% to 60%,50% to 60%,58%,98%,99%,99%,99.80%,NA,99%,negligible,not specified,90%,90%,90%,90%,90%,98-99%,20%,85-90%,50-60%,40-55%,15%,90-95%,95%,25%,13-17%,70%,45%,96%,70-805,80-90%,NA,70-805,80-90%,93-96%,55%,99%,95%,86-88%,99%,83-93%,99%,90-95%,35%,55%,90-95%,92-97%,78%,95%,24%,85.7-99.5%,23-53%,98-99%,36%,NA,54%,25%,NA,70%,30 to 40%.,NA,NA,Baricitinib is rapidly absorbed from the gastrointestinal tract,74% oral absorption (absolute bioavailability),Upadacitinib was rapidly absorbed.Upadacitinib displays a dose-proportional pharmacokinetic profile over the therapeutic dose range,Methotrexate has a bioavailability of 64-90%,"Well absorbed, peak plasma concentrations appear 6-12 hours after dosing","Following oral administration of 1 g of sulfasalazine to 9 healthy males, less than 15% of a dose of sulfasalazine is absorbed as the parent drug","Oral azathioprine is well absorbed, with a Tmax of 1-2h",Absorption occurs mainly in the intestine.Absorption is highly variable with a peak bioavailability of 30% ,Well absorbed,Well absorbed Bioavailability: High,subcutaneous bioavailability of 56.9% ,Oral prednisolone reaches a Cmax of 113-1343ng/mL with a Tmax of 1.0-2.6 hours and 70% bioavailable,The bioavailability of anakinra is 95% in healthy subjects administered a subcutaneous bolus injection.,Adalimumab is given via injection hence highly bioavailable,given via injection hence highly bioavailable,NA,90-95% In vitro,8-12%,Vismodegib has high plasma protein binding (>99%).,Sonidegib is over 97% bound to plasma protien,not expected to bind to plasma protien,60%,97% bound to human plasma protein,86% BOUND to human plasma protiens in vitro,95% bound to human plasma protiens in vitro,99.7% bound to human plasma proteins,less than 5%,99.10%,>99%,NA,NA,"which usually bind 60–90% to plasma proteins,",Amoxicillin exhibits approximately 20% plasma protein binding.,50%, highly bound (90-95%) at low concentrations (less than 100 micrograms/ml) but considerably less bound (approx.,20% bound to plasma proteins,meropenem has very weak plasma protein binding (2%) ,vancomycin is thought to be approximately 50%,low plasma protein binding (21.3%),25.5–33.6%. , high degree of plasma protein binding., about 40%,antibiotic (20%-40%),binding values of approximately 16 to 19%. ,"Ceftaroline binds to the PBP-1, 2, and 3 as well as PBP-2a of S.",60%,>5%,<5%,10-20%,1-2%,90%,5-10%,6-16%,94%,70-80%,98%,25%,92-98%,99%,~99%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Penetrates gastric parietal cells where it acts on the proton pumps.,Penetrates gastric parietal cells where it acts on the proton pumps.,Penetrates gastric parietal cells where it acts on the proton pumps,Penetrates gastric parietal cells where it acts on the proton pumps,Penetrates gastric parietal cells where it acts on the proton pumps,Penetrates gastric parietal cells where it acts on the proton pumps,Penetrates various tissues including the gastric mucosa.,Penetrates various tissues including the gastric mucosa.,Penetrates various tissues including the gastric mucosa.,Penetrates various tissues including the gastric mucosa.,Penetrates various tissues including the gastric mucosa.,Penetrates various tissues including the gastrointestinal tract.,Penetrates various tissues including the gastrointestinal tract.,"Misoprostol is distributed to various tissues, including the uterus.","Rioprostil distributes to various tissues, including the gastrointestinal tract.","Zanamivir has limited plasma protein 
binding (<10%)", Plasma protein binding is less than 30%, Plasma protein binding is less than 42%, Plasma protein binding is less than 50%," Plasma protein binding is low at about
15%", Plasma protein binding is low ranges 3.5% to 17.9%, Plasma protein binding is 90%, Plasma protein binding is less than 6%, Plasma protein binding is low (<5%), Plasma protein binding is low (88.40%), Plasma protein binding is low (7.2%), Plasma protein binding is (90%), Plasma protein binding is (90%), Plasma protein binding is (85%), Plasma protein binding is (<36%),90-95%,70-80%,~90-95%,Low (55%),Low (less than 10%),Approximately 15-41% bound to plasma proteins,40-50%,Approximately 80%,Approximately 22%,Low (20%),~96%,Approximately 70%,~20%,40-60%,About 90% bound to plasma proteins,90-95%,70-80%,~90-95%,Low (55%),Low (less than 10%),Approximately 15-41% bound to plasma proteins,40-50%,Approximately 80%,Approximately 22%,Low (20%),~96%,Approximately 70%,~20%,40-60%,About 90% bound to plasma proteins
Blood-brain barrier penetration,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,NA,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Crosses the blood-brain barrier,Yes,Yes,Yes,Yes,Yes,Yes,Penetrates the blood-brain barrier,Yes,M,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Limited,Limited,Yes,Wide,Yes,Limited,Limited,Limited,Limited,Limited,"Yes, readily crosses the blood-brain barrier",Blood-brain barrier penetration:,Negligible,Negligibale,Yes,Good,Limited,Limited,Limited,Limited,NA,NA,NA,Limited,Limited,Poor,POOR,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Blood-brain barrier penetration:,moderate penetration,moderate penetration,moderate penetration,moderate penetration,high penetration,moderate pentration,high penetration,high penetration,high penetration,high penetration,moderate penetration,NA,NA,677.45 ± 58.72 ng/ml,Alectinib:638 ng/ml M4: 246 ng/ml,­,552ng/ml,1080ng/ml,­,­,2.41?g/ml,195 ng/ml,350mg/m^2,­,242?g/kg,6 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The peak plasma concentration (C-max) of Azathioprine can vary based on factors such as the dose, individual patient characteristics, and the specific formulation or product. C-max is typically reached within a few hours after oral administration",NA,NA,It is limited under normal conditions.And it may also reach therapeutic concentrations in the cerebrospinal fluid for the treatment of certain central nervous system disorders.,The maximum penetration of a relatively inert small molecule such as hydroxyurea into the brain is 2 mm,limited permibility across BBB,: Limited penetration across the blood-brain barrier.,Betamethasone has limited penetration through the blood-brain barrier.,Limited penetration across the blood-brain barrier,Tazarotene has minimal penetration through the blood-brain barrier,Pimecrolimus does not penetrate the blood-brain barrier to a significant extent.,not readily cross bbb,limted permiability,NA,yes,yes,yes,yes,yes,no,yes,yes,yes,yes,yes,yes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Tissue distribution:,"Wide distribution, accumulates in lysosomes",Wide distribution,"wide distribution eg liver,kidney,lungs, spleen",Widely distributed,Widely distributed,"heart, liver, kidneys, lungs, and skeletal muscles",NA,NA,"liver, spleen, kidneys, lungs, and skeletal muscles",NA,NA,NA,"bone, skin, soft tissues, and the respiratory tract.",NA,NA,penetrate the BBB to some extent,Cimetidine is known to cross the blood-brain barrier,Famotidine may cross the blood-brain barrier to some extent,Cimetidine is known to cross the blood-brain barrier,: Bepridil may cross the blood-brain barrier to some extent.,Cisapride may cross the blood-brain barrier to some extent.,: Dofetilide may cross the blood-brain barrier to some extent.,may cross the blood-brain barrier,Pimozide crosses the blood-brain barrier and exerts its effects on the central nervous system.,: Piperaquine may cross the blood-brain barrier to some extent.,Sparfloxacin may cross the blood-brain barrier to some extent.,"Terfenadine may cross the blood-brain barrier to some extent, leading to central nervous system effects.",Ziprasidone crosses the blood-brain barrier and exerts its effects on the central nervous system.,: Mesoridazine crosses the blood-brain barrier and exerts its effects on the central nervous system.,Nizatidine may cross the blood-brain barrier to a limited extent.,"amikacin can reach therapeutic concentrations in various tissues, its ability to cross the BBB is generally limited.","Plazomicin has limited penetration across the blood-brain barrier, resulting in low concentrations in the central nervous system.",azithromycin has been demonstrated to penetrate the blood-brain barrier effectively,"Amoxicillin has limited penetration through the blood-brain barrier, which is a protective barrier that separates the bloodstream from the brain and central nervous system.","Third-generation cephalosporins, such as ceftriaxone and cefotaxime, are known for better penetration of the blood-brain barrier, making them suitable for treating infections in the central nervous system.",NA,"penetration may not be as efficient as some other antibiotics. In cases of infections in the central nervous system, alternative antibiotics with better penetration may be considered.","Sulfadiazine has limited penetration across the blood-brain barrier (BBB), which is a protective barrier that separates the bloodstream from the brain. The ability of a drug to cross the BBB is crucial for treating central nervous system infections.",Eravacycline has limited penetration across the blood-brain barrier (BBB). The BBB is a protective barrier that restricts the passage of certain substances from the bloodstream into the brain.,"Penicillin has limited penetration across the blood-brain barrier (BBB), which is a protective barrier that separates the bloodstream from the brain and central nervous system.","Meropenem has good penetration through the blood-brain barrier, making it effective in treating certain infections in the central nervous system.","Cephalexin has limited penetration through the blood-brain barrier, particularly when the meninges (membranes covering the brain and spinal cord) are not inflamed. As a result, its concentration in the central nervous system is generally lower compared to other tissues.","Ciprofloxacin has the ability to penetrate the blood-brain barrier to some extent, especially when inflammation of the meninges is present.","High serum concentration of ceftriaxone causes higher penetration through the inflamed blood-brain barrier. Higher antibiotic penetration correlated with the extent of systemic inflammatory response. However, no inflammatory marker predicted the rate of ceftriaxone crossing the blood-brain barrier.","Clarithromycin can penetrate the blood-brain barrier to some extent, allowing it to reach therapeutic concentrations in the central nervous system. This property makes clarithromycin effective in treating certain infections that involve the brain or central nervous system.",Poor,Yes,Limited (no uptake),Yes,NA,Minimal,Minimal,Minimal,Low,limited,Limited,low,Low,LOW,LOW,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,yes,yes,Yes,Yes,Yes,Yes,Yes,Yes,yes,Yes,Yes,Yes,Yes,yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Penetrates,it can penetrate the blood-brain barrier.,does cross the blood-brain barrier to some extent.,blood-brain barrier penetration is limited.,"Lidocaine does penetrate the blood-brain barrier,","limited penetration through the blood-brain barrier,",does not readily cross the blood-brain barrier,Adenosine can cross the blood-brain barrier,Digoxin has limited penetration across the blood-brain barrier,can penetrate the blood-brain barrier,Diltiazem crosses the blood-brain barrier,"crosses the blood-brain barrier to some extent, allowing it to exert its effects in the central nervous system.","Limited, resulting in minimal central nervous system effects.",Limited penetration across the blood-brain barrier.,Sotalol crosses the blood-brain barrier to some extent.,Limited penetration to blood brain barrier,low,Minimal,Limited,minimal,minimal,minimal,limited,limited,limited,limited,Limited,limited,limited,Limited,limited,"depend on several factors, including the dose, route of administration",blood-brain barrier (BBB) value of 0.9735,some ability to cross the BBB,selective semipermeable,penetrate the blood-brain barrier to some extent, It can enter the brain through the neutral amino acid transporter. ,permeability of drug through the blood brain barrier (BBB) ,"easily crosses the blood–brain barrier,",penetrates the blood—brain barrier and CNS parenchyma well., penetrated slowly into the CSF,has limited penetration across the blood-brain barrier,has limited penetration across the blood-brain barrier,has limited penetration across the blood-brain barrier,"This ability to cross the blood-brain barrier is important when treating diseases that involve the central nervous system, such as certain types of leukemia that may affect the brain and spinal cord",does cross the blood-brain barrier to some extent,+,NA,+,+,+,NA,+,+,+,+,+,+,NA,NA,+,It faces challenges in penetrating the BBB due to its large molecular size and hydrophobic nature.,Limited penetration,Good penetration,Limited penetration,Low penetration,5%,Poor penetration,poor Penetration,NA,NA,10%,Good penetration,readily crosses the blood brain barrier,NA,"First-generation H1-antagonist antihistamines, such as hydroxyzine, have the ability to cross the blood-brain barrier and cause sedation, which limits their usefulness in the treatment of allergic disorders.",(BBB) and is detected in brain tissue in greater quantities compared to atenolol and nadolol.,centrally acting drugs lacks the ability to penetrate the bbb,Its metabolite 3'-OH-gepirone crossed the blood-brain barrier,Lorazepam crosses the blood/brain barrier freely by passive diffusion.,"To reach neurons in brain areas protected by the blood–brain barrier, clonidine has to cross also this barrier. ",", bypassing the blood-brain barrier and a direct nose-to-brain transfer.","the sodium salt of amobarbital a di-alkyl substiyuted oxybarbiturate is very lipid soluble, it crosses the blood brain barrier easily",It is lipid soluble and readily crosses the blood–brain barrier.,increase drug permeation through blood brain barrier,Pentobarbital attenuated the BBB disruption induced by hyperosmolar mannitol. , drug penetration is restricted because of the brain's permeability characteristics. , a toughest barrier for transporting the drug to brain,extensively distributed in the body,volume of distribution of eletriptan following IV administration is 138L,NA,tryptamine,Passage across the placental barrier and into milk,NA,"erytrocytes, with binding reversible and time dependent","brain, kideny, skin ,liver, skeletal muscle","liver, kidney, spleen, blood, muscle, colon, heart","lungs, liver, kidney and heart",liver,liver,0.16 l/kg,800 liters,throughout body water,widely distributed,high volume of distribution,low distribution,5.4-5.8 l/kg disributed,widely through body including CNS,"liver,spleen,thymus,heart",volume of distribuyion 0.35+or-0.02l/kg,predominntaly into peripheral tissue,react with local tissue,wide distribution,wide distribution,widely distributes in liver,wide tissue distribution,wide distribution,widely distributed,yes,yes,Widely distributed,Penetrates well into tissues,Wide distribution throughout the body,Widely distributed,Widely distributed,widely distributed,widely distributed,widely distributed,widely distributed,widely distributed,lymphoid tissues,widely distributed,widely distributed,"Widely distributed in tissues, with high concentrations in adrenal glands, pituitary gland, brain, and liver.","Found in significant amounts in the liver, kidneys, and spleen.","Widely distributed in tissues, with significant amounts in the liver.","Found in various tissues, including the liver and kidneys","Found in high concentrations in the liver, kidneys, and heart.","Distributed in various tissues, with higher levels in the liver.","Synthesized in the skin upon exposure to sunlight; then, it undergoes metabolic conversion in the liver and kidneys.","Present in small amounts in various tissues, with higher concentrations in the liver and kidneys.","Found in all tissues, particularly in the liver and kidneys.",Accumulates in the retina of the eye.,"Found in marine organisms, especially in seafood such as salmon and krill.","Found in the skin of red grapes and, consequently, in red wine","Essential for blood clotting, found in the liver.",NA,"Widely distributed in tissues, with higher concentrations in adipose tissue and the liver.",Tissue distribution:,Minimal,approx 80%,50-90%,38%,4.6 L/kg,80%,NA,71%,60%,80%,70%,0.9514,97%,NA,96%,+,+,NA,+,+,+,+,+,+,+,+,+,+,NA,NA,the specific tissue distribution of glimepiride and its metabolites is not readily available in the public domain,"Glipizide is primarily distributed to tissues with high blood flow, including the liver and kidneys, where it exerts its pharmacological effects on insulin secretion. It may also distribute to other tissues to a lesser extent","Gliclazide is extensively distributed in tissues with high blood flow, including the liver and kidneys. It has been found in pancreatic tissue, where it acts to stimulate insulin secretion.","Tolbutamide distributes to various tissues, including the liver, kidneys, and skeletal muscle. It may also distribute to adipose tissue.","Chlorpropamide distributes to tissues with high blood flow, including the liver and kidneys. It has been found to distribute to pancreatic tissue, where it acts on pancreatic beta cells to stimulate insulin secretion","Tolazamide distributes to various tissues, including the liver, kidneys, and skeletal muscle","Acetohexamide distributes to various tissues, including the liver, kidneys, and skeletal muscle",NA,glibornuride (5 mg/kg) on the liver tissue of streptozotocin-induced,There is roughly 0.2 l/kg of distribution volume.,The distribution volume is roughly 0.2 l/kg.,There is roughly 0.2 l/kg of distribution volume.,NA,NA,NA,NA,Distributed widely throughout the body,NA,NA,NA,Distributed widely throughout the body,Widely distributed in body tissues,Widely distributed in body tissues,"Widely distributed in body tissues, including bone and teeth",Widely distributed in body tissues,Distributes throughout the extracellular fluid compartment.,"Distributed widely into tissues, including the uterus, gastrointestinal tract, and kidneys.",Widely distributed in body tissues,Distributes throughout the extracellular fluid compartment.,distributes widely throughout the body.,Is rapidly distributed taken up by skeletal tissues following absorption and distribution into extracellular fluids.,Distributed widely throughout the body.,Throughout the body's fluid compartments.,"distributed to various tissues in the body,",Distributed to various tissues in the body,"Distributed throughout the body,",distributed throughout the body via the bloodstream.,distributed throughout the body,distributed throughout the body via the bloodstream,distributed throughout the body via the bloodstream.,distributed throughout the body via the bloodstream,distributed to various tissues throughout the body,distributed throughout the body via the bloodstream.,distributed throughout the body,distributed throughout the body,NA,NA,concentrates in bones,Wide distribution,widely distributed,NA,widely distributed,widely distributed,widely distributed,broad,wide,wide,extensive,targeted,NA,Penetrates into various tissues,Penetrates into various tissues including liver,Penetrates into various tissues,Penetrates into various tissues,Penetrates into various tissues,Penetrates into various tissues,Penetrates into various tissues,Penetrates well into tissues,Tissue distribution:,wide,wide,"Liver,kidney,lungs",vascular permeability,"blood flow,tissue permeability",cell growth & proliferation,widely,monoclonal antibody,hypoxia-inducible factor 2-alpha,widely,liver,"kidneys, inner ear",carmustine,CNS,"liver,kidney",Tissue distribution:,wide distribution in tissue,wide distribution in tissue,NA,Penetrates well into various tissue,Penetrates well into various tissue,Vaginal mucosa,adipose tisue,conc in tissue candidiasis is present,not specified,conc in tissue and cells,con in skin and nails,limited distributiob beyond vaginal mucosa,including lung tissue,crossed into tissue,extensively distributed in the body,volume of distribution of eletriptan following IV administration is 138L,NA,tryptamine,Passage across the placental barrier and into milk,NA,"erytrocytes, with binding reversible and time dependent","brain, kideny, skin ,liver, skeletal muscle","liver, kidney, spleen, blood, muscle, colon, heart","lungs, liver, kidney and heart",liver,liver,0.16 l/kg,800 liters,throughout body water,widely distributed,high volume of distribution,low distribution,5.4-5.8 l/kg disributed,widely through body including CNS,"liver,spleen,thymus,heart",volume of distribuyion 0.35+or-0.02l/kg,predominntaly into peripheral tissue,react with local tissue,wide distribution,wide distribution,widely distributes in liver,wide tissue distribution,wide distribution,widely distributed,yes,yes,Widely distributed,Penetrates well into tissues,Wide distribution throughout the body,Widely distributed,Widely distributed,widely distributed,widely distributed,widely distributed,widely distributed,widely distributed,lymphoid tissues,widely distributed,widely distributed,NA,Tissue distribution:,"Widely distributed in tissues, with high concentrations in adrenal glands, pituitary gland, brain, and liver.","Found in significant amounts in the liver, kidneys, and spleen.","Widely distributed in tissues, with significant amounts in the liver.","Found in various tissues, including the liver and kidneys","Found in high concentrations in the liver, kidneys, and heart.","Distributed in various tissues, with higher levels in the liver.","Synthesized in the skin upon exposure to sunlight; then, it undergoes metabolic conversion in the liver and kidneys.","Present in small amounts in various tissues, with higher concentrations in the liver and kidneys.","Found in all tissues, particularly in the liver and kidneys.",Accumulates in the retina of the eye.,"Found in marine organisms, especially in seafood such as salmon and krill.","Found in the skin of red grapes and, consequently, in red wine","Essential for blood clotting, found in the liver.",NA,"Widely distributed in tissues, with higher concentrations in adipose tissue and the liver.",NA,NA,NA,NA,NA,Minimal,approx 80%,50-90%,38%,4.6 L/kg,80%,NA,71%,60%,80%,70%,0.9514,97%,NA,96%,NA,Blood-brain barrier penetration:,+,+,NA,+,+,+,+,+,+,+,+,+,+,NA,NA,Tissue distribution:,the specific tissue distribution of glimepiride and its metabolites is not readily available in the public domain,"Glipizide is primarily distributed to tissues with high blood flow, including the liver and kidneys, where it exerts its pharmacological effects on insulin secretion. It may also distribute to other tissues to a lesser extent","Gliclazide is extensively distributed in tissues with high blood flow, including the liver and kidneys. It has been found in pancreatic tissue, where it acts to stimulate insulin secretion.","Tolbutamide distributes to various tissues, including the liver, kidneys, and skeletal muscle. It may also distribute to adipose tissue.","Chlorpropamide distributes to tissues with high blood flow, including the liver and kidneys. It has been found to distribute to pancreatic tissue, where it acts on pancreatic beta cells to stimulate insulin secretion","Tolazamide distributes to various tissues, including the liver, kidneys, and skeletal muscle","Acetohexamide distributes to various tissues, including the liver, kidneys, and skeletal muscle",NA,glibornuride (5 mg/kg) on the liver tissue of streptozotocin-induced,There is roughly 0.2 l/kg of distribution volume.,The distribution volume is roughly 0.2 l/kg.,There is roughly 0.2 l/kg of distribution volume.,NA,NA,NA,Tissue distribution:,NA,Distributed widely throughout the body,NA,NA,NA,Distributed widely throughout the body,Widely distributed in body tissues,Widely distributed in body tissues,"Widely distributed in body tissues, including bone and teeth",Widely distributed in body tissues,Distributes throughout the extracellular fluid compartment.,"Distributed widely into tissues, including the uterus, gastrointestinal tract, and kidneys.",Widely distributed in body tissues,Distributes throughout the extracellular fluid compartment.,distributes widely throughout the body.,Tissue distribution:,Is rapidly distributed taken up by skeletal tissues following absorption and distribution into extracellular fluids.,Distributed widely throughout the body.,Throughout the body's fluid compartments.,"distributed to various tissues in the body,",Distributed to various tissues in the body,"Distributed throughout the body,",distributed throughout the body via the bloodstream.,distributed throughout the body,distributed throughout the body via the bloodstream,distributed throughout the body via the bloodstream.,distributed throughout the body via the bloodstream,distributed to various tissues throughout the body,distributed throughout the body via the bloodstream.,distributed throughout the body,distributed throughout the body,Tissue distribution:,NA,NA,concentrates in bones,Wide distribution,widely distributed,NA,widely distributed,widely distributed,widely distributed,broad,wide,wide,extensive,targeted,NA,Penetrates into various tissues,Penetrates into various tissues including liver,Penetrates into various tissues,Penetrates into various tissues,Penetrates into various tissues,Penetrates into various tissues,Penetrates into various tissues,Penetrates well into tissues,Tissue distribution:,wide,wide,"Liver,kidney,lungs",vascular permeability,"blood flow,tissue permeability",cell growth & proliferation,widely,monoclonal antibody,hypoxia-inducible factor 2-alpha,widely,liver,"kidneys, inner ear",carmustine,CNS,"liver,kidney",wide distribution in tissue,wide distribution in tissue,NA,Penetrates well into various tissue,Penetrates well into various tissue,Vaginal mucosa,adipose tisue,conc in tissue candidiasis is present,not specified,conc in tissue and cells,con in skin and nails,limited distributiob beyond vaginal mucosa,including lung tissue,crossed into tissue,widely,NA,Wide distriution,Widely distriuted,NA,Widely distriuted,widely distriuted,widely distriuted,widely distriuted,widely distriuted,Widely,moderate,widely distributed,minimal distribution,widely distriuted,NA,minimal distribution,widely distributed,Widely distributed,widely distributed,widely distributed,widely distriuted,widely distributed,widely distriuted,widely distriuted,widely distributed,widely distributed,widely distriuted,YES,widely distributed,widely distributed,soft tissue and bone,skeletal tissues,bone tissue,bone tissue,bone tissue,bone tissue,bone tissue,bone tissue,bone tissue,bone tissue,bone tissue,bone tissue,bone tissue,RANK ligand (protein),NA,80%,74%,Upadacitinib demonstrated an oral bioavailability of 76%,64-90%,Approximately 80-90% of an oral dose,The oral bioavailability of sulfasalazine is reported to be approximately 10-30%.,Oral bioavailability is reported to be around 37% for azathioprine.,30%,~ 75%,70% to 80%,subcutaneous bioavailability of 56.9% ,70%,95%,Adalimumab is typically considered to have a bioavailability of 100% following subcutaneous injection,typically considered to have a bioavailability of 100% following subcutaneous injection,NA,Tissue distribution includes liver,tissue distribution includes liver,Vol of distribution ranges between 16.4 and 26.6L,VOL of distribution is 9166L,6 litres,0.18I/kg of distribution,92L (45%),Apparent vol of distribution is 164 L (70%),Apparent volume of distribution was 806 L,Apparent vol of distribution is 70.3L,more than 90%,NA,106L,7.21L,NA,"evenly distributed in all tissues, but with highest concentrations in kidney and liver. ",The central volume of distribution of amoxicillin is 27.7L. Amoxicillin is 17% protein bound in serum.,Cephalexin is widely distributed to body fluids and tissues.,"Tissue Distribution Penetration of ceftriaxone into lung, nasal mucosa, tonsil, and middle ear mu cosa ", imipenem ranges from 0.23-0.31 L/kg. Imipenem is 20% bound to plasma proteins, widespread and rapid penetration of meropenem into the interstitial fluid of those tissues not protected by a tight epithelial barrier.,with a volume of distribution ranging from 0.4 to 1 L/kg,Omadacycline was widely distributed into tissues and bile in rats ,"Cefotaxime appears to penetrate most body tissues and fluids, including cerebrospinal fluid.",The high lipid solubility of tiamulin accounts for its extensive distribution throughout the tissues of birds and mammals,"muscle and subcutaneous adipose tissue,",It is distributed mainly into the extra-cellular space.,"Cefepime, like most cephalosporins, is widely distributed throughout body tissue and fluids, including pleural fluid, synovial fluid, bones,",ceftaroline soft tissue and cerebrospinal fluid (CSF) distributions,3 L/kg,2-4 L/kg,0.6 L/kg,Not known,4.2L/kg,4L/Kg,4.2L/kg,50 L/kg,3.8 L/kg,3-13 L/kg,21 L/kg,1.4 L/kg,2.2 L/kg,10 L/kg,2.3 L/kg,3.93±1.13mg/L,28.5 ± 14.5 µg/mL ,1.8 ± 0.6 ?g/mL,0.35-0.45 ?g/ml,2?g/ml,13.9?g/ml,6.2 ± 1.0 µg/mL,1.02 ± 0.53 ?g/mL,155 µG/mL,15.3mg/L,163.9 ?g/mL,11.6 ?g/m,22.20?g/ml,1.61 + or - 0.51 ug/m,15.25 µg/ml,Limited penetration,Limited penetration.,Limited penetration.,Limited penetration.,Limited penetration.,Limited penetration,"Yes, but limited.",Limited penetration.,Limited penetration.,Limited penetration.,Limited penetration.,Limited penetration.,Limited penetration.,Limited penetration,NA,"Zanamivir distributes primarily to Bronchial epithelial cells and lung tissues,where it exerts its antiviral effects against influenza viruses","It can reach various tissues, including the 
respiratory tract, where it exerts its antiviral effects against influenza viruses.","Active metabolite of oseltamivir distribution includes 
respiratory tract tissues whew influenza viruses replicate, after oral administration
oseltamivir carboxylate by esterase in the
liver and other tissues


","Abacavir tissues typically found in organs
like Liver,spleen,kidneys","Acyclovir tissues typically found in organs
like Liver,kidneys,skin","Valacyclovir tissues typically found in organs
like CNS,kidneys,skin","Bolaxavir tissues found in respiratory tract
tissue,includes lungs and bronchial 
epithelial cells","Cidofovir tissues typically found in organs
like liver,spleen,eyes,kidneys,skin","Adefovir tissues typically found in organs
like liver,kidneys,","Fostemsavir is distributed throughout
the body","Tenofovir includes liver,kidneys,lymphoid
tissue and genital tract","Amprenavir includes organs like liver,
spleen,lymph nodes,and CNS","Atazanavir includes organs like liver,
spleen,lymph nodes,and CNS","Boceprevir is distributed throughout
the body","Combivir includes organs like liver,
spleen,lymph nodes,and CNS","Crosses placenta, enters breast milk",Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier and distributed in the brain,Distributed throughout various tissues,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Not specified,Penetrates well into tissues,Crosses the blood-brain barrier,Crosses the blood-brain barrier,"Crosses placenta, enters breast milk",Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier and distributed in the brain,Distributed throughout various tissues,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Crosses the blood-brain barrier,Not specified,Penetrates well into tissues,Crosses the blood-brain barrier,Crosses the blood-brain barrier
C-max,20-60 ng/mL,20-200 ng/mL,10-20 ng/mL,NA,2- 4 ?g/mL,2- 4 ?g/mL,200-800 ng/mL,NA,3-6 mg/L (100mg of caffeine),5-10 mins (smoking),~1-2 hours,~3-4 hours,10-30 ng/mL,200-300 ng/mL,1-2 hours,Variable,0.6 ng/mL (after a single 1 mg dose),0.2-0.7 µg/mL,1-2 hours post-dose,Achieved within 1 hour post-dose,Not available,Achieved within 2 hours of oral administration,1-2 hours,Achieved within 2-4 hours after administration,10–30 ng/mL (subcutaneous),1-2 hours,1-2 hours post-dose,Not specified,~ 1-2 hours,Cytochrome P450 enzymes:,CYP3A4,CYP3A4,CYP3A4,CYP3A4,CYP3A4,NA,CYP3A4,CYP2D6 & CYP2C16,CYP3A4 & CYP3A5,CYP3A4,CYP3A4,CYP3A4 & CYP2D6,CYP3A4,CYP1A2 & CYP3A4,CYP3A4,Rapidly achieved,Variable,1-2 hours post-dose,Yes,Variable,Not applicable,Not specified,Not applicable,Variable,Not specified,Variable,C-max,Variable,Variable,Variable,Variable,Variable,Variable,Variable,Variable,NA,NA,NA,NA,NA,Variable,NA,4.84 ng/mL,1 - 3 hrs,3-5hrs,NA,NA,2-3 hrs,NA,2-3 hrs,2-4 hrs,1- 2 hrs,0.5 to 2.5 hrs,40 - 50 min,1 hrs,NA,C-max,4 hours,2-4 hours,2-3 hours,6 hours,3 hours,5 hours,2-12 hours,0.5-2 hours,2 hours,4 hours,2 hours,NA,NA,3.50 ± 0.21 h,Alectinib: 33hr M4: 31hr,3.5 hours,25 hours,41 hours,30-100 hours,6-12 hours,11 hours,5.8 hours,1.7 to 19.4 hours,3.5 hours,27.7 to 43.6 hours,48 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Azathioprine generally has limited penetration across the blood-brain barrier. Its ability to enter the central nervous system is restricted, which is often desirable for drugs used to treat systemic conditions without causing central nervous system effects.","the maximum concentration of Acitretin, amedication used to reat several psoriasis , typically occure within 2 to 4 hours after oral administration. C max can vary based on factor such as dosage and individual patient characteristic.",NA,It depends on the dose and route of administration. Oral administration reached within 1-2 hours,NA,"for oral formulation, its typcally reached within 1 to 3 hours",The peak concentration in plasma occurs after topical application and varies depending on the formulation.,): The peak plasma concentration of betamethasone depends on the route of administration. Intravenous administration would result in a quicker and higher peak concentration compared to oral or topical administration,The peak concentration in plasma occurs after topical application and varies depending on the formulation.,"Specific values may vary based on the formulation, but systemic levels are generally low due to topical use.",Systemic levels are generally low due to topical use,adalimumab typicallyccurwithin 3 to 5 days,3-4 hours,NA,6-7 hrs,NA,NA,NA,NA,1-4hrs,NA,4hrs,NA,NA,2-6hrs,NA,NA,NA,82mU/ml,100uU/ML,3 to 10nmol/L,100units/ml,200units/ml,40 to 300uU/ml,83microunits/ml,50 to 100pg/ml,82mU/ml,2 to 3hours,1.67-2.5hours,NA,NA,40-50 minutes,1.5 to 2.5 hours,NA,Blood-brain barrier penetration:,Yes,Limited,Limited,Yes,Yes,Yes,Yes,Yes,limited,Yes,limited,yes,limited,Yes,yes,(Cmax) is typically achieved within 2 to 3 hours after administration.,within 1 to 2 hours after oral administration.,occurs within 1 to 3 hours,within 1 to 2 hours after oral administration.,within 2 to 4 hours after oral administration.,s within 1 to 2 hours after oral administration.,within 2 to 3 hours after oral administration.,within a few hours after oral administration.,within 6-8 hours after oral administration.,3-4 hours after oral administration.,within 1-2 hours after oral administration.,within 1-2 hours after oral administration.,within 6-8 hours after oral administration with food,within 1-2 hours after oral administration.,Nizatidine typically occurs within 1-3 hours after oral administration.,The peak concentration (Cmax) of amikacin in the bloodstream depends on the dose and the rate of administration.,"The maximum concentration of plazomicin in the bloodstream, also known as Cmax, is influenced by factors such as the dose and administration method. Generally, when plazomicin is administered intravenously (IV), peak concentrations are reached within 1 to 2 hours.","The C(max) of AZM was 0.67 +/- 0.31 mg/L in plasma and 2.01 +/- 0.74 mg/L in blood, of which 1.44 +/- 0.69 mg/L was found in PMNNs.",Cmax 3.93±1.13mg/L,NA,Cmax 1 g intramuscular injection. 1 g rapid intravenous infusion. 70 mg/L. 172 mg/L after 5 min.,"Cmax is typically achieved within 1 to 2 hours after ingestion. Intravenous administration results in a faster onset, with Cmax reached within 5 to 10 minutes.","Cmax (37.5, 0.8 ?g/mL)",0.164 ± 0.04 mg/L in the 100 mg every 12 hours group,C max = 2.2 ng/ml,The peak plasma concentration (Cmax) of meropenem typically occurs within one hour after intravenous administration.,Cmax: 20.7mcg/ml,"Generally, peak concentrations are reached within 1 to 2 hours after oral administration",The Cmax on day one of the above dose of ceftolozane-tazobactam was 69.1 mcg/mL.13,"Generally, after oral administration, Cmax is reached within 2 to 3 hours.",NA,1-2 hrs,0.5-2 hours,1-2 hrs,1-2HRS,5 min to 1 hr,2-4 hrs,3-5 hrs,15 min,2-4 hrs,1-2hrs,1-2 hrs,0.5-1.5 hrs,1-2 hrs,0.5-2 hrs,10-20 ?g/mL,2-8 hours,"Variable, dependent on dosage and formulation",Achieved within 1.4 to 4.8 hours after oral administration,Achieved within 1 hour after oral administration,Reached within 2-4 hours after oral administration,2-4 hours,Not specified,30-60 µg/mL,1-2 hours,Not specified,Not specified,Reached within 2-3 hours post-dose,2-6 hours,Reached within 1-2 hours,5.5 mg/lit at 2.3 hours after the dose,10-20 ?g/mL,Reached within 1-2 hours,2-6 hours,Reached within 2-3 hours post-dose,Not specified,Not specified,1-2 hours,4-6 hours,"Variable, dependent on dosage and formulation",Achieved within 1.4 to 4.8 hours after oral administration,2-8 hours,Achieved within 1 hour after oral administration,1-2 hours,30-60 µg/mL,1-4 hours,2-4 hours,Not specified,Varies,2-6 hours,1-4 hours after oral administration,1-2 hours,Achieved within 1-2 hours,3-5 hours post-dose,Achieved in 4-5 hours,2-4 hours,2-6 hours,Varies,Not Available,Not available,peak concentration,1 to 2 hours after oral administration.,2-3 hours,highest concentration of lidocaine in the blood after administration,2 to 4 hours after oral administration.,3-4 hours,depending on the route of administration and dose,1-3 hours after oral administration,1-2 hours after oral administration.,2-3 hours after oral administration.,1 to 2 hours,within minutes.,3 to 7 hours after oral administration.,NA,1-3 hours post-dose.,50 to 200 ug/ml,Depends on treatment protocol,Depends on treatment protocol,Depends on treatment protocol,not applicable,variable,not applicable,2 hrs,3 hours,5 hours,NA,not applicable,2-4 hours,2-4 hours,not specified,0.11 to 2.3 micromolar after a 20 mg/m. 2 dose,"can vary depending on various factors such as the dose,",vary depending on several factors.,vary depending on factors such as the dose,400 to 1500 ng/mL,212 ± 74 ng/mL ,100 to 400 ng/mL,2 to 10 ?g/mL,"between 15 min and 120 min following dose 1, ranging from 9.8–114.6 ?g/ml ",30 to 50 ?g/mL,10 to 20 ?g/mL, 492 ± 160 ng/mL,0.1 to 1 ?g/mL,based on mode of administration, 492 ± 160 ng/mL,2-3hrs,2-3 hrs,1-2 hrs,1-3 hrs,2-3hrs,1-3hrs,30min - 3hrs,1-2hrs,30min - 1hr,30min-1hr,1-2hr,1-3hr,1-2hr,2-3hr,1-2hr,0.2 to 5 mcmol/L,3 to 30 mcmol/L,NA,1 to 6 mcmol/L,NA,NA,120–135 ng/mL,"1,446.30 ng/mL",180 mg (1452 ng/mL),NA,NA,2to4hrs,2.38 ng/mL , 450 mg/mL ,0.01 ?M," 18±15ng/mL, 52±51ng/mL, 121±98ng/mL, and 245±110ng/mL", 2.5 micrograms/L, 62.0%,33.4±4.8 ng ml?1,400.72pg/mL ,12-22 ?g/L,NA,19.9 (17.9–27.9) mg l?1.,20 - 25 c,NA,500 mg, 2 to 8 hours after an oral dose.,Not cross,active P-glycoprotein,unable to cross blood brain barrier,about 0.5 mg/ml at 30 min,Unable to cross the blood-brain barrier,penetrate into the brain,unable to cross blood brain barrier,an effective coc. Of ergotamine could penetrate,pass blood brain barrier,crosses the blood brain barrier and the placenta,easily cross blood brain barrier,unable to cross blood brain barrier,NSAIDs cross the blood brain barrier,not able to cross blood brain barrier,easily cross blood brain barrier,Retained,low affinity for crossing BBB,limited penetration to cross,Inability to cross,activate uptake at the BBB,lack of penetration throgh BBB,cross the BBB,penetrate BBB,anbility to cross BBB,cross BBB,cross BBB,penetrate BBB,cross BBB,does not penetrate BBB,easily cross BBB,No,yes,NA,YES,Limited,Yes,Yes,Limited,yes,Limited,Limited,Limited,limited,limited,limited,Ascorbic acid has limited ability to cross the blood-brain barrier (BBB) in significant amounts.,positive,"Vitamin B12 has a complex transport mechanism, and its ability to cross the blood-brain barrier is limited. Specialized transport proteins are required for its entry into the brain.","Niacin can cross the blood-brain barrier, and some studies suggest it may have neuroprotective effects.",Riboflavin is water-soluble and may have limited ability to penetrate the blood-brain barrier.,"Thiamine can cross the blood-brain barrier, facilitated by specific transporters.","Choline can cross the blood-brain barrier, and it is a precursor to acetylcholine, an essential neurotransmitter.","Vitamin D, including cholecalciferol, may have limited ability to cross the blood-brain barrier.",Biotin is a water-soluble vitamin that may have limited ability to penetrate the blood-brain barrier.,Pantothenic acid can cross the blood-brain barrier.,Lutein is a carotenoid that may have limited ability to cross the blood-brain barrier.,Astaxanthin's ability to cross the blood-brain barrier is not well-established.,Resveratrol may have limited ability to cross the blood-brain barrier.,Vitamin K1 (phylloquinone) has limited penetration of the blood-brain barrier.,"Alpha-tocopherol, a form of vitamin E, has some ability to cross the blood-brain barrier.",Blood-brain barrier penetration:,limited penetration,10-20%,10-20%,0.6151,0.9047,0.5499,0.9208,0.9514,NA,0.96,0.9381,0.9214,0.9876,NA,NA,NA,0.5?g/ml,9.2?g/ml,11 ?g/ml,417 ±218 ?g/ml,10.71 ?g/ml,95.12 ?g/ml,2.5-3 ?g/ml,2.51?g/ml,1?g/ml,1?g/ml,1.4- 0.8?g/ml,4.84?g/ml,13.07?g/ml,0.86- 1.06?g/ml,may cross the blood-brain barrier to some extent. ts penetration and its direct effects on the central nervous system are not as well understood as its effects on peripheral tissues.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,NA,Limited,NA,limited penetration,NA,Limited,Limited,Limited,Limited,Limited,"Limited penetration
due to its polar nature.",Limited penetration into the central nervous system.,Limited,Limited penetration due to its polar nature.,Limited penetration.,"poorly penetrates the BBB due to its large molecular size & low
lipid solubility.","limited extent, potentially affecting central nervous system functions.","some extent, primarily due to its small size and ability to diffuse across membranes.","limited penetration across the blood-brain barrier, which restricts its access to the brain.","Its large size and hydrophilic nature, restricting its
direct access to the brain.","limited extent, potentially due to its small molecular
size and lipophilic properties.","poorly penetrates the BBN, limiting its central nervous system effects","Its physicochemical properties, potentially reducing
its central nervous system effects.","limited extent, allowing it to potentially affect central nervous system functions.","its physicochemical properties and efflux mechanisms, potentially reducing its central nervous system effects.","limited ability to penetrate the BBB due to its hydrophilic
nature and large molecular size.",demonstrates limited penetration of the blood-brain barrier.,"limited extent due to its small size and solubility, potentially affecting brain function.","limited extent due to its small size and solubility, potentially affecting brain function.",NA,NA,limited,NA,limited,limited,NA,NA,limited,limited,limited,NA,NA,NA,NA,NA,Limited,Limited,Limited,Limited,Limited,Limited,Limited,Limited,Blood-brain barrier penetration:,CNS,CNS,pharmacokinetics & therapeutics,brain tumors,pharmacokinetics & therapeutics,cancer treatment,CNS,vascular permeability,CNS,carmustine,hydrophilic,CNS,carmustine,lomustine,brain &7 spinal cord,Blood-brain barrier penetration:,penetrates well,penetrates well,limited information,moderate into cns,limited into cns,NA,limited penteration into cns,limited,not specified,limited in penteration into cns,limited in penterates into cns,limited in penterates into cns,limited penteration into cns,limited penteration into cns,Not cross,active P-glycoprotein,unable to cross blood brain barrier,about 0.5 mg/ml at 30 min,Unable to cross the blood-brain barrier,penetrate into the brain,unable to cross blood brain barrier,an effective coc. Of ergotamine could penetrate,pass blood brain barrier,crosses the blood brain barrier and the placenta,easily cross blood brain barrier,unable to cross blood brain barrier,NSAIDs cross the blood brain barrier,not able to cross blood brain barrier,easily cross blood brain barrier,Retained,low affinity for crossing BBB,limited penetration to cross,Inability to cross,activate uptake at the BBB,lack of penetration throgh BBB,cross the BBB,penetrate BBB,anbility to cross BBB,cross BBB,cross BBB,penetrate BBB,cross BBB,does not penetrate BBB,easily cross BBB,No,yes,NA,YES,Limited,Yes,Yes,Limited,yes,Limited,Limited,Limited,limited,limited,limited,NA,Blood-brain barrier penetration:,Ascorbic acid has limited ability to cross the blood-brain barrier (BBB) in significant amounts.,positive,"Vitamin B12 has a complex transport mechanism, and its ability to cross the blood-brain barrier is limited. Specialized transport proteins are required for its entry into the brain.","Niacin can cross the blood-brain barrier, and some studies suggest it may have neuroprotective effects.",Riboflavin is water-soluble and may have limited ability to penetrate the blood-brain barrier.,"Thiamine can cross the blood-brain barrier, facilitated by specific transporters.","Choline can cross the blood-brain barrier, and it is a precursor to acetylcholine, an essential neurotransmitter.","Vitamin D, including cholecalciferol, may have limited ability to cross the blood-brain barrier.",Biotin is a water-soluble vitamin that may have limited ability to penetrate the blood-brain barrier.,Pantothenic acid can cross the blood-brain barrier.,Lutein is a carotenoid that may have limited ability to cross the blood-brain barrier.,Astaxanthin's ability to cross the blood-brain barrier is not well-established.,Resveratrol may have limited ability to cross the blood-brain barrier.,Vitamin K1 (phylloquinone) has limited penetration of the blood-brain barrier.,"Alpha-tocopherol, a form of vitamin E, has some ability to cross the blood-brain barrier.",NA,NA,NA,NA,NA,limited penetration,10-20%,10-20%,0.6151,0.9047,0.5499,0.9208,0.9514,NA,0.96,0.9381,0.9214,0.9876,NA,NA,NA,C-max,NA,0.5?g/ml,9.2?g/ml,11 ?g/ml,417 ±218 ?g/ml,10.71 ?g/ml,95.12 ?g/ml,2.5-3 ?g/ml,2.51?g/ml,1?g/ml,1?g/ml,1.4- 0.8?g/ml,4.84?g/ml,13.07?g/ml,0.86- 1.06?g/ml,Blood-brain barrier penetration:,may cross the blood-brain barrier to some extent. ts penetration and its direct effects on the central nervous system are not as well understood as its effects on peripheral tissues.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Limited BBB penetration.,Blood-brain barrier penetration:,NA,Limited,NA,limited penetration,NA,Limited,Limited,Limited,Limited,Limited,"Limited penetration
due to its polar nature.",Limited penetration into the central nervous system.,Limited,Limited penetration due to its polar nature.,Limited penetration.,Blood-brain barrier penetration:,"poorly penetrates the BBB due to its large molecular size & low
lipid solubility.","limited extent, potentially affecting central nervous system functions.","some extent, primarily due to its small size and ability to diffuse across membranes.","limited penetration across the blood-brain barrier, which restricts its access to the brain.","Its large size and hydrophilic nature, restricting its
direct access to the brain.","limited extent, potentially due to its small molecular
size and lipophilic properties.","poorly penetrates the BBN, limiting its central nervous system effects","Its physicochemical properties, potentially reducing
its central nervous system effects.","limited extent, allowing it to potentially affect central nervous system functions.","its physicochemical properties and efflux mechanisms, potentially reducing its central nervous system effects.","limited ability to penetrate the BBB due to its hydrophilic
nature and large molecular size.",demonstrates limited penetration of the blood-brain barrier.,"limited extent due to its small size and solubility, potentially affecting brain function.","limited extent due to its small size and solubility, potentially affecting brain function.",NA,Blood-brain barrier penetration:,NA,limited,NA,limited,limited,NA,NA,limited,limited,limited,NA,NA,NA,NA,NA,Limited,Limited,Limited,Limited,Limited,Limited,Limited,Limited,Blood-brain barrier penetration:,CNS,CNS,pharmacokinetics & therapeutics,brain tumors,pharmacokinetics & therapeutics,cancer treatment,CNS,vascular permeability,CNS,carmustine,hydrophilic,CNS,carmustine,lomustine,brain &7 spinal cord,penetrates well,penetrates well,limited information,moderate into cns,limited into cns,NA,limited penteration into cns,limited,not specified,limited in penteration into cns,limited in penterates into cns,limited in penterates into cns,limited penteration into cns,limited penteration into cns,yes,YES,YES,YES,YES,YES,YES,YES,YES,YES,YES,YES,YES,YES,YES,NA,YES,YES,YES,YES,YES,YES,YES,YES,YES,YES,YES,yes,50%,YES,YES,limited,limited,limited,limited,limited,linited,limited,limited,Limited,Limited,NA,NA,limited,limited,NA,None specified,none,None reported,Transcutol and salicylic acid,none,Not specified,"dimethylsulfoxide (DMSO), dimethylformamide (DMF), and urea ",Acetazolamide.,None specified,None commonly used,N/A,Not commonly used,Not commonly used,administered via subcutaneous injection and does not typically require absorption enhancers,does not typically require absorption enhancers,NA,claudin-5 is the dominant tight junction protien and its absence contributes to an increased permeability of BBB for molecules gr,partially cross the BBB,The protien binding affects the CNS delivery as protein bound vismodegib is unable to penetrate BBB,High tissue penetration and favourable BBB penetration,limited BBB PENETRATION,limited BBB penetration,limited BBB penetration it has poor penetration in CNS,LOW BBB penetration,low BBB penetration,low permeability,"dacarbazine, which resulted in a poor median survival of 5–6 months ... penetrate the BBB but also reach the intended target within the brain.",low permeablity,permeable,Permeable,NA," Ampicillin is the exception to this drug class, with high levels of CNS penetration being achieved despite",". The drug proved capable of passing the blood-brain barrier when employed in sufficiently high doses, even in the absence of meningeal inflammation.",They are able to penetrate the blood–brain barrier. Third-generation cephalosporins have improved ?-lactamase stability ,"The protein-unbound, free fraction of ceftriaxone can passively penetrate the blood-brain barrier",imipenem was transported through the blood-brain barrier principally via passive diffusion,CSF concentrations would highly underestimate the target site activity of meropenem beyond the blood–brain barrier.,VCM administered intravenously must pass the blood-brain barrier (BBB) to enter the CSF,Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections. ,hey cross the blood–brain barrier (BBB) and reach therapeutic concentrations in the central nervous system (CNS).,". Penetration of penicillin, ampicillin, oxacillin, tetracycline, streptomycin and gentamycin through the hemato-encephalic barrier", good penetration through healthy meninges within 2–6 h post-dose ,Piperacillin crosses both the inflamed and non-inflamed blood-brain barrier albeit in unpredictable amounts,Background. Cefepime is a widely used antibiotic with neurotoxicity attributed to its ability to cross the blood–brain barrier, Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections,Less,Less,Limited,Limited,Limited,Crosses,Good,Limited,Cross,Limited,Crosses,Limited,Limited,Limited,Crosses,61.3 minutes,49.5 minutes,1.6 ± 0.4 hours,68 hours,6-11 hours,346 hours,6-8 hours,3 hours,2.5 hours ,NA,13.5 hours, 5.4 ± 1.0 hours,1.5 hours,7± 2 hours,2-3 hours,Typically reached within 2 hours after oral administration,Typically reached within 2 hours after oral administration,Typically reached within 2 hours after oral administration,Typically reached within 2 hours after oral administration,Typically reached within 1-2 hours after oral administration.,Typically reached within 2-5 hours after oral administration.,reached within 1-2 hours after oral administration.,reached within 1-3 hours after oral administration.,reached within 1-3 hours after oral administration.,Typically reached within 1-3 hours after oral administration.,Typically reached within 1-2 hours after oral administration.,NA,NA,2.6830±1.2161ng/mL,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes
Half life,9-14 hours,9-12 hours,2-3 hours,~10 hours,~15 hours,~12-15 hours,~3-6 hours,~1 hour (short due to rapid metabolism),~3-5 hours,~2 hours,"~4-5 hours (children), ~10-12 hours (adults)",~19-24 hours,~5-8 hours,~4-6 hours,1.5-2 hours,~17 hours,Approximately 1 hour,1.5-2 hours,Approximately 1.5 hours,Terminal half-life is approximately 1.5 hours,6-12 hours,Approximately 8 hours,6 hours,Approximately 20 hours,Approximately 40 minutes,15 hours,Approximately 20 hours,Approximately 3-6 hours,~ 2-3 hours,Inactive metabolites,alpha-hydroxy triazolam,oxazepam,7-aminonitrazepam,"desmethyldiazepam , oxazepam",3-0-phenolic glucorunide,conjugates of glucoronide,5-oxodesethylzaleplon,conjugates of glucoronide,7-Aminoclonazepam & hydroxyclonazepam,Hydroxybutabarbital,Desalkylflurazepam,Meta-Chlorophenylpiperazine,conjugates of glucoronide,Hydroxylated metabolites,NA,Approximately 20-30 minutes,Approximately 3-10 hours,1.8-2.5 hours,Reached in 2-4 hours,Approximately 10-20 hours,Approximately 24 hours,2-4 hours,Approximately 6-12 hours,Approximately 4-11 hours,Approximately 24-48 hours,"Approximately 3-4 hours (short-acting), 36-54 hours (long-acting)",Half life,Short,Short,Long(2-8hrs),6-7hours,25 hours,20-50 hours,21 hours (average),16-18 hours,NA,NA,NA,10-17 hours,10-17 hours,9-24 hours,NA,81 min,2 to 5 hrs,7hrs,NA,2hrs,approx 5-9 hrs,approx 2hrs,3-7 hrs,4-8.7 hrs,12 hrs,1 to 1.5 hrs,NA,approx 1hrs,NA,Half life,27-32 hours,35 hours,5 hours,12 hours,21 hours,21 hours,10-26 hours,5-9 hours,20-40 hours,18-44 hours,15 hours,NA,NA,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,26-80 min 3-5 hours (drug pius metabolites),approximitely 49 hours,14 to 16 hours,"2] low-dose oral administration - It is approximately 3-10 hours. high-dose intravenous administration - It may be longer, extending to 8-15 hours or more.", 2–4 hours,aprox 6-20 hours,"The half-life of Clobetasol is relatively short, typically less than 2 hours","The half-life of betamethasone is relatively short, typically ranging from hours to a few hours. The exact half-life can be influenced by factors such as formulation and individual patient characteristics","The half-life of Calcipotriene is relatively short, typically less than 6 hours",The elimination half-life of Tazarotene and its active metabolites is relatively short,The elimination half-life of Pimecrolimus is relatively short,6-9 hours,120-180 houes,NA,2-4 hrs,2-4 hrs,1-2 hrs,16-19hrs,6hrs,3-6hrs,5-8 hrs,9-13hrs,5-6hrs,30 hrs,14-26hrs,NA,NA,Half life,81Minutes,12 hours,5-7 hours,120-206Minutes,25 hours,1 to 1.5 hours,42minutes,48minutes,81minutes,5 to 8 hours,2.3-2.7 hours,4.5 days,8 to 14 hours,NA,120-206min.,NA,C-max,650-1300µg/L,2-4 hours,3-6 hours,12-24 hours,10 to 20 µg/mL,6-8 hours,2 to 3 hours,2-6 hours,NA,2-6 hours,NA.,NA,1-3 hours,NA,2 to 3 hours,approximately 2 to 3 hours,2.5 to 3.5 hours,approximately 2 to 3 hours,approximately 10 to 20 hours.,approximately 10 hours.,approximately 10 hours.,may vary depending on individual patient factors and dosing regimen.,approx 6-7 hours,approximately 15-30 days.,approximately 12-16 hours.,approximately 3-4 hours,approximately 7 hours.,approximately 24-48 hours.,approximately 1-2 hours.,The half-life of amikacin is approximately 2 to 3 hours in individuals with normal kidney function.,The mean (±SD) half-life of plazomicin was 3.5 h (±0.5) in healthy adults with normal renal function receiving 15 mg/kg plazomicin via intravenous infusion Label.,The mean terminal elimination half-life of azithromycin is 2 to 4 days.,half life of amoxicillin is 61.3 minutes.8,with serum half-lives (t1/2s) of 1 to 2 hours.,half-life of approximately 5 h.,Ampicillin is poorly bound to plasma protein (10%) and has a half-life of 2 to 4 hours;,Sulfadiazine has an elimination half-life of 8 to17 h (mean 10 h) in healthy volunteers,18 ± 3 hours,1.4 hours or less.,The half-life of meropenem (approximately 1 hour in healthy volunteers) is prolonged up to 13.7 hours in anuric patients with end-stage renal disease.,Half-life: 0.6hr,The elimination half-life of ciprofloxacin is typically around 3 to 5 hours in individuals with normal kidney function.,"2.77 hours on day 1 of treatment on a dose of 1 g/0.5 g every 8 hours.13,6 3.12 hours on day 10 of treatment on a dose of 1 g/0.5 g every 8 hours.13","general, the half-life is approximately 3 to 4 hours.","3-5 hrs (oral), 2-7 hrs (inhaler), 5-7 hrs (IV)",6-8hrs,3-4 hrs,7-9 hrs,1.6HRS,25-30 hrs,3-6hrs,8-12 hrs,1-2 hrs,12 hrs,1.5-2hrs,2-4 hrs,0.5-1.5 hrs,2-3 hrs,2-3 hrs,19-24 hours,36 hours (average),9-16 hours,Average of 25 to 33 hours,Approximately 6-8 hours,Approximately 21 hours,9 hours (average),36-42 hours,20-23 hours,5-8 hours,5 to 8 hours,6-10 hours,5-7 hours,63-69 hours,Approximately 6 hours,"100 hours for adult , 103 - 141 hours for preterms infants",19-24 hours,Approximately 6 hours,63-69 hours,5-7 hours,6-10 hours,5 to 8 hours,5-8 hours,40-60 hours,9-16 hours,Average of 25 to 33 hours,36 hours (average),Approximately 6-8 hours,20-50 hours,20-23 hours,30 hours,21-27 hours,~6-8 hours,3-6 hours,14-26 hours,6-8 hours,12 hours,20 hours,Approximately 75 hours,91 hours,~24 hours,3 days,7-12 hours,Approximately 2-4 days,18-24 hours,6 to 8 hours,3 to 4 hours,6-10 hours.,1.5 to 2 hours,10 to 12 hours,10 to 20 hours,1 to 2 minutes,36 to 48 hours,"2 to 7 hours, with an average of around 4-5 hours in most individuals.",3 to 6 hours,3 to 6 hours,9 minutes,40 to 100 days,12 hours,3-4 hours,27 days,20 days,1-3 hours,55 hours,18 days,55 hours,7 days,28 hours,24-48 hours,21 hours,2.9-4.3 hours,18 hours,20-30 hours,20-30 hours,36 hours,8 to 15 hours., less than one minute.,1.5 to 4.1 hours,4.7-10.2 hours,NA,1.5 ± 0.83 hours.,~40 minutes.,16 to 48 hours.,3 to 12 hours,5 to 6 hours," 4 to 8 hours,",1.5 hours,10 minutes ,"The half-life of fludarabine is relatively long, allowing for less frequent dosing",10 to 20 hours,3 hrs,0.9-1.6 hrs,2 hrs,2.5-3 hrs,2.5-3 hrs,1.6 hrs,1.04+-0.5,1.5-2hrs,18-54min,2hrs,6-20hrs,0.5-3hr,1hr,3-4hrs,2.1-2.5 hrs,13 to 27 hrs,25 to 49 min,33 hrs,11 to 19 hrs,3.5 hrs,16.5 hr,42 hr,20 and 40 hrs,25 hours,36.2 hrs (median),"Short infusions: 32–94 minutes
Long infusions: 245–638 minutes",37 hrs,30–56 hours,8.2 hours.,20.0 hours in adults (mean age 29.3 years) and 7.1 hours in children.,8 hours.,2 to 3 hours.,5 hours,10–20 hours, 5 and 13 hours., 12 hours,"between 16 and 40 hours, with a mean of 25 hours",50–160 h in adults,5 to 30 hours ,15–48 hours, ? 9 hours, 21 h,1.5-4 hours,>=264 ng/ml,8.0 ng/mL,NA,16.5 ng/mL,2.5-15 mg/mL,4.23-7.0 mg/mL,9-10 mg/ml,3.3 microgram/ml,161+-41 ng/ml,30ng/mL,NA,50-60 microgram/ml,5.2 mg/ml,3.74+-1.09,10.0ng/ml,1-2 hours after orally administration,1-2 hours after orally administrtion,1367ng/ml,83.7ng/ml,4 ng/ml,0.27+or- 0.04ug/ml,409pg/ml,6 mg to 8mg/day,reached in few hours,1-2 hours after oral administration,2 to 3hours,1-3 hours,360-396 ng/ml,118.21 ng/ml,NA,2966.0 ± 1595.0 ng/mL,NA,(17-44%),26%-40%,113-1343ng/mL,970 ng\ml,82.2 ng/mL and 397 ng/mL*hr,64.4 ?g l,750 ± 403 ng/mL,5 mg/m2 to 75 mg/m2,1500 mg/m2,NA,20 mg/kg,492 ± 160 nanograms/ml,NA,NA,NA,0.06µg/mL,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,T-max,up to 3 days,7 hours,3 hours,1 to 2 hours,10 days,5 hours,4-6 hours,15 ± 8 hours,168 hrs,1-2 hrs,2 hours,2-3 hours,8 hours,6 hours,3 hours,20-50 hours,21 hours,9-11 hours,Not available,Not available,24 hours,3- 5 hours,2-8 hours,non-linear kinetics and has a terminal half-life of elimination which is dose-dependent,36 hours,48 hours,35 hours,0.8 hours,0.96 - 1.51 hours,20 - 66 hours,102.4±47.7 ng/mL,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1-2 hours,NA,1-2 hours,NA,1-2 hours,2 to 4 hours,2 hours,NA,3-4 hours,NA,NA,1-2 hours,NA,2-3 hours,2.5 to 4 mg/dL.,800 to 1600 ng/mL,NA,NA,NA,NA,300 to 700 ng/mL,2.5 to 3.0 µg/mL,300 to 600 ng/mL,0.5 to 3µg/mL,NA,0.5 to 2.0 µg/mL.,2 to 10 mM/L,NA,NA,0.5,14 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Varies based on dosage and route of administration,Achieved within 0.5-4 hours after oral administration,Achieved within 0.5-1.5 hours after oral administration,Achieved within 4 hours after oral administration,Achieved within 3-4 hours after oral administration,Achieved within 1-2 hours after infusion,Achieved within 2-3 hours after oral administration,1-2 hours (after oral administration),C-max,10-50(?g/mL),NA,1 to 2 hr,NA,NA,NA,1 to 2 hrs (0.5 to 2),(60 to 120),(MK-6482),2 to 30 microgram,1 to 2 hrs (30 to 100ug/mL),1 to 2 hrs (1 to 3 ug/mL),NA,2 to 10 ug/mL,30 min to 2hrs (0.5 to 1 ug/mL),C-max,2-3hr,3-8hr,end of infusion,1-2hr,3 to 4hr,minimal to none,2hr,NA,not specified,not applicable for formulation,NA,NA,reached shortly end of infusion,NA,1.5-4 hours,>=264 ng/ml,8.0 ng/mL,NA,16.5 ng/mL,2.5-15 mg/mL,4.23-7.0 mg/mL,9-10 mg/ml,3.3 microgram/ml,161+-41 ng/ml,30ng/mL,NA,50-60 microgram/ml,5.2 mg/ml,3.74+-1.09,10.0ng/ml,1-2 hours after orally administration,1-2 hours after orally administrtion,1367ng/ml,83.7ng/ml,4 ng/ml,0.27+or- 0.04ug/ml,409pg/ml,6 mg to 8mg/day,reached in few hours,1-2 hours after oral administration,2 to 3hours,1-3 hours,360-396 ng/ml,118.21 ng/ml,NA,2966.0 ± 1595.0 ng/mL,NA,(17-44%),26%-40%,113-1343ng/mL,970 ng\ml,82.2 ng/mL and 397 ng/mL*hr,64.4 ?g l,750 ± 403 ng/mL,5 mg/m2 to 75 mg/m2,1500 mg/m2,NA,20 mg/kg,492 ± 160 nanograms/ml,NA,C-max,NA,NA,NA,0.06µg/mL,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,up to 3 days,7 hours,3 hours,1 to 2 hours,10 days,5 hours,4-6 hours,15 ± 8 hours,168 hrs,1-2 hrs,2 hours,2-3 hours,8 hours,6 hours,3 hours,NA,Half life,20-50 hours,21 hours,9-11 hours,Not available,Not available,24 hours,3- 5 hours,2-8 hours,non-linear kinetics and has a terminal half-life of elimination which is dose-dependent,36 hours,48 hours,35 hours,0.8 hours,0.96 - 1.51 hours,20 - 66 hours,C-max,102.4±47.7 ng/mL,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,C-max,NA,1-2 hours,NA,1-2 hours,NA,1-2 hours,2 to 4 hours,2 hours,NA,3-4 hours,NA,NA,1-2 hours,NA,2-3 hours,C-max,2.5 to 4 mg/dL.,800 to 1600 ng/mL,NA,NA,NA,NA,300 to 700 ng/mL,2.5 to 3.0 µg/mL,300 to 600 ng/mL,0.5 to 3µg/mL,NA,0.5 to 2.0 µg/mL.,2 to 10 mM/L,NA,NA,C-max,0.5,14 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Varies based on dosage and route of administration,Achieved within 0.5-4 hours after oral administration,Achieved within 0.5-1.5 hours after oral administration,Achieved within 4 hours after oral administration,Achieved within 3-4 hours after oral administration,Achieved within 1-2 hours after infusion,Achieved within 2-3 hours after oral administration,1-2 hours (after oral administration),C-max,10-50(?g/mL),NA,1 to 2 hr,NA,NA,NA,1 to 2 hrs (0.5 to 2),(60 to 120),(MK-6482),2 to 30 microgram,1 to 2 hrs (30 to 100ug/mL),1 to 2 hrs (1 to 3 ug/mL),NA,2 to 10 ug/mL,30 min to 2hrs (0.5 to 1 ug/mL),2-3hr,3-8hr,end of infusion,1-2hr,3 to 4hr,minimal to none,2hr,NA,not specified,not applicable for formulation,NA,NA,reached shortly end of infusion,NA,12-34ng/ml,45-70 ng/ml,1-4 hrs,NA,NA,1-4 hrs,NA,NA,NA,4-9 mcg/ml,1.6-2.4 mg/L,NA,NA,2-12 microgram/ml,NA,NA,2-12 microgram/ml,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2 hrs,EXTANSIVE,2-3 hrs,6-25 ng/ml,NA,0.50 and 1.36 ng/mL,NA,4.1±2.6ng/mL,Achieved rapidly after IV administration.,NA,16.1mg/L,NA,1.92±1.08µg/mL,NA,NA,812 (118) pg/mL,NA,301 ng/mL,NA,None specified,none,None reported,neomycin and paromomycin ,Cholestyramine decreases levels of leflunomide by inhibition of GI absorption.,Not specified,Not specified,"rifampicin, rifabutin, isoniazid, barbiturates, phenytoin, etc",None specified,None commonly used,N/A,Not commonly used,Not commonly used,none,none,NA,"For 1.25mg, 25mg, 75mg -0.1ng/ml,0.2ng/ml,3.5ng/ml respectively",0.77 ng/ml,6909.32 ng/ml,160 ng/ml,65%,90%,40%,86%,273 ng/ml (60%),38%,6.51?g/ml,NA,cmax is reached in 3 hours,"cmax is 65.8 micro grams per ml for 2-6 year olds, 70.1 micro grams per ml for 6<12 year olds",NA," The Cmax of ampicillin was 6.8 (2.3) micrograms/ml, ",Cmax 3.93±1.13mg/L ," 34% and 24%, respectively",Cmax after intramuscular injection were 1.4 h and 131 micrograms/ml,Cmax: 69.9mcg/ml; Half-life: 1.11 hours, concentrations reach a peak (Cmax) of approximately 30 mg/L after administration , The reference range for vancomycin peak levels is 20-40 mcg/mL.,0.57 ± 0.15,Cmax: 102 mcg/L,Cmax/MBC ratio is very high at 95.,Cmax of 3.62 mg/l,Cmax: 29 mcg/L, Cmax: 66-82 mcg/L,Cmax: 52-63 mcg/ml,2.1 ng/mL,5-10 min,30-60 min,1-2 hrs,1-2 hrs,1-2 hrs,1-2 hrs,2-4 hrs,1-2 hrs,2-4 hrs,6-12 hrs,30 min- 2 hrs,1-3 hrs,2-5 hrs,2 hrs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,~ 0.5-1 hour.,~ 1 hour.,~1-1.5 hours.,~ 1-2 hours,~ 1-1.5 hours.,~1-2 hours.,~2-3 hours.,Approximately 2.5-3.5 hours.,Approximately 1-2 hours,Approximately 2-3 hours.,Approximately 1-2 hours,Approximately 2-5 hours,Approximately 1-2 hours,Approximately 20-40 minutes,Approximately 30 minutes,7-20ng/Ml, 800 mg dose,300 to 900mg,600 mg,0.3-3mg,0.003 to 0.005 mg,10-20mg,1.0–10.0 mg/kg,18.4 ± 6.26 ng/mL,2-5µg/mL, 302 ng/ml,9.11µg/ML,3190 ng/mL,1723 ng/mL,1.6 µg/mL,10-20 ?g/mL,2-8 hours,"Variable, dependent on dosage and formulation",Achieved within 1.4 to 4.8 hours after oral administration,Achieved within 1 hour after oral administration,Reached within 2-4 hours after oral administration,2-4 hours,Not specified,30-60 µg/mL,1-2 hours,Not specified,Not specified,Reached within 2-3 hours post-dose,2-6 hours,Reached within 1-2 hours,10-20 ?g/mL,2-8 hours,"Variable, dependent on dosage and formulation",Achieved within 1.4 to 4.8 hours after oral administration,Achieved within 1 hour after oral administration,Reached within 2-4 hours after oral administration,2-4 hours,Not specified,30-60 µg/mL,1-2 hours,Not specified,Not specified,Reached within 2-3 hours post-dose,2-6 hours,Reached within 1-2 hours
Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Peripheral (mainly liver),Minimal,Hepatic metabolism via CYP1A2,"Hepatic, extensive metabolism",Extensive hepatic metabolism,Hepatic metabolism via cholinesterases,Metabolized in the liver,Extensively metabolized by the liver,Extensively metabolized in the liver,"Hepatic metabolism, involving mainly CYP3A4",Hepatic,Extensive hepatic metabolism,Hepatic metabolism via CYP1A2,Hepatic metabolism by cytochrome P450 enzymes,Hepatic metabolism via COMT,First-pass metabolism:,hepatic first pass metabolism,hepatic first pass metabolism,hepatic metabolism,hepatic first pass metabolism,hepatic first pass metabolism,hepatic first pass metabolism,hepatic first pass metabolism,hepatic first pass metabolism,hepatic first pass metabolism,hepatic first pass metabolism,hepatic first pass metabolism,hepatic first pass metabolism,hepatic first pass metabolism,hepatic first pass metabolism,Not specified,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Largely CYP3A4,Mainly CYP3A4,CYP1A2 and CYP2C19,CYP2C8 and CYP3A4,CYP3A,­,Liver (CYP3A4),CYP3A4 /5,CYP2C8 (primarily) and CYP 3A4,­,­,CYP3A4 and UTG1A4 along with CYP2C8/19/3A5 and UGT1A3,CYP3A OXIDATION and dealkylation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Half life,1-2 months,1-4 hours,14 to 30 days,6-24 hours,1-3 hours,2-4 hours,12-21 hours,3 to 5 days,6-15 hours,5-8 days,7-12 hours,12-16 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Hepatic, primarily through CYP2C9",Hepatic metabolism via CYP3A4,"Hepatic, primarily through glucuronidation and mitochondrial beta-oxidation",Extensively metabolized in the liver through glucuronidation,"Minimal metabolism in the liver, largely excreted unchanged",Minimal; not extensively metabolized,Extensive hepatic metabolism via CYP3A4 to active metabolite (MHD),Hepatic metabolism via CYP3A4,Hepatic metabolism to inactive metabolites,"Minimal, mainly unchanged",Hepatic via CYP3A4,Hepatic,"Minimal, not metabolized extensively",Hepatic metabolism; CYP3A4 involved,Negligible metabolism in humans,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Hepatic metabolism,Hepatic metabolism,Hepatic metabolism,Hepatic,Hepatic,Hepatic metabolism,"Hepatic, CYP1A2, CYP3A4",Hepatic metabolism,Hepatic metabolism via CYP2D6 and CYP3A4,Hepatic metabolism,Hepatic metabolism,Hepatic,Hepatic metabolism,Hepatic metabolism by CYP3A4,Hepatic metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,undergoes hepatic metabolism. liver converts methotrexate to inactive metabolites through a process involving the enzyme dihydrofolate reductase.,"Mechlorethamine is not extensively metabolized in the body. It is known to undergo chemical reactions such as hydrolysis, but these reactions do not result in the formation of significant metabolites. The primary mechanism of action is through alkylation of DNA.","Thiotepa undergoes hepatic metabolism. The primary metabolic pathway involves the liver enzyme cytochrome P450, specifically CYP2B6 and CYP3A4. Thiotepa is metabolized into active and inactive metabolites, including the formation of TEPA (triethylenephosphoramide), which is considered a major active metabolite.",undergoes biotransformation in the liver.,"undergoes hepatic metabolism primarily through the enzyme glutathione S-transferase (GST). The metabolism involves conjugation with glutathione, leading to the formation of a less toxic metabolite. Genetic variations in GST can influence individual variations in busulfan metabolism.","undergoes limited metabolism. It is primarily metabolized in the liver by a process of hydrolysis, leading to the formation of inactive metabolites.",undergoes hepatic metabolism.,"undergoes hepatic metabolism. primary metabolic pathway involves the conversion of lomustine to its active metabolite, 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea (AMNU).","undergoes hepatic metabolism.Cytochrome P450 enzymes, particularly CYP2B6 and CYP3A4, are involved in the metabolism of cyclophosphamide.primary metabolite is 4-hydroxycyclophosphamide, which is further converted to aldophosphamide.",undergoes metabolism primarily in the liver and kidneys,Etoposide undergoes metabolism primarily in the liver,metabolic transformation primarily in the liver.,primarily in the liver,"Fludarabine undergoes limited metabolism in the body. It is primarily phosphorylated intracellularly to its active metabolite, fludarabine triphosphate, by deoxycytidine kinase.",extensive metabolism in the liver,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3-4 hours,4 hours,6 hour,3 hour,2 hour,2-2.5 hours,26 hours,2-2.5 hrs,0.22 hrs,8 hrs,8hours,5.7 hrs,12-17 hrs,0.7-10 hrs,5 hrs,10 to 19 hours,8-10 hours,8-14 hours,14.4 hours,3.4 to 9.2 hours,27 hours,8 to 9 hpurs,22 hours,26 hours,21 hours,20 to 25 hours,5 to 6,8-37 hours,15-19 hours,10 hours,17.4 hours.,26 hours,21 hrs,3 hours,18 hr,3 to 4 hours,0.5 to 3 hours,0.5 to 6 hours,3-4 hours.,20 to 30 minutes.,2 to 3 hours.,20 minutes ,1.3 days,26 to 48 hours.,1.5-2 hours.,16 days (3.4 hours in people who have excess levels of vitamin C),3 to 4 hours.,few days to a week.,0.9h,66 to 84 minutes.,0.9 to 1.2 hours.,1 to 2 hours.,5 days to a few weeks.,NA,NA,NA,NA,9 to 16 minutes.,ess than 1 hour.,ranging from a few days to a few weeks.,Half life,3.5-5 hr,20 to 25 hours,30 hours,34 to 42 hours,6 hours,15-35 hours,9-21 hours,35 hours,5.5 days,9-11hrs,16 hours,35 hours,2-3 days,2 days,3 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"half-life of glimepiride is approximately 5 to 8 hours,",The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus,10.4 hours. Duration of action is 10-24 hours.,"Approximately 7 hours with interindividual variations ranging from 4-25 hours. Tolbutamide has the shortest duration of action, 6-12 hours, of the antidiabetic sulfonylureas.",Approximately 36 hours with interindividual variation ranging from 25-60 hours. Duration of effect persists for at least 24 hours.,The average biological half-life of the drug is 7 hours.,Elimination half-life of the parent compound is 1.3 hours and the elimination half-life of the active metabolite is approximately 5-6 hours.,4 hours.,9.20 hours,has a short half-life and is excreted in both the bile and urine.,The mean terminal half-life was approximately 8 hours (range 5.7-9.4 hours), 4.0 hours and is excreted mainly by the kidneys., 0.730 Days (12-hr day), 12 hours ,10 hours,0.5-1 hour,1-2 hours,1-1.5 hours,1-2 hours.,0.5 to 1.5 hours.,1-2 hours,12 to 14 hr,1-2 hours,6-8 hours,1-2 hours,2-6 hours.,NA,2-3 hours,20-40 minutes.,2-3 hours in healthy adults.,NA,2 to 3 hours,"It depends on various factors, such as temp. & pH.",NA,NA,NA,1-1.2 hours,1-2 hours,2 to 3 hours,1-2 hours.,3 to 6 months,1-1.5 hours.,18-54 min,NA,2-3 hours,27 to 32 hrs,NA,28 ± 7 hrs,42hrs,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,120-170 hours,0.5 hours (active metabolite),5-7 hours,~5-6 hours,~15 hours,"~1 hour (active metabolite, GS-441524)",~2-5 hours,2-3 hours,Half life,15 to 90 min,16 to 30 hours,30 hours,20 to 50 days,30 hours,30 hours,6 to 10hrs,20 to 30 days,12 to 24hrs,15 to 90 minu,3 to 12 hrs,20 to 30 minutes,NA,16 to 50 hrs,3 to 10 hrs,Half life,6hr,25hr,10-17hr,2hr,21hr,NA,16 to 18 hr,NA,not specified,not applicable for formulation,NA,not well documented,24hr,24 hr,3-4 hours,4 hours,6 hour,3 hour,2 hour,2-2.5 hours,26 hours,2-2.5 hrs,0.22 hrs,8 hrs,8hours,5.7 hrs,12-17 hrs,0.7-10 hrs,5 hrs,10 to 19 hours,8-10 hours,8-14 hours,14.4 hours,3.4 to 9.2 hours,27 hours,8 to 9 hpurs,22 hours,26 hours,21 hours,20 to 25 hours,5 to 6,8-37 hours,15-19 hours,10 hours,17.4 hours.,26 hours,21 hrs,3 hours,18 hr,3 to 4 hours,0.5 to 3 hours,0.5 to 6 hours,3-4 hours.,20 to 30 minutes.,2 to 3 hours.,20 minutes ,1.3 days,26 to 48 hours.,1.5-2 hours.,NA,Half life,16 days (3.4 hours in people who have excess levels of vitamin C),3 to 4 hours.,few days to a week.,0.9h,66 to 84 minutes.,0.9 to 1.2 hours.,1 to 2 hours.,5 days to a few weeks.,NA,NA,NA,NA,9 to 16 minutes.,ess than 1 hour.,ranging from a few days to a few weeks.,NA,NA,NA,NA,NA,3.5-5 hr,20 to 25 hours,30 hours,34 to 42 hours,6 hours,15-35 hours,9-21 hours,35 hours,5.5 days,9-11hrs,16 hours,35 hours,2-3 days,2 days,3 days,NA,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Half life,"half-life of glimepiride is approximately 5 to 8 hours,",The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus,10.4 hours. Duration of action is 10-24 hours.,"Approximately 7 hours with interindividual variations ranging from 4-25 hours. Tolbutamide has the shortest duration of action, 6-12 hours, of the antidiabetic sulfonylureas.",Approximately 36 hours with interindividual variation ranging from 25-60 hours. Duration of effect persists for at least 24 hours.,The average biological half-life of the drug is 7 hours.,Elimination half-life of the parent compound is 1.3 hours and the elimination half-life of the active metabolite is approximately 5-6 hours.,4 hours.,9.20 hours,has a short half-life and is excreted in both the bile and urine.,The mean terminal half-life was approximately 8 hours (range 5.7-9.4 hours), 4.0 hours and is excreted mainly by the kidneys., 0.730 Days (12-hr day), 12 hours ,10 hours,Half life,0.5-1 hour,1-2 hours,1-1.5 hours,1-2 hours.,0.5 to 1.5 hours.,1-2 hours,12 to 14 hr,1-2 hours,6-8 hours,1-2 hours,2-6 hours.,NA,2-3 hours,20-40 minutes.,2-3 hours in healthy adults.,Half life,NA,2 to 3 hours,"It depends on various factors, such as temp. & pH.",NA,NA,NA,1-1.2 hours,1-2 hours,2 to 3 hours,1-2 hours.,3 to 6 months,1-1.5 hours.,18-54 min,NA,2-3 hours,Half life,27 to 32 hrs,NA,28 ± 7 hrs,42hrs,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,120-170 hours,0.5 hours (active metabolite),5-7 hours,~5-6 hours,~15 hours,"~1 hour (active metabolite, GS-441524)",~2-5 hours,2-3 hours,Half life,15 to 90 min,16 to 30 hours,30 hours,20 to 50 days,30 hours,30 hours,6 to 10hrs,20 to 30 days,12 to 24hrs,15 to 90 minu,3 to 12 hrs,20 to 30 minutes,NA,16 to 50 hrs,3 to 10 hrs,6hr,25hr,10-17hr,2hr,21hr,NA,16 to 18 hr,NA,not specified,not applicable for formulation,NA,not well documented,24hr,24 hr,NA,7-8 hrs,18-50 hrs,52-120 hrs,40-60 hrs,13 hrs,22-36 hrs,10-20 hrs,5-18 hrs,21 hrs,6-10 hrs,4-8 hrs,7-9 hrs,25-26 hrs,9-16 hrs,NA,25-26 hrs,9-16 hrs,30 hrs,24-35 hrs,75 hrs,24 hrs,2-5 days,7 hrs,6 hrs,18 hrs,20 hrs,12-17 hrs,10-14 hrs,15-14 hrs,14-20 hrs,10 years,27 to 32 hours,initial half-life of about 1.5 hours and a terminal exponential half-life of 480 hours.,37-157 hours,146 hours,30 hours.,5.6hours,1-6 hours.,28±7 hours,60 hours,5 minutes for IV and 1 hour when administered by subcutaneous injection.,1 hour,"(I.M - 58min.), (subcutaneous - 59 to 64min.) and (Nasal - 18 to 23min.)",25.4 days,"
12.8 days","Following intravenous administration, the volume of distribution was 76 L, indicating distribution into tissues.",VOLUME OF DISTRIBUTION= 87L after intravenous administration. Distribution is equal between red blood cells and plasma,The volume of distribution of upadacitinib in rheumatic patient (74 kg) is estimated to be 224 L following orally given extended-release formula,The volume of distribution of methotrexate at steady state is approximately 1L/kg.,The volume of distribution of leflunomide at steady state is approximately 0.13 L/kg,"Following intravenous injection, the calculated volume of distribution for sulfasalazine was 7.5 ± 1.6 L",Azathioprine is distributed widely throughout the body following absorption.,volume of distribution of cyclosporine ranges from 4-8 L/kg.,Widely distributed,"Widely distributed vol.: 5522L from blood and 44,257L from plasma.",Vd of 5.49 L,"A 0.15mg/kg dose of prednisolone has a volume of distribution of 29.3L, while a 0.30mg/kg dose has a volume of distribution of 44.2L","In rheumatoid arthritis (RA) treated with anakinra (n=35), the volume of distribution averaged 18.5 L.",The distribution volume ranged from 4.7 to 6.0 L following IV administration of doses ranging from 0.25 to 10 mg/kg,"In rheumatoid arthritis patients, the central volume of distribution is 3.5L",NA,"20 hours (topical dose), 2 hours (subcutaneous dose)",10-20 minutes,for single dose 12 days and with continous dosing it becomes 4 days,28 days,22 days,13-85 minutes,3.5 hours,3.5 hours,range 23-70 hours,21 to 22 hours,5 HOURS,5 hours,57 hours,14.7 days,NA,2 to 4 hours,The half-life of amoxicillin is 61.3 minutes.,The half-life is approximately 60 minutes in patients with normal renal function,elimination half-life (5.8 to 8.7 hours) ,half-life of the IM injection ranges from 1.3-5.1 h,The half-life of meropenem (approximately 1 hour in healthy volunteers) is prolonged up to 13.7 hours,Mean terminal half-life of omadacycline was about 13.5 hours on day 1 ,NA,Mean terminal half-life of omadacycline was about 13.5 hours on day 1,"The half-life was in the range of 1.15–1.39 h,", half-life ranges from 8.2-15.1 h ,0.7 to 1.2 hours, 2.3 hours, (5.8 to 8.7 hours) ,6 min,1 hour,5 hrs,30 min -2 hrs,45 min - 1 hr,3-6 hrs,3-7 hrs,6-7 hrs,2-12 hrs,3.5-4.5 hrs,30-50 hrs,1-2 hrs,2-6 hrs,11-16 hrs,40 min - 4 hrs,Non-substrate,Non- substrate,Non- substrate,Non substrate,Non- substrate,Non- substrate,CYP1A2,Not substrate,Not substrate,CYP4503A4,CYP4503A4,CYP4503A4,CYP4503A4,Not substrate,Not substrate,metabolized in the liver via the cytochrome P450 enzyme system,"extensive hepatic metabolism, primarily via the cytochrome P450 enzyme system","extensive hepatic metabolism, primarily via the cytochrome P450 enzyme system","extensive hepatic metabolism, primarily via the cytochrome P450 enzyme system","extensive hepatic metabolism, primarily via the cytochrome P450 enzyme system","metabolism, primarily via the cytochrome P450 enzyme",hepatic metabolism primarily via the cytochrome P450 enzyme system,"Famotidine undergoes hepatic metabolism, primarily via oxidation and sulfation.","Nizatidine undergoes hepatic metabolism, primarily via oxidation and glucuronidation.","Ranitidine undergoes hepatic metabolism, primarily via oxidation and N-glucuronidation.","Pirenzepine undergoes hepatic metabolism, primarily via oxidation and conjugation reactions.","Propantheline undergoes hepatic metabolism, primarily through hydrolysis and oxidation.","Oxyphenonium undergoes hepatic metabolism, primarily through hydrolysis and conjugation reactions.",Misoprostol undergoes extensive metabolism in the liver via oxidation and fatty acid oxidation pathways.,"Rioprostil undergoes rapid metabolism in the liver, primarily through fatty acid oxidation pathways.",2.5 and 5.05 hours,20 hours,1 to 3 hours,1.5 hours,2.5-3.3 hours,2.5-3.3 hours,80 hours,2.4 to 3.2 hours ,5 to 7.5 hours,7 to 15 hours,12 to 50 hours,8 hour,7 and 12 hour,3.4 hours,5 to 7 hours,19-24 hours,36 hours (average),9-16 hours,Average of 25 to 33 hours,Approximately 6-8 hours,Approximately 21 hours,9 hours (average),36-42 hours,20-23 hours,5-8 hours,5 to 8 hours,6-10 hours,5-7 hours,63-69 hours,Approximately 6 hours,19-24 hours,36 hours (average),9-16 hours,Average of 25 to 33 hours,Approximately 6-8 hours,Approximately 21 hours,9 hours (average),36-42 hours,20-23 hours,5-8 hours,5 to 8 hours,6-10 hours,5-7 hours,63-69 hours,Approximately 6 hours
Cytochrome P450 enzymes,CYP2D6,"CYP2D6, CYP2B6","CYP2D6,CYP3A4",CYP2D6,"CYP3A4, CYP2B6, CYP2C19","CYP3A4, CYP2C19","CYP2D6,CYP3A4,CYP2E1","CYP3A4, CYP2D6, CYP1A2",CYP1A2,"CYP2A6, CYP2B6, and CYP2D6","CYP2D6 (major), CYP1A2 & CYP2C19 (minor)","CYP2D6 (major), CYP3A4 (minor)",CYP2B6 & CYP3A4 (not exact),"CYP2B6, CYP2D6 & CYP3A4",Minimal,Not significantly involved,Metabolized by CYP1A2,Metabolized by CYP2B6 and CYP3A4,Primarily CYP3A4,Minimal involvement of CYP450 enzymes,Mainly metabolized by CYP2D6,Primarily CYP1A2 and CYP3A4,"CYP1A2, CYP2D6",Mainly metabolized by CYP3A4,CYP3A4,Metabolized by CYP3A4,Metabolized by CYP1A2,CYP2D6 and CYP3A4,Not a substrate or inhibitor of CYP enzymes,T-max,1–2 h,1-2 hrs,2-4hrs,1–2 hrs,1-6hrs,Not specified,1 hr,2-8 hrs,1-4 hrs,2-4hrs,0.5-3 hrs,0.5-2 hrs,1-3 hrs,0.75 hrs,Not specified,Minimal metabolism,Not metabolized by cytochrome P450 enzymes,Primarily metabolized by CYP3A4 and to a lesser extent by CYP2B6 and CYP2C19,"CYP2C19, CYP3A4",Primarily metabolized by CYP2B6 and CYP3A4,Not metabolized by cytochrome P450 enzymes,Primarily metabolized by CYP3A4,Primarily metabolized by CYP3A4,Primarily metabolized by CYP3A4 and CYP3A5,Primarily metabolized by CYP3A4,Primarily metabolized by CYP3A4,Cytochrome P450 enzymes:,CYP3A4,CYP3A4,CYP3A4 CYP3A5 CPY3A7,CYP2C19 CYP2C9,CYP3A4,"CYP2C9, CYP3A4",CYP3A4,CYP2D6,NA,NA,NA,NA,NA,CYP3A4,NA,"CP450 enzyme plays a minimal role in 
metabolism of insulin aspart.",CYP2C9 is involved in the breakdown of glipizide in the liver,CYP2C9 is responsible for the conversion of tolbutamide into its active metabolites,Cytochrome P450 enzymes play a minimal role in the metabolism,primarily metabolized by non-CYP450 pathways,CYP450 plays a crucial role in metabolism,metabolise by non-CYP pathway,CYP2C8 and CYP3A4,not major contributor,no role in insulin metabolism,no role in insulin metabolism,no role in insulin metabolism,NA,NA,Cytochrome P450 enzymes:,Primarily metabolished by CYP2C19 and CYP3A4,Primarily metabolished by CYP2C19 and CYP3A4,Primarily metabolished by CYP2D6 and CYP3A4,Primarily metabolished by CYP1A2 and CYP2D6,metabolished by CYP2b6,Primarily metabolished by CYP2D6 and CYP3A4,Primarily metabolished by CYP2D6 and CYP2C19,metabolished by CYP3A4,"Primarily metabolished by CYP1A2,CYP2D6,CYP3A4",Primarily metabolished by CYP2D6,"Primarily INHIBIT CYP1A2,CYP2C19,CYP3A4",NA,NA,­,No information found,No information found,No information found,"11 identified, low circulating plasma levels","9- Yes, which are highly bound to plasma protein",­,"M1, M2, M3, M4","Minor metabolites: 3?-p-hydroxypaclitaxel and 6a,3?-p-dihydroxypaclitaxel by CYP3A4",Difluorofeoxyuridine(dFdU),No information found,vinorelbine N-oxide,Yes (unnamed),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Azathioprine undergoes metabolic transformation primarily through the action of thiopurine methyltransferase (TPMT), which is not a cytochrome P450 enzyme.","Acitretn is metabolized in liver primarily by cyt P450 enzyme system, speciicaally the CYP2C9 nd CYP3A4 enzyme these enzyme play crucial role in breaking down and eliminating the drug from the body",NA,It contribute to increase oxidative stress in MTX-exposed cells by increasing TNF alpha and depleting both cGSH and mGSH. This enhances MTX-cytotoxicity and promotes apoptosis.,NA,cyclosporin is a substrate and inhibitor of cytochrome P450 3A4.,NA,"Betamethasone undergoes metabolism mainly through hepatic enzymes, and it is not extensively metabolized by cytochrome P450 enzymes.",NA,"Metabolism occurs via various pathways, including cytochrome P450 enzymes.",NA,catabolise by proteolytic enzyme,CYP3A subfamily (specifically CYP3A4 and CYP3A5,NA,CYP2D6,CYP3A4,CYP2D6,"CYP2D6 ,CYP2C9",CYP3A4,"CYP3A4,CYP1A2","CYP1A2,CYP3A4",CYP3A4,CYP1A2,CYP2D6,"CYP3A4,CYP2D6","CYP2D6,CYP3A4",NA,NA,"CP450 enzyme plays a mi-
nimal role in metabolism of insulin aspart.","CP450 do not have role in 
metabolism of insulin.","CP450 do not have role in 
metabolism of Insulin det-
ermir.",CP450 do not have role in metabolism of humulin N.,"Cytochrome P450 enzymes primarily met-
abolize drugs and xenobiotics,but they
are not directly involved in the metabolis
m of insulin degludec.","CP450 do not have role in m-etabolis-
m of insulin lispro","Insulin glulisine is a peptide hor-mone and is not metabolized by
cytochrome P450 (CYP450) enzy-
mes","Cytochrome P450 (CYP450) enzymes play a min
imal role in the metabolism of Symlin
(pramlintide).","CYP450 enxyme do not have significant role in 
metabolism of fiasp",NA,"Octreotide, being a peptide anal-
og of somatostatin, is not metab-
olized by the cytochrome P450
(CYP450) enzyme",NA,"CYP450 enxyme t have significant role in 
metabolism of rezvoglar.","CYP450 enxyme do not have signif
icant role in metabolism of Novolog
R",NA,NA,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,CYP2C19 and CYP3A4,"CYP1A2, CYP2C9, CYP2D6, and CYP3A4",CYP2C19 and CYP3A4.,"CYP1A2, CYP2C9, CYP2D6, and CYP3A4",CYP3A4.,CYP3A4.,CYP3A4 and CYP3A5.,CYP3A4.,CYP3A4.,CYP3A4.,CYP3A4.,CYP3A4,CYP3A4 and CYP1A2.,CYP2D6 and CYP3A4.,Not reacting with cytochrome p- 450 enzymes.,"Amikacin is primarily eliminated through renal excretion, and its metabolism does not significantly involve cytochrome P450 enzymes. Therefore, it is not a substrate for CYP450-mediated metabolism","Plazomicin is not metabolized by cytochrome P450 enzymes. Instead, it is primarily eliminated unchanged through the kidneys. Cytochrome P450 enzymes, commonly involved in the metabolism of many drugs, are not a significant part of the metabolic pathway for plazomicin.","Azithromycin is not extensively metabolized by cytochrome P450 enzymes. It undergoes minimal hepatic metabolism, and the small portion that is metabolized involves CYP3A4 to produce N-desmethyl-azithromycin, which has limited pharmacological activity.","Amoxicillin is not significantly metabolized by cytochrome P450 enzymes. It undergoes minimal hepatic metabolism, and the majority of the drug is excreted unchanged in the urine.","Cephalosporins are not extensively metabolized by cytochrome P450 enzymes in the liver. Their primary route of elimination is through renal excretion, with the kidneys playing a crucial role in clearing these antibiotics from the body.",Temocillin is not extensively metabolized by cytochrome P450 enzymes. It primarily undergoes renal elimination. Cytochrome P450 enzymes are a group of liver enzymes responsible for the metabolism of many drugs.,"Ampicillin is mainly metabolized by renal deacetylation and is not significantly metabolized by cytochrome P450 enzymes in the liver. Therefore, it is not a substrate for the cytochrome P450 system.","Sulfadiazine is primarily metabolized by hepatic (liver) enzymes, including cytochrome P450 enzymes. The specific cytochrome P450 isoforms involved in sulfadiazine metabolism are CYP2C9 and CYP2C8. These enzymes play a role in the conversion of sulfadiazine to its inactive metabolites.","Eravacycline is primarily metabolized by cytochrome P450 (CYP) enzymes, with CYP3A4 being the main enzyme responsible for its metabolism.","Plazomicin, an aminoglycoside antibiotic, is not metabolized by cytochrome P450 enzymes. Instead, aminoglycosides like plazomicin primarily undergo renal excretion in their unchanged form.","Meropenem is primarily eliminated by renal excretion, and it is not extensively metabolized by cytochrome P450 enzymes. Therefore, it is less likely to be involved in significant drug interactions mediated by the cytochrome P450 system compared to some other drugs that undergo hepatic metabolism.","Cephalexin is primarily eliminated through the kidneys, and it is not extensively metabolized by cytochrome P450 enzymes in the liver. Therefore, it has minimal interactions with the cytochrome P450 system.","Ciprofloxacin is primarily metabolized by cytochrome P450 1A2 (CYP1A2) in the liver. This enzyme plays a significant role in the metabolism of ciprofloxacin, converting it into several metabolites.","ceftolozane is not significantly metabolized by cytochrome P450 enzymes. Therefore, it is less likely to be involved in significant drug interactions mediated by the cytochrome P450 system.","Clarithromycin is known to inhibit various cytochrome P450 enzymes, particularly the CYP3A4 enzyme. It acts as a reversible inhibitor of CYP3A4, potentially leading to interactions with other drugs metabolized by this enzyme.",Inhibits or enduce co-adminisration of drugs,hepatic 450CYP,Glucoronic acid conjugate,CYP1A2,Not metabolised,not metabolised,"Hepatic (CYP2C8, CYP3A4)",Hepatic (CYP3A4),Not a significant substrate or inhibitor,NA,CYP450 enzyme inhibition,CYP3A4,CYP3A4,CYP3A4,CYP3A4,CYP2C9,"CYP3A4, minor involvement of CYP2C8",Minor involvement; CYP2C9 may be involved,Minimal involvement,Not significantly metabolized by CYP enzymes,Not significantly metabolized by CYP enzymes,CYP3A4,CYP3A4,Primarily CYP2C19,Not a substrate or inhibitor,Metabolized by CYP3A4,Metabolized by CYP3A4,Not significantly metabolized by CYP450,CYP3A4,Not metabolized by CYP enzymes,potent cytchrome P450 enzyme inducer,CYP2C9,Not metabolized by CYP enzymes,CYP3A4,Not significantly metabolized by CYP450,Metabolized by CYP3A4,Metabolized by CYP3A4,Not a substrate or inhibitor,CYP3A4,Minor involvement; CYP2C9 may be involved,Minimal involvement,"CYP3A4, minor involvement of CYP2C8",Not significantly metabolized by CYP enzymes,CYP3A4 and CYP2C19,Primarily CYP2C19,"CYP2D6, CYP1A2","CYP2D6, CYP1A2",Involvement not well-defined,Mainly CYP2D6 and CYP1A2,CYP3A4,"CYP1A2, CYP3A4","Metabolized by CYP1A2, CYP3A4","CYP2D6, CYP3A4","CYP2D6, CYP3A4",CYP3A4 and CYP2D6,"CYP1A2, CYP3A4","CYP2D6, CYP3A4","CYP1A2, CYP2D6, CYP3A4",CYP3A4,"CYP3A4, CYP2D6","P450 enzymes, mainly CYP3A4 and CYP2D6.",CYP1A2 and CYP2D6.,NA,NA,CYP1A2,cytochrome P450 enzymes,"Adenosine is primarily metabolized by adenosine deaminase, not by cytochrome P450 enzymes.","metabolized by the liver via cytochrome P450 enzymes, particularly CYP3A4 and to a lesser extent CYP2D6.","metabolized by the liver, primarily by the cytochrome P450 enzyme system, specifically the CYP3A4 enzyme",CYP3A4. It can inhibit CYP3A4 and other CYP enzymes,"metabolized by the liver through the cytochrome P450 enzyme system, particularly CYP2D6 and CYP1A2.","particularly CYP2D6,minimal hepatic metabolism","cytochrome P450 enzymes, including CYP3A4, CYP2C9, and CYP2D6",P450 enzymes.,Mainly metabolized by CYP2D6.,not involve,n/a,Not metabolized by CYP enzymes,CYP3A4,n/a,CYP3A4,not applicable,CYP3A4,CYP3A4,",CYP3A4,CYP2C9",CYP3A4,not applicable,CYP3A4,CYP3A4,CYP2C9,"dihydrofolate reductase (DHFR),",membrane-bound hemoproteins that are important for the metabolism of many medications,not been extensively characterized,CYP3A4 and CYP1A2,glutathione S-transferases,not extensively metabolized,not extensively metabolized by CYP450 enzymes.,not been extensively characterized.,"CYP2B6, CYP2C9, CYP3A4, and CYP2C19",does not significantly involve,CYP3A4 isoenzyme,have not been extensively characterized.,CYP2B6 and CYP3A4,these enzymes play a role in the breakdown and elimination of fludarabine from the body,CYP2B6 and CYP3A4,"CYP2C19 ,CYP3A4",CYP2C19S,"CYP1A2, CYP3A4","CYP2C19, CYP3A4","CYP3A4 , CYP1A2",CYP1A2,CYP2C19S,"CYP3A4, CYP1A2",CYP2C19S,CYP2C19S,CYP1A2,CYP3A4,"CYP3A4, CYP2C19S",CYP3A4,CYP1A2,"P45034A ,P4502C8",NA,"CYP3A4, CYP3A5","P4503A4, CYP3A4", CYP3A4,"CYP2J , CYP2E1","CYP34A,CTP3A5",CYP3A,CYP2C8,"CYP3A4,CYP1A2",NA,not involved,Diazepam is metabolized in the liver by enzymes of the P-450 cytochrome system. ,"rifampin, phenytoin, phenobarbital", inhibitors of the polymorphic cytochrome P450 (CYP) isozyme CYP2D6.,strongly affected by cytochrome P450 inducers and inhibitors. ," primarily metabolized by CYP3A, mostly likely CYP3A4, in HLMs.",1-PP was formed from gepirone exclusively by pure P450-3A4 with a Km of 849 microM,lorazepam directly undergoes glucuronide conjugation.,"CYP2D6, 1A2, 3A4, 1A1, and 3A5—catalyzed measurable formation of 4-hydroxyclonidine.","CYP3A4, a member of the Cytochrome P450 (CYP) enzyme family, plays a crucial role in the oxidative metabolism of various drugs.",will increase the level or effect of fexinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism," Phenobarbital is a potent cytochrome P450 enzyme inducer, leading to interactions with other drugs by increasing their clearance.",Chlordiazepoxide is the most potent inducer of cytochrome P-450 in rats exposed to an ambient temperature of 28 degrees C,NA,"barbiturates are substrates of cytochrome P450 (CYP), specifically the 2B and 2C families, in rats","Paroxetine is a strong inhibitor of the cytochrome P450 2D6 isotype (CYP2D6), ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CYP3A4, CYP2D6, CYP2D9",CYP450 3A4,CYP3A4,CYP3A4,CYP3A4,CYP3A4,CYP3A4,"CYP3A4, CYP2D6,","CYP2C9, CYP2C19, CYP3A4",CYP2D6,CYP2C9,"CYP2C19, CYP3A4",NA,CYP2C8,CYP3A4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Intracellular phosphorylation,Metabolized to the active form (GS-461203),Intracellular phosphorylation,Hepatic metabolism,Extensively metabolized by CYP3A4,Metabolized to GS-441524 (active metabolite),Metabolized to inactive metabolites,Hepatic,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,cytochrome P450 enzymes:,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Cytochrome P450 enzymes:,"CYP3A4, CYP2D6, CYP2D9",CYP450 3A4,CYP3A4,CYP3A4,CYP3A4,CYP3A4,CYP3A4,"CYP3A4, CYP2D6,","CYP2C9, CYP2C19, CYP3A4",CYP2D6,CYP2C9,"CYP2C19, CYP3A4",NA,CYP2C8,CYP3A4,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Metabilism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Intracellular phosphorylation,Metabolized to the active form (GS-461203),Intracellular phosphorylation,Hepatic metabolism,Extensively metabolized by CYP3A4,Metabolized to GS-441524 (active metabolite),Metabolized to inactive metabolites,Hepatic,Metabolism,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Baricitinib is approximately 50% bound to plasma proteins and 45% bound to serum proteins,"40%, mostly bound to albumin.",Upadacitinib is 52% bound to human plasma proteins,Methotrexate is 46.5-54% bound to plasma proteins.,Leflunomide is >99.3% bound to plasma proteins.,Sulfasalazine is highly bound to albumin (>99.3%) while sulfapyridine is only about 70% bound to albumin.,Azathioprine is 30% bound to proteins such as human serum albumin in circulation,About 50% of the administered dose is taken up by erythrocytes while about 34% is bound to lipoproteins.,"High, approximately 50%",64% protein bound in plasma.,No significant protein binding has been identified.,"Prednisolone's protein binding is highly variable, ranging from 65-91% in healthy patients",Low,High,High (approx. 97-98%),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Penicilloic acid,NA,Cefditotren pivoxil,NA,4-epitetracyclin,NA,NA,NA,desethyl-entrapenem metabolite,Epimers,No any inactive metabolite,No any inactive metabolite,No any inactive metabolite,No any inactive metabolite,No any inactive metabolite,metabolite being the pharmacologically inactive 5-hydroxyomeprazole.,metabolite being the pharmacologically inactive desmethylpantoprazole.,metabolite being the pharmacologically inactive 5-hydroxylansoprazole.,metabolite being the pharmacologically inactive thioether derivative.,metabolite being the pharmacologically inactive 5-hydroxyesomeprazole.,metabolite being the pharmacologically inactive sulfone derivative.,"Several metabolites are formed, including the sulfoxide and the guanyl urea.",Metabolites include the sulfoxide and the sulfone derivatives.,"Several metabolites are formed, including the sulfoxide and the sulfone derivatives.","Several metabolites are formed, including the N-oxide and the S-oxide.","Several metabolites are formed, including the hydroxylated and glucuronidated derivatives.",NA,NA,Misoprostol metabolites are pharmacologically inactive.,Rioprostil metabolites are pharmacologically inactive.,Zanamivir is almost exclusively eliminated from the body via the kidney and undergoes no metabolic biotransformation,"Peramivir is not significantly metabolized
in humans and 90% is excreted unchanged in the urine",It is extensively converted by predominantly hepatic esterases to the active metabolite oseltamivir carboxylate,"Abacavir is primarily metabolized via two pathways,
 uridine diphosphate glucuronyltransferase and alcohol dehydrogenase, resulting in the inactive glucuronide metabolite and the inactive carboxylate metabolite","15% and 1% of the acyclovir dose is
metabolized to 9-[(carboxymethoxy)methyl]guanine (CMMG) and 8-hydroxy-acyclovir (8-OH-ACV), respectively "," valacyclovir is converted to acyclovir by the liver, 
which is metabolized intracellularly in viral infected cells and is excreted largely unchanged by the kidneys","It is subsequently metabolized by
CYP3A4 to form sulfoxide","Cidofovir is metabolized intracellularly
to mono- and diphosphate moieties, as well as to cidofovir monophosphate choline"," Adefovir dipivoxil is taken up into 
the liver cell and is cleaved into adefovir by intracellular esterases",fostemsavir undergoes rapid and extensive metabolism by alkaline phosphatase on the luminal surface of the small intestine brush border membranes ,"tenofovir is not metabolized by CYP450 
isoenzymes, nor is it an inducer or inhibitor of these enzymes. Tenofovir is renally eliminated as unchanged drug by a combination of glomerular filtration and active tubular secretion ","Amprenavir is metabolized in the 
liver by the cytochrome P450 3A4 (CYP3A4) enzyme system","Atazanavir is metabolized in the
liver by the cytochrome P450 3A4 (CYP3A4) enzyme system","Boceprevir is metabolized primarily by 
aldoketoreductase to ketone-reduced metabolites but also by oxidative metabolism via CYP3A4","the only known metabolite of lamivudine
is the trans-sulfoxide metabolite. This biotransformation is catalyzed by sulfotransferases. The majority of lamivudine is eliminated unchanged in urine by active organic cationic secretion","Hepatic, primarily through CYP2C9",Hepatic metabolism via CYP3A4,"Hepatic, primarily through glucuronidation and mitochondrial beta-oxidation",Extensively metabolized in the liver through glucuronidation,"Minimal metabolism in the liver, largely excreted unchanged",Minimal; not extensively metabolized,Extensive hepatic metabolism via CYP3A4 to active metabolite (MHD),Hepatic metabolism via CYP3A4,Hepatic metabolism to inactive metabolites,"Minimal, mainly unchanged",Hepatic via CYP3A4,Hepatic,"Minimal, not metabolized extensively",Hepatic metabolism; CYP3A4 involved,Negligible metabolism in humans,"Hepatic, primarily through CYP2C9",Hepatic metabolism via CYP3A4,"Hepatic, primarily through glucuronidation and mitochondrial beta-oxidation",Extensively metabolized in the liver through glucuronidation,"Minimal metabolism in the liver, largely excreted unchanged",Minimal; not extensively metabolized,Extensive hepatic metabolism via CYP3A4 to active metabolite (MHD),Hepatic metabolism via CYP3A4,Hepatic metabolism to inactive metabolites,"Minimal, mainly unchanged",Hepatic via CYP3A4,Hepatic,"Minimal, not metabolized extensively",Hepatic metabolism; CYP3A4 involved,Negligible metabolism in humans
Inactive metabolites,4-hydroxynorephedrine,p-hydroxymethamphetamine,Alpha-phenyl-piperidine acetic acid,"Para-hydroxy-amphetamine
Para-hydroxy-norephedrine, Para-hydroxy-amphetamine",modafinil acid,armodafinil acid or R-modafinil acid,norpseudoephedrine & various hydroxylated&conjugated derivatives,benzoylecgonine and ecgonine methyl ester,"Paraxanthine, 1,3,7-trimethyluric acid, 1,3-dimethyluric acid","cotinine, trans-3'-hydroxycotinine, nicotine N'-oxide, norcotinine",4-hydroxyatomoxetine,"hydroxyphentermine, N-desmethylphentermine",N-ethylamphetamine,Not known,HVA (homovanillic acid),Yes,3 major inactive metabolites,"Amphetamine, methamphetamine",Yes,Yes,Yes,Yes,Yes,Several inactive metabolites,Conjugated forms,"Yes, several inactive metabolites",Yes (M1 and M17 metabolites),Not specified,Yes,E,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not applicable,Not specified,Not specified,not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Inactive metabolites,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,YES,Yes,YES,Yes,YES,Yes,YES,NA,NA,NA,NA,NA,hydroxy and carboxy derivatives,M1 and M2,M-III and M-IV,unchange drug,"m-cresol , glycerol",peptides and amino acids,NA,main metabolites include the hydroxylation of the cyclopropylmethyl side chain and the dehydrogenation of the benzylic position,NA,Inactive metabolites,s-demethylcitalopram,desmethylcitalopram,o-desmethylvenlafaxine,n-desmethylduloxetine,hydroxybupricon,desmethylparoxetine,nortriptyline,meta-chlorophenylpiperazine,n-desmethylmirtazapine,10-hydroxynortriptyline,fluvoamino acid,NA,NA,Yes,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,Yes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Azathioprine undergoes extensive metabolism in the body. One of the major metabolites is 6-mercaptopurine (6-MP). 6-MP is considered the active metabolite responsible for the immunosuppressive effects of Azathioprine.,NA,"The 7-hydroxyglucuronide and the sulfoxide metabolites, considered to be pharmacologically inactive (Creese et al., 1978; Dutton et al., 1977), are bound weakly by the antibodies","1] It undergoes hepatic metabolism, primarily in the liver. 2] The main inactive metabolite is 7-hydroxymethotrexate",NA,major metabolite are found through oxidation andare pharmacologiclly inactive,NA,": Betamethasone is metabolized into inactive metabolites through various pathways, including reduction and conjugation",NA,Tazarotene undergoes metabolism to inactive metabolites,: Pimecrolimus is metabolized to inactive metabolites,"it breackdown into small peptide and amino acid proteolytic enzyme, leading to inactive metabolites","inactive 13-cis acid form, chain-shortened breakdown products,",NA,NA,NA,NA,promethazine sulphate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"m-cresol, glycerol",NA,"Does not contain inactive 
metabolites",NA,Peptides and amino acids,NA,NA,NA,"The primary inactive metabolite of 
glimepiride is carboxyglimepiride.",NA,NA,NA,NA,NA,NA,Cytochrome P450 enzymes:,CYP3A4,"CYP2C8, CYP3A4","CYP3A4,CYP2D6",CYP3A4,CYP3A4,CYP3A4,Minimal,minimal,P450,P450,Cytochrome P450 enzymes,P450,CYP,CYP2A6,P450,desmethylranitidine-N-oxide and ranitidine-S-oxide.,"hydroxycimetidine, guanylurea, and sulfanilamide.","Iron oxides,Talc Waxes,etc","hydroxycimetidine, guanylurea, and sulfanilamide.","Magnessium Stearate, Talc",Norcisapride,"magnessium stearate, gums",Magnessium stearate,sulfanilamide,"Bisethylpiperaquine,Desethylpiperaquine",desmethylsparfloxacin,Fexofenadine,"sulfone metabolites,sulfoxide metabolite",Thioridazine,"N-Oxide,Desmethylnizatidine","there are no significant inactive metabolites of amikacin. The majority of the administered drug is excreted in the urine in its original, active form.","Plazomicin is primarily eliminated unchanged through the kidneys, and it is not extensively metabolized in the body. Therefore, there are no major inactive metabolites of plazomicin that contribute significantly to its pharmacological effects.","Inactive metabolites include N-desmethyl-azithromycin, which has minimal antibacterial activity.","Amoxicillin is primarily excreted unchanged in the urine. It undergoes minimal metabolism in the liver, and there are no major inactive metabolites formed.","Cephalosporins are primarily eliminated through the kidneys, often as unchanged drug or as active metabolites. In general, cephalosporins do not undergo extensive metabolism in the liver to form inactive metabolites. Instead, they are mainly excreted in their active form through renal clearance.","Temocillin is primarily excreted unchanged in the urine, and its metabolism is not extensive.","The main inactive metabolite of ampicillin is ampicilloic acid, which is formed through the hydrolysis of the amide bond in the parent drug.","Sulfadiazine undergoes hepatic metabolism, leading to the formation of inactive metabolites. One major metabolite is acetylsulfadiazine, which is considered inactive. This metabolite, along with other inactive forms, is excreted primarily through the kidneys.","Eravacycline is primarily metabolized in the liver, and its major inactive metabolites include M1 and M2. M1 is formed by N-dealkylation, and M2 is the result of hydrolysis of the carbomethoxy group.","Penicillin is primarily eliminated in the unchanged form, and it does not undergo extensive metabolism to inactive metabolites","Meropenem undergoes hydrolysis in the kidneys, where it is primarily eliminated. The primary metabolite resulting from this process is the inactive metabolite known as the microbiologically inactive open-ring metabolite. This metabolite does not contribute significantly to the antimicrobial activity of meropenem.",there are no significant inactive metabolites of cephalexin. The majority of the drug is excreted in its original form via the kidneys.,The main inactive metabolites of ciprofloxacin result from glucuronidation and sulfate conjugation processes. These metabolites are generally present in small amounts compared to the unchanged drug.,"The main metabolic pathway involves the hydrolysis of the beta-lactam ring in ceftolozane, which can result in the formation of various metabolites.","The primary inactive metabolite of clarithromycin is 14-OH clarithromycin, which is formed through hepatic metabolism. While 14-OH clarithromycin is considered inactive, it still retains some antimicrobial activity, contributing to the overall effectiveness of the medication.",NA,NA,NA,"1,3-dimethyluric acid",NA,NA,NA,NA,NA,N-desmethylketotifen,11-beta hydroxysteroid dehydrogenase.,Prednisone,Beclomethasone-17-monopropionate,NA,NA,Yes,"Several, including carbamazepine-10,11-epoxide",Conjugated forms (glucuronide),Lamotrigine 2-N-glucuronide (major metabolite),Not applicable,Mostly excreted unchanged,Conjugated metabolites,N-desmethylclobazam,"4'-hydroxyfelbamate, felbamate glucuronide",Not specified,Yes,Not specified,N/A,"Several metabolites, inactive",No major inactive metabolites,"p-hydroxyphenobarbital ,p- hydroxyphenobarbital glucoronids . Phenobarbital N-glucoronoid",yes,No major inactive metabolites,"Several metabolites, inactive",N/A,Not specified,Yes,Not specified,not specified,Conjugated forms (glucuronide),Lamotrigine 2-N-glucuronide (major metabolite),"Several, including carbamazepine-10,11-epoxide",Not applicable,nordazepam,"4'-hydroxyfelbamate, felbamate glucuronide",NA,Yes,Yes,Yes,Yes,Yes,Norclozapine,9-hydroxyrisperidone (active),"Yes, mainly dehydroaripiprazole",Several metabolites,NA,Yes,Yes,Yes,Yes,3-hydroxyquinidine.,NA,NA,CYP3A4.,2-hydroxymexiletine,CYP2D6,inosine,"undergoes minimal hepatic metabolism, and the metabolites formed are inactive","several inactive metabolites, which are then excreted through the urine and feces.",desacetyldiltiazem and N-monodesmethyldiltiazem,glucuronide conjugates and sulfate conjugates.,carboxylic acid,undergoes extensive metabolism in the liver to produce various inactive metabolites,NA,Several inactive metabolites are produced.,proteolytic degradation,Not specified,Not applicable,yes,n/a,YES,yes,present,present,present,yes,not applicable,yes,yes,present,7-hydroxy-methotrexate,2-chloro-N-methylacetamide.,triethylenephosphoramide,N-methyldimethyltetrahydrotriazine,"tetrahydrothiophene-1,1-dioxide",1.5 ± 0.8 hours,monohydroxy (HP1) and dihydroxy (HP2,not form inactive metabolites,Carboxyphosphamide,not form inactive metabolites,etoposide catechol,phenylacetic acid,p-hydroxyphenylacetone,"One of the main inactive metabolites of fludarabine is 2-
fluoro-ara-A (2-FAA). This metabolite is considered less pharmacologically active than the parent drug.",not form,5-hydroxyomeprazole,5-hydroxylansoprazole,"Sulfometuron, Guanylurea",desmethylranitidine,pirenzepine,N-desmethylpropantheline,misoprostol,hydroxyl metabolite,NA,NA,NA,megaldrate,amox,14-hydroxyclarithromycin,2-hydroxymetronidazole,"6?-hydroxypaclitaxel, 3'-p-hydroxypaclitaxel",NA,NA,"4'-O-deacetyl docetaxel, 4'-O-deacetyl docetaxel",NA,7-hydroxy-methotrexate,N-desmethyl crizotinib and crizotinib lactum,N-oxide vinorelbine,NA,NA,NA,NA,CYP3A4 (major route) to desmethyldiazepam.,glucuronide conjugate. ,Cetrizine,"propranolol glucuronide, naphthyloxylactic acid and glucuronic acid, and sulfate conjugates of 4-hydroxy propranolo", 5-hydroxybuspirone, 1- (2-pyrimidinyl)-piperazine (1-PP) and 3-OH-gepirone,3-0-phenolic glucuronide., <50% metabolized in the liver to inactive metabolites.,"4-hydroxyalprazolam and ?-hydroxyalprazolam, as well as an inactive benzophenone.",Azatadine, 5-p-hydroxyphenyl-5-ethyl-barbituric acid,fentanyl., hydroxypentobarbital.,Thiobarbiturates ,"polacrilin potassium, microcrystalline cellulose, propylene glycol",3A4 and 2D6 iso-enzymes.,"rifampin , phenytoin ,phenobarbital","troleandomycin, erythromicin, micronazole.","CYP1A2, as well as monoamine oxidase",mediated demethylation,"CYP2C9, CYP2C19,CYP2E1",CYP1A2,in liver,"CYP1A2, CYP2B6",inhibitor of CYP2D6,NA,did not inhibit the activity of other CYP450 enzymes,"CYP450, CYP1A2 and CYP2C9",CYP4503A metabolism,dimethylxanthine metabolites,CTP2D6,undergo hepatic metabolism,udergo metabolism,terfenadine,CYP2D6,CYP2C8,CYP3A4,desmethylazelastine,"CYP2D6 ,CYP3A4",CYP3A4 & CYP2D6,CYP3A4 &CYP2D6,CYP2D6,CYP3A4 and CYP2D6,CYP2J2,"CYP2D6,CYP1A2,CYP2C9",CYP3A4, CYP3A4/5,CYP3A4,CYP3A4,CYP3A4,CYP3A4.,CYP3A4.,CYP2C8 and CYP2C9.,CYP3A4.,NA,CYP4503A4.,NA,NA,CYP450 3A4,CYP3A4,NA,NA,NA,"3A4, 2D6, 2E1,",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Cytochrome P450 enzymes:,CYP3A4,CYP2C9,CYP450,CYP2C9,CYP3A4,CYPA12,CYP2D6,CYP2D6,CYP3A4,CYP2C1,CYP2D6,CYP2D6,CYP2D6,CYTP2D6,CYTP2C1,NA,Hydroxyitraconazole,N-acetylated form,2-[(chlorophenyl)diphenylmethyl]-1H-imidazole,econazole sulfoxide,Desethylmiconazole,NA,N-deacetylketoconazole,N- Oxide voriconazole,Desmethylterbinafine,1- naphthol,Desmethylbutenafine,Hippuric acid,NA,Hydroxyposaconazole,Low CYP Inhibitory Promiscuity CYP2C9.,CYP2C9.,"Limited information is available on its metabolism, but it may undergo hepatic metabolism involving CYP enzymes.",CYP2C9.,Metabolism is not primarily through the CYP system.,"Limited information is available, but it may undergo hepatic metabolism involving CYP enzymes",Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,CYP2C9.,"CYP2C19
and CYP3A4 enzymes",NA,"Primarily hepatic
(CYP2C19 and
CYP3A4 enzymes)","Pantoprazole undergoes
hepatic metabolism via
CYP2C19 and CYP3A4
enzymes.",NA,Primarily metabolized by the CYP2C19 and CYP3A4 enzymes,Mainly metabolized by CYP3A4,Metabolized by CYP2C19 and CYP3A4,Not a significant substrate or inhibitor of cytochrome P450 enzymes,Metabolized by CYP2C19 and CYP3A4,Not metabolized,metabolized primarily by hepatic metabolism via oxidation and conjugation pathways.,Metabolized by CYP1A2 and CYP3A4,Not metabolized,Minimal interaction with cytochrome P450 enzymes.,CYP1A2 and CYP2C9,"CYP1A2,CYP2D6",NA,NA,NA,CYP2C9.,CYP2C19,CYP2C19.,CYP1A2 and CYP3A4.,CYP2C19.,NA,CYP2C19.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,minimal metabilism,CYP3A4 substrate,NA,PARP inhibition,CYP3A4,NA,NA,Not significantly metabolized by CYP enzymes,Minor involvement; mainly by CYP2B6,Not significantly metabolized by CYP enzymes,Extensively metabolized by CYP3A4,Metabolized by CYP3A4,Not specified,Minimal involvement,Primarily via CYP3A4,Cytochrome P450 enzymes:,CYP2E1 &CYP3A4,CCNU(1-(2-CHLOROETHYL)-3-CYCLOHEXYL-1-NITROSOUREA),CYP3A4,NOT metabolized by cytochrome P450,CYP3A4,CYP3A4,CYP2B6,NA,CYP2C8,NA,CYP2B4,NA,NA,NA,CYP2J2 & CYP2C8,Cytochrome P450 enzymes:,"CYP2C19,CYP2C9",CYP3A4,not appriciable metabolised,cyp3a4,cyp3a4,NA,cyp3a4,NA,hepatic metabolised via cytochrome p450 enzyme,cyp3a4,cyp3a4,not studied,pathway not studied,minimal,3A4 and 2D6 iso-enzymes.,"rifampin , phenytoin ,phenobarbital","troleandomycin, erythromicin, micronazole.","CYP1A2, as well as monoamine oxidase",mediated demethylation,"CYP2C9, CYP2C19,CYP2E1",CYP1A2,in liver,"CYP1A2, CYP2B6",inhibitor of CYP2D6,NA,did not inhibit the activity of other CYP450 enzymes,"CYP450, CYP1A2 and CYP2C9",CYP4503A metabolism,dimethylxanthine metabolites,CTP2D6,undergo hepatic metabolism,udergo metabolism,terfenadine,CYP2D6,CYP2C8,CYP3A4,desmethylazelastine,"CYP2D6 ,CYP3A4",CYP3A4 & CYP2D6,CYP3A4 &CYP2D6,CYP2D6,CYP3A4 and CYP2D6,CYP2J2,"CYP2D6,CYP1A2,CYP2C9",CYP3A4, CYP3A4/5,CYP3A4,CYP3A4,CYP3A4,CYP3A4.,CYP3A4.,CYP2C8 and CYP2C9.,CYP3A4.,NA,CYP4503A4.,NA,NA,CYP450 3A4,CYP3A4,NA,Cytochrome P450 enzymes:,NA,NA,NA,"3A4, 2D6, 2E1,",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,CYP3A4,CYP2C9,CYP450,CYP2C9,CYP3A4,CYPA12,CYP2D6,CYP2D6,CYP3A4,CYP2C1,CYP2D6,CYP2D6,CYP2D6,CYTP2D6,CYTP2C1,NA,Inactive metabolites,NA,Hydroxyitraconazole,N-acetylated form,2-[(chlorophenyl)diphenylmethyl]-1H-imidazole,econazole sulfoxide,Desethylmiconazole,NA,N-deacetylketoconazole,N- Oxide voriconazole,Desmethylterbinafine,1- naphthol,Desmethylbutenafine,Hippuric acid,NA,Hydroxyposaconazole,Cytochrome P450 enzymes:,Low CYP Inhibitory Promiscuity CYP2C9.,CYP2C9.,"Limited information is available on its metabolism, but it may undergo hepatic metabolism involving CYP enzymes.",CYP2C9.,Metabolism is not primarily through the CYP system.,"Limited information is available, but it may undergo hepatic metabolism involving CYP enzymes",Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,Metabolism is not primarily through the CYP system.,CYP2C9.,Cytochrome P450 enzymes:,"CYP2C19
and CYP3A4 enzymes",NA,"Primarily hepatic
(CYP2C19 and
CYP3A4 enzymes)","Pantoprazole undergoes
hepatic metabolism via
CYP2C19 and CYP3A4
enzymes.",NA,Primarily metabolized by the CYP2C19 and CYP3A4 enzymes,Mainly metabolized by CYP3A4,Metabolized by CYP2C19 and CYP3A4,Not a significant substrate or inhibitor of cytochrome P450 enzymes,Metabolized by CYP2C19 and CYP3A4,Not metabolized,metabolized primarily by hepatic metabolism via oxidation and conjugation pathways.,Metabolized by CYP1A2 and CYP3A4,Not metabolized,Minimal interaction with cytochrome P450 enzymes.,Cytochrome P450 enzymes:,CYP1A2 and CYP2C9,"CYP1A2,CYP2D6",NA,NA,NA,CYP2C9.,CYP2C19,CYP2C19.,CYP1A2 and CYP3A4.,CYP2C19.,NA,CYP2C19.,NA,NA,NA,Cytochrome P450 enzymes:,NA,NA,NA,NA,NA,NA,NA,NA,minimal metabilism,CYP3A4 substrate,NA,PARP inhibition,CYP3A4,NA,NA,Not significantly metabolized by CYP enzymes,Minor involvement; mainly by CYP2B6,Not significantly metabolized by CYP enzymes,Extensively metabolized by CYP3A4,Metabolized by CYP3A4,Not specified,Minimal involvement,Primarily via CYP3A4,Cytochrome P450 enzymes:,CYP2E1 &CYP3A4,CCNU(1-(2-CHLOROETHYL)-3-CYCLOHEXYL-1-NITROSOUREA),CYP3A4,NOT metabolized by cytochrome P450,CYP3A4,CYP3A4,CYP2B6,NA,CYP2C8,NA,CYP2B4,NA,NA,NA,CYP2J2 & CYP2C8,"CYP2C19,CYP2C9",CYP3A4,not appriciable metabolised,cyp3a4,cyp3a4,NA,cyp3a4,NA,hepatic metabolised via cytochrome p450 enzyme,cyp3a4,cyp3a4,not studied,pathway not studied,minimal,CYP3A4,minimal,CYP3A4,CYP2C19,NA,metabolism neglible,CYP2C9,CYP3A4,hepatic enymes,NA,sodium channel Blocker,NA,CYP23A8,CYP3A4,CYP2C9 & CYP2C19,NA,CYP3A4,CYP2C9 & CYP2C19,CYP1A2 & CYP2D6,"Metabolised minimally, primarily y gluronidation",CYP3A4 & CYP2D6,CYP1A2 & CYP2D6,CYP3A4,CYP3A4,CYP3A4 & CYP2D6,CYP3A4,CYP2D6 &CYP3A4,NA,Minimal metaolism,CYP2D6,CYP3A4,Not metabolised,Metabolised primarily by glucuronidation (UGT1A1),Not Metabolised,Not metabolised,Not metabolised,Metabolised by UGT1A1 and CYP3A4,Not Metabolised,Not Metabolised,Not metabolised,Not metabolised,Not metabolised,Metabolized,Metabolised,NA,Not Metabolised,"The volume of distribution was 76 L, indicating distribution into tissues",Volume of distribution= 87L,Distribution to tissues is wide,Methotrexate is widely distributed in tissues. Volume of distribution is approx 1 L/kg,Leflunomide distributes widely in the tissues and it crosses the blood-brain barrier,"Sulfapyridine, Sulfasalazine metabolite, is distributed to most body tissues. ","Azathioprine and its active metabolite, 6-mercaptopurine, distribute into various tissues throughout the body.", It concentrates mainly in leucocyte-rich tissues as well as tissues that contain high amounts of fat,"Concentrates in liver, spleen, kidney, and lung tissues",Widely distributed in tissues,Systemic,"Widely distributed, crosses placenta and enters breast milk",Wide,"Distributed systemically, targeting sites of inflammation","Wide distribution within the body, including joints",NA,Metabolized by aryl hydrocarbon receptor-regulated cytochromeP450 enzyme in human keratinocytes,"Tegafur, an anticaner prodrug, is bioactivated to 5-fluorouracil mainly by cytochrome P450 enzyme",Metabolized by cytochrome P450 (CYP) 2C9 AND 3A4,Metabolized by cytochrome P 450 (CYP) 3A,The cytochrome P-450 system is not directly involved in the metabolism of IgG monclonal antibodies,undergoes hepatic metabolism where cytochrome P 450 play minimal role,BINIMETINIB undergoes hepatic metabolism primarily through the CYP3A4 ENZYME,it is metabolized by CTP3A4 (83%) and to a lesser extent by CYP2C19 (16%) and CYP2C19 (1%),Metabolized by CYP3A oxidation and UGT2B7 glucuronidation with no major metabolites formed,metabolism is primarily mediated by CYP2C8 and CYP3A4 to form hydroxy-dabrafenib.which is further oxidised via CYP3A4 to form carboxydabrafenib,CYP1A2 is the predominant P450 that catalyzes DTIC hepatic metabolism; CYP2E1 contributes to hepatic DTIC metabolism at higher substrate concentrations,"Liver (CYP3A4-mediated oxidation, also isomerised to tretinoin) ?",vemurafenib is metabolized by CYP3A4 and the metabolites make up 5% of components in plasma,it does not involve Cytochrome P450 enzyme for metabolism,NA,Fluoroquinolone antibiotics inhibit cytochrome P450,"Studies have shown that amoxicillin does not affect the metabolic activity of P450 liver drug enzymes (e.g., CYP2C9 and CYP3A4) ",Cephalexin is a first generation cephalosporin used to treat certain susceptible bacterial infections.,. Enterohepatic circulation of ceftriaxone may either induce cytochrome P450 enzyme of the liver,. Imipenem acts as an antimicrobial through the inhibition of cell wall ...," Meropenem lessens valproic acid blood levels, putting patients at risk for seizures. It is not known to impact cytochrome p450 enzymes","The cytochrome P450 OxyD from the balhimycin glycopeptide antibiotic biosynthetic operon of Amycolatopsis mediterranei is involved in the biosynthesis of the modified amino acid beta-R-hydroxytyrosine, an essential precursor for biosynthesis of the vancomycin-type aglycone.",Omadacycline was metabolically stable in human liver microsomes and hepatocytes and did not inhibit or induce any of the nine cytochrome P450 ,"Cefotaxime is an antibiotic used to treat a number of bacterial infections in human,","Tiamulin has been suggested to be an inhibitor of P450 enzymes, especially those of CYP3A subfamily","moxifloxacin has little interaction with the cytochrome P450 enzyme system, ",", is an extended-spectrum penicillin ... The cytochrome P450 enzyme system or glutathione are not involved.",cefepime on hepatic drug metabolising enzyme activity in rats ... Cytochrome P-450 Enzyme System / metabolism,Ceftaroline lacks a p450-dependent mechanism of metabolism and is unlikely to interfere with drugs metabolized through cytochromes,aldehyde dehydrogenase,CYP3A4,Aldehyde dehydrogenase,NA,Aldehyde dehydrogenase,CYP2D6 and CYP1A2,CYP2D6,CYP2D6,CYP3A4,CYP3A4,CYP3A4,CYP2A6 and CYP2C9,CYP3A4,CYP3A4,CYP2C8 and CYP2C9,Gastrointesstinal tract,Gastrointesstinal tract,Gastrointesstinal tract,Liver,Liver,NA,Liver,Gastrointestinal systeam,Gastrointestinal tract,Gastrointestinal tract,Gatrointestinal tract,Gatrointestinal tract,No,Gastrointestinal tract,No,Omeprazole undergoes significant first-pass metabolism.,Pantoprazole undergoes significant first-pass metabolism,Lansoprazole undergoes significant first-pass metabolism.,Rabeprazole undergoes significant first-pass metabolism,Esomeprazole undergoes significant first-pass metabolism.,Dexlansoprazole undergoes significant first-pass metabolism,"Yes, cimetidine undergoes significant first-pass metabolism","Yes, famotidine undergoes significant first-pass metabolism","Yes, nizatidine undergoes significant first-pass metabolism.","Yes, ranitidine undergoes significant first-pass metabolism.","Yes, pirenzepine undergoes significant first-pass metabolism.",Likely undergoes significant first-pass metabolism,Likely undergoes significant first-pass metabolism.,"Yes, misoprostol undergoes significant first-pass metabolism.","Yes, rioprostil undergoes significant first-pass metabolism.",does not interact with cytochrome P450, monooxygenases,influenza neuraminidase enzymes , adenosine phosphotransferase,HSV-specific thymidine kinase,does not interact with cytochrome P450,does not interact with cytochrome P450,does not interact with cytochrome P450,does not interact with cytochrome P450,interact with cytochrome P450,does not interact with cytochrome P450,does not interact with cytochrome P450,interact with cytochrome P450,does not interact with cytochrome P450,does not interact with cytochrome P450,CYP2C9,"CYP3A4, minor involvement of CYP2C8",Minor involvement; CYP2C9 may be involved,Minimal involvement,Not significantly metabolized by CYP enzymes,Not significantly metabolized by CYP enzymes,CYP3A4,CYP3A4,Primarily CYP2C19,Not a substrate or inhibitor,Metabolized by CYP3A4,Metabolized by CYP3A4,Not significantly metabolized by CYP450,CYP3A4,Not metabolized by CYP enzymes,CYP2C9,"CYP3A4, minor involvement of CYP2C8",Minor involvement; CYP2C9 may be involved,Minimal involvement,Not significantly metabolized by CYP enzymes,Not significantly metabolized by CYP enzymes,CYP3A4,CYP3A4,Primarily CYP2C19,Not a substrate or inhibitor,Metabolized by CYP3A4,Metabolized by CYP3A4,Not significantly metabolized by CYP450,CYP3A4,Not metabolized by CYP enzymes
First-pass metabolism,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Limited,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Extensive first-pass metabolism,Extensive,Yes,Yes,Renal excretion:,present,present,present,present,present,present,present,present,present,present,present,present,present,present,Not specified,Not applicable,Variable,Not specified,Yes,Significant,Not applicable,Not applicable (IV administration),SN-38G (inactive glucuronide metabolite),Not applicable (IV administration),: Not applicable,Yes (oral administration),First-pass metabolism:,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,YES,Yes,NA,NA,NA,Yes,NA,NA,"liver, primarily through the CYP2C9 enzyme",NA,NA,NA,liver by CYP450 enzyme,liver by alpha-glucosidase,liver by CYP2C8 & CYP34A,liver by CYP450 34A,yes,no,no,yes,NA,First-pass metabolism:,Undergoes minimal first-pass metabolism.,Undergoes minimal first-pass metabolism.,Undergoes extensive first-pass metabolism.,Undergoes extensive first-pass metabolism.,Undergoes extensive first-pass metabolism.,Undergoes extensive first-pass metabolism.,Undergoes extensive first-pass metabolism.,Undergoes extensive first-pass metabolism.,Undergoes minimal first-pass metabolism.,Undergoes extensive first-pass metabolism.,Undergoes extensive first-pass metabolism.,NA,NA,6 hours (approx.),4 to 6 hr,1.6 hours,1 to 4 hours,Approx 6 hours,­,­,­,­,­,­,­,­,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Azathioprine undergoes significant first-pass metabolism in the liver. During the first pass through the liver after oral administration, it is metabolized to 6-MP, which is then further metabolized to active and inactive metabolites.",it absorbed from te gastroitestinal tract nd enters the live before reching the sytemic circulation,"It is extensively metabolised, undergoing 'first pass' metabolism by the liver and is excreted in both the urine and faeces","While Methotrexate undergoes hepatic metabolism, the major route of elimination is renal excretion. A small fraction of the drug may be eliminated through the biliary route.",NA,undergo first pss metabolism in liver,NA,"Betamethasone experiences significant first-pass metabolism when administered orally, leading to reduced oral bioavailability",NA,Not a significant factor as Tazarotene is primarily used topically.,Not a significant factor as it is applied topically,"adalimumab is typically administered via subcutaneous injection, by passing the first pass metabolism that would occur if it were administered orally",carboxylic acid,NA,yes,yes,yes,yes,yes,negligible,yes,yes,NA,NA,NA,NA,NA,NA,NA,Yes,No,No,No,No,No,No,No,No,No,No,NA,No,No,NA,Inactive metabolites,Yes,Yes,hydroxylated,Yes,yes/3-hydroxyquinine,Yes,present,NA,demethylated,NA,yes,Yes,Yes,yes,Yes,undergoes first-pass metabolism when administered orally,approximately 20-30%,Famotidine may undergo some degree of first-pass metabolism in the liver.,approximately 20-30%,Bepridil may undergo extensive first-pass metabolism in the liver.,Cisapride may undergo some degree of first-pass metabolism in the liver.,: Dofetilide undergoes minimal first-pass metabolism in the liver.,Levoketoconazole may undergo first-pass metabolism in the liver.,Pimozide undergoes significant first-pass metabolism in the liver.,Piperaquine undergoes extensive first-pass metabolism in the liver.,Sparfloxacin undergoes significant first-pass metabolism in the liver.,Terfenadine undergoes extensive first-pass metabolism in the liver to its active metabolite fexofenadine.,Ziprasidone undergoes significant first-pass metabolism in the liver.,Mesoridazine undergoes extensive first-pass metabolism in the liver.,Nizatidine undergoes minimal first-pass metabolism,"amikacin is usually administered intravenously or intramuscularly, it bypasses the gastrointestinal tract and liver, entering the systemic circulation directly. As a result, the drug undergoes minimal first-pass metabolism,","Plazomicin is primarily eliminated unchanged through the kidneys and does not undergo significant hepatic metabolism. Therefore, it does not undergo first-pass metabolism in the liver to a substantial extent.",Azithromycin has a low first-pass metabolism as it is primarily eliminated through the bile.,Amoxicillin undergoes minimal first-pass metabolism in the liver. The majority of the drug is excreted unchanged in the urine,"Cephalosporins, when administered orally, generally undergo some degree of first-pass metabolism in the liver. However, the extent of first-pass metabolism can vary among different cephalosporins based on their chemical properties and susceptibility to hepatic enzymes.","Temocillin is primarily excreted unchanged in the urine, and its metabolism is not extensive.","pass metabolism in the liver. During this process, the drug is partially metabolized, leading to a reduced bioavailability when taken orally. As a result, ampicillin is often administered intravenously to bypass the first-pass effect and ensure higher systemic availability.","Sulfadiazine undergoes first-pass metabolism in the liver after oral administration. During this process, the drug is partially metabolized before it reaches the systemic circulation.",Eravacycline undergoes minimal first-pass metabolism. First-pass metabolism refers to the initial metabolism of a drug in the liver before it reaches systemic circulation.,Penicillin undergoes minimal first-pass metabolism in the liver. is absorbed in the gastrointestinal tract and reaches the bloodstream relatively unchanged,"Meropenem undergoes minimal first-pass metabolism since it is primarily administered intravenously. The intravenous route allows the drug to bypass the liver initially, reducing the extent of first-pass metabolism.","Cephalexin undergoes minimal first-pass metabolism in the liver. The drug is absorbed in the gastrointestinal tract, and a significant portion is excreted unchanged in the urine without undergoing extensive hepatic metabolism.","Ciprofloxacin undergoes limited first-pass metabolism in the liver. The oral bioavailability of ciprofloxacin is relatively high (around 70-80%), indicating that a significant portion of the drug reaches the systemic circulation without being extensively metabolized during its first pass through the liver.","Ceftolozane/tazobactam is typically administered intravenously, bypassing the gastrointestinal tract and avoiding first-pass metabolism in the liver.","Clarithromycin undergoes extensive first-pass metabolism in the liver. During this process, a significant portion of the drug is metabolized before it enters the systemic circulation. The primary metabolite of clarithromycin, 14-OH clarithromycin, is formed through hepatic metabolism.",In Liver (oral bioavailability 50%),Metabolised by parellel first order &Michaelis-menten pathway,Glucoronic acid conjugate (High metabolism 70%),in Liver (CYP1A2 & CYP2E1),NA,NA,Minimal,NA,20-30%,60-70%,varies,Varies based on condition,Beclomethasone-17-monopropionate,LIVER,Liver,Yes,Yes,Minimal,Yes,Limited first-pass metabolism,Negligible,Yes,Yes,Extensive,Minimal,Yes,Yes,Limited,Yes,Limited,metabollize in liver by CYP2C9 and CYP2E1,yes,Limited,Yes,Limited,Yes,Yes,Minimal,yes,Minimal,Yes,Yes,Limited first-pass metabolism,yes,Extensive,Yes,Extensive,Yes,Yes,Significant,Extensive,Significant,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,NA,NA,liver,liver,liver,20-30% of the orally administered,does not undergo significant first-pass metabolism.,Digoxin does not undergo significant first-pass metabolism in the liver.,"significant first-pass metabolism in the liver, meaning a large portion of the drug is metabolized before it reaches systemic circulation","Diltiazem undergoes significant first-pass metabolism in the liver,","undergoes significant first-pass metabolism in the liver, resulting in reduced bioavailability when administered orally.",undergoes extensive first-pass metabolism when administered orally,"Yes, amiodarone undergoes extensive first-pass metabolism in the liver.",First-pass metabolism: Sotalol does not undergo significant first-pass metabolism.,Not extensively metabolized during first-pass metabolism.,no,Not specified,Not applicable,significant,significant,significant,not applicable,yes,yes,yes,extensive,not applicable,yes,yes,limited, in the liver, undergoes rapid spontaneous hydrolysis after intravenous injection,first-pass metabolism in the liver,first-pass metabolism in the liver,first-pass metabolism in the liver,variable first-pass hepatic metabolism,Bendamustine undergoes extensive first-pass metabolism, it undergo extensive metabolism in liver with a half-life of 94 min,first-pass metabolism in the liver,first-pass metabolism in the liver,There is no evidence of first-pass effect for etoposide.,first-pass metabolism in the liver,first-pass metabolism in the liver,first-pass metabolism in the liver,in liver,Cytochrome 450,Cytochrome 450,Cytochrome 450,Cytochrome 450,Cytochrome 450,Cytochrome 450,Cytochrome 450,Cytochrome 450,Cytochrome 450,Cytochrome 450,Cytochrome 450,Cytochrome 450,Cytochrome 450,Cytochrome 450,Cytochrome 450,In liver,NA,NA,NA,NA,NA,NA,NA,cytochrome P450 (CYP) 3A,NA,NA,NA,"With thiopental, an acidic lipophilic barbiturate, only 14% of the injected drug accumulated in the lung during the first pass.a nonbasic lipophilic amine, there was 30% .","to nordiazepam and oxazepam. These metabolites have one-third the anticonvulsant activity of diazepam. As a result of extensive first-pass metabolism, the bioavailability of unchanged diazepam is only 1–3%.",Hydroxyzine undergoes hepatic metabolism and is eliminated through urine. it is frequently administered in conjunction with either meperidine or chloral hydrate for enhanced management.,"a lipophilic ?-adrenergic blocking agent that has been clinically validated, experiences significant and unpredictable hepatic metabolism during its initial passage when administered in the form of a traditional oral formulation.",The mean systemic availability is approximately 4 percent. ,"First-pass metabolism of gepirone is extensive, with little of the parent compound excreted unchanged in the urine.",low (approximately by 0.05) extraction ratio and only a small first-pass effect.,the active ingredient of clonidine hcl inj. Is well absorbed from gastrointestunal tract and undergoes minoe first pass metabolism,hydroxylation catalyzed by cytochrome P450 3A (CYP3A). ,NA, metabolized in the liver by CYP2C9 with minor metabolism by CYP2C19 and CYP2E1. ," N-demethylation to desmethylchlordiazepoxide, followed by deamination to demoxepam; ", in the liver.,"an acidic lipophilic barbiturate, only 14% of the injected drug accumulated in the lung during the first pass.",undergoes a partially saturated first pass metabolism ,"Indoleacitic acid , g-aminobutyric acid &N-oxide",partially metabolized in the liver to inactive metabolite,metabolites of naratriptan are inactive,N-oxide and indoleacetic acid are inactive,indole acetic acid & indole acetic acid glucuronide,partially metabolised in the liver,partially metabolized in the liver,metabolised by the liver,"CYP2B6,CYP2C19 and CYP3A4",hepatic enzymes,"lactose monohydrate, magnessium stearate",M7 and M18,glucoronide metabolite,CYP4503A catalyzed,fluvoxamine,Sulfoxides,no significant metabolite,desloratadine in liver,"cellulose,lactose","citric acid,Na citrate",Hydroydesloratodine,Micricrystalline cellulose,benzalkonium chloride,Citric acid,desmethylclemastine,ceterizine,"N,N-dimethyl-2-methylthio0rthylamine",despmethylcyproheptadine,desalkyl ebastic,N-desmethyl doxylamine,NA,NA,NA,mosapride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ascorbic acid-2-sulfate and oxalic acid,5-methyltetrahydrofolate (5-MTHF),"Methylcobalamin, Adenosylcobalamin",Niacinamide (Nicotinamide),"Flavin Mononucleotide (FMN), Flavin Adenine Dinucleotide (FAD)",hiamine Pyrophosphate (TPP),Betaine,"25-hydroxycholecalciferol (Calcifediol), 1,25-dihydroxycholecalciferol (Calcitriol)",NA,Bisnorbiotin,Pantethine,No specific inactive metabolite identified,No specific inactive metabolite identified,Menadione (Vitamin K3),No specific inactive metabolite identified,Inactive metabolites,Benzyl alcohol,Benzoic acid,microcrystalline cellulose,Hydroxyitraconazole,glycerol triacetate,N-oxide,6-desmethylgriseofulvin,Oleic acid,NA, N-acetylation,N- demethyl terbinafine,Hcl,NA,NA,NA,Through cytochrome P450,Through cytochrome P450,gastrointestinal tract and avoids significant first-pass metabolism in the liver.,"Skin, vagina, reduces systematic absorption,",Gastrointestinal tract,Gastrointestinal tract,Liver,Liver,Liver,Liver,Liver,Liver,Liver,Gastrointestinal tract and liver,Liver, carboxyl derivative ,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,sulfone derivative,Yes,sulfone derivative.,sulfone derivative,NA,Yes,Yes,Yes,Yes,Yes,Not applicable,depending on the route of administration.,Yes,Not applicable.,"Yes, it forms inactive metabolites.",carbonate ion (CO3^2-).,"1-methyl-1,2-dihydroimidazole-2-thione.",carbon dioxide (CO2) and water (H2O),"aluminum phosphate and aluminum sulfate,",NA,salicylate component,"5-hydroxyomeprazole, omeprazole sulfone",demethylpantoprazole and sulfone,"desmethylranitidine, ranitidine S-oxide, and N-oxide",desmethyl-rabeprazole and thioether-rabeprazole,oxaloacetic acid and ?-ketoglutaric acid,hydroxyesomeprazole and desmethylesomeprazole.,sodium citrate are bicarbonate ions.,magnesium oxide and carbon dioxide,oxide and silicon dioxide,NA,Endoxifen,NA,NA,NA,NA,yes,yes,NA,present,NA,NA,NA,NA,NA,Not specified,GS-461203 (active metabolite),Not specified,Form active metabolites,Several inactive metabolites,GS-441524 (active metabolite),Metabolites are inactive,Penciclovir (active metabolite),Inactive metabolites,non-enzymatic hydrolysis.,Antitumor activity,1-0-glucuronide,enzymatic & non-enzymatic process,1-0-glucuronide,1-0-glucuronide,p-hydroxyprocarbazine,amino acid,"oxidation , reduction",hydrolysis,liver,enzymatic,enzymatic process,N-desmethyl-lomustine,7-hydroxymethotrexate,Inactive metabolites,SEVERAL IN ACTIVE METABOLITES,SEVERAL IN ACTIVE METABOLITES,NA,yes,yes,NA,yes,NA,cyp3a4,several inactive metabolites,several inactive metabolites,inactive metabolites,inactive metabolites,NA,"Indoleacitic acid , g-aminobutyric acid &N-oxide",partially metabolized in the liver to inactive metabolite,metabolites of naratriptan are inactive,N-oxide and indoleacetic acid are inactive,indole acetic acid & indole acetic acid glucuronide,partially metabolised in the liver,partially metabolized in the liver,metabolised by the liver,"CYP2B6,CYP2C19 and CYP3A4",hepatic enzymes,"lactose monohydrate, magnessium stearate",M7 and M18,glucoronide metabolite,CYP4503A catalyzed,fluvoxamine,Sulfoxides,no significant metabolite,desloratadine in liver,"cellulose,lactose","citric acid,Na citrate",Hydroydesloratodine,Micricrystalline cellulose,benzalkonium chloride,Citric acid,desmethylclemastine,ceterizine,"N,N-dimethyl-2-methylthio0rthylamine",despmethylcyproheptadine,desalkyl ebastic,N-desmethyl doxylamine,NA,NA,NA,mosapride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Inactive metabolites,ascorbic acid-2-sulfate and oxalic acid,5-methyltetrahydrofolate (5-MTHF),"Methylcobalamin, Adenosylcobalamin",Niacinamide (Nicotinamide),"Flavin Mononucleotide (FMN), Flavin Adenine Dinucleotide (FAD)",hiamine Pyrophosphate (TPP),Betaine,"25-hydroxycholecalciferol (Calcifediol), 1,25-dihydroxycholecalciferol (Calcitriol)",NA,Bisnorbiotin,Pantethine,No specific inactive metabolite identified,No specific inactive metabolite identified,Menadione (Vitamin K3),No specific inactive metabolite identified,NA,NA,NA,NA,NA,Benzyl alcohol,Benzoic acid,microcrystalline cellulose,Hydroxyitraconazole,glycerol triacetate,N-oxide,6-desmethylgriseofulvin,Oleic acid,NA, N-acetylation,N- demethyl terbinafine,Hcl,NA,NA,NA,NA,First-pass metabolism:,Through cytochrome P450,Through cytochrome P450,gastrointestinal tract and avoids significant first-pass metabolism in the liver.,"Skin, vagina, reduces systematic absorption,",Gastrointestinal tract,Gastrointestinal tract,Liver,Liver,Liver,Liver,Liver,Liver,Liver,Gastrointestinal tract and liver,Liver,Inactive metabolites, carboxyl derivative ,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Inactive metabolites,sulfone derivative,Yes,sulfone derivative.,sulfone derivative,NA,Yes,Yes,Yes,Yes,Yes,Not applicable,depending on the route of administration.,Yes,Not applicable.,"Yes, it forms inactive metabolites.",Inactive metabolites,carbonate ion (CO3^2-).,"1-methyl-1,2-dihydroimidazole-2-thione.",carbon dioxide (CO2) and water (H2O),"aluminum phosphate and aluminum sulfate,",NA,salicylate component,"5-hydroxyomeprazole, omeprazole sulfone",demethylpantoprazole and sulfone,"desmethylranitidine, ranitidine S-oxide, and N-oxide",desmethyl-rabeprazole and thioether-rabeprazole,oxaloacetic acid and ?-ketoglutaric acid,hydroxyesomeprazole and desmethylesomeprazole.,sodium citrate are bicarbonate ions.,magnesium oxide and carbon dioxide,oxide and silicon dioxide,Inactive metabolites,NA,Endoxifen,NA,NA,NA,NA,yes,yes,NA,present,NA,NA,NA,NA,NA,Not specified,GS-461203 (active metabolite),Not specified,Form active metabolites,Several inactive metabolites,GS-441524 (active metabolite),Metabolites are inactive,Penciclovir (active metabolite),Inactive metabolites,non-enzymatic hydrolysis.,Antitumor activity,1-0-glucuronide,enzymatic & non-enzymatic process,1-0-glucuronide,1-0-glucuronide,p-hydroxyprocarbazine,amino acid,"oxidation , reduction",hydrolysis,liver,enzymatic,enzymatic process,N-desmethyl-lomustine,7-hydroxymethotrexate,SEVERAL IN ACTIVE METABOLITES,SEVERAL IN ACTIVE METABOLITES,NA,yes,yes,NA,yes,NA,cyp3a4,several inactive metabolites,several inactive metabolites,inactive metabolites,inactive metabolites,NA,yes,NA,NA,NA,NA,NA,YES,YES,NA,NA,NA,NA,NA,YES,YES,NA,YES,YES,YES,YES,YES,YES,NA,YES,YES,YES,YES,YES,YES,YES,YES,None,Glucuronide conjugates,None,None,None,Yes,None,None,None,None,None,NA,Present,NA,NA,Baricitinib croses the BBB.,Tofacitninb croses the BBB.,Upadacitinib shows lower level of BBB permeation.,Standard dose MTX does not cross the BBB but high-dose methotrexate shows modest BBB penetration.,It crosses the blood-brain barrier,Sulfasalazine itself does not readily cross the blood-brain barrier (BBB),"Azathioprine and active metabolite, 6-mercaptopurine, have the ability to cross the blood-brain barrier (BBB)",Cyclosporine does have the ability to cross the blood-brain barrier (BBB).,Limited,Crosses the blood-brain barrier,Limited,Moderate,Poor,Limited due to large size and polarity,Limited,NA,YES (Desethylamino analog),"YES( 5,6-dihydro-5-fluorouracil(DHFU)",NA,N-desmethyl sonidegib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"to 5R,6R-penicilloic acid and 5S,6R-penicilloic acid and to piperazine-2,5-dione after oral intake",Amoxicillin is inactivated by beta lactamases,"Like most other cephalosporins, cefalexin is not metabolized or otherwise inactivated in the body","Like most other cephalosporins, cefalexin is not metabolized or otherwise inactivated in the body","mipenem is degraded by dehydropeptidase-1, a brush border enzyme in the proximal renal tubules, which results in production of an inactive metabolite",Meropenem is metabolised by hydrolysis of the b-lactam ring generating a microbiologically inactive metabolite,vancomycin metabolism in ... inactivated rat liver microsomes system confirms that vancomycin is not metabolized in the liver.,NA, cefotaxime leads to desacetylcefotaxime leads to desacetylcefotaxime lactone leads to M metabolites,NA,NA, Piperacillin metabolized to a minor microbiologically active desethyl metabolite and an inactive metabolite.," About 50% of the dose is metabolized in the liver to three inactive metabolites,","eftaroline occurs to form the microbiologically inactive, open-ring metabolite, ceftaroline ",Glycerol dinitrate,isosorbide-2-mononitrate.,isosorbide-5-mononitrate glucuronide.,dinitrates and mononitrates.,pentaerythritol dinitrate and pentaerythritol mononitrate,4-hydroxypropranolol.,?-hydroxymetoprolol.,None,Norverapamil,desacetyldiltiazem.,Pyridine analogue,SG-86,dehydronifedipine.,deesterified felodipine.,"2,6-bis-(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine",1.31±0.33h,1-2 hours,1.5 hour,2.2 (0.9) hours.,2-4 hours,NA, 1 hour,1 hour,2.3 hours,4 hours,1.5 hours, 0.12 ± 0.05 h,1.22 ± 0.64 h,0.21 hours, 1.89 h,reached within 2 hours after oral administration.,reached within 2 hours after oral administration,reached within 2-3 hours after oral administration.,reached within 3-4 hours after oral administration.,reached within 1-2 hours after oral administration.,reached within 2-5 hours after oral administration.,reached within 1-2 hours after oral administration.,reached within 1-3 hours after oral administration.,reached within 1-3 hours after oral administration.,reached within 1-3 hours after oral administration.,reached within 1-2 hours after oral administration.,NA,NA,0.345±0.186h,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Several, including carbamazepine-10,11-epoxide",Conjugated forms (glucuronide),Lamotrigine 2-N-glucuronide (major metabolite),Not applicable,Mostly excreted unchanged,Conjugated metabolites,N-desmethylclobazam,"4'-hydroxyfelbamate, felbamate glucuronide",Not specified,Yes,Not specified,N/A,"Several metabolites, inactive",No major inactive metabolites,Yes,"Several, including carbamazepine-10,11-epoxide",Conjugated forms (glucuronide),Lamotrigine 2-N-glucuronide (major metabolite),Not applicable,Mostly excreted unchanged,Conjugated metabolites,N-desmethylclobazam,"4'-hydroxyfelbamate, felbamate glucuronide",Not specified,Yes,Not specified,N/A,"Several metabolites, inactive",No major inactive metabolites
T-max,immediate-release formulations 3-7 hours,3 hours,1-2 hours,2-3 hours,~2-4 hours,~2-4 hours,1-2 hours,30 mins-1 hour,30-60 minutes,10-20 minutes (smoking),1-2 hours,~3-4 hours,1-4 hours,2-4 hours,0.5-2 hours,2-4 hours,0.5-1 hour,0.5-2 hours,1-2 hours post-dose,1-2 hours,1-3 hours,2-3 hours,1-2 hours,2-4 hours,10–60 minutes,1-2 hours,1-2 hours,1-2 hours,~ 1-2 hours,Hepatic excretion:,Glucoronide conjugation,Glucoronide conjugation,reduction and hydroxylation,Glucoronide conjugation,Glucoronide conjugation and oxidation,Glucoronide conjugation,NA,NA,Glucoronide conjugation,Glucoronide conjugation,Glucoronide conjugation,Glucoronide conjugation,Glucoronide conjugation,Glucoronide conjugation,Not specified,Rapid,Variable,1-2 hours,Significant,Variable,Not applicable,Not applicable,Not applicable,Variable,: Not applicable,Not specified,T-max,Variable,Variable,Variable,2-3hrs,3-5 hours,0.5-1.5 hours,2-5 hours,2-5 hours,NA,NA,NA,NA,NA,2-4 hours,NA,50.3 (min)e,1 - 3 hrs,3 -4 hrs,approx 1 -2 hrs,approx 1 -2 hrs,2-3 hrs,1-2 hrs,2 hrs,2-4 hrs,1.5 - 22.5 hrs,30 to 90 minutes,1-2 hrs,1 hrs,NA,T-max,5 hours,4 hours,2-4 hours,6 hours,2-3 hours,5 hours,6-8 hours,1 hours,2 hours,4 hours,2-8 hours,NA,NA,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The time to reach peak plasma concentration (T-max) of Azathioprine can vary based on factors such as the dose, individual patient characteristics, and the specific formulation or product. Generally, T-max is reached within a few hours after oral administration.",around 2-4 hours after administration,12–24 hours of administration,The time to reach peak plasma concentration (T-max) for Methotrexate depends on the route of administration and reached within 1-2 hours.,NA,usually 1-3 hours after oral admin,NA,"The time to reach peak plasma concentration varies depending on the route of administration. For oral administration, it typically occurs within a few hour",NA,T-max is not typically relevant for topically applied medications.,): T-max is not typically relevant for topically applied medications.,2-3 hours after oeal administered,120 days,NA,NA,0.5-1 hrs,1-1.5 hrs,NA,1-1.5 hrs,1-2 hrs,1-2 hrs,4hrs,3-4hrs,2-4hrs,1-2 hrs,NA,NA,T-max,50.3(min)e,1.5 to 22.5 hours,NA,6 to 12 hours,1-1.5 hours,30 to 90 minutes,120minutes,20 to 30 minutes,20 to 30 minutes,NA,0.5 to 2 hours,NA,12hours,1 to 2Hours,NA,NA,First-pass metabolism:,Extensive,Yes,Yes,yes,yes,Yes,Yes,yes,Yes,Yes,yes,no,yes,Yes,2 to 3 hours after ingestion.,2 hours after oral administration.,within 1 to 3 hours after oral administration.,2 hours after oral administration.,within 2 to 4 hours,within 1 to 2 hours after oral administration.,within 2 to 3 hours,may vary,6-8 hours,3-4 hours after oral administration.,2-4 hours,1-2 hours,5-6 hours,2-4 hours,1-3 hours,"The Tmax (time to reach maximum concentration) of amikacin, an antibiotic, typically occurs within 1 to 2 hours after intramuscular injection.","Plazomicin, the time to reach maximum concentration is typically within 1 to 2 hours after intravenous (IV) administration. The exact timing can depend on factors such as the specific formulation and individual patient characteristics",Time to peak concentration (Tmax) in adults is 2.1 to 3.2 hours for oral dosage forms.,Tmax 1.31±0.33h,160 — tmax (h).,NA,"Tmax is typically around 1 to 2 hours after ingestion. Intravenous administration results in a more rapid onset, with Tmax occurring within 5 to 10 minutes.",2.5 and 3.3 hours,generally observed around 1 to 2 hours after intravenous (IV) administration.,(T max. = 0.5 h.),The Tmax in blister fluid occurred at 1.22 ± 0.64 h.,The Tmax (time to reach maximum concentration) of cephalexin is typically around 1 to 2 hours after oral administration.,T max of ciprofloxacin is generally around 1 to 2 hours after oral administration.,Tmax can be influenced by factors such as the specific formulation of the drug and whether it is administered alone or in combination with tazobactam.,concentration (Tmax) for clarithromycin typically occurs around 2 to 3 hours after oral administration.,2-3 Hours,1-2hrs,0.5-2 hours,1-2 hours,1-2 HRS,5 min,3-4 hours,3-5 hrs,15 min,2-4 hrs,1-2hrs,1-2 hrs,0.5-1.5 hrs,1-2 hrs,0.5-2 hrs,1-4 hours,2-4 hours,1-4 hours,Varies,1 to 2 hours after oral administration,1-4 hours,1-4 hours,1-4 hours,2-6 hours,2-4 hours,1-2 hours,1-4 hours,2-3 hours,2-6 hours,1-2 hours,2-4 hour,1-4 hours,1-2 hours,2-6 hours,2-3 hours,1-4 hours,1-2 hours,2-4 hours,4-6 hours,1-4 hours,Varies,2-4 hours,1 to 2 hours after oral administration,0.5 - 2 hours,2-6 hours,2-4 hours,2-4 hours,1-2 hours,2-4 hours,2-6 hours,1-3 hours,2-4 hours,1-2 hours,3-5 hours post-dose,4-5 hours,0.5-4 hours,3-4 hours,2-4 hours,Not Available,4-6 hours,2 to 4 hours after oral administration,2-4 hours after oral administration.,3-6 hours,1 to 1.5 hours,2 to 4 hours,3 to 4 hours,"very short, usually within a few minutes.",1-3 hours after oral administration,1 to 2 hours after administration,2-3 hours,NA,"rapidly after intravenous administration, typically within minutes.",3 to 7 hours,2 to 3 hours.,1-2 hours,Not specified,Not specified,Not specified,4 hours,n/a,4 hours,not applicable,1-4 hours,2-4 hours,2-5 hours,NA,not applicable,2-4 hours,2-4 hours,not specified,0.67 to 4 hrs after a 15 mg/m2 dose), 37.5 ± 0.56 minutes,1 to 2 hours,1 to 2hr,1 to 4 hours,one hour in patients who received single oral doses of 0.2 mg/kg to 0.25 mg/kg of melphalan.,30 minutes to 2 hours,1 to 6 hour,1.7 ± 1.3 h),0.5 ± 0.0 h, 1.1 to 3.5 h,0.83 +/- 0.53 hour,15 to 30 min,15 to 30 minutes after the end of the infusion,40 min,3hrs,1.5 hrs,2hrs,2-3 hrs,1.5 hrs,2-3 hrs,90min-3hrs,2-4 hrs,1-2 hrs,2hrs,1-2 hrs,2-4 hrs,90min- 3 hrs,1.5 hrs,1.2hrs,1 to 3 hrs,1 to 2 hrs,4 to 6 hrs,1 to 2 hrs,2 hrs,0.67 to 4 hrs after a 15 mg/m2 dose,4 to 6 hrs,6 hrs,2 to 5 hrs,3 to 4 hrs,3 hrs,2.2 hrs,1.93 h (Tmax).,shortly 2 hrs, 2 hours following administration.,2 hours, 40 to 90 minutes. , 1.3 h , 40 min after oral administration and 60 min after sublingual administration, 12 to 478 min , ~10 hours compared to 1-2 hours.,NA,2–4 h, not more than 300 mg per day.,NA, 4.8 to 30 mg.l-1,4.3 hours in healthy patients. ,monoamine oxidase-A,through CYP3A4,CYP450,first- pass metabolism in liver is avoided with the nasal spray formulation,serotonin 5-HT1 receptor agonist undergoes first-pass metabolism,moderate first pass metabolism,high first pass metabolism,high first pass metabolism,rapidly metabolized to DHA,undergo first pass metabolism,do not undergo first pass metabolism,hepatic and extrahepatic metabolism by CYP enzymes,do not undergo first pass metabolism,do not undergo first pss metabolism,3-ethyl demethylation to paraxanthine,in liver,minimum in liver,significant to pass,intestine significant,rapid &extensive,through liver,"oxidation,o-dealkylation","CYP3A,CYP2D6,CYP2C19","oxidatin,demethylation",in liver,CYP3A4 &CYP2D6,in liver,liver,liver,oxidation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,it does not undergo significant first-pass metabolism.,it does not undergo significant first-pass metabolism,it does not undergo significant first-pass metabolism,first-pass metabolism in the liver,it does not undergo significant first-pass metabolism,it does not undergo significant first-pass metabolism.,it undergoes first-pass metabolism to some extent,it undergoes first-pass metabolism in the liver.,it undergoes first-pass metabolism in the liver.,it does not undergo significant first-pass metabolism,it does not undergo significant first-pass metabolism.,it does not undergo significant first-pass metabolism.,it does not undergo significant first-pass metabolism.,it undergoes first-pass metabolism.,it does not undergo significant first-pass metabolism.,First-pass metabolism:,liver,Liver,GI Tract,liver,Liver,Liver,NA,Liver,GI Tract,Liver,Kidney,NA,Urine,Gi tract,urine,3 hours,3 to 4 hours,1 to 2 hours,1 to 3 hours,4 to 6 hours,18.4 hours,4 hours,1-4 hours,1-2 hours,2 hours,2 hours,6 hours,NA,30 min,3 to 5 hours,"Undergoes extensive hepatic metabolism, primarily by CYP2C9 and CYP3A4 enzymes.","Undergoes extensive metabolism in the liver, primarily by CYP2C9.","Subjected to extensive metabolism in the liver, mainly through CYP2C9.","Experiences significant first-pass metabolism in the liver, primarily by CYP2C9.","Undergoes hepatic metabolism, and its active metabolites contribute to its hypoglycemic effects.","Metabolized in the liver, but specific details about first-pass metabolism may be limited.","Metabolized in the liver, and the exact details of first-pass metabolism may vary.",Information about the first-pass metabolism of Glymidine is limited.,Information about the first-pass metabolism of Glibornuride is limited.,"Metabolized in the liver, but detailed information about first-pass metabolism may be limited.",Information about the first-pass metabolism of Gliquidone is limited.,Information about the first-pass metabolism of Glyclopyramide is limited.,Information about the first-pass metabolism of Glyhexamide is limited.,Information about the first-pass metabolism of Glibuzole is limited.,"Undergoes significant hepatic metabolism, primarily by CYP2C9, producing active and inactive metabolites.",yes,Yes,yes,yes,yes,Yes,Yes,Yes,No,Yes,minimal,NA,Yes,Minimal,"Some, but not extensively.",Yes,Yes,Yes,Yes,No,Yes,Yes in the liver,Yes in the liver,Yes in the liver,Yes in the liver,Yes,Yes,Yes,Yes in the liver,Yes,NA,NA,hepatic via CYP3A4,NA,NA,NA,moderated,extensive,yes,yes,limited,extensive,extensive,NA,NA,Minimal,Extensive,Minimal,Extensive,Extensive,Not applicable (administered intravenously),Minimal,Yes,First-pass metabolism:,liver,liver,liver,livers,liver,liver,liver,intravenously,liver,liver gastrointestinal tract,liver systemic circulation,liver,liver,liver,liver,First-pass metabolism:,YES,YES,NA,significant first pass,significant in 1st pass metabolised,NA,yes,NA,not specified,1st metabolised,1st metabolised,not applicable,NA,NA,monoamine oxidase-A,through CYP3A4,CYP450,first- pass metabolism in liver is avoided with the nasal spray formulation,serotonin 5-HT1 receptor agonist undergoes first-pass metabolism,moderate first pass metabolism,high first pass metabolism,high first pass metabolism,rapidly metabolized to DHA,undergo first pass metabolism,do not undergo first pass metabolism,hepatic and extrahepatic metabolism by CYP enzymes,do not undergo first pass metabolism,do not undergo first pss metabolism,3-ethyl demethylation to paraxanthine,in liver,minimum in liver,significant to pass,intestine significant,rapid &extensive,through liver,"oxidation,o-dealkylation","CYP3A,CYP2D6,CYP2C19","oxidatin,demethylation",in liver,CYP3A4 &CYP2D6,in liver,liver,liver,oxidation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,First-pass metabolism:,it does not undergo significant first-pass metabolism.,it does not undergo significant first-pass metabolism,it does not undergo significant first-pass metabolism,first-pass metabolism in the liver,it does not undergo significant first-pass metabolism,it does not undergo significant first-pass metabolism.,it undergoes first-pass metabolism to some extent,it undergoes first-pass metabolism in the liver.,it undergoes first-pass metabolism in the liver.,it does not undergo significant first-pass metabolism,it does not undergo significant first-pass metabolism.,it does not undergo significant first-pass metabolism.,it does not undergo significant first-pass metabolism.,it undergoes first-pass metabolism.,it does not undergo significant first-pass metabolism.,NA,NA,NA,NA,NA,liver,Liver,GI Tract,liver,Liver,Liver,NA,Liver,GI Tract,Liver,Kidney,NA,Urine,Gi tract,urine,NA,T-max,3 hours,3 to 4 hours,1 to 2 hours,1 to 3 hours,4 to 6 hours,18.4 hours,4 hours,1-4 hours,1-2 hours,2 hours,2 hours,6 hours,NA,30 min,3 to 5 hours,First-pass metabolism:,"Undergoes extensive hepatic metabolism, primarily by CYP2C9 and CYP3A4 enzymes.","Undergoes extensive metabolism in the liver, primarily by CYP2C9.","Subjected to extensive metabolism in the liver, mainly through CYP2C9.","Experiences significant first-pass metabolism in the liver, primarily by CYP2C9.","Undergoes hepatic metabolism, and its active metabolites contribute to its hypoglycemic effects.","Metabolized in the liver, but specific details about first-pass metabolism may be limited.","Metabolized in the liver, and the exact details of first-pass metabolism may vary.",Information about the first-pass metabolism of Glymidine is limited.,Information about the first-pass metabolism of Glibornuride is limited.,"Metabolized in the liver, but detailed information about first-pass metabolism may be limited.",Information about the first-pass metabolism of Gliquidone is limited.,Information about the first-pass metabolism of Glyclopyramide is limited.,Information about the first-pass metabolism of Glyhexamide is limited.,Information about the first-pass metabolism of Glibuzole is limited.,"Undergoes significant hepatic metabolism, primarily by CYP2C9, producing active and inactive metabolites.",First-pass metabolism:,yes,Yes,yes,yes,yes,Yes,Yes,Yes,No,Yes,minimal,NA,Yes,Minimal,"Some, but not extensively.",First-pass metabolism:,Yes,Yes,Yes,Yes,No,Yes,Yes in the liver,Yes in the liver,Yes in the liver,Yes in the liver,Yes,Yes,Yes,Yes in the liver,Yes,First-pass metabolism:,NA,NA,hepatic via CYP3A4,NA,NA,NA,moderated,extensive,yes,yes,limited,extensive,extensive,NA,NA,Minimal,Extensive,Minimal,Extensive,Extensive,Not applicable (administered intravenously),Minimal,Yes,First-pass metabolism:,liver,liver,liver,livers,liver,liver,liver,intravenously,liver,liver gastrointestinal tract,liver systemic circulation,liver,liver,liver,liver,YES,YES,NA,significant first pass,significant in 1st pass metabolised,NA,yes,NA,not specified,1st metabolised,1st metabolised,not applicable,NA,NA,extensive,NA,Extensive,Extensive,NA,NA,Moderate,extensive,extensive,negligile,NA,NA,minimal,EXTENSIVE,SIGNIFICANT,NA,EXTENSIVE,SIGNIFICANT,EXTENSIVE,SIGNIFICANT,SIGNIFICANT,EXTENSIVE,EXTENSIVE,EXTENSIVE,EXTENSIVE,EXTENSIVE,EXTENSIVE,EXTENSIVE,EXTANSIVE,Moderate,High,Not applicable,Yes,Not applicable,Not applicable,Not applicable,Yes,Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,NA,NA,NA,NA, Cmax was reached after one hour of oral drug administration. ,30 minutes to 1 hour ,reaches after 2 to 4 hours,0.4 to 1 micromoles per liter (µmol/L) and typically occurs within 1-2 hours,The maximum plasma concentration (Cmax) of leflunomide is typically reached within several hours after oral administration.,"Typically, peak concentrations are observed around 2 to 6 hours after dosing",1-2 hours ,he Cmax of a 0.1% cyclosporine ophthalmic emulsion is 0.67 ng/mL ,65-128µg/L,129.6 ng/mL,1.1 mcg/L,Cmax of 113-1343ng/mL,3628 ng/mL,4.7 ± 1.6 ?g/mL,51.3±23.2µg/mL,NA,yes,YES,YES,YES,NO,no,YES,Yes,yes,yes,no,yes,yes,no,NA,"black iron oxide, gelatin, magnesium stearate, titanium dioxide, shellac, propylene glycol,", first-pass effects through those organs. Approximately 50–70% of the administered amoxicillin and 25–40%,Cephalexin is not metabolized in the body,Metabolism of ceftriaxone is negligible. Ceftriaxone is primarily eliminated in the urine (33-67%).,"n imipenem is administered alone by the intravenous route, the levels excreted in the urine are low and variable (6%-38% of the dose)","Meropenem is primarily excreted in the urine, with negligible fecal excre- tion","n the first 24 hours, about 75-80% of an administered dose of vancomycin is excreted in urine by glomerular filtration",NA," Cefotaxime is metabolized by the liver and excreted through the kidneys, and dysfunctions may result in decreased ",NA,NA,Piperacillin is metabolized to a minor microbiologically active desethyl metabolite., Less than 1% of cefepime is metabolized in the liver. , Ceftaroline lacks a p450-dependent mechanism of metabolism and is unlikely to interfere with drugs metabolized through cytochromes ,No,No,Yes,Yes,Yes,Significant,50%,Minimal,80%,40%,Significant,Significant,90%,80%,66-90%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,eliminated via the urine (about 77%) and feces (about 18%) as metabolites.,eliminated via the urine (about 80%) and feces (about 20%) as metabolites.,eliminated via the urine (about 65-70%) and feces (about 25-30%) as metabolites.,eliminated via the urine (about 90%) and feces (about 10%) as metabolites.,Primarily eliminated via the urine (about 80-85%) and feces (about 15-20%) as metabolites.,Primarily eliminated via the urine (about 51%) and feces (about 47%) as metabolites.,"Excreted mainly unchanged in the urine (approximately 70-80% of the dose), with a small fraction excreted in the feces.","Excreted mainly unchanged in the urine (approximately 70-80% of the dose), with a small fraction excreted in the feces.","Excreted mainly unchanged in the urine (approximately 60-70% of the dose), with a small fraction excreted in the feces.","Excreted mainly unchanged in the urine (approximately 70-80% of the dose), with a small fraction excreted in the feces.","Excreted mainly unchanged in the urine (approximately 70-80% of the dose), with a small fraction excreted in the feces","Propantheline and its metabolites are excreted mainly in the urine, with a small portion excreted in the feces.","Oxyphenonium and its metabolites are excreted mainly in the urine, with a small portion excreted in the feces.",Misoprostol and its metabolites are primarily excreted in the urine.,Rioprostil and its metabolites are primarily excreted in the urine.,"zanamivir is eliminated from the body 
via the kidney and undergoes no
metabolic biotransformation","In humans, peramivir is not significantly
metabolized, and approximately 90% of
administered peramivir is excreted
unchanged in urine.","At least 75% of an oral dose of the 
prodrug is converted into OC by 
first-pass metabolism, and <5% is recovered in urine as OP","Abacavir is extensively metabolized
 by the liver; less than 2% is excreted as unchanged drug in the urine",valacyclovir is rapidly and nearly completely hydrolyzed to acyclovir by first-pass intestinal and hepatic metabolism,Valacyclovir is well absorbed via intestinal brush border membranes and undergoes rapid and extensive first-pass intestinal/hepatic metabolism by the enzyme valacyclovir hydrolase to acyclovir and L-valine.," baloxavir marboxil, the proportion of total radioactivity excreted in faeces was 80.1 % of the administered dose, with the urine accounting for 14.7 % (3.3 % and 48.7 % of the administered dose was excreted as baloxavir in urine and faeces respectively)","Cidofovir is metabolized intracellularly to mono- and diphosphate moieties, as well as to cidofovir monophosphate choline. The long intracellular half-lives of the diphosphate and choline derivatives (17 and > 48 hours, respectively) contribute to long-acting activity"," adefovir dipivoxil is rapidly converted 
to adefovir. 45% of the dose is recovered as adefovir in the urine over 24 hours at steady state following 10 mg oral doses","
fostemsavir undergoes rapid and extensive metabolism by alkaline phosphatase on the luminal surface of the small intestine brush border membranes"," tenofovir is not metabolized by CYP450
isoenzymes, nor is it an inducer or inhibitor of these enzymes. Tenofovir is renally eliminated as unchanged drug by a combination of glomerular filtration and active tubular secretion","Intestinal first-pass metabolism by 
cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.","Atazanavir undergoes metabolism by the 
hepatic CYP3A enzymes and has a terminal half-life of 7 hours when administered alone, or 12 hours when co-administered with ritonavir. The drug is eliminated in feces (79% – primarily as metabolites) and in urine (13% – primarily as metabolites"," Boceprevir is metabolized by the
liver predominantly; approximately 79% is eliminated in stool and approximately 9% in urine.150 Because food (independent of fat content) increases boceprevir exposure by as much as 65%, boceprevir is taken with food ","Approximately 70% of an intravenous dose of lamivudine is recovered as unchanged drug in the urine. Metabolism of lamivudine is a minor route of elimination. In humans, the only known metabolite is the trans-sulfoxide metabolite (approximately 5% of an oral dose after 12 hours)",Yes,Yes,Minimal,Yes,Limited first-pass metabolism,Negligible,Yes,Yes,Extensive,Minimal,Yes,Yes,Limited,Yes,Limited,Yes,Yes,Minimal,Yes,Limited first-pass metabolism,Negligible,Yes,Yes,Extensive,Minimal,Yes,Yes,Limited,Yes,Limited
Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Renal and hepatic,Renal and unchanged,Renal and fecal,Primarily urine (approximately 10% unchanged),Renal and fecal excretion,Primarily through urine (approximately 97% as metabolites),Primarily excreted in urine,Renal excretion (90%) and feces (2%),Renal and fecal,Primarily via urine (mainly as metabolites),Renal and hepatic,Primarily hepatic,Renal and fecal excretion,Renal and fecal,Primarily renal excretion,Dose,0.125-0.25mg,15-30mg,5-10mg,NA,NA,NA,5-10mg,NA,NA,6mg/kg,15-30mg,50-400mg,15-60mg,8mg,10mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Urine- 4.5%,Urine- 0.456%,Urine:31%,Urine: 25%,Urine: 1.3%,Urine: >90%,Urine: 44-60%,Unchanged: 5-6%,Urine: 14%,Urine: 92-98%,Urine: 70-90%,Urine:48%,Urine:14%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,T-max,2-4 hours,1-4 hours,3 to 6 hours,6-24 hours,1-3 hours,2-4 hours,~2 hours,2-4 hours,1-4 hours,2-6 hours,NA,2-3 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Renal and hepatic excretion,Primarily renal excretion (70-90%),"Renal (30-50% unchanged), fecal",Primarily renal excretion of glucuronide metabolites,Renal excretion (66-68% unchanged); hepatic excretion also occurs,"Renal excretion (70-80%), some through feces",Primarily renal excretion,Renal and hepatic,Renal and hepatic excretion,"Renal excretion (95%), unchanged drug",Renal and fecal,Renal excretion (70-80% unchanged),Renal excretion (94% as unchanged drug),Renal and hepatic,Renal excretion (90% as unchanged drug),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Renal and hepatic,Renal and fecal,Renal and hepatic excretion,Renal and fecal,Renal and fecal,Mostly hepatic,Renal and fecal,Renal and hepatic,Renal and fecal,Renal and fecal,Renal and fecal,Renal and fecal,Renal and hepatic excretion,Renal and fecal,Renal and hepatic excretion,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,excreted through the kidneys,through the urine. The relatively short half-life of mechlorethamine necessitates careful dosing schedules during chemotherapy.,"Thiotepa and its metabolites are excreted primarily through the urine. Renal elimination is a significant route of excretion, with unchanged thiotepa and its metabolites being detected in the urine.",primarily excreted through the urine.,"excreted primarily through the urine. Renal function plays a role in the elimination of the drug, and dosage adjustments may be necessary in patients with impaired kidney function.",primarily excreted through the urine.,eliminated through the urine.,eliminated through the urine.,primarily excreted through the urine.,eliminated from the body via the kidneys through urine.,etoposide and its metabolites are eliminated from the body primarily through the kidneys.,metabolites are eliminated from the body primarily via urine.,from the body primarily via urine,"One of the main inactive metabolites of fludarabine is 2-
fluoro-ara-A (2-FAA). This metabolite is considered less pharmacologically active than the parent drug.",eliminated within a few hr,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1-3 hours,2.0 hours,4 hours,1.5 hour,1.50 hour,2-2.5 hours,2-3 hours,2 hrs,0.5-15 min,2hrs,4-9.6hrs,1.8 hrs,4.0-1.9 hrs,37.5 min,30-120 min,1.5-3 hours,1-2 hours after orally administration,1-2 hours after orally administrtion,1-3 hours post dose,2 to 2.5 hours,3 hours,0.9 hours,4.2~5.19,11.6+_3.0 ng/ml,2 to 4 hours after orally,1 to 2 hours after orally administration,3 to 4 hours,2 to 4 hours after orally administration,1.25 to 2.25 hours,1.5 to 2.5 hours,NA,6 hours,1.5 to 4 hours,3 hours,2-4 hours,1 to 2 hours,2.5 to 3.5 hours.,3 to 5 hours., 0.5 to 4 hours,0.5 hours,10 to 20 min,30 min, 30min,30 minutes,1 hour,2-4 hours after oral administration.,within a few hours after oral administration.,within 1-3 hours after oral administration.,"30 minutes to 3 hours, depending on the formulation.",within 2 hours after oral administration.,within 45 minutes to 2 hours after oral administration.,within a few hours after oral administration.,around 5-7 hours after oral administration.,within a few hours after oral administration.,within 1-2 hours after oral administration.,NA,NA,within 1-2 hours after oral administration.,within a few hours after oral administration.,within a few hours after oral administration.,C-max,2 hr after administration,48 h ,1 to 2 hours,1 to 2 hours,12 hours,3-5 hrs,4 hours,NA,NA,2 hours,2 hours,5.0 ± 2.0 ng/m,8 hours,NA,4 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2.1–2.8 h,1-3 hours.,2-4 hours,2-3 hours.,2-6 hours,2-4 hours,NA,NA,NA,NA,NA,NA,NA,NA,2-4 hours.,2 hours,1-2 hours,1-2 hours,2-2.5 hours,NA,1-2 hours,2 to 4 hours,2 hours,NA,3-4 hours,NA,NA,1-2 hours,NA,2-3 hours,1 to 2 hours,1 to 3 hours,1 to 2 hours,1 to 3 hours,2 to 4 hours,30 minutes to 2 hours,1 to 2 hours,2 to 2.5 hours,2 to 3 hours,1 to 2 hours,30 minutes to 2 hours,1 to 4 hours,1 to 2 hours,1 to 4 hours,30 minutes to 2 hours,NA,NA,1-2 hrs,1-2hrs,1-3 hrs,3-5 Hours,not significant,4-6hrs,1-2 hrs,time to peak concentration,not specified,NA,NA,NA,NA,2 hours (oral administration),0.5-4 hours,0.5-1.5 hours,4 hours,3-4 hours,1-2 hours after infusion,2-3 hours after oral administration,1-2 hours,T-max,30 min -2 hrs,1 to 4 hrs,1 to 2 hrs,NA,1 to 2 hrs,2 to 4 hrs,90 min to 6hrs,NA,NA,NA,1 to 2 hrs,1 to 3 hrs,NA,1 to 6 hrs,1 to 2 hrs,T-max,2HR,3-5HR,NA,1-2hr,3 to 4 hr,NA,2hr,NA,not specified,not applicable for formulation,NA,NA,reached shortly end of infusion,1 to 2 %,1-3 hours,2.0 hours,4 hours,1.5 hour,1.50 hour,2-2.5 hours,2-3 hours,2 hrs,0.5-15 min,2hrs,4-9.6hrs,1.8 hrs,4.0-1.9 hrs,37.5 min,30-120 min,1.5-3 hours,1-2 hours after orally administration,1-2 hours after orally administrtion,1-3 hours post dose,2 to 2.5 hours,3 hours,0.9 hours,4.2~5.19,11.6+_3.0 ng/ml,2 to 4 hours after orally,1 to 2 hours after orally administration,3 to 4 hours,2 to 4 hours after orally administration,1.25 to 2.25 hours,1.5 to 2.5 hours,NA,6 hours,1.5 to 4 hours,3 hours,2-4 hours,1 to 2 hours,2.5 to 3.5 hours.,3 to 5 hours., 0.5 to 4 hours,0.5 hours,10 to 20 min,30 min, 30min,30 minutes,1 hour,NA,T-max,2-4 hours after oral administration.,within a few hours after oral administration.,within 1-3 hours after oral administration.,"30 minutes to 3 hours, depending on the formulation.",within 2 hours after oral administration.,within 45 minutes to 2 hours after oral administration.,within a few hours after oral administration.,around 5-7 hours after oral administration.,within a few hours after oral administration.,within 1-2 hours after oral administration.,NA,NA,within 1-2 hours after oral administration.,within a few hours after oral administration.,within a few hours after oral administration.,NA,NA,NA,NA,NA,2 hr after administration,48 h ,1 to 2 hours,1 to 2 hours,12 hours,3-5 hrs,4 hours,NA,NA,2 hours,2 hours,5.0 ± 2.0 ng/m,8 hours,NA,4 hours,NA,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,T-max,2.1–2.8 h,1-3 hours.,2-4 hours,2-3 hours.,2-6 hours,2-4 hours,NA,NA,NA,NA,NA,NA,NA,NA,2-4 hours.,T-max,2 hours,1-2 hours,1-2 hours,2-2.5 hours,NA,1-2 hours,2 to 4 hours,2 hours,NA,3-4 hours,NA,NA,1-2 hours,NA,2-3 hours,T-max,1 to 2 hours,1 to 3 hours,1 to 2 hours,1 to 3 hours,2 to 4 hours,30 minutes to 2 hours,1 to 2 hours,2 to 2.5 hours,2 to 3 hours,1 to 2 hours,30 minutes to 2 hours,1 to 4 hours,1 to 2 hours,1 to 4 hours,30 minutes to 2 hours,T-max,NA,NA,1-2 hrs,1-2hrs,1-3 hrs,3-5 Hours,not significant,4-6hrs,1-2 hrs,time to peak concentration,not specified,NA,NA,NA,NA,2 hours (oral administration),0.5-4 hours,0.5-1.5 hours,4 hours,3-4 hours,1-2 hours after infusion,2-3 hours after oral administration,1-2 hours,T-max,30 min -2 hrs,1 to 4 hrs,1 to 2 hrs,NA,1 to 2 hrs,2 to 4 hrs,90 min to 6hrs,NA,NA,NA,1 to 2 hrs,1 to 3 hrs,NA,1 to 6 hrs,1 to 2 hrs,2HR,3-5HR,NA,1-2hr,3 to 4 hr,NA,2hr,NA,not specified,not applicable for formulation,NA,NA,reached shortly end of infusion,1 to 2 %,1-2 hrs,1-2 hrs,1-5 hrs,2-4 hrs,NA,NA,1-3 hrs,NA,2-4 hrs,NA,3-4 hrs,1-4 hrs,1-2 hrs,4-6 hrs,1-4 hrs,NA,4-6 hrs,1-4 hrs,5-8 hrs,1.6-4.5 hrs,3-5 hrs,0.5-1 hrs,3-6 hrs,6-8 hrs,1.5-6 hrs,1-3 hrs,1-2 hrs,2 hrs,1-2 hrs,2-3 hrs,1-3 hrs,0.5 to 2 hours,6 hours,1 hour,0.5 to 2 hours (IV),Achieved rapidly after IV administration.,NA,0.5 to 1 hour,NA,4hours,NA,NA,"0.51 hours, with a range from 0.25 to 0.52 hours.",NA,8.0 (7.9 to 21),NA,The elimination half-life in patients with rheumatoid arthritis is approximately 12 hours.,~3 hours,half-life of upadacitinib ranged from 8 to 14 hours,The half life of low dose methotrexate is 3 to 10 hours in adults and the half life for high dose methotrexate is 8 to 15 hours. ,Active metabolite has a long t½ of 2- 3 weeks,The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.,The half life of azathioprine is approximately 5 hours.,"The half-life of cyclosporine is biphasic, variable on different conditions but it is seen in general to last 19 hrs.",~ 40-60 days,Approximately 40-50 days,Approximately 70 hours,~2-4 hours,~4-6 hours,Approximately 2 weeks,Approximately 11-13 days,NA,12 hours after dosing,Ranging from 2 to 4 hrs,ranging for 3 hours,2-3 hours (range 1-48hr) for all dosing regimens and doses,14.30%,NA,1.6 hours,2 hours,range 1-24 hours,2 hours,NA,2 hours,NA,NA,NA, tmax was also delayed in young volunteers: 45 +/- 18 vs 23 +/- 6 min,Tmax 1.31±0.33h,"T max (h), 0.97 ± 0.31","T max (h), 0.97 ± 0.31",Tmax ranged from 0.55 hour to 0.98 hour,"23, 49 and 115 ?g/mL",1.02 (±0.06),Tmax of2.5 h, 102 mg/L,102mg/ml,90mg/ml,100mg/ml,Tmax was attained in 1-1.6 h,Tmax 39.2°C),7.2 min,5-10 min,1-2 h,1-2 hrs,30 min - 2 hrs,2 hrs,1-2 hrs,2-4 hrs,1-2 hrs,2-4 hrs,6-12 hrs,30 min -2 hrs,1-3 hrs,2-5 hrs,2 hrs,Urine,Glomerular filtration and tubular filtration,Urine,Minor role,Kidney,Kidney,Urine 87%,70-90% tjrough urine,Kidney,Kidney,Kidney,Kidney,Kidney (glomeruli),Kidney,Kidney,About 77% of the dose is excreted in the urine.,About 80% of the dose is excreted in the urine.,About 65-70% of the dose is excreted in the urine.,About 90% of the dose is excreted in the urine.,About 80-85% of the dose is excreted in the urine.,About 51% of the dose is excreted in the urine.,Majority of the dose is excreted in the urine.,Majority of the dose is excreted in the urine.,Majority of the dose is excreted in the urine.,Majority of the dose is excreted in the urine,Majority of the dose is excreted in the urine.,Majority of the dose is excreted in the urine,Majority of the dose is excreted in the urine.,Major route of elimination,Major route of elimination.,2 to 4 hours,30-40 min,3-4 hours,1.5 & 1.0 hours,1.1±0.4 hours, 1.1±0.4 hours,4 hours,3 hours,0.58 - 4 hours,2 hours,0.75 hour,1 & 2 hours,2.5 hours,2 hours,0.75 & 0.50 hours,1-4 hours,2-4 hours,1-4 hours,Varies,1 to 2 hours after oral administration,1-4 hours,1-4 hours,1-4 hours,2-6 hours,2-4 hours,1-2 hours,1-4 hours,2-3 hours,2-6 hours,1-2 hours,1-4 hours,2-4 hours,1-4 hours,Varies,1 to 2 hours after oral administration,1-4 hours,1-4 hours,1-4 hours,2-6 hours,2-4 hours,1-2 hours,1-4 hours,2-3 hours,2-6 hours,1-2 hours
Renal excretion,30-40%,Yes,Yes,Yes,Main route,Main route,Yes,Yes,Yes,Yes,~1-2 hours,Yes,Yes,Yes,~80%,~50%,Approximately 87%,Yes,Approximately 80%,Approximately 97%,Approximately 70%,90%,~90% of the dose,Approximately 77% of the dose,74% (as metabolites),Minor (less than 6%),Approximately 67%,Approximately 80% excreted unchanged in urine,~ 60-70%,Brand name,Halcion,Restoril,Mogadon,Valium,Ativan,Seconal,sonata,Sinequan,Rivotril,Butisol,Dalmane,Oleptro,Serax,Rozerem,Belsomra,Major,Significant,Significant,minimal,Minor,Minimal,Minimal,Minor,Minor,Minimal,Minimal,Renal excretion:,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,NA,NA,Minimal,Yes,Yes,Minimal,Minimal,less than 1%,90%,75-85%,NA,95%,58%,87%,urine 15-30 %,approx 90%,less than 1%,less than 2%,approx 40%,90%,NA,Renal excretion:,"Mainly metabolized in the liver, with minimal excretion of unchanged drug in the urine.","Primarily metabolized in the liver, with minimal excretion of unchanged drug in the urine","Metabolized extensively in the liver, with less than 5% excreted unchanged in the urine.","Metabolized mainly in the liver, with less than 1% excreted unchanged in the urine.","Metabolized extensively in the liver, with less than 10% excreted unchanged in the urine.","Mainly metabolized in the liver, with less than 2% excreted unchanged in the urine.","Metabolized extensively in the liver, with about 30% excreted unchanged in the urine.","Metabolized primarily in the liver, with about 15-20% excreted unchanged in the urine.","Metabolized extensively in the liver, with about 60-70% excreted unchanged in the urine.","Metabolized mainly in the liver, with less than 5% excreted unchanged in the urine.","Metabolized in the liver, with most excreted as metabolites in the urine.",NA,NA,Feces-75%,Feces- 97.8%,Feces- 62%,Feces- 65%,Feces- 92.3%,Feces: Insignificant,Feces- up to 16%,Biliary excretion in feces,Feces: 71%,­,­,Biliary excretion,Feces- 68%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Azathioprine is primarily metabolized in the liver, and its metabolites are eliminated via the urine. However, the renal excretion of unchanged azathioprine is relatively low",renal excretion os minor pathway for the elimination of the drug only small percentage in urine,"primarily metabolized in liver, and its metabolites are excreted mainly through urine",Methotrexate is primarily eliminated by renal excretion.The kidneys play a significant role in clearing Methotrexate from the body.,"In children, the fraction of hydroxyurea excreted unchanged into the urine comprised about 50%.",approx 6 - 9% excrete unchnge in urine,"A small percentage is excreted in the urine, primarily as metabolites.",Betamethasone and its metabolites are primarily eliminated through the kidneys,"A small percentage is excreted in the urine, primarily as metabolites","Tazarotene and its metabolites are eliminated, at least in part, through renal excretion.",Pimecrolimus and its metabolites are eliminated through the kidneys,proteolytic degradation,excreated in bile as metabolited,NA,yes,yes,yes,<5%,70%,70%,11%,70%,10-15%,30-40%,70%,50%,NA,NA,less than 1%,less than 1%,less than 1%,less than 1%,"30%-80% of ciculating insulin
is removed by the kidney.",less than 2%,NA,NA,Minimal,40%,30-40%,Less,minimal excretion,NA,39%,NA,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,", approximately 70% to 85% of the dose is excreted in the urine within 24 hours",Cimetidine is eliminated primarily by the kidneys through renal excretion.,"Famotidine is primarily eliminated from the body through renal excretion, with a significant portion of the dose excreted unchanged in the urine.",Cimetidine is eliminated primarily by the kidneys through renal excretion.,: Bepridil is eliminated from the body primarily through renal excretion,Cisapride is eliminated from the body primarily through renal excretion,approximately 80% of the administered dose excreted unchanged in the urine.,Eliminated from body through renal excretion,Pimozide is primarily eliminated from the body via hepatic metabolism and subsequent renal excretion.,Piperaquine is primarily eliminated from the body via hepatic metabolism and subsequent renal excretion.,"Sparfloxacin is primarily eliminated from the body via renal excretion, both as unchanged drug and metabolites.",Terfenadine and its metabolites are primarily eliminated from the body via renal excretion.,Ziprasidone and its metabolites are primarily eliminated from the body via renal excretion.,Mesoridazine and its metabolites are primarily eliminated from the body via renal excretion.,Nizatidine and its metabolites are primarily eliminated from the body via renal excretion.,"Amikacin is eliminated by the kidneys. In adults with normal renal function, 94-98% of a single IM or IV dose of amikacin is excreted unchanged by glomerular filtration in the kidney within 24 hours.","Plazomicin predominantly undergoes renal excretion, where 56% of the total administered drug was recovered in the urine within 4 hours",Urinary excretion is a minor elimination route: about 6% and an oral dose and 12% of an intravenous dose are recovered unchanged in urine.,"Amoxicillin is predominantly excreted through the kidneys via renal excretion. The unchanged drug is eliminated in the urine, making renal function an important consideration in dosing adjustments for individuals with impaired kidney function","Cephalosporins are primarily eliminated through renal excretion. After being metabolized in the liver to various extents, they are excreted through the kidneys, either in their original form or as active metabolites.",Temocillin is primarily eliminated from the body through renal excretion.,"Ampicillin is primarily eliminated from the body through renal excretion. After absorption, ampicillin is excreted in the urine, largely unchanged. The kidneys play a significant role in clearing the drug from the body.","Sulfadiazine is predominantly eliminated through renal (kidney) excretion. After absorption in the gastrointestinal tract, sulfadiazine undergoes metabolism in the liver, forming metabolites that are then excreted via the kidneys into the urine. Monitoring renal function is important during sulfadiazine therapy to prevent potential adverse effects, and dosage adjustments may be necessary.","Eravacycline, a tetracycline antibiotic, undergoes both hepatic and renal excretion. While hepatic excretion plays a prominent role, a portion of the drug is eliminated through the kidneys.","Penicillin is primarily excreted through the kidneys via renal excretion. After being metabolized to some extent, penicillin and its metabolites are filtered by the glomerulus and subsequently eliminated in the urine.",Meropenem is predominantly eliminated through renal excretion. Approximately 70-80% of the administered dose is excreted unchanged in the urine.,"Cephalexin is primarily eliminated from the body through renal excretion. After absorption, the drug is excreted unchanged in the urine by the kidneys.","Renal excretion is a crucial route for eliminating ciprofloxacin from the body, making proper kidney function important for its clearance.","Ceftolozane/tazobactam is primarily eliminated from the body through renal excretion. The kidneys play a crucial role in clearing the drug from the bloodstream, with a significant portion of the administered dose excreted unchanged in the urine.","Clarithromycin absorption can be enhanced by taking it with food, particularly a high-fat meal. This is because clarithromycin is a macrolide antibiotic, and its absorption is improved in the presence of dietary fat.",60-70%,10-20%,90%,80-100%,Not significant,<1%,86%,90%,2-5%,40%,NA,18%,18%,less than 1 %,less than 1%,10-25% unchanged,"Yes, as metabolites",Yes,Approximately 94%,Approximately 66-68%,70-80%,49% (as unchanged drug),4% as unchanged drug,Approximately 90%,~95%,~70%,Yes,~94%,25-30% unchanged,90%,20-40 % of given dose excrated unchange in urine,10-25% unchanged,90%,90%,~94%,Yes,~70%,~95%,60-70 %,Yes,Approximately 94%,"Yes, as metabolites",Approximately 66-68%,yes it metaboolize,Approximately 90%,10-20% unchanged,10-20%,~40%,~6%,~1%,<1% unchanged,50-70% of the dose,70% (as metabolites),25% (urine),~45% unchanged in urine,50%,~ 3% unchanged,50-60%,26% unchanged,~50%,kidney,kidney,renally excreted,liver,"excreted in the urine, with approximately 70-80%",30-50% of the dose excreted unchanged in the urine,Primarily renal excretion.,renal excretion about 70-80%,70-80%,60-70%,95%,excreted unchanged in the urine.,excreted through the biliary route into the feces,"excreted unchanged in the urine, with approximately 80% of an administered dose eliminated via renal excretion.",30-40% excreted unchanged in the urine.,low,minimal,Yes,minor,minor,mionor,minor,64%,77%,62%,13%,not applicable,19%,19%,20%,large portion of the administered dose being eliminated unchanged in the urine,excreted in urine,70-80% of the administered dose excreted unchanged or as metabolites in the urine,excreted by the kidneys into the urine,kidney,10% to 30% is eliminated by the kidneys.,mean elimination half-life of 28.2 min and mean total clearance of 639.4 ml/min,"43%, 50%, and 47%","impair water excretion as manifested by weight gain, hyponatremia, and inappropriately concentrated urine.",between 29% and 89% of a single 600 mg dose is excreted in the urine within 24 hours,excreted by the kidneys into the urine,approximately 20% to 60% of the radioactivity appears in the urine after 24 hours. ,Some 25–75% is excreted by the urinary tract,The major route of excretion for fludarabine and its metabolites is through the kidneys,kidney,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,yes,yes,Yes,Yes,Yes,Yes,Yes,12%,15 to 30 %,NA,>10%,47%,84%,NA,<20% ,65%,NA,70%,5%, 119.58 h and 65.77 L/h,83--92% of the dosage are eliminated via urine. ,"Due to the higher probability of elderly patients having reduced renal function, caution should be exercised when choosing the appropriate dosage.","propranolol is metabolized by hepatic enzymes and excreted through the renal system, prescribers should proceed with caution when prescribing it to a patient with known hepatic or renal impairments.",approximately 29–63% in urine and 18– 38% in faeces. ,The presence of hepatic or renal impairment did affect the apparent clearance of gepirone,About 90% of administered lorazepam is excreted in the urine largely as the glucuronide and urinary excretion is virtually complete in 4 days., usually transient and may be avoided if a diuretic is used concomitantly., excreted primarily in the urine.,NA,Approximately 20–40% of a given dose of Phenobarbital is excreted unchanged in the urine, excretion is via the urine., pentobarbital elimination is normal in renal failure., 0.3% of an administered dose being excreted unchanged in the urine., 64% of a 30-mg oral solution dose of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites over a 10-day post-dosing period.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Urine,Urine,Urine,Urine,Liver,Liver,Urine,Liver,feces,Liver,Liver,Liver,Urine,Kidney,Liver,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Primarily excreted unchanged in urine,Renal and fecal excretion,Renal excretion (approximately 70%),Primarily hepatic and fecal excretion,Primarily hepatic and fecal excretion,Renal excretion (primarily as GS-441524),Primarily renal excretion,Renal and hepatic,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,monor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Renal excretion:,Urine,Urine,Urine,Urine,Liver,Liver,Urine,Liver,feces,Liver,Liver,Liver,Urine,Kidney,Liver,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Excretion,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Primarily excreted unchanged in urine,Renal and fecal excretion,Renal excretion (approximately 70%),Primarily hepatic and fecal excretion,Primarily hepatic and fecal excretion,Renal excretion (primarily as GS-441524),Primarily renal excretion,Renal and hepatic,Elimination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Baricitinib is metabolized by CYP3A4. Approx. 6% of the orally given dose were seen as metabolites in urine and feces,Metabolized in the liver by CYP3A4 and CYP2C19. Metabolites produced are inactive.,Upadacitinib predominantly undergoes CYP3A4-mediated metabolism,Methotrexate is metabolized by folylpolyglutamate synthase to methotrexate polyglutamate in the liver as well as in tissues,Leflunomide is rapidly converted in the body to an active metabolite which inhibits dihydro-orotate dehydrogenase and pyrimidine synthesis,"In the intestine, sulfasalazine is metabolized by intestinal bacteria to sulfapyridine and 5-aminosalicylic acid.",Azathioprine is converted to 6-mercaptopurine nonenzymatically,"Cyclosporine is metabolized in the intestine and the liver by CYP450 enzymes, predominantly CYP3A4 with contributions from CYP3A5","Hepatic, via CYP2C8, CYP3A4","Metabolized by hepatic enzymes, primarily CYP2C8 and CYP3A4",it is assumed to be metabolized via proteinases similarly to endogenous proteins,Prednisolone can be reversibly metabolized to prednisone and further metabolized to its metabolites,"As a protein-based therapy, anakinra is expected to be metabolized by proteases throughout the body.", Adalimumab is a biological product with no influence by liver enzymes on its metabolic pathway,"Tocilizumab, like other monoclonal antibodies, is expected to be metabolized to smaller proteins and amino acids by proteolytic enzymes.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Minimal,Not,Minor role,Liver,Liver,Not,4%,Minimal,Minimal- liver,Minimal,Minimal,Liver,Liver,Liver,Minimal,About 18% of the dose is excreted in the feces.,About 20% of the dose is excreted in the feces.,25-30% of the dose is excreted in the feces,About 10% of the dose is excreted in the feces.,About 15-20% of the dose is excreted in the feces.,About 47% of the dose is excreted in the feces.,A small fraction is excreted in the feces.,A small fraction is excreted in the feces.,A small fraction is excreted in the feces.,A small fraction is excreted in the feces.,A small fraction is excreted in the feces.,A small fraction is excreted in the feces.,small fraction is excreted in the feces.,Minor route of elimination.,Minor route of elimination.,"It is excreted unchanged in the urine with
excretion of a single dose completed within 24 hours. Unabsorbed drug is excreted in the feces","Renal excretion is the only documented 
route of elimination of peramivir and its metabolites","oseltamivir is more than 90 % eliminated
through conversion to oseltamivir carboxylate and subsequent elimination entirely through renal excretion"," Abacavir is excreted in the urine 
as the parent compound (1%) and as metabolites (81%) with 16% eliminated in the feces.","Acyclovir is eliminated primarily
by glomerular filtration with a small addition from tubular secretion","The prodrug valacyclovir is fecally 
excreted, whereas the active drug, acyclovir, is eliminated by the kidneys via tubular secretion and glomerular filtration","Baloxavir is primarily eliminated 
by biliary excretion","cidofovir diphosphate, an active metabolite,
is eliminated more slowly with first and second phase intracellular half-lives of 24 and 65 hours, respectively",Adefovir is eliminated by renal excretion," The major route of TMR 
elimination was through biotransformation","Tenofovir is eliminated by renal 
elimination, including tubular secretion","Amprenavir elimination is hepatic 
etabolism by cytochrome P450 (CYP) 3A4",It is primarily eliminated through feces,"Boceprevir is mainly eliminated in the
feces (79%) with a small amount eliminated in the urine (9%)","Combivir is primarily eliminated
by hepatic metabolism",Renal and hepatic excretion,Primarily renal excretion (70-90%),"Renal (30-50% unchanged), fecal",Primarily renal excretion of glucuronide metabolites,Renal excretion (66-68% unchanged); hepatic excretion also occurs,"Renal excretion (70-80%), some through feces",Primarily renal excretion,Renal and hepatic,Renal and hepatic excretion,"Renal excretion (95%), unchanged drug",Renal and fecal,Renal excretion (70-80% unchanged),Renal excretion (94% as unchanged drug),Renal and hepatic,Renal excretion (90% as unchanged drug),Renal and hepatic excretion,Primarily renal excretion (70-90%),"Renal (30-50% unchanged), fecal",Primarily renal excretion of glucuronide metabolites,Renal excretion (66-68% unchanged); hepatic excretion also occurs,"Renal excretion (70-80%), some through feces",Primarily renal excretion,Renal and hepatic,Renal and hepatic excretion,"Renal excretion (95%), unchanged drug",Renal and fecal,Renal excretion (70-80% unchanged),Renal excretion (94% as unchanged drug),Renal and hepatic,Renal excretion (90% as unchanged drug)
Hepatic excretion,30-40%,Yes,Yes,Yes,Minor,Minor,Minor,Minor,Minor,Minor,Minor,Minor,Minor,Minor,~10%,~15%,Approximately 7%,Yes,Approximately 10%,Negligible,Approximately 30%,2%,~2% of the dose,Approximately 21% of the dose,21% (as unchanged drug),Yes,Approximately 30%,Metabolites excreted in bile,~ 23-24%,Toxic effect,"drowsiness, slurred speech, motor inco-ordination, respiratory depression","somnolence, confusion, and coma, with reduced or absent reflexes","sedation,respiratory depression,coma","respiratorty depression ,CNS depression","respiratorty depression ,CNS depression","respiratorty depression ,CNS depression","drowsiness, slurred speech, motor inco-ordination, respiratory depression","symptoms of convulsions, dysrhythmias, coma, severe hypotension, central nervous system depression","drowsiness, slurred speech, motor inco-ordination, respiratory depression","sedation,respiratory depression,coma","angioedema,angioedema 
anaphylactoid reactions,
neonatal abstinence syndrome,
neonatal respiratory depression","Serotonin syndrome, cardiac arrhythmias, priapism","sedation,respiratory depression,coma,overdose","Drowsiness,Fatigue , Headache","Drowsiness,Fatigue , Headache",Minor,Minor,Minor,20%,Major,Major,Major,Major,Major,Minimal,Minimal,Hepatic excretion:,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,NA,NA,NA,NA,NA,Yes,Yes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Hepatic excretion:,Metabolized in the liver primarily by the CYP2C19 and CYP3A4 enzymes.,Metabolized in the liver primarily by the CYP2C19 and CYP3A4 enzymes.,Metabolized extensively in the liver primarily by the CYP2D6 and CYP3A4 enzymes.,Metabolized in the liver primarily by the CYP1A2 and CYP2D6 enzymes.,Metabolized extensively in the liver primarily by the CYP2B6 enzyme.,Metabolized in the liver primarily by the CYP2D6 and CYP3A4 enzymes.,Metabolized extensively in the liver primarily by the CYP2C19 and CYP2D6 enzymes.,Metabolized in the liver primarily by the CYP3A4 enzyme.,"Metabolized in the liver primarily by the CYP1A2, CYP2D6, and CYP3A4 enzymes.",Metabolized in the liver primarily by the CYP2D6 and CYP2C19 enzymes.,Metabolized in the liver primarily by the CYP1A2 and CYP2C19 enzymes.,NA,NA,krazati,"Alecensa, Alecensaro",Mektovi,Alunbrig,Zykadia,Platinol,"Vepesid, Etopophos, Toposar",Taxotere,"Taxol, Abraxane",Gemzar,"Alimta, Pemfexy, Ciambra",Navelbine,Tagrisso,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The major route of elimination for azathioprine is through hepatic metabolism. The drug undergoes extensive metabolism in the liver, leading to the formation of active and inactive metabolites. These metabolites are subsequently excreted, with a portion eliminated through bile.",primiraly eliminate though the body from hepatic metabolism and subsequently bilary excretion,mainly through the liver enzyme cyt p450 2D6,"While Methotrexate undergoes hepatic metabolism, the major route of elimination is renal excretion. A small fraction of the drug may be eliminated through the biliary route.", probably hepatic metabolism; the other is first-order renal excretion.,the majority of drug is metabolized n liver,NA,Metabolism in the liver contributes to the elimination process,NA,Metabolism in the liver contributes to elimination.,"Metabolism occurs in the skin, and hepatic excretion is not a major route",not primarily eliminated via hepatic excreation,primarily excreate through hepatic metabolism and biiary excreation,NA,yes,yes,yes,yes,16%,10%,40%,30%,35%,60-70%,56%,45%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Renal excretion:,10-20% unchanged,35%,10-20% unchanged,~20%,~20%,40-50%,moderte,70-90%,moderate,80-90%,high,NA,10%,Minimal (primarily as metabolites),NA,"The liver metabolizes ranitidine through various pathways, including oxidation, N-glucuronidation, and S-oxidation","The liver metabolizes cimetidine through oxidation, hydroxylation, and N-demethylation, with the formation of several metabolites, including hydroxycimetidine and guanylurea.",Famotidine undergoes hepatic metabolism to inactive metabolites before being eliminated from the body.,"The liver metabolizes cimetidine through oxidation, hydroxylation, and N-demethylation, with the formation of several metabolites, including hydroxycimetidine and guanylurea.",Major metabolite form is N-desalkylbepridil,significant portion of the dose excreted unchanged in the urine.,: Dofetilide undergoes minimal hepatic metabolism before being eliminated from the body primarily via renal excretion.,Levoketoconazole is primarily eliminated from the body via hepatic metabolism followed by renal excretion,: Pimozide is primarily eliminated from the body via hepatic metabolism followed by renal excretion.,Piperaquine is primarily eliminated from the body via hepatic metabolism followed by renal excretion.,"Sparfloxacin is primarily eliminated from the body via renal excretion, both as unchanged drug and metabolites.",Terfenadine and its metabolites are primarily eliminated from the body via hepatic metabolism followed by renal excretion.,Ziprasidone and its metabolites are primarily eliminated from the body via hepatic metabolism followed by renal excretion.,Mesoridazine and its metabolites are primarily eliminated from the body via hepatic metabolism followed by renal excretion.,"Nizatidine is primarily eliminated unchanged in the urine via renal excretion, with minimal hepatic metabolism.","Amikacin is primarily excreted unchanged by the kidneys, not the liver. Hepatic excretion of amikacin is minimal","Hepatic excretion plays a minor role in its elimination, with the majority being cleared through the kidneys.","Metabolism is predominantly hepatic (to inactive metabolites), with biliary excretion a major pathway of elimination.","While amoxicillin undergoes minimal hepatic metabolism, it is primarily eliminated through renal excretion.","Cephalosporins are primarily eliminated through renal excretion, not hepatic excretion. The liver does play a role in the initial metabolism of some cephalosporins, but the majority of the drug is excreted unchanged or as active metabolites through the kidneys.","the body through renal excretion. It is excreted largely unchanged in the urine. Renal excretion is a significant route for the removal of drugs from the body, and in the case of temocillin, this process plays a major role in its elimination.","Ampicillin is primarily excreted through the kidneys, with minimal hepatic excretion. The liver plays a minor role in eliminating ampicillin from the body compared to the kidneys.","Sulfadiazine is primarily eliminated through renal excretion, meaning it is excreted by the kidneys. Hepatic (liver) excretion plays a minimal role in the elimination of sulfadiazine.","Eravacycline, a tetracycline antibiotic, undergoes hepatic excretion primarily through the bile.","Penicillin is primarily eliminated from the body through renal excretion, meaning it is excreted through the kidneys in the urine.","Meropenem is primarily eliminated through renal excretion, and it is not extensively metabolized in the liver. Hepatic excretion does not play a significant role in the elimination of meropenem.","Hepatic excretion of cephalexin is minimal. Cephalexin is primarily eliminated through renal excretion, where it is excreted unchanged in the urine. The liver plays a minor role in the elimination process, and the drug is not extensively metabolized in the liver.
Message ChatGPT…","Ciprofloxacin is primarily eliminated through renal excretion, with minimal hepatic excretion. The liver plays a limited role in the elimination of ciprofloxacin, as the drug is not extensively metabolized in the liver. The majority of ciprofloxacin is excreted unchanged in the urine, making renal function a key factor in its elimination from the body.","Ceftolozane/tazobactam is primarily eliminated by the kidneys through renal excretion. There is limited information regarding hepatic excretion of ceftolozane/tazobactam. The liver may play a role in the metabolism of ceftolozane, but the primary route of elimination is renal, where the drug is excreted in the urine.","Clarithromycin absorption can be affected by substances that alter gastric acidity. Therefore, it's advisable to avoid taking clarithromycin with acid-reducing agents like proton pump inhibitors (PPIs) or H2 blockers, as they can decrease the absorption of clarithromycin.",20-30%,11.60%,60%,80%,Not significant,NA,83%,NA,Biliary excretion,Small portion remains unchanged in Bile.,NA,less than 5 %,less than 5 %,NA,NA,Metabolites,"Yes, as metabolites",Yes,"Minor, through glucuronidation",Approximately 24%,Minor,39% (as metabolites),Mainly as metabolites,Approximately 10%,~5%,~25%,Yes,Minor,Major metabolites excreted in bile,Negligible,20-40 % of given dose excrated unchange in urine rest metabollize in liver slowly,Metabolites,negligible,Negligible,Minor,Yes,~25%,~5%,less than 10 %,Yes,"Minor, through glucuronidation","Yes, as metabolites",Approximately 24%,yes it metaboolize,Approximately 10%,Major route,60-70%,~60%,Major part,~20%,NA,Metabolites,14% (as unchanged drug),55% (feces),~47% in feces,20%,~ 77% unchanged,30-40%,52% unchanged,~32%,NA,30-40%,50-70%,"Yes, metabolized in the liver.",liver,NA,Minimal hepatic excretion.,Hepatic metabolism plays a minor role in the elimination of digoxin.,Verapamil undergoes extensive hepatic metabolism.,"Diltiazem is also excreted in the bile, primarily as metabolites","hepatic metabolism via the cytochrome P450 system, mainly through CYP2D6 and CYP1A2 enzymes",primarily metabolized in the liver,liver is the primary route of excretion for amiodarone,"minimally metabolized in the liver, with less than 10% of the drug undergoing hepatic metabolism.",A portion undergoes hepatic metabolism before excretion.,no,Not specified,Not specified,major,major,major,minor,27%,19%,32%,Predominant,not applicable,Predominant,Predominant,Predominantly via feces,"eliminated from the body through renal excretion, with the kidneys being the main route of elimination.",biliary excretion into the gastrointestinal tract and subsequent elimination via feces.,small portion undergoing hepatic metabolism, less than 1% of the drug is retrieved in the urine 24 hours after administration,liver,About 5.8% to 21.3% is excreted in urine,"Bendamustine is extensively metabolized, with subsequent excretion in both urine and feces",about half of the radioactivity given was excreted in the urine in the form of degradation products within 24 hours.,"in the liver,",with minimal hepatic metabolism in liver,"undergoes hepatic metabolism, primarily through glucuronidation and oxidation reactions","undergoes hepatic metabolism, primarily through oxidation and hydrolysis reactions, forming active metabolites","undergoes hepatic metabolism, primarily through oxidation and demethylation reactions, forming active metabolites","Fludarabine is primarily eliminated from the body through renal excretion, not hepatic excretion.",renal excretion,No,No,No,No,No,No,No,No,Yes,No,No,No,No,Yes,No,NA,NA,NA,49%,83%,NA,NA,10%,25%,NA,34%,85%,low hepatic extraction ratio (<0.3),excreted in the urine. ,"Within the field of dentistry, the utilization of hydroxyzine as a standalone medication is restricted to addressing mild to moderate anxiety in children.","The clearance of propranolol in infants below 90 days is approximately 2.7±0.03L/h/kg, while in infants above 90 days it is around 3.3±0.35L/h/kg.", Buspirone is excreted in the urine as metabolites(29% to 63%); fecal excretion accounts for 18% to 38% of the dose.,The presence of hepatic or renal impairment did affect the apparent clearance of gepirone,eliminated mainly by the kidneys.,Approximately 50% of a clonidine dose is excreted in the urine as the unchanged drug and 20% is eliminated in the feces.,NA,NA,"Approximately 20–40% of a given dose of Phenobarbital is excreted unchanged in the urine, the rest is slowly metabolized in the liver.", metabolized extensively in the liver ," the metabolic products are excreted in the urine, and less commonly, in the feces.",Thiopental is subject to a relatively low hepatic extraction of 0.29.,About 2/3 of a single paroxetine dose is found to be excreted in the urine and the remainder is found to be excreted in feces.,50%,3.9 L/h,220 mL/min,65%,20%,7-14%,40%,90%,10.3-10.6 mol/L,15%,34%,41%,95%,6-7%,0.468 n/mol,5.9ml/min and renal clearance,predominantly eliminated through renal excretion,eliminated through hepatic metabolism,Approximatly 4.32l/h,excreted in urine about 1 % of single dose,mean plasma elimination,excreted both by glomerular filtration and active tubular secretion,compromised renal function,urinary excretionis major route,minimum portion,through urine,primarily eliminated through renal,relatively low through urine,urinary excretion accounts for 66%,urine and 40% in feces,NA,"A minor portion of venetoclax is excreted unchanged in the urine, primarily as inactive metabolites.",16%,"Approximately 68% of the dose is excreted in the urine, primarily as metabolites.",Moderate renal excretion,Approximately 50% of prednisone and its metabolites are excreted renally.,Approximately 25% to 30% of the dose is excreted unchanged in the urine,Approximately 4% to 22% of the dose is excreted unchanged in the urine.,Approximately 20-30% of the dose is excreted unchanged in the urine.,Approximately 85% of the administered dose is excreted unchanged in the urine.,Approximately 80% to 90% of the dose is excreted unchanged in the urine.,pproximately 75% of the dose is excreted unchanged in the urine.,Rituximab is excreted into urine and peritoneal fluid.,: Approximately 10% to 15% of the dose is excreted unchanged in the urine.,Approximately 50% of the dose is excreted unchanged in the urine.,Primarily through glomerular filtration in the kidneys.,"olate is filtered in the glomerulus, and approximately 90% is reabsorbed in the renal tubules. The small amount that remains is excreted in the urine.",The excretion of vitamin B12 is minimal through the kidneys. Most of it is excreted through bile into the feces.,Primarily through urinary excretion in the form of metabolites.,Excreted in the urine after being metabolized.,Thiamine is excreted in the urine.,"Choline is metabolized to various metabolites, including betaine, and excreted in the urine.","Metabolites of vitamin D, including cholecalciferol, are excreted in the bile and eliminated in the feces.",Biotin is excreted in the urine after being metabolized.,Pantothenic acid and its metabolites are excreted in the urine.,"Lutein is metabolized and excreted, with some elimination in the urine.","Astaxanthin is metabolized and excreted, and some is eliminated in the urine.","Resveratrol is metabolized and excreted, with some elimination in the urine.",Vitamin K1 is excreted in the urine.,"Vitamin E is metabolized and excreted, with some elimination in the urine.",Renal excretion:,less than 1%,less than 1%,Approximately 80%,less than 0.03%,95%,5%,1%,1%,Less than 1%,1%,2%,Less than 1%,5%,NA,Less than 1%,Minimum,Liver,Liver,Liver,Liver,Urine and feces,Liver,Liver,Urine,Urine,Bile and feces,Bile,Liver,Liver,Feces,"Primarily excreted in the urine, and its metabolites are also eliminated renally.","Excreted in the urine, with about 50% of the dose being eliminated as unchanged drug.","Excreted in the urine, and the majority of the drug is unchanged.","Excreted primarily in the urine, with both unchanged drug and metabolites being eliminated.","Excreted in the urine, and the majority is as unchanged drug.","Excreted in the urine, primarily as the unchanged drug.","Information on the renal excretion of Glymidine is not widely available, and it may be less commonly used compared to other sulfonylureas.","Excreted in the urine, and the majority is as unchanged drug.","Information on the renal excretion of Glisoxepide is limited, and it may vary.","Excreted in the urine, and the majority is as unchanged drug.","Excreted in the urine, and the majority is as unchanged drug.",Excreted in the urine.,Information on the renal excretion of Glibuzole is not widely available.,Information on the renal excretion of Glibuzole is limited.,"Primarily excreted in the urine, with about 50% as unchanged drug.","Around 80% excreted in
the urine",28-36% of the dose is excreted unchanged in the urine,"Around 80%
excreted in
the urine.","80% excreted
in the urine.","Renal excretion plays a role
in the elimination of rebamipide.",90% of the dose is excreted in the urine,20-25% of the administered dose,65% of the dose is excreted unchanged in the urine,"Excreted mainly in the urine, with about 60-80%",90% of the dose is excreted in the urine as metabolites,"excreted unchanged
in the urine.",Misoprostol and its metabolites are primarily excreted in the urine.,75% of the dose is excreted unchanged in the urine,Primarily excreted unchanged in the urine.,Both renal and hepatic excretion occur.,NA,Urine 48-75%,NA,urine through the kidneys,Urine 70-80%,NA,Urine3-5%,Urine 80%,Urine30-70%,NA,NA,NA,NA,NA,NA,NA,30%,NA,NA,NA,NA,44%,minimal,10-30%,partial,minimal,NA,minimal,NA,NA,~61%,~80%,~70%,Minor,~41%,~74%,~62-66%,75-80% (mainly as penciclovir),renal excretion:,less than 5%,5 % to 10%,5%,no renal excretion,5%,5%,urine,NA,NA,hepatic & non-hepatic,urine,NA,NA,NA,NA,Renal excretion:,80%,77%,20-30%,minor,minor,NA,70%,NA,not specified,minimal,minimal excreations,vaginal yeast infections,minimal excreation,minimal,50%,3.9 L/h,220 mL/min,65%,20%,7-14%,40%,90%,10.3-10.6 mol/L,15%,34%,41%,95%,6-7%,0.468 n/mol,5.9ml/min and renal clearance,predominantly eliminated through renal excretion,eliminated through hepatic metabolism,Approximatly 4.32l/h,excreted in urine about 1 % of single dose,mean plasma elimination,excreted both by glomerular filtration and active tubular secretion,compromised renal function,urinary excretionis major route,minimum portion,through urine,primarily eliminated through renal,relatively low through urine,urinary excretion accounts for 66%,urine and 40% in feces,NA,"A minor portion of venetoclax is excreted unchanged in the urine, primarily as inactive metabolites.",16%,"Approximately 68% of the dose is excreted in the urine, primarily as metabolites.",Moderate renal excretion,Approximately 50% of prednisone and its metabolites are excreted renally.,Approximately 25% to 30% of the dose is excreted unchanged in the urine,Approximately 4% to 22% of the dose is excreted unchanged in the urine.,Approximately 20-30% of the dose is excreted unchanged in the urine.,Approximately 85% of the administered dose is excreted unchanged in the urine.,Approximately 80% to 90% of the dose is excreted unchanged in the urine.,pproximately 75% of the dose is excreted unchanged in the urine.,Rituximab is excreted into urine and peritoneal fluid.,: Approximately 10% to 15% of the dose is excreted unchanged in the urine.,Approximately 50% of the dose is excreted unchanged in the urine.,NA,Renal excretion:,Primarily through glomerular filtration in the kidneys.,"olate is filtered in the glomerulus, and approximately 90% is reabsorbed in the renal tubules. The small amount that remains is excreted in the urine.",The excretion of vitamin B12 is minimal through the kidneys. Most of it is excreted through bile into the feces.,Primarily through urinary excretion in the form of metabolites.,Excreted in the urine after being metabolized.,Thiamine is excreted in the urine.,"Choline is metabolized to various metabolites, including betaine, and excreted in the urine.","Metabolites of vitamin D, including cholecalciferol, are excreted in the bile and eliminated in the feces.",Biotin is excreted in the urine after being metabolized.,Pantothenic acid and its metabolites are excreted in the urine.,"Lutein is metabolized and excreted, with some elimination in the urine.","Astaxanthin is metabolized and excreted, and some is eliminated in the urine.","Resveratrol is metabolized and excreted, with some elimination in the urine.",Vitamin K1 is excreted in the urine.,"Vitamin E is metabolized and excreted, with some elimination in the urine.",NA,NA,NA,NA,NA,less than 1%,less than 1%,Approximately 80%,less than 0.03%,95%,5%,1%,1%,Less than 1%,1%,2%,Less than 1%,5%,NA,Less than 1%,NA,Hepatic excretion:,Minimum,Liver,Liver,Liver,Liver,Urine and feces,Liver,Liver,Urine,Urine,Bile and feces,Bile,Liver,Liver,Feces,Renal excretion:,"Primarily excreted in the urine, and its metabolites are also eliminated renally.","Excreted in the urine, with about 50% of the dose being eliminated as unchanged drug.","Excreted in the urine, and the majority of the drug is unchanged.","Excreted primarily in the urine, with both unchanged drug and metabolites being eliminated.","Excreted in the urine, and the majority is as unchanged drug.","Excreted in the urine, primarily as the unchanged drug.","Information on the renal excretion of Glymidine is not widely available, and it may be less commonly used compared to other sulfonylureas.","Excreted in the urine, and the majority is as unchanged drug.","Information on the renal excretion of Glisoxepide is limited, and it may vary.","Excreted in the urine, and the majority is as unchanged drug.","Excreted in the urine, and the majority is as unchanged drug.",Excreted in the urine.,Information on the renal excretion of Glibuzole is not widely available.,Information on the renal excretion of Glibuzole is limited.,"Primarily excreted in the urine, with about 50% as unchanged drug.",Renal excretion:,"Around 80% excreted in
the urine",28-36% of the dose is excreted unchanged in the urine,"Around 80%
excreted in
the urine.","80% excreted
in the urine.","Renal excretion plays a role
in the elimination of rebamipide.",90% of the dose is excreted in the urine,20-25% of the administered dose,65% of the dose is excreted unchanged in the urine,"Excreted mainly in the urine, with about 60-80%",90% of the dose is excreted in the urine as metabolites,"excreted unchanged
in the urine.",Misoprostol and its metabolites are primarily excreted in the urine.,75% of the dose is excreted unchanged in the urine,Primarily excreted unchanged in the urine.,Both renal and hepatic excretion occur.,Renal excretion:,NA,Urine 48-75%,NA,urine through the kidneys,Urine 70-80%,NA,Urine3-5%,Urine 80%,Urine30-70%,NA,NA,NA,NA,NA,NA,Renal excretion:,NA,30%,NA,NA,NA,NA,44%,minimal,10-30%,partial,minimal,NA,minimal,NA,NA,~61%,~80%,~70%,Minor,~41%,~74%,~62-66%,75-80% (mainly as penciclovir),renal excretion:,less than 5%,5 % to 10%,5%,no renal excretion,5%,5%,urine,NA,NA,hepatic & non-hepatic,urine,NA,NA,NA,NA,80%,77%,20-30%,minor,minor,NA,70%,NA,not specified,minimal,minimal excreations,vaginal yeast infections,minimal excreation,minimal,30-50%,95%,20-30%,25-50%,NA,NA,10-15%,90%,NA,70%,85%,47%,60-70%,2-30%,30-50 %,NA,2-30%,30-50 %,7-10%,57-73%,27%,50%,NA,20-40%,73%,9%,70%,80%,50%,>1%,1-2 %,Negligible,Minimal,Negligible,Negligible,Negligible,Negligible,Yes,Yes,Yes,NA,NA,Main route,Yes,Minimal,NA,Baricitinib is metabolized by CYP3A4,Metabolized by CYP3A4 and CYP2C19,It undergoes CYP3A4-mediated metabolism.,it is not extensively metabolized by the cytochrome P450 (CYP) enzyme system.,Leflunomide is primarily metabolized in the liver through non-CYP450 pathways.,Sulfasalazine is not significantly metabolized by cytochrome P450 (CYP450) enzymes.,Azathioprine is not primarily metabolized by the cytochrome P450 (CYP450) enzyme system.,"it is metabolized in the liver by CYP450 enzymes, predominantly CYP3A4 with contributions from CYP3A5","CYP2C8, CYP3A4",CYP2C8 and CYP3A4,No,"Predominantly metabolized by CYP3A4, CYP2C9",Not metabolized by CYP enzymes,Not metabolized by CYP enzymes,Not metabolized by CYP450 enzymes,NA,less than 0.9% as unchanged drug and metabolites,7% to 20% of parent drug is excreted unchanged in the urine in 6 hrs.,"Fecal (82%), Urinary (4.4%)",30% is eleminated through urine,Approximately 25-30% of pembrolizumab is excreted unchanged in urine,5-10%,32% unchanged,47% unchanged,1.6% of unchanged drug,23%,40%,64%,1% excreted through urine,NA,NA,"most are eliminated, almost completely unchanged, in the urine","Most renal excretion occurs in the first 6 h and is unaffected by probenecid, although probenecid prolongs the renal excretion of amoxicillin.",Excretion: Approximately 90% of the unchanged drug is excreted in the urine.,Ceftriaxone is primarily eliminated in the urine (33-67%).,"When imipenem is administered alone by the intravenous route, the levels excreted in the urine are low and variable (6%-38% of the dose)","Approximately 70% of meropenem is excreted via the kidneys,",About 80%–90% of a vancomycin dose is excreted in urine as the unchanged drug,The cumulative amount of omadacycline excreted in the urine ,NA,NA,Only 20% of the drug is excreted unchanged by the kidney,Renal clearance of both drugs occurs by glomerular filtration and tubular secretion. Urinary excretion of piperacillin is 68%,Renal clear- ance ... Renal excretion of intact cefepime accounted for. 82.9% and 80.2%," largely excreted renally as conjugates. The elimination half-life of sertraline ranges from 22-36 hours,",30%,95%,93%,5%,5%,30-40%,5-10 %,40-50%,70%,70%,10%,75%,60-80%,37%,58-96%,500 mg every 12 hours,250 mg every 6 hours.,500mg,500mg on a day,500mg every 12hours,100mg,"Oral, intravenous, opthalmic",3mg per day,500mg,100mg twice day,1g,500mg,500mg,320 mh per day,250mg,"Prilosec, Losec, and Zegerid.","Protonix, Pantoloc, and Pantozol.","Prevacid, Zoton, and others.","Aciphex, Pariet, and others.","Nexium, Esotrex, and others.",Dexilant.,Tagamet and various generic formulations.,"Pepcid, Pepcid AC, and others.",Axid and others.,Zantac and others.,"Gastrozepin, Piremze, and others.","Pro-Banthine, Propanthel, and others.",Ditropan and Ditrospam,"Cytotec, Arthrotec, and others.",Rioprostil may be marketed under various brand names depending on the manufacturer and country.,"Zanamivir has limited plasma protein
(<10%). It is excreted unchanged in 
urine with excretion of a single dose
completed within 24 hours.
Unabsorbed drug is excreted in the 
feces. Zanamivir is renally excreted 
as unchanged drug","Renal excretion is the only documented 
route of elimination of peramivir and its
metabolites",Oseltamivir carboxylate is eliminated entirely (>99%) by renal excretion,"The main route of metabolite excretion
is renal, with 83% of a dose recovered in urine","Renal excretion accounts for 60–90% 
of acyclovir elimination ","Renal excretion accounts for 43.1% and 5.0% in 24 hour
after oral administration of 1000mg valacyclovir ","It is eliminated through hepatic metaolism,
via carboxylesterase 1 enzyme,and 
subsequent renal excretion. 80% of dose
is eliminated in feces","Cidofovir is eliminated by the kidney 
and excreted extensively as unchanged
drug in the urine via both glomerular
filtration and active tubular secretion","Adefovir is eliminated unchanged by renal excretion through a combination of glomerular filtration and tubular secretion. After intravenous (IV) dosing, more than 98% is
recovered in urine within 24 hours.","Fostemsavir is highly metabolized, after
which it is excreted in the urine and feces as inactive metabolites","Tenofovir is primarily excreted in the
urine both via glomerular filtration and active tubular secretion following TDF administration","Amprenavir is an HIV-1 protease inhibitor 
which is hepatically metabolized (>80%) with a low renal elimination"," 7% of the atazanavir dose is excreted 
unchanged in the urine. Like indinavir, the solubility of atazanavir is increased in acid fluids. The effects of hepatic impairment on the pharmacokinetics of ritonavir-boosted atazanavir are not known",Boceprevir is mainly eliminated in the feces (79%) with a small amount eliminated in the urine (9%). Approximately 8% and 3% is excreted as the parent compound,Metabolism of lamivudine is a minor route of elimination. Lamivudine is predominately cleared unchanged by renal excretion,10-25% unchanged,"Yes, as metabolites",Yes,Approximately 94%,Approximately 66-68%,70-80%,49% (as unchanged drug),4% as unchanged drug,Approximately 90%,~95%,~70%,Yes,~94%,25-30% unchanged,90%,10-25% unchanged,"Yes, as metabolites",Yes,Approximately 94%,Approximately 66-68%,70-80%,49% (as unchanged drug),4% as unchanged drug,Approximately 90%,~95%,~70%,Yes,~94%,25-30% unchanged,90%
Dose,NA,NA,NA,NA,100-200 mg/day,150-250 mg/day,NA,NA,NA,NA,NA,15-37.5 mg once daily,25-75 mg once daily,25-50 mg once daily,Individualized,NA,0.5 mg once daily,Varies depending on the condition being treated,200 mg per administration,"Variable, depending on indication",NA,Varies based on medical condition,Varies depending on condition,Varies based on the condition being treated,Varies depending on condition,Varies based on condition,20 mg once daily,Varies depending on the condition being treated,NA,Side effect,"nervousness, gastrointestinal effects, memory impairment, allergic reactions,","fatigue,dry mouth,behavioural changes,complex sleep problems,changes in appetite","drowsiness,headache,confusion","drowsiness,dizziness ,confusion","drowsiness,dizziness ,confusion","drowsiness,dizziness ,confusion","fatigue,dry mouth,behavioural changes,complex sleep problems,changes in appetite","dry mouth, constipation, dizziness, lightheadedness, tachycardia, and prolonged QT interval","respiratorty depression ,CNS depression,nervousness, gastrointestinal effects, memory impairment, allergic reactions,","drowsiness,dizziness ,confusion","hyperbilirubinemia, constipation,blurred vision,memory impairment,complex sleep-related behaviors","Drowsiness, dizziness, dry mouth, blurred vision","drowsiness,dizziness ,confusion","drowsiness,dizziness ,confusion","Abnormal dreams,dizziness",Depends on indication and patient condition,Depends on indication and patient condition,Depends on indication and patient condition,80%,Depends on indication and patient condition,Depends on indication and patient condition,Depends on indication and patient condition,Depends on indication and patient condition,Depends on indication and patient condition,Depends on indication and patient condition,Depends on indication and patient condition,Dose,Varies,Varies,Varies,Varies,Varies,Varies,Varies,Varies,Varies,VARIES,VARIES,VARIES,Varies,Varies,Varies,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Dose,10mg/day,20mg/day,7.5mg,60mg,150 mg,20 mg,25-50 mg,150mg/day,15mg/day,25-50mg,50mg/day,NA,NA,"Hepatoxicity- drug induced liver injury,etc","Fatigue, constipation, edema, myalagia ,etc","Effects during pregnancy and lactation Protein binding,etc","Hepatoxicity, Effects during Pregnanacy and lactation, Protein binding,etc","Increase sugar levels, pancreatitis","Renal insufficiency, ototoxicity, nausea and vomiting","Alopecia, constipation, diarrhea, nausea and vomiting and leukemia,etc","Skin rash, swelling of the lips, face or throat, breathing difficulties, fever and chills",Changes to the heart including heart attack and fast breathing heart rate,Myleosuppression,Serious skin reaction,"Hematologic, Neurologic, Dermatologic Respiratory, Gastrointestinal,etc","Stomatitis, rashes, low platelet counts, low leukocytecounts, itchy skin, etc",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The dose of azathioprine can vary based on the medical condition being treated, individual patient characteristics, and the specific treatment regimen. It is typically administered orally.",25 to 50 mg/day,"Initial dose: 2.5 to 10 mg orally in divided doses every 6 to 8 hours
Maintenance dose: 1 to 5 mg/day
Maximum dose: Up to 40 mg/day","The dose of Methotrexate varies depending on the medical condition being treated.Doses may range from low (e.g., in the treatment of autoimmune diseases) to high (e.g., in cancer chemotherapy).",15 milligrams (mg) per kilogram (kg) of body weight per day,dose can vary depending on the ndication,NA,": The dosage of betamethasone can vary based on the condition being treated, the formulation used, and individual patient factors. Specific dosages should be determined by a healthcare professional",NA,The dosage can vary based on the specific condition being treated and the formulation,The dosage can vary based on the specific skin condition being treated,40 mg every otherweek,2-50mg,NA,50mg,10mg,40 mg,12mg,50mg,4mg,varies,12mg,25mg,varies,100mg/ml,5ml,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Hepatic excretion:,minimal,minimal,7%,~60%,~80%,40-50%,minimal,minimal,minimal,minimal,high,high,90%,Yes,high,150 mg,"200 mg to 800 mg,",20-40 mg,"200 mg to 800 mg,",NA,10 mg to 20 mg,15 ug orally,20-`40 mg,2-4 mg,320-640 mg,200-400 mg,60-120 mg,80 mg,50 mg,150 mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Varies with condition,"Varies with condition, typically 100-400 mg every 8 hours","Varies, typically 2.5-5 mg orally every 4-6 hours.","Varies with condition, typically 100-200 mg every 8 hours",4 times a day,Once,once daily,Daily twice,Varies based on condition,Varies based on condition,Trice a day,Varies based on condition,"twice a day, not more than 4 times",twice,twice a day,NA,"Individualized, based on condition",Varies based on indication and patient response,"Varies based on condition, typically up to 500 mg daily",Varies based on condition; typically 1000-3000 mg/day,Varies depending on the condition; typical starting dose for epilepsy: 25-50 mg/day,Varies depending on the condition; consult a healthcare professional,Varies depending on the condition being treated,As prescribed by healthcare provider,NA,Varies based on the condition,"Varies depending on the condition, consult healthcare provider",Varies depending on the condition,Varies based on indication,"Variable, depending on the condition",53-118 hours in adult,NA,"variable, depending on the condition","Variable, depending on the condition",Varies depending on the condition,"Varies depending on the condition, consult healthcare provider",Varies based on the condition,500 mg per day,250 mg daily,Varies based on indication and patient response,"Varies based on condition, typically up to 500 mg daily","Individualized, based on condition",Varies based on condition; typically 1000-3000 mg/day,2-10 mg taken twice or thrice daily,As prescribed by healthcare provider,Varies,As prescribed by a healthcare professional,NA,Varies,Varies,Varies based on condition,Individualized,NA,Varies depending on the condition,Varies depending on condition,NA,NA,"Individualized, typically 75-300 mg/day",Varies depending on condition,As prescribed by a healthcare professional,based on the specific medical condition it is being used to treat,NA,NA,1 to 3 mg/kg for IV use.,started at a low dose and adjusted based on response.,100-150 mg every 12 hours (twice daily).,3 to 18 mg,0.125 to 0.25 mg daily for adults.,80 mg to 480 mg per day.,120 to 240 mg once daily.,80 to 320 mg/day,2g/100mL,"high dose for the first few weeks, followed by a maintenance dose.",80 mg to 320 mg per day,200-800 mg/day.,1200 mg to 1680 mg,variable,variable,variable,variable,variable,variable,variable,variable,varies,varies,Variable based on indication,Varies,varies,Individualized,15-30mg/day,7.8 mg/kg,260 mg/day,260 mg/m^2 per day,2-6mg per day,10 mg daily,70 to 120 mg/m^2 per day,130 mg/m^2,500 to 1500 mg/m^2,500 to 1000 mg/m^2 per day,50 to 100 mg/m^2 per day,0.1 to 0.2 mg/kg,100mg/day,25mg,2-4.5mg/kg,40mg,30mg,200-400mg,75-300mg,50-150mg,30-60mg,200mg,500mg,230mg,50mg,1g,800mg,250mg,500mg,250mg,135 to 250mg/m²,20 to 120 mg/m²,300-600mg,60 to 100 mg/m²,50 mg to 700 mg,25 to 75 milligrams,NA,25mg,90mg,150mg,1000 mg/m2,250mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20%,16%,partial,30%,40%,10%,20%,NA,8 mol/L,NA,NA,3%,NA,NA,NA,63.5+or- 2.7 ug/100g/min,occours,eliminated through hepatic metabolism,80% feces urine 11-12%,excreted in urine about 1 % of single dose,feces of human,unchnged by kidneys,with active metabolite,urine excretion,primirily eliminated through hepatic,eliminated through hepatic with liver,through renal,liver,occurs,liver,NA,"Mainly metabolized in the liver, with fecal excretion being the primary route of elimination.",NA,"Metabolized mainly in the liver, with fecal excretion being a minor route of elimination.",Minor hepatic excretion,Prednisone and its metabolites are also excreted in bile.,NA,Dasatinib and its metabolites are primarily excreted via the feces.,Dexamethasone and its metabolites are primarily excreted in the bile.,NA,"The primary route of elimination of cytarabine is metabolism to the inactive compound ara-U, followed by urinary excretion of ara-U",NA,NA,Daunorubicin is eliminated hepatically. 40% of daunorubicin is excreted in the bile while 25% is excreted in an active form (daunorubicin or daunorubicinol) in the urine,NA,Primarily excreted through the kidneys rather than the liver.,"Metabolized in the liver, and the metabolites are excreted in the urine.","Excreted in the bile, and a significant portion of B12 is reabsorbed in the terminal ileum.",Metabolized in the liver and excreted in urine.,Water-soluble and excreted in the urine.,Metabolized in the liver and excreted in the urine.,"Metabolized in the liver, and excess choline is excreted in the urine.","Converted to its active form in the liver and kidneys, then excreted in the bile.",Water-soluble and excreted in the urine.,Water-soluble and excreted in the urine.,Carotenoids like lutein are generally stored in body tissues rather than rapidly excreted.,"Similar to lutein, carotenoids are often stored in tissues.",Metabolized in the liver and excreted in the urine.,Primarily excreted in bile and feces.,"The liver metabolizes vitamin E, and the metabolites are excreted in the bile.",Hepatic excretion:,less than 1%,Approximately 50-60%,less than 10%,18-35%,less than 2%,95%,70-80%,80%,75%,35%,90%,90-95%,60-70%,NA,70%,200 mg,200 mg,70 mg,100 mg,200 mg,50 mg,10 mg,200mg,200mg,250mg,1000 to 2000mg,1% Cream,6%,4-6 ml,100 mg,"Primarily excreted unchanged in the urine, with a minor contribution from hepatic metabolism.","Mainly eliminated through the liver, with the metabolites being excreted in the urine and feces.","Primarily excreted in the urine, and only a small percentage undergoes hepatic metabolism.","Metabolized in the liver to inactive metabolites, and the metabolites are primarily excreted in the urine.","Metabolized in the liver, and both the parent drug and its metabolites are excreted in the urine.","Metabolized in the liver, and the metabolites are excreted in the urine.",Primarily excreted unchanged in the urine.,"Information on hepatic excretion is limited, but it is primarily excreted in the urine.","Metabolized in the liver, and the metabolites are excreted in the urine.","Hepatic metabolism contributes to its elimination, and the metabolites are excreted in the urine.","Metabolized in the liver, and both the parent drug and its metabolites are excreted in the urine.","Information on hepatic excretion is limited, but it is primarily excreted in the urine.","Hepatic metabolism contributes to its elimination, and the metabolites are excreted in the urine.",Information on hepatic excretion is limited,"Extensively metabolized in the liver, and both the parent drug and its metabolites are excreted in the urine.",Via the bile,Minimal,Via the bile.,Via the bile.,"The liver is involved in
the metabolism and
excretion of rebamipide.",Minimal,Major route of elimination,Mainly excreted in the feces,Minimal,Mainly excreted in the feces,Minimal hepatic excretion.,Metabolites are also excreted in the bile.,Mainly excreted in the feces,Minimal hepatic excretion.,"Yes, it undergoes hepatic metabolism.",NA,Feces 2-3%,NA,NA,Feces 10%,Feces 80-90%,Feces 77%,Feces 77%,Feces 35% to 70%,Feces 90%,NA,Feces 80%,NA,NA,NA,NA,NA,NA,10%,NA,NA,42%,predominal,minor,yes,mainly fecal,NA,biliary,not specified,NA,Minor,~15%,Minor,Major,~41%,Minor,Minor,Minor,hepatic excretion:,biliary,extensively,extensive,proteolytic degradation,extensive,extensive,monoamine oxidase,hepatic excretion,NA,carmustine,"kidney,liver",cytochrome,carmustine,alkylating agent used in chemotherapy,kidney,Hepatic excretion:,2% UNCHANGES IN URINE,13%,NA,main route elimination,main route elimination,NA,minor,NA,not specified,primarily excreation,primarily hepatic exceation,hepatic excreation,hepatic metabolites,excreated in bile,20%,16%,partial,30%,40%,10%,20%,NA,8 mol/L,NA,NA,3%,NA,NA,NA,63.5+or- 2.7 ug/100g/min,occours,eliminated through hepatic metabolism,80% feces urine 11-12%,excreted in urine about 1 % of single dose,feces of human,unchnged by kidneys,with active metabolite,urine excretion,primirily eliminated through hepatic,eliminated through hepatic with liver,through renal,liver,occurs,liver,NA,"Mainly metabolized in the liver, with fecal excretion being the primary route of elimination.",NA,"Metabolized mainly in the liver, with fecal excretion being a minor route of elimination.",Minor hepatic excretion,Prednisone and its metabolites are also excreted in bile.,NA,Dasatinib and its metabolites are primarily excreted via the feces.,Dexamethasone and its metabolites are primarily excreted in the bile.,NA,"The primary route of elimination of cytarabine is metabolism to the inactive compound ara-U, followed by urinary excretion of ara-U",NA,NA,Daunorubicin is eliminated hepatically. 40% of daunorubicin is excreted in the bile while 25% is excreted in an active form (daunorubicin or daunorubicinol) in the urine,NA,NA,Hepatic excretion:,Primarily excreted through the kidneys rather than the liver.,"Metabolized in the liver, and the metabolites are excreted in the urine.","Excreted in the bile, and a significant portion of B12 is reabsorbed in the terminal ileum.",Metabolized in the liver and excreted in urine.,Water-soluble and excreted in the urine.,Metabolized in the liver and excreted in the urine.,"Metabolized in the liver, and excess choline is excreted in the urine.","Converted to its active form in the liver and kidneys, then excreted in the bile.",Water-soluble and excreted in the urine.,Water-soluble and excreted in the urine.,Carotenoids like lutein are generally stored in body tissues rather than rapidly excreted.,"Similar to lutein, carotenoids are often stored in tissues.",Metabolized in the liver and excreted in the urine.,Primarily excreted in bile and feces.,"The liver metabolizes vitamin E, and the metabolites are excreted in the bile.",NA,NA,NA,NA,NA,less than 1%,Approximately 50-60%,less than 10%,18-35%,less than 2%,95%,70-80%,80%,75%,35%,90%,90-95%,60-70%,NA,70%,NA,Dose,200 mg,200 mg,70 mg,100 mg,200 mg,50 mg,10 mg,200mg,200mg,250mg,1000 to 2000mg,1% Cream,6%,4-6 ml,100 mg,Hepatic excretion:,"Primarily excreted unchanged in the urine, with a minor contribution from hepatic metabolism.","Mainly eliminated through the liver, with the metabolites being excreted in the urine and feces.","Primarily excreted in the urine, and only a small percentage undergoes hepatic metabolism.","Metabolized in the liver to inactive metabolites, and the metabolites are primarily excreted in the urine.","Metabolized in the liver, and both the parent drug and its metabolites are excreted in the urine.","Metabolized in the liver, and the metabolites are excreted in the urine.",Primarily excreted unchanged in the urine.,"Information on hepatic excretion is limited, but it is primarily excreted in the urine.","Metabolized in the liver, and the metabolites are excreted in the urine.","Hepatic metabolism contributes to its elimination, and the metabolites are excreted in the urine.","Metabolized in the liver, and both the parent drug and its metabolites are excreted in the urine.","Information on hepatic excretion is limited, but it is primarily excreted in the urine.","Hepatic metabolism contributes to its elimination, and the metabolites are excreted in the urine.",Information on hepatic excretion is limited,"Extensively metabolized in the liver, and both the parent drug and its metabolites are excreted in the urine.",Hepatic excretion:,Via the bile,Minimal,Via the bile.,Via the bile.,"The liver is involved in
the metabolism and
excretion of rebamipide.",Minimal,Major route of elimination,Mainly excreted in the feces,Minimal,Mainly excreted in the feces,Minimal hepatic excretion.,Metabolites are also excreted in the bile.,Mainly excreted in the feces,Minimal hepatic excretion.,"Yes, it undergoes hepatic metabolism.",Hepatic excretion:,NA,Feces 2-3%,NA,NA,Feces 10%,Feces 80-90%,Feces 77%,Feces 77%,Feces 35% to 70%,Feces 90%,NA,Feces 80%,NA,NA,NA,Hepatic excretion:,NA,NA,NA,10%,NA,NA,42%,predominal,minor,yes,mainly fecal,NA,biliary,not specified,NA,Minor,~15%,Minor,Major,~41%,Minor,Minor,Minor,hepatic excretion:,biliary,extensively,extensive,proteolytic degradation,extensive,extensive,monoamine oxidase,hepatic excretion,NA,carmustine,"kidney,liver",cytochrome,carmustine,alkylating agent used in chemotherapy,kidney,2% UNCHANGES IN URINE,13%,NA,main route elimination,main route elimination,NA,minor,NA,not specified,primarily excreation,primarily hepatic exceation,hepatic excreation,hepatic metabolites,excreated in bile,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,57%,NA,64%,NA,NA,NA,NA,NA,15%,20%,50%,NA,55-65%,Minimal,Main route,Minimal,Minimal,Minimal,Yes,Negligible,Negligible,Negligible,NA,NA,NA,NA,NA,NA,hydroxylated metabolites.,"Tofacitinib N-oxide, Demethylated Metabolites",M15.,Polyglutamated forms,teriflunomide,Sulfapyridine and 5-aminosalicylic acid (5-ASA).,Methylated Derivatives,"Cyclosporine M1, Cyclosporine M17, Cyclosporine M21, Cyclosporine M9","Yes, desethylchloroquine",None,none,"Prednisone, Prednisolone-11-glucuronide",none,"As a large protein molecule, adalimumab is not metabolized into inactive metabolites",none,NA,NA,NA,82%,70%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The percentage of penicillin G extracted by the kidney was 34%-40% at all times. ,Amoxicillin is poorly metabolized by the liver (< 30%) and around 60% of an oral dose is excreted unchanged in urine.,Approximately 90% of the unchanged drug is excreted in the urine. ,", between 30 and 60 percent of administered ceftriaxone is eliminated by nonrenal (biliary) mechanisms","Imipenem is almost exclusively eliminated renally, after being metabolized in renal tubules by a dipeptidase","65%-79% of the drug [18-23, 32, 33, 39] is excreted as meropenem ","In the first 24 hours, about 75-80% of an administered dose of vancomycin is excreted in urine by glomerular filtration","omadacycline is cleared hepatically (i.e., by biliary excretion) and renally (15)"," metabolized in the liver, cefotaxime is excreted by the kidneys",NA,About 22% of a moxifloxacin dose is excreted via the kidneys ,The excretion of Piperacillin can be decreased when combined with Apalutamide.," mainly eliminated by the kidneys, and most of it is excreted unchanged. Approximately 85% of cefepime administered ",excretion of unchanged drug in urine is a minor route of ...,70%,5%,7%,95%,95%,70-60%,95-90%,60-50%,30%,30%,90%,35%,20-40%,63%,42%,"Amoxil®, Moxilin®, Sumox® and Trimox®.",Keflex,Spectracef,"Azasite, Zithromax, Zmax","Pylera, Sumycin",Dalvance,NA,"Tobrex, Zylet, Nebcin",Invanz,"Apprilon, Atrdox, Doxycin, Doxy",Maxipime,Lincocin,Vabomre,Factive,Arikayce,"hypomagnesemia, osteoporosis-related fractures, diarrhea","hypomagnesemia, osteoporosis-related fractures, diarrhea","hypomagnesemia, osteoporosis-related fractures, diarrhea","hypomagnesemia, osteoporosis-related fractures, diarrhea","hypomagnesemia, osteoporosis-related fractures, diarrhea","hypomagnesemia, osteoporosis-related fractures, diarrhea","CNS effects such as confusion and hallucinations, gynecomastia (in men), hematologic effects","CNS effects such as confusion and hallucinations, gynecomastia (in men), hematologic effects","CNS effects such as confusion and hallucinations, gynecomastia (in men), hematologic effects","CNS effects such as confusion and hallucinations, gynecomastia (in men), hematologic effects","Major toxic effects may include anticholinergic effects such as dry mouth, blurred vision, urinary retention, and constipation.","Major toxic effects may include anticholinergic effects such as dry mouth, blurred vision, urinary retention, and constipation.","Major toxic effects may include anticholinergic effects such as dry mouth, blurred vision, urinary retention, and constipation.","Major toxic effects may include uterine hyperstimulation, uterine rupture, diarrhea, abdominal pain, and fever.","Major toxic effects may include gastrointestinal disturbances such as diarrhea, abdominal pain, and nausea.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Metabolites,"Yes, as metabolites",Yes,"Minor, through glucuronidation",Approximately 24%,Minor,39% (as metabolites),Mainly as metabolites,Approximately 10%,~5%,~25%,Yes,Minor,Major metabolites excreted in bile,Negligible,Metabolites,"Yes, as metabolites",Yes,"Minor, through glucuronidation",Approximately 24%,Minor,39% (as metabolites),Mainly as metabolites,Approximately 10%,~5%,~25%,Yes,Minor,Major metabolites excreted in bile,Negligible
Brand name,"Adderall, Dexedrine",Desoxyn,"Ritalin, Concerta",Dexedrine,Provigil,Nuvigil,Various generics,Not applicable (illicit drug),Various generics,nicotine transdermal,Strattera,"Adipex-P, Lomaira","Tenuate, Tenuate Dospan",Didrex,"Sinemet, others",Symmetrel (example),Azilect,"Emsam, Eldepryl, Zelapar",Comtan,Exelon,"Cogentin, among others","Mirapex, Sifrol","Requip, Adartrel",Xadago,"Apokyn (Subcutaneous), Kynmobi (Tablet)","Parlodel, Cycloset",Nourianz,"Artane, Trihexy",Tasmar,Fast fed variability,"fasted state-rapid absorption,high fat meals slows the absorption","rapid absorption in fasting state,fatty meals delay absorption",rapid absorption in empty stomach,"fasted state-rapid absorption,high fat meals slows the absorption",NA,Absent,NA,NA,"fasted state-rapid absorption,high fat meals slows the absorption",Rapid absorption when administered with food,Taking flurazepam with food may slow down its absorption rate and decrease its peak plasma concentration compared to taking it on an empty stomach (fasted condition),Rapid absorption when administered with food,NA,Not specified,Rapid absorption when administered with food,Platinol,"Rheumatrex, Trexal",Temodar,celexa,Matulane,Velban,Hycamtin,Camptosar,"Etopophos, Vepesid",Taxol,"Decadron, Dexasone",Brand name,"Lotrimin, canesten","Monistat, micatin",Nizoral,Vfend,Noxafil,Diflucan,Sproanox,Lamisil,"Lotrimin ultra,Mentax",Naftin,"Mycostatin, nystop",Mycamine,Cancidas,Gris-PEG,"Tinactin, absorbine",Novo Log,Glian,Orinase,Precose,Glyset,Glucotrol,Volix,Actos,Fortamet,Soliqua,Humalog,Novomix,PRANDIN,NA,Brand name,lexapro,celexa,effexor XR,cymbalta,wellbutrin,paxil,elavil,desyrel,remeron,pamelor,luvox,NA,NA,"Hives, difficulty in breathing, swelling of the face, lips, tongue, or throat, nausea, vomiting, diarrhea, fainting, heart palpitations, seizures, etc","Tiredness , constipation, swelling in your hands, feet, ankles, face and eyelids,etc","Dizziness, Irregular breathing, bleeding, diarrhea, chest pain, decreased urine output,muscle problems,etc","Diarrhea, difficulty having a bowel momvement, ear congestion, nausea, loss of voice, runny nose,etc.","Diarrhea, constipation, fatigue, rash, abdominal pain, decrease haemoglobin, increased liver enzymes, etc","Pain, burning, redness at the injection site, numbness,loss of reflexes, weakness, etc","Infusion site reactions, low blood pressure, hair loss, constipation or diarrhea, metallic food taste, etc","Allergic reactons, tissue damage, low blood cell counts, infections mouth or lip sores,etc","Nausea and vomiting, loss of appetite, pain in jointschange in taste, etc","Bone marrow suppression, liver and kidney problems, nausea, fever, rash, diarrhea, shortness of breath,etc","Low blood cell counts, mental fatigue, sleepiness, nausea and vomiting, diarrhea,etc","Bone marrow suppression, vomiting, pain at the site of infection, shortness of breath,etc","Diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation around nails, sore mouth, etc",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Azathioprine is available under various brand names, and the availability of specific brands may vary by region. Common brand names include Imuran",soratane,Prolixin® and Permitil®.,"Methotrexate is available under various brand names, including Rheumatrex, Trexall,",: Hydrea and Droxia.,"Neoral, Sabdimmune, and other","Clobetasol is available under various brand names, including Temovate, Dermovate, and others.","Betamethasone is available under various brand names, such as Celestone, Diprolene, and others, depending on the formulation.",": Calcipotriene is available under various brand names, including Dovonex and Daivonex",Tazorac.,Pimecrolimus is commonly sold under the brand name Elidel,humira,Tegison,NA,"Gravol ,Dramamine",transderm scop,bentyl,phenergan,ganaton,Zofran,Nasea,Emend,"antivert,bonine",thorazine,haldol,aloxi,NA,NA,Novolog,"Basaglar, Soliqua",levemir,"Actraphane, Humulin 
N, Humulin R",Xultophy,"Admelog, Humalog, liprolog",Apidra,AstraZeneca,"Fiasp, Novolg mix, Novomix","Amaryl, Glimepil","Bynfezia, Mycapsa",Tzield,"Basaglar, Soliqua","Novolog mix, Novomix, Ryzodeg","Actraphane, Afrezza",NA,Dose,1000mg,200-600mg,640-960mg,750mg,oral/IV 600mg,200-400mg,200mg,25-75mg,15-30mg,1500mg,50-100mg,100mg,150-450 mg,2.4mg,80mg,"Zantac,Ranitab",Tagamet,"Pepsid,Pepsid-AC",Tagamet,Vascor,Propulsid,Tikosyn,Recorlev,Orap.,"Artesiane,Duocotecxin","Zagam, Spacin",Seldane,Geodon.,Serentil,"Axid, Axid AR, Nizatidine Sandoz","Amikin, Amiglyde-V, Arikayce, others",The famous brand name for plazomicin is Zemdri.,"Zithromax, and Zmax.","Amoxil®, Moxilin®, Sumox® and Trimox®.","Biocef®, Daxbia®, Keflex®, Keftab®.",Negaban,Principen®,"Lantrisul, Neotrizine, Sulfa-Triple #2, Sulfadiazine, Sulfaloid, Sulfonamides Duplex, Sulfose, Terfonyl, Triple Sulfa, Triple Sulfas, and Triple Sulfoid.",Xerava,"Amoxil, Augmenting, Pen-Vee, Veetids, Pfizerpen",Merrem,"Biocef®, Daxbia®, Keflex®, Keftab®.","Ciproxin, Ciloxan, Cetraxal",Zerbaxa,Biaxin®,Ventolin (common brand),"Various (e.g., Theo-Dur)","Bricanyl, Brethine, others","Phyllocontin, Truphylline, others","Atrovent, Apovent, others","Spiriva, Tiova, others","Singulair, Lukotas, others","Accolate, Vanticon, others","Intal, Opticrom, others","Zaditor, Alaway (ophthalmic); Zyrtec (combined with cetirizine)",Cortef (common trade name),"Prelone, Pediapred, others","Various, including Qvar, Beconase, and others","Various, including Pulmicort, Entocort, Rhinocort","Aerobid (inhalation), Nasalide (nasal spray), others","Dilantin, Phenytek","Tegretol, Carbatrol, Epitol, others","Depakote, Depakene, Depacon, others",Lamictal,"Keppra, among others",Topamax,Trileptal,Onfi,Felbatol,Sabril,Gabitril,Banzel,Neurontin (commonly known),Zonegran,Lyrica,Luminal,"Dilantin, Phenytek",Lyrica,zonegram,Neurontin (commonly known),Banzel,Gabitril,Sabril,celontin,"Depakote, Depakene, Depacon, others",Lamictal,"Tegretol, Carbatrol, Epitol, others","Keppra, among others","valium , diastat",Felbatol,Thorazine,Mellaril,Stelazine,Navane,Haldol,Loxitane,Clozaril,Risperdal,Abilify,Rexulti,Saphris,Serdolect,"Zoleptil, Nipolept, Zotepin",Vraylar,Caplyta,"Quinaglute, Quinidex, Cardioquin",Pronestyl,Norpace,Xylocaine,Mexitil,"Tambocor, Apocard, and Flecatab",Adenocard,"Lanoxin, Digitek, and Digox.",verapamil,"Cardizem, Dilacor XR, Tiazac","Inderal, Inderal LA, InnoPran XL, and Hemangeol",Brevibloc,"Cordarone, Pacerone, and Nexterone.",Betapace and Betapace AF.,Sectral,Tecentriq,Avastin,Gemzar,Cabometyx,Imfinzi,Cabometyx,Cyramza,Lenvima,Nexavar,Rozlytrek,Vitrakvi,Imfinzi,Stivarga,Stivarga,Pemazyre,"Trexall, Reditrex, Rasuvo, Otrexup, and Xatmep",Mustargen,thioplex,hexalen,Myleran.,Alkeran ,Treanda ,"CeeNU,",Cytoxan,"Streptomycin Sulfate
Streptomycin Injection
Streptomycin Sulphate Injection
Streptomycin for Injection
Streptomycin-Rivo",Vepesid,Leukeran ,Matulane,Fludara,DTIC-Dome,"Konvomep, Losec","Prevacid, Prevpac",Tagamet,"Zantac, Wal-zan",Gaspin,Medic,"Arthrotec, Cytotec",Tindamax,"Dalmacol, EnLyte","Bibag, Bicart","Carafate, Sulcrate",Actavis,"Amoxil, Taclicia,Clavulin","Biaxin, Prevpac","Flagyl, Nidagel",Taxol,Platinol,Alecensa,Taxotere,Braftovi,"Trexall,Xatmep",Xalkori,Navelbine,Alunbrig,Tarceva,Gemzar,Gilotrif,"Valium, Diastat, and Diastat AcuDial."," Alepam, Alepan, Anoxa, Comedormir, durazepam, Murelax.",Atarax and Vistaril,Inderal LA, Buspar®.,Exxua,Ativan , Catapres®.,"Xanax, Niravam, and Xanax XR.", Amytal Sodium or Tuinal, Solfoton,Librium,Nembutal (pentobarbital sodium),Sodium Pentothal," Aropax, Paxil, Pexeva, Seroxat, Sereupin and Brisdelle",6.25 mg to 12.5 mg,20-40 mg,1-2.5 mg,1.25-2.5 mg,25-100 mg,10mg,2.5-7.5 mg,750mg,2.4 mg/kg for IV,8-320 mg,4-32 mg/day,50-200 mg,750-825 mg,2mg/24 hrs IV route,400 mg,12.5 to 25 mg every 4 to6 hr,5 to 10mg,10 mg,60 ml,50 mg,5 mg,5mg,1 or 2 sprays in nostril,0.125mg/kg,1.34 mg,25 to 100 mg/day,25 to 50 mg,4 mg,10 mg,25 to 50 mg,"25mg, 100mg",400 mg once daily for CLL,50mg,300 mg,400mg,5-60mg,60mg,100mg,"4,6 mg",75MG,100mg,5 mg,10mg/mL,5mg/mL,2 mg,NA,400 micrograms (mcg),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Dose of the drug,100 mg ,200-400mg,100 to 400 mg,10 milliliters,less than 2%,300-400 mg,500 - 1000 mg,100-300mg,?3 mg,70 mg,250 mg,25 mg/kg/day ,2%,NA,3%,Diflucan,Sporanox,Cancidas,"Alevazol, Dermacinrx",Ecoza,"Aloe Vesta Antifungal, Baza",Oxistat,"Extina, Ketodan",Vfend,Lamisil,Absorbine Jr Antifungal,Lotrimin Ultra,"Ammonul, Hyophen","Mycostatin, Flagystatin","Noxafil, Posanol",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Varies depending on the indication and treatment regimen,NA,NA,150 mg twice daily or 300 mg once daily for GERD,"Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.",NA,NA,NA,NA,NA,NA,variable,variable,variable,as prescribed,NA,NA,as prescribed,variable,NA,Varies based on indication and combination with other drugs,Varies based on indication and combination with other drugs,Varies based on indication and combination with other drugs,Varies based on indication,Varies based on indication,Varies based on indication and severity,Varies based on indication and severity,Varies depending on the condition,Dose,150 to 200 mg/m²,130 to 200 mg/m^2,twise in 2 week,once in month,twice in 6 months,NA,weekly,monthly,50 mg,100mg,NA,50mg/50ml,7.7mg,130mg/m2,25 to 75 mg,Dose,varies based on indication and route,VARIES BASED,VARIES BASED,oral,oral,oral,minor,NA,not specified,varies depending on formulation and indication,varies depending on formulation and indication,local irritation,varies depending on patients,excreated in bile,6.25 mg to 12.5 mg,20-40 mg,1-2.5 mg,1.25-2.5 mg,25-100 mg,10mg,2.5-7.5 mg,750mg,2.4 mg/kg for IV,8-320 mg,4-32 mg/day,50-200 mg,750-825 mg,2mg/24 hrs IV route,400 mg,12.5 to 25 mg every 4 to6 hr,5 to 10mg,10 mg,60 ml,50 mg,5 mg,5mg,1 or 2 sprays in nostril,0.125mg/kg,1.34 mg,25 to 100 mg/day,25 to 50 mg,4 mg,10 mg,25 to 50 mg,"25mg, 100mg",400 mg once daily for CLL,50mg,300 mg,400mg,5-60mg,60mg,100mg,"4,6 mg",75MG,100mg,5 mg,10mg/mL,5mg/mL,2 mg,NA,Dose,NA,400 micrograms (mcg),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,100 mg ,200-400mg,100 to 400 mg,10 milliliters,less than 2%,300-400 mg,500 - 1000 mg,100-300mg,?3 mg,70 mg,250 mg,25 mg/kg/day ,2%,NA,3%,NA,Brand name,Diflucan,Sporanox,Cancidas,"Alevazol, Dermacinrx",Ecoza,"Aloe Vesta Antifungal, Baza",Oxistat,"Extina, Ketodan",Vfend,Lamisil,Absorbine Jr Antifungal,Lotrimin Ultra,"Ammonul, Hyophen","Mycostatin, Flagystatin","Noxafil, Posanol",Dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Varies depending on the indication and treatment regimen,NA,NA,150 mg twice daily or 300 mg once daily for GERD,Maximum Daily Dose,"Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.","Based on age, gender, and health conditions.",Dose,NA,NA,NA,NA,NA,NA,variable,variable,variable,as prescribed,NA,NA,as prescribed,variable,NA,Varies based on indication and combination with other drugs,Varies based on indication and combination with other drugs,Varies based on indication and combination with other drugs,Varies based on indication,Varies based on indication,Varies based on indication and severity,Varies based on indication and severity,Varies depending on the condition,Dose,150 to 200 mg/m²,130 to 200 mg/m^2,twise in 2 week,once in month,twice in 6 months,NA,weekly,monthly,50 mg,100mg,NA,50mg/50ml,7.7mg,130mg/m2,25 to 75 mg,varies based on indication and route,VARIES BASED,VARIES BASED,oral,oral,oral,minor,NA,not specified,varies depending on formulation and indication,varies depending on formulation and indication,local irritation,varies depending on patients,excreated in bile,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,NA,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIABLE,VARIBALE,VARIABLE,VARIABLE,70mg,60mg,35mg,"6mg (IV), 50mg (tab)",5mg/100ml,20mg,400mg,200mg,9mg/ml,2g,20mcg,80mcg/40mcl,200 [USP'U]/1mL,60 mg/ml,105mg,undergoes first-pass metabolism.,tofacitinib undergoes first-pass metabolism,Upadacitinib undergoes first-pass metabolism,"Yes, methotrexate undergoes first-pass metabolism",leflunomide undergoes first-pass metabolism,Sulfasalazine undergoes extensive first-pass metabolism.,Azathioprine does not undergo significant first-pass metabolism in the liver.,Cyclosporine does undergo first-pass metabolism to some extent.,Yes,"Yes, hydroxychloroquine undergoes first-pass metabolism to some extent",Not applicable (protein),"yes, Significant
",Does not undergo significant first-pass metabolism.,Does not undergo significant first-pass metabolism.,Does not undergo significant first-pass metabolism,NA,Aldara and Zyclara,"Carac,Tolak, Efudex, and Fluoroplax",Erivedge,Odomzo,Keytruda,Proleukin,Mektovi,BRAFTOVI,Cotellic,Tafinlar,DTIC-Dome,Panretin( gel),Zelboraf,Yervoy,NA,The normal dose ranges from 125 mg to 500 mg every 6 to 8,The usual dose is 20 to 40 milligrams (mg) per kilogram (kg) of body weight per day,"Adults and children 15 years of age and older—1000 to 4000 milligrams (mg) per day, taken in divided doses.","This medication is given by injection into a muscle or vein as directed by your doctor, usually once or twice daily. The dosage is based ","Dosages based on imipenem component. <1 week, >1.5 kg: 25 mg/kg IV q12hr for non-CNS infections. ", Meropenem Dosage · 1 g IV every 8 hours., ; capsule (Vancocin). 125mg; 250mg ,older—450 milligrams (mg) once a day on Day 1 and 2, 1 to 2 g IM or IV every 8 hours,5 - 10 mg tiamulin hydrogen fumarate/kg bodyweight daily,under 30 kg: 10 to 15 mg/kg once daily, IV: 3-4 g/dose q4-6hr,1 to 2 g every 8 to 12 hours , 600 mg IV every 12 hours,0.6mg,2.5-5 mg,20 mg,10-20 mg,100mg,40-320 mg,25-200 mg,25-100 mg,80-480 mg,420 mg,2.5-10 mg,5-20 mg,30-90mg,2.5-10 mg,25-75 mg,"hematuria, oliguria, abdominal pain, acute renal failure, vomiting, diarrhea, rash, hyperactivity, and drowsiness",Allergic reactions like anaphylaxis,"Nausea, vomiting, itching, selling, liver problem, change blood count","Cardiovascular effects, cebtral nervous system, hepatic effects","Jaundicce, dark urine, fatigue, nausea and vomiting","Hypersensitivity reactions, Hematologic effects, Hepatic effects","Tendinitis, tendon rupture, peripheral neuropathy","Nephrotoxicity, ototoxicity","Hypersensitivity reaction, hematologic effect","Gastrointestinal disturbance, photosensitivity, hepatotoxicity","Neurotoxicity, hepatic effect, hypersensitivity reaction","Vomiting, nausea, gastrointstinal distirbance","Liver toxicity, hypersensitivity reaction, hematologic effect","Cardiovascular effect, hypersensitivity,hepatotoxicity","Kidney damage, nephrotoxixcity","headache, diarrhea, abdominal pain, nausea, vomiting, and rash.","headache, diarrhea, abdominal pain, nausea, vomiting, and rash.","headache, diarrhea, abdominal pain, nausea, vomiting, and rash.","headache, diarrhea, abdominal pain, nausea, vomiting, and rash.","headache, diarrhea, abdominal pain, nausea, vomiting, and rash.","headache, diarrhea, abdominal pain, nausea, vomiting, and rash.","headache, dizziness, diarrhea, constipation, and skin rash.","headache, dizziness, diarrhea, constipation, and skin rash.","headache, dizziness, diarrhea, constipation, and skin rash.","headache, dizziness, diarrhea, constipation, and skin rash.","Major side effects may include headache, dizziness, drowsiness, and gastrointestinal disturbances.","dry mouth, blurred vision, urinary retention, constipation, tachycardia, and central nervous system effects such as drowsiness and confusion.","dry mouth, blurred vision, urinary retention, constipation, tachycardia, and central nervous system effects such as drowsiness and confu","e effects may include diarrhea, abdominal pain, uterine cramps, vaginal bleeding, nausea, and vomiting","Major side effects may include gastrointestinal disturbances, headache, dizziness, and uterine contractions (if used in pregnancy).",Inhaled twice daily for 5 days,"600 mg once a day, administered
intravenously for 5 to 10 days."," 75 mg twice daily or 12.5 ML of oral
suspension twice daily","300mg twice per day or 600mg once per
day",for oral adults & children 12 yrs age & older 200mg five times a day for 10 days,"20mg per kg taken three times a day 
for 5 days",80mg taken as a single dose per day,"5mg per kg is injected slowly into a 
vein once a week for two weeks in a row","500 mg daily for 2 weeks and 250 mg
daily for 12 weeks","600mg tablet taken orally twice daily 
with or without food",300 mg orally once a day, 1200 mg orally twice a day,300mg with 100mg ritonavir once a day,"800 mg orally three times daily
(every 7 to 9 hours) with food in combination with peginterferon and ribavirin", 150mg/300mg twice daily,NA,"Individualized, based on condition",Varies based on indication and patient response,"Varies based on condition, typically up to 500 mg daily",Varies based on condition; typically 1000-3000 mg/day,Varies depending on the condition; typical starting dose for epilepsy: 25-50 mg/day,Varies depending on the condition; consult a healthcare professional,Varies depending on the condition being treated,As prescribed by healthcare provider,NA,Varies based on the condition,"Varies depending on the condition, consult healthcare provider",Varies depending on the condition,Varies based on indication,"Variable, depending on the condition",NA,"Individualized, based on condition",Varies based on indication and patient response,"Varies based on condition, typically up to 500 mg daily",Varies based on condition; typically 1000-3000 mg/day,Varies depending on the condition; typical starting dose for epilepsy: 25-50 mg/day,Varies depending on the condition; consult a healthcare professional,Varies depending on the condition being treated,As prescribed by healthcare provider,NA,Varies based on the condition,"Varies depending on the condition, consult healthcare provider",Varies depending on the condition,Varies based on indication,"Variable, depending on the condition"
Toxic effects(major),"Hyperthermia, seizures","Cardiovascular effects, hyperthermia, psychosis","Cardiovascular effects, psychiatric symptoms",Potential for abuse,"Rare, but potential for skin reactions, psychiatric symptoms","Rare, but potential for skin reactions, psychiatric symptoms","Hypertension, arrhythmias, CNS stimulation","Cardiovascular effects, neurological effects, addiction","Anxiety, insomnia, palpitations","Cardiovascular effects, addiction","Suicidal thoughts, liver injury","Cardiovascular effects, CNS stimulation","Cardiovascular effects, CNS stimulation","Cardiovascular effects, CNS stimulation","Dyskinesias, hallucinations",CNS toxicity,"Hypertension, serotonin syndrome, hallucinations",Hypertensive crisis if used with certain substances,Not specified,"Nausea, vomiting, and gastrointestinal disturbances","Anticholinergic toxicity, hallucinations, confusion","Hallucinations, hypotension, dyskinesia","Hallucinations, orthostatic hypotension",Not specified,"Nausea, hypotension, syncope","Hallucinations, confusion (rare)","Limited information available, consult prescribing information","Tachycardia, blurred vision, hallucinations",Hepatic toxicity (rare but serious),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Nephrotoxicity, ototoxicity, neurotoxicity","Myelosuppression, hepatotoxicity, nephrotoxicity","Myelosuppression, nausea, vomiting, fatigue",QT prolongation,"Myelosuppression, nausea, vomiting","Myelosuppression, neurotoxicity, gastrointestinal toxicity","Myelosuppression, nausea, vomiting","Myelosuppression, diarrhea, nausea","Myelosuppression, nausea, vomiting","Myelosuppression, peripheral neuropathy, hypersensitivity reactions","Adrenal suppression, immunosuppression, osteoporosis",Toxic effects(major),Rare,Rare,Rare hepatotoxiccity,Visual disturbances hepatotoxiccity,Rare hepatotoxicity,Rare hepatotoxicity,Rare hepatotoxicity,"Rare, hepatotoxicity",Rare,Rare,Rare,"Rare , hepatotoxicity",Rate hepatotoxicity,"Rare, hepatotoxicity","Rare ,local irritation",Itching,"coma , seizure",NA,NA,NA,Hypoglycemia,liver dysfunction,Bladder cancer,severe lactic acidosis,Hypoglycemia,uncounciousness seizure,Allergic reaction,Unconciousness,NA,Toxic effects(major),serotonin syndrome,serotonin syndrome,serotonin syndrome,serotonin syndrome,serotonin syndrome,serotonin syndrome,cardiac toxicity,serotonin syndrome,serotonin syndrome,cardiac toxicity,serotonin syndrome,NA,NA,Yes,yes,­,­,­,­,­,­,­,­,­,­,­,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Major toxic effects of azathioprine include the potential for bone marrow suppression, leading to leukopenia, thrombocytopenia, and anemia. Hepatotoxicity, including liver enzyme elevations, has also been reported. Severe myelosuppression and hepatotoxicity are considered major concerns","teratogenicity, hyperliidemic, hepatotoxicity",nsomnia. nightmares. dry mouth. skin more sensitive to sunlight than usual,".Major toxic effects include bone marrow suppression, hepatotoxicity, renal dysfunction, and gastrointestinal toxicity.",Hydroxyurea can cause severe interstitial pneumonitis.,"kidney damage, liver damage. And hypertension","Prolonged or excessive use may lead to skin atrophy, telangiectasia, and systemic effects if absorbed in large amounts.","Prolonged or high-dose use may lead to systemic effects such as Cushing's syndrome, adrenal suppression, and metabolic disturbances","Potential side effects include skin irritation, burning, itching, or rash at the application site.",Prolonged or excessive use may lead to local irritation. Systemic toxic effects are unlikely with proper topical application,"Local reactions like burning or itching at the application site are possible, but serious systemic toxic effects are rare","increase risk or various infection , fungal infection, tuberculosis","hepatoxicity, hyperlipidemia, hypertention",NA,hallucination,delirium hallucination,severe allergic reaction,respiratory depression,hallucination,no,allergic reaction,no,"rare,",neuroleptic malignant syndrome,neuroleptic malignant syndrome,rare,NA,NA,Itching,Hypoglycemia,Lipodystrophy,"Hypoglycemia,Hypokelmia",NA,"severe hypoglycemia, unconciousness
seizures","Sweating, anxiety, hunger","Hypoglycemia, weight loss, gastrointestinal effe-
cts","Trembling, hunger, nausea","Hypoglycemia, Hematological effects","Gall bladder and billiary tract dis-
order, Hypoglycemia","Infections, Hyper sensitivity reactions, Infusion reactions, Reversible lymphopenia.","Gastrointestinal tract, Hormonal effects,
Blood thining","Huypoglycemia, Allergic reactions","Huypoglycemia,Hypokalemia",NA,Brand name,Aralen,"Coarsucam, Flavoquine, Camoquin",Arterak,Lariam,Qualaquin,"Quinidex, Cardioquin",Proguanil,Daraprim,"Primacin-S,Primaquine,
Primaquine phosphate,
Malirid,
Primacin",Fansidar,Tagremin,"Vibramycin, Doryx, Monodox",Cleocin,Artesunate,"Coartem, Artenam, Artequick",allergic reactions or changes in liver function may occur.,"confusion, hallucinations, or allergic reactions may occur.","confusion, hallucinations, and cardiac arrhythmias.","confusion, hallucinations, or allergic reactions may occur.",cardiac arrhythmias and QT interval prolongation.,cardiac arrhythmias,"QT interval prolongation, ventricular arrhythmias, bradycardia",cortisol suppression.,"weight gain, and changes in cardiac rhythm (including QT prolongation).","dizziness, headache","nausea, vomiting, diarrhea",cardiac arrhythmia,"weight gain, metabolic disturbances (such as hyperglycemia and dyslipidemia), and cardiac effects (such as QT interval prolongation).","tremor, rigidity, and akathisia","allergic reactions, liver problems, and changes in heart rhythm.","Amikacin Sulfate Injection is potentially nephrotoxic, ototoxic and neurotoxic.","In case of suspected overdose, plazomicin therapy should be discontinued with initiation of supportive care. Maintenance of glomerular filtration and careful monitoring of renal function is recommended. Hemodialysis may be used to facilitate drug elimination, and this may be especially clinically useful in patients with compromised renal function",This may cause liver damage and irregular heart rhythm.,"Patients experiencing an overdose may present with hematuria, oliguria, abdominal pain, acute renal failure, vomiting, diarrhea, rash, hyperactivity, and drowsiness.",Cephalosporins have low toxicity and are generally safe.,"gastrointestinal symptoms, skin rashes, and, less frequently, allergic reactions.",anaphylaxis (a serious allergic reaction) or other serious skin reactions.,Toxicity increasing with time,"increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests,","potential toxicity is an allergic reaction, ranging from mild rashes to severe anaphylaxis. Additionally, high doses of penicillin may cause neurotoxicity, resulting in seizures or other neurological symptoms",Hepatotoxicity,Serious adverse reactions are rare but can include allergic reactions and severe skin conditions.,ciprofloxacin has been associated with an increased risk of tendinitis and tendon rupture,"effects are relatively uncommon but can include severe allergic reactions. If you experience symptoms such as rash, itching, swelling, severe dizziness, or difficulty breathing, it's crucial to seek immediate medical attention","adverse effects, especially in cases of overdose. Symptoms of overdose may include nausea, vomiting, abdominal discomfort, and hearing loss. In severe cases, it can lead to cardiovascular issues.","Rare, overdose may lead to toxicity.","Nausea, vomiting, arrhythmias in high doses","Palpitations, tremor, headache, nausea","Nausea, vomiting, arrhythmias in high doses","Dry mouth, blurred vision, urinary retention in high doses","Dry mouth, blurred vision, urinary retention in high doses",Generally well-tolerated; rare cases of neuropsychiatric events reported,Generally well-tolerated; rare cases of hepatotoxicity reported,"Generally well-tolerated, minimal toxicity","Generally well-tolerated, minimal toxicity",Risk of adrenal suppression with prolonged use,Risk of adrenal suppression with prolonged use,Adrenal suppression with prolonged use,Adrenal suppression with prolonged use,Adrenal suppression with prolonged use,"Gingival hyperplasia, hepatotoxicity","Agranulocytosis, Stevens-Johnson syndrome","Hepatotoxicity, pancreatitis","Serious skin reactions, including Stevens-Johnson syndrome",Generally well-tolerated; psychiatric and nervous system disorders reported in some cases,"Metabolic acidosis, kidney stones (rare)","Hyponatremia, hematologic effects","Respiratory depression, sedation","Hepatic toxicity, aplastic anemia (rare but serious)","Visual field defects (serious risk), neuropsychiatric effects","Central nervous system effects, potential for seizures if abruptly discontinued",Not specified,"Limited, generally well-tolerated","Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), metabolic acidosis","Dizziness, somnolence, peripheral edema","Symptoms include lethargy, slurred speech, ataxia, hypotension and arrhythmias.","milg nystagmus to ataxia , vomiting , lrthary , coma or death","Dizziness, somnolence, peripheral edema","Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), metabolic acidosis","Limited, generally well-tolerated",Not specified,"Central nervous system effects, potential for seizures if abruptly discontinued","Visual field defects (serious risk), neuropsychiatric effects","gastro intestinal disturbance , hematological effect","Hepatotoxicity, pancreatitis","Serious skin reactions, including Stevens-Johnson syndrome","Agranulocytosis, Stevens-Johnson syndrome",Generally well-tolerated; psychiatric and nervous system disorders reported in some cases,"respiratory depression , lead to coma ,","Hepatic toxicity, aplastic anemia (rare but serious)","Neuroleptic malignant syndrome, agranulocytosis","Cardiac toxicity, agranulocytosis","Neuroleptic malignant syndrome, Extrapyramidal symptoms","Neuroleptic malignant syndrome, extrapyramidal symptoms","Neuroleptic Malignant Syndrome, Extrapyramidal symptoms",Neuroleptic malignant syndrome,Agranulocytosis (monitoring required),"Neuroleptic malignant syndrome, QT prolongation","Neuroleptic malignant syndrome (NMS), tardive dyskinesia",Increased mortality in elderly patients with dementia-related psychosis,QT interval prolongation,QT interval prolongation,"QT prolongation, sedation",Not Available,Not available,ventricular arrhythmias,lupus erythematosus and hematologic disorders.,"proarrhythmia, which can exacerbate existing arrhythmias","Central nervous system (CNS) toxicity, seizures, and cardiovascular effects at high doses.","proarrhythmia, which is an increased risk of certain arrhythmias",proarrhythmia,bronchoconstriction,"cardiac arrhythmias, such as ventricular tachycardia or fibrillation, as well as gastrointestinal disturbances like nausea, vomiting, and diarrhea.","hypotension, bradycardia, heart block, and congestive heart failure","overdose include hypotension, bradycardia, heart block, and cardiac arrest","bradycardia, hypotension, heart failure exacerbation, bronchospasm, and hypoglycemia.","severe bradycardia, hypotension, heart block, and cardiac arrest.","hepatotoxicity, thyroid dysfunction and ocular toxicity","proarrhythmia, bradycardia, QT interval prolongation, and torsades de pointes","bradycardia, hypotension, heart block, and exacerbation of heart failure.","pneumonitis,dermatitis","hypertension,gastrointestinal perforation","Myelosuppression, nausea, vomiting, mucositis","Hepatotoxicity,hypertension",immune-related adverse events,"Hepatotoxicity,hypertension","Hypertension,hemorrhage","Hypertension, hepatotoxicity","Hand-foot skin reaction, hypertension","Fatigue,constipation",Hepatotoxicity,Immune-related adverse events,"Hepatotoxicity, hypertension","Hepatotoxicity, hypertension","Increased liver enzymes (AST, ALT)
Hyperphosphatemia
Fatigue",hepatotoxicity, cause lung complications,coughing up blood, severe nerve damage.,anemia,Reproductive and developmental toxicity,"  necrolysis, and drug reaction with eosinophilia and systemic symptoms"," , vomiting, diarrhea, gastrointestinal upset, nephrotoxicity, oral ulcers and bone marrow suppression."," damage to the bladder (haemorrhagic cystitis), immunosuppression (when not desired) and alopecia","Neurotoxicity,ototoxicity,nephrotoxicity","Mild thrombocytopenia, mucositis, nausea, alopecia, and emesis are common.","nausea, vomiting, diarrhea, alopecia, oral ulcers, bone marrow suppression, hypersensitivity reactions and rash",nausea and emesis,Gastrointestinal Effects,myelsosuppression,"vomiting, Headache","Constipation, Diarrhea","Vomiting , Dizziness","Trachycardia, Bradycardia","Fever, Sedation","Hallucinations, Flushing","Fever, Tremor, Dyspnea","Sedation,Fever","Alkalosis,Tetany","Hand tremors, Alkalosis",Constipation,"Pancreatitis, hepatotoxicity","Hematuria,Renal failure","Dyspepsia,Diarrhea","Seizures, Metallic taste","Heart attack, inflammation of blood vessels.","Hepatotoxicity, retinopathy,peripheral neuropathy","Pneumonitis, Myalgia, Hepatotoxicity","Bone marrow suppression, Fluid retention, Peripheral neuropathy",Skin cancer,"Mucosal ulcer, Loss of apetite","Interstitial lund disease, QT prolongation",peripheral neuropathy or constipation., interstitial lung disease or pneumonitis,"Anorexia, Fatigue,Mucocitosis",capillary leak syndrome,"interstitial lung disease (ILD), keratitis, LVEF/heart failure, hepatic failure, and pancreatitis."," your skin turns yellow, or the whites of your eyes turn yellow although this may be less obvious on brown or black skin. ","increase the risk of serious or life-threatening breathing problems, sedation, or coma ","Drowsinesss ,dry mouth, fast heart beat, headache,Tremor.","Propranolol, a ?-blocker (BB), is a medication that can be abused for the purpose of suicide.seizures and unconsciousness, cardiac shock, and potentially fatal outcomes."," nausea, vomiting, dizziness, drowsiness, miosis, and gastric distress."," dizziness, nausea, insomnia, abdominal pain, and dyspepsia (indigestion). ","increase the risk of serious or life-threatening breathing problems, sedation, or coma "," somnolence, respiratory depression, hypotension, bradycardia, and miosis. ","increased weight, diziness,blurred vission", an oral dose of 1 g of most barbiturates produces serious poisoning in an adult,"Lethargy, slurred speech, ataxia, respiratory depression, coma.","acute rage, stimulation, and excitement","airway compromise, cardiovascular collapse, coma, and death."," cardiac arrhythmias, prolonged somnolence and recovery, sneezing, coughing, bronchospasm, laryngospasm and shivering."," clammy extremities, bradycardia and a fall in the BP, disorientation, restlessness and incoherence of speech. ",Axert,Relpax,Amerge,Zomig,"Imitex, Sumavel DosePro, Sumavel,Alsuma, and Zembrace",Maxalt,frova,Cafergot and Ergomar,ARTEEMAX,Inderal LA,Periactin,Reyvow,"Aleve,Anaprox,Antslgin,Flanax,Inza",D.H.E. and Migranal,"Cafcit, Lucidex","phenergan,phenadoz",zyrtec,claritin,Allerga ODT,Benadryl,clarine &Aerius,Xyzal,Astepro & Astellin,Dimetapp,Tavist,Atarax,"Antivert,Bonine","Periactin,perriton,ciplactine","ebast,ebatin,ebatin fast",unisom,Daurismo,venclexta,Rydapat,Tasigna,Gleevec or Glivec,"Deltasone, Prednisone Intensol, Rayos",Busulfex,Sprycel.,"Decadron, DexPak",Vidaza.,"Cytosar-U, DepoCy",NA,Rituxan and MabThera.,Cerubidine.,Leukeran.,"Ascor, Citranatal B-calm Kit, Concept Ob, Ferralet 90, Hematogen, Infuvite, Infuvite Pediatric, Moviprep, Mvc-fluoride, Mvi Pediatric, Natafort, Plenvu, Pregvit, Vitafol-one","Animi-3 With Vitamin D, Citranatal B-calm Kit, Citranatal Harmony, Concept Ob, EnBrace HR, EnLyte, Ferralet 90, Folbic, Foltabs, Hematogen, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Magnebind 400 Rx, Mvc-fluoride, Mvi Pediatric, Natafort, Nicomide, Pregvit, Tandem Plus, Vitafol-one","EnBrace HR, EnLyte","Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one","Alertonic, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Natafort, Pregvit, Tandem Plus, Vitafol-one","Alertonic, Concept Ob, Fortaplex, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Mvc-fluoride, Mvi Pediatric, Natafort, Neo-bex, Pregvit, Tandem Plus, Vitafol-one",Alertonic,"Adrovance, Animi-3 With Vitamin D, Citranatal B-calm Kit, Citranatal Harmony, Fosamax Plus D, Fosavance, Infuvite, Infuvite Pediatric, Mvc-fluoride, Natafort, Pregvit, Vidextra","Concept Ob, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Mvi Pediatric","Concept Ob, Irospan 24/6 Kit, Pregvit, Tandem Plus",NA,NA,NA,"Aquamephyton, Infuvite, Infuvite Pediatric, Mephyton, Mvi Pediatric, Phytonadione","Mvc-fluoride, Vitafol-one",Brand name,Lotrimin,Monista,Diflucan,Tosura,Vfend,Posacon,S-Fulvin,Mentax,REZZAYO,Cancidas ,Terbinex,Butop,EXODERIL CREAM,NA,Grifulvin V,"Abdominal pain, yellowing of the skin or eyes, Dark urine.","Abdominal pain, Dark urine, yellowing of the skin or eyes and fatigue.","Rash, swelling, and nausea (rare)",Allergic reaction,Localised irritation,"headache, skin irritation, diarrhea, nausea, vomiting, abdominal pain, and dysgeusia","Skin irritation, Redness, Burning sensation","anorexia, fatigue, nausea, and jaundice","Liver problem, Visual disturbance, Skin irritation","Headache, Nausea, Diarrhea","Swelling, Severe itching or difficulty in breathing","Difficulty in breathing, Severe itching","Vomitting, Metabolic acidosis, Nausea and abdominal pain","Gastrointestinal upset, Rashes, Vomitting, Dizziness","Headache, Changes in liver, Change in electrolyte levels such as potassium and magnesium",Glimepiride,Glucotrol XL,Diamicron,Orinase,Diabinese,Tolinase,Dymelor,Gondafon,NA,NA,Glurenorm,Deamelin-S,NA,  Bimode SR (10 mg),  Afdiex (5 mg),NA,"Mucosta, Rebagen",NA,NA,NA,"Aciphex, Pariet","Fasigyn, Tindamax",Prevacid,NA,"Aciphex, Pariet",NA,NA,Tagamet,NA,Zantac,"Tums®, Alka-Seltzer® and Rolaids®",Tagamet,Alka-Seltzer Heartburn Relief.,"Amphojel®, AlternaGEL® , Alu-Cap®",Milk of Magnesia,"Kaopectate, Pepto Bismol, Maalox Total Relief.",Prilosec and Losec,Protonix®,Protonix®,Aciphex,NA,"Nexium [or Neksium,]","Albrights Solution, Bicitra",Metabolics,Gaviscon Regular Strength Tablets,"evista ,optruma",Saltomax(tamoxifen cirtate),Aredia,"Femara, Kisqali Femara Co-pack",Kisqu,NA,lynparza,fareston,"cytoxan,neosar",capivasertib,faslodex,NA,laximerpa,margenza,NA,"Various (e.g., Copegus, Rebetol, Virazole)",Sovaldi,"Epivir, Zeffix, Heptovir, Lamivir",Kaletra,Prezista,Veklury,"Avigan (Japan), Favilavir (China)",Famvir,Brand name,BiCNU,Gleostine,Afinitor,Avastin,Afinitor,Afinitor disperz,Matulane,Bevacizumab,welireg,BiCNU,Cytoxan,platinol,Carmustine,lomustine,Rheumatrex,Brand name,Vfend,NOXAFIL,mycamine,nizoral,sporanox,terazole,lamisil,mycostatin,monistat,spectazole,lotrimin,gynazole,eraxis,ambisome,Axert,Relpax,Amerge,Zomig,"Imitex, Sumavel DosePro, Sumavel,Alsuma, and Zembrace",Maxalt,frova,Cafergot and Ergomar,ARTEEMAX,Inderal LA,Periactin,Reyvow,"Aleve,Anaprox,Antslgin,Flanax,Inza",D.H.E. and Migranal,"Cafcit, Lucidex","phenergan,phenadoz",zyrtec,claritin,Allerga ODT,Benadryl,clarine &Aerius,Xyzal,Astepro & Astellin,Dimetapp,Tavist,Atarax,"Antivert,Bonine","Periactin,perriton,ciplactine","ebast,ebatin,ebatin fast",unisom,Daurismo,venclexta,Rydapat,Tasigna,Gleevec or Glivec,"Deltasone, Prednisone Intensol, Rayos",Busulfex,Sprycel.,"Decadron, DexPak",Vidaza.,"Cytosar-U, DepoCy",NA,Rituxan and MabThera.,Cerubidine.,Leukeran.,NA,Brand name,"Ascor, Citranatal B-calm Kit, Concept Ob, Ferralet 90, Hematogen, Infuvite, Infuvite Pediatric, Moviprep, Mvc-fluoride, Mvi Pediatric, Natafort, Plenvu, Pregvit, Vitafol-one","Animi-3 With Vitamin D, Citranatal B-calm Kit, Citranatal Harmony, Concept Ob, EnBrace HR, EnLyte, Ferralet 90, Folbic, Foltabs, Hematogen, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Magnebind 400 Rx, Mvc-fluoride, Mvi Pediatric, Natafort, Nicomide, Pregvit, Tandem Plus, Vitafol-one","EnBrace HR, EnLyte","Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one","Alertonic, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Natafort, Pregvit, Tandem Plus, Vitafol-one","Alertonic, Concept Ob, Fortaplex, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Mvc-fluoride, Mvi Pediatric, Natafort, Neo-bex, Pregvit, Tandem Plus, Vitafol-one",Alertonic,"Adrovance, Animi-3 With Vitamin D, Citranatal B-calm Kit, Citranatal Harmony, Fosamax Plus D, Fosavance, Infuvite, Infuvite Pediatric, Mvc-fluoride, Natafort, Pregvit, Vidextra","Concept Ob, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Mvi Pediatric","Concept Ob, Irospan 24/6 Kit, Pregvit, Tandem Plus",NA,NA,NA,"Aquamephyton, Infuvite, Infuvite Pediatric, Mephyton, Mvi Pediatric, Phytonadione","Mvc-fluoride, Vitafol-one",NA,NA,NA,NA,NA,Lotrimin,Monista,Diflucan,Tosura,Vfend,Posacon,S-Fulvin,Mentax,REZZAYO,Cancidas ,Terbinex,Butop,EXODERIL CREAM,NA,Grifulvin V,NA,Toxic effect (major),"Abdominal pain, yellowing of the skin or eyes, Dark urine.","Abdominal pain, Dark urine, yellowing of the skin or eyes and fatigue.","Rash, swelling, and nausea (rare)",Allergic reaction,Localised irritation,"headache, skin irritation, diarrhea, nausea, vomiting, abdominal pain, and dysgeusia","Skin irritation, Redness, Burning sensation","anorexia, fatigue, nausea, and jaundice","Liver problem, Visual disturbance, Skin irritation","Headache, Nausea, Diarrhea","Swelling, Severe itching or difficulty in breathing","Difficulty in breathing, Severe itching","Vomitting, Metabolic acidosis, Nausea and abdominal pain","Gastrointestinal upset, Rashes, Vomitting, Dizziness","Headache, Changes in liver, Change in electrolyte levels such as potassium and magnesium",Brand name,Glimepiride,Glucotrol XL,Diamicron,Orinase,Diabinese,Tolinase,Dymelor,Gondafon,NA,NA,Glurenorm,Deamelin-S,NA,  Bimode SR (10 mg),  Afdiex (5 mg),Brand name,NA,"Mucosta, Rebagen",NA,NA,NA,"Aciphex, Pariet","Fasigyn, Tindamax",Prevacid,NA,"Aciphex, Pariet",NA,NA,Tagamet,NA,Zantac,Brand name,"Tums®, Alka-Seltzer® and Rolaids®",Tagamet,Alka-Seltzer Heartburn Relief.,"Amphojel®, AlternaGEL® , Alu-Cap®",Milk of Magnesia,"Kaopectate, Pepto Bismol, Maalox Total Relief.",Prilosec and Losec,Protonix®,Protonix®,Aciphex,NA,"Nexium [or Neksium,]","Albrights Solution, Bicitra",Metabolics,Gaviscon Regular Strength Tablets,Brand name,"evista ,optruma",Saltomax(tamoxifen cirtate),Aredia,"Femara, Kisqali Femara Co-pack",Kisqu,NA,lynparza,fareston,"cytoxan,neosar",capivasertib,faslodex,NA,laximerpa,margenza,NA,"Various (e.g., Copegus, Rebetol, Virazole)",Sovaldi,"Epivir, Zeffix, Heptovir, Lamivir",Kaletra,Prezista,Veklury,"Avigan (Japan), Favilavir (China)",Famvir,Brand name,BiCNU,Gleostine,Afinitor,Avastin,Afinitor,Afinitor disperz,Matulane,Bevacizumab,welireg,BiCNU,Cytoxan,platinol,Carmustine,lomustine,Rheumatrex,Vfend,NOXAFIL,mycamine,nizoral,sporanox,terazole,lamisil,mycostatin,monistat,spectazole,lotrimin,gynazole,eraxis,ambisome,valium,Briviact,klonopin,Luminal,ZARONTIN,Vimpal,Dilantin,Ativan,mysoline,"TOPAMAX,TOPMAXSPRINKLE",Banzel,Diamox,gabitril,tegretol,Depakote,NA,tegretol,Depakote,Zyprexa,Lamictal,Ailify,Saphris,Vraylar,Geodon,Seroquel,Latuda,Risperdal,Pradaxa,savaysa,"Prolixin, Modecaste",Haldol,Binosto,Evista,Actonel,Bondronat,Aclasta,Conbriza,Clasteon,Etidronate disodium,Pamisol,Osseor,Forteo,Eladynos,Miacalcin,Prolia,Evenity,typically around 1 to 2 hours.,0.5-1 hour.,Approximately 1 to 2 hours.,Methotrexate has a Tmax of 1 to 2 hours.,Tmax is generally around 6 to 12 hours after administration.,Tmax for sulfasalazine is typically often reached around 2 to 6 hours after dosing.,Tmax of 1-2h,1.5 to 2 hours,~ 1-3 hours,3.3 hours (plasma Tmax 3.7 hours).,69 h.,Tmax of 1.0-2.6 hours,~3-7 hours,131 ± 56 hours ,approximately 4 to 7 days,NA,no toxic effects seen,"Mucositis,stomatitis, nausea,vomitting and diahhrea",patients treated with vismodegib have an increased risk of embryo-fetal death and significant birth defects.,"with higher doses like 800mg once daily effects were seen as elevated creatine phosphokinase(13%), increased lipase(5%), muscle spasm","fatigue, rash, diarrhea and musculoskeletal pain",this medicines may cause kidney failure,heart failure,NA,NA,NA,NA,NA,NA,NA,NA,Amoxil.,"Amoxil, Trimox, "," Biocef®, Daxbia®, Keflex®, Keftab®.",Ceftrisol Plus® and Rocephin®., Primaxin, Merrem IV.,CutisPharma's Firvanq,"Nuzyra,",Claforan,Mycozip T-80, Avelox (in some countries also Avalox),"azovex,Tazact, Biopiper TZ, Brodactam", Maxipime, Zoloft,"Gonitro, Minitran, Mylan-nitro, Nitro-bid","Bidil, Dilatrate, Isordil","Imdur, Ismo, Monoket",Cardorit,NA,"Hemangeol, Hemangiol, Inderal, Innopran","Kapspargo, Lopressor, Lopressor Hct, Toprol","Tenoretic, Tenormin","Calan, Isoptin, Tarka, Verelan","Cardizem, Cartia, Matzim, Taztia, Tiadylt, Tiazac","Amlobenz, Azor, Caduet, Dafiro",Ikorel,Adalat and Procardia,Plendil,"Aggrenox, Persantine",feeling sick (nausea) and diarrhoea.,"Nausea,vomiting and diarrhea,skin reaction","Diarrhea, abdominal pain,severe allergic reactions","Dizziness, nausea, mild and transient elevation in liver ezymes are rare","Rash, itching, swelling, difficult breathing, anaphylaxis","Nausea, headache and diarrhea","GI upset, headache, dizziness","Rash , pain at injection site, vomiting","Injection site reaction, central nervous systeam effect","Tooth discoloration, esophageal irritation",clostridium difficile-associated diarrhea,"Allergic raection, neurotoxicity, hematologic effect",Clostridium difficile-associated diarrhea (CDAD) and pseudomembranous colitis.,"Tendinitis and tendon rupture,promt discontinuation, pain","Ototoxicity, pre-existing hearing impairement",No,No,No,No,No,No,"Yes, food may affect the absorption of cimetidine, leading to reduced bioavailability when taken with food.","No, food does not significantly affect the absorption of famotidine.","No, food does not significantly affect the absorption of nizatidine.","No, food does not significantly affect the absorption of ranitidine.","No, food does not significantly affect the absorption of pirenzepine.",No,No,Food increases the absorption of misoprostol.,No,Relenza,Rapivab,Tamiflu,Ziagen,Zovirax,Valtrex, Xofluza, Vistide,Hepsera,Rukobia,Viread,"Agenerase, GlaxoSmithKline",Reyataz, Victrelis,Lamivudine/zidovudine,"Dilantin, Phenytek","Tegretol, Carbatrol, Epitol, others","Depakote, Depakene, Depacon, others",Lamictal,"Keppra, among others",Topamax,Trileptal,Onfi,Felbatol,Sabril,Gabitril,Banzel,Neurontin (commonly known),Zonegran,Lyrica,"Dilantin, Phenytek","Tegretol, Carbatrol, Epitol, others","Depakote, Depakene, Depacon, others",Lamictal,"Keppra, among others",Topamax,Trileptal,Onfi,Felbatol,Sabril,Gabitril,Banzel,Neurontin (commonly known),Zonegran,Lyrica
Side effects(major),"Insomnia, increased heart rate","Insomnia, decreased appetite, increased heart rate","Insomnia, decreased appetite, increased heart rate","Insomnia, appetite loss, increased heart rate","Headache, nausea, insomnia, anxiety","Headache, nausea, insomnia, anxiety","Palpitations, anxiety, tremor","Increased heart rate, hypertension, anxiety, paranoia","Jitters, gastrointestinal discomfort, increased heart rate","Nausea, headache, dizziness","Decreased appetite, insomnia, increased heart rate","Increased heart rate, hypertension, insomnia","Increased heart rate, hypertension, insomnia","Increased heart rate, hypertension, insomnia","Nausea, hypotension","Insomnia, dizziness, hallucinations","Headache, dyskinesia, insomnia, nausea","Insomnia, dizziness, nausea, hallucinations","Dyskinesias, nausea, diarrhea, orthostatic hypotension","Bradycardia, anorexia, weight loss, insomnia","Dry mouth, blurred vision, constipation","Nausea, dizziness, insomnia, constipation","Nausea, dizziness, dyskinesias","Common: Dyskinesia, falls, insomnia, nausea","Nausea, vomiting, dizziness, orthostatic hypotension","Nausea, dizziness, hypotension, etc.","Dyskinesia, constipation, hallucinations, dizziness, etc.","Dry mouth, constipation, urinary retention","Dyskinesia, diarrhea, orthostatic hypotension",References,https://www.pmda.go.jp/files/000229751.pdf,https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9185627.htm,"https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/nitrazepam#:~:text=NAT1%20is%20ubiquitously%20expressed%20and,88%20polymorphisms%20of%20NAT2%20recognized.",NA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014376/,https://go.drugbank.com/drugs/DB00418,https://go.drugbank.com/drugs/DB00962,"https://www.ncbi.nlm.nih.gov/books/NBK542306/#:~:text=Doxepin%20is%20a%20tricyclic%20antidepressant,beneficial%20in%20treating%20other%20disorders.",NA,https://go.drugbank.com/drugs/DB00237,https://pubchem.ncbi.nlm.nih.gov/compound/3393#section=Solubility,"https://www.ncbi.nlm.nih.gov/books/NBK470560/#:~:text=Trazodone%20is%20an%20FDA%2Dapproved,in%20patients%20with%20sleep%20problems.",https://pubchem.ncbi.nlm.nih.gov/compound/4616#section=Names-and-Identifiers,https://go.drugbank.com/drugs/DB00980,https://pubchem.ncbi.nlm.nih.gov/compound/24965990,"Nausea, vomiting, bone marrow suppression","Nausea, vomiting, mucositis","Thrombocytopenia, lymphopenia, anemia","Nausea, insomnia,","Neurotoxicity, hepatotoxicity, dermatologic reactions","Nausea, vomiting, hair loss","Neutropenia, diarrhea, fatigue","Neutropenia, anemia, vomiting","Neutropenia, anemia, alopecia","Neutropenia, anemia, alopecia","Hyperglycemia, hypertension, mood changes",Side effects(major),Local iritation,Local irritation,Gastrointestinal disturbances hepatotoxiccity,Gastrointestinal disturbances,"Gastrointestinal disturbances, hepatotoxic city",Gastrointestinal disturbances hepatotoxicity,Gastrointestinal disturbances,Gastrointestinal disturbances hepatotoxicity,Local skin reaction,Local skin infections,Local irritation,Gastrointestinal disturbances,Gastrointestinal disturbances,"Gastrointestinal disturbances,","Skin irritation, allergic reactions",Severe hypos,dizziness,High fever,"Flatulence,abdominal discomfort",NA,headache,diarrhea,Edema,nausea,low blood sugar,lipodystrophy,itching,hypoglycemia,NA,Side effects(major),"insomnia,nausea,sexual dsyfunction","insomnia,nausea,sexual dsyfunction","insomnia,nausea,sexual dsyfunction","insomnia,nausea","insomnia,nausea,dry mouth","insomnia,nausea,sexual dsyfunction","sedation,dry mouth","sedation , dry mouth","sedation , dry mouth","sedation , dry mouth","nausea , insomina",NA,NA,400 mg,450 mg,45mg,90 mg,450 mg,­,­,­,­,­,­,­,80 mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Major side effects of azathioprine include gastrointestinal symptoms such as nausea, vomiting, and abdominal discomfort. Immunosuppression may lead to an increased risk of infections. Skin reactions and allergic reactions have also been reported","drouiness, blurry vission, vomating, nausea","loss of appetite, sweating, dry mouth, blurred vision, headache, and constipation","Common side effects of Methotrexate include nausea, vomiting, mucositis, and myelosuppression (reduction in blood cell counts).Hepatotoxicity and renal dysfunction can occur, especially with high doses.","Black, tarry stools. Headache, drousness , pale skin","tremors, hypertrichosis, gastrointestinal issues","Potential side effects include skin irritation, burning, itching, or rash at the application site","Common side effects include skin atrophy, striae, and local reactions. Systemic side effects are more likely with prolonged use",NA,"Common side effects include skin irritation, dryness, and redness","Common side effects include skin irritation, redness, and a feeling of warmth at the application site.",redness swelling auto immunedisorder,"dryness of skin, lips, eyes, myalagia",NA,drowsiness,"dry mouth ,blurred vision",dry mouth,"sedation ,dry mouth",well toletrated,vwell tolerated,dry mouth,tolerated,"drowsiness,drymouth",sedation,extrapyramidal,headache,NA,NA,sevier hypos,"Low blood pottasium,
low blood sugar","low blood sugar,allergic reaction","Hypoglycemia, Hypok-
elmia, allergic reaction","Low blood sugar, body fat 
redistribution, itching, weight gain",Lipodystrophy,"Edema, hypoglycemia, weight gain
lipodystrophy","Headache,fatigue, diziness, allergic reactions","Hypoglycemia, hypersensitivity, weight gain,
lipodystrophy","Hypoglycemia,weight gain, liver problems",Gstrrointestinal disorder,"Dizziness, Fatigue, Diarrhea, constipation","Gastrointestinal tract disorder, 
allergic reaction","Itching, Hypokalemia","Weight gain, allergic reactiond",NA,Toxic effects(major),Retinopathy at high doses,Potential for hepatotoxicity,"Cardiotoxicity,Hepatotoxicity",Neurological symptoms,Cinchonism,Cinchonism,"Limited toxicity, primarily gastrointestinal",Potential for bone marrow suppression,NA,Hematologic toxicity,"leukopenia, thrombocytopenia, or hemolytic anemia,renal toxicity",Photosensitivity,"Gastrointestinal disturbances, Clostridium difficile-associated diarrhea",neurotoxicity,"Generally well-tolerated, but may cause neurotoxicity at high doses","headache, dizziness, constipation, diarrhea, and abdominal pain.","headache, dizziness, diarrhea, constipation, and drowsiness","headache, dizziness, diarrhea, constipation, and fatigue","headache, dizziness, diarrhea, constipation, and drowsiness","nausea, vomiting, and diarrhea","diarrhea, abdominal pain, and nausea","headache, dizziness, and gastrointestinal disturbances.","gastrointestinal disturbances, electrolyte imbalances","tremor, rigidity, and dystonia",QT interval prolongation,tendon rupture and QT interval prolongation.,"drowsiness, dry mouth, headache, gastrointestinal disturbances","drowsiness, dizziness",", blurred vision, dry mouth, constipation, weight gain","headache, dizziness, drowsiness, diarrhea, constipation, nausea, vomiting, and abdominal pain","Agitation, bloody or cloudy urine, bluish lips or skin, burning, crawling, itching, numbness, prickling, ""pins and needles"", or tingling feelings.
chills, coma, decrease in the amount of urine.
decreased urine output.","Blood in the urine, change in the frequency of urination or amount of urine.
difficulty in breathing, drowsiness, increased thirst, loss of appetite.
nausea, swelling of the feet or lower legs.","This medicine may increase the risk of serious heart or blood vessel problems. Call your doctor right away if you have blurred vision, chest pain, confusion, lightheadedness, dizziness, fainting, fast or irregular heartbeat, trouble breathing, or unusual tiredness or weakness",The most common side effects of amoxicillin are feeling sick (nausea) and diarrhoea.,"nausea, vomiting, lack of appetite, and abdominal pain.","Rash • Itchy skin • Swelling of the face, tongue or throat • Shortness of breath • Unusual bruising or bleeding.","nausea, vomiting, stomach pain, diarrhea;
rash;
swollen, black, or ""hairy"" tongue; or.
vaginal itching or discharge.","fever, chills, pale skin, pinpoint red or purple spots on the skin, sore throat, pain in the upper stomach, or yellow eyes or skin.","difficult breathing; swelling of your face, lips, tongue, or throat.","side effects of penicillin include nausea, vomiting, diarrhea, and allergic reactions such as rash or itching. Serious but rare side effects can include severe allergic reactions like anaphylaxis, which can be life-threatening.","Bluish lips or skin, chills, cold, clammy skin, fainting, fast heartbeat, fast, weak pulse, itching, skin rash, lightheadedness.","Common side effects of cephalexin can include gastrointestinal symptoms such as nausea, vomiting, or diarrhea. Allergic reactions, though rare, can also occur and may manifest as rash, itching, or swelling.","Common side effects of ciprofloxacin include gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain. Other potential side effects may include headache, dizziness, or rash. Serious but uncommon side effects can include tendon rupture, central nervous system effects, and Clostridium difficile-associated diarrhea.","nausea, diarrhea, headache, and fever. Serious allergic reactions are possible but rare.","Common side effects may include nausea, diarrhea, abdominal pain, and changes in taste. Less frequently, it can lead to more serious side effects such as liver problems or irregular heartbeats","Tremor, headache, increased heart rate","Insomnia, gastrointestinal disturbances","Tachycardia, nervousness, restlessness","Insomnia, gastrointestinal disturbances","Cough, headache, bronchitis-like symptoms","Dry mouth, constipation, throat irritation","Headache, abdominal pain, upper respiratory infection","Headache, abdominal pain, nausea","Mild, transient irritation (inhalation)","Mild, transient sedation (common)",Depends on dosage and duration of use,Depends on dosage and duration of use,Depends on dosage and duration of use,Depends on dosage and duration of use,Depends on dosage and duration of use,"Nausea, dizziness, ataxia, rash","Dizziness, drowsiness, nausea, rash","GI disturbances, weight gain, hair loss, tremor","Headache, dizziness, nausea, rash (common side effects)","Headache, dizziness, fatigue, and gastrointestinal disturbances","Dizziness, somnolence, cognitive dysfunction, weight loss","Dizziness, drowsiness, headache, nausea","Drowsiness, dizziness, headache, constipation","Nausea, vomiting, insomnia, dizziness, headache","Dizziness, drowsiness, fatigue, headache","Dizziness, drowsiness, nervousness, and tremor","Common side effects include dizziness, somnolence, nausea, and vomiting","Dizziness, drowsiness, peripheral edema, ataxia","Dizziness, somnolence, anorexia, weight loss, renal stones","Weight gain, blurred vision, headache","Dizziness, drowsiness, excitaion, headache, redness, loss of appetite","Nausea, dizziness, ataxia, rash","Weight gain, blurred vision, headache","Dizziness, somnolence, anorexia, weight loss, renal stones","Dizziness, drowsiness, peripheral edema, ataxia","Common side effects include dizziness, somnolence, nausea, and vomiting","Dizziness, drowsiness, nervousness, and tremor","Dizziness, drowsiness, fatigue, headache","leukopenia , thrombocytopenia , ataxia","GI disturbances, weight gain, hair loss, tremor","Headache, dizziness, nausea, rash (common side effects)","Dizziness, drowsiness, nausea, rash","Headache, dizziness, fatigue, and gastrointestinal disturbances","muscle weakness , dizziness , drowsiness","Nausea, vomiting, insomnia, dizziness, headache","Sedation, weight gain, orthostatic hypotension","Sedation, weight gain, blurred vision","Sedation, weight gain, blurred vision","Sedation, weight gain, orthostatic hypotension, blurred vision","Sedation, EPS, Hyperprolactinemia","Sedation, weight gain, extrapyramidal symptoms","Weight gain, sedation, hypersalivation","Weight gain, sedation, extrapyramidal symptoms","Weight gain, somnolence, akathisia, anxiety","Akathisia, weight gain, somnolence, agitation","Weight gain, sedation","Weight gain, sedation, dizziness","Weight gain, hyperlipidemia, EPS","Common: Extrapyramidal symptoms, akathisia, sedation","Sedation, somnolence, hypersensitivity reactions","its potential to cause gastrointestinal issues, such as nausea, vomiting, and diarrhea.","gastrointestinal disturbances, hypotension, and various arrhythmias.","anticholinergic effects, such as dry mouth, blurred vision, and constipation.","Allergic reactions, dizziness, and nausea are possible side effects.","dizziness, nausea, and tremor","dizziness, visual disturbances, and gastrointestinal upset.","flushing, chest pain or discomfort, dyspnea, headache, and palpitations.","bradycardia, visual disturbances (such as blurred or yellow-green halos around objects), confusion, and fatigue.","constipation, dizziness, headache, fatigue, and peripheral edema","peripheral edema, dizziness, headache, flushing, and constipation","fatigue, cold extremities, bradycardia, hypotension, depression, and impotence.","bradycardia, hypotension, bronchospasm, and heart failure exacerbation.","bradycardia, hypotension, QT prolongation, photosensitivity, and gastrointestinal disturbances.","not significantly affected by food intake, so there is typically no significant variability in its absorption when taken with or without food.","fatigue, dizziness, headache, and gastrointestinal disturbances.",decrased appetite,"fatigue,headache,gastrointestinal disturbance","Fatigue, fever, alopecia","fatigue,diarrhea,nausea","rash,fatigue,diarrhea","fatigue,diarrhea,nausea","Fatigue,nausea","Fatigue, diarrhea, decreased appetite","Fatigue, diarrhea, rash","dizziness, dysgeusia, increased weight","Fatigue, dizziness, increased liver enzymes","Fatigue, diarrhea, pneumonitis","Fatigue, diarrhea, hand-foot skin reaction","Fatigue, diarrhea, hand-foot skin reaction",NA,"nausea, vomiting, mucosal ulcers, and loss of appetite",Nausea and throwing up (vomiting),"bleeding gums.
blood in the urine.
blurred or double vision.
confusion.
coughing up blood.
cracked l","Decrease in red blood cells,nausea,vomitting","anemia, amenorrhea, impaired spermatogenesis, and increased risk of malignancy"," feeling like your tongue or throat are swelling, trouble breathing, rash, itching, fever,","Cough.
, bleeding.
Constipation, diarrhea, nausea, vomiting.
Loss of appetite.","nausea, vomiting, mucosal ulcers, and loss of appetite","loss of appetite or weight.
abdominal pain.
diarrhea.
hair loss.
sores on the mouth or tongue.
changes in skin color","Neurotoxicity,ototoxicity,nephrotoxicity","Increased risk of getting an infection, tiredness,weakness,bleeding gums,breathlessness","unexpected bleeding or bruising,blood in your urine or stool,extreme tiredness,fever","Confusion,convulsion,hallucination,missing menstrual period,shortness of breath,tiredness or weakness","dizziness, weakness, depression, nervousness, confusion, chest pain, stomach pain, back pain, muscle pain, colored urine, and other less common effects.",dizziness,"Nausea, Abdominal pain",Abdominal pain Constipation,"Nausea, Vomiting , Dizziness","Fatigue, Mucle pain","Headache, Nausea","Dry mouth, Constipation","Flatulence , Diarrhea","Nausea, Headache","Bloating gas, Swelling","Vomiting, Confusion","Dry mouth, Nausence","Pain,Muscle pain","skin rashes, anaphylaxis","Nausea,Vomiting","Constipation,Swelling","Burning, Numbness, Tingling, or Painful sensations","Black tarry stools, blood in urine or stools","Myalgia, Anemia","Neuropathy, Fluid retention","Decreased appetite, Nausea, Vomitting","Pain full urination, liver problems","Double vision, decreased appetite,fast heart beat","Numbness, Exhaution","burning, crawling, itching, numbness, prickling, ""pins and needles"", or tingling feelings.","Skin Rash, Diarrhea.","Black tarry stools, Bleeding Gums","Bloody or cloudy urine.
burning, dry, or itching eyes.
diarrhea.","Drowsiness, dizziness, tiredness, blurred vision, or unsteadiness","drowsiness, ataxia, nystagmus, slurred speech, memory loss, disorientation, difficulty concentrating, nausea, etc.","Chest pain, tightness,fainting,itching, skin rashes, trouble breathing.","Dirrarhea, dizziness, congestion, cough ,bodyache, stomach cramp.","dizziness , nausea,headache.","spinning sen sation,lightheadness","changes in appetite, nausea, tiredness.","constipoation,sleppy,dry mouth,erection problems.","beign forgetdull, sad or empty","Signs of depression, thoughts of suicide, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.","Dizziness, drowsiness, excitation, headache, tiredness, loss of appetite, nausea, or vomiting ","severe drowsiness, dizziness, confusion, clumsiness, or unsteadiness","weak or shallow breathing; slow heart rate, weak pulse; or. a light-headed feeling, ","weak and shallow breathing,slow heartbeats"," serotonin syndrome, bleeding, and suicidal thoughts and behaviors.","chest tightness, pain, or pressure","chest tightness, pain or pressure","tightness, pain, pressure, or heaviness in the chest, throat, neck","pain, tightness, pressure or heaviness in the chest ,throat , neck","Sweating, transient hypertension, tachycardia, fatigue","tightness, pain, pressure, or heaviness in chest, throat","coronary artery vasospasm, cardiac arrest, and myocardial infraction","drowsiness, vomiting,pounding in your neck","Hives, confusion, fever, seizures","seizures and loss of consciousness , cardiac shock, even death","somnolence,excitation, hallucinations, ataxia, tachycardiac","dizziness, impaired balance, somnolence, fatigue, sedation","blurred vision, headache, heartburn, rash","nausea, ischemia, headache,rarely","hypertention, hypotension, bradycardia","sedation,disorientation","headache,dry mouth","rapid heart rate,headache",coughing,respiratory failure,"fatige,sore throat","cough,fever","nasal pain,cold symptoms","dizziness,upset stomach","confusion,respiratory depression","confusion,seizures","drawziness,dry mouth",confusion,headache,seizures,anemia,"Potential toxic effects include gastrointestinal disturbances, hepatotoxicity,","Potential toxic effects include gastrointestinal disturbances, myelosuppression (neutropenia, thrombocytopenia), QT interval prolongation, and increased risk of infections.","Potential toxic effects include myelosuppression (neutropenia, thrombocytopenia), hepatotoxicity, QT interval prolongation, pancreatitis, and cardiovascular events.","Myelosuppression, hepatotoxicity, cardiotoxicity","Prednisone can have various adverse effects, including immunosuppression, gastrointestinal disturbances, osteoporosis, psychiatric effects, and others.","Busulfan is associated with various toxic effects, including myelosuppression (bone marrow suppression), gastrointestinal toxicity, pulmonary toxicity, and others.","Dasatinib can cause various toxic effects, including myelosuppression, fluid retention, cardiovascular events, pulmonary arterial hypertension, gastrointestinal disturbances, and others.","Dexamethasone can cause various adverse effects, including immunosuppression, hyperglycemia, osteoporosis, gastrointestinal disturbances, psychiatric effects, and others.","Common toxic effects of azacitidine include myelosuppression (bone marrow suppression), gastrointestinal disturbances, fatigue, injection site reactions, and others.","Common toxic effects of cytarabine include myelosuppression (bone marrow suppression), gastrointestinal disturbances, hepatotoxicity, neurotoxicity, and others.","Common toxic effects of nelarabine include myelosuppression (bone marrow suppression), neurotoxicity, hepatotoxicity, gastrointestinal disturbances, and others.","Rituximab can cause infusion-related reactions, including fever, chills, nausea, vomiting, headache, rash, and others.","Common toxic effects of daunorubicin include myelosuppression (bone marrow suppression), cardiotoxicity (including cardiomyopathy and arrhythmias), gastrointestinal disturbances, and others.","Common toxic effects of chlorambucil include myelosuppression (bone marrow suppression), gastrointestinal disturbances, hepatotoxicity, and increased risk of infections.","High doses may cause gastrointestinal upset, diarrhea, and can potentially lead to kidney stones in susceptible individuals.","Excessive folate intake from supplements can mask vitamin B12 deficiency, leading to neurological damage.","Generally considered safe in high doses, but extremely high doses might cause acne or skin reactions.","High doses can lead to flushing, itching, liver damage, and in rare cases, can cause gout.",No known major toxic effects from high dietary intake; excess is typically excreted in the urine.,No known major toxic effects from high dietary intake; excess is typically excreted in the urine.,"High doses may cause fishy body odor, low blood pressure, and gastrointestinal distress.","Excessive intake can lead to hypercalcemia, causing nausea, vomiting, weakness, and in severe cases, organ damage.",No known major toxic effects from high dietary intake; excess is typically excreted in the urine.,No known major toxic effects from high dietary intake; excess is typically excreted in the urine.,"Generally considered safe, but excessive intake may cause yellowing of the skin (carotenodermia).","No well-established major toxic effects, but excessive intake may cause skin pigmentation.","High doses may cause gastrointestinal issues, and its long-term safety is not well-established.",No known major toxic effects from high dietary intake; excess is typically excreted in the urine.,High doses may interfere with blood clotting and increase the risk of bleeding.,Toxic effects(major),Allergic reaction,Hepatotoxicity,Skin reactions,Cardiac effects,Cardiotoxicity,Renal Toxicity,Bone Marrow Suppression,Allergic reactions,Hepatotoxicity,Electrolyte abnormalities,liver toxicity,swelling of the face or throat,Allergic reaction,NA,Liver cancer,"Nausea, Skin rashes, Headache","Nausea, Vomiting, headache","Itching, Upper stomach pain, dark urine","Local irritation, itching, burning","Skin irritation, Itching or redness","Headache, Urinating more than usual, Diarrhea","Pruritus, burning, irritation, erythema, stinging and allergic contact dermatitis and folliculitis, fissuring","Nausea, Vomitting, Abdominal pain, headache","Diarrhea, Dizziness, Nausea, Hallucinations","Abdominal pain, Change in taste or loss of taste","Skin irritation, Burning sensation, itching","Mild redness, Itching, burning sensation","Skin irritation, Respiratory irritation,Eye irritation","Change in taste, Manifest as rash","Liver problem, Change in heart rhythm, Leading to elevated liver enzymes","hypoglycemia (low blood sugar), nausea, and allergic reactions.",the major concern is hypoglycemia.,"Hypoglycemia is a primary side effect, and it may be severe in some cases.","Hypoglycemia is a significant risk, and the drug may cause allergic skin reactions.","Can cause a disulfiram-like reaction with alcohol, leading to nausea and flushing.",Hypoglycemia,hypoglycemia,Information on major toxic effects is limited,Hypoglycemia,Hypoglycemia,Hypoglycemia,Hypoglycemia,Hypoglycemia,Hypoglycemia,Hypoglycemia,liver toxicity,"nausea, vomiting, diarrhea), headache, dizziness, and rash.",NA,NA,NA,"Risk of hypomagnesemia, increased risk of bone fractures with long-term use","Potential for neurotoxicity, gastrointestinal disturbances, and hypersensitivity reactions","Potential for increased risk of infections, bone fractures, and hypomagnesemia with long-term use","Potential for gastrointestinal disturbances, hepatotoxicity,photosensitivity, and allergic reactions","Potential for increased risk of infections, bone fractures , and hypomagnesemia with long-term use","metabolic alkalosis, electrolyte disturbances (e.g., hypernatremia), and fluid overload.","Potential adverse e
ffects include gastrointestinal disturbances such as diarrhea, abdominal pain, and nausea. In rare cases, uterine hyperstimulation and rupture can occur, particularly when misoprostol is used for obstetric indications.","Potential for central nervous system effects, gynecomastia, and drug interactions due to its inhibition of cytochrome P450 enzymes","metabolic alkalosis, hypernatremia, and electrolyte imbalances.","NDMA ,contamination, which can potentially lead to adverse effects including cancer.","Hypercalcemia,Constipation,Gas and Bloating,kidney stones","diarrhea, & In cases liver toxicity or blood disorders.",cardiac arrhythmias or seizur,"bone pain, muscle weakness, confusion, and seizures","diarrhea, abdominal discomfort,","nausea, vomiting, abdominal pain, confusion,","vomiting,stomach pain.","diarrhea, and abdominal pain.",liver damage or allergic reaction,"diarrhea,liver problems or allergic reactions.","nausea,diarrhea","headache, abdominal pain.","nausea, vomiting,",gastrointestinal irritation and potential respiratory,gastrointestinal disturbances such as diarrhea or constipation,"vomiting,rash,dizziness,cramps","Skeletal building blocakages,respiratory difficulty",Hypocalcemia,NA,infection,potential neutropenia,myelodysplastic syndrom,hepatotoxicity,bone marrow suppression,potrntial,potential,low red bone marrow,potential for neurotoxicity,NA,NA,"Hemolytic anemia, teratogenicity","Fatigue, headache, nausea, insomnia",Peripheral neuropathy (rare),"Hyperlipidemia, hepatotoxicity, gastrointestinal symptoms","Rash, hepatotoxicity, gastrointestinal symptoms","Increased liver enzymes, hypersensitivity reactions","Teratogenicity (in animal studies), QT prolongation","Generally well-tolerated, headache, nausea, diarrhea",Toxic effects(major),"Bone marrow suppression,Pulmonary toxicity",pulmonary toxicity,Immunosuppression,hypertension (high blood pressure),Metabolic effects,Renal toxicity,myelosuppression,hypertension,headache,pulmonary toxicity,nausea & vomiting,Nephrotoxicity,CNS toxicity,Renal toxicity,Gastrointestinal toxicity,Toxic effects(major),hepatotoxicity,hepatotoxicity,hepatic reactions,hepatotoxicity,hepatotoxicity,local irritation,hepatotoxicity,local irritation,rarely,local irritation,allergic reactions,itching,rash flushing,fever,"chest tightness, pain, or pressure","chest tightness, pain or pressure","tightness, pain, pressure, or heaviness in the chest, throat, neck","pain, tightness, pressure or heaviness in the chest ,throat , neck","Sweating, transient hypertension, tachycardia, fatigue","tightness, pain, pressure, or heaviness in chest, throat","coronary artery vasospasm, cardiac arrest, and myocardial infraction","drowsiness, vomiting,pounding in your neck","Hives, confusion, fever, seizures","seizures and loss of consciousness , cardiac shock, even death","somnolence,excitation, hallucinations, ataxia, tachycardiac","dizziness, impaired balance, somnolence, fatigue, sedation","blurred vision, headache, heartburn, rash","nausea, ischemia, headache,rarely","hypertention, hypotension, bradycardia","sedation,disorientation","headache,dry mouth","rapid heart rate,headache",coughing,respiratory failure,"fatige,sore throat","cough,fever","nasal pain,cold symptoms","dizziness,upset stomach","confusion,respiratory depression","confusion,seizures","drawziness,dry mouth",confusion,headache,seizures,anemia,"Potential toxic effects include gastrointestinal disturbances, hepatotoxicity,","Potential toxic effects include gastrointestinal disturbances, myelosuppression (neutropenia, thrombocytopenia), QT interval prolongation, and increased risk of infections.","Potential toxic effects include myelosuppression (neutropenia, thrombocytopenia), hepatotoxicity, QT interval prolongation, pancreatitis, and cardiovascular events.","Myelosuppression, hepatotoxicity, cardiotoxicity","Prednisone can have various adverse effects, including immunosuppression, gastrointestinal disturbances, osteoporosis, psychiatric effects, and others.","Busulfan is associated with various toxic effects, including myelosuppression (bone marrow suppression), gastrointestinal toxicity, pulmonary toxicity, and others.","Dasatinib can cause various toxic effects, including myelosuppression, fluid retention, cardiovascular events, pulmonary arterial hypertension, gastrointestinal disturbances, and others.","Dexamethasone can cause various adverse effects, including immunosuppression, hyperglycemia, osteoporosis, gastrointestinal disturbances, psychiatric effects, and others.","Common toxic effects of azacitidine include myelosuppression (bone marrow suppression), gastrointestinal disturbances, fatigue, injection site reactions, and others.","Common toxic effects of cytarabine include myelosuppression (bone marrow suppression), gastrointestinal disturbances, hepatotoxicity, neurotoxicity, and others.","Common toxic effects of nelarabine include myelosuppression (bone marrow suppression), neurotoxicity, hepatotoxicity, gastrointestinal disturbances, and others.","Rituximab can cause infusion-related reactions, including fever, chills, nausea, vomiting, headache, rash, and others.","Common toxic effects of daunorubicin include myelosuppression (bone marrow suppression), cardiotoxicity (including cardiomyopathy and arrhythmias), gastrointestinal disturbances, and others.","Common toxic effects of chlorambucil include myelosuppression (bone marrow suppression), gastrointestinal disturbances, hepatotoxicity, and increased risk of infections.",NA,Toxic effects(major),"High doses may cause gastrointestinal upset, diarrhea, and can potentially lead to kidney stones in susceptible individuals.","Excessive folate intake from supplements can mask vitamin B12 deficiency, leading to neurological damage.","Generally considered safe in high doses, but extremely high doses might cause acne or skin reactions.","High doses can lead to flushing, itching, liver damage, and in rare cases, can cause gout.",No known major toxic effects from high dietary intake; excess is typically excreted in the urine.,No known major toxic effects from high dietary intake; excess is typically excreted in the urine.,"High doses may cause fishy body odor, low blood pressure, and gastrointestinal distress.","Excessive intake can lead to hypercalcemia, causing nausea, vomiting, weakness, and in severe cases, organ damage.",No known major toxic effects from high dietary intake; excess is typically excreted in the urine.,No known major toxic effects from high dietary intake; excess is typically excreted in the urine.,"Generally considered safe, but excessive intake may cause yellowing of the skin (carotenodermia).","No well-established major toxic effects, but excessive intake may cause skin pigmentation.","High doses may cause gastrointestinal issues, and its long-term safety is not well-established.",No known major toxic effects from high dietary intake; excess is typically excreted in the urine.,High doses may interfere with blood clotting and increase the risk of bleeding.,NA,NA,NA,NA,NA,Allergic reaction,Hepatotoxicity,Skin reactions,Cardiac effects,Cardiotoxicity,Renal Toxicity,Bone Marrow Suppression,Allergic reactions,Hepatotoxicity,Electrolyte abnormalities,liver toxicity,swelling of the face or throat,Allergic reaction,NA,Liver cancer,NA,Side effect (major),"Nausea, Skin rashes, Headache","Nausea, Vomiting, headache","Itching, Upper stomach pain, dark urine","Local irritation, itching, burning","Skin irritation, Itching or redness","Headache, Urinating more than usual, Diarrhea","Pruritus, burning, irritation, erythema, stinging and allergic contact dermatitis and folliculitis, fissuring","Nausea, Vomitting, Abdominal pain, headache","Diarrhea, Dizziness, Nausea, Hallucinations","Abdominal pain, Change in taste or loss of taste","Skin irritation, Burning sensation, itching","Mild redness, Itching, burning sensation","Skin irritation, Respiratory irritation,Eye irritation","Change in taste, Manifest as rash","Liver problem, Change in heart rhythm, Leading to elevated liver enzymes",Toxic effects(major),"hypoglycemia (low blood sugar), nausea, and allergic reactions.",the major concern is hypoglycemia.,"Hypoglycemia is a primary side effect, and it may be severe in some cases.","Hypoglycemia is a significant risk, and the drug may cause allergic skin reactions.","Can cause a disulfiram-like reaction with alcohol, leading to nausea and flushing.",Hypoglycemia,hypoglycemia,Information on major toxic effects is limited,Hypoglycemia,Hypoglycemia,Hypoglycemia,Hypoglycemia,Hypoglycemia,Hypoglycemia,Hypoglycemia,Toxic effects(major),liver toxicity,"nausea, vomiting, diarrhea), headache, dizziness, and rash.",NA,NA,NA,"Risk of hypomagnesemia, increased risk of bone fractures with long-term use","Potential for neurotoxicity, gastrointestinal disturbances, and hypersensitivity reactions","Potential for increased risk of infections, bone fractures, and hypomagnesemia with long-term use","Potential for gastrointestinal disturbances, hepatotoxicity,photosensitivity, and allergic reactions","Potential for increased risk of infections, bone fractures , and hypomagnesemia with long-term use","metabolic alkalosis, electrolyte disturbances (e.g., hypernatremia), and fluid overload.","Potential adverse e
ffects include gastrointestinal disturbances such as diarrhea, abdominal pain, and nausea. In rare cases, uterine hyperstimulation and rupture can occur, particularly when misoprostol is used for obstetric indications.","Potential for central nervous system effects, gynecomastia, and drug interactions due to its inhibition of cytochrome P450 enzymes","metabolic alkalosis, hypernatremia, and electrolyte imbalances.","NDMA ,contamination, which can potentially lead to adverse effects including cancer.",Toxic effects(major),"Hypercalcemia,Constipation,Gas and Bloating,kidney stones","diarrhea, & In cases liver toxicity or blood disorders.",cardiac arrhythmias or seizur,"bone pain, muscle weakness, confusion, and seizures","diarrhea, abdominal discomfort,","nausea, vomiting, abdominal pain, confusion,","vomiting,stomach pain.","diarrhea, and abdominal pain.",liver damage or allergic reaction,"diarrhea,liver problems or allergic reactions.","nausea,diarrhea","headache, abdominal pain.","nausea, vomiting,",gastrointestinal irritation and potential respiratory,gastrointestinal disturbances such as diarrhea or constipation,Toxic effects(major),"vomiting,rash,dizziness,cramps","Skeletal building blocakages,respiratory difficulty",Hypocalcemia,NA,infection,potential neutropenia,myelodysplastic syndrom,hepatotoxicity,bone marrow suppression,potrntial,potential,low red bone marrow,potential for neurotoxicity,NA,NA,"Hemolytic anemia, teratogenicity","Fatigue, headache, nausea, insomnia",Peripheral neuropathy (rare),"Hyperlipidemia, hepatotoxicity, gastrointestinal symptoms","Rash, hepatotoxicity, gastrointestinal symptoms","Increased liver enzymes, hypersensitivity reactions","Teratogenicity (in animal studies), QT prolongation","Generally well-tolerated, headache, nausea, diarrhea",Toxic effects(major),"Bone marrow suppression,Pulmonary toxicity",pulmonary toxicity,Immunosuppression,hypertension (high blood pressure),Metabolic effects,Renal toxicity,myelosuppression,hypertension,headache,pulmonary toxicity,nausea & vomiting,Nephrotoxicity,CNS toxicity,Renal toxicity,Gastrointestinal toxicity,hepatotoxicity,hepatotoxicity,hepatic reactions,hepatotoxicity,hepatotoxicity,local irritation,hepatotoxicity,local irritation,rarely,local irritation,allergic reactions,itching,rash flushing,fever,respiratory depression,"sedation, depression, anxiety",respiratory depression,Respiratory depression,NA,"Dizziness, Nausea, Headache","ginigival hyperplasia, hypotension","coma, depression, hypotension","sedation, hyperplasia","kidney stones, acidosis, impairment","coma, depression","metabolic acidosis, paresthesis","come, death, impairment","one marrow sppersion, hepato toxicity","hepatotoxicity, pencreatits",NA,"one marrow sppersion, hepato toxicity","hepatotoxicity, pencreatits","Neuroleptic malignat syndrome, QT interval prolongation","stevens-Johnson syndrome, aseptic, meningitic",neurolrptic malignant syndrome,QT interval prolongation,QT interval prolongation,QT interval prolongation,"Neurolrptic maligant syndrome, QT interval prolongation",QT interval prolongation,"Neuroleptic, malignant syndrome","Bleeding, gastrointestinal issues, hematoma, thrombocytopenia.",Bleeding,"Neuroplasti syndrome, QT prolongation","neuroplastic, maligant syndrome","Osteonecrosis of the jaw, esophageal Irritation",Venous Thromboembolism,"Osteonecrosis of the jaw, Esophageal Irritation","osteonecrosis of the jaw, esophageal irritation.","Osteonecrosis of the jaw, renal impairment.",thromboembolic events and an increased risk of stroke.,renal impairment and hypocalcemia,"hypocalcemia, renal impairment","renal impairment, hypocalcemia, and osteonecrosis of the jaw",myocardial infarction (heart attack).deep vein thrombosis and pulmonary embolism,"Osteosarcoma risk, hypercalcemia","Osteosarcoma risk, hypercalcemia",Hypersenstivity reaction,"Osteonecrosis of the jaw, hypocalcemia","Hypocalcemia, hypersensitivity reactions",Baricitinib is predominantly excreted via renal elimination. Approx 75% was eliminated in urine and 20% beng unchanged,30% renally eliminated as unchanged drug.,About 43% of the total dose was excreted in the urine where 24% of that dose was in the unchanged parent drug form.,Methotrexate is >80% excreted as the unchanged drug and approximately 3% as the 7-hydroxylated metabolite.,The active metabolite is eliminated by further metabolism and subsequent renal excretion as well as by direct biliary excretion.,Absorbed sulfapyridine and 5-aminosalicylic acid and their metabolites are primarily eliminated in the urine either as free metabolites or as glucuronide conjugates. ,Azathioprine and its metabolites are eliminated from the body through both renal and non-renal pathways.,Cyclosporine excretion is primarily biliary with only 3-6% of the dose (including the parent drug and metabolites) excreted in the urine.,Renal and hepatic,Renal and hepatic,Renal Excretion: Minor Hepatic Excretion: Minor,Prednisolone is over 98% eliminated in urine.,Anakinra is mostly excreted by the kidney,Adalimumab is most likely removed by opsonization via the reticuloendothelial system.,primarily eliminated from the body via proteolytic degradation and clearance mechanisms,NA,"redness, swelling, itching, burning, pain/tenderness, thickening/hardening of skin","Pain or burning sensation, photosensitivity,peeling and crusting, erythema","muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation","headache,itching skin, diarrhea","afeecting organs like lungs, liver, and colon","confusion, chills, drowsiness","nausea,vomitting,diarrhea and abdominal pain","nausea, vomitting, diarrhea, fatigue","Fever, diarrhea, rash, sensitivity to light","diarrhes, bleeding on probing, chills, dry skin","Allergic reaction, damage to liver, increased risk of sunburn","itching, headache , rash","itching,burning of skin,back or bone pain","cough, constipation",NA,Penicillin possesses minimal direct toxicity.," In higher-dose cases, it may lead to kidney failure.","blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting",Parenteral administration of ceftriaxone has been associated with development of biliary sludge in 3% to 46% of patients., inactivated by metabolism in the kidney to products that are potentially toxic to renal tubules,Serious skin reactions can occur with this medicine. ,Red Man Syndrome,"neuropathy and neuromuscular blockade to confusion, non-specific encephalopathy, "," convulsions, dyspnea, hypothermia, cyanosis, reversible encephalopathy, and death."," induces signs of iono- phore toxicity by blocking the metabolism of narasin,",moxifloxacin is directly toxic to retinal vascular cells at high doses., toxic side effects of piperacillin-tazobactam and how they may be more frequent at lower dosages ,"Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal.","Ceftaroline is a well-tolerated antibiotic whose side effect profile includes rash, diarrhea, constipation, nausea",methemoglobinemia or rebound angina.,methemoglobinemia or rebound angina.,"hypotension, headaches, and reflex tachycardia","headache, dizziness, and hypotension","headache, dizziness, and hypotension","bradycardia (slow heart rate), hypotension (low blood pressure), heart failure","bradycardia (slow heart rate), hypotension (low blood pressure), and other cardiovascular symptoms","Bradycardia , hypo tension, bronchospasm","hypotension, bradycardia, and cardiac conduction abnormalities","Bradycardia , hypertension",hypotension (low blood pressure) and peripheral edema,"severe hypotension, gastrointestinal ulcerations","severe hypotension, reflex tachycardia, cardiac arrest","lowering of blood pressure, leading to symptoms like dizziness or fainting","gastrointestinal symptoms, headache, and dizziness",No significant variability,No significant variability,No significant variability,No significant variability,No significant variability,NA,No,No,No,No,No,No,No,No,No,"20-40 mg,","40 mg,","30 mg,","20-40 mg,","20-40 mg,","~60 mg,",~800 mg,~40 mg,usually 300 mg twice daily or 600 mg daily,"usually 300 mg twice daily or 600 mg daily,",usually 100 mg,"usually around 120 mg,",around 40 mg,maximum recommended daily dose varies depending on the indication and formulation,maximum recommended daily dose varies depending on the indication and patient factors.,"Zanamivir may cause people 
with lung disease (e.g., chronic obstructive lung disease or asthma) to have shortness of breath, trouble breathing, or wheezing"," hypersensitivity reactions, anaphylaxis, 
Stevens Johnson syndrome and acute delirium and hallucination","Serious skin reactions can occur
with this medicine","stomach discomfort or cramping, dark urine, 
decreased appetite, diarrhea, general feeling of discomfort, light-colored stools, muscle cramping or pain, nausea, unusual tiredness or weakness, trouble breathing, vomiting","Rash,nausea,hair loss,drowsiness,
itching","Headache,depression,cramps,abdominal
pain,confusions,dizziness,nausea,rash","diarrhea,vomitng,headache"," increased serum creatinine, 
proteinuria, and tubular dysfunction","extreme tiredness, weakness, nausea, 
vomiting, loss of appetite, yellowing of the skin or eyes, dark-colored urine, light-colored bowel movements, and muscle or joint pain. Adefovir may cause kidney damage","Fostemsavir can cause serious 
side effects. These include heart rhythm problems and liver problems","Tenofovir can cause serious,
life-threatening side effects. These include a buildup of lactic acid in the blood (lactic acidosis), liver problems, and new or worsening kidney problems, including kidney failure","The adverse effects of amprenavir 
in patients treated with combination therapy included nausea, vomiting, diarrhea, epigastric pain, flatulence, paresthesia, headache, rash, and fatigue","Atazanavir can cause serious, life-threatening 
side effects. These include changes in heart rhythm, severe skin rash and allergic reactions, liver problems, and drug interactions","The main toxicities attributed to 
boceprevir include anemia and dysgeusia","Combivir can cause serious, life-threatening side effects. These include a buildup of lactic acid in the blood (lactic acidosis), liver problems, muscle disease (myopathy), and blood disorders such as a very low number of red blood cells (severe anemia) or lower than normal number of white blood cells (neutropenia)","Gingival hyperplasia, hepatotoxicity","Agranulocytosis, Stevens-Johnson syndrome","Hepatotoxicity, pancreatitis","Serious skin reactions, including Stevens-Johnson syndrome",Generally well-tolerated; psychiatric and nervous system disorders reported in some cases,"Metabolic acidosis, kidney stones (rare)","Hyponatremia, hematologic effects","Respiratory depression, sedation","Hepatic toxicity, aplastic anemia (rare but serious)","Visual field defects (serious risk), neuropsychiatric effects","Central nervous system effects, potential for seizures if abruptly discontinued",Not specified,"Limited, generally well-tolerated","Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), metabolic acidosis","Dizziness, somnolence, peripheral edema","Gingival hyperplasia, hepatotoxicity","Agranulocytosis, Stevens-Johnson syndrome","Hepatotoxicity, pancreatitis","Serious skin reactions, including Stevens-Johnson syndrome",Generally well-tolerated; psychiatric and nervous system disorders reported in some cases,"Metabolic acidosis, kidney stones (rare)","Hyponatremia, hematologic effects","Respiratory depression, sedation","Hepatic toxicity, aplastic anemia (rare but serious)","Visual field defects (serious risk), neuropsychiatric effects","Central nervous system effects, potential for seizures if abruptly discontinued",Not specified,"Limited, generally well-tolerated","Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), metabolic acidosis","Dizziness, somnolence, peripheral edema"
Fast fed variability(Yes/No),Yes,Yes,Yes,Yes,No,No,Yes,typically doesn't exhibit (illicit drug),No,No,No,No,Not known,Not known,Yes,No,No,No,No,No,Not available,Not specified,No,No,Not specified,No,Not readily available,Not specified,Not specified,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not specified,Not specified,Not specified,not applicable,Not specified,Not applicable,Not specified,Not specified,Not specified,Not specified,No,Fast fed variability(Yes/No),Negligible,Negligible,Yes,No,No,No,No,No,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Fast fed variability(Yes/No),yes,yes,yes,yes,yes,yes,yes,yes,yes,yes,yes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,yes,NA,NA,"yes, food can sufficiently affect the cyciosporine. It isrecommended to administently with or without food.",NA,NA,NA,The absorption of topical Tazarotene is not significantly influenced by food.,The absorption of Pimecrolimus is not significantly influenced by food,no,not applicable in oral administration,NA,yes,no,no,yes,no,no,yes,yes,no,yes,no,NA,NA,Fast fed variability(Yes/No),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Side effects(major),"Gastrointestinal disturbances, headache","Nausea, vomiting, diarrhea, headache",NA,"Neuropsychiatric effects, gastrointestinal disturbances","Tinnitus, hearing impairment","Gastrointestinal disturbances, Hypotension",Gastrointestinal disturbances,"Gastrointestinal disturbances, allergic reactions","Gastrointestinal upset, hemolysis in individuals with G6PD deficiency",Gastrointestinal disturbances,"Gastrointestinal disturbances,Skin reactions,Hepatic effects","Gastrointestinal upset, tooth discoloration in children","Nausea, vomiting, rash",gastrointestinal symptoms,yes,yes,yes,yes,yes,No,yes,Yes,Yes,yes,yes,yes,yes,yes,yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,YES,YES,NA,NA,NA,NA,NA,NA,NA,NA,yes,No,No,No,No,Yes,No,Yes (food increases absorption),No,No,No,No,No,No,No,Not specified,Not specified,No,Not specified,No,no,Yes,No,not specified,No,Not specified,Not specified,No,yes,Yes (food increases absorption),No,No,No,yes,No,No,Yes,No,Yes,No,No,No,Yes,No,Not specified,Yes,No,Not available,Not Available,No,NA,NA,NA,"No, food does not significantly affect the absorption of",cardiac arrhythmias,"absorption can be affected by food intake, with decreased absorption observed when taken with food",Not applicable as adenosine is typically administered intravenously,Digoxin does not exhibit significant food effect variability,Verapamil can exhibit variability in absorption when taken with food,Diltiazem exhibits variability in its absorption rate when taken with food,"No,",are not significantly affected by food intake,there is no significant variability in absorption when taken with food.,NA,No significant variability observed with food intake.,no,Not specified,Not specified,Not specified,not specified,not specified,not specified,not specified,not specified,not specified,not specified,not specified,not specified,not specified,not specified,no,no,no,no,no,no,no,no,no,no,no,no,no,no,no,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Diazepam will work quite quickly or more slowly depending on what you're taking it for: seizures or fits,NA,"Some people feel its effects within 15-30 minutes, but for others it may take up to 1-2 hours for full effect.",NA,"102.32–165.97%, 79.60–152.21%, and 126.39–214.58%",NA,Maximum mean lorazepam concentrations were achieved 10 and 11 hours after dosing under fasted and fed conditions,NA,NA,NA, in the absorption of drugs predominantly due to the presence or absence of food, in the absorption of drugs predominantly due to the presence or absence of food. , in the absorption of drugs predominantly due to the presence or absence of food. , redistribution into muscle and eventually fat ,an exponential linear curve with increasing doses,"chest pain,eye irritation, burning","nausea, dizziness, headache, slow heartbeats","weakness, tiredness, upset stomach, nausea, dizziness.","feeling warm or cold, drowsiness, dry mouth, nausea, sweating.","Dizziness, Tingling feeling, slow heartbeat ,Drowsiness","dry mouth, agitation, chest pain, tingling or prickling feeling","dizziness, headache, dry mouth","chest pain, discomfort or tightness","agitation, coma, confusion,depression","feeling dizzyor tired, cold handsor feet, difficulties sleeping and nightmare","dizziness, chest congestion","nausea, sleepiness, fast heartbeat","ringing in ears, changes in vision, rashes, feeling dizzy","chest pain, swelling, itching","insomnia , nervousness, restlessness, nausea",confusion,drowsiness,"rash ,itching","diarrhea,menstrual cramps","feeling sleepy,dizzy","nausea,dizziness","dizziness,diarrhea","body pain,burning inside",",constipation","dry mouth,blurred vision","dry mouh,headache",blurred vision,halucinations,insomia,urinary retansion,Fever with low white blood cell count.,"Common side effects include nausea, diarrhea, fatigue, neutropenia, thrombocytopenia, and upper respiratory tract infection.","Common side effects include nausea, vomiting, diarrhea, fatigue, febrile neutropenia, and peripheral edema.","Common side effects include headache, fatigue, nausea, vomiting, diarrhea, rash, and musculoskeletal pain.","Nausea, vomiting, diarrhea, fatigue","Common side effects may include weight gain, fluid retention, insomnia, mood changes, increased appetite, and others.","Common side effects may include nausea, vomiting, diarrhea, mucositis, alopecia, and others.","Common side effects may include fatigue, headache, nausea, diarrhea, rash, and others.","Common side effects may include insomnia, increased appetite, weight gain, fluid retention, mood changes, and others.","Side effects may include nausea, vomiting, diarrhea, anemia, thrombocytopenia, neutropenia, and other","Side effects may include nausea, vomiting, diarrhea, mucositis, alopecia, and others.","Side effects may include nausea, vomiting, diarrhea, fever, fatigue, headache, and others","Side effects may include fatigue, low blood cell counts, respiratory infections, gastrointestinal disturbances, and others.","Side effects may include nausea, vomiting, hair loss, mucositis, and others.","Side effects may include nausea, vomiting, diarrhea, alopecia, and others.","diarrhea, stomach cramps, and nausea in high doses.",may cause gastrointestinal issues.,"may cause diarrhea, itching, or blood clots.","can cause flushing (warmth, redness, or tingling), itching, and digestive issues. Very high doses can lead to liver problems.",excess is usually excreted in urine.,No major side effects reported with normal dietary intake.,"High doses may cause fishy body odor, low blood pressure, or gastrointestinal issues.","can lead to hypercalcemia (high levels of calcium in the blood), causing symptoms like nausea, vomiting, weakness, and confusion.",High doses may interfere with certain lab tests and cause inaccurate results.,No major side effects reported with normal dietary intake.,"Generally considered safe, but high doses may cause yellowing of the skin (carotenemia).","Generally considered safe, but high doses may cause skin pigmentation.","Generally considered safe, but high doses may cause digestive issues",No major side effects reported with normal dietary intake.,High doses may increase the risk of bleeding and interact with anticoagulant medications.,Side effects(major),local irritation or allergic reactions,Liver toxicity,Seizures,Hormonal effect,Neurological effects,Fatigue,Photosensitivity,swelling,Gastrointestinal symptom swelling,Swelling,Pale skin,Dry skin,skin irritation,NA,Dry skin,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,"hypoglycemia (low blood sugar), dizziness, headache, nausea, and allergic reactions.","hypoglycemia, nausea, and skin reactions. Serious side effects may include jaundice and allergic reactions.","hypoglycemia, gastrointestinal issues, and skin reactions. Rare but serious side effects can include blood disorders and liver problems.","Major side effects may include hypoglycemia, skin reactions, and gastrointestinal disturbances","Common side effects include hypoglycemia, gastrointestinal upset, and skin reactions. Serious side effects may involve blood disorders and liver dysfunction","Major side effects may include hypoglycemia, gastrointestinal disturbances, and skin reactions.","Major side effects may include hypoglycemia, gastrointestinal disturbances, and skin reactions.","Major side effects may include hypoglycemia, gastrointestinal disturbances, and skin reactions.","Major side effects may include hypoglycemia, gastrointestinal issues, and skin reactions.","Major side effects may include hypoglycemia, gastrointestinal issues, and skin reactions.","Major side effects may include hypoglycemia, gastrointestinal issues, and skin reactions.","Limited information is available on Glyclopyramide,","Major side effects may include hypoglycemia, gastrointestinal issues, and skin reactions.","Information about Glibuzole is limited, and it may not be a widely recognized medication. It's advisable to consult a healthcare professional for specific details.","Major side effects may include hypoglycemia, gastrointestinal issues, skin reactions, and rarely, blood disorders or liver problems.","headache,
nausea,
diarrhea","headache, dizziness, rash.","headache, nausea, diarrhea","May include headache, nausea","gastrointestinal
symptoms, headache, and rash.","Headache, diarrhea, nausea, abdominal pain.","nausea, vomiting, metallic taste, and dizziness","headache, nausea, diarrhea, and abdominal pain","nausea, vomiting, diarrhea, and discoloration of teeth","headache,nausea, diarrhea and abdominal pain","belching, flatulence, and stomach cramps.","diarrhea, abdominal cramps, and vaginal bleeding.","Common side effects include headache, dizziness, diarrhea, and rash","gastrointestinal disturbances such as bloating, gas, and diarrhea.","headache, dizziness, constipation, diarrhea, and rash. Rarely, it may cause more serious side effects such as liver problems or allergic reactions.","High calcium levels,Low phosphate levels,Vomiting,Nausea,Gas.","dizziness, headache, and Somnolence,constipation","gas, bloating, or increased thirst when consumed
in excess.","Nausea,Vomiting,Low blood phosphates,","diarrhea, upset stomach, or nausea","black tongue or stools, constipation, and in rare cases, allergic reactions like swelling or difficulty breathing","headache, nausea, diarrhea, abdominal pain,","Joint pain,Diarrhea,Headache,Nausea or vomiting.","headache, dizziness, diarrhea, constipation, and fatigue.","headache, nausea, diarrhea, stomach pain, and gas","stomach upset, diarrhea,","headache, nausea, diarrhea, abdominal pain, and fatigue",stomach upset or diarrhea.,"Diarrhea, stomach upset, and nausea.","High blood magnesium,Vomiting,Headache,Dizziness,",NA,"nausea,leg cramps,muscles aches,pain joints.","nausea,vomiting ,trouble sleeping","hair loss, sweating","shortness of breath,headache","fatigue,nausea,alopecia",anemia,"hot flashes,nausea","vomiting,alopecia",variable,variable,bone marrow problem,nausea,NA,NA,"Fatigue, nausea, anemia, rash","Serious rash, hepatic decompensation (rare)","Nausea, headache, fatigue, abdominal pain","Nausea, diarrhea, rash, elevated liver enzymes","Nausea, diarrhea, headache, elevated liver enzymes","Nausea, vomiting, respiratory failure","Elevated uric acid levels (hyperuricemia), gastrointestinal symptoms","Headache, nausea, diarrhea, fatigue",Side effects(major),Nausea and vomiting,NA,"Nausea and vomiting,Loss of appetite,Headache",NA,NA,Hypertensive Crisis,Delayed wound healing,Proteinuria,NA,Hepatotoxicity,Hemorrhagic Cystitis,Ototoxicity,Intracranial hypertension,Secondary Malignamcies,Gastrointestinal toxicity,Side effects(major),mausea vomitting,nausea vomitting,diarrhea,nausea,"nausea ,vomiting",nausea,nausea,rarely,rarely,local skin reaction,itching,irritation occur,gastrointestinal disturbance,similar to toxic effects,"chest pain,eye irritation, burning","nausea, dizziness, headache, slow heartbeats","weakness, tiredness, upset stomach, nausea, dizziness.","feeling warm or cold, drowsiness, dry mouth, nausea, sweating.","Dizziness, Tingling feeling, slow heartbeat ,Drowsiness","dry mouth, agitation, chest pain, tingling or prickling feeling","dizziness, headache, dry mouth","chest pain, discomfort or tightness","agitation, coma, confusion,depression","feeling dizzyor tired, cold handsor feet, difficulties sleeping and nightmare","dizziness, chest congestion","nausea, sleepiness, fast heartbeat","ringing in ears, changes in vision, rashes, feeling dizzy","chest pain, swelling, itching","insomnia , nervousness, restlessness, nausea",confusion,drowsiness,"rash ,itching","diarrhea,menstrual cramps","feeling sleepy,dizzy","nausea,dizziness","dizziness,diarrhea","body pain,burning inside",",constipation","dry mouth,blurred vision","dry mouh,headache",blurred vision,halucinations,insomia,urinary retansion,Fever with low white blood cell count.,"Common side effects include nausea, diarrhea, fatigue, neutropenia, thrombocytopenia, and upper respiratory tract infection.","Common side effects include nausea, vomiting, diarrhea, fatigue, febrile neutropenia, and peripheral edema.","Common side effects include headache, fatigue, nausea, vomiting, diarrhea, rash, and musculoskeletal pain.","Nausea, vomiting, diarrhea, fatigue","Common side effects may include weight gain, fluid retention, insomnia, mood changes, increased appetite, and others.","Common side effects may include nausea, vomiting, diarrhea, mucositis, alopecia, and others.","Common side effects may include fatigue, headache, nausea, diarrhea, rash, and others.","Common side effects may include insomnia, increased appetite, weight gain, fluid retention, mood changes, and others.","Side effects may include nausea, vomiting, diarrhea, anemia, thrombocytopenia, neutropenia, and other","Side effects may include nausea, vomiting, diarrhea, mucositis, alopecia, and others.","Side effects may include nausea, vomiting, diarrhea, fever, fatigue, headache, and others","Side effects may include fatigue, low blood cell counts, respiratory infections, gastrointestinal disturbances, and others.","Side effects may include nausea, vomiting, hair loss, mucositis, and others.","Side effects may include nausea, vomiting, diarrhea, alopecia, and others.",NA,Side effects(major),"diarrhea, stomach cramps, and nausea in high doses.",may cause gastrointestinal issues.,"may cause diarrhea, itching, or blood clots.","can cause flushing (warmth, redness, or tingling), itching, and digestive issues. Very high doses can lead to liver problems.",excess is usually excreted in urine.,No major side effects reported with normal dietary intake.,"High doses may cause fishy body odor, low blood pressure, or gastrointestinal issues.","can lead to hypercalcemia (high levels of calcium in the blood), causing symptoms like nausea, vomiting, weakness, and confusion.",High doses may interfere with certain lab tests and cause inaccurate results.,No major side effects reported with normal dietary intake.,"Generally considered safe, but high doses may cause yellowing of the skin (carotenemia).","Generally considered safe, but high doses may cause skin pigmentation.","Generally considered safe, but high doses may cause digestive issues",No major side effects reported with normal dietary intake.,High doses may increase the risk of bleeding and interact with anticoagulant medications.,NA,NA,NA,NA,NA,local irritation or allergic reactions,Liver toxicity,Seizures,Hormonal effect,Neurological effects,Fatigue,Photosensitivity,swelling,Gastrointestinal symptom swelling,Swelling,Pale skin,Dry skin,skin irritation,NA,Dry skin,NA,Fast fed variability (Yes/No),Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Side effects(major),"hypoglycemia (low blood sugar), dizziness, headache, nausea, and allergic reactions.","hypoglycemia, nausea, and skin reactions. Serious side effects may include jaundice and allergic reactions.","hypoglycemia, gastrointestinal issues, and skin reactions. Rare but serious side effects can include blood disorders and liver problems.","Major side effects may include hypoglycemia, skin reactions, and gastrointestinal disturbances","Common side effects include hypoglycemia, gastrointestinal upset, and skin reactions. Serious side effects may involve blood disorders and liver dysfunction","Major side effects may include hypoglycemia, gastrointestinal disturbances, and skin reactions.","Major side effects may include hypoglycemia, gastrointestinal disturbances, and skin reactions.","Major side effects may include hypoglycemia, gastrointestinal disturbances, and skin reactions.","Major side effects may include hypoglycemia, gastrointestinal issues, and skin reactions.","Major side effects may include hypoglycemia, gastrointestinal issues, and skin reactions.","Major side effects may include hypoglycemia, gastrointestinal issues, and skin reactions.","Limited information is available on Glyclopyramide,","Major side effects may include hypoglycemia, gastrointestinal issues, and skin reactions.","Information about Glibuzole is limited, and it may not be a widely recognized medication. It's advisable to consult a healthcare professional for specific details.","Major side effects may include hypoglycemia, gastrointestinal issues, skin reactions, and rarely, blood disorders or liver problems.",Side effects(major),"headache,
nausea,
diarrhea","headache, dizziness, rash.","headache, nausea, diarrhea","May include headache, nausea","gastrointestinal
symptoms, headache, and rash.","Headache, diarrhea, nausea, abdominal pain.","nausea, vomiting, metallic taste, and dizziness","headache, nausea, diarrhea, and abdominal pain","nausea, vomiting, diarrhea, and discoloration of teeth","headache,nausea, diarrhea and abdominal pain","belching, flatulence, and stomach cramps.","diarrhea, abdominal cramps, and vaginal bleeding.","Common side effects include headache, dizziness, diarrhea, and rash","gastrointestinal disturbances such as bloating, gas, and diarrhea.","headache, dizziness, constipation, diarrhea, and rash. Rarely, it may cause more serious side effects such as liver problems or allergic reactions.",Side effects(major),"High calcium levels,Low phosphate levels,Vomiting,Nausea,Gas.","dizziness, headache, and Somnolence,constipation","gas, bloating, or increased thirst when consumed
in excess.","Nausea,Vomiting,Low blood phosphates,","diarrhea, upset stomach, or nausea","black tongue or stools, constipation, and in rare cases, allergic reactions like swelling or difficulty breathing","headache, nausea, diarrhea, abdominal pain,","Joint pain,Diarrhea,Headache,Nausea or vomiting.","headache, dizziness, diarrhea, constipation, and fatigue.","headache, nausea, diarrhea, stomach pain, and gas","stomach upset, diarrhea,","headache, nausea, diarrhea, abdominal pain, and fatigue",stomach upset or diarrhea.,"Diarrhea, stomach upset, and nausea.","High blood magnesium,Vomiting,Headache,Dizziness,",Side effects(major),NA,"nausea,leg cramps,muscles aches,pain joints.","nausea,vomiting ,trouble sleeping","hair loss, sweating","shortness of breath,headache","fatigue,nausea,alopecia",anemia,"hot flashes,nausea","vomiting,alopecia",variable,variable,bone marrow problem,nausea,NA,NA,"Fatigue, nausea, anemia, rash","Serious rash, hepatic decompensation (rare)","Nausea, headache, fatigue, abdominal pain","Nausea, diarrhea, rash, elevated liver enzymes","Nausea, diarrhea, headache, elevated liver enzymes","Nausea, vomiting, respiratory failure","Elevated uric acid levels (hyperuricemia), gastrointestinal symptoms","Headache, nausea, diarrhea, fatigue",Side effects(major),Nausea and vomiting,NA,"Nausea and vomiting,Loss of appetite,Headache",NA,NA,Hypertensive Crisis,Delayed wound healing,Proteinuria,NA,Hepatotoxicity,Hemorrhagic Cystitis,Ototoxicity,Intracranial hypertension,Secondary Malignamcies,Gastrointestinal toxicity,mausea vomitting,nausea vomitting,diarrhea,nausea,"nausea ,vomiting",nausea,nausea,rarely,rarely,local skin reaction,itching,irritation occur,gastrointestinal disturbance,similar to toxic effects,"sedation, drowsiness, dizziness","dizziness, somnolence","drowsiness, dizziness, cognitive impairment","Drowsiness, sedation, confusion","Dizziness, Drowsiness, nausea","Dizziness, Drowsiness","vision loss, nausea","sedation, dizziness, fatigue","nausea, vommiting","weight loss, dizziness, vommiting","sedation, diziness, fatigue","diuresis, paresthesia","fatigue, tremors","dizziness,nausea",sss,NA,"dizziness,nausea","Nausea, tremor, weight gain","Weight gain, sedation, Dizziness","Rash, dizziness, headache","weight gain, akathisia","drowsiness, weight gain, headache","Akathisia, Sedation, Nausea","Dizziness, drowsiness, nausea","weight gain, sedation, dizziness","Sedation, Akathisia, nausea","Weight gain, sedation, dizziness","Dyspepsia, gastritis-like symptoms, bleeding.",NA,"Extrapyramidal symptoms, sedation",Extrapramidal symptoms,"GI disturbances, musculoskeletal pain.","Hot Flashes, Leg Cramps & Arthralgia (Joint Pain)","Gastrointestinal Issues, Musculoskeletal Pain, Headache","GI disturbances, musculoskeletal pain.","flu-like symptoms, musculoskeletal pain","hot flashes, leg cramps, and muscle spasms","gastrointestinal discomfort, musculoskeletal pain, and fever.","gastrointestinal discomfort, musculoskeletal pain",flu-like symptoms after infusion,"Skin rashes, Dizziness nausea, diarrhea, and abdominal pain.","Dizziness, leg cramps","Dizziness, nausea","Nasal irritation, flushing","Back pain, muscle pain","Joint pain, headache","Approximately 75% of the administered dose was eliminated in the urine, with 20% of that dose being the unchanged drug.",30% renally,About 43% of the total dose was excreted in the urine,Approximately 80% to 90% of a methotrexate dose is excreted unchanged in the urine,Approximately 10-15% of the dose is excreted in the urine,Approximately 15-30% of the sulfasalazine dose is excreted in the urine.,A portion of the administered dose of azathioprine and its metabolites is excreted in the urine.,3-6% of the dose,~ 50%,40-50% of hydroxychloroquine is excreted renally,Minor,98%,mostly renal,undergoes minimal renal excretion.,minimal,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA," nausea, vomiting, stomach pain; · vaginal itching or discharge; headache; ", feeling sick (nausea) and diarrhoea.," diarrhea, nausea, and stomach pain.","eosinophilia, leukopenia, thrombocytopenia, diarrhea, rash, and increased hepatic enzymes.","Swelling, redness, pain, or soreness at the injection site may occur. This medication may also rarely cause upset stomach, nausea, vomiting, "," Bluish lips or skin · chills · cold, clammy skin · confusion · dizziness · fainting · fast heartbeat · fast, weak pulse",NA," Black, tarry stools · bleeding gums · blistering, peeling, or loosening of the skin · blurred vision · chest pain", nausea · vomiting · diarrhea,"transitory salivation, vomiting and an apparent calming",nausea; diarrhea; headache; vomiting; dizziness; nervousness;," Nausea, constipation, diarrhea, headache, or trouble sleeping ","Swelling, redness, or pain at the injection site may occur.",Feeling sleepy. ...,hypotension and reflex tachycardia.,hypotension and reflex tachycardia.,"headaches, dizziness, and hypotension.","headache, dizziness, and hypotension","headache, dizziness, and hypotension","fatigue, dizziness, bradycardia (slow heart rate), hypotension (low blood pressure), and gastrointestinal issues",bradycardia (slow heart rate) and worsening of heart failure,Bradycardia,"constipation, dizziness, headache, and edema.","dizziness, headache, and flushing","swelling of the ankles or legs (peripheral edema), dizziness, and flushing","hypotension and ulcerations,","hypotension, palpitations, and, rarely, allergic reactions","irregular heartbeat, chest pain, or signs of liver problems","bleeding disorders, severe allergic reactions, or liver problems",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Convulsions,dizziness and fainting, fast-
slow and irregular heart beats,itching,
pain,redness,swelling,joint pain,severe
skin rash","Rash,confusion,chills,constipation 
difficulty 
in swallowing,cough,hallucinations","Vomiting,headache,seizures,diarrhea,
hallucinations,rash,facial swelling","Stomach pain,fever,headache,nausea,
redness soreness of eyes","Common acyclovir side effects
include nausea, vomiting, and diarrhea","Heavy bleeding,loss of voice,cramps,ear 
congestion,difficulty in moving","headache,diarrhea,
bronchitis,cough,voice changes,runny nose","Rash,eye pain,fever,chills,cough,
shortness of breath","Weakness,headache,diarrhea,gas,
indigestion,sore throat,runny nose","nausea,stomach pain,diarrhea,headache,
depression,rash,vomiting","depression,pain,back pain,headache,
trouble in sleeping","The side effects of amprenavir in patien
ts treated with combination therapy included nausea, vomiting, diarrhea, epigastric pain, flatulence, paresthesia, headache, rash, and fatigue","nausea,stomach pain,diarrhea,headache,
depression,fever,vomiting","anemia, fatigue, headache,
nausea, itching, rash and neutropenia","Headache, tiredness, loss of appetite,
nausea, vomiting, diarrhea, trouble sleeping, dizziness, or stuffy nose may occur","Nausea, dizziness, ataxia, rash","Dizziness, drowsiness, nausea, rash","GI disturbances, weight gain, hair loss, tremor","Headache, dizziness, nausea, rash (common side effects)","Headache, dizziness, fatigue, and gastrointestinal disturbances","Dizziness, somnolence, cognitive dysfunction, weight loss","Dizziness, drowsiness, headache, nausea","Drowsiness, dizziness, headache, constipation","Nausea, vomiting, insomnia, dizziness, headache","Dizziness, drowsiness, fatigue, headache","Dizziness, drowsiness, nervousness, and tremor","Common side effects include dizziness, somnolence, nausea, and vomiting","Dizziness, drowsiness, peripheral edema, ataxia","Dizziness, somnolence, anorexia, weight loss, renal stones","Weight gain, blurred vision, headache","Nausea, dizziness, ataxia, rash","Dizziness, drowsiness, nausea, rash","GI disturbances, weight gain, hair loss, tremor","Headache, dizziness, nausea, rash (common side effects)","Headache, dizziness, fatigue, and gastrointestinal disturbances","Dizziness, somnolence, cognitive dysfunction, weight loss","Dizziness, drowsiness, headache, nausea","Drowsiness, dizziness, headache, constipation","Nausea, vomiting, insomnia, dizziness, headache","Dizziness, drowsiness, fatigue, headache","Dizziness, drowsiness, nervousness, and tremor","Common side effects include dizziness, somnolence, nausea, and vomiting","Dizziness, drowsiness, peripheral edema, ataxia","Dizziness, somnolence, anorexia, weight loss, renal stones","Weight gain, blurred vision, headache"
